2020 AAN Annual Meeting Science Program by American Academy of Neurology

2O2O SCIENCE PROGRAM Registration Guide Meeting Schedule Abstract Listing

April 25–May 1 • Toronto, Canada

The High Cost of Treatment The Opioid Crisis

Artificial Intelligence

Sorting Out Vascular Dementia

Your Science at Your Annual Meeting

Mood Disorders After Traumatic Brain Injuries

Detection of Covert Consciousness in Coma

Stem Cells and Spinal Cord Recovery Tailored/Precision Medicine for Epilepsy Treatment

Science Talks that Impact Your Daily Interactions. Learn more throughout this book or at AAN.com/view/20AM.

CONTENTS Introduction Welcome and 2020 Highlights. . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Registration, Hotels, and Travel Information. . . . . . . . . . . . . . . . 8 Meeting Transportation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Program Glossary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

Annual Meeting Schedule Meeting-at-a-glance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Daily Schedule Saturday, April 25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sunday, April 26. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Monday, April 27. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tuesday, April 28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Wednesday, April 29. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thursday, April 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Friday, May 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

28 31 35 41 44 48 52

Awards

Poster Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117 Saturday, April 25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118 Sunday, April 26. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124 Monday, April 27. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .141 Tuesday, April 28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 Wednesday, April 29 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176 Thursday, April 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194 Friday, May 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211 Experiential Learning Areas . . . . . . . . . . . . . . . . . . . . . . . . . . . 219 Academic Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220 Advancing Leadership in Neurology. . . . . . . . . . . . . . . . . 222 HeadTalks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224 Innovation Hub. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226 Live Well. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228 Navigating Your Career . . . . . . . . . . . . . . . . . . . . . . . . . . . 230 Policy, Practice, and Performance: Staying Ahead of Change. . . . . . . . . . . . . . . . . . . . . . . . . . 233 Research. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235

2020 Award Recipients. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 2020 Research Program Recipients. . . . . . . . . . . . . . . . . . . . . . 60

Index

Annual Meeting Sessions

Programs by Topic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237

Plenary Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 Hot Topics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Presidential. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 Contemporary Clinical Issues. . . . . . . . . . . . . . . . . . . . . . . . 64 Clinical Trials. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 Frontiers in Neuroscience . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Controversies in Neurology. . . . . . . . . . . . . . . . . . . . . . . . . 67 Neurology Year in Review. . . . . . . . . . . . . . . . . . . . . . . . . . 68 Neuroscience in the Clinic Sessions. . . . . . . . . . . . . . . . . . . . . . 69 Sunday, April 26. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Monday, April 27. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71 Tuesday, April 28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 Wednesday, April 29 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 Thursday, April 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Invited Science Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75 Sunday, April 26. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 Monday, April 27. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76 Tuesday, April 28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 Scientific Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Sunday, April 26. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Monday, April 27. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 Tuesday, April 28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 Wednesday, April 29 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 Thursday, April 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 Friday, May 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114

Current as of January 31, 2020. Program subject to change.

General Annual Meeting Information Accreditation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Disclaimers/Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Meeting Policies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hotel and Registration Policies. . . . . . . . . . . . . . . . . . . . . . . . . 72nd Annual Meeting Exhibitors . . . . . . . . . . . . . . . . . . . . . . .

262 263 264 264 265

The 72nd AAN Annual Meeting Location

Metro Toronto Convention Centre

Co-headquarter Hotels Hotel Fairmont Royal York Delta Hotels by Marriott Toronto

Advance Registration Deadline April 2, 2020

AAN.com/view/20AM

AAN.com/view/20AM 1

We’re thrilled to introduce in the following pages the 72nd Annual Meeting’s scientific program to round out the 500+ education programs and Experiential Learning Area talks announced in the fall. Here is a preview of what’s in store for Annual Meeting science: Every year, scientific plenary sessions bring the most exciting developments to the thousands of attendees, including the cutting-edge neuroscience, the latest clinical trials across the spectrum of neurologic diseases, hot topics in neurology, scientific advances that have already entered our clinical practice, and of course the controversies in neurology. I am always in the front row in those sessions, learning what’s new and am inspired about what’s yet to come! I also highly recommend our Neuroscience in the Clinic (NIC) sessions, the Invited Science (IS) sessions, and of course everyone’s favorite—the original science presented in scientific sessions and electronic posters. One thing is for sure, there is no shortage of exciting science. Over the years and despite my many subspecialty research commitments, the AAN Annual Meeting has become my most important conference to attend. I see it as a “full immersion” experience, where not only I reconnect with the entire spectrum of neurologic science but also have the opportunity to engage with my neurology community and participate in activities (such as leadership development, mentorship, and well-being strategies, to name a few) that make our profession so unique and dynamic.

I invite all my colleagues and friends to experience these opportunities at the Annual Meeting—and I’m looking forward to seeing you all in Toronto!

Natalia S. Rost, MD, MPH, FAAN, FAHA Chair, AAN Science Committee

2020 AAN Annual Meeting

2020 HIGHLIGHTS Inspiration and Innovation Talks and Opening Reception Kick off the Annual Meeting on Saturday, April 25, 2020, with the first talk in this series by David Eagleman, PhD, followed by the opening reception. The second talk in the series will feature Maria Konnikova, PhD. See pages 26 and 49.

Sunday Night at the ROM Join us for an extravaganza at the Royal Ontario Museum– food, beverages, and entertainment! See page 33.

Health Care Equity Symposium An afternoon to learn about and discuss quality health care for all. See page 38.

Electronic Posters All scientific posters in the poster hall will be digital. Presentations are more immersive, interactive, engaging–and environmentally friendly. See page 78.

Two New Experiential Learning Areas Visit the Academic Neurology and Advancing Leadership in Neurology experiential learning areas to explore topics in leadership and academics. See pages 220 and 222.

Beyond the Bedside Series Come learn the business side of treating patients during these discussions that precede select clinical courses. See page 261.

Career-focused Program Tracks These audience-based programming tracks offer focused programming geared specifically toward a variety of neurology professionals, including a track specifically for Spanishlanguage speakers. See page 55.

Friday Grand Finale Program You’ll want to make sure and stay until the end of the week to take in this year’s enhanced Friday experience. The streamlined schedule for the day includes a Science Innovation Lunch in the Poster Hall featuring neuroinflammation abstracts and the day will end with a Closing Party featuring Second City’s improv crew. See page 51.

Physical Activities and Wellness Sign up for the popular Run/Walk (see page 40) and The Great Neuro Race (see page 27). You can also stay active all week with a new step challenge. Download the Heka Health App, available for iOS and Android, and select “American Academy of Neurology” to compete with other attendees on total steps for the week.

AAN.com/view/20AM 3

40+ years of scientific expertise. One leading portfolio of choice. MultiplechoiceS Biogen Ad

For over 40 years, the scientists and researchers at Biogen have been pioneers in creating multiple choices for the treatment of multiple sclerosis (MS). Visit us at the 2020 AAN Annual Meeting to learn more about our treatment choices for patients with MS. Discover more at

BOOTH 411

Or visit Biogen.com

EXPLORE, DISCOVER, CONNECT

4 FULL DAYS OF INTERACTIVE EXHIBITS, EVENTS, & EXPERIENCES DON’T MISS EVERYTHING GOING ON IN THE

Association Neighborhood | Connect with health organizations. Technology Pavilion | Discover emerging technologies. Publishers’ Row | Keep up-to-date on what’s new.

EXHIBIT HALL

Career Fair | Gather career resources and more.

SUN, APR 26–WED, APR 29

Innovation Hub | Experience an array of dynamic events.

AT THE ANNUAL MEETING

Vendor Booths | Preview the latest products and services. Buzz Cafes | Grab a cup of joe and mingle. Picnic Areas | Join in fun daily competitions and activities. Charging Lounges | Keep your devices charged in comfort. Opening Luncheon | Enjoy complimentary lunch and beverages. Networking Reception | Join us for food, music, and fun.

DYSKINESIA AND OFF TIME DISRUPT DAILY LIFE - GOCOVRI® IS CLINICALLY PROVEN TO REDUCE BOTH1,2 GOCOVRI® is the first and only FDA-approved medication indicated for the treatment of dyskinesia in patients with Parkinson’s disease (PD) receiving levodopa-based therapy, with or without concomitant dopaminergic medications.1 In clinical trials, GOCOVRI® reduced dyskinesia (UDysRS; primary endpoint) while also reducing OFF time (key secondary endpoint) through Week 12, leading to increased “good” ON time (ON time without troublesome dyskinesia; key secondary endpoint) throughout the day.1

41% DECREASE IN DYSKINESIA

vs 14% with placebo (UDysRS; primary endpoint) 2†

36% DECREASE IN OFF TIME

(1 hour) placebo-adjusted2,3† (key secondary endpoint)

45% INCREASE IN “GOOD” ON TIME

(3.8 hours) vs 17% with placebo (1.4 hours)2,3† (key secondary endpoint)

All GOCOVRI® material is intended only for U.S. HCPs in attendance at the 2020 AAN Annual Meeting in Toronto, Canada. GOCOVRI® is not authorized for sale in Canada.

Please visit us at booth 1433 to learn more. “Good” ON time = ON time without troublesome dyskinesia, UDysRS = Unified Dyskinesia Rating Scale.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m

WARNINGS AND PRECAUTIONS (CONT’D) Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

WARNINGS AND PRECAUTIONS Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression. Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications. ADVERSE REACTIONS The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

Please see full Prescribing Information at booth 1433.

References: 1. GOCOVRI® (amantadine) [Prescribing Information]. Emeryville, CA: Adamas Pharma LLC; 2017. 2. Elmer LW, Juncos JL, Singer C, et al. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson’s disease. CNS Drugs. 2018;32(4):387-398. 3. Data on File. Adamas Pharma LLC, Emeryville, CA.

CALLING ALL MEDICAL STUDENTS AND RESIDENTS

This Annual Meeting has been designed with you in mind. The AAN Annual Meeting is free for medical students. AAN Intern and Junior members receive discounted registration of $325 when registering by April 2, 2020.

MEDICAL STUDENTS

RESIDENTS

• Digital Scavenger Hunt Saturday, April 25–Wednesday, April 29 • Futures in Neurological Research Boot Camp Saturday, April 25, 12:00 p.m. – 4:00 p.m. • Medical Student Symposium Sunday, April 26, 12:30 p.m. – 5:00 p.m. • Futures in Neurological Research Luncheon Monday, April 27, 12:00 p.m. – 2:00 p.m. • Student Interest Group in Neurology (SIGN) Meeting Monday, April 27, 4:30 p.m. – 6:00 p.m. • Trainee and Faculty Networking Reception Monday, April 27, 6:00 p.m. – 8:00 p.m.

• Resident Basic Science I: Neuropharmacology* Saturday, April 25, 12:00 p.m. – 4:00 p.m. • Futures in Neurological Research Boot Camp Saturday, April 25, 12:00 p.m. – 4:00 p.m. • Chief Resident Leadership Program Sunday, April 26, 12:00 p.m. – 4:00 p.m. • Resident Basic Science II: Neuroanatomy: All the Lesions* Sunday, April 26, 1:00 p.m. – 5:30 p.m. • Futures in Neurological Research Luncheon Monday, April 27, 12:00 p.m. – 2:00 p.m. • Resident Basic Science III: Neuropathology* Monday, April 27, 1:00 p.m. – 5:30 p.m. • Trainee and Faculty Networking Reception Monday, April 27, 6:00 p.m. – 8:00 p.m.

*Open to all career levels. In addition to this curated list, be sure to check out the Experiential Learning Areas for even more career-focused programming. Learn more: AAN.com/view/AMTrainee

REGISTRATION, HOTELS, AND TRAVEL INFORMATION REGISTER NOW Online

AAN.com/view/20AM

Phone

(800) 676-4226 (US/Canada) (415) 979-2283 (International)

Deadlines

Early Registration Deadline March 5, 2020 Advance Registration Deadline April 2, 2020 On-site Rates April 3, 2020, and after

Protect yourself from fraudulent booking companies. Convention Management Resources (CMR) is the official and only housing and registration partner of the AAN.

Special Accommodations and Dietary Restrictions The Metro Toronto Convention Centre and the AAN strive to accommodate all visitors. If you require special accommodation or meals while attending the Annual Meeting, submit your request while registering online or contact Brooke Martin at bmartin@aan.com.

What's Included In Registration? The Annual Meeting’s single registration rate offers exceptional value, providing access to: • All the CME you need for the entire year • 250+ expert-led education courses • 50+ scientific sessions (including posters and abstract presentations) • 7 plenary sessions • 300+ talks across eight different experiential learning areas (including two new areas) • Networking events tailored to your career stage, interests, and more • Inspiration and Innovation Talks – featuring David Eagleman, PhD, and Maria Konnikova, PhD • Access to program syllabi and slides

• Yoga classes and other physical challenges throughout the week • Complimentary bookbag • Booths – learn about all that the AAN and its affiliates have to offer (educational and scientific publications, careers, membership, and more) • Exhibit Hall access • Industry Therapeutic Updates • One free ticket each to Sunday Night at the ROM and the closing party (while supplies last!) • Breakfast, lunch, and coffee breaks every day of the meeting

Some courses or social events require pre-registration, may have a separate registration fee, and/or have a limited capacity. Courses or events that aren’t included in registration will include a indicating that an additional fee is required.

2020 AAN Annual Meeting

UPGRADE TO GOLD REGISTRATION

With so much programming and so little time, don’t miss anything by upgrading your registration to include Annual Meeting On Demand – the AAN’s comprehensive, CME-accredited digital library that gives access to Annual Meeting programming for two years after the event (learn more on the following page).

Note: All prices in US dollars

Early Rates

Advance Rates

On-site Rates

(By March 5, 2020)

(March 6-April 2, 2020)

(April 3, 2020, and after)

Registration

Gold Registration

Registration

Gold Registration

Registration

Gold Registration

Student Members and Nonmember Students

$99

Honorary and Senior Members

$289

Intern and Junior Members

$295

$394

$325

$424

$385

$484

Non-physician Members and Non-neurologists (Advanced Practice Providers, Business Administrators, and Researchers)

$495

$594

$545

$644

$645

$744

Neurologist and Physician Affiliate Members

$795

$1,084

$880

$1,169

$1,055

$1,344

$1,320

$1,749

$1,465

$1,894

$1,760

$2,189

Nonmembers

AAN.com/view/20AM 9

Anywhere. Anytime. Annual Meeting On Demand. You have only so much time at the Annual Meeting, but don’t worry about missing out. With Annual Meeting On Demand, you’ll get two full years of access to 500+ hours of sessions and presentations to watch anytime, anywhere for one low price. Content is available to view online within 24 hours. Plus, earn CME credits for one year after the event.

Just $99 more to upgrade to Gold Registration for Student, Intern, and Junior members!

Save Today by Upgrading Your Annual Meeting Registration to “Gold” AAN.com/view/20AMOD

BOOK YOUR HOTEL Why Book a Hotel Through the AAN? Online

AAN.com/view/20AM

Phone

(800) 676-4226 (US/Canada) (415) 979-2283 (International)

• Greater networking opportunities • Pre-vetted hotels • Discounted rates and easy-to modify reservations • Friendly booking terms: No change fees or full prepayment upon booking • Housing representatives are available in advance and on-site for assistance with official hotels

Check out pages 12-13 for a list of the official Annual Meeting hotels. 4 Important Things to Remember 1. CMR is the only official housing provider for the 2020 AAN Annual Meeting.

Protect yourself from fraudulent booking companies. Only book through the AAN’s official housing vendor, Convention Management Resources (CMR), which is accessible via AAN.com/view/20AM.

2. Neither the AAN nor CMR will contact you via phone to book a hotel reservation or register. 3. Scammers and poachers generally request full payment for your hotel stay. CMR will only request a credit card guarantee for one night room and tax deposit. 4. If it seems too good to be true, it probably is.

FLIGHT & RENTAL CAR DISCOUNTS Delta Airlines

Alamo Car Rentals

Meeting Code NMTN2 Book online – Delta.com > More Options Call 1-800-328-1111

Contract ID (CD) LEADERS Book online – Alamo.com Call 1-844-354-6962

United Airlines

Hertz Car Rentals

Offer Code ZHKC298978 Book online – United.com > Advanced Search Call 1-800-426-1122

Rate Code (RQ) 1170024 Book online – Hertz.com > Discount Code Call 1-800-654-3131

Travel Tips Visit AAN.com/view/FAQ for travel tips, including: • Currency • Travel documents/passport and entry requirements • Customs and immigration • Letter of Announcement request • Health insurance • Airport

• Public transportation • Weather • And more!

AAN.com/view/20AM 11

OFFICIAL ANNUAL MEETING HOTEL BLOCK* Transit Option Lowest Available to MTCC Rate**(Canadian Dollars)

Hotel Name

Hotel Address

Fairmont Royal York (Co-HQ)

100 Front Street West

$328

Delta Hotels Toronto Downtown (Co-HQ)

75 Lower Simcoe Street

$329

The Bond Place

65 Dundas Street East

$259

Chelsea Hotel, Toronto

33 Gerrard Street West

$215

Courtyard Toronto Downtown

475 Yonge Street

$262

Hilton Toronto

145 Richmond Street West

$289

Holiday Inn Toronto Downtown Centre

30 Carlton Street

$209

Hotel X Toronto

111 Princes' Blvd

$369

Hyatt Regency Toronto

370 King Street West

$299

10 InterContinental Toronto Centre

225 Front Street West

$325

11 Marriott Downtown at CF Toronto Eaton Centre

525 Bay Street

$295

12 Novotel Toronto Centre Hotel

45 The Esplanade

$279

13 Omni King Edward Hotel

37 King Street East

$429

14 Radisson Admiral Hotel Toronto-Harbourfront

249 Queen's Quay West

$270

15 Sheraton Centre Toronto Hotel

123 Queen Street West

$322

16 Strathcona Hotel

60 York Street

$295

17 Toronto Marriott City Centre Hotel

1 Blue Jays Way

$237

18 The Westin Harbour Castle, Toronto

One Harbour Square

$322

19 Delta Hotels Toronto Airport & Conference Centre 655 Dixon Road

$209

20 Doubletree by Hilton Toronto Airport

925 Dixon Road

$169

21 Embassy Suites by Hilton Toronto Airport

262 Carlingview Drive

$219

22 Hilton Toronto Airport Hotel & Suites

5875 Airport Road

$225

23 Holiday Inn Torontoâ&#x20AC;&#x201C;Airport East

600 Dixon Road

$199

24 Radisson Suite Hotel Toronto Airport

640 Dixon Road

$179

*All hotels booked through the AAN include complimentary internet. **All hotel rates are in Canadian dollars. Availability may be limited; other room categories may be available at a higher rate. Rates do not include hotel tax. Rates include a Can $8 per night assessment fee to offset the expense of the meeting. For deposit and other information, visit AAN.com/view/20AM.

12 2020 AAN Annual Meeting

KEY Co-headquarter Hotels

Downtown Toronto Hotels

No transit passes provided. Transportation provided for Sunday Night at the ROM.

Hotels more than 1 mile from MTCC: TTC pass provided for each day of stay. Transportation provided for Sunday Night at the ROM. Hotels less than 1 mile from MTCC: No transit passes provided. Transportation provided for Sunday Night at the ROM.

Airport Hotels UP Express passes provided for each day of stay. Shuttle operates daily between hotels and UP Express Station. Transportation provided for Sunday Night at the ROM.

Walkable

Union Station

Shuttle ve

Metro Toronto Convention Centre

A ville Toronto York Transit Commission Station St

ve er A

Low

Prin

St G

eorg e St

das

Univ

Dun

urne St

Way

g Yon

CT ISTRI NTd D E M se lv RTAIN dhou Roun ark ENTE n P m

n natio Coro ark P

erbo

Jays

ore

er Sh

ding W xpy Blvd e Lan iner E Cano Park Lake Shore Gard

t F or

laid

Ade

Low

Blue

Ave

Ave han

on Garrismon m Co

vd k Bl Yor

is St

e St

16 1

St E

n Fro

W n St

King

Bay

oe S

can

r St

St King

g Yon

Simc

Dun

John

Pete ve ina A Spad

urst Bath

Strac

W id St

Jarv

lvd W

ore B

Lake Sh

Fleet St

’ Blv

t St

Fron

tW nd S

Rich

Ade

gsto

in Well

en S

rch S

for

Que

Ren

S MOSK PAR

er St

Shut

en S

Que

St E

Chu

e ood Osg all H

W ATO

CHIN

das

Dun

y Av

ersit

St W

St E

ndra Alexa rk Pa

The G

ces

Gerr

3 das

AGE

Prin

ard S

Dun

e Que

itob

is St

Cres

view

ling

ve W on A

W n St

L Y VIL IBER Man

ard S

KING WEST VILLAGE

on S

Carlt

t Gerr

y Trinit ods o Bellwark P

ville Gren

ge S

Colle

AIRPORT

E Liberty

Jarv

Park

5 ge S

int

W BELL

ley S

es Well

Colle

Egl

ITY TRIN

rch S

en’s

409

Chu

Que

ve kin A

Hos

S OOD

e St

Bay

l ire P onsh

rove

Join us for Sunday Night at the ROM for a fun evening of networking, W l a s St y le r entertainment, and refreshments. o a R rio Ch Onta um Learn more on page 33. se r St

Bloo

on R

Dix

Car

Dev

e eorg St G

tin G Mar

Hwy

427

24 23

berla

Cum

Ave

g Yon

r St

Bloo

ur Arth

een

ay Qu

urst Bath ay Qu

AAN.com/view/20AM 13

uay

een

MEETING TRANSPORTATION GETTING AROUND TORONTO Public transit will be the primary mode of transportation for attendees to and from the convention center throughout the 2020 Annual Meeting. Torontoâ&#x20AC;&#x2122;s public transportation system provides quick, easy, and environmentally friendly access to the Metro Toronto Convention Centre. The AAN is also pleased to be able to provide attendees a free transit pass or shuttle access when they book within the official AAN Annual Meeting hotel block at a hotel not within walking distance of the convention center. To be eligible for these passes, you must have booked the hotel through the AAN's official housing vendor, CMR.

The AAN will use the following transit options in Toronto: Walking: Many hotels in the official AAN Annual Meeting hotel block are in walking distance (approximately 1 mile) of the Metro Toronto Convention Centre. Walking maps will be available at hotel front desks to assist in getting to the convention center. Toronto Transit Commission (TTC): The Toronto Transit Commission is the public transport agency that operates bus, subway, and streetcar services in Toronto. The AAN will provide complimentary TTC transit passes for each day of your stay if you book in the official hotel block at a downtown hotel that is not in walking distance of the convention center. If you book within one of the hotels receiving a TTC pass, you will receive instructions on how to pick up your pass via email closer to the date of the Annual Meeting. Shuttle and Accessible Van: Shuttle service will be provided for attendees booked within the official AAN hotel block for Hotel X, Airport hotels, and attendees of select events, such as the Sunday Night at the ROM party and Run/Walk for Brain Research. An accessible van will also be available throughout the AAN Annual Meeting with service to and from hotels in the official hotel block and the convention center on an as-needed basis for those who require it.

14 2020 AAN Annual Meeting

FAMILY RESOURCES WHILE ATTENDING THE MEETING The AAN is committed to supporting families at the AAN Annual Meeting. Your family is a priority, and thatâ&#x20AC;&#x2122;s a priority for the AAN.

Childcare:

Choose the childcare option that works best for you while in Toronto. Childcare options in the Toronto area*: Imagine That Family Care: ImagineThatCare.ca Nannies on Call: NanniesOnCall.com *This is not a comprehensive list of childcare agencies in the Toronto area, and these particular agencies have not been reviewed or endorsed by the Academy.

Annual Meeting On-site Facilities: Convenient family resources while you are at the meeting.

Private family room with changing stations, refrigerator for milk storage, private nursing space, books, and live streaming of conference programs.

See page 264 for Annual Meeting Child Attendance Policies.

TRUSTED FOR PATIENTS WORLDWIDE6

GLOBAL PATIENT-YEARS OF EXPERIENCE6 COMBINED CLINICAL TRIAL AND REAL-WORLD EXPERIENCE6

RRMS=relapsing-remitting multiple sclerosis. References: 1. Boster A, Nicholas J, Wu N, et al. Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Neurol Ther. 2017;6(1):91-102. 2. Braune S, Grimm S, van Hövell P, et al. Comparative effectiveness (CE) of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265:2980–2992. 3. Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101-111. 4. Buron MD, Chalmer TA, Sellebjerg F, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study. Neurology. 2019;92(16):e1811-e1820. 5. TECFIDERA Product Monograph, Biogen Canada Inc. November 28, 2019. 6. Patient data as of August 31, 2019. Biogen Canada Inc.

IN THE TREATMENT OF RRMS

CONFIDENCE COMES FROM EXPERIENCE Extensive real-world evidence supports clinical efficacy1-4 Established safety profile5 Twice-a-day oral medication5 Indication and clinical use:

TECFIDERA (dimethyl fumarate) is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of disability. The efficacy of TECFIDERA in patients with primary progressive multiple sclerosis has not been established. TECFIDERA should only be prescribed by clinicians experienced in the diagnosis and management of MS. Clinical studies of TECFIDERA did not include sufficient numbers of patients aged 65 and over to determine whether the safety and efficacy of TECFIDERA may differ in elderly patients compared to younger patients. Physicians who choose to treat geriatric patients should consider that treatment with TECFIDERA in the context of a greater frequency of other concomitant diseases and concomitant drug therapy warrants caution and may necessitate additional or more frequent monitoring. TECFIDERA is not indicated in patients below 18 years of age. Contraindications: • Hypersensitivity to this drug or to any ingredient in the formulation or component of the container Relevant warnings and precautions: • Simultaneous use of other fumaric acid derivatives (topical or systemic) is not recommended • Progressive Multifocal Leukoencephalopathy • Decreased lymphocyte counts • Patients who are immunocompromised due to other treatments or disease • Do not initiate in patients with signs and symptoms of a serious infection; live vaccines are not recommended during treatment; consider hypersensitivity or anaphylactoid reactions in the case of severe flushing symptoms • Herpes zoster infections • Flushing • Gastrointestinal adverse events (nausea, vomiting, diarrhea, abdominal pain, upper abdominal pain, gastroenteritis and dyspepsia) • Risk of elevations in liver transaminases • Renal cautions: risk of proteinuria; caution in patients receiving chronic treatment with medications associated with potential nephrotoxic risk • Use in pregnant women • Use in nursing women • Monitoring and laboratory tests: CBC, urinalysis and liver transaminases For more information: Consult the product monograph at www.biogen.ca/content/dam/corporate/en _CA/pdfs/products/TECFIDERA/TECFIDERA_PM_EN_28Nov2019.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by contacting Biogen Canada Inc. at 1-855-676-6300.

PROGRAM GLOSSARY The Annual Meeting offers seven days of programming for neurologists and neuroscience professionals at every career stage. To help you plan your experience, this book is organized primarily by neurologic topic with other color coding, symbols, and at-a-glance information for quick scanning of items of interest to you.

PROGRAMS All Annual Meeting programs are color-coded throughout the schedule and programming pages of this book to make it easier to spot presentations of interest and types of programs. Given the wide range of opportunities at the Annual Meeting, many programs are also indicated by one of the letter codes below, followed by sequential numbers, to help you spot a specific program quickly.

C = Course: An education program using one or more teaching methods, including didactic, interactive, and case-based. IS = Invited Science Session: An AAN scientific session featuring authors giving encore presentations of top abstracts previously presented at a subspecialty meeting. 2020 Invited Science sessions will feature abstracts previously presented at the Peripheral Nerve Society, the Child Neurology Society, and the International Parkinson and Movement Disorder Society. N = Neuroscience in the Clinic Session: A two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic and end with a panel discussion. P = Poster Session: A series of thematic abstract presentations in digital format presented Saturday through Friday. Standby times with the authors vary by day. S = Scientific Session: A group of abstracts covering a similar topic presented in an oral format. Presentations are 12 minutes in length with eight minutes for presentation and four minutes for questions and answers with the author. = Experiential Learning Area: An interactive way of learning that will engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally. Plenary Session: A premier session highlighting the latest advances in neuroscience presented by some of the most cutting-edge and well-known thought leaders in the field of neurology. Events: A must-see entertainment or social event to complement the meetingâ&#x20AC;&#x2122;s science and education programming.

18 2020 AAN Annual Meeting

SYMBOLS & ICONS Get additional at-a-glance information about an individual program.

CME

= Additional Fee Required

= Abstract of Distinction

= Research

= New Offering in 2020

= Clinical Knowledge

= Technology

= CME Credit

PROGRAM LEVELS Match your knowledge with specific programs. Introductory: Content that may be utilized as a foundation or introduction to more advanced learning; may be geared toward novice or early career attendees; or content that is related to an emerging area of knowledge or practice. Intermediate: Content that builds upon the attendeesâ&#x20AC;&#x2122; foundational knowledge; may focus on integration of skills/experience or recent research; may be geared towards mid-level career attendees; or may serve as an update for attendees who have background in a content area. Advanced: Content that builds upon established experience, knowledge, and skills within a content area; may provide advanced concepts, challenging or complex information; may be geared towards specialists/experts in the field; or content that tends to be more specialized in nature.

AAN.com/view/20AM 19

MEETING-AT-A-GLANCE Sat April 25 Sun April 26 6:00 a.m.

7:00 a.m.

C37-C48

C1-C36 7:00 a.m.– 5:45 p.m.

7:00 a.m.–4:00 p.m. 8:00 a.m.

Education Blitz: 8:00 a.m.–9:00 a.m.

9:00 a.m.

7:00 a.m.– 8:45 a.m.

7:00 a.m.–9:00 a.m. 8:00 a.m.– 9:00 a.m.

Presidential Plenary Session 9:15 a.m.–12:00 p.m.

10:00 a.m.

11:00 a.m.

12:00 p.m.

12:00 p.m.– 1:00 p.m. 1:00 p.m.

C49-C78

11:30 a.m.–4:00 p.m. Exhibit Hall Opening

12:00 p.m.–5:30 p.m.

12:00 p.m.– Luncheon 1:00 p.m. 11:30 a.m.–1:00 p.m.

S1-S12

1:00 p.m.–3:00 p.m.

1:00 p.m.–5:30 p.m.

2:00 p.m.

AAN Business Meeting

3:00 p.m.

3:00 p.m.–4:00 p.m. 4:00 p.m.

Hot Topics Plenary Session

5:00 p.m.

IS1 Invited Science Session

3:30 p.m.–5:30 p.m.

4:15 p.m.-–5:30 p.m.

Inspiration and Innovation Talks 1

6:00 p.m.

5:30 p.m.– 6:30 p.m.

5:45 p.m.–7:30 p.m. Featuring David Eagleman, PhD Followed by Opening Reception

7:00 p.m.

Industry Therapeutic Updates

8:00 p.m.

7:00 p.m.–10:00 p.m. 9:00 p.m.

10:00 p.m.

20 2020 AAN Annual Meeting

Sunday Night at the ROM 7:00 p.m.–10:00 p.m.

11:00 a.m.–5:45 p.m.

Exhibit Hall

N = Neuroscience in the Clinic Session

C = Course

S = Scientific Session

IS = Invited Science Session

Mon April 27

P = Poster Session = Experiential Learning Area

Tue April 28 6:00 a.m.

5K Run/1K Walk for Brain Research C124-C137

C79-C92 7:00 a.m.–9:00 a.m.

Education Blitz: 8:00 a.m.–9:00 a.m.

7:00 a.m.– 8:45 a.m.

6:30 a.m.–8:30 a.m.

7:00 a.m.–9:00 a.m.

Education Blitz: 8:00 a.m.–9:00 a.m.

8:00 a.m.– 9:00 a.m.

Contemporary Clinical Issues Plenary Session

7:00 a.m. 7:00 a.m.– 8:45 a.m.

8:00 a.m.

8:00 a.m.– 9:00 a.m. 9:00 a.m.

Clinical Trials Plenary Session

10:00 a.m.

9:15 a.m.–11:30 a.m.

9:15 a.m.-11:30 a.m. 11:00 a.m.

S13-S24

C94-C123

1:00 p.m.– 3:00 p.m.

1:00 p.m.– 5:30 p.m.

C138-C168 IS3 1:00 p.m.– 5:30 p.m.

S25-S35

Invited Science Session

1:00 p.m.– 5:30 p.m.

1:00 p.m.– 3:00 p.m.

IS2

Invited Science Session

3:30 p.m.– 5:30 p.m.

3:30 p.m.–5:30 p.m.

P9 12:00 p.m.– 1:00 p.m.

11:30 a.m–5:45 p.m.

12:00 p.m.– 1:00 p.m.

11:30 a.m.–4:00 p.m.

Exhibit Hall Networking Reception 4:00 p.m.-6:00 p.m.

Exhibit Hall

11:00 a.m.–12:00 p.m.

11:30 a.m.-4:00 p.m.

11:00 a.m.–6:00 p.m.

C93

Exhibit Hall

12:00 p.m.

1:00 p.m.

2:00 p.m.

3:00 p.m.

4:00 p.m.

5:00 p.m.

P10

5:30 p.m.– 6:30 p.m.

Industry Therapeutic Updates 7:00 p.m.-–10:00 p.m.

Trainee and Faculty Networking Reception 6:00 p.m.–8:00 p.m.

6:00 p.m.

Industry Therapeutic Updates

7:00 p.m.

7:00 p.m.-–10:00 p.m.

8:00 p.m.

9:00 p.m.

10:00 p.m.

AAN.com/view/20AM 21

MEETING-AT-A-GLANCE Wed April 29 6:00 a.m.

7:00 a.m.

C169-C182 7:00 a.m.– 8:45 a.m.

7:00 a.m.–9:00 a.m. 8:00 a.m.

Education Blitz: 8:00 a.m.–9:00 a.m.

P11 8:00 a.m.– 9:00 a.m.

9:00 a.m.

Frontiers in Neuroscience Plenary Session

10:00 a.m.

9:15 a.m.–11:30.m. 11:00 a.m.

12:00 p.m.

P12

11:30 a.m.–4:00 p.m.

1:00 p.m.

2:00 p.m.

12:00 p.m.– 1:00 p.m.

S36-S46

C183-C213

1:00 p.m.– 5:30 p.m.

3:00 p.m.

N4 3:30 p.m.-5:30 p.m.

4:00 p.m.

5:00 p.m.

P13 6:00 p.m.

5:30 p.m.– 6:30 p.m.

Commitment to Cures 6:00 p.m.-10:00 p.m.

7:00 p.m.

Industry Therapeutic Updates

8:00 p.m.

7:00 p.m.-–10:00 p.m.

9:00 p.m.

10:00 p.m.

22 2020 AAN Annual Meeting

11:30 a.m.–5:45 p.m.

Exhibit Hall

N = Neuroscience in the Clinic Session

C = Course

S = Scientific Session

IS = Invited Science Session

Thurs April 30

P = Poster Session = Experiential Learning Area

Fri May 1

C214-C224

FRIDAY GRAND FINALE

7:00 a.m.

C258-C267 7:00 a.m.– 8:45 a.m.

7:00 a.m.–9:00 a.m.

P14

Education Blitz: 8:00 a.m.–9:00 a.m.

7:00 a.m.– 8:45 a.m.

7:00 a.m.–9:00 a.m.

8:00 a.m.

Education Blitz: 8:00 a.m.–9:00 a.m.

8:00 a.m.– 9:00 a.m.

Controversies in Neurology Plenary Session

Neurology Year in Review Plenary Session

9:15 a.m.–11:30 a.m.

6:00 a.m.

9:00 a.m.

10:00 a.m.

11:00 a.m.

P17 P15

1:00 p.m.–2:00 p.m.

Featuring Maria Konnikova, PhD

C225-C252

S47-S57

11:30 a.m.–1:00 p.m.

C268-C271

S58-S61

1:00 p.m.–3:00 p.m.

1:00 p.m.–5:30 p.m. 1:00 p.m.–5:30 p.m. 1:00 p.m.–6:00 p.m.

12:00 p.m.–3:45 p.m.

Inspiration and Innovation Talks 2

12:00 p.m.

Innovation Lunch 12:00 p.m.–5:45 p.m.

12:00 p.m.– 1:00 p.m.

1:00 p.m.

2:00 p.m.

3:00 p.m.

C272-C275 Neurology Update 5-8 'Encore' Update Programs

3:30 p.m.–4:30 p.m.

NeuroZone

4:00 p.m.

4:00 p.m.–5:00 p.m.

Closing Party P16 5:30 p.m.– 6:30 p.m.

5:00 p.m.

5:00 p.m.–7:00 p.m. 6:00 p.m.

C253-C257 6:30 p.m.–9:30 p.m.

7:00 p.m.

8:00 p.m.

9:00 p.m.

10:00 p.m.

AAN.com/view/20AM 23

Your daily connection to

neuroscience

Biogen 3/4 Ad

A website for independent and scientifically validated content. NEWS Daily abstracts of selected publications in neuroscience Articles written by leading neurologist contributors

TALKS Expert Talks and scientific presentations by national and international clinicians and scientists

CONFERENCES Highlights of key conferences in neurology

www.neurodiem.com

*The medical information presented on Neurodiem will in no way be selected, modified, or altered by Biogen. ÂŠ2020 Biogen. All rights reserved. NEURODIEM is a trademark of Biogen. Neurodiem is a service from Biogen. Biogen-38145 02/20

INSPIRATION AND INNOVATION TALKS EXPLORING SUBJECTS WHERE NEUROSCIENCE INTERSECTS WITH GLOBAL THEMES OPENING RECEPTION Free food and beverages will be available immediately following the talk. Saturday, April 25, 2020, at 5:45 p.m. Located on Level 800 Hall FG

DAVID EAGLEMAN, PhD David Eagleman is a neuroscientist, New York Times bestselling author, TED speaker, and Guggenheim Fellow. He is the writer and presenter of the Emmy-nominated series The Brain with David Eagleman on PBS, and The Creative Brain on Netflix. He teaches at Stanford University, serves as CEO of the neurotech company Neosensory, and directs the Center for Science and Law. He is the author of eight booksâ&#x20AC;&#x201C;most recently of Livewired, a book on brain plasticity which hits the shelves in August of 2020. He also currently serves on the American Brain Foundation Board of Directors.

Can we create new senses for humans? What would it be like if we could expand our senses beyond the capacities that we come to the table with? To this end, we use sensory substitution to feed sensory signals into the nervous system through atypical sensory pathways. In one example, we turn sound into a series of vibrating patterns on the skin, such that a person can come to pick up the auditory world through somatosensation. This is done via Buzz, a small wristband with vibratory motors in the band. In a series of examples, Eagleman will demonstrate uses for Buzz with information streams such as infrared light to olfactory information to the stock market. Using this approach, we can translate and feed in almost any kind of data, thereby expanding the human sensory experience.

New in 2020

WIN PRIZES!

THE GREAT

NEURO RACE

PHYSICAL ACTIVITIES AND WELLNESS

ARE YOU READY FOR A FUN-FILLED CHALLENGE? The Great Neuro Race is a half-day event on Thursday, April 30, 2020, from 11:30 a.m. to 2:30 p.m. of the AAN Annual Meeting that takes you through the streets of Toronto with mental and physical challenges as your team uses clues to figure out the next step in the game. Updates from the race will be shown on the overflow viewing wall at the convention center so you can cheer for participants as they compete. Join us at 4:00 p.m. on the HeadTalks stage as we announce the winners of the first ever Great Neuro Race! Film/TV: This challenge is for anyone who loves movies. Lots of movies have been filmed in Toronto and movie-lovers are bound to have a leg up in this challenge. Arts/Museums: Interested in the arts? This is a mental challenge to use the given clues to find the right spot to move ahead in this category. Food: Any foodies around? This category is geared towards food-lovers and may include trying unique foods from around the city of Toronto. Extreme Sports: This category is intense and physical. This is for the competitive, sporty individual who isnâ&#x20AC;&#x2122;t afraid of a difficult challenge. Interested in joining in the fun? Email Brooke Martin at bmartin@aan.com to sign up.

SATURDAY, APRIL 25 7:00 a.m.-7:45 a.m. Yoga—Vinyasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

7:00 a.m.-9:00 a.m. C1 C2 C3 C4 C5 C6 C7 C8

Neurocognitive Assessment for Neurologists Update on Medical Management of Stroke Child Neurology: Neuromuscular/Autoimmune Neurology Video EEG: Name That Spell Neuroendocrine Update: Nuts and Bolts of What You Need to Know Good Neurology in Challenging Conditions: Lessons from Military Neurology Neuroimaging for the General Neurologist: Spine Nystagmus and Saccadic Intrusions Made Simple

SCHEDULE

7:00 a.m.-12:30 p.m. C9

Clerkship and Program Directors Conference

7:00 a.m.-4:00 p.m. C10 C11

Neurology Continuing Certification Prep Course Women in Leadership: Empower or Imposter: Leveraging Your Strengths as a Leader in Neurology

8:00 a.m.-8:30 a.m. C276

Program Coordinator’s Role and Opportunities

9:30 a.m.-10:00 a.m. C278

9:30 a.m.-11:30 a.m. C13 C14 C15 C16 C17 C18 C19 C20 C21 C22

C279

10:00 a.m.-11:00 a.m. Implementing a Flipped Classroom Model to Enhance Student Education in Neurology. . . . . . . . . . 221

8:30 a.m.-9:30 a.m.

10:30 a.m.-11:00 a.m.

C277

C280

Surf’s Up: Riding the Wave to Onboarding and Offboarding

9:00 a.m.-9:45 a.m. Saturday, April 25

Saving Time and Seeing the Bigger Picture with Your Data

Expert Witness and Medical-legal Neurology 101: What Is It and Is It for You?. . . . . . . . . . . . . . . . . . . . . . 231 How Your Social Life Might Be Helping (Or Harming) Your Brain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

8:00 a.m.-9:00 a.m. Vital Roles of the Clerkship Coordinator/ Administrator. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221

Actualización en desordenes cognitivos y epilepsia (Update in Cognitive Disorders and Epilepsy)

10:00 a.m.-10:45 a.m.

Dancing with Parkinson’s . . . . . . . . . . . . . . . . . . . . . . . 229

Education Blitz: Evolution of Autoimmune Neurology

Behavioral Neurology 1: Network Anatomy of Behavior and Language Hot Topics in Headaches and Related Disorders 1: Unusual Headaches, Childhood Headaches, and Concussion Management Severe TBI: From ICU to Rehabilitation Addiction Tourette Syndrome: Assessment and Management Clinical EMG 1: Principles and Practice of NCS and Needle EMG Neurogenetics: Diagnostic Dilemmas and Therapeutic Implications Acute and Chronic Clinical Epilepsy Update Explained in Six Cases Approaching the Management of Common Sleep Disorders

10:00 a.m.-10:30 a.m.

8:00 a.m.-8:45 a.m.

C12

Administrative Overview for the Academic Administrator

11:00 a.m.-11:45 a.m. Parenting While Doctoring . . . . . . . . . . . . . . . . . . . 229

Mindfulness Based Stress Reduction (MBSR). . . . . . . 229 What Should Applicants Look for in a Program?. . . . . 231

9:00 a.m.-10:00 a.m. Clerkship Administrators Part 1: Understanding the Liaison Committee on Medical Education (LCME) Standards for Accreditation. . . . . . . . . . . . . . . . . . . . . 221 28 2020 AAN Annual Meeting

Foundations of Resident Orientation Planning

11:00 a.m.-12:00 p.m. C281

Resident Education and Clinical Training Model: “4 + 2 System” Identifying and Eliminating Barriers/Challenges for Medical Students Choosing the Field of Neurology as a Specialty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area

12:00 p.m.-12:30 p.m. Welcome to the Annual Meeting (Navigating the App). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

12:00 p.m.-12:45 p.m. The Ripple Effect of Positive Psychology. . . . . . . . . . . 229

C35

1:30 p.m.-4:00 p.m. C36

Build a Better Foundation: Making Smart Decisions Early for a Better Career. . . . . . . . . . . . . . . . . . . . . . . . 231

Poster Session 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118

Peer Review of Scientific Articles – Tips on How to Respond to the Dreaded Reviewer #2. . . . . . . . . . . . . 236

12:00 p.m.-3:00 p.m. C23

Your First Job: Private Practice vs. Academic Practice: Pros and Cons. . . . . . . . . . . . . . . . . . . . . . . . . 221

Leadership Challenges in Practice

Learning Healthcare Systems (LHS): An Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

12:00 p.m.-4:00 p.m. Skills Workshop: Neurostimulation

C25

Resident Basic Science 1: Neuropharmacology Futures in Neurological Research Boot Camp

1:00 p.m.-1:45 p.m. #ilooklikeaneuroonc. . . . . . . . . . . . . . . . . . . . . . . . . 231 So Your Paper Didn’t Get Accepted, Now What?. . . . 236

1:00 p.m.-2:00 p.m. C283

Preparing for Resident Recruitment

1:00 p.m.-4:00 p.m. C282

Clerkship Administrators Part 2: Understanding Leadership Qualities

1:30 p.m.-2:15 p.m. Is There a Neurologist on the Flight?. . . . . . . . . . . . . . 225

2:00 p.m.-3:00 p.m. C284

Using Milestones and Clinical Competency Committee Results for Program Improvement

2:30 p.m.-3:15 p.m. Reflections from Women in Medicine: The Other Side of Doctoring. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

3:00 p.m.-3:45 p.m. Case Studies in Neuropalliative Care: How My Patients Impacted My Career Choice. . . . . . . . . . . . . . 231 Eleven Things Not to Say to Your Female Colleagues. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Tips for Better Sleep: More Reasons to Love Bedtime . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

SCHEDULE

C24

Educators’ Leadership Program

2:00 p.m.-2:45 p.m.

12:00 p.m.-1:00 p.m. P1

Clinical EMG 2: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography

Philanthropy for Education. . . . . . . . . . . . . . . . . . . . 221 From Disease Detectives to Disease Preventers: Neurology and Neuroscience Opportunities at CDC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

1:30 p.m.-3:30 p.m. C26 C27

C31 C32 C33 C34

AAN.com/view/20AM 29

Saturday, April 25

C28 C29 C30

3:00 p.m.-4:00 p.m. Case Studies: Challenging Acute Ischemic Stroke Cases C285 Myelopathies: Recognizing and Evaluating Myelopathic Surveys, Surveys, Surveys! How to prepare for the Patients for Inflammatory and Vascular Causes ACGME Survey, and what to do with the results Child Neurology: Metabolic AAN Business Meeting Critical Care Consultations for Neurohospitalists 3:30 p.m.-4:15 p.m. Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome Movement Disorders Case Studies: Diagnostic and Behavioral Neurology 2: Memory and Attention Therapeutic Challenges. . . . . . . . . . . . . . . . . . . . . . . . . 225 Hot Topics in Headaches and Related Disorders 2: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances 4:00 p.m.-4:45 p.m. Disparities in Care The Daily Coding Struggle: How to Make It Update in Movement Disorders Work. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

SATURDAY, APRIL 25 4:15 p.m.-5:30 p.m. Hot Topics Plenary Session. . . . . . . . . . . . . . . . . . . .62

5:00 p.m.-5:45 p.m. The How and Why of eConsults in Neurology. . . . 234

5:45 p.m.-7:30 p.m. Inspiration and Innovation Talk Featuring David Eagleman, PhD, and followed by Opening Reception. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

7:00 p.m.-10:00 p.m. Industry Therapeutic Updates. . . . . . . . . . . . . . . . 268

Currículo en

PROGRAMACIÓN Y OPORTUNIDADES DE NETWORKING PARA PARTICIPANTES EN LA REUNIÓN ANUAL DE LA AAN QUE HABLAN ESPAÑOL

PROGRAMAS EDUCATIVOS: • Epilepsia • Actualizaciones científicas (dos sesiones) • Cuidados críticos • Estudios de cohortes de pacientes latinoamericanos • Esclerosis múltiple y neuromielitis óptica • Trastornos del movimiento CHARLAS EN LAS ZONAS DE APRENDIZAJE VIVENCIAL (EXPERIENTIAL LEARNING AREAS) • Cómo obtener una residencia o fellowship en Estados Unidos • Cómo involucrarse en las actividades de la AAN, incluyendo participación en secciones, publicaciones en revistas y presentaciones en la reunión anual • Consejos y trucos para el examen neurológico ALMUERZO CON COLEGAS: Reúnase a comer con colegas de Latinoamérica, España, y Estados Unidos para charlar sobre temas de interés común durante el almuerzo el domingo, lunes, y martes. Visite AAN.com/view/20AM para todas las ofertas de la programación en español.

SUNDAY, APRIL 26 7:00 a.m.-7:45 a.m.

9:15 a.m.-12:00 p.m. Presidential Plenary Session. . . . . . . . . . . . . . . . . . 63

Yoga—Vinyasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Making the Most of Fellowship—Setting Yourself Up for Success and Finding Your First Job. . . . . . . . . . 231 Much More Than Traumatic Brain Injury: Identifying Funding Opportunities from the Department of Defense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

11:00 a.m.-12:00 p.m. C288

Identifying Areas of Burnout of Clerkship Coordinators and Improving Wellness. . . . . . . . . . . . . 221

7:00 a.m.-9:00 a.m. C37 C38 C39 C40 C41

C44 C45 C46 C47

Endovascular Management of Ischemic and Hemorrhagic Stroke Maximizing Quality of Life in Stroke, ALS, Parkinson’s Disease, and Dementia: A Palliative Approach Neuro-ophthalmology 1: Visual Loss, Optic Neuropathies, and Papilledema Neuroimaging Biomarkers Across the Dementia Spectrum Clinical EEG: Normal EEG, Normal Variants, and How to Avoid the Common Pitfall of Overreading Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-making Clinical EMG 3: Practical Applications of EMG in Neuromuscular Disease United We Stand: Enhancing Your Practice with APPs Contemporary Concerns About Brain Death Determination

8:00 a.m.-8:30 a.m. Meditation: Awareness of Breath. . . . . . . . . . . . . . 229

8:00 a.m.-8:45 a.m. Are You My Mentor? How to Select a Good Mentor for Your Research Career. . . . . . . . . . . . . . . . . . . . . . . 236 Neurology: We Want YOU!. . . . . . . . . . . . . . . . . . . 221 Great Expectations: How to Utilize Strength Coaching to Expect the Best for Your Future. . . . . . . . 231 Talks for Trainees: Why Should I Care About Coding?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

8:00 a.m.-9:00 a.m.

11:30 a.m.-1:00 p.m. Exhibit Hall Opening Luncheon

11:30 a.m.-4:00 p.m. Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

12:00 p.m.-12:45 p.m. Combating the Scientific Irreproducibility Crisis: Using Principles of Reproducible Scientific Design to Critically Evaluate Scientific Papers for Best-informed Patient Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

12:00 p.m.-1:00 p.m. P3

Poster Session 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130

12:00 p.m.-4:00 p.m. C49

Chief Resident Leadership Program

12:15 p.m.-1:15 p.m. Who Wants to Be a Millionaire?. . . . . . . . . . . . . . . . . . 225

12:30 p.m.-1:00 p.m. Non-epileptic Seizures—A Multidisciplinary Clinic Model, What Would Freud Say?. . . . . . . . . . . . . . . . . . 227

12:30 p.m.-5:30 p.m. Medical Student Symposium: Careers in Neurology

1:00 p.m.-1:30 p.m. You Died of Dysentery: Gaming in Education. . . . . 227

1:00 p.m.-1:45 p.m. Clinical Genetic Testing for Parkinson’s: Are We There Yet?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

AAN.com/view/20AM 31

Sunday, April 26

C48 Education Blitz: Child Neurology: Concussion C286 Program Outcomes and the Next Accreditation System: The Self-Study, Site Visit and the A to Z’s of Program Coordination – An Opportunity, Not a Burden C287 Clerkship Coordinator Speed Mentoring Poster Session 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124 P2

Beyond the Bedside: The Business of Epilepsy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261

SCHEDULE

C42 C43

Access in Academic Neurology: Strategies to Improve Access and Improve Ambulatory Clinic Workflow Rehabilitation in Neurology

ACGME Web ADS: The Overview and Implementation in Accredited Programs

SUNDAY, APRIL 26 So You’ve Been Sued/Named in a Medical Malpractice – Now What?. . . . . . . . . . . . . . . . . . . . . . 231 The Prevention of Stroke: No Pill’s Gonna Cure This Ill. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Gratitude and Other “Soft” Skills That Help You Thrive as a Leader. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Quality Improvement Innovation Awards. . . . . . . . . . . 234

1:00 p.m.-3:00 p.m. C50 C51 C52 C53

SCHEDULE

C54 C55 C56 C57 C58 C59 C60 C61 N1 S1 S2 S3 S4 S5

Sunday, April 26

Creating a Roadmap for a Diverse Workforce in Academic Neurology Child Neurology: A Case-based Approach Controversies in Stroke Treatment and Prevention Neuro-ophthalmology 2: Optic Neuritis, Visual Fields, and Anisocoria Clinical EEG: Focal, Diffuse, and Epileptiform Abnormalities in Adults Neuro-rheumatology: Neurologic Manifestations of Systemic Inflammatory and Autoimmune Disease 1 Nonmotor Manifestations of Parkinson’s Disease 1 Neuromuscular Junction Disorders 1: Myasthenia Gravis, Ocular, and MuSK Myasthenia Recent History: The Development of Neurologic Subspecialties 1 Coding 101: E&M, Basic Procedures, Non-face-to-face, and New Codes Functional Neurologic Disorders 1: Truth, Myth, and Misunderstanding Neurology Update 1: Movement Disorders, Behavioral Neurology, and Neuromuscular Diseases Neuroscience in the Clinic: Novel Approaches to Pain Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Headache I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Infectious Disease: Neurovirology and Bacterial Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Sleep Medicine: Highlights 2020. . . . . . . . . . . . . . . . . . 82 Aging and Dementia: Risk Factors and Genetics. . . . . . 82 Multiple Sclerosis: Clinical Trials and Disease-modifying Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Neuromuscular and Clinical Neurophysiology (EMG): Genetic Muscle Disorders. . . . . . . . . . . . . . . . . . . . . . . . 84

1:00 p.m.-5:00 p.m. Consortium of Neurology Program Directors Business Meeting

1:00 p.m.-5:30 p.m. C62 C63

Skills Workshop: Brain Death: How to Perform a Brain Death Evaluation, Avoid Pitfalls, and Convey the News to the Family Resident Basic Science 2: Neuroanatomy: All the Lesions

32 2020 AAN Annual Meeting

1:30 p.m.-2:00 p.m. The Future Is Now: Bringing Accessibility, Availability, Affordability, Appropriateness, and Acceptability with Telehealth and Digital Medicine in Neurology. . . . . . . 227

1:30 p.m.-2:15 p.m. The Teenage Brain: A Neuroscientist’s Survival Guide to Raising Adolescents and Young Adults. . . . . . . . . . 225

2:00 p.m.-2:30 p.m. Rotten Eggs: A Dozen Things to Be Wary of When Considering Treatments or Trials on the Internet . . . . 227

2:00 p.m.-2:45 p.m. Enhancing Personal and Professional Well-being Through Appreciative Inquiry. . . . . . . . . . . . . . . . . . . . 229 Still Kicking and Crazy After All These Years: How to Remain Relevant and Engaged in Mid- to Late-career. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 How to Write and Publish Neurology Research. . . 236 What Is Value?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

2:30 p.m.-3:00 p.m. Live Tweeting: Don’t Just Join the Conversation, Influence It! . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

2:30 p.m.-3:15 p.m. Neuro-oncology Around the World – Global Perspective on Brain Cancer Patient Care. . . . . . . . . . 225

3:00 p.m.-3:30 p.m. Medical Improv: Comedy as a Tool for Improving Patient Interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

3:00 p.m.-3:45 p.m. From All Different Practice Settings: How to Navigate Discussions with Your Department Leadership. . . . . . 231 Different Pathways to Becoming a Department Chair. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Practical Wellness Tips for the Busy Neurologist. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Conflict Management: An Essential Leadership Competency. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223

3:10 p.m.-3:20 p.m. BusinessBytes: Decoding Coding. . . . . . . . . . . . . . 234

Sunday Night at the ROM Get Ready to Party!

Sunday, April 26, 2020 7:00 p.m.–10:00 p.m. Take your AAN Annual Meeting experience up a notch with a party at the Royal Ontario Museum (ROM): • Visit galleries showcasing a world-class collection of art, culture, and nature • Enjoy amazing food and beverage stations throughout the museum • Listen to entertainment while networking with colleagues The first 4,000 registered Annual Meeting attendees get a free ticket. Additional tickets can be purchased for $115. Secure your ticket: AAN.com/view/20AM With the permission of the Royal Ontario Museum, © ROM

SUNDAY, APRIL 26 3:30 p.m.-4:00 p.m.

4:00 p.m.-4:45 p.m.

From Research to Clinic: Implementing Brain Perfusion Quantification in an Outpatient Center . . . . . . . . . . . . 227

Mindfulness-based Chronic Pain Management. . . 229 Blind Spots: The Impact of Conscious and Unconscious Biases. . . . . . . . . . . . . . . . . . . . . . . . . . . . 223

3:30 p.m.-4:15 p.m. S7

A Career in General Neurology: Knowing Everything About Everything!. . . . . . . . . . . . . . . . . . . . 231

Global Health. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

The Neurologist’s Guide to the ABCs of Drug Pricing in the US. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

3:30 p.m.-5:30 p.m. C64 C65 C66

SCHEDULE

C67 C68 C69 C70 C71 C72 C73 C74 C75 C76 C77 C78 IS1 S8 S9 S10

Sunday, April 26

S11 S12

Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room Neuro-ophthalmology 3: Diplopia, Ocular Motility Disorders, and Nystagmus Frontotemporal Dementias Clinical EEG: Neonatal and Pediatric Neuro-rheumatology: Neurologic Manifestations of Systemic Inflammatory and Autoimmune Disease 2 Nonmotor Manifestations of Parkinson’s Disease 2 Neuromuscular Junction Disorders 2: Toxins, LambertEaton Syndrome, and Less Common Disorders of Neuromuscular Transmission Recent History: The Development of Neurologic Subspecialties 2 Burnout and Resilience: Strategies and Evidence for Enhancing Well-being Functional Neurologic Disorders 2: Neurobiology and Management of Functional Disorders Cognitive Behavioral Sleep Medicine: A Primer to a Discipline Neurology Update 2: Multiple Sclerosis, Neuro-oncology, and Headache Actualización científica 1 (Scientific Update 1)

4:30 p.m.-5:15 p.m. Standing on the Shoulders of Giants. . . . . . . . . . . . . . 225

5:00 p.m.-5:45 p.m. Self Promotion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Success in Residency? Let’s Talk About It. . . . . . . . . . 231 Zumba. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 What Can I Do to Help Lower Drug Prices for My Patients?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

5:00 p.m.-7:00 p.m. Consortium of Neurology Education Coordinators Business Meeting

5:30 p.m.-6:30 p.m. P4

Poster Session 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136

7:00 p.m.-10:00 p.m. Sunday Night at the ROM. . . . . . . . . . . . . . . . . . . . . . 33

Accelerating Equity, Diversity, and Inclusion for Women in Medicine Invited Science: Child Neurology. . . . . . . . . . . . . . . .76 Migraine Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . 85 Cerebrovascular Disease: Intracerebral Hemorrhage. . 85 Multiple Sclerosis: Biomarkers and Outcome Measures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 Huntington’s Disease, Tardive Dyskinesia, and Functional Movement Disorders. . . . . . . . . . . . . . . . . . . 86 General Neurology: Neurotherapeutics and Clinical Trials. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

34 2020 AAN Annual Meeting

Have a great idea for a course at the 2021 Annual Meeting? Submit your course proposal for consideration by May 21, 2020, at AAN.com/view/20AM

MONDAY, APRIL 27 7:00 a.m.-7:45 a.m.

8:00 a.m.-8:45 p.m. Talks for Trainees: Personal Finances for Residents and Fellows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

Yoga—Vinyasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Ask Me Anything About Choosing a Career in Teleneurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 Core Curriculum for a Required Neurology Experience. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Social Networking Sites for Researchers and Using Social Media Platforms. . . . . . . . . . . . . . . . . . . . 236

7:00 a.m.-9:00 a.m. C79 C80 C81

C85 C86 C87 C88 C89 C90 C91

Epidemiology and Neurology: The Importance of Data for Disease Prevention and Control Neurologic Case Studies in Pregnancy Residents in Private Practice Peripheral Neuropathy 1: Anatomical Basis and Acquired Demyelinating Neuropathies Life After Stroke Service Line Models: Successes and Challenges Clinicopathological Correlation Session in Dementia Skills Workshop: Practical Training in Injection Techniques in the Treatment of Headache Disorders

Contemporary Clinical Issues Plenary Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64

11:00 a.m.-12:00 p.m. C93

Complex Scheduling in an Academic Neurology Department

C290

It’s a Professional Career! Program Administrator Education and Title Reclassification Creating a Handbook for Clerkship Administrators and Beyond….. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Beyond the Beside: The Business of Multiple Sclerosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261

11:30 a.m.-12:00 p.m. The Nerve: A Talk Show for our Neurology Community About What Makes Us Nervous and What Gets on Our Nerves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

11:30 a.m.-6:00 p.m Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

12:00 p.m.-12:30 p.m. Delivering Personalized Care to Patients at Risk for Alzheimer’s Dementia. . . . . . . . . . . . . . . . . . . . . . . . . . 227

12:00 p.m.-12:45 p.m. TRANSCENDS (Training in Research for Academic Neurologists to Sustain Careers and Enhance the Numbers of Diverse Scholars) Program Overview . . . 236

8:00 a.m.-8:45 a.m. The Mentor-Mentee Relationship: What Works and What Doesn’t? . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 Mistakes, Mentoring, and Miracles: Transitioning from a Career Development Award to Independence. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236 How to Create a Department That Promotes Wellness. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Neurological Disease Prevention with Food . . . . . 229

8:00 a.m.-9:00 a.m.

Different Practice Models for Success. . . . . . . . . . 234

12:00 p.m.-1:00 p.m. Neuro-Jeopardy: Telencephalon Twisters. . . . . . . . . . 225

Poster Session 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147

12:30 p.m.-1:00 p.m. Incorporating a Pharmacist into your Neurology Practice for Free–Results of a Pilot . . . . . . . . . . . . . . . 227

1:00 p.m.-1:30 p.m. An Overwatch of Video Games in Neurology: Peak Performance Is Less Than a Fortnite Away. . . . . . . . . 227

AAN.com/view/20AM 35

Monday, April 27

C92 Education Blitz: Insomnia C289 Program Evaluation Committee (PEC) Review and Best Practices C291 Clerkship Coordinator Speed Mentoring Poster Session 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141 P5

SCHEDULE

C82 C83 C84

Neuro-rehabilitation Update Child Neurology: Genetic and Metabolic Testing in Pediatric Epilepsy Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia Critical Care EEG Monitoring Parkinson’s Disease Update

9:15 a.m.-11:30 a.m.

MONDAY, APRIL 27 1:00 p.m.-1:45 p.m. How to Get from Diversity to Inclusion: The Difference of Being Invited to a Dance vs. Being Asked to Dance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Pursuing a Career in Movement Disorders . . . . . . . . . 231 Are You Including Underrepresented Populations in Your Clinical Research?. . . . . . . . . . . . . . . . . . . . . . . . . 236 Fireside Chat: Burnout–What Do You Want to Know?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 ICD-11: Global Impact on the Future of Neurology for the Next Generation. . . . . . . . . . . . . . . . . . . . . . . . . 234 Navigating the Political Terrain: The Art of Avoiding Organizational Potholes. . . . . . . . . . . . . . . . . . . . . . . . . 221

1:00 p.m.-3:00 p.m.

SCHEDULE

C94 C95 C96 C97 C98 C99 C100 C101 C102

Monday, April 27

C103 C104 C105

Starting a Practice From the Ground Up: A Guide for Neurologists Sleep-Disordered Breathing in Neurology Populations: From Lab to Clinic Neurologic Intensive Care 1: The Essentials Core Concepts in Pain Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids Chronic Traumatic Encephalopathy: Update Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management Treatment of Pediatric Multiple Sclerosis in the Current Era The Dystonias: Diagnosis, Treatment and Update on Etiologies Peripheral Neuropathy 2: Approach to Sensory Neuropathies and Neuropathies Associated with Rheumatologic and Hematologic Disorders Clinical Neurology for Advanced Practice Providers Neurology Update 3: Stroke, Epilepsy, and Sleep Faculty Development: Enhancing Your Role in Student and Resident Training

C106 Source of Truth Actualización en trastornos del movimiento (Update in C107 Movement Disorders) C108 Leadership in the Era of Burnout: A Practical Approach to Becoming a True Physician Leader N2 Neuroscience in the Clinic: Multimodal Tools for Cardiac Arrest Neuroprognostication. . . . . . . . . . . . . . . 71 S13 Epilepsy/Clinical Neurophysiology (EEG) 1. . . . . . . . . . . 88 S14 Neuro-oncology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 S15 Behavioral and Cognitive Neurology . . . . . . . . . . . . . . . 89 S16 Autoimmune Neurological Disorders: Diagnosis, Biomarkers, and Epidemiology. . . . . . . . . . . . . . . . . . . . 89 S17 Parkinson’s Disease Biomarkers and Pathophysiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 36 2020 AAN Annual Meeting

S18

Neuromuscular and Clinical Neurophysiology (EMG): Neuroimaging, Outcome Measures, and Biomarkers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91

1:00 p.m.-5:30 p.m. C109 Skills Workshop: Neuromuscular Ultrasound C110 Resident Basic Science 3: Neuropathology AAN Health Care Equity Symposium. . . . . . . . 38

1:30 p.m.-2:00 p.m. Development of Speech-based, Digital Biomarkers for Neuropsychiatric Disease. . . . . . . . . . . . . . . . . . . . 227

1:30 p.m.-2:15 p.m. Neuro HeadTalk: Story Slams. . . . . . . . . . . . . . . . . 225

2:00 p.m.-2:30 p.m. Author Your Own Future: Self-publishing in Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

2:00 p.m.-2:45 p.m. Grantwriting 101: Getting Started . . . . . . . . . . . . . . . . 236 Emotional Intelligence and Leadership. . . . . . . . . . 223 Clinical Practice Through the Life Cycle. . . . . . . . . . . . 231 Understanding Essential Oils, Nature’s Relief. . . . 229 The Economics of APPs. . . . . . . . . . . . . . . . . . . . . . 234 Cómo participar en la Resident & Fellow Section de Neurology® (How to Get Involved in the Resident & Fellow Section of Neurology®) . . . . . . . . . . . . . . . . . . 221

2:00 p.m.-3:00 p.m. ABPN Continuing Certification Information Session

2:30 p.m.-3:00 p.m. Twitter for Neurologists: Basics and Beyond. . . . . . . . 227

2:30 p.m.-3:15 p.m. The Benefits and Barriers in Practicing Neurology in Canada vs. the US. . . . . . . . . . . . . . . . . . . . . . . . . . . 225

3:00 p.m.-3:30 p.m. Medical Improv: Comedy as a Tool for Improving Patient Interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

3:00 p.m.-3:45 p.m. The Sleep Mythbuster!: Illuminating the Facts and Fiction Toward Achieving the Sleep-healthy Neurologist. . . . 229

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area

Interviewing Skills for Students and Residents—How to Get into the Program You Want. . . . . . . . . . . . . . . . 231 Academic Neurology: What Is the AAN Doing to Help Academic Neurology?. . . . . . . . . . . . . . . . . . . . . . 221 Top Strengths and Shadow Sides in Neurology. . . 223

3:10 p.m.-3:20 p.m.

S21 S22 S23 S24

4:00 p.m.-4:45 p.m. Are You Woke Enough to Lead?. . . . . . . . . . . . . . . 223 Top Ten Clinical, Educational, and Leadership Pearls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221

3:30 p.m.-4:15 p.m.

Advancing Your Career with the Resident and Fellow Section of Neurology: How to Write, Review, Join the Editorial Board, and Use the RFS for Your Residency. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231

Neuro Exam Tricks and Tips . . . . . . . . . . . . . . . . . . . . . 225

3:30 p.m.-4:30 p.m.

4:00 p.m.-5:30 p.m. Brainstorm: A Competition for the Innovator in All of Us. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227 Exhibit Hall Networking Reception

4:30 p.m.-5:15 p.m. Standing on the Shoulders of Giants. . . . . . . . . . . . . . 225

5:00 p.m.-5:45 p.m. One Day Fellow, Next Day Boss: Reflections on Early-career Leadership. . . . . . . . . . . . . . . . . . . . . . . . . 223 Applying for AAN Research Fellowships 101. . . . 236 Using Cybersecurity in Your Practice. . . . . . . . . . . . . . 234 Pursuing an Additional Degree: Is It for Me?. . . . . 231

5:00 p.m.-6:00 p.m. Happiness Hour. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

5:30 p.m.-6:30 p.m. P7

Poster Session 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153

6:00 p.m.-8:00 p.m. Trainee and Faculty Networking Reception

7:00 p.m.-10:00 p.m. Industry Therapeutic Updates. . . . . . . . . . . . . . . . 268 AAN.com/view/20AM 37

Monday, April 27

4:00 p.m.-6:00 p.m.

SCHEDULE

What Your Practice Administrator Wants You to Know. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

3:30 p.m.-5:30 p.m. C111 Neurologic Complications of Medical Disease C112 Neurologic Intensive Care 2: Vascular Disease C113 Core Concepts in Pain Management: Safe and Appropriate Opioid Prescribing in Neurology C114 Higher Cortical Visual Disorders: Case-based Review C115 The Evaluation and Care of Seizures in Adults with Intellectual and Developmental Disabilities (IDD): Challenges and Solutions C116 Emergency and Inpatient Management of Migraine and Other Headache Disorders C117 Pregnancy and Breastfeeding in Multiple Sclerosis C118 Spinocerebellar and Spastic Ataxias: Diagnosis and Management C119 Peripheral Neuropathy 3: Genetic Neuropathies: Molecular Diagnosis and Treatment Perspectives C120 Advances in Neurogenetics C121 Neurology Update 4: Neuro-infectious Disease, Neurootology, and Neuro-ophthalmology C122 Faculty Compensation Plans C123 Estudios de cohorte de latinoamericanos: enfermedad de Alzheimer, enfermedad de Huntington y derrame cerebral (Latin American Cohort Studies: Alzheimer’s, Huntington’s, and Stroke) IS2 Invited Science: Movement Disorders. . . . . . . . . . . 76 S20 Cerebrovascular Disease: Large Vessel Occlusions and Thrombectomy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92

93 93 94

Guided Meditation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

2019 Brainstorm Competition Winner ALSUntangled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

S19 Autonomic Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . 91 C292 How to Think Like a Neurologist: A.B. Baker Award for Lifetime Achievement in Neurologic Education Keynote Address

4:00 p.m.-4:30 p.m.

BusinesBytes: #AANAdvocacy. . . . . . . . . . . . . . . . 234

3:30 p.m.-4:00 p.m.

Neuroepidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Practice, Policy, and Ethics: Improving Patient Care and the Rise of Telemedicine . . . . . . . . . . . . . . . . . . . . . Aging and Dementia: Biomarkers and Clinical Trials. . . Pregnancy, Pediatric MS, and Early MS. . . . . . . . . . . . .

Health Care Equity Symposium Quality Health Care for All

Monday, April 27, 2020, 1:00 p.m.–5:30 p.m. In today’s world, the reality is that access to quality health care varies greatly depending on race, gender, socioeconomic status, and sexual identity. Join us at the Health Care Equity Symposium as we explore ways we can eliminate the disparity gap. Timeline of events: 1:00 p.m.–1:10 p.m.—Welcome 1:10 p.m.–2:00 p.m.—Keynote Lecture 2:00 p.m.–2:15 p.m.—Question and Answer Session 2:15 p.m.–2:45 p.m.—“Reducing Black-White Stroke Disparities in the U.S: What Can Neurologists Do?” by Olajide Williams, MD, MS 2:45 p.m.–3:00 p.m.—Break 3:00 p.m.–3:45 p.m.—Poster Blitz Presentations 3:45 p.m.–4:15 p.m.—“Lifecourse Mechanisms of Disparities in Cognitive Aging and Dementia” by Jennifer Manly, PhD 4:15 p.m.–5:00 p.m.—Panel Discussion 5:00 p.m.–5:30 p.m.—Networking Reception Learn more: AAN.com/view/20AM

Jennifer Manly, PhD Professor of Neuropsychology in Neurology Taub Institute for Research in Alzheimer’s Disease and the Aging Brain at Columbia University. Her research focuses on mechanisms of disparities in cognitive aging and Alzheimer’s Disease.

Olajide Williams, MD, MS Chief of Staff of the Department of Neurology and Associate Professor at Columbia University. He is also the Co-director of Columbia University’s Wellness Center and Founder of Hip Hop Public Health. Dr. Williams’ research is focused on community-based behavioral interventions with an emphasis on therapeutic lifestyle programs, stroke preparedness, and health disparities.

NEW THIS YEAR!

ACADEMIC NEUROLOGY BUSINESS ADMINISTRATOR LINEUP Take your academic department to the next level Academic neurology departments face unique challenges and opportunities. Thatâ&#x20AC;&#x2122;s why the AANâ&#x20AC;&#x2122;s Academic Neurology Business Administrators created a set of programming on Monday, April 27, at the Annual Meeting specifically for Academic Neurology Business Administrators. Talks will cover a variety of topics, including service lines, faculty compensation plans, and more. After the talks, network with other Business Administrators during a reception with light appetizers and beverages. Learn more: AAN.com/view/20AM Located in Room 714B

PHYSICAL ACTIVITIES AND WELLNESS

Come Out for Fresh Air, Good Fun, & a Great Cause 2020 RUN/WALK

FUNDRAISER

Fundraiser for Brain Research Along Torontoâ&#x20AC;&#x2122;s Waterfront On Tuesday, April 28, 2020, at 6:30 a.m. come participate in this friendly run/walk along the Toronto waterfront. All proceeds will be donated to support brain research. Sign up: AAN.com/view/RunWalk20 Sponsored by:

TUESDAY, APRIL 28 6:30 a.m.-8:30 a.m

9:15 a.m.-11:30 a.m.

Run/Walk for Brain Research. . . . . . . . . . . . . . . . . . 40

7:00 a.m.-7:45 a.m.

Clinical Trials Plenary Session . . . . . . . . . . . . . . . . 65

11:00 a.m.-12:00 p.m. Beyond the Bedside: The Business of Telestroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261

Yoga—Vinyasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Key Findings from the Neurology Compensation and Productivity Survey for Academics. . . . . . . . . . . . 221

11:30 a.m.-12:00 p.m. Methods and Directions for Applying Data Science in Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

7:00 a.m.-9:00 a.m.

8:00 a.m.-8:30 a.m. Mindfulness of Sound. . . . . . . . . . . . . . . . . . . . . . . 229

8:00 a.m.-8:45 a.m.

8:00 a.m.-9:00 a.m. C137 Education Blitz: Emerging Infectious Diseases of the Central Nervous System C293 Associate Professors – What Are Your Needs? How Can The AAN Support You Poster Session 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 P8

Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

12:00 p.m.-12:30 p.m. The Evolving Use of Scribes in the Neurology Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

12:00 p.m.-12:45 p.m. Onboarding Your APPs: Prepare for Success. . . . . 234

12:00 p.m.-1:00 p.m.

What’s that in Your Brain: 50 Essential Instant Pathological Recognition Cases. . . . . . . . . . . . . . . . . . 225 Poster Session 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165

12:30 p.m.-1:00 p.m. Models of Care That Work for You and Your Patients. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

1:00 p.m.-1:30 p.m. Addictive by Design: The Evolution of Video Games. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227 Learn About Opportunities to Work with the NIH Intramural Program. . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

1:00 p.m.-1:45 p.m. Outsmart Stress. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 The Eyes Have It: Neuro-ophthalmology Is the Career for You!. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 Navigating a Career in Academic Neurology: Accolades and Challenges . . . . . . . . . . . . . . . . . . . . . . 221 EDI 101 for Neurology Leaders: The Benefit of Diversity on Your Team. . . . . . . . . . . . . . . . . . . . . . . . . 223 How to Successfully Publish Quality Improvement Projects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

AAN.com/view/20AM 41

Tuesday, April 28

Turning “Diversity Tax” into Currency in Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 How to Successfully Incorporate APPs into Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 Welcome to NIH Day/Overview of NIH Funding. . . . . 236 Talks for Trainees: How to Negotiate Your Employment Contract. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

11:30 a.m.-4:00 p.m.

SCHEDULE

C124 Multiple Sclerosis Therapy: Symptom Management C125 Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease C126 The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurologic Disorders C127 Spinal Cord Rehabilitation C128 Sports Neurology: Enhancing Athletic Performance C129 Neuro-ophthalmology: Overview and Update C130 Women With Epilepsy (WWE): Beyond Seizure Control C131 Becoming an Agent of Change in Neurology Using Quality Improvement C132 Drugs and Toxin-induced Neurologic Emergencies C133 Neurologic Conditions in Transgender Patients C134 Movement Disorders for the General Neurologist 1: New Concepts in the Diagnosis and Management of Parkinson’s Disease C135 Update in Aging and Dementia C136 Negotiating Like a Boss: Narrowing the Gender Gap

TUESDAY, APRIL 28 1:00 p.m.-3:00 p.m. C138 C139 C140 C141 C142 C143 C144 C145

SCHEDULE

C146 C147 C148

An Engaged Patient Is a Healthy Patient: Patient Engagement in Theory and Practice How to Deliver Bad News Mitochondrial Disorders in Neurology Cerebrovascular Disease 1: Prevention Neurologic Intensive Care 3: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction Young Onset and Atypical Alzheimer’s Dementia How to Design Meaningful Clinical Trials Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches, Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches Multiple Sclerosis Overview 1: Clinical Pearls Movement Disorders for the General Neurologist 2: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia Clinical Approach to Muscle Disease 1: Role of Antibodies, Muscle Imaging, and Genetic Testing

C149

Leading Your Successful Transition Out of Fellowship or Final Year of Residency C150 Therapy in Neurology 1: Epilepsy and Neuromuscular Disorders C151 Education Research Methodology Course IS3 Invited Science: Neuromuscular. . . . . . . . . . . . . . . . 77 S25 Epilepsy/Clinical Neurophysiology (EEG) 2. . . . . . . . . . . 95 S26 Cerebrovascular Disease: Systems of Stroke Care. . . . 95 S27 Child Neurology and Developmental Neurology: Neurogenetics: Translating Knowledge to Therapy . . . 96 S28 Infectious Disease: Chronic Meningitis and the Immunosuppressed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 S29 Multiple Sclerosis: Disease-modifying Therapy . . . . . . 97

1:00 p.m.-3:30 p.m. C152 Good to Great, Great to Gold: Applying the (3 G) Strengths-based Approach to Enhance Your Toolkit as a Leader

1:00 p.m.-4:00 p.m.

Tuesday, April 28

C153 Mitigating the Impact of Unconscious Bias

1:00 p.m.-5:30 p.m. C154 Skills Workshop: Neurophysiologic Intraoperative Monitoring

1:30 p.m.-2:00 p.m. Social Media for the Modern Neurologist: How Twitter Allows You to Amplify Your Voice and Engage Your Community of Physicians and Patients. . . . . . . . . . . . . 227 NIH Grant Review Process & Tips for Writing a Successful Grant Application. . . . . . . . . . . . . . . . . . . . 236

1:30 p.m.-2:15 p.m. The Effects of Brain Damage on Creativity. . . . . . 225

2:00 p.m.-2:30 p.m. Office Practice Mechanisms to Provide Services for the New CPT Codes. . . . . . . . . . . . . . . . . . . . . . . . . 227

2:00 p.m.-2:45 p.m. Magnifying Your Life Through Poetry. . . . . . . . . . . . . . 229 Understanding and Negotiating a Physician Employment Contract . . . . . . . . . . . . . . . . . . . . . . . . . . 231 All Work and No Play: Don’t Let Work Interfere with Your Fun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Do You Need a Sponsor, Mentor(s), or Collaborator(s)? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 K Awards and Training Programs – Planning for a Career as an NIH Investigator. . . . . . . . . . . . . . . . . . . . 236 Making the Most of Your Career as an APP. . . . . . 234

2:30 p.m.-3:00 p.m. Lessons from the California Parkinson’s Disease Registry and What’s Next?. . . . . . . . . . . . . . . . . . . . . . 227

2:30 p.m.-3:15 p.m. All Things Ice Cream . . . . . . . . . . . . . . . . . . . . . . . . 225

2:45 p.m.-3:15 p.m. NIH Funding and Professional Development Opportunities for Diverse Researchers . . . . . . . . . . . . 236

3:00 p.m.-3:30 p.m. Medical Improv: Comedy as a Tool for Improving Patient Interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

3:00 p.m.-3:45 p.m. The Importance of Mission, Vision, and Purpose. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Just Enough IS Good Enough: Parenting While Paving Your Career Path. . . . . . . . . . . . . . . . . . . . . . . . 231

42 2020 AAN Annual Meeting

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area

The Third Leg? The Clinician in Academic Medicine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Mindful Snacking. . . . . . . . . . . . . . . . . . . . . . . . . . . 229

3:15 p.m.-4:00 p.m. Clinical Trials and Networks – NeuroNEXT, StrokeNET, SIREN, Alzheimer’s Clinical Trials Consortium and ADRD Opportunities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

3:30 p.m.-4:00 p.m. Telemedicine FAILS: Limitations and Legal Liability. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

S32 S33 S34 S35

Neuro-ophthalmology/Neuro-otology. . . . . . . . . . . . . . 98 Aging and Dementia: Non-Alzheimer Dementia. . . . . . 99 Clinical Trials and Therapeutics in Autoimmune Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 Amyotrophic Lateral Sclerosis . . . . . . . . . . . . . . . . . . . 100

4:00 p.m.-4:00 p.m. Translational Research . . . . . . . . . . . . . . . . . . . . . . . . . 236

4:00 p.m.-4:45 p.m. Leading Interdisciplinary Teams. . . . . . . . . . . . . . . 223 Fireside Chat: Work-Life Balance. . . . . . . . . . . . . . 229

3:30 p.m.-4:15 p.m.

Private Practice: Can you be Successful?. . . . . . . . 231

The Neuroscience of Magic: Sleight of Hand. . . . . 225

3:30 p.m.-4:45 p.m.

Standing on the Shoulders of Giants. . . . . . . . . . . . . . 225

Sports Neurology and Neuro Trauma. . . . . . . . . . . . . . . 97

Funding Opportunities in Pain Research and the HEAL Initiative. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

3:30 p.m.-5:30 p.m. C155 C156

New Therapeutic Options for CNS Infections

Next Level Leadership: Building Your Personal Development Plan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Mentorship: Pearls and Pitfalls. . . . . . . . . . . . . . . . 221 Yoga - Vinyasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Learn Something New Every Day—The Life of the Academic Neurohospitalist. . . . . . . . . . . . . . . . . . . . . . 231 How Can I Prepare for the E/M Changes that are Coming in 2021?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

5:30 p.m.-6:30 p.m. P10

Poster Session 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171

7:00 p.m.-10:00 p.m. Industry Therapeutic Updates. . . . . . . . . . . . . . . . 268

Tuesday, April 28

Pediatric Neuro-oncology Update: Advances in Cures and Long-term Survivorship C157 Cerebrovascular Disease 2: Update on Guidance-based Diagnosis and Management of Hemorrhagic Stroke C158 Neurologic Intensive Care 4: Case Studies in the ICU C159 Behavioral Management of Dementia C160 LGBTQI Health in Neurology C161 Introduction to Primary Headache Disorders: Migraine and Other Primary Headaches, Including Tension-type, Hypnic, Primary Stabbing, Nummular Headache Syndromes, Epicrania Fugax, and Retinal Migraine C162 Multiple Sclerosis Overview 2: Clinical Advances C163 Movement Disorders for the General Neurologist 3: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics C164 Clinical Approach to Muscle Disease 2: Inflammatory Myopathies and Muscle Pathology C165 Digital Technology for Neurology Education: Creation, Curation, Collaboration C166 Therapy in Neurology 2: Neuro-ophthalmology and Critical Care C167 Funds Flow Models: What Works? What Doesn’t Work? C168 Actualización en esclerosis múltiple y optica de neuromyelitis (Update in MS and Neuromyelitis Optica) N3 Neuroscience in the Clinic: Melatonin and Disrupted Sleep in Neurologic Disorders. . . . . . . . . . . . . . . . . . . . . 72 S31 Epilepsy/Clinical Neurophysiology (EEG) 3. . . . . . . . . . . 98

5:00 p.m.-5:45 p.m.

SCHEDULE

S30

4:30 p.m.-5:15 p.m.

AAN.com/view/20AM 43

WEDNESDAY, APRIL 29 7:00 a.m.-7:45 a.m.

11:00 a.m.-12:00 p.m. Beyond the Bedside: The Business of Sleep . . . 261

Yoga—Vinyasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Too Many Fellowship Choices: How to Zero in to Find the Subspecialty of Your Choice and the Best Job for Life. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231

11:30 a.m.-12:00 p.m. Patient-centered Innovations and AI in Transition of Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

K Is for Career Development. . . . . . . . . . . . . . . . . . . . . 236

SCHEDULE

7:00 a.m.-9:00 a.m. C169 Infections of the Nervous System 1: Diagnostic Testing of Neurologic Infections C170 Update in Epilepsy C171 Child Neurology: Headache C172 Neuro-oncology in 2020: Navigating Current Trends C173 Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders C174 Clinical Pearls in Autoimmune Neurology: Real-world Cases C175 Paroxysmal Movement Disorders C176 Mastering EMG Waveform Recognition Skills in Just Two Hours! C177 The Global Burden of Neurologic Diseases C178 Emergency Room Neuro-ophthalmology C179 Current Management of Incidental and Asymptomatic Cerebrovascular Lesions C180 Division Chief Roundtable: Chair-Chief Synergy: Working with the Department Chair to “Manage Up” C181 How to Run a Practice: Business Strategies for Neurology Private Practices and the Future

11:30 a.m.-4:00 p.m. Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

12:00 p.m.-12:30 p.m. Project ECHO and Neurology: Demand Shaping and Bridging Knowledge Gaps. . . . . . . . . . . . . . . . . . . . . . . 227

12:00 p.m.-12:45 p.m. Meet Your Practice Support Network: Ask Us Anything About Managing Your Practice. . . . . . . . . . . 234

12:00 p.m.-1:00 p.m. Neurology Pictionary. . . . . . . . . . . . . . . . . . . . . . . . . . . 225

P12

12:30 p.m.-1:00 p.m. What If? Digital Assessments Transforming Neurology Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

1:00 p.m.-1:30 p.m. Video Games in Neuro-rehab: Big Bucks or Xbox. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

8:00 a.m.-8:45 a.m. Pursuing a Career in Industry . . . . . . . . . . . . . . . . . . . . 231 How to Successfully Publish Quality Improvement Projects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

1:00 p.m.-1:45 p.m. Tools and Resources to Combat Imposter Phenomenon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223

Grit, Resilience, and a Healthy Dose of Fun: How to Succeed at Your Professional Organization. . . . . . . . . 221

Much Ado About Something: Pursuing a Career in Autoimmune Neurology. . . . . . . . . . . . . . . . . . . . . . . 231 How to Put Together an Effective Research Presentation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236

Acupuncture Demonstration - 4 Gates. . . . . . . . . . . . . 229 Talks for Trainees: Understanding Patients as Consumers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

Advancing the Educational Mission in Neurology Departments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221

Wednesday, April 29

8:00 a.m.-9:00 a.m.

The Power of One. . . . . . . . . . . . . . . . . . . . . . . . . . . 229

C182 Education Blitz: Multiple Sclerosis P11 Poster Session 11. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176

9:15 a.m.-11:30 a.m. Frontiers in Neuroscience Plenary Session. . . . . 66

44 2020 AAN Annual Meeting

Poster Session 12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182

Preparing to Use Artificial Intelligence in Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

1:00 p.m.-2:00 p.m. S36

History of Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . 102

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area

1:00 p.m.-3:00 p.m.

Shared Medical Appointments in the Memory Clinic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

2:00 p.m.-2:45 p.m. From Private Practice to Academics. . . . . . . . . . . . . . . 231 Patient-centered Care in Clinical Neurology . . . . . 229 Ethical Issues in Clinical Research . . . . . . . . . . . . . 236 Factors that Perpetuate Disparities in Academic Medicine: A Path Forward. . . . . . . . . . . . . . . . . . . . . . . 221 Time for a Check Up: How to Successfully Navigate Compensation Negotiations as Women in Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 How Does Advocacy Help Build My Practice?. . . . . . . 234

2:30 p.m.-3:00 p.m. The Midas Touchscreen: Turn Your App Idea into Gold. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

2:30 p.m.-3:15 p.m. Consejos prácticos para un buen examen neurológico (Neuro Exam Tips and Tricks) . . . . . . . . . . . . . . . . . . . . 225

3:00 p.m.-3:30 p.m. Medical Improv: Comedy as a Tool for Improving Patient Interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

3:00 p.m.-3:45 p.m. Café Talk: Growth Mindset. . . . . . . . . . . . . . . . . . . . . . 229

1:00 p.m.-5:00 p.m. C196 Strengths Foundations Workshop

Fit For Duty: Practicing Neurology in the Military. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231

1:00 p.m.-5:30 p.m.

Microaggressions: How to Address Discrimination and Unprofessional Behavior at Your Workplace . . . . 223

C197 Research Career Symposium C198 Skills Workshop: Clinical Uses of Botulinum Toxin for Dystonia C199 Skills Workshop: Neuro-ophthalmology and Neurovestibular Exam Lab

Nutritional Neurology: Back to Basics and What to Look for Moving Forward . . . . . . . . . . . . . . . . . . . . . . . 227

1:30 p.m.-2:15 p.m. The Salem Witch Trials: How Could That Possibly Happen?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

3:10 p.m.-3:20 p.m. BusinessBytes: Why Should I Be Using Data from the Neurology Compensation and Productivity Survey in My Practice?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

3:30 p.m.-4:15 p.m. Ethical Conundrums in Neurology. . . . . . . . . . . . . . . . . 225

3:30 p.m.-4:30 p.m. S42

Neuro-rehabilitation . . . . . . . . . . . . . . . . . . . . . . . . . . . 105

AAN.com/view/20AM 45

Wednesday, April 29

1:30 p.m.-2:00 p.m.

SCHEDULE

C183 Infections of the Nervous System 2: Neuro-ID Emergencies C184 Evaluation and Management of Autonomic Disorders: Autonomic Testing, Failure, and Peripheral Neuropathies C185 Cerebrovascular Disease 3: Telestroke C186 Concussion: Topics in Acute Concussion C187 Neurologic Consultations in Cancer Patients 1 C188 Neuro-otology Basics: Peripheral Vestibular Disorders C189 Assessment of Rapidly Progressive Dementias 1: Prion and Non-prion Neurodegenerative Diseases C190 Clinical Epilepsy 1: Basics C191 Multiple Sclerosis Therapy: Disease-modifying Treatment 1 C192 Therapy of Movement Disorders: A Case-based Approach C193 Clinical Pearls: Learning from Complex Cases: Simple Lessons that Apply to Everyday Problems C194 Therapy in Neurology 3: Stroke and Headache C195 Sleep for the Practicing Neurologist: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence S37 Stroke Epidemiology: Risk Factors, Incidence, and Unique Populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 S38 Child Neurology and Developmental Neurology: Acquired Brain Injury: Brain-Behavior Relationships. . . . . . . . . . 103 S39 Autoimmune and Paraneoplastic Neurological Disorders: Clinical Characteristics and Diagnosis. . . . . . . . . . . . . 103 S40 Multiple Sclerosis: Clinical Trials . . . . . . . . . . . . . . . . . 104 S41 Parkinson’s Disease Interventions and Clinical Trials. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104

2:00 p.m.-2:30 p.m.

WEDNESDAY, APRIL 29

SCHEDULE

3:30 p.m.-5:30 p.m. C200 Infections of the Nervous System 3: Advanced Topics in Infectious Neurology C201 Sleep for the Practicing Neurologist 2: Disordered Sleep in Common Neurologic Diseases C202 Autism Spectrum Disorders: What We Know and Where We Are Going C203 Cerebrovascular Disease 4: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke C204 Concussion: Chronic Symptoms—Selected Considerations for Why Your Patient May Not be Getting Better C205 Neurologic Consultations in Cancer Patients 2 C206 Neuro-otology Advanced: Central Disorders of Dizziness C207 Assessment of Rapidly Progressive Dementias 2: Infections and Autoimmune Mediated Conditions C208 Clinical Epilepsy 2: Considerations Across the Age Span: Pediatrics, Pregnancy, and Elderly C209 Multiple Sclerosis Therapy: Disease-modifying Treatment 2 C210 Evaluating Tremor in the Office C211 Expanding the Neurologist’s Toolbox: When and How to Recommend Cognitive Behavioral or Mindfulnessbased Psychotherapies C212 Therapy in Neurology 4: Movement Disorders and Neuroimmunology C213 Actualización científica 2 (Scientific Update 2) N4 Neuroscience in the Clinic: The Neurology of Obesity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 S43 Stroke Recovery and Outcomes. . . . . . . . . . . . . . . . . . 105 S44 Research Methodology and Education. . . . . . . . . . . . . 106 S45 Multiple Sclerosis: Imaging. . . . . . . . . . . . . . . . . . . . . . 106 S46 Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron/Charcot Marie Tooth. . . . . . . . . . . . . . .107

4:00 p.m.-4:45 p.m. Fireside Chat: Thriving in Medicine–What Is Your Purpose?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Health Care Disparities in Populations. . . . . . . . . . 223

Wednesday, April 29

How I Tried to Retire from Neurology but Couldn’t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231

4:00 p.m.-5:30 p.m. EHR Pain Points: A Conversation with Representatives from Epic and Cerner. . . . . . . . . . . . . 234

4:30 p.m.-5:15 p.m. Standing on the Shoulders of Giants. . . . . . . . . . . . . . 225

46 2020 AAN Annual Meeting

5:00 p.m.-5:30 p.m. Nature Meditation. . . . . . . . . . . . . . . . . . . . . . . . . . 229

5:00 p.m.-5:45 p.m. Why Neurology? (for Medical Students) . . . . . . . . 231 Neurohospitalist Models of Care in an Academic Department: Opportunities and Challenges. . . . . . . . .221 ”But We Always Use 20 Patients”—How NOT to Determine Sample Size. . . . . . . . . . . . . . . . . . . . . . . . . 236 Women in Neurology: Thriving Through Challenges. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223

5:30 p.m.-6:30 p.m. P13

Poster Session 13. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188

7:00 p.m.-10:00 p.m. Industry Therapeutic Updates. . . . . . . . . . . . . . . . 268

April 30, 2020 • Toronto, Canada

BrainHealthFair.org

CALLING ALL VOLUNTEERS!

Join us on Thursday, April 30, 2020, for the free Brain Health Fair open to the general public where we teach about the brain and support neurology patients and caregivers! A variety of volunteer opportunities are available for AAN Annual Meeting attendees. Time commitments range from two hours to all day. Volunteer registration is required to attend this event. Sign up today by emailing Michaela Morris at mmorris@aan.com

“The AAN Brain Health Fair is such a great way to give back. It’s rewarding to engage with members of the local community who are interested in learning about neurologic conditions and therapies.” – Justin T. Jordan, MD, MPH “It’s been both satisfying and rewarding to volunteer at the Brain Health Fair for the past eight years. In one city after another, we make the AAN mission–to promote the highest quality patient-centered neurologic care–come to life!”– Lisa M. Shulman, MD, FAAN “It is amazing to see all of the Brain Health Fair attendees take the time to learn about the brain and to see our AAN members provide guidance and resources to improve their lives.” – Rujuta Bhatt Wilson, MD

THURSDAY, APRIL 30 7:00 a.m.-7:45 a.m.

1:00 p.m.-1:45 p.m.

Yoga—Vinyasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

Pursuing a Career in Neurocritical Care. . . . . . . . . . . . 231

Neuroscience of Bias in Research . . . . . . . . . . . . . . . . 236

How and When to Speak Up as a Bystander. . . . . 223 Poetry and Neurology Workshop . . . . . . . . . . . . . . 229

SCHEDULE

7:00 a.m.-9:00 a.m. C214 Women’s Neurology: Beyond Pregnancy Sports Concussion: Event Coverage Foundational Skills C215 and Sport Specific Pearls C216 Integrating Sleep Medicine Concepts into Your Child Neurology Practice C217 MS Across the Lifespan C218 Diagnosis and Treatment of Functional Movement Disorders C219 Neurologic Complications of Medical and Surgical Therapies C220 Cannabis Update in Neurology C221 Epileptologists’ Secrets for the Busy General Neurologist: Localization, Imaging, and Fear of Surgery C222 Now You See It, Now You Know It: Pathognomonic Neuroophthalmology Examination Findings C223 Mid-career Faculty Development Course

8:00 a.m.-8:45 a.m. Launching a Successful Research Program and Tips for Early-career Neurologists: Funding Clinically Oriented/Translational Research Before R01 . . . . . . . 236 How to Increase Your International Presence? . . . 221 Bed Side to Boardroom: Tales of a Neurohospitalist. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231

8:00 a.m.-9:00 a.m. C224 Education Blitz: Neonatal Neurology Update P14 Poster Session 14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194

8:00 a.m.-8:45 p.m. Talks for Trainees: Thinking About Practice Models in My Future Career. . . . . . . . . . . . . . . . . . . . . 234

9:15 a.m.-11:30 a.m. Thursday, April 30

Controversies in Neurology Plenary Session . . . 67

12:00 p.m.-12:45 p.m. Using Axon Registry to Ease Your Data-collection Burden. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

12:00 p.m.-1:00 p.m. P15

Poster Session 15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200

48 2020 AAN Annual Meeting

Team Science: Implications for Promotions and Tenure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Small Group Mock Review Sessions. . . . . . . . . . . 236

1:00 p.m.-2:00 p.m. Inspiration and Innovation Talk Featuring Maria Konnikova, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49

1:00 p.m.-3:00 p.m. C225

Developing a Successful and Solvent Clinical Trials Program in an Academic Department: Why and How C226 Differential Diagnosis of Neurologic Infections C227 Using Sleep Medicine to Help Solve Difficult Neurologic Cases C228 Stroke in the Young Adult C229 Ophthalmic Imaging for Neurologists: OCT and Funduscopy in the 21st Century C230 Clinical Epilepsy 3: Advanced (Status, Beyond AED, Video EEG) C231 Comprehensive Migraine Update 1: Migraine Diagnosis, Pathophysiology, and Comorbidities C232 Autoimmune Neurology 1 Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes of the CNS and PNS C233 Deep Brain Stimulation 1: Basic Principles and Programming in Movement Disorders C234 Small Fiber Neuropathies: Sensory, Autonomic, and Both 1: Focus on Autonomic Nervous System C235 Neuroimaging for the General Neurologist 1: Brain C236 Mild Cognitive Impairment: Implications for Clinicians C237 Continuum® Test Your Knowledge: A Multiple-choice Question Review 1 N5 Neuroscience in the Clinic: Testing for Common Neurodegenerative Disorders. . . . . . . . . . . . . . . . . . . . . 74 S47 Headache II. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 S48 Neurocritical Care: Traumatic Brain Injury and Goals-of-care Decision-making. . . . . . . . . . . . . . . . . . . 108 S49 Multiple Sclerosis: Basic Science. . . . . . . . . . . . . . . . . 109 S50 Ataxia, Dystonia, and Atypical Parkinsonism. . . . . . . .109 S51 General Neurology: Models of Clinical Care and Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110

1:00 p.m.-5:30 p.m. C238 Skills Workshop: EMG: Basic

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area

What About Wellness for Residents and Fellows?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

1:30 p.m.-2:15 p.m. Live Intraoperative Monitoring. . . . . . . . . . . . . . . . . . . 225

3:30 p.m.-4:15 p.m.

2:00 p.m.-2:45 p.m.

The Effects of Loneliness: Connectivity Matters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

Café Talk: Mindfulness in the Practice of Clinical Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Get Social on Social Media—#Networking101 for Professional Development. . . . . . . . . . . . . . . . . . . . . . .231 Residency Case Reports: How to Make a Small Amount of Effort Go a Long Way . . . . . . . . . . . . . . . . . 236 Managing Neurologic Disorders in Transgender and Gender Diverse Patients. . . . . . . . . . . . . . . . . . . . . 223 FMLA, Disability, Legal Questions, and Other Paperwork . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

2:30 p.m.-3:15 p.m. Lost in Translation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

3:00 p.m.-3:45 p.m. Women in Health Care Leadership: Time for Change. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Optimizing Communication in Difficult Patient Relationships. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232

3:30 p.m.-4:45 p.m. S52

From Bench to Bedside with Novel Treatments for Pain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110

3:30 p.m.-5:30 p.m. C239 Boot Camp for Division Chiefs and Aspiring Leaders Tropical Neurology C240 C241 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist C242 Child Neurology: Stroke C243 Core Principles of Brain Tumors C244 Cognitive Impairment Due to Alzheimer’s Disease: Using Old Skills and New Tools for Diagnosis and Treatment C245 Clinical Epilepsy 4: Surgery C246 Comprehensive Migraine Update 2: Advances in Acute, Preventive and Cognitive Behavioral Therapies

INSPIRATION AND INNOVATION TALKS EXPLORING SUBJECTS WHERE NEUROSCIENCE INTERSECTS WITH GLOBAL THEMES Thursday, April 30, 2020, from 1:00 p.m.–2 :00 p.m. Located in Room 106

MARIA KONNIKOVA, PhD Konnikova is a New York Times best-selling author. She is a contributing writer for The New Yorker and hosts the podcast “The Grift” from Panoply Media. She graduated magna cum laude from Harvard, where she studied psychology, creative writing, and government. A former producer on the “Charlie Rose” show on PBS, she received her PhD in psychology from Colombia.

How to Think Like Sherlock Holmes: The Scientific Method of the Mind No fictional character is more renowned for his powers of thought and observation than Sherlock Holmes. But is his extraordinary intellect merely a gift of fiction, or can we learn to cultivate these abilities ourselves, to improve our lives at work and at home? We can, as Maria Konnikova shows us in this talk. Beginning with the “brain attic” – Holmes’s metaphor for how we store information and organize knowledge – she unpacks the mental strategies that lead to clearer thinking and deeper insights.

SCHEDULE

THURSDAY, APRIL 30 C247 Autoimmune Neurology 2 Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience C248 Deep Brain Stimulation 2: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders C249 Small Fiber Neuropathies: Sensory, Autonomic, and Both 2: Focus on Sensory Nervous System C250 Neuroimaging for the General Neurologist 2: Brain C251 Continuum® Test Your Knowledge: A Multiple-choice Question Review 2 C252 Cuidados neurocríticos (Neurocritical Care) S53 Stroke Prevention. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 S54 Multiple Sclerosis: Disease Progression, Diseasemodifying Therapy, and Clinical Considerations. . . . . 111 S55 Movement Disorders: Neuromodulation, Circuits, and Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112 S56 Neuromuscular Therapeutics. . . . . . . . . . . . . . . . . . . . 113 S57 General Neurology: Diagnostic Testing and Disease Biomarkers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113

4:00 p.m.-4:45 p.m. Consejos para publicar en revistas neurológicas (Getting Published in Neurology Journals: Tips and Tricks) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Fireside Chat: Self-care–The Radical Idea That YOU Are a Priority. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

4:30 p.m.-5:15 p.m. Standing on the Shoulders of Giants. . . . . . . . . . . . . . 225

5:00 p.m.-5:45 p.m. Consejos para dar una charla científica efectiva (How to Prepare and Present Abstracts at the AAN Annual Meeting). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236 Hawaiian Hula Dance. . . . . . . . . . . . . . . . . . . . . . . . 229 How to Become a Leader in Your Health System. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223

5:30 p.m.-6:30 p.m. P16

Poster Session 16. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206

Thursday, April 30

6:30 p.m.-9:30 p.m. C253 Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration C254 Case Studies: Challenging Headache Cases C255 Case Studies: Unusual Movement Disorders C256 Case Studies: Diagnosis and Management of Unusual Cases in Neuromuscular Disease C257 Case Studies: Test Your Knowledge: A Case-based Approach to Neuroimaging 50 2020 AAN Annual Meeting

Continuing the

Conversation

This popular education program enhancement will return with the director and faculty relocating to a reception setting to engage in small group conversations with interested audience members. Saturday, April 25, 2020 C35: Clinical EMG II: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography Sunday, April 26, 2020 C66: Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus Monday, April 27, 2020 C116: Emergency and Inpatient Management of Migraine and Other Headache Disorders Tuesday, April 28, 2020 C162: Multiple Sclerosis Overview II: Clinical Advances Wednesday, April 29, 2020 C207: Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions C210: Evaluating Tremor in the Office Thursday, April 30, 2020 C247: Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience

A Great Week Deserves an Amazing Finish Don’t miss out on FRIDAY’S incredible lineup

SCHEDULE

While you’ll find fresh and creative programming all week long, you’ll want to make sure and stay until the end of the week to take in the enhanced Friday experience. The streamlined schedule for the day will offer even more opportunity for networking and community with your peers. Here’s a quick look at the Friday highlights:

7:00 a.m.–9:00 a.m. Course programming Get the latest on a variety of topics from experts in the field, including the Friday Education Blitz on normal pressure hydrocephalus from 8:00 a.m.–9:00 a.m. delivering updates in an energetic one-hour format. 9:15 a.m.–11:30 a.m. Neurology Year in Review Plenary Session Speakers will focus on the latest research that has happened in the last year within a specific subspecialty topic. 11:30 a.m.–1:00 p.m. Science Innovation Lunch Head to the digital poster hall to view more than 160 of the best scientific posters and presentations from the week focusing on neuroinflammation. 1:00 p.m.–3:00 p.m. Courses and Scientific Sessions Four major scientific sessions will focus on headache, stroke, epilepsy, and neurocritical care and four programs will highlight new information on hyperkinetic movement disorders, Lewy body dementias, neuromyelitis optica spectrum disorders, and therapy of neuromuscular disease. 3:30 p.m.–4:30 p.m. Encore Update Programs Look for encore presentations of neurology update programs presented earlier in the week on movement disorders, headache, stroke, and epilepsy. 4:00 p.m.–5:00 p.m. NeuroZone Gear up for the Closing Party with this unconventional, interactive activity full of neuro-related game shows that are designed to engage you intellectually, emotionally, and socially. Audience participation is encouraged! 5:00 p.m.–7:00 p.m. Closing Party Celebrate the end of a great meeting with the infamously hilarious Second City improv crew.

FRIDAY, MAY 1 7:00 a.m.-7:45 a.m. Yoga—Vinyasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Finding Neverland: Pathways to a Successful Academic Career in Global Neurology. . . . . . . . . . . . . 232

7:00 a.m.-9:00 a.m.

SCHEDULE

C258 Vascular Cognitive Impairment and Dementia: Current Status and Future C259 Sleep for Resiliency, Recovery, and Performance C260 Pediatric Neuro-ophthalmology Update C261 Status Epilepticus C262 Diagnostic Pearls in Myelitis: a Case-based Approach C263 Balance and Gait Disorders C264 Video Case Studies in Neuromuscular Disorders C265 CNS Toxicities C266 Food for Thought: Nutrition and Neurologic Disease

C268 Neuromyelitis Optica Spectrum Disorders C269 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment C270 Lewy Body Dementias C271 Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis S58 Headache Therapeutics. . . . . . . . . . . . . . . . . . . . . . . . . 114 S59 Epilepsy/Clinical Neurophysiology (EEG) 4. . . . . . . . . . 114 S60 Cerebrovascular Imaging and Biomarkers. . . . . . . . . . 114 S61 Neurocritical Care: Cerebrovascular Disease . . . . . . . 115

2:00 p.m.-2:45 p.m. Navigating Conflict. . . . . . . . . . . . . . . . . . . . . . . . . . 223 Setting the Stage for Success: Building Your Career by Finding Your Mentor and Mentee Match. . . . . . . . 232 Fireside Chat: Self-compassion–Learning to Ignore Your Inner Critic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229

8:00 a.m.-8:45 a.m. Statistically Speaking: How to Engage in Productive Collaborations with Statistical Colleagues. . . . . . . . . 236

2:30 p.m.-3:15 p.m. Werewolves and Vampires: The Quest for the Truth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

Taking Neurology Outside of the Office: Turning Advocacy into a Career Game-changer. . . . . . . . . . . . 232 Acupuncture Demonstration–Auriculotherapy. . . . . . 229

3:00 p.m.-3:45 p.m. Discovering What Drives You...and What Keeps You Going. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232

8:00 a.m.-9:00 a.m. C267 Education Blitz: Normal Pressure Hydrocephalus

9:15 a.m.-11:30 a.m. Neurology Year in Review Plenary Session. . . . . 68

11:30 a.m.-1:00 p.m. P17

Poster Session 17: Neuroinflammation . . . . . . . . . . . . 211

12:00 p.m.-1:00 p.m. The Neurology of Creativity at the Keyboard . . . . . . . 225

1:00 p.m.-1:45 p.m. Pursuing a Career in Sports Neurology. . . . . . . . . . 232 Mindful Eating. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 Friday, May 1

1:00 p.m.-3:00 p.m.

Communicate Better! Presenting and Pitching New Ideas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223

52 2020 AAN Annual Meeting

3:30 p.m.-4:30 p.m. C272 C273 C274 C275

Neurology Update 5: Movement Disorders Neurology Update 6: Headache Neurology Update 7: Stroke Neurology Update 8: Epilepsy

4:00 p.m.-5:00 p.m. NeuroZone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

5:00 p.m.-7:00 p.m. Closing Party. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53

BE FIRST IN LINE FOR SECOND CITY This year’s closing party is full of fun, laughter, and improv! Let’s celebrate an amazing week with a closing party featuring a reception with food, beverages, and the infamously hilarious Second City improv crew. Join us for a good time, a good laugh, and some good camaraderie. Metro Toronto Convention Centre Friday, May 1, 5:00 p.m.–7:00 p.m. Seating is limited Free for registered attendees $50 per ticket for guests

#NeurologyProud and proud to call the AAN my home. Share why you are #NeurologyProud on social media.

RES

FUTU

BU SIN ESS

ESSENTIAL EER S CAR

NEUR

OLOGY

INE MEDIC MIC

ACA DE

GIC

OLO

UR N NE

ADVANCED PR

ARC

ESE AL R

RS VIDE O R EP ACTIC

NAVIGATE THE MEETING WITH PROGRAM TRACKS

NEUROHOSPITALIST

SPANISH–LANGUAGE

WE’VE DESIGNED PROGRAMMING SPECIFICALLY FOR YOUR INDIVIDUAL INTERESTS Academic Medicine Track for Academic Neurologists Providing a variety of offerings across career roles and stages, including, Vice Chairs, Division Chiefs, Diversity Officers, Residents, Fellows, Clerkship Directors, Faculty, Medical Students, SIGN Directors, Business Administrators, Neuroscience Nurses, and more.

Advanced Practice Providers Track for Advanced Practice Providers Created for cutting-edge providers who are new to neurology.

Business of Neurology Track for Private Practitioners, Business Administrators Perfect for individuals interested in starting a new practice or learning the fundamentals of neurology business.

Career Essentials Track for Medical Students, Residents Offering help with early career and development or if you are looking to launch into private practice or academics.

Futures in Neurological Research Track for Early Career Researchers Providing both formal coursework and learning sessions for advancing your career in research.

Neurohospitalist Track for Neurohospitalists, Inpatient Care Providers Created specifically for neurohospitalists whose primary focus is inpatient care.

Spanish-language Track for Spanish Speakers Education courses, scientific updates, and experiential learning area talks offered in Spanish on a wide range of topics. Learn more about this specially curated list of program tracks at AAN.com/view/20AM.

2020 Award Recipients The research we celebrate, with the recipients below, has generated paradigm-changing discoveries in epilepsy, fundamental insights in multiple sclerosis, and pioneering breakthroughs in pain, to name a few of the transformative advances conceived by these luminaries. We honor those researchers and pay tribute to all those who play a role in the search for cures for brain disease, from mentors to colleagues to those just starting out on their journey. The American Academy of Neurology thanks the American Brain Foundation for its philanthropic support of many of the American Academy of Neurology’s awards program. A.B. Baker Award for Lifetime Achievement in Neurologic Education

Award for Creative Expression of Human Values in Neurology

Recipient:

Funded by an endowment created by matching funds from the A.B. Baker Family Trust and Novartis Pharmaceuticals.

José Biller, MD, FAAN, FACP, FAHA Chicago, IL

Alliance Awards

Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Founders Recipient: Abhimanyu Mahajan, MD, MHS Cincinnati, OH S50: Ataxia, Dystonia, and Atypical Parkinsonism Thursday, April 30, 1:00 p.m. S.Weir Mitchell Recipient: Amir Hadi Maghzi, MD Boston, MA S49: Multiple Sclerosis: Basic Science Thursday, April 30, 1:00 p.m.

Ambassador Award

Sponsored by the American Brain Foundation.

Recipient:

Jim Cramer New York, NY Commitment to Cures Wednesday, April 29, 6:00 p.m.

American Academy of Neurology President’s Award This award is given by the American Academy of Neurology President for outstanding service to the American Academy of Neurology and the profession of neurology.

Recipient:

Gregory D. Cascino, MD, FAAN Rochester, MN

American Brain Foundation Board Chair Award Sponsored by the American Brain Foundation.

Recipient:

Catherine M. Rydell, CAE Minneapolis, MN Commitment to Cures Wednesday, April 29, 6:00 p.m.

Association of Indian Neurologists in America Lifetime Achievement Award Sponsored by the Association of Indian Neurologists in America Fund of the American Brain Foundation.

Recipient:

Prakash Kotagal, MD Cleveland, OH AINA Annual Meeting Monday, April 27, 6:00 p.m.

56 2020 AAN Annual Meeting

This award is sponsored by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology, the American Neurological Association, and the Child Neurology Society.

This award was not given in 2020.

Bruce S. Schoenberg International Award in Neuroepidemiology

Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.

Recipient:

Jorge Llibre-Guerra, MD, MSc La Habana, Cuba S21: Neuroepidemiology Monday, April 27, 3:30 p.m.

Commitment to Cures Award

Sponsored by the American Brain Foundation.

Recipient:

Sidney Crosby Pittsburgh, PA Commitment to Cures Wednesday, April 29, 6:00 p.m.

Dreifuss-Penry Epilepsy Award

Sponsored by the American Academy of Neurology and endowed by members of the American Academy of Neurology Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Corporation; GlaxoSmithKline, Inc.; Novartis; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc; Shire Pharmaceuticals Group; and UCB Pharma.

Recipient:

Vikram Rao, MD San Francisco, CA S31: Epilepsy/Clinical Neurophysiology (EEG) 3 Tuesday, April 28, 3:30 p.m.

Harold Wolff-John Graham Award: An Award for Headache/Facial Research

Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.

Recipient:

Mia Minen, MD, MPH New York, NY S1: Headache 1 Sunday, April 26, 1:00 p.m.

H. Richard Tyler Award

Sponsored by the AAN History and Archives Committee.

Recipient

Michael Young, MD, MPhil, Boston, MA History Section Meeting

International Scholarship Award

Sponsored by the American Academy of Neurology.

Gianmarco Abbadessa Naples, Italy Ifeyinwa Ani-Osheku Abuja, Nigeria Luca Baldelli Bologna, Italy Hanna Belay Addis Ababa, Ethiopia Rok Berlot Ljubljana, Slovenia Mashina Chomba Lusaka, Zambia Marcelo Houat de Brito Sao Paulo, Brazil Raul Anwar Garcia Santos Mexico City, Mexico Daniela Laura Giardino Buenos Aires, Argentina Mar Guasp Barcelona, Spain Katrina Hannah Ignacio Manila, Phillipines Ümmügülsüm Koc Bochum, Germany Anand Kumar New Delhi, India Durjoy Lahiri Kolkata, India Shanglin Li Beijing, China Jingyi Liu Beijing, China Amina Mohamed Eldoret, Kenya Amina Nasri Tunis, Tunisia

Samir Patel Ahmedabad, India Gabriel Pinilla-Monsalve Valle del Cauca, Colombia Hebatallah Rashed Cairo, Egypt Mario Ricciard Buenos Aires, Argentina Moises Misael Rubio Hernandez Jalisco, Mexico María Agustina Ruiz Yanzi Buenos Aires, Argentina Lokesh Saini Chandigarh, India Laura Sander Basel, Switzerland Yi Shen Beijing, China Mei-Jun Shu Beijing, China Duncan James Street Cambridge, United Kingdom Ya Su Shanghai, China Naohiro Uchio Tokyo, Japan Nisa Vorasoot Khon Kean, Thailand Garik Yeganyan Yerevan, Armenia Gulshan Yunisova Istanbul, Turkey Ramdinal Aviesena Zairinal Jakarta, Indonesia

Irwin Schatz Award for Autonomic Disorders

Sponsored by the American Academy of Neurology and endowed by Lundbeck, Inc.

Recipient:

Horacio Kaufman, MD, FAAN New York, NY S19: Autonomic Disorders Monday, April 27, 3:30 p.m.

John Dystel Prize for Multiple Sclerosis Research

Sponsored by the American Academy of Neurology and National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society.

Recipient:

Ian Duncan, BVMS, MRCVS, PhD Madison, WI S5: Multiple Sclerosis: Clinical Trials and Diseasemodifying Therapy Sunday, April 26, 1:00 p.m.

Jon Stolk Award in Movement Disorders for Young Investigators

Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma.

Recipient:

Aasef Shaikh, MD, PhD Cleveland, OH S55: Movement Disorders: Neuromodulation, Circuits, and Management Thursday, April 30, 3:30 p.m.

Kenneth M. Viste Jr., MD Patient Advocate of the Year Award Sponsored by the American Academy of Neurology and endowed by gifts from Dr. Viste’s colleagues, friends, and patients.

Recipient:

Tissa Wijeratne, MD, FAHA, FAAN Melbourne, Australia

Lawrence C. McHenry: An Award for the History of Neurology Sponsored by the American Academy of Neurology.

Recipient:

Elizabeth Coon, MD Rochester, MN S36: History of Neurology Wednesday, April 29, 1:00 p.m.

Medical Student Essay Awards

Sponsored by the American Academy of Neurology.

Extended Neuroscience Recipient: Samuel Belfer, PhD Philadelphia, PA Poster Session 4 Sunday, April 26, 5:30 p.m. G.Milton Shy Recipient: Christopher Tran, BMSc Toronto, ON, Canada Poster Session 4 Sunday, April 26, 5:30 p.m. Roland P. Mackay Recipient: Jimmy Zheng, BS Stanford, CA Poster Session 4 Sunday, April 26, 5:30 p.m. Saul R. Korey Recipient: Laura Lavette, BS Winston-Salem, NC Poster Session 4 Sunday, April 26, 5:30 p.m. AAN.com/view/20AM 57

2020 Award Recipients Michael S. Pessin Stroke Leadership Prize

Neuro-oncology Scientific Award

Recipient: Ashkan Shoamanesh, BSc, MD Hamilton, ON, Canada S9: Cerebrovascular Disease: Intracerebral Hemorrhage Sunday, April 26, 3:30 p.m.

Recipient: David Gutmann, MD, PhD and Jaishri Blakeley, MD St. Louis, MO, and Baltimore, MD S14: Neuro-oncology Monday, April 27, 1:00 p.m.

Mitchell B. Max Neuropathic Pain Award

Sponsored by the American Academy of Neurology.

Sponsored by the American Academy of Neurology and endowed by Dr. Pessin’s family, friends, and colleagues.

Sponsored by the American Academy of Neurology and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max.

Recipient:

Anne Louise Oaklander, MD, PhD, FAAN, FANA Boston, MA S52: From Bench to Bedside with Novel Treatments for Pain Thursday, April 30, 3:30 p.m.

Movement Disorders Research Award

Sponsored by the American Academy of Neurology, the Parkinson’s Foundation, and the American Academy of Neurology Movement Disorders Section and endowed by the Parkinson’s Foundation.

Recipient:

Henry Paulson, MD, PhD, FAAN Ann Arbor, MI S11: Huntington’s Disease, Tardive Dyskinesia, and Functional Movement Disorders Sunday, April 26, 3:30 p.m.

Mridha Spirit of Neurology Humanitarian Award

Sponsored by the American Brain Foundation and funded through the philanthropy of Dr. and Mrs. Mridha.

Recipient:

Karen L. Parko MD, FAAN San Francisco, CA Global Health Section Meeting

Neuroendocrine Research Award

Sponsored by the American Academy of Neurology and supported by friends of Dr. Andrew Herzog.

Recipient:

This award was not given in 2020.

Neuro-infectious Disease Award

Sponsored by the American Academy of Neurology.

Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung.

Neuroscience Research Prize Recipients:

Abe Baker-Butler Rye Brook, NY Poster Session 4 Sunday, April 26, 5:30 p.m. Bryan Dong Baltimore, MD Poster Session 4 Sunday, April 26, 5:30 p.m. Nikhil Boddu Chesterfield, MO Poster Session 4 Sunday, April 26, 5:30 p.m.\

Neuroscience Research Prize in Child Neurology

Sponsored by the American Academy of Neurology and the Child Neurology Society.

Recipient:

Pratik Vangal Portland, OR Child Neurology Society Annual Meeting

Norman Geschwind Prize in Behavorial Neurology

Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology.

Recipient:

Richard Ryan Darby, MD Nashville, TN S15: Behavioral and Cognitive Neurology Monday, April 27, 1:00 p.m.

Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases Sponsored by the American Academy of Neurology and the American Brain Foundation and funded through the philanthropy of the Potamkin family.

Recipient: Pria Anand, MD Boston, MA S2: Infectious Disease: Neurovirology and Bacterial Complications Sunday, April 26, 1:00 p.m.

Recipient:

Neuro-oncology Investigator Award

Sponsored by the American Brain Foundation.

Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner.

Recipient:

Adrienne Boire, MD, PhD New York, NY S14: Neuro-oncology Monday, April 27, 1:12 p.m.

58 2020 AAN Annual Meeting

J. Paul Taylor. MD, PhD Memphis, TN Tuesday, April 28, 2:00 p.m.

Public Leadership in Neurology Award Recipient:

Emilia Clarke London, United Kingdom Commitment to Cures Wednesday, April 29, 6:00 p.m.

QI Innovation Award

Sponsored by the American Academy of Neurology.

Recipients:

Anita Fletcher, MD Louisville, KY Project Title: Applying EBM to Autoimmune and Paraneoplastic Neurologic Disease Ordering Practice to Improve Quality of Diagnostic Evaluation Dheeraj Khurana, MD, DM Chandigarh, India Project Title: Quality of Life and Caregiver Burden with Medical Application Based Post Stroke Care Strategy (MAPSS): A Pilot Study

Sheila Essey Award: An Award for ALS Research

Sponsored by the American Academy of Neurology, the American Brain Foundation and the ALS Association and supported through the philanthropy of the Essey Family and the ALS Association.

Recipient:

Guy Rouleau, MD, PhD Montreal, QC, Canada Tuesday, April 28, 2:00 p.m.

Scientific Breakthrough Award

Sponsored by the American Brain Foundation.

Recipients:

Michael D. Hill, MD, Andrew M. Demchuk, MD, and Mayank Goyal, MD, Calgary, AB, Canada Commitment to Cures Wednesday, April 29, 6:00 p.m.

Sleep Science Award

Sponsored by the American Academy of Neurology and the American Academy of Neurology Sleep Section and endowed by Cephalon, Inc.

Recipient:

RenĂŠe Shellhaas, MD, MS Ann Arbor, MI S3: Sleep Medicine: Highlights 2020 Sunday, April 26, 1:00 p.m.

Ted Burns Humanism in Neurology Award Sponsored by the American Brain Foundation.

Recipient:

Jon Stone, MB, ChB, FRCP, PhD Edinburgh, United Kingdom Commitment to Cures Wednesday April 29, 6:00 p.m.

Wayne A. Hening Sleep Medicine Investigator Award

Sponsored by the American Academy of Neurology and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening.

Recipient:

Mark Boulos, BSc, MD, FRCP(C), CSCN(EEG), MSc Toronto, ON, Canada S3: Sleep Medicine: Highlights 2020 Sunday, April 26, 1:24 p.m.

AAN.com/view/20AM 59

2020 Research Program Recipients The AAN is committed to supporting all types of research across discovery stages. Research is not only critical to the future of neurology but also in dire need of funding. The 2020 AAN Research Program exemplifies the AAN’s commitment to making a profound difference in the lives of researchers, which ultimately makes a difference in the lives of patients with brain disease.

Career Development Award

Funded by the American Academy of Neurology.

Recipients:

Oluwole Awosika, MD University of Cincinnati Hugo Aparicio, MD Boston University Medical Center

Clinical Research Training Scholarship Funded by the American Academy of Neurology.

Recipients:

Mark Etherton, MD, PhD Massachusetts General Hospital Carlyn Patterson Gentile, MD, PhD Children’s Hospital of Philadelphia David Lin, MD Massachusetts General Hospital

Clinical Research Training Scholarship in Tourette Syndrome

Funded by the Tourette Association of America and American Brain Foundation, in collaboration with the American Academy of Neurology.

Recipient:

Alonso Zea Vera, MD Cincinnati Children’s Hospital Medical Center

McKnight Clinical Translational Research Scholarship in Cognitive Aging and Age-Related Memory Loss Funded by the McKnight Brain Research Foundation through the American Brain Foundation and the American Academy of Neurology.

Recipients:

Bryan Baxter, PhD Massachusetts General Hospital Sarah Getz, PhD University of Miami

Clinical Research Training Scholarship in ALS

Neuroscience Research Training Scholarship

Recipient:

Recipients: William Zeiger, MD, PhD UCLA Richard Krolewski, MD, PhD Brigham and Women’s Hospital

Funded by The ALS Association and American Brain Foundation, in collaboration with the American Academy of Neurology.

Sarah Berth, MD, PhD Johns Hopkins University

Clinical Research Training Scholarship in Lewy Body Diseases

Funded by The Mary E. Groff Charitable Trust, the Alzheimer’s Association, and the American Brain Foundation, in collaboration with the American Academy of Neurology.

Recipient:

Lenora Higginbotham, MD Emory University

Clinical Research Training Scholarship in Neuromuscular Disease

Funded by the Muscle Study Group and American Brain Foundation, in collaboration with the American Academy of Neurology.

Recipient:

Paloma Gonzalez-Perez, MD, PhD Massachusetts General Hospital

Funded by the American Academy of Neurology.

Practice Research Training Scholarship Funded by the American Academy of Neurology.

Recipient:

Deanna Saylor, MD Johns Hopkins University

Richard Olney Clinician Scientist Development Award in ALS Funded by The ALS Association and American Brain Foundation, in collaboration with the American Academy of Neurology.

Recipient:

Collin Kreple, MD, PhD Washington University in St. Louis

Robert W. Katzman, MD Clinical Research Training Scholarship in Alzheimer’s or Related Disorders

Clinical Research Training Scholarship in Parkinson’s Disease

Funded by the Alzheimer’s Association and the American Brain Foundation, in collaboration with the American Academy of Neurology.

Recipient:

Susan Spencer, MD Clinical Research Training Scholarship in Epilepsy

Funded by the Parkinson’s Foundation and American Brain Foundation, in collaboration with the American Academy of Neurology.

James Curtis, MS, CCC-SLP, BCS-S Columbia University Teachers College

Recipient:

Lawren VandeVrede, MD, PhD University of California, San Francisco

Funded by the American Epilepsy Society, the Epilepsy Foundation, and American Brain Foundation, in collaboration with the American Academy of Neurology.

Recipient: 60 2020 AAN Annual Meeting

Colin Ellis, MD University of Pennsylvania

PLENARY SESSIONS Premier sessions highlighting the latest advances in neuroscience and presented by some of the most well-known and respected thought leaders in the field of neurology.

Hot Topics Plenary Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Saturday, April 25

4:15 p.m.–5:30 p.m.

Presidential Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 Sunday, April 26

9:15 a.m.–12:00 p.m.

Contemporary Clinical Issues Plenary Session. . . . . . . . . . . . . . . . . . . . . . . . 64 Monday, April 27

9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 Tuesday, April 28

9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Wednesday, April 29

9:15 a.m.–11:30 a.m.

Controversies in Neurology Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . 67 Thursday, April 30

9:15 a.m.–11:30 a.m.

Neurology Year in Review Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . 68 Friday, May 1

9:15 a.m.–11:30 a.m.

AAN.com/view/20AM 61

HOT TOPICS PLENARY SESSION Saturday, April 25

4:15 p.m.â&#x20AC;&#x201C;5:30 p.m.

CME

1.25

PLENARY SESSIONS

This session features the latest, cutting-edge translational research related to clinical issues of importance. Four outstanding speakers provide summaries of their recent research findings and describe the clinical implications of the results.

Moderator Temitayo Oyegbile, MD, PhD Health Peak Incorporated, McLean, VA Member, AAN Science Committee

Blood-Based Biomarkers To Predict Current And Future Alzheimerâ&#x20AC;&#x2122;s Disease

Emerging and Reemerging Viruses

Randall Bateman, MD Washington University School of Medicine, St. Louis, MO

TBD

Artificial Intelligence to Detect Papilledema and Other Optic Nerve Disorders on Ocular Fundus Photographs

Impairment and Recovery of Consciousness

Valerie Biousse, MD Emory University, Atlanta, GA

Jan Claassen, MD, PhD Columbia University, New York, NY

62 2020 AAN Annual Meeting

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

PRESIDENTIAL PLENARY SESSION Sunday, April 26

9:15 a.m.–12:00 p.m.

CME

2.75

This session features the AAN’s premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2020.

Natalia S. Rost, MD, MPH, FAAN, FAHA Massachusetts General Hospital, Boston, MA Chair, AAN Science Committee

Presidential Lecture–Physician Leadership and the Future of Health Care: A Conversation with John Noseworthy

Sidney Carter Award in Child Neurology: Precision Medicine in the Epilepsies – Reality or Fantasy?

John H. Noseworthy, MD, FAAN Past President and CEO of Mayo Clinic, Rochester, MN

Ingrid E. Scheffer, AO, MBBS, PhD, FRACP Melbourne Brain Centre, Heidelberg, Victoria, Australia

George C. Cotzias Lecture: Endogenous Retroviral Elements in Neurodegenerative Diseases

Robert Wartenberg Lecture: The Threatened Brain: Preventing Stroke and Dementia Together

Avindra Nath, MD, MBBS, FAAN National Institutes of Health, Bethesda, MD

Vladimir Hachinski, MD, DSc, FAAN London Health Sciences Centre, London, ON, Canada

AAN.com/view/20AM 63

PLENARY SESSIONS

Moderator

CONTEMPORARY CLINICAL ISSUES PLENARY SESSION Monday, April 27

9:15 a.m.â&#x20AC;&#x201C;11:30 a.m.

CME

2.25

This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. Commentary and discussion follow each presentation.

Moderator

PLENARY SESSIONS

Randolph S. Marshall, MD, FAAN Columbia University, New York, NY Vice Chair, AAN Science Committee

Improvement in Mood in Patients Receiving Blue Light Therapy Following a Mild Traumatic Brain Injury (mTBI) Presenter Bradley Shane University of Arizona, Tucson, AZ Discussant

Gene Therapy for Childhood Neuromuscular Syndromes Perry Shieh, MD, PhD, FAAN University of California, Los Angeles, CA

Phyllis C. Zee, MD, PhD Northwestern University Medical School, Chicago, IL

Radiologically Isolated Syndrome: A 10-year Follow-up Study to Identify Factors Predicting a First Clinical Event Presenter Christine Lebrun-Frenay, MD, PhD, FAAN Centre Hospitalier Universitaire, Nice, France

Neurologic Complications of New Anti-neoplastic Therapy TBD

Discussant Luanne Metz, MD Foothills Hospital, Calgary, AB, Canada

Leisure Time Physical Activity and MRI-based Brain Measures in a Multi-ethnic Elderly Cohort Presenter Yian Gu, PhD Columbia University, New York, NY

Stem Cell Tourism/Regenerative Medicine Sean I. Savitz, MD University of Texas, Houston, TX

Discussant TBD

64 2020 AAN Annual Meeting

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

CLINICAL TRIALS PLENARY SESSION Tuesday, April 28

9:15 a.m.â&#x20AC;&#x201C;11:30 a.m.

CME

2.25

This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented.

Moderators Deborah Hall, MD, PhD, FAAN Rush University, Chicago, IL Member, AAN Science Committee

Comparison of Two LDL Cholesterol Targets after Ischemic Stroke Pierre Amarenco, MD Bichat Hospital, Paris, France

Efficacy and Safety of JZP-258 in a Phase 3, Placebo-controlled, Double-blind, Randomized Withdrawal Study in Adults with Narcolepsy with Cataplexy Nancy R. Foldvary-Schaefer, DO, FAAN Cleveland Clinic, Cleveland, OH

Randomized Double Blind Placebo Controlled Trial of Intravenous Immunoglublins in LGI1/CASPR2-antibody Associated Epilepsies Divyanshu Dubey, MD Mayo Clinic, Rochester, MN

Ofatumummab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials Ludwig Kappos, MD, FAAN University Hospital Basel, Basel, Switzerland

Characterization of Treatment Emergent Adverse Events in Headache Pain-free Patients After Lasmiditan Dosing for the Acute Treatment of a Single Migraine Attack TBD

Established Status Epilepticus Treatment Trial (ESETT) Jaideep Kapur, MD, PhD University of Virginia, Charlottesville, VA

AAN.com/view/20AM 65

PLENARY SESSIONS

Holly Hinson, MD, MCR, FAAN Oregon Health and Science University, Portland, OR Member, AAN Science Committee

FRONTIERS IN NEUROSCIENCE PLENARY SESSION Wednesday, April 29

9:15 a.m.–11:30 a.m.

CME

2.25

This plenary session features basic and translational research related to clinical issues of importance. Six outstanding speakers provide summaries of their recent research findings and describe the clinical implications of the results.

Moderator

PLENARY SESSIONS

Paul M. George, MD, PhD, MSE Stanford Hospital, Stanford, CA Member, AAN Science Committee

Organization and Control of Hippocampal Circuits

Restoration of Brain Circulation and Cellular Functions Hours Post-mortem

Ivan Soltesz, PhD Stanford University School of Medicine, Stanford, CA

Nenad Sestan, MD, PhD Yale University, New Haven, CT

Decoding Speech Cortex

Stem Cell Therapy for Spinal Cord Injury: Transition to the Clinic

Edward F. Chang, MD University of California, San Francisco, CA

Microtubules in Health and Disease Antonina Roll-Mecak, PhD National Institute of Neurological Disorders and Stroke, Bethesda, MD

66 2020 AAN Annual Meeting

Mark H. Tuszynski, MD, PhD, FAAN University of California San Diego, La Jolla, CA

Dissecting the Control of Blood Flow Through Brain Capillaries Andy Shih, PhD Seattle Children’s Research Institute, Seattle, WA

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

CONTROVERSIES IN NEUROLOGY PLENARY SESSION Thursday, April 30

9:15 a.m.–11:30 a.m.

CME

2.25

This session features experts discussing the most current and controversial issues in neuroscience. It is set up as a debate format in which two speakers argue one side of a single topic, followed by a rebuttal.

Moderators Amy Brooks-Kayal, MD, FAAN Children’s Hospital Colorado, Aurora, CO Member, AAN Science Committee

CNS Antibodies: To Test or Not to Test?

Emerging Therapies: Can We Afford the Cost?

Yes

Sean J. Pittock, MD Mayo Clinic, Rochester, MN

Jason L. Crowell, MD Beth Israel Deaconess Medical Center, Boston, MA No

No TBD

A. Gordon Smith, MD, FAAN VCU Health System, Richmond, VA

Is Placebo Therapy a Sham? Yes TBD

No Helen S. Mayberg, MD Mt. Sinai School of Medicine, New York, NY

AAN.com/view/20AM 67

PLENARY SESSIONS

Brent L. Fogel, MD, FAAN University of California, Los Angeles, CA Member, AAN Science Committee

NEUROLOGY YEAR IN REVIEW PLENARY SESSION Friday, May 1

9:15 a.m.â&#x20AC;&#x201C;11:30 a.m.

CME

2.25

This session will feature six speakers, each focusing on the latest research that has happened in the last year within a specific subspecialty topic.

Moderator

PLENARY SESSIONS

Martinson K. Arnan, MD Bronson Health Group/Western Michigan University, Kalamazoo, MI

Epilepsy Seizure Detection and Device Intervention Kathryn A. Davis, MD University of Pennsylvania, Philadelphia, PA

Immunotherapies in Neuro-oncology

Headache Jennifer Bickel, MD, FAAN Childrens Mercy Hospital, Kansas City, MO

Amyloid Therapies

John F. De Groot, MD University of Texas, MD Anderson Cancer Center, Houston, TX

Jeffrey L. Cummings, MD, FAAN Cleveland Clinic, Las Vegas, NV

Therapeutics in Movement Disorders

Stroke Recovery

Irene Malaty, MD, FAAN University of Florida, Gainesville, FL

Heidi M. Schambra, MD New York University, New York, NY

68 2020 AAN Annual Meeting

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

NEUROSCIENCE IN THE CLINIC SESSIONS Two-hour sessions featuring a mix of scientists and clinicians actively engaged in lively case discussions to integrate scientific research with clinical application. Scientists will provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic and end with a panel discussion. Neuroscience in the Clinic: Novel Approaches to Pain Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Sunday, April 26

1:00 p.m.–3:00 p.m.

Neuroscience in the Clinic: Multimodal Tools for Cardiac Arrest Neuroprognostication . . . . . . . . . . . . . . . . . . . . 71 Monday, April 27

1:00 p.m.–3:00 p.m.

Neuroscience in the Clinic: Melatonin and Disrupted Sleep in Neurologic Disorders. . . . . . . . . . . . . . . . . . . . . . 72 Tuesday, April 28

3:30 p.m.–5:30 p.m.

Neuroscience in the Clinic: The Neurology of Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 Wednesday, April 29

3:30 p.m.–5:30 p.m.

Neuroscience in the Clinic: Testing for Common Neurodegenerative Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Thursday, April 30

1:00 p.m.–3:00 p.m.

AAN.com/view/20AM 69

NEUROSCIENCE IN THE CLINIC N1

Neuroscience in the Clinic: Novel Approaches to Pain Management Directors:

Sunday, April 26 1:00 p.m.–3:00 p.m.

Jessica Robinson Papp, MD, FAAN, New York, NY A. M. Barrett, MD, FAAN, Atlanta, GA

CME

NEUROSCIENCE IN THE CLINIC

Program Description:

The US opioid epidemic has highlighted the urgent need for effective, non-addictive treatments for people living with chronic pain, patients who neurologists often feel ill-equipped to treat. In this session, we will explore how improving knowledge of the mechanisms underlying chronic pain is informing the development of new pain treatments, and ways in which science and public policy are shaping our approach to these complex patients today. Upon Completion:

Participants will become familiar with mechanisms underlying chronic pain, promising new pain medications in development, and changes in public policy which affect neurologists and their patients with chronic pain. 1:00 p.m–1:05 p.m.

»» Introduction Jessica Robinson Papp, MD, FAAN, New York, NY 1:05 p.m.–1:15 p.m.

»» Patient Presentation: The Complex Chronic Pain Patient A. M. Barrett, MD, FAAN, Atlanta, GA 1:15 p.m.–1:45 p.m.

»» Coming Down the Pipeline: Novel Targets for Pain Management Shaheen E. Lakhan, MD, PhD, MEd, FAAN, Newton, MA 1:45 p.m.-2:00 p.m.

»» NIH HEAL Initiative: National Institute of Neurological Disorders and Stroke ININDS) Programs for Accelerated Development of Novel Approaches to Pain Management Barbara Karp, MD, FAAN, Rockville, MD 2:00 p.m.–2:15 p.m.

»» Decoding Acute and Chronic Pain State from Ambulatory Intracranial Recordings: Towards Closed-Loop Brain Stimulation Prasad Shirvalkar, MD, PhD, San Francisco, CA 2:15 p.m.–2:45 p.m.

»» Translating Discovery to Better Outcomes in Chronic Pain Jessica Robinson Papp, MD, FAAN, New York, NY 2:45 p.m.–3:00 p.m.

»» Clinical Wrap Up and Conclusion A. M. Barrett, MD, FAAN, Atlanta, GA

70 2020 AAN Annual Meeting

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

NEUROSCIENCE IN THE CLINIC N2

Neuroscience in the Clinic: Multimodal Tools for Cardiac Arrest Neuroprognostication Directors:

Monday, April 27 1:00 p.m.–3:00 p.m.

Martinson K. Arnan, MD, Kalamazoo, MI Holly E. Hinson, MD, MCR, FAAN, Portland, OR

CME

The science of prognosticating neurologic outcome following cardiac arrest in the era of targeted temperature management has been fast-moving over the past few years. This session features case vignettes and expert clinical commentary on how best to utilize biomarkers, imaging, and emerging technologies when making outcome predictions. Top abstracts related to post-cardiac arrest care and prognostication will be presented, with opportunities for panel discussion. Upon Completion:

Participants will be able to summarize the pros and cons of utilizing emerging biomarkers and tools for cardiac arrest prognostication and integrate this knowledge into their personal approaches for predicting post-arrest outcomes 1:00 p.m–1:05 p.m.

»» Introduction Martinson K. Arnan, MD, Kalamazoo, MI 1:05 p.m.–1:15 p.m.

»» Case Presentation Sachin Agarwal, MD, MPH, New York, NY 1:15 p.m.–1:55 p.m.

»» Current Clinical Algorithms for Neurologists Approaching the Cardiac Arrest Patient Karen Hirsch, MD, Palo Alto, CA 1:55 p.m.–2:20 p.m.

»» Case Presentation: Follow Up Sachin Agarwal, MD, MPH, New York, NY 2:20 p.m.–2:35 p.m.

»» Invasive Neuromonitoring Predicts Awakening After Diffuse Hypoxic Ischemic Brain Injury Swarna Rajagopalan, MD, Philadelphia, PA 2:35 p.m.–2:50 p.m.

»» Resting EEG Spectral Features Related to Cortico-thalamic Integrity in Post-cardiac Arrest Patients Correlate with Outcomes Kurt Qing, MD, New York, NY 2:50 p.m.–3:00 p.m.

»» Summary of Discussion and Questions and Answers Holly E. Hinson, MD, MCR, FAAN, Portland, OR

AAN.com/view/20AM 71

NEUROSCIENCE IN THE CLINIC

Program Description:

NEUROSCIENCE IN THE CLINIC N3

Neuroscience in the Clinic: Melatonin and Disrupted Sleep in Neurologic Disorders Directors:

Tuesday, April 28 3:30 p.m.–5:30 p.m. CME

Amy Gelfand, MD, San Francisco, CA Temitayo Oyegbile, MD, PhD, McLean, VA

NEUROSCIENCE IN THE CLINIC

Program Description:

Adults and children with neurologic disorders such as epilepsy, migraine,autism, Parkinson’s, stroke, and concussion often experience significantly disrupted sleep. There is accumulating evidence suggesting that melatonin may play a role in this interaction between neurologic disorders and sleep disruption. This program will address what is known about the role of melatonin in brain activity, and how this may pertain to fluctuations in neurologic function and sleep abnormalities. The program will draw on examples from multiple sclerosis, Parkinson’s, autism, headache, epilepsy, cerebrovascular disease, and other neurologic conditions. The program will also emphasize potential approaches to modulating the effect of melatonin to optimize sleep and treatment of neurologic disorders. Upon Completion:

Upon completion, participants should be familiar with sleep abnormalities observed in multiple neurologic disorders and how melatonin may affect neurologic function. 3:30 p.m.–3:40 p.m.

»» General Overview: Specific Neurologic Disorders and Disrupted Sleep: Highlighting the Role of Melatonin Temitayo Oyegbile, MD, PhD, McLean, VA 3:40 p.m.–3:50 p.m.

»» Clinical Vignette: Sleep Disruption and Migraine Amy Gelfand, MD, San Francisco, CA 3:50 p.m.–4:20 p.m.

»» Sleep, Clocks, and Melatonin in Neurologic Disorders Aleksandar Videnovic, MD, MSc, FAAN, Boston, MA 4:20 p.m.–4:35 p.m.

»» A Computational Model of the Role of Melatonin in the Pathogenesis and Disrupted Sleep in Multiple Sclerosis Joao Marcos Brandet, Londrina, Brazil 4:35 p.m.–4:50 p.m.

»» Peak Seizure Frequency Correlates with Disruptive Spiking in Rapid Eye Movement Sleep Marna McKenzie, Winnipeg, MB, Canada 4:50 p.m.–5:05 p.m.

»» Strategies to Modulate Melatonin to Affect Sleep Temitayo Oyegbile, MD, PhD, McLean, VA 5:05 p.m.–5:15 p.m.

»» Clinical Vignette Wrap Up Amy Gelfand, MD, San Francisco, CA 5:15 p.m.–5:30 p.m.

»» Panel Discussion Faculty

72 2020 AAN Annual Meeting

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

NEUROSCIENCE IN THE CLINIC N4

Neuroscience in the Clinic: The Neurology of Obesity Directors:

Riley Bove, MD, San Francisco, CA Deborah Gustafson, PhD, Brooklyn, NY

Wednesday, April 29 3:30 p.m.–5:30 p.m. CME

Program Description:

Upon Completion:

Participants will be able to identify the major neurological disorders whose risk is increased by obesity; articulate mechanisms through which obesity influences brain health; and be familiar with emerging treatment approaches such as intermittent fasting, intranasal insulin, growth hormone, among others. 3:30 p.m.–3:40 p.m.

»» Case Presentation: An Obese Patient with TIA Illana Katz Sand, MD, New York, NY Satya Dash, MD, PhD, Toronto, ON, Canada 3:40 p.m.–4:00 p.m.

»» The Neuroepidemiology of Obesity Deborah Gustafson, PhD, Brooklyn, NY 4:00 p.m.–4:20 p.m.

»» Genetics of Body Weight Regulation Illana Katz Sand, MD, New York, NY Satya Dash, MD, PhD, Toronto, ON, Canada 4:20 p.m.–4:30 p.m.

»» Clinician Follow Up: Treatment Approaches Faculty 4:30 p.m.–4:45 p.m.

»» Circulating Leptin in the Preclinical Stage of Alzheimer’s Disease Carrie Sha, New York, NY 4:45 p.m.–5:00 p.m.

»» Short-Term Home-Based Lifestyle Management Helps Reduce Weight and Improve Quality of Life in Persons with Epilepsy Sudhindra Vooturi, Secunderabad, India 5:00 p.m.–5:30 p.m.

»» Panel Discussion Faculty

AAN.com/view/20AM 73

NEUROSCIENCE IN THE CLINIC

The epidemic of obesity has resulted in a host of physiological changes - vascular, immune and reproductive - that influence susceptibility to neurological disease. In this NIC, we will examine the neuroepidemiology of obesity. Our invited scientist will review specific endocrine (including growth hormone, insulin-like growth hormone, and insulin) and other mechanisms through which obesity influences susceptibility to disease. Then, we will discuss the impact of treatments aimed at curbing the effects of obesity (inhaled insulin, intermittent fasting, growth hormone treatment) on neurological health. The session will focus on cerebrovascular disease, cognition, and neuroinflammatory diseases.

NEUROSCIENCE IN THE CLINIC N5

Neuroscience in the Clinic: Testing for Common Neurodegenerative Disorders Directors:

Thursday, April 30 1:00 p.m.–3:00 p.m. CME

Brent L. Fogel, MD, PhD, FAAN, Los Angeles, CA Karen S. Marder, MD, MPH, FAAN, New York, NY

NEUROSCIENCE IN THE CLINIC

Program Description:

The utilization of genetic testing in the diagnostic evaluation and management of patients with common neurodegenerative disorders is becoming more widespread, creating new challenges for the practicing neurologist. In addition to identifying familial forms and phenotypically overlapping rare neurogenetic disorders, testing can reveal genetic polymorphisms and other alterations contributing to disease risk that may be clinically useful for both diagnosis and further management. This program will provide an overview of the role of genetics in common neurodegenerative disease, guidance on how to identify pathogenic mutations in rare disorders, updates on the current state-of-the-art regarding interpretation of variants in genes associated with risk of disease, and suggest how to communicate this information to patients and their families. Upon Completion:

Participants should become familiar with the application of genetic testing to the evaluation and management of common neurodegenerative diseases, including the contribution of pathogenic mutations causing rare phenotypically similar neurogenetic disorders as well as variants in genes associated with risk of disease. Strategies on sharing this information with patients and their families will be discussed. 1:00 p.m.–1:30 p.m.

»» Identifying Rare and Common Genetic Variation in Patients with Neurodegenerative Disease Laurie J. Ozelius, PhD, Charlestown, MA 1:30 p.m.–1:45 p.m.

»» A Diagnostic Ceiling for Exome Sequencing in Cerebellar Ataxia and Related Neurological Disorders Brent L. Fogel, MD, PhD, FAAN, Los Angeles, CA 1:45 p.m.–2:15 p.m.

»» Utilizing Genetics to Improve the Clinical Management of Common Neurodegenerative Disorders Matthew Harms, MD, New York, NY 2:15 p.m.–2:30 p.m.

»» From Bedside to Bench and Back to Bedside and Clinical Practice: A Comprehensive Study of the Mitochondrial Neurodegenerative Disease MELAS Andrea Gropman, MD, Washington, DC 2:30 p.m.–3:00 p.m.

»» The Role of Genetic Risk in the Diagnosis and Treatment of Common Neurodegenerative Disorders Suman Jayadev, MD, Seattle, WA

74 2020 AAN Annual Meeting

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

INVITED SCIENCE SESSIONS Scientific sessions featuring authors giving encore presentations of top abstracts and presentations previously presented at subspecialty meetings. 2020 Invited Science sessions will feature abstracts previously presented at the Peripheral Nerve Society, the Child Neurology Society, and the International Parkinson and Movement Disorder Society.

IS1 | Invited Science: Child Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 Sunday, April 26

3:30 p.m.–5:30 p.m.

IS2 | Invited Science: Movement Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . 76 Monday, April 27

3:30 p.m.–5:30 p.m.

IS3 | Invited Science: Neuromuscular. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 Tuesday, April 28

1:00 p.m.–3:00 p.m.

AAN.com/view/20AM 75

INVITED SCIENCE SESSIONS IS1

Invited Science: Child Neurology Sunday, April 26

3:30 p.m.–5:30 p.m.

CME

This session will highlight cutting-edge science and hot topics in child neurology, in partnership with the Child Neurology Society.

INVITED SCIENCE SESSIONS

3:30 p.m.–3:50 p.m.

4:30 p.m.–4:50 p.m.

»» Gene Therapy for AADC deficiency: MRI-Guided Delivery of AAV2hAADC to the Midbrain Toni Pearson, MD, St Louis, MO 3:50 p.m.–4:10 p.m.

»» Exome sequencing in patients with cerebral palsy identifies an etiology in one-third of cases, underscoring the need for broad genetic testing and a significant recurrence risk for families Francisca Millan Zamora, MD, Gaithersburg, MD 4:10 p.m.–4:30 p.m.

»» Effect of Anti-Epileptic Drug Prophylaxis on Time to First Seizure Diagnosis in Children with Brain Tumors, Using National Medicaid Claims from 2009 to 2012 Michelle Yun, New York, NY

IS2

»» Adaptor Protein Complex 4 Deficiency: A Paradigm of Childhood-onset Hereditary Spastic Paraplegia Associated With Defective Protein Trafficking Darius Ebrahimi-Fakhari, MD, PhD, Brookline, MA 4:50 p.m.–5:10 p.m.

»» TBD 5:10 p.m.–5:30 p.m.

»» Physiologic dysfunction, demyelination, and retinal ganglion cell loss in mice with neurofibromatosis and optic pathway gliomas Steven F. Stasheff, MD, Cambridge, MA

Invited Science: Movement Disorders Monday, April 27

3:30 p.m.–5:30 p.m.

CME

This session will highlight cutting edge science and hot topics in movement disorders, in partnership with the International Parkinson and Movement Disorder Society. 3:30 p.m.–3:50 p.m.

»» TBD 3:50 p.m.–4:10 p.m.

»» The Economic Burden of Parkinson’s Disease (PD) in the United States Caroline M. Tanner, MD, PhD, FAAN, San Francisco, CA 4:10 p.m.–4:30 p.m.

»» Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD Blair Leavitt, MD, Vancouver, BC, Canada

4:50 p.m.–5:10 p.m.

»» Structural connectome of brainstem nuclei in REM sleep behavior disorder, a model of premanifest synucleinopathy Maria Guadalupe Garcia-Gomar, Boston, MA 5:10 p.m.–5:30 p.m.

»» Relative Preservation of Serotonergic Function Increases Response to Treatment in Early PD Vesna Sossi, PhD, Vancouver, BC, Canada

4:30 p.m.–4:50 p.m.

»» Tremoroton, a new open source tool for tremor analysis Felipe Vial, MD, Santiago, MD

76 2020 AAN Annual Meeting

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

INVITED SCIENCE SESSIONS IS3

Invited Science: Neuromuscular Tuesday, April 28

1:00 p.m.–3:00 p.m.

CME

This session will highlight cutting-edge science of hot topics in neuromuscular disease in partnership with the Peripheral Nerve Society.

INVITED SCIENCE SESSIONS

1:00 p.m.–1:20 p.m.

»» Improving Neuropathy and Mobility in Diabetes: the INMED trial Lindsay A. Zilliox, MD, Baltimore, MD 1:20 p.m.–1:40 p.m.

»» Gut Microbiome and its Potential Role in Obesity-Induced Allodynia Raiza Bonomo, MD, Chicago, IL 1:40 p.m.–2:00 p.m.

»» TBD 2:00 p.m.–2:20 p.m.

»» Gene Replacement Therapy For CMT1X Neuropathy Alexia Kagiava, Nicosia, Cyprus 2:20 p.m.–2:40 p.m.

»» Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study Michael J. Polydefkis, MD, FAAN, Baltimore, MD 2:40 p.m.–3:00 p.m.

»» Targeting a core axonal degeneration program to treat vincristine and bortezomib-induced axonal degeneration Stefanie Geisler, MD, Saint Louis, MO

AAN.com/view/20AM 77

The Poster Hall is Going All Electronic All scientific posters will be digital. Poster presentations are now more immersive, interactive, and engaging than ever before. Don’t miss this one-of-a-kind opportunity to participate with presenters and colleagues. Visit the Poster Hall for three different daily sessions to catch all the latest science: Saturday (Poster Session 1): •12:00 p.m. to 1:00 p.m. Sunday-Thursday (Poster Sessions 2-16) •8:00 a.m. to 9:00 a.m. •12:00 p.m. to 1:00 p.m. •5:30 p.m. to 6:30 p.m. Friday (Poster Session 17 and Innovation Lunch) •11:30 a.m. to 1:00 p.m.

SCIENTIFIC SESSIONS Scientific Sessions are a group of abstracts covering a similar topic presented in an oral format. Presentations are 12 minutes in length with eight minutes for presentation and four minutes for questions and answers with the author.

Sunday, April 26 1:00 p.m.–3:00 p.m. S1 Headache I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 S2 Infectious Disease: Neurovirology and Bacterial Complications. . . 81 S3 Sleep Medicine: Highlights 2020. . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 S4 Aging and Dementia: Risk Factors and Genetics. . . . . . . . . . . . . . . . 82 S5 Multiple Sclerosis: Clinical Trials and Disease-modifying Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 S6 Neuromuscular and Clinical Neurophysiology (EMG): Genetic Muscle Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 3:30 p.m.–4:15 p.m. S7 Global Health. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 3:30 p.m.–5:30 p.m. S8 Migraine Therapeutics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 S9 Cerebrovascular Disease: Intracerebral Hemorrhage. . . . . . . . . . . . 85 S10 Multiple Sclerosis: Biomarkers and Outcome Measures. . . . . . . . 86 S11 Huntington’s Disease, Tardive Dyskinesia, and Functional Movement Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 S12 General Neurology: Neurotherapeutics and Clinical Trials. . . . . . . 87

Monday, April 27 1:00 p.m.–3:00 p.m. S13 Epilepsy/Clinical Neurophysiology (EEG) 1. . . . . . . . . . . . . . . . . . . 88 S14 Neuro-oncology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 S15 Behavioral and Cognitive Neurology. . . . . . . . . . . . . . . . . . . . . . . . 89 S16 Autoimmune Neurological Disorders: Diagnosis, Biomarkers, and Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 S17 Parkinson’s Disease Biomarkers and Pathophysiology. . . . . . . . . . 90 S18 Neuromuscular and Clinical Neurophysiology (EMG): Neuroimaging, Outcome Measures, and Biomarkers. . . . . . . . . . . . . . . 91

3:30 p.m.–4:30 p.m. S19 Autonomic Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91 3:30 p.m.–5:30 p.m. S20 Cerebrovascular Disease: Large Vessel Occlusions and Thrombectomy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92 S21 Neuroepidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92 S22 Practice, Policy, and Ethics: Improving Patient Care and the Rise of Telemedicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93 S23 Aging and Dementia: Biomarkers and Clinical Trials . . . . . . . . . . . 93 S24 Pregnancy, Pediatric MS, and Early MS . . . . . . . . . . . . . . . . . . . . . 94

Tuesday, April 28 1:00 p.m.–3:00 p.m. S25 Epilepsy/Clinical Neurophysiology (EEG) 2. . . . . . . . . . . . . . . . . . . 95 S26 Cerebrovascular Disease: Systems of Stroke Care . . . . . . . . . . . . 95 S27 Child Neurology and Developmental Neurology: Neurogenetics: Translating Knowledge to Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 S28 Infectious Disease: Chronic Meningitis and the Immunosuppressed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 S29 Multiple Sclerosis: Disease-modifying Therapy. . . . . . . . . . . . . . . 97 3:30 p.m.–4:45 p.m. S30 Sports Neurology and Neuro Trauma . . . . . . . . . . . . . . . . . . . . . . . 97 3:30 p.m.–5:30 p.m. S31 Epilepsy/Clinical Neurophysiology (EEG) 3. . . . . . . . . . . . . . . . . . . 98 S32 Neuro-ophthalmology/Neuro-otology. . . . . . . . . . . . . . . . . . . . . . . 98 S33 Aging and Dementia: Non-Alzheimer Dementia. . . . . . . . . . . . . . . 99 S34 Clinical Trials and Therapeutics in Autoimmune Neurology. . . . . 100 S35 Amyotrophic Lateral Sclerosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . 100

AAN.com/view/20AM 79

Wednesday, April 29 1:00 p.m.–2:00 p.m. S36 History of Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 1:00 p.m.–3:00 p.m. S37 Stroke Epidemiology: Risk Factors, Incidence, and Unique Populations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 S38 Child Neurology and Developmental Neurology: Acquired Brain Injury: Brain-Behavior Relationships. . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 S39 Autoimmune and Paraneoplastic Neurological Disorders: Clinical Characteristics and Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 S40 Multiple Sclerosis: Clinical Trials. . . . . . . . . . . . . . . . . . . . . . . . . . 104 S41 Parkinson’s Disease Interventions and Clinical Trials. . . . . . . . . . 104 3:30 p.m.–4:30 p.m. S42 Neuro-rehabilitation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105 3:30 p.m.–5:30 p.m. S43 Stroke Recovery and Outcomes. . . . . . . . . . . . . . . . . . . . . . . . . . . 105 S44 Research Methodology and Education. . . . . . . . . . . . . . . . . . . . . 106 S45 Multiple Sclerosis: Imaging. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 S46 Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron/Charcot Marie Tooth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107

Thursday, April 30 1:00 p.m.–3:00 p.m. S47 Headache II. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 S48 Neurocritical Care: Traumatic Brain Injury and Goals-of-care Decision-making. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 S49 Multiple Sclerosis: Basic Science . . . . . . . . . . . . . . . . . . . . . . . . . 109 S50 Ataxia, Dystonia, and Atypical Parkinsonism. . . . . . . . . . . . . . . . 109 S51 General Neurology: Models of Clinical Care and Disease. . . . . . . 110 3:30 p.m.–4:45 p.m. S52 From Bench to Bedside with Novel Treatments for Pain. . . . . . . . 110 3:30 p.m.–5:30 p.m. S53 Stroke Prevention. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 S54 Multiple Sclerosis: Disease Progression, Disease-modifying Therapy, and Clinical Considerations. . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 S55 Movement Disorders: Neuromodulation, Circuits, and Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112 S56 Neuromuscular Therapeutics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113 S57 General Neurology: Diagnostic Testing and Disease Biomarkers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113

Friday, May 1 1:00 p.m.–3:00 p.m. S58 Headache Therapeutics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114 S59 Epilepsy/Clinical Neurophysiology (EEG) 4. . . . . . . . . . . . . . . . . . . 114 S60 Cerebrovascular Imaging and Biomarkers. . . . . . . . . . . . . . . . . . . . 114 S61 Neurocritical Care: Cerebrovascular Disease. . . . . . . . . . . . . . . . . 115

80 2020 AAN Annual Meeting

SUNDAY, APRIL 26 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m. S1

Headache I

1:00 p.m. Harold Wolff-John Graham Award: An Award for Headache/Facial Pain Research Presentation This award recognizes individuals who have submitted research results in the field of headache and facial pain. Recipient: Mia Minnen, MD, MPH New York, NY

2:48 p.m. S1.010 Resting State Functional Connectivity Changes of the Hypothalamus in Migraine Patients: A Cross-Sectional and Longitudinal Study–Roberta Messina, Maria Assunta Rocca, Paola Valsasina, Paolo Misci, Massimo Filippi

Infectious Disease: Neurovirology and Bacterial Complications

CME

1:00 p.m. AAN Neuro-infectious Disease Award Presentation This award recognizes individuals who have made a contribution to neuro-infectious disease research. Recipient: Pria Anand, MD Boston, MA 1:12 p.m. S2.002 Eastern Equine Encephalitis: Case Series in Southern New England–Mayra Montalvo Perero, Dana Ayoub, Katrina Byrd, Michael McGary, Ali Mahta, Shyam Sudarshan Rao, Nicholas S. Potter, Michael E. Reznik, Leonard Mermel, Douglas Anthony, Bradford B. Thompson, Linda C. Wendell 1:24 p.m. S2.003 The Conundrum of Inherited Chromosomally Integrated Human Herpes Virus 6 (HHV-6) in an Allogenic Hematopoietic Stem Cell Transplant (HSCT) Recipient–Claire Emmanuelle Delpirou Nouh, Kathy Hoang, Nelson Iván Agudelo Higuita 1:36 p.m. S2.004 Human Pegivirus-1 is Neurotropic and Associated with Neuroinflammation–Matthew Doan, William Branton, Tom Hobman, Benjamin Gelman, Christopher Power 1:48 p.m. S2.005 Microglia Have a Protective Role in Neurotropic Picornavirus Infection–John Michael Sanchez, Ana Beatriz DePaula-Silva, Daniel Doty, Tyler James Hanak, Jane Libbey, Robert Fujinami 2:00 p.m. S2.006 MRI Findings in Patients with Herpes Simplex Virus Central Nervous System Infection and Its Clinical Correlations–Tracey Huijun Fan, Jean Khoury, Adarsh Bhimraj, Ken Uchino, Sung Min Cho 2:12 p.m. S2.007 Reduced Vitamin D Levels Are Associated with Stroke-associated Pneumonia in Patients with Acute Ischemic Stroke–Gui-Qian Huang, Zhen Wang, Jin-Cai He 2:24 p.m. S2.008 Misdiagnosed Sporadic Creutzfeldt-Jakob Disease with Unique CN6 Palsy Presentation–Jessie Jacobson, Kelsey Cacic, Francis Cloran 2:36 p.m. S2.009 Ehrlichia Meningoencephalitis: A Case Series– Jonathan Morena, Marika Antimisiaris, Zak Boggs, Dilip Singh, Mark Lustberg 2:48 p.m. S2.010 Elizabethkingia Meningoseptica Lumbar Discitis Presenting with Sciatica in a Clinical Setting–Kayla Rodriguez, Salman Assad, Alexandra Gillispie, Meagen Carter, Justin Michael Nolte, Samrina Hanif

AAN.com/view/20AM 81

Sunday, April 26

SCIENTIFIC SESSIONS

1:12 p.m. S1.002 New Evidence from the Italian chROnic migraiNe Registry (IRON Registry): An Update on 866 Patients–Piero Barbanti, Luisa Fofi, Gabriella Egeo, Cinzia Aurilia, Licia Grazzi, Fabrizio Vernieri, Claudia Altamura, Cecilia Camarda, Paola Torelli, Sabina Cevoli, Antonio Russo, Francesco Bono, Cinzia Finocchi, Renata Rao, Stefano Messina, Roberto De Simone, Florindo D’Onofrio, Marco Aguggia, Fabio Frediani, Antonio Carnevale, Massimo Autunno, Chiara Lia, Giovanni Battista Allais, Alfonso Coppola, Francesco Perini, Patrizia Balsamo, Silvia Strumia, Bruno Colombo, Stefania Proietti, Nicola Vanacore, Stefano Bonassi 1:24 p.m. S1.003 Acute Treatment Optimization Influences Disability and Quality of Life in Migraine: Results of the ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) Study–Dawn C. Buse, Amy J Kovacik, Robert Nicholson, Erin G. Doty, Andre B Araujo, Sait Ashina, Michael L. Reed, Robert E. Shapiro, Yongin Kim, Richard B. Lipton 1:36 p.m. S1.004 Evaluation of Triggers of Status Migrainosus and its impact on morbidity.–Urvish K. Patel, Liseth Katia Lavado, Dhaivat Janakbhai Shah, Preeti Malik, Maryam Hussain, Vikrant Bhatnagar, Ashish Vikrant Kapoor, Kogulavadanan Arumaithurai, Tapan R. Kavi 1:48 p.m. S1.005 Environmental and Genetic Circadian Disruption Increases Migraine-Associated Phenotypes in Mice–Lauren Strother, Louis J. Ptacek, Peter Goadsby, Philip R. Holland 2:00 p.m. S1.006 Admission for Migraine is Increasing Over Time–Daniel Mandel, Liqi Shu, Amanda Tinsley, Shawna M. Cutting, Julie Roth 2:12 p.m. S1.007 Executive Function in Adolescents with Chronic Headache: A Population Study–Renato Arruda, Luis Anunciacao, Marco Antonio Arruda 2:24 p.m. S1.008 The Profile and Prognosis of Youth with Status Migrainosus: Results From an Observational Study– Serena Orr, Abigail Turner, Marielle Kabbouche, Paul Horn, Hope O’Brien, Joanne Kacperski, Susan LeCates, Shannon White, Jessica Weberding, Mimi Miller, Scott Powers, Andrew D. Hershey 2:36 p.m. S1.009 Diagnostic Delay in Patients Prior to being Seen in the Headache Clinic–Pooja Puvvadi, Melissa Schorn, Sau Mui Chan-Goh, Daniel Krashin, Natalia Murinova

CME

SUNDAY, APRIL 26 1:00 p.m.–3:00 p.m. S3

Sleep Medicine: Highlights 2020

Sunday, April 26

SCIENTIFIC SESSIONS

1:00 p.m. Sleep Science Award This award recognizes distinguished academic contributions by neurologists to the field of sleep medicine or the contributions of non-neurologists to the interface area of sleep-neurology. Recipient: Renée Shellhaas, MD, MS Ann Arbor, MI

1:00 p.m.–3:00 p.m. CME

2:48 p.m. S3.010 Microstructural and connectivity brainstem changes in REM Sleep Behavior Disorder by 7 Tesla MRI–Marta Bianciardi, Maria Guadalupe Garcia-Gomar, Kavita Singh, Matthew Stauder, Laura Lewis, Berkin Bilgic, Lawrence Wald, Bruce R. Rosen, Aleksandar Videnovic

1:24 p.m. Wayne A. Hening Sleep Medicine Investigator Award This award recognizes scientific contributions in sleep from promising young investigators. The goal of this award is to reward productive young investigators and to emphasize the essential role of neurology in sleep medicine Recipient: Mark Boulos, BSc, MD, FRCP(C), CSCN(EEG), MSc Toronto, ON, Canada 1:36 p.m. S3.004 Hypersomnolence is a Significant Predictor of New Medical Conditions Among Elderly People in a Longitudinal Study of the General Population– Maurice Moyses Ohayon, Shannon Sullivan, Marie-Lise Cote 1:48 p.m. S3.005 Autoimmunity to Hypocretin/Orexin and Molecular Mimicry to Flu in Type 1 Narcolepsy–Guo Luo, Aditya Ambati, Ling Lin, Markku Partinen, Xuhuai Ji, Holden Maecker, Emmanuel Mignot 2:00 p.m. S3.006 Kleine-Levin Syndrome is Associated with TRANK1 and Temporally Influenced by Year of Birth–Aditya Ambati, Ryan Hillary, Smaranda Leu, Hanna Ollila, Ling Lin, Emmanuel H. During, Neal Farber, Thomas Rico, Juliette Faraco, Eileen Leary, Yu-shu Huang, Fang Han, Yakov Sivan, Anne-Marie Lantblom, Makrina Daniilidou, Michel Lecendreux, Makoto Honda, Natan Gadoth, Sona Nevsimalova, Fabio Pizza, Takashi Kanbayashi, Rosa Peraita Adrados, Francesca Canellas, Kazuhiko Kume, Guy Leschziner, Taku Miyagawa, Patrice Bourgin, Jose L Vicario, Birgit E. Hogl, ADI ARAN, Catherine M Simpson, Giuseppe Plazzi, Geert K. Mayer, Yves Dauvilliers, Isabelle Arnulf, Emmanuel Mignot 2:12 p.m. S3.007 Cognitive Function Declines in REM Sleep Behavior Disorder with Dopamine Transporter Binding Deficit–Noriko Nishikawa, Youhei Mukai, Takashi Sakamoto, Nobutaka Hattori, Ryosuke Takahashi, Hideki Mochizuki, Tomohiko Nakamura, Hiroshi Matsuda, Yuji Takahashi 2:24 p.m. S3.008 Cognitive Determinants in Isolated REM Sleep Behavior Disorder: a Cross-sectional and Longitudinal Approach–Luca Baldelli, Luisa Sambati, Giovanna Calandra-Buonaura, Pietro Guaraldi, Pietro Cortelli, Federica Provini 2:36 p.m. S3.009 Abnormal REM Sleep Atonia Control in Patients With Chronic Post-Traumatic Stress Disorder–John Craig Feemster, Tyler Steele, Kyle Palermo, Yumeng Tao, David Bauer, Sonia Rivera, Maxwell WaltersSmith, Thomas Gossard, Luke Teigen, Paul Timm, Stuart McCarter, Erik Kent St. Louis

82 2020 AAN Annual Meeting

Aging and Dementia: Risk Factors and Genetics

CME

1:00 p.m. S4.001 Neuropsychological Decline Up to 20 Years Before Incident Mild Cognitive Impairment–Richard J. Caselli, Blake Langlais, Amylou C. Dueck, Yinghua Chen, Yi Su, Dona Locke, Bryan Keith Woodruff, Eric M. Reiman 1:12 p.m. S4.002 Neurodegenerative Outcomes Following Diagnosis of REM Sleep Behavior Disorder or Isolated REM Sleep Without Atonia–Carol Swetlik, Robert Unger, James Bena, Nancy R. Foldvary-Schaefer, Carlos Rodriguez, Babak Tousi 1:24 p.m. S4.003 Transcriptome Analysis of Single Nucleus RNA-seq from Alzheimer Disease APOE4 Carrier Brains in African American (AA) and Non-Hispanic Whites (NHW) Reveals Differences in APOE Expression–Katrina Celis, Anthony J. Griswold, Parker L. Bussies, Farid Rajabli, Patrice Whitehead, Daniel Dorfsman, Kara Hamilton-Nelson, Eileen Bigio, M. Marsel Mesulam, Changiz Geula, Sandra Weintraub, Marla Gearing, Gary W. Beecham, William K. Scott, Margaret A. Pericak-Vance, Juan young, Jeffery M. Vance 1:36 p.m. S4.004 Cardiovascular Health Across Young Adulthood, Cerebral Autoregulation, and Cognitive Function in Midlife–Meghana Shownkeen, Simin Mahinrad, Kristine Yaffe, Donald M Lloyd-Jones, Farzaneh Aghdassi Sorond 1:48 p.m. S4.005 Evidence of a Causal Association Between Cancer and Alzheimer’s Disease: A Mendelian Randomization Analysis–Sahba Seddighi, Alexander Houck, Alexander Houck, Paul Pharoah 2:00 p.m. S4.006 Using the Lens of Local Ancestry to Focus Risk in Alzheimer Disease–Farid Rajabli, Briseida Feliciano-Astacio, Katrina Celis, Jeffery M. Vance, Farid Rajabli, Margaret A. Pericak-Vance 2:12 p.m. S4.007 Vesicular Transport Related Genes Impact Age of Onset in Alzheimer’s Disease (AD)–Jagan Pillai, William Bush, Nicholas Wheeler, James B. Leverenz, Jonathan Haines 2:24 p.m. S4.008 In a Large Belgian AD Cohort Loss of ABCA7 Mutations Are Associated with Alzheimer’s Disease and Cerebral Amyloid Angiopathy.– Elisabeth Hens, Liene Bossaerts, Tobi Van den Bossche, Sebastiaan Engelborghs, Karin Peeters, Marleen Van Den Broeck, Yannick Vermeiren, Annelies Laureys, Naomi De Roeck, Bernard J. Hanseeuw, Anne Sieben, Rik Vandenberghe, JeanJacques Martin, Peter P. De Deyn, Patrick Cras, Christine Van Broeckhoven 2:36 p.m. S4.009 Genome-wide Association Study of Tau PET in the Mayo Clinic Study of Aging–Vijay K. Ramanan, Xuewei Wang, Scott Przybelski, Sheela Raghavan, David S. Knopman, Jonathan Graff-Radford, Val John Lowe, Michelle M. Mielke, Clifford R. Jack, Ronald C. Petersen, Owen A. Ross, Prashanthi Vemuri

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

SUNDAY, APRIL 26 1:00 p.m.–3:00 p.m. S4

Aging and Dementia: Risk Factors and Genetics

CME

2:48 p.m. S4.010 Genome-wide Association Study Identifies Variants in FAM171A2 Associated with Cerebrospinal Fluid Progranulin Levels and Neurodegenerative Diseases–Wei Xu, Jin-Tai Yu, Lan Tan

Multiple Sclerosis: Clinical Trials and Disease-modifying Therapy

1:00 p.m. John Dystel Prize for Multiple Sclerosis Research Presentation The John Dystel Prize recognizes outstanding contributions to research in the understanding, treatment, or prevention of multiple sclerosis. Recipient: Ian Duncan, BVMS, MRCVS, PhD Madison, WI

2:48 p.m. S5.010 Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis–Gavin Giovannoni, Ludwig Kappos, Jerome De Seze, Stephen L. Hauser, James Overell, Harold Koendgen, Kalpesh Prajapati, Marianna Manfrini, Qing Wang, Jerry S. Wolinsky

Sunday, April 26

SCIENTIFIC SESSIONS

1:24 p.m. S5.003 Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 mAb, in Patients with RMS–Edward J. Fox, Sibyl E. Wray, Richard A. Shubin, Deren Huang, Ann D. Bass, Michael S. Weiss, Sean Power, Jenna Bosco, Koby Mok 1:36 p.m. S5.004 Effect of Interferon ß-1a Treatment on Serum Neurofilament Light Chain Levels in Patients with a First Clinical Demyelinating Event–Jens Kuhle, David Leppert, Giancarlo Comi, Nicola De Stefano, Ludwig Kappos, Mark S. Freedman, Sanjeev Roy, Delphine Issard 1:48 p.m. S5.005 Effects of Fingolimod and Natalizumab on Slowly Expanding Lesion Occurrence over Two Years of Treatment in Relapsing-remitting Multiple Sclerosis–Paolo Preziosa, Elisabetta Pagani, Lucia Moiola, Mariaemma Rodegher, Massimo Filippi, Maria Assunta Rocca 2:00 p.m. S5.006 Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis–Barry A. Singer, Stuart J. Shafer, Douglas L. Arnold, James D. Bowen, Christopher C. LaGanke, Hailu Chen, Jerome Hanna, Catherine Miller, Richard Leigh-Pemberton, Robert T. Naismith 2:12 p.m. S5.007 Patterns of Cerebellar Atrophy and Resting State Functional Connectivity Changes in RelapsingRemitting MS Patients Starting Fingolimod and Natalizumab: A 2-Year Study–Paolo Preziosa, Paola Valsasina, Loredana Storelli, Elisabetta Pagani, Lucia Moiola, Mariaemma Rodegher, Maria Assunta Rocca, Massimo Filippi 2:24 p.m. S5.008 Effect of Siponimod on Disability in EXPAND Reexamined with Two New Subscales of the Expanded Disability Status Scale in Patients with SPMS–Gary Raymond Cutter, Xiangyi Meng, Amit Bar-Or, Ralph H. B. Benedict, Stanley L. Cohan, Nina Jaitly, Wendy Su, Davorka Tomic, Bruce A. C. Cree 2:36 p.m. S5.009 Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients–Annette Wundes, Jerry S. Wolinsky, Sibyl E. Wray, Tjalf Ziemssen, Elzbieta Jasinska, Mark S. Freedman, Ilda Bidollari, Hailu Chen, Jerome Hanna, Richard Leigh-Pemberton, Jennifer Lyons, Jordan Messer, Robert T. Naismith

CME

AAN.com/view/20AM 83

SUNDAY, APRIL 26 3:30 p.m.–4:15 p.m.

1:00 p.m.–3:00 p.m.

Sunday, April 26

SCIENTIFIC SESSIONS

Neuromuscular and Clinical Neurophysiology (EMG): Genetic Muscle Disorders

1:00 p.m. S6.001 ASPIRO Gene Therapy Trial In X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety And Efficacy Findings up to 72 Weeks PostTreatment–Perry Shieh, Nancy L. Kuntz, Barbara Smith, James Dowling, Wolfgang Mueller-Felber, Carsten G. Bonnemann, Laurent Servais, Francesco Muntoni, Astrid Blaschek, Sarah Berten Neuhaus, Lindsay N. Alfano, Alan Beggs, Anna Buj-Bello, Martin K. Childers, Tina Duong, Robert Graham, Minal Jain, Emma S James, Michael W Lawlor, Jun Lee, Victoria MacBean, Fulvio Mavilio, Michael Murtagh, Mojtaba Noursalehi, Suyash Prasad, Salvador Rico 1:12 p.m. S6.002 NEO1 and NEO-EXT Studies: Long-Term Safety and Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for 5.5 Years in Late-Onset Pompe Disease Patients–Mazen M. Dimachkie, Richard J. Barohn, Barry Byrne, Ozlem Goker-Alpan, Priya Kishnani, Shafeeq Ladha, Pascal Laforet, Eugen Mengel, Loren DM Pena, Sabrina Sacconi, Volker Straub, Jaya Raghav Trivedi, Philip Van Damme, Ans Van Der Ploeg, John Vissing, Peter Young, Kristina an Haack, Carmen Fleurinck, Judith Johnson, Kejian Liu, Benedikt Schoser 1:24 p.m. S6.003 Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD): Safety, Tolerability, and Target Engagement– Michelle L. Mellion, Lucienne Ronco, Lorin Thompson, Michelle Hage, Sander Brooks, Emilie van Brummelen, Lisa Pagan, Umesh Arvind Badrising, Shane Raines, William Tracewell, Baziel G M van Engelen, Geert-Jan Groeneveld, Diego Cadavid 1:36 p.m. S6.004 Design of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD): ReDUX4–Alrabi Tawil, Michelle L. Mellion, Lucienne Ronco, Shane Raines, William Tracewell, Alisa Rahilly, Alejandro Rojas, Michelle Hage, Kathryn Rae Wagner, Jeffrey Statland, Leo Hong-Li Wang, Teresinha Evangelista, Angela L. Genge, Summer Gibson, Namita Goyal, Johanna Hamel, Lawrence J. Hayward, Nicholas Elwood Johnson, Cornelia Kornblum, Hanns Lochmuller, Samantha Jo LoRusso, Jordi Diaz Manera, Juan Jesus Vilchez Padilla, Alan Pestronk, Sabrina Sacconi, Benedikt Schoser, Perry Shieh, S H. Subramony, Diego Cadavid 1:48 p.m. S6.005 WITHDRAWN 2:00 p.m. S6.006 Delays in Progression of Duchenne Muscular Dystrophy with Eteplirsen Treatment: Attenuation of Pulmonary Function Decline and Projected Freedom from Continuous Ventilation–Joel Iff, Charles Gerrits, Erica Birk, Ed Tuttle, Yeya Zheng, Erik K. Henricson, Craig McDonald

84 2020 AAN Annual Meeting

CME

2:12 p.m. S6.007 A Biomarker of DUX4 Activity to Evaluate losmapimod Treatment Effect in FSHD Phase 2 Trials–Lucienne Ronco, Perry Shieh, Alrabi Tawil, Kathryn Rae Wagner, Jeffrey Statland, Shane Raines, Alan Robertson, Jayashree Chadchankar, Aaron Chang, Alan Robertson, Diego Cadavid, Michelle L. Mellion, Alejandro Rojas, Owen Wallace, Baziel G M van Engelen, Leo Hong-Li Wang, Nicholas Elwood Johnson 2:24 p.m. S6.008 Thymidine Phosphorylase Intracellular Enzyme Replacement Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE)–Jonathan Shintaku, Wenlong Lian, Xiang Li, Saba Tadesse, May Theng Ting, Xingfu Xu, Nicholas E Long, Josell RamirezPaz, Ziqing Qian, Natarajan Sethuraman, Michio Hirano 2:36 p.m. S6.009 Initial Analysis of Responsiveness of an FSHD Optimized Timed Up and Go (oTUG) Across the Disability Spectrum in FSHD–Maya Hatch, Vicky Chan, Diego Cadavid, Jay Han 2:48 p.m. S6.010 Clinicogenetic Lessons from 370 Patients with Autosomal Recessive Limb-Girdle Muscular Dystrophy–Marcondes C. Franca, Marcondes C. Franca, Marcondes C. Franca, Regina C.B. Duarte, Bruna Cristine Chwal, Rodrigo H. Mendonca, Isabel C.N. de Souza, Ana Cotta, Marcondes C. Franca, Antonette S. El Husny, Regina C.B. Duarte, Ana Cotta, Marcondes C. Franca, Edmar Zanotelli, Regina C.B. Duarte, Marcondes C. Franca, Pablo Brea Winckler, Marcondes C. Franca, Camila de Aquino Cruz, Marcondes C. Franca, Umbertina C. Reed, Renata B. Tenorio, Edmar Zanotelli, Marcondes C. Franca, Umbertina C. Reed, Marcondes C. Franca, Pablo Brea Winckler, Rodrigo H. Mendonca, Jonas Alex Morales Saute

Global Health

CME

0.5

3:30 p.m. S7.001 Inpatient Stroke Epidemiology in Zambia– Aparna Nutakki, Stanley Zimba, Mashina Chomba, Lorraine Chishimba, David Bearden, Deanne Saylor 3:42 p.m. S7.002 Neighborhood Effects on Cognition in the HIVAssociated Neurocognitive Disorders in Zambia (HANDZ) study: A Quantitative Geographic Information Systems Approach–Alexandra Buda, Owen Dean, Heather Adams, Sylvia MwanzaKabaghe, Michael Potchen, Esau G. Mbewe, Pelekelo Kabundula, Sarah Mohajeri, Milimo Mweemba, Beauty Matoka, Manoj Mathews, Gretchen L. Birbeck, David Bearden 3:54 p.m. S7.003 Viral Causes of Meningitis Detected by Metagenomic Next-generation Sequencing in a Ugandan Tuberculous Meningitis Cohort–Carson Quinn, Prashanth Ramachandran, Morris Rutakingirwa, Ananta Bangdiwala, Enock Kagimu, Kiiza Tadeo Kandole, Fiona Cresswell, David Meya, David R. Boulware, Michael R. Wilson

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

SUNDAY, APRIL 26 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m. S8

Migraine Therapeutics

CME

3:30 p.m. Michael S. Pessin Stroke Leadership Prize Presentation This award recognizes emerging neurologists who have a strong interest in and have demonstrated a passion for learning and expanding the field of stroke research. Recipient: Ashkan Shoamanesh, BSc, MD Hamilton, ON, Canada

CME

5:18 p.m. S9.010 Does the Pre- or Post-stroke Statin Therapy Increase the Risk of Intracerebral Hemorrhage in Poststroke Patients? A Meta-analysis of Randomized and Nonrandomized Studies–Ammad Ishfaq, Muhammad Fawad Ishfaq, Fnu Abhi Pandhi, Aman Deep, Ana Hossein Zadeh Maleki, Reza Bavarsad Shahripour

3:42 p.m. S9.002 Mortality and Functional Outcomes After Minimally Invasive Endoscopic Intracerebral Haemorrhage Evacuation–Miryam Alkayyali, Rui Song, Dominic Nistal, on Behalf of the Mt Sinai NEMAT Research Group, Jay Mocco, Christopher Kellner, John Liang 3:54 p.m. S9.003 Women Fare Worse Than Men After Acute Nontraumatic Intracerebral Hemorrhage–Rohan Mangal, Alexandra Craen, Tej Stead, Latha Ganti 4:06 p.m. S9.004 Cardiac Function Indices May Predict Outcomes After Primary ICH–Rajeel Imran, Vivek Misra, Harsh Patel, Destiny Hooper, Nishath Naseem, John Buergler, Tariq Nisar, Jason Z. Lee, Ken Ling, Charles David McCane, David Chiu 4:18 p.m. S9.005 Causes of Death in a Longitudinal Analysis of Spontaneous Intracerebral Hemorrhage Survivors– Lindsey Ray Kuohn, Audrey Leasure, Julian Acosta, Kevin Nhat Vanent, Santosh Bhaskar Murthy, Hooman Kamel, Charles Matouk, Lauren Hachmann Sansing, Guido Jose Falcone, Kevin N. Sheth 4:30 p.m. S9.006 Long-term Outcomes in Patients with Intracerebral Hemorrhage and Delayed Hospital Presentation– Michael E. Reznik, Scott Moody, Brian Mac Grory, Christoph Stretz, Tracy E Madsen, Ali Mahta, Shyam Sudarshan Rao, Linda C. Wendell, Bradford B. Thompson, Karen L. Furie 4:42 p.m. S9.007 Accuracy of Artificial Intelligence in Measuring Intracerebral Hemorrhage Volumes and Expansion Compared to Human Estimates–Masaki Nagamine, Paul Kohanteb, Wengui Yu, Peter Chang, Daniel Chow 4:54 p.m. S9.008 Portable, Bedside, Low-field Magnetic Resonance Imaging in an Intensive Care Setting for Intracranial Hemorrhage–Jill T. Shah, Bradley Cahn, Samantha By, E Brian Welch, Laura Sacolick, Matthew Yuen, Mercy Mazurek, Charles R. Wira, Audrey Leasure, Charles Matouk, Adrienne Ward, Sam Payabvash, Rachel Beekman, Stacy C. Brown, Guido Jose Falcone, Kevin Gobeske, Nils Petersen, Adam S. Jasne, Richa Sharma, Joseph Schindler, Lauren Hachmann Sansing, Emily Jean Gilmore, Gordon Sze, Matthew Rosen, W. Taylor Kimberly, Kevin N. Sheth 5:06 p.m. S9.009 The Reinstitution of Anticoagulation After Intracerebral Bleeding – A Meta-analysis and Literature Review–Salman Assad, Justin Michael Nolte, Samrina Hanif, Paul Brent Ferguson

Sunday, April 26

Cerebrovascular Disease: Intracerebral Hemorrhage

SCIENTIFIC SESSIONS

3:30 p.m. S8.001 Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+ Year Results of a 5-year, Open-label Treatment Period–Messoud Ashina, Peter Goadsby, Uwe Reuter, Stephen D. Silberstein, David W. Dodick, Fei Xue, Feng Zhang, Sunfa Cheng, Daniel D. Mikol 3:42 p.m. S8.002 Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2–David W. Dodick, Christopher Gottschalk, Stewart J. Tepper, Deborah I. Friedman, Roger Cady, Jeff Smith, Joe Hirman, Steven Snapinn 3:54 p.m. S8.003 Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays–Charlie Conway, Robert Croop, Gene Dubowchik, Vlad Coric, Richard B. Lipton 4:06 p.m. S8.004 Cardiovascular Safety of Fremanezumab in Patients with Episodic and Chronic Migraine: A Pooled Analysis of Phase 3 Studies–Stephanie J. Nahas, Yoel Kessler, Xiaoping Ning, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Stephen D. Silberstein 4:18 p.m. S8.005 Ubrogepant for the Acute Treatment of Migraine: Pooled Safety and Tolerability From ACHIEVE I and ACHIEVE II Phase 3 Studies–Susan Hutchinson, David W. Dodick, Christina Treppendahl, Nathan L. Bennett, Sung Y. Yu, Hua Guo, Joel M. Trugman 4:30 p.m. S8.006 Benefit of Migraine Prevention with Erenumab in Patients Receiving Background Standard-of-care Acute Treatment–Amaal J. Starling, Stewart J. Tepper, Carolyn Bernstein, Jessica Ailani, Feng Zhang, Gabriel Paiva Da Silva Lima, Denise Chou 4:42 p.m. S8.007 Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study–John F. Rothrock, Richard Stark, Katherine Sommer, Andrew M. Blumenfeld 4:54 p.m. S8.008 Oral Rimegepant 75 mg Is Well-tolerated When Used Concomitantly with Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-term, Open-label Safety Study–Gary D. Berman, David B. Kudrow, Philip Halverson, Richard B. Lipton, Meghan Lovegren, Alexandra Thiry, Christopher Jensen, Yushan Zhang, Elyse Stock, Charlie Conway, Robert Croop, Vlad Coric 5:06 p.m. S8.009 Ubrogepant Achieves Onset of Pain Relief at 1 Hour for the Acute Treatment of Migraine–David W. Dodick, Peter Goadsby, Kaifeng Lu, Abhijeet Jakate, Michelle Finnegan, Armin Szegedi, Joel M. Trugman 5:18 p.m. S8.010 Chiropractic Care for Migraine: A Pilot Randomized Clinical Trial–Pamela M. Rist, Carolyn Bernstein, Matthew Kowalski, Kamila Osypiuk, Julie Connor, Robert Vining, Cynthia Long, Eric A. Macklin, Peter Wayne

AAN.com/view/20AM 85

SUNDAY, APRIL 26 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m.

Sunday, April 26

SCIENTIFIC SESSIONS

S10 Multiple Sclerosis: Biomarkers and Outcome Measures 3:30 p.m. S10.001 Clinical Relevance of Multiparametric MRI Assessment of Spinal Cord Damage in Multiple Sclerosis–Raffaello Bonacchi, Maria Assunta Rocca, Elisabetta Pagani, Alessandro Meani, Laura Cacciaguerra, Ermelinda De Meo, Paolo Preziosa, Massimo Filippi 3:42 p.m. S10.002 Story Repetition Reflects Memory Dysfunction in Multiple Sclerosis Better than Traditional Metrics: Implications for Language-Mediated Deficits– Colleen Marino, James F. Sumowski 3:54 p.m. S10.003 Novel Biomechanical Outcomes for Upper Extremity Function–Marisa P. McGinley, Jingan Qu, Christina Felix, Karissa Hastilow, Joshua Johnston, David Schindler, Robert A. Bermel, Jeffrey Alan Cohen, Daniel Ontaneda, Jay Alberts 4:06 p.m. S10.004 Serum Neurofilament Light Chain Levels Differentiate Spinal Cord Infarction from Inflammatory Myelitis–Nicholas L. Zalewski, Elia Sechi, Andrew McKeon, Sean J. Pittock, Sergio Ferrari, Salvatore Monaco, Eoin P. Flanagan, Alejandro A. Rabinstein, Sara Mariotto 4:18 p.m. S10.005 Blood Neurofilament Light Chain Levels and Association with Brain Volume Change in Patients with Primary Progressive Multiple Sclerosis and Relapsing Multiple Sclerosis Before and During Ocrelizumab Treatment–Xiaoming Jia, Ann Herman, Christopher Harp, Anne H. Cross, Damian Fiore, Stephen L. Hauser, Ludwig Kappos, Harold Koendgen, Jens Kuhle, David Leppert, Marianna Manfrini, Fabian Model, Jorge Oksenberg, Annette Sauter, Gian-Andrea Thanei, Amit Bar-Or 4:30 p.m. S10.006 Plasma Glial Fibrillary Acidic Protein Correlates with Characteristics of Advanced Disease and Treatment Response in Secondary Progressive Multiple Sclerosis–Jens Kuhle, Harald Kropshofer, Aleksandra Maleska Maceski, Frank Dahlke, Thomas Hach, Davorka Tomic, Ludwig Kappos, David Leppert 4:42 p.m. S10.007 Early Neuropsychological Markers of Cognitive Involvement in Multiple Sclerosis–Tehila EilamStock, Michael Shaw, Lauren B. Krupp, Leigh Elkins Charvet 4:54 p.m. S10.008 Serum Neurofilament Light Chain Predicts Long-term Clinical Outcomes in Multiple Sclerosis–Simon Thebault, Mohammad Abdoli, Seyed-Mohammad Fereshtehnejad, Daniel Tessier, Vincent Tabard-Cossa, Mark S. Freedman 5:06 p.m. S10.009 Serum Neurofilament Light (sNfL) Levels in Patients with Relapsing-remitting Multiple Sclerosis (RRMS) Switching from Natalizumab Every-4-week (Q4W) Dosing to Extended Interval Dosing (EID)–John F. Foley, Kuangnan Xiong, Tamara Hoyt, Carol Singh, Evan Riddle, Carl DeMoor, Nolan Campbell, Tatiana Plavina

86 2020 AAN Annual Meeting

CME

5:18 p.m. S10.010 Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials– Amit Bar-Or, Gian-Andrea Thanei, Christopher Harp, Anne H. Cross, Damian Fiore, Stephen L. Hauser, Xiaoming Jia, Ludwig Kappos, Harold Koendgen, Jens Kuhle, David Leppert, Marianna Manfrini, Fabian Model, Annette Sauter, Ann Herman

S11 Huntington’s Disease, Tardive Dyskinesia, and Functional Movement Disorders

CME

3:30 p.m. Movement Disorders Research Award Presentation This award recognizes an individual for outstanding work in the field of Parkinson’s disease or other movement disorders for either a single outstanding contribution or for lifetime achievement. Recipient: Henry Paulson, MD, PhD, FAAN Ann Arbor, MI 3:54 p.m. S11.003 Influence of Age of Onset on Huntington’s Disease Phenotype–Lauren Kwa, Danielle Larson, Chen Yeh, Danny Bega 4:06 p.m. S11.004 The Organisational Impact of Upcoming Treatments in Huntington’s Disease: Resource Capacity Gaps and Access to Care Implications–Marco Pedrazzoli, Marina Ponomareva, Mattia Moro, Marsha Pelletier, Louisa Townson, Kopano Mukelabai, Aaron Levine, Anna-Lena Nordstrom, Mark Guttman, Jean-Marc Burgunder, Ralf Reilmann 4:18 p.m. S11.005 HAP40 is a conserved partner and regulator of Huntingtin and a pathogenic modifier of Huntington’s disease–Erin Furr-Stimming, Shiyu XU, Gang li, Xin Ye, Sheng Zhang 4:30 p.m. S11.006 Changes in Gray Matter Volume Predict Longitudinal Development of Apathy in Huntington’s Disease– Audrey Elizabeth DePaepe, Alberto Ara, Clara Garcia-Gorro, Saul Martinez-Horta, Jesus Perez, Jaime Kulisevsky, Nadia Rodriguez-Dechicha, Irene Vaquer, Susana Subira, Matilde Calopa, Esteban Munoz, Pilar Santacruz, Jesus Ruiz-Idiago, Celia Mareca, Ruth de Diego-Balaguer, Estela Camara 4:42 p.m. S11.007 Quantitative Oculomotor Biomarkers for Huntington’s Disease–Samuel A. Frank, Marc Albert Bouffard, Rachael Dawson, Alexander R. Lim, Nurhan Torun, Wasim Malik 4:54 p.m. S11.008 Adipose-derived Mesenchymal Stem Cells Ameliorate Neuroinflammation and promote neurogenesis in a Transgenic Mouse Model of Huntington’s disease–Erin Furr-Stimming, Jose Moruno-Manchon, Karthik Prabhakara, Akshita Kumar, Naama Toledano Furman, Alex Villarreal, Gabriela D. Colpo, Antonio Teixeira, Andrey Tsvetkov, Scott Douglas Olson 5:06 p.m. S11.009 Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia–Joohi Jimenez-Shahed, Hadas Barkay, Karen E. Anderson, Hubert H. Fernandez, Stewart A. Factor, Robert A. Hauser, Maria Wieman, Mark Forrest Gordon, JuhaMatti Savola 5:18 p.m. S11.010 TPH2 Gene and Childhood Trauma moderates the clinical and circuit-level phenotype of functional movement disorders–Primavera Spagnolo, Gina Norato, Carine W. Maurer, Sepideh Akbaripanahi, Coiln Hodgkinson, David Goldman, Silvina Horovitz, Mark Hallett

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

SUNDAY, APRIL 26 3:30 p.m.–5:30 p.m. S12 General Neurology: Neurotherapeutics and Clinical Trials

5:06 p.m. S12.009 Clinical Efficacy and Management of Thrombocytopenia and Glomerulonephritis in Patients With Hereditary ATTR Amyloidosis Treated With Inotersen: Results From >5 Years of Clinical Trial and Postmarketing Surveillance–Morie A. Gertz, Sami L. Khella, Annabel K. Wang, Teresa Coelho, Marcia Waddington Cruz, Michael J. Polydefkis, Violaine Plante-Bordeneuve, John L. Berk, Fabio Adrian Barroso, Thomas H. Brannagan, Giampaolo Merlini, Isabel Conceicao, Shiangtung W. Jung, Steven G. Hughes, Peter Aquino, Louis St. L. O’Dea, Arvind Narayana, Noel Dasgupta, Merrill Benson 5:18 p.m. S12.010 Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Results From the Phase 2 NURTURE Study–Richard S. Finkel, Madhu Nagappa, Kathryn J. Swoboda, Enrico Silvio Bertini, Wuh-Liang Hwu, Richard Foster, Ishir Bhan, Stephanie Fradette, Wildon Farwell

SCIENTIFIC SESSIONS

3:30 p.m. S12.001 Experience of Using Edaravone in a US-based ALS Center–Anem Kohli, Sandeep S. Rana 3:42 p.m. S12.002 Escalating Dose and Randomized, Controlled Study of Nusinersen in Participants with Spinal Muscular Atrophy; Study Design of the Phase 2/3 DEVOTE (232SM203) Study to Explore High Dose Nusinersen–Richard S. Finkel, John W. Day, Nancy Mitchell-Sweeney, Richard Foster, Peng Sun, Ishir Bhan, Boris Kandinov, Wildon Farwell 3:54 p.m. S12.003 Risk of Recurrent Stroke or Transient Ischemic Attack due to Abrupt Discontinuation of Aspirin: A Case Series–Rachael Wojcik, Jessica Greger, Kory Zelen, Traci Aladeen, Michelle Rainka, Erica S. Westphal, Vernice E. Bates, Francis Michael Gengo 4:06 p.m. S12.004 A Description of Prescribing Habits of Emergency Physicians for a Diagnosis of Non-traumatic Headache using Cerner Health Facts, a National EHR Database–Sean Gratton, Nikita M. Maniar, Monica Gaddis, matthew gratton 4:18 p.m. S12.005 Clinical Spectrum of Symptoms and Treatment Response Behaviour in Long-term Treated Neurological Wilson Disease Patients: A Retrospective Analysis Over 10 Years–Sara Samadzadeh, Philipp Albrecht, Harald Hefter 4:30 p.m. S12.006 Evaluation of Nusinersen on Impact of Caregiver Experience and HRQOL in Later-onset Spinal Muscular Atrophy (SMA): Results from the Phase 3 CHERISH Trial–Nicole Johnson, Angela Paradis, Sarah Naoshy, Janice Chun Yee Wong, Jacqueline Montes, Debra C Krasinski 4:42 p.m. S12.007 Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study–Michael J. Polydefkis, Alejandra GonzalezDuarte, Teresa Coelho, Jonas Wixner, Arnt Kristen, Hartmut H.J. Schmidt, John L. Berk, Erhan Berber, Marianne T. Sweetser, Matthew White, Jing Jing Wang, David Adams 4:54 p.m. S12.008 Nusinersen in Infantile-onset Spinal Muscular Atrophy: Results from Longer-term Treatment from the Open-label SHINE Extension Study–Diana Castro, Richard S. Finkel, Michelle Farrar, Mar Tulinius, Kristin J. Krosschell, Kyoko Saito, Giulia Gambino, Richard Foster, Ishir Bhan, Janice Chun Yee Wong, Boris Kandinov, Wildon Farwell

CME

Sunday, April 26

AAN.com/view/20AM 87

MONDAY, APRIL 27 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m.

Monday, April 27

SCIENTIFIC SESSIONS

S13 Epilepsy/Clinical Neurophysiology (EEG) 1

CME

1:00 p.m. S13.001 Quantifying “Clinically Meaningful Changes” in Seizure Frequency - Data from Three Phase 3 Studies of ZX008 (Fenfluramine Hydrochloride Oral Solution) in Dravet Syndrome: Do Expectations and Views Change Over Time?–Arnold Gammaitoni, Joseph Sullivan, Dennis J. Dlugos, Gail M. Farfel, Bradley Galer, Glenn Morrison, Douglas Haney, Rima Nabbout 1:12 p.m. S13.002 Advantages of Face-to-face Contact Versus Video Conferencing in the Delivery of a Self-management Program for People with Epilepsy–Samantha Schmidt, Nicholas Streltzov, Wenyan Zhao, Robert Roth, Lindsay Schommer, Elaine T. Kiriakopoulos, Morgan Mazanec, Felicia Chu, Catherine Phillips, Barbara C. Jobst 1:24 p.m. S13.003 Quantitative Positron Emission Tomography Using MRI-informed Segmentation for Focal Epilepsy– Idelle Vaynberg, Shaotong Zhu, Sweta Joshi, Mohamad Koubeissi, Taha Gholipour 1:36 p.m. S13.004 Combining 3D-printing Technology with Preoperative Sterotactic Planning for Placement of Intracranial Depth Electrodes for Improved Patient Safety and Operative Efficiency: An Institutional Experience–Liana Theroux, David Bonda, Rachel Pruitt, Todd Goldstein, Anish Varghese, Amar Shah, Shaun Rodgers, Sanjeev V. Kothare, Shefali Karkare 1:48 p.m. S13.005 Identification of Candidates for Genetic Testing in the Adult Epilepsy Monitoring Unit–Jannis Raye Brea, Irena Bellinski, Elizabeth Bachman, Lisa Kinsley, Gemma L Carvill, Elizabeth Gerard 2:00 p.m. S13.006 EEG Education in Neurology Residency – Baseline EEG Knowledge and Resident Perception–Fabio Nascimento, Atul Maheshwari, Jennifer G. Chu, Jay Gavvala 2:12 p.m. S13.007 Analysis of Human Brain Tissue Transcriptome Reveals Risk Genes and Altered Molecular Pathways in Glioma-related Seizures–Anteneh Mekonnen Feyissa, Anna Carrano, Xue Wang, Mariet Allen, Nilufer Taner, William O. Tatum, Steven S. Rosenfeld, Hugo Guerrero Cazares, Alfredo Quinones-Hinojosa 2:24 p.m. S13.008 Life Challenges and Goals Among Patients Living with Epilepsy: Adult Patient, Caregiver, and Health Care Professional Perspectives–Lucretia Long, Danielle Becker, Nancy Santilli, Jane Babrowicz, Eugenia Peck 2:36 p.m. S13.009 Comparative Acute Impact of Focal and Generalized Tonic-clonic Seizures on Cardiac Electrical Instability in the Epilepsy Monitoring Unit–Trudy Pang, Bruce Nearing, Bryan Olin, Steven C. Schachter, Richard Verrier 2:48 p.m. S13.010 EEG Abnormalities in Patients with Suspected Encephalopathy Receiving Cefepime vs PiperacillinTazobactam–Jumana Tariq A Alshaikh, Natasha Pettit, Aditi Rangarajan, Jennifer Pisano, Naoum P. Issa

88 2020 AAN Annual Meeting

S14 Neuro-oncology

CME

1:00 p.m. Neuro-oncology Scientific Award Presentation This award recognizes an individual from any discipline and of any academic rank for a singular scientific achievement that has advanced the field of neuro-oncology. Recipients: David Gutmann, MD, PhD and Jaishri Blakeley, MD St. Louis, MO and Baltimore, MD 1:12 p.m. Neuro-oncology Investigator Award Presentation This award recognizes young investigators who have advanced the field of neuro-oncology. Recipient: Adrienne Boire, MD, PhD New York, NY

2:36 p.m. S14.009 Multiparametric MRI Assessment of Proton Radiation Therapy Post-treatment Effects on Brain Tissue for CNS and Head-neck Cancers–Robin A. Buerki, Kevin Chaung, Andrew Gross, Michael Kharouta, Aashish Bhatt, David Mansur, Rajesh Pidikiti, Serah Choi, Lisa R. Rogers 2:48 p.m. S14.010 Transcriptomic Analysis of Rapid Glioblastoma Progressors–Justin Thomas Low, David Ashley

1:24 p.m. S14.003 Pilot Study of Glucarpidase in Combination with Rituximab and Methotrexate (MTX) in CNS Lymphoma (CNSL)–Lauren Rhea Schaff, Ugur Sener, Igor T. Gavrilovic, Alexandra M. Miller, Jacqueline Stone, Anna Skakodub, Juli Madzsar, Alyssa Schumpp, Edward Acosta, Mina Lobbous, Kevin Ryan, Dean Carlow, Burt Nabors, Christian Grommes 1:36 p.m. S14.004 Long-term Follow-up of Adult Neurofibromatosis Type 1 Patients Using Whole-body MRI Demonstrates Dynamic Changes in Internal Neurofibroma Size–Ina Ly, Raquel D. Thalheimer, Wenli Cai, Miriam Bredella, Vanessa Merker, Scott R. Plotkin, Justin T. Jordan 1:48 p.m. S14.005 Alimta (Pemetrexed) in recurrent or progressive primary central nervous system lymphoma: A Phase I multicenter Clinical Trial–Jorg Dietrich, Laura Versmee, Jan Drappatz, April Fitzsimmons Eichler, Lakshmi Nayak, Andrew David Norden, Eric Tai-Lee Wong, Michelle Pisapia, SooAe Jones, Amanda Gordon, Bruce Chabner, Fred H. Hochberg, Tracy T. Batchelor 2:00 p.m. S14.006 Reconstituting Molecularly-distinct Patient Pathology in a Bio-engineered ‘Glioblastoma-on-aChip’ to Dissect Immunotherapy Responses–ReneeTyler Tan Morales, Xin Cui, Haoyu Wang, Dimitris Placantonakis, Matija Snuderl, Weiqiang Chen 2:12 p.m. S14.007 The Economic Impact of Glioma Survivorship: Unraveling the Cost of Care from a Patient Perspective–Tobias Walbert, James Snyder, Asmaro Karam, David R. Nerenz, Steven Kalkanis, Lonni Schultz, Michael Bazydlo, Ian Lee, Ramzi Salloum, Sameah Haider 2:24 p.m. S14.008 Whole Exome Sequencing Identifies Novel SLIT2 Mutations in Primary CNS Lymphoma–Leon Kaulen, E. Zeynep Erson-Omay, Octavian Henegariu, Philipp Karschnia, Anita J Huttner, Murat Gunel, Joachim M. Baehring

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

MONDAY, APRIL 27 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m. S15 Behavioral and Cognitive Neurology 1:00 p.m. Norman Geschwind Prize in Behavioral Neurology Presentation This prize is awarded to an individual for outstanding research in the field of behavioral neurology. Recipient: Richard Ryan Darby, MD Nashville, TN

2:48 p.m. S15.010 Tau-PET in a Former American Football Player with Pathologically Confirmed Chronic Traumatic Encephalopathy–William Guntars Mantyh, Salvatore Spina, Alex Lee, Leonardo Iaccarino, David Nima Soleimani-Meigooni, Elena Tsoy, Taylor Mellinger, Harli Grant, Lawren VandeVrede, Renaud La Joie, Orit Lesman-Segev, Stephanie E. Gaus, Katherine L. Possin, Lea Grinberg, Bruce L. Miller, William Seeley, Gil Dan Rabinovici

S16 Autoimmune Neurological Disorders: Diagnosis, Biomarkers, and Epidemiology

CME

1:00 p.m. S16.001 Investigations on Myelin Oligodendrocyte Glycoprotein Autoimmunity in Children–Thais Armangue, Gemma Olive-Cirera, Eugenia MartinezHernandez, Maria Sepúlveda, Raquel Ruiz-Garcia, Georgina Arrambide, Cristina Auger, Mar Tinore, Xavier Montalban, Adeline Vanderver, Francesc R. Graus, Albert Saiz, Josep O. Dalmau 1:12 p.m. S16.002 Do MOG-IgG+ Patients Fulfill the 2015 International Diagnostic Criteria for NMOSD?–Amy Kunchok, Eoin P. Flanagan, John Chen, Ruba Shihadeh Saadeh, Solmaz Asnafi, Andrew McKeon, Dean M. Wingerchuk, Brian G. Weinshenker, Sean J. Pittock 1:24 p.m. S16.003 Lesion Evolution on MRI in Myelitis Associated with MS, Aquaporin-4-IgG and Myelin Oligodendrocyte Glycoprotein-IgG–Elia Sechi, Karl Krecke, Marina Buciuc, Sean J. Pittock, Brian G. Weinshenker, Sebastian Lopez, Nicholas L. Zalewski, Eoin P. Flanagan 1:36 p.m. S16.004 Frequency and Phenotype of Coexisting AQP4-IgG with Synaptic Autoantibodies in Patients Undergoing Serological Testing for CNS Inflammatory Disease–Amy Kunchok, Eoin P. Flanagan, John Chen, Divyanshu Dubey, Christopher J. Klein, Daniel H. Lachance, Anastasia Zekeridou, Nusrat Ahsan, Karen Fernandez, Rosanna Fulchiero, Wendy G. Mitchell, Kurt Michael Sieloff, Huidy Shu, Emmanuelle Waubant, Brian G. Weinshenker, Andrew McKeon, Sean J. Pittock 1:48 p.m. S16.005 Analysis of Lesion Localization Pattern of Patients with Parenchymal Neuro-Behçet’s Disease Using Probability Mapping–Ahmed Serkan Emekli, Ersin Ersozlu, Tuncay Gunduz, Murat Kurtuncu 2:00 p.m. S16.006 Serum Neurofilament Light Chain Levels (sNfL) Correlate Best with Attack-related Disability in Neuromyelitis Optica–Orhan Atkas, Hans-Peter Hartung, M.A. Smith, W. Rees, Kazuo Fujihara, Friedemann Paul, Romain Marignier, Jeffrey L. Bennett, Ho Jin Kim, Brian G. Weinshenker, Sean J. Pittock, Dean M. Wingerchuk, Gary Raymond Cutter, Ari Green, Maureen Anne Mealy, Jorn Drappa, G. Barron, Soraya Madhani, L. Wang, Dewei She, Dewei She, John Ratchford, Eliezer Katz, Bruce A. C. Cree 2:12 p.m. S16.007 A Prospective Clinical Validation of Neuronal Intermediate Filament IgGs–Eati Basal, Shahar Shelly, Sean J. Pittock, Andrew McKeon 2:24 p.m. S16.008 Clinical Significance of Kelch-like Protein 11 Antibodies–Jon Landa, Estibaliz Maudes, Amaia Munoz, Thais Armangue, Albert Saiz, Francesc R. Graus, Josep O. Dalmau, Lidia Sabater

AAN.com/view/20AM 89

Monday, April 27

SCIENTIFIC SESSIONS

1:12 p.m. S15.002 Automated Analysis of Natural Speech in Amyotrophic Lateral Sclerosis–Naomi Nevler, Sharon Ash, Corey McMillan, Lauren B. Elman, Leo McCluskey, David Irwin, Sunghye Cho, Mark Liberman, Murray Grossman 1:24 p.m. S15.003 Mood Disturbances as a Prodrome to Behavioral Variant Frontotemporal Dementia–Leila Parand, Golnoush Akhlaghipour, Mario F. Mendez 1:36 p.m. S15.004 Amyloid-ß Deposition, Brain Metabolism and Neuropsychological Profile in Elderly with Subjective Cognitive Decline and SuperAgers– Adalberto Studart Neto, Artur Coutinho, Camila de Godoi Carneiro, Natalia Cristina Moraes, Raphael Ribeiro Spera, Mônica Sanches Yassuda, Sonia Brucki, Claudia Leite, Carlos Buchpiguel, Ricardo Nitrini 1:48 p.m. S15.005 Diastolic Dysfunction and Cognitive Impairment– Alicia S. Parker, Jayandra J. Himali, Alexa Beiser, Vasan Ramachandran, Vasan Ramachandran, Sudha Seshadri 2:00 p.m. S15.006 Defining and predicting transdiagnostic categories of neurodegenerative disease–Eli Cornblath, John Robinson, Virginia Lee, John Q. Trojanowski, Danielle S Bassett 2:12 p.m. S15.007 Early Motor Phenotype Influences Neuropsychiatric and Cognitive Disorders in Huntington&rsquo;s Disease–Parunyou Julayanont, Kenneth M. Heilman, Nikolaus McFarland 2:24 p.m. S15.008 24(S)-Hydroxycholesterol Levels are Decreased in Early Huntington&rsquo;s Disease and Are Associated with Deficits in Several Cognitive Domains–Michael Lewis, Jing Dai, Amrita Mohan, Sarah J. Tabrizi, James Doherty, Albert Robichaud, Michael Quirk 2:36 p.m. S15.009 The Vagus Nerve Is Critical for the Rapid and Widespread Response in the Brain Following Oral Administration of a Physiologically Active Bacteria–Aadil Bharwani, Christine R. West, Kevin Champagne-Jorgensen, Karen-Anne McVey Neufeld, Joseph Ruberto, Wolfgang Kunze, John Bienenstock, Paul Forsythe

CME

MONDAY, APRIL 27 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m. CME

2:36 p.m. S16.009 Seasonal Variation in Incidence of Anti-GQ1b Antibody Syndrome – A Population-based Study– Chun Yin William Leung, Yun Hin Ian Leung, Elaine Yuen Ling Au, Eric HY Lau, Shek Kwan Chang 2:48 p.m. S16.010 Improved Accuracy in Myasthenia Gravis Using Combinatorial Algorithmic Autoantibody Testing–Shahar Shelly, Pritikanta Paul, Hongyan Bi, Divyanshu Dubey, Eati Basal, Sean J. Pittock, Anastasia Zekeridou, Andrew McKeon, John R. Mills, Christopher J. Klein

Monday, April 27

SCIENTIFIC SESSIONS

S16 Autoimmune Neurological Disorders: Diagnosis, Biomarkers, and Epidemiology

90 2020 AAN Annual Meeting

S17 Parkinson’s Disease Biomarkers and Pathophysiology 1:00 p.m. S17.001 Biomarkers for Parkinson’s Disease with Reflex Tears Correlate with Disease Duration–Mark F. Lew, Srikanth Janga, Danielle Feigenbaum, Dan Freire, Maria Edman, Wendy Mack, Curtis Okamoto, Sarah Hamm-Alvarez 1:12 p.m. S17.002 Head Injury and Parkinson’s Disease (PD) Phenotype– Ethan G. Brown, Samuel Goldman, Cheryl Meng, Caroline M. Tanner 1:24 p.m. S17.003 Metabolic syndrome and genetic Parkinson’s disease –the case of LRRK2 and GBA–Ofer Rotchild, Anat Mirelman, Tanya Gurevich, Mali Gana-Weiss, Orly Goldstein, Meir Kestenbaum, Jesse M. Cedarbaum, Avi Orr-Urtreger, Nir Giladi, Avner Thaler 1:36 p.m. S17.004 PREDIGT Score: Diagnosing Parkinson’s Disease Without a Movement Disorder Examination–Juan Li, Tiago Mestre, Julianna Tomlinson, Claudia Trenkwalder, Brit Mollenhauer, Tim Ramsay, Douglas Manuel, Michael G. Schlossmacher 1:48 p.m. S17.005 Cutaneous Alpha-Synuclein Deposition Across the Synucleinopathies–Christopher H. Gibbons, Ningshan Wang, Sharika Rajan, Drew S. Kern, JoseAlberto Palma, Horacio C. Kaufmann, Roy L. Freeman 2:00 p.m. S17.006 Does the Truth Lie Within the Gut? Investigating the Gut Microbiome in an Australian Cohort of Parkinson’s Disease Patients–Jade Kenna 2:12 p.m. S17.007 Gender Differences in Distribution of Lewy Body Pathology in Individuals with Parkinson’s Disease– Katherine Iannuzzelli, Catherine Bakker, Jumana Tariq A Alshaikh, Jee Bang, Ankur Butala, Cherie Marvel, Emile Sami Moukheiber, Maitreyi Murthy, Alexander Pantelyat, Olga Pletnikova, Gregory Pontone, Gerson Suarez-Cedeno, Juan C. Troncoso, Kelly A. Mills, Ted M. Dawson, Liana Rosenthal 2:24 p.m. S17.008 APOE e4-related differences in visuospatial impairment in female Parkinson’s Disease patients–Ashley Rawls, Laurice T. Yang, Kathryn Anne Chung, Amie L. Hiller, Alberto J. Espay, Fredy J. Revilla, Johnna Devoto, Jennifer G. Goldman, Glenn Thurston Stebbins, Bryan A. Bernard, Zbigniew K. Wszolek, Owen A. Ross, Dennis W. Dickson, Liana Rosenthal, Ted M. Dawson, Marilyn Albert, Stewart A. Factor, Daniel Weintraub, John Q. Trojanowski, Vivianna Van Deerlin, Tanya Simuni, Steven Lubbe, Niccolo Emanuele Mencacci, Shu-Ching Hu, James B. Leverenz, Joseph F. Quinn, Thomas J. Montine, Cyrus P. Zabetian, Kathleen Poston, Brenna Cholerton 2:36 p.m. S17.009 Parkinson’s Disease with Rapid Eye Movement Sleep Behaviour Disorder: PET Imaging Extrastriatal D2 Receptors–Mikaeel Valli, Sang Soo Cho, Yuko Koshirmori, Maria Diez-Cirarda, Jinhee Kim, Alexander Mihaescu, Antonio Strafella

CME

2:48 p.m. S17.010 A novel strategy to improve inclusion criteria, assess target engagement and determine efficacy in alpha-synucleinopathy treatment trials–Todd D. Levine, Bailey Bellaire, Christopher H. Gibbons, Roy L. Freeman

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

MONDAY, APRIL 27 3:30 p.m.–4:30 p.m.

1:00 p.m.–3:00 p.m. S18 Neuromuscular and Clinical Neurophysiology (EMG): Neuroimaging, Outcome Measures, and Biomarkers

2:00 p.m. S18.006 Longitudinal changes in MRI and functional outcome measures in facioscapulohumeral dystrophy–Leo Hong-Li Wang, Dennis W. Shaw, Anna Faino, Katy Eichinger, Christopher Budech, Leann Lewis, Jeffrey Statland, Stephen J. Tapscott, Seth Friedman, Alrabi Tawil 2:12 p.m. S18.007 Development and Evaluation of a Whole-body MRI Imaging Protocol and Analysis Algorithms to Measure Changes in Skeletal Muscle in FSHD– Diego Cadavid, Michelle L. Mellion, Shane Raines, Per Wildholm, Olof Dahlqvist Leinhard 2:24 p.m. S18.008 The NIH Toolbox for Cognitive Surveillance in Duchenne Muscular Dystrophy–Mathula Thangarajh, Aaron Kaat, Genila Bibat, Kristina Hardy, Kathryn Rae Wagner 2:36 p.m. S18.009 A New Ultrasonographic Parameter to Enhance Diagnostic Yield of Ultrasonography in Patients with Ulnar Mononeuropathy at the Elbow–Mansoureh Mamarabadi, John A. Morren, Steven Shook 2:48 p.m. S18.010 Age-based Normative Values of Meissner’s Corpuscle Density using In-Vivo Reflectance Confocal Microscopy–Khai Du, Peter Dunbar Creigh, Elizabeth Lynne Wood, Joan Mountain, Janet Sowden, Julie Charles, David N. Herrmann

S19 Autonomic Disorders

CME

3:30 p.m. Irwin Schatz Award for Autonomic Disorders Presentation This award recognizes young investigators who have advanced the field of autonomic disorders, or senior investigators that have made major contributions to the field. Recipient: Horacio Kaufman, MD, FAAN New York, NY 3:42 p.m. S19.002 Effects of Once-Daily Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, on Blood Pressure in Subjects With Symptomatic Neurogenic Orthostatic Hypotension–Horacio C. Kaufmann, Italo Biaggioni, Ashok Panneerselvam, Brett Haumann, Ross Vickery 3:54 p.m. S19.003 Presentation, Causes, and Hemodynamic Features of Acquired Afferent Baroreflex Failure–Bhumika Balgobin, Jose-Alberto Palma, Miguel Perez, Lucy Norcliffe-Kaufmann, Horacio C. Kaufmann 4:06 p.m. S19.004 Differences and Similarities Between the Parkinsonian Variant of Multiple System Atrophy and Parkinson Disease in the Natural History Study of the Synucleinopathies–Patricio Millar Vernetti, Jose-Alberto Palma, Alessandra Fanciulli, Florian Krismer, Wolfgang Singer, Phillip A. Low, Maria Teresa Pellecchia, Han-Joon Kim, Cyndya Shibao, Amanda C. Peltier, Italo Biaggioni, Maria J. Marti, Cinthia Terroba-Chambi, Marcelo Merello, David S. Goldstein, Roy L. Freeman, Christopher H. Gibbons, Steven Vernino, Lucy Norcliffe-Kaufmann, Gregor K. Wenning, Horacio C. Kaufmann 4:18 p.m. S19.005 Predicting Phenoconversion in Pure Autonomic Failure–Elizabeth A. Coon, Jayawant Narayan Mandrekar, Sarah E. Berini, Eduardo E. Benarroch, Paola Sandroni, Phillip A. Low, Wolfgang Singer

SCIENTIFIC SESSIONS

1:00 p.m. S18.001 Neuroimaging Reveals Widespread Thalamic, Hippocampal, and Basal Ganglia Atrophy in Primary Lateral Sclerosis–Eoin Finegan, Rangariroyashe Chipika, Stacey Li Hi Shing, Mark A Doherty, Jennifer C Hengeveld, Alice Vajda, Colette G. Donaghy, Russel McLaughlin, Siobhan Hutchinson, Orla Hardiman, Peter Bede 1:12 p.m. S18.002 MRI Predictors of Longitudinal Functional Decline in Amyotrophic Lateral Sclerosis–Edoardo G. Spinelli, Federica Agosta, Paola MV Rancoita, Nilo Riva, Yuri Falzone, Clelia Di Serio, Vincenzo Silani, Massimo Filippi 1:24 p.m. S18.003 A 18F-FDG-PET Study on Brain Metabolic Correlates of King’s Staging System in ALS–Adriano Chio, Marco Pagani, Andrea Calvo, Cristina Moglia, Umberto Manera, Rosario Vasta, Maurizio Grassano, Vincenzo Arena, Alessandro Bombaci, Antonio Canosa 1:36 p.m. S18.004 A Data-Driven Characterisation of the Evolution of White Matter Damage in Amyotrophic Lateral Sclerosis–Peter N. Leigh, Matt C. Gabel, Matt C. Gabel, Alexandra L. Young, Sharon Abrahams, Mark Bastin, Ricarda Menke, Ammar Al-Chalabi, Laura G. Goldstein, Stella Tsermentseli, Daniel Alexander, Martin Robert Turner, Mara Cercignani 1:48 p.m. S18.005 Hippocampal, Fornix, Uncinate, and Amygdala Degeneration in Amyotrophic Lateral Sclerosis: the Pathological Substrate of Memory Impairment–Peter Bede, Efstratios Karavasilis, Michail Rentzos, Georgios Velonakis, Vasiliki Zouvelou, Vasiliki Zouvelou, Georgios Argyropoulos, Ioannis Papatriantafyllou, Varvara Pantolewn, Panagiotis Ferentinos, Nikolaos Kelekis, Ioannis Seimenis, Ioannis Evdokimidis, Foteini Christidi

CME

Monday, April 27

AAN.com/view/20AM 91

MONDAY, APRIL 27 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m.

Monday, April 27

SCIENTIFIC SESSIONS

S20 Cerebrovascular Disease: Large Vessel Occlusions and Thrombectomy 3:30 p.m. S20.001 Predicting Symptomatic Intracranial Hemorrhage After Mechanical Thrombectomy: The TAG Score–Mayra Montalvo Perero, Eva Mistry, Andrew D. Chang, Aleksandra Yakhkind, Katarina B. Dakay, Idrees Azher, Akshitkumar Mistry, Rohan Chitale, Shawna M. Cutting, Tina Mariko Burton, Brian Mac Grory, Michael E. Reznik, Ali Mahta, Bradford B. Thompson, Koto Ishida, Jennifer A. Frontera, Howard Riina, David Gordon, David Turkel-Parrella, Erica Scher, Jeffrey Farkas, Ryan A McTaggart, Pooja Khatri, Karen L. Furie, Mahesh Jayaraman, Shadi Yaghi 3:42 p.m. S20.002 Association of Elevated Troponin Levels on Stroke Outcomes After Mechanical Thrombectomy– Melissa Bailey, Vasu Saini, Juan Sebastian Diaz, Sishir Mannava, Elizabeth Jordan, Nastajjia Krementz, Mario Phillip Zamora, Luis GuadaDelgado, Daniel Robert Kogan, Dileep R. Yavagal, Nicole Beaton Sur 3:54 p.m. S20.003 Comparing Thrombectomy Outcomes Amongst Patients Who Present to Comprehensive Stroke Centers and Transfers–Rakhee Lalla, Aaron Patrick Noles, Helio Carvalho, Karen L. Yarbrough, Gaurav Jindal, Michael Phipps, Marcella A. Wozniak, Carolyn Cronin, Jose G. Merino, John Cole, Seemant Chaturvedi 4:06 p.m. S20.004 Short-term Blood Pressure Variability After Successful Re-canalization Is Associated with Discharge Outcomes in Large Vessel Occlusion Strokes–Saurav Das, Thomas Chandler, Connor J. Elliott, Stephen Furmanek, Wei Liu, Kerri S. Remmel, Ozan Akca 4:18 p.m. S20.005 Poor Functional Outcome Is Associated with Blood Pressure Trajectories 72 Hours After Thrombectomy: A Multicenter Analysis–Sreeja Kodali, Can Meng, Sumita Strander, Andrew Silverman, Krithika Umesh Peshwe, Cindy Khanh Phuong Nguyen, Anson Wang, Alexandra Kimmel, Mohammad Anadani, Alejandro Spiotta, Ka-Ho Wong, Adam De Havenon, Andrea Holcombe, Cynthia Zevallos, Santiago Ortega Gutierrez, Eva Mistry, Akshitkumar Mistry, Eva Mistry, Ilko Maier, Marios-Nikos Psychogios, Jan Liman, Adam Arthur, Fnu Abhi Pandhi, Nitin Goyal, Stacey Wolfe, Fabio Nascimento, Peter Kan, Nolwenn Riou-Comte, Benjamin Gory, Joontae Kim, Kevin N. Sheth, Nils Petersen 4:30 p.m. S20.006 Blood Pressure Decreases Occur Throughout Endovascular Thrombectomy and Are Associated with Poor Functional Outcome–Alexandra Kimmel, Andrew Silverman, Sreeja Kodali, Sumita Strander, Cindy Khanh Phuong Nguyen, Krithika Umesh Peshwe, Anson Wang, Gloria Lopez Cardenas, Andrea Holcombe, Cynthia Zevallos, Sudeepta Dandapat, Lauren Hachmann Sansing, Joseph Schindler, Guido Jose Falcone, Charles Matouk, Kevin N. Sheth, Santiago Ortega-Gutierrez, Nils Petersen

92 2020 AAN Annual Meeting

CME

4:42 p.m. S20.007 Risk of Worse Outcome in Stroke Patients with High Blood Pressure Variability After Endovascular Thrombectomy May Be Amplified by Impaired Cerebral Autoregulation–Cindy Khanh Phuong Nguyen, Andrew Silverman, Anson Wang, Sreeja Kodali, Sumita Strander, Alexandra Kimmel, Krithika Umesh Peshwe, Adam De Havenon, Emily Jean Gilmore, Lauren Hachmann Sansing, Joseph Schindler, Charles Matouk, Kevin N. Sheth, Nils Petersen 4:54 p.m. S20.008 Quality of Life for Younger Versus Older Patients Following Endovascular Thrombectomy in the Extended Window: A Secondary Analysis of DEFUSE 3–Adam De Havenon, Jennifer J. Majersik, Alexandra Terrill, Kirby Taylor, Gregory W. Albers 5:06 p.m. S20.009 Age-specific Differences in the Use of Endovascular Treatment and Hospital Outcomes in Patients with Acute Ischemic Stroke: A Community-wide Perspective–Mohammad-Rauf A. Chaudhry, Saqib A. Chaudhry, Iqra N Akhtar, Ameer Hassan, Sairah Bashir, Mohsain Gill, Farhan Siddiq, Muhammad Fareed Suri, Camilo Ramiro Gomez, Adnan I. Qureshi 5:18 p.m. S20.010 Clinical Characteristics of Fast and Slow Progressors of Infarct Growth in Anterior Circulation Large Vessel Occlusion Stroke–Marcelo Rocha, Shashvat Desai, Ashutosh P. Jadhav, Tudor G. Jovin

S21 Neuroepidemiology

CME

3:30 p.m. Bruce S. Schoenberg International Award in Neuroepidemiology Presentationn In tribute to the career of Bruce S. Schoenberg, MD, in training neurologists internationally in epidemiologic methods, this award salutes a promising young investigator from a developing country or Eastern Europe. Recipient: Jorge Llibre-Guerra, MD, MSc La Habana, Cuba 3:54 p.m. S21.003 Healthcare utilization and inpatient/emergency department costs in adult and pediatric functional neurological disorders: a growing problem– Christopher D. Stephen, Codrin I. Lungu, Alberto J. Espay 4:06 p.m. S21.004 Environmental and Occupational Risk Factors for ALS: A Nested Case Control Study–Evelyn Talbott, Angela Malek, Vincent Arena, Ruopu Song, Judith Rager, James Stewart, Jeff Yanosky, Duanping Liao, Eric Whitsel 4:18 p.m. S21.005 Completeness and Validation of Automated Reporting to the California Parkinson’s Disease Registry–Allan Ding Wu, Camille Malatt, Betty Truong, Wesley Wu, Kayla Bryant-Dunmire, Federica Agosta, Beate Ritz, Caroline M. Tanner, Eric M. Cheng 4:30 p.m. S21.006 Adverse Childhood Experiences in Patients with Neurological Disease–Adys Mendizabal, Cody Louis Nathan, Pouya Khankhanian, Gloria Young, Louise Breen, Nabila Dahodwala 4:42 p.m. S21.007 Mitochondrial DNA Variation in Sudden Cardiac Death: A Population-based Study–Laura Kytovuori, Juhani Junttila, Heikki Huikuri, Sirkka KeinanenKiukaanniemi, Kari G. Majamaa, Mika Martikainen 4:54 p.m. S21.008 Twelve-year Rates and Causes of Admissions Among Those with Neurological Conditions in the US: A Nationally Representative Study–Charlotte Solmssen, Parul Agarwal, Churl-Su Kwon, Mandip Singh Dhamoon, Madhu Mazumdar, Huaqing Xi, Nathalie Jette 5:06 p.m. S21.009 Awareness Regarding Stroke Amongst CommunityDwelling Elderly Hypertensives in a Rural Area of Bangalore District, Karnataka State, India–Vivek Bhat, Thanmayi G. S, Arvind Kasthuri 5:18 p.m. S21.010 Assocation Between Social Deprivation and the Incidence of First Seizures, New Diagnosis of Epilepsy and Seizure Mimics–Eimer Maloney, Paul Corcoran, Daniel Costello, Eilis J O’Reilly

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

MONDAY, APRIL 27 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m. S22 Practice, Policy, and Ethics: Improving Patient Care and the Rise of Telemedicine

CME

5:18 p.m. S23.010 Nighttime Behavior in Cognitively Intact Patients with Pathologically Confirmed AD Are Associated with Rapid Cognitive Decline–Adrienne L Atayde, Corinne Fischer, Tom Schweizer, David G. Munoz

Monday, April 27

3:30 p.m. S23.001 Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease–Chad J Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Heather Bradley, Martin Rabe, Keiichiro Totsuka, Robert YK Lai, Robert Gordon, Lynn D. Kramer 3:42 p.m. S23.002 [18F]Flortaucipir PET to Autopsy Pathology Correlation in Alzheimer’s Disease and Other Neurodegenerative Diseases–David Nima Soleimani-Meigooni, Leonardo Iaccarino, Renaud La Joie, Suzanne L. Baker, Viktoriya Bourakova, Adam L. Boxer, Lauren M. Edwards, Rana Eser, Maria Gorno Tempini, William J. Jagust, Mustafa Janabi, Joel Kramer, Orit Lesman-Segev, Taylor Mellinger, Bruce L. Miller, Julie Pham, Howard J. Rosen, Salvatore Spina, Amelia Strom, William Seeley, Lea Grinberg, Gil Dan Rabinovici 3:54 p.m. S23.003 Investigation of the Positron-Emission Tomography [18F]MK-6240 Tau Ligand in Genetic Frontotemporal Dementia–Jake Levy, Melissa Savard, Tharick A. Pascoal, Elizabeth Finger, JeanPaul Soucy, Pedro Rosa Neto, Simon Ducharme 4:06 p.m. S23.004 Evaluation of Fluid Biomarkers for Use in Clinical Trials in Individuals at Risk for Prion Disease–Eric Vallabh Minikel, Victoria Williams, Becky Carlyle, Alison McManus, Chase Wennick, Hien Zhao, Kaj Blennow, Henrik Zetterberg, Steven E. Arnold, Sonia Minikel Vallabh 4:18 p.m. S23.005 TDP-43 Is as Important as Alzheimer’s Disease Neuropathology in the Oldest Old–S. Ahmad Sajjadi, Maria M. Corrada, Michael Phelan, Claudia Kawas 4:30 p.m. S23.006 Generation of Antibodies Selective for Misfolded Disease-associated TDP-43–Neil R. Cashman, Sarah Louadi, Neil R. Cashman, Ebrima Gibbs, Anke Dijkstra, Johanne M. Kaplan 4:42 p.m. S23.007 Tau Status Portends Different Baseline and Longitudinal Cognitive Performance in Amyloidand Neurodegeneration-positive Mild Cognitive Impairment (MCI)–Lauren McCollum, Laura Wisse, Salena Cui, Robin de Flores, Sandhitsu Das, Long Xie, Paul Yushkevich, David A. Wolk 4:54 p.m. S23.008 Nucleoporin 98 Localization Is Disrupted in Primary Tauopathies–John Dickson, Bradley T. Hyman 5:06 p.m. S23.009 Mechanism of Brain Capillary Blood Flow Compromise in Alzheimer’s Disease: The Interplay of Pericytes, Amyloid Beta, Reactive Oxygen Species, and Endothelin–Chanawee Hirunpattarasilp, Ross Nortley, Nils Korte, Pablo Izquierdo, David Attwell

CME

SCIENTIFIC SESSIONS

3:30 p.m. S22.001 Neuro-hospitalist Program Increases Outpatient Productivity and Reduces Turnover–Kelly Baldwin, Megan Brosious, John Reibsome, Anthony Noto, Neil R. Holland 3:42 p.m. S22.002 Geographical Distribution of Neurologists in the United States–Kyra Curtis, Sama Elrahi, Josh Bilello, Prashant Kumar Rai 3:54 p.m. S22.003 Analyzing the Online Presence of Neurologists in the United States–Sama Elrahi, Kyra Curtis, Josh Bilello, Prashant Kumar Rai 4:06 p.m. S22.004 Early Inpatient Readmissions of Acute Care Neurology Patients to Higher Level of Care Units: Opportunity for Quality Improvement in Transitions of Care–Amanda Crooks, Casey Olm-Shipman 4:18 p.m. S22.005 Converting to Atraumatic Lumbar Puncture Needles; Experience from the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK–Pawel Obrocki, Ross W. Paterson, Ashvini Keshavan, Catherine Mummery 4:30 p.m. S22.006 Teleneurology for Epilepsy: Improving Access to Care in Rural Nebraska–Proleta Datta, Brooke A Denigris, Geri M Hansen 4:42 p.m. S22.007 The Use of Leadership Training to Improve Access to Care in a Deployed Setting–Virginia Baker, Nawaz Hack 4:54 p.m. S22.008 Implementation of a Risk-Stratified Multiple Sclerosis Treatment Algorithm: Improved Quality and Affordability–Annette M. Langer-Gould, Stephen Wing Ho Cheng, Jessica Betty Smith, Bonnie Li, Michael H Kanter 5:06 p.m. S22.009 The Shifting World of Genomic Testing in Neurological Diseases: Ethical Obligations of the Health Care System–Drew Thodeson, Jillian MacDonald, Jeffrey SoRelle, Jason Andrew Park 5:18 p.m. S22.010 Kaiser Permanente’s Rational, Risk-Stratified, CostSensitive Multiple Sclerosis Treatment Algorithm– Annette M. Langer-Gould, Shilpa Klocke, Douglas Monroe, Brandon Emet Beaber, Sonu Malik Brara, Allen Scott Nielsen, Julie DeBacker, Oluwasheyi Akin Ayeni

S23 Aging and Dementia: Biomarkers and Clinical Trials

AAN.com/view/20AM 93

MONDAY, APRIL 27 3:30 p.m.–5:30 p.m.

Monday, April 27

SCIENTIFIC SESSIONS

S24 Pregnancy, Pediatric MS, and Early MS 3:30 p.m. S24.001 Nulliparity is associated with earlier evolution of progressive multiple sclerosis in women–Burcu Zeydan, Elizabeth Atkinson, Carin Smith, Liliana Gazzuola Rocca, Walter A. Rocca, Mark Keegan, Brian G. Weinshenker, Kejal Kantarci, Orhun H. Kantarci 3:42 p.m. S24.002 Optic Nerve Head Volume is Significantly Decreased in Pediatric MS and Not Pediatric MOGrelated Disorders.–Giulia Longoni, Tara Berenbaum, Sunil R Yadav, Ella Kadas, Arun Y. Reginald, Michael Wan, Donald Mabbott, Alexander U. Brandt, E. Ann Yeh 3:54 p.m. S24.003 Changes in Management of Pediatric-onset Multiple Sclerosis: Are We Really Modifying the Disease Course? Data from the Italian MS Registry–Damiano Baroncini, Pietro Iaffaldano, Marta Simone, Vincenzo Brescia Morra, Massimo Filippi, Marzia Romeo, Francesco Patti, Clara Chisari, Eleonora Cocco, Giuseppe Fenu, Giuseppe Salemi, Paolo Ragonese, Matilde Inglese, Maria Cellerino, Giancarlo Comi, Mauro Zaffaroni, Angelo Ghezzi, Damiano Baroncini 4:06 p.m. S24.004 Two-year results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior diseasemodifying therapy–Bianca Weinstock-Guttman, Robert A. Bermel, Csilla Csoboth, Gary Raymond Cutter, Mark S. Freedman, Thomas Leist, Xiaoye Ma, Bruno C. Musch, Anthony Reder, James M. Stankiewicz, Jerry S. Wolinsky 4:18 p.m. S24.005 Early Factors Associated with Later Conversion to Multiple Sclerosis in Patients Presenting with Isolated Myelitis–Olwen Murphy, Loulwah Mukharesh, Carlos A. Pardo-Villamizar, Scott Douglas Newsome 4:30 p.m. S24.006 Can Digital Biomarkers Acquired on a Smarphone Distinguish Healthy Controls from Radiologically Isolated Syndrome Subjects?–Mikael Cohen, Salim Fakir, Lydiane Mondot, Cassandre Landes, Christine Lebrun-Frenay 4:42 p.m. S24.007 Association of the Central Vein Sign and “Paramagnetic Rims” with Cognitive Impairment in Radiologically Isolated Syndrome–Suradech Suthiphosuwan, Anthony Feinstein, Pascal Sati, Martina Absinta, Melanie Guenette, Blake Dewey, Daniel Reich, Aditya Bharatha, Jiwon Oh 4:54 p.m. S24.008 OCT Measures are Associated with Disease Burden and Inflammatory Activity in Newly Diagnosed MS and Clinically Isolated Syndromes–Marco pisa, Tommaso Croese, Gloria Dalla Costa, Su-Chun Huang, Francesca Sangalli, Bruno Colombo, Giancarlo Comi, Roberto Furlan, Letizia M. Leocani

94 2020 AAN Annual Meeting

CME

5:06 p.m. S24.009 Mapping the Baseline Gut Microbiome Landscape in People at Risk for Multiple Sclerosis–Zongqi Xia, Charles White, Wei Zong, Chris Gaiteri, Wei Jia, Yian Gu, Aleksandar Kostic, George Tseng, Philip De Jager 5:18 p.m. S24.010 The Use of Human Brain Microphysiological Systems to Diagnose Autoimmune Central Nervous System Diseases–Alexander Carvajal- Gonzalez, Laura Muñoz-Arcos, Paula Barreras, David Pamies, Carlos A. Pardo-Villamizar, Arun Venkatesan

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

TUESDAY, APRIL 28 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m. S25 Epilepsy/Clinical Neurophysiology (EEG) 2

2:48 p.m. S25.010 Genomic Analysis of a South Indian Community with Autosomal Dominant Cortical Tremor, Myoclonus, and Epilepsy (ADCME) Suggests a Founder Repeat Expansion Mutation in the SAMD12 gene–Radha Mahadevan, Natarajan Visvanathan, Bobby Essaki, Raichel Chelladurai, Varun Suroliya, Saravanan Sankaralingam, Ganesan Shanmugam, Rahul Bhoyar, Mohammed Faruq, Vinod Scaria, Sridhar Sivasubbu, Shantaraman Kalyanaraman

S26 Cerebrovascular Disease: Systems of Stroke Care

CME

1:00 p.m. S26.001 CT Perfusion Imaging in Telestroke Facilitates Treatment Decisions Without Delaying Door to Needle Time–Chris Hackett, Russell Mitesh Cerejo, Robert Fishman, David G. Wright, Sandeep S. Rana, Ashis H. Tayal 1:12 p.m. S26.002 National Trends in Utilization and Outcomes of Thrombolytic Use by Drip and Ship Paradigm in Acute Ischemic Stroke Patients in United States–Saqib A. Chaudhry, Mohammad-Rauf A. Chaudhry, Mohsain Gill, Sairah Bashir, Iqra N Akhtar, Adnan I. Qureshi 1:24 p.m. S26.003 Multi-Incident Analysis of near-miss incidents of alteplase and tenecteplase mix-up in Hyperacute Stroke Care–Cynthia Lam, Vincent Teo, Michaela Tonna, Courtney Wong, Patti Madorin, Houman Khosravani 1:36 p.m. S26.004 Cost-effectiveness of Rapid MRI in the Emergency Department Evaluation of Suspected Stroke–Adam De Havenon, Alen Delic, Scott McNally, Vivek Reddy, Yoshimi Anzai, Jennifer J. Majersik, Christopher Michael Orlando 1:48 p.m. S26.005 Mobile Observation Video Exam For Acute Stroke Triage En Route – “MOVE FASTER” a Pilot Feasibility Atudy of Pre-Hospital Stroke Telemedicine–Constance Katsafanas, Constance Katsafanas 2:00 p.m. S26.006 Can We Improve Clinical Detection of Right Hemisphere Large Vessel Occlusion?–Sana Somani, Toby I. Gropen, Melissa Gazi 2:12 p.m. S26.007 Effect of “Opt-out” CT-Angiography (CT-A) Protocol for Evaluation of Large Vessel Occlusion (LVO) in the Emergency Department on Incidence of Contrast-induced Acute Kidney Injury (CI-AKI) and Rate of Endovascular Therapy (EVT): Single Center Cohort Study–Nathanael Lee, Fred Rincon, Robin N. Dharia 2:24 p.m. S26.008 Predictors of Readmission After Stroke in a Cohort of Privately Insured Patients–Haitham Hussein, Ella Chrenka, Amanda Ann Herrmann, Carol Droegemueller 2:36 p.m. S26.009 Predictors of 30-day Readmissions Following Index Hospitalizations for Transient Ischemic Attack– Aayushi Garg, Kaustubh S. Limaye, Amir Shaban, Enrique C. Leira 2:48 p.m. S26.010 Retinal Microvascular Changes Differentiate Mild Stroke and Transient Ischemic Attack (TIA) from Mimics among Patients Presenting to the Emergency Department (ED) with Suspected TIA: The FOTO-TIA Study–Beau Benjamin Bruce, Samuel Bidot, Fadi B. Nahab, Jeffery Siegelman, Nicolas Antonio Bianchi, Kaitlin Sandor, Mung Yan Lin, Sharrill Bell, Michael Ross, David W. Wright, Valerie Biousse, Nancy J. Newman

AAN.com/view/20AM 95

Tuesday, April 28

SCIENTIFIC SESSIONS

1:00 p.m. S25.001 An Online Survey of Caregivers of Patients with KCNQ2 Developmental & Epileptic Encephalopathy (KCNQ2-DEE)–Cynthia L. Harden, Noam Butterfield, Celene Grayson, Constanza Luzon, Simon Pimstone, Ernesto Aycardi, John J. Millichap 1:12 p.m. S25.002 Mood and Quality of Life in Patients Treated with Brain-responsive Neurostimulation: The Value of Earlier Intervention–David W. Loring, Beata Jarosiewicz, Kimford J. Meador, Andres M. Kanner, Tara Crowder Skarpaas, Martha Morrell 1:24 p.m. S25.003 Long-term Outcomes in Surgical Patients with Intractable Temporal Lobe Epilepsy–Jake Torrison, Allison Osen, Sepehr Sani, Richard Edmund Byrne, Bichum Ouyang, Rebecca O’Dwyer 1:36 p.m. S25.004 Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome (LGS): 3-Year Results of an Open-Label Extension (OLE) Trial (GWPCARE5)–Anup D. Patel, Richard Chin, Wendy G. Mitchell, Scott Perry, Leon A. Weinstock, Daniel Checketts, Eduardo Dunayevich 1:48 p.m. S25.005 The Effects of Paternal Seizure Disorders and Antiseizure Medication Use on Offspring Neurodevelopmental Outcomes, Psychiatric Comorbidities, and Sexual Health.–Hernan Nicolas Lemus Esquivel, Marc Joseph Casale, James J. Young, Lara Vanessa Marcuse, Ji-Yeoun Yoo, Bridget Rita Mueller, Madeline Cara Fields 2:00 p.m. S25.006 Long-term Safety of Adjunctive Cenobamate in Patients with Uncontrolled Focal Seizures: Open-label Extension of a Randomized Clinical Study–Steve S. Chung, Jacqueline French, Gregory L. Krauss, Sang Kun Lee, Maciej Maciejowski, William E. Rosenfeld, Michael R. Sperling, Marc Kamin 2:12 p.m. S25.007 Pharmacokinetics of Diazepam Buccal Film in Adult Patients with Epilepsy: Comparison with Diazepam Rectal Gel–Michael A. Rogawski, Allen H Harevy Heller, Simon J. Farrow, Cassie Jung, Pavel Klein, Sylvie Boudreault, Gary Slatko 2:24 p.m. S25.008 Safety and Efficacy of Add-on ZX008 (Fenfluramine HCl Oral Solution) in Sunflower Syndrome: An Open-label Pilot Study of 5 Patients–Elizabeth Thiele, Patricia L Bruno, Uyen Vu, Kennedy Geenen, Samarth P Doshi, Sandip Patel, Jo Sourbron 2:36 p.m. S25.009 Sub-cortical Patho-connectivity in Medial Temporal Lobe Epilepsy: A VBM Meta-analysis–Vahid Eslami, Daniel Barron, Heath Pardoe, Peter T. Fox

CME

TUESDAY, APRIL 28 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m.

Tuesday, April 28

SCIENTIFIC SESSIONS

S27 Child Neurology and Developmental Neurology: Neurogenetics: Translating Knowledge to Therapy 1:00 p.m. S27.001 Onasemnogene Abeparvovec-xioi GeneReplacement Therapy for Spinal Muscular Atrophy Type 1 (SMA1): Phase 3 US Study (STR1VE) Update–John W. Day, Claudia A. Chiriboga, Thomas O. Crawford, Basil T. Darras, Richard S. Finkel, Anne M. Connolly, Susan T. Iannaccone, Nancy L. Kuntz, Loren DM Pena, Perry Shieh, Edward Clinton Smith, Meredith Schultz, Douglas Feltner, Sitra Tauscher-Wisniewski, Francis Ogrinc, Ankita Shah, Haojun Ouyang, Thomas Macek, Elaine Kernbauer, Douglas M. Sproule, Jerry R. Mendell 1:12 p.m. S27.002 Gene-Replacement Therapy in Spinal Muscular Atrophy Type 1: Long-Term Follow-Up From the Onasemnogene Abeparvovec-xioi Phase 1/2a Clinical Trial–Jerry R. Mendell, Richard Shell, Kelly Lehman, Markus McColly, Linda Pax Lowes, Lindsay N. Alfano, Natalie Fae Miller, Megan Iammarino, Kathleen Church, Francis Ogrinc, Haojun Ouyang, Elaine Kernbauer, Shivani Joshi, Douglas M. Sproule, Matthew N. Meriggioli, Douglas Feltner, Samiah A. Al-Zaidy 1:24 p.m. S27.003 Onasemnogene Abeparvovec-xioi GeneReplacement Therapy in Presymptomatic Spinal Muscular Atrophy: SPR1NT Study Update–Kevin Strauss, Michelle Farrar, Kathryn J. Swoboda, Kyoko Saito, Claudia A. Chiriboga, Richard S. Finkel, Susan T. Iannaccone, Jena M. Krueger, Jennifer M. Kwon, Hugh John McMillan, Laurent Servais, Jerry R. Mendell, Julie Anne Parsons, Mariacristina Scoto, Perry Shieh, Craig M. Zaidman, Meredith Schultz, Elaine Kernbauer, Shivani Joshi, Francis Ogrinc, Sarah Kavanagh, Douglas Feltner, Sitra Tauscher-Wisniewski, Bryan McGill, Douglas M. Sproule, Francesco Muntoni 1:36 p.m. S27.004 CSF Biomarkers of Disease Severity and Response to Nusinersen Treatment in Children with Spinal Muscular Atrophy–Giulia Fadda, Elizabeth Anne Kichula, Micky Bacchus, Robert Allan Brown, Ling Zhao, Amy T. Waldman, Brian Augelli, Brenda Banwell, Amit Bar-Or 1:48 p.m. S27.005 Transpher A, a multicenter, single-dose, phase 1/2 clinical trial of ABO-102, an intravenous AAV9based gene therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA)–Kevin M. Flanigan, Nicholas JC Smith, ML Couce, KV Truxal, KL McBride, TR Simmons, MJ de Castro, KL Cope, MT Oreiro, L Jaensch, M Fuller, J Ruiz 2:00 p.m. S27.006 Safety, Tolerability, and Preliminary Evidence of Biopotency in Transpher B, a Multicenter, Single-dose, Phase 1/2 Clinical Trial of ABO-101 Gene Therapy for Sanfilippo Syndrome Type B (Mucopolysaccharidosis IIIB)–KL McBride, Nicholas JC Smith, ML Couce, Kevin M. Flanigan, KV Truxal, TR Simmons, MJ de Castro, Federica Rinaldi, MT Oreiro, L Jaensch, M Fuller, J Ruiz

96 2020 AAN Annual Meeting

CME

2:12 p.m. S27.007 Cross-sectional and Longitudinal Natural History of CLN3 Disease Progression–Margaux Cecille Masten, Jennifer Anne Vermilion, Heather Adams, Amy Vierhile, Frederick J. Marshall, Christopher Beck, Jonathan W. Mink, Erika Fullwood Augustine 2:24 p.m. S27.008 Safety and Improved Efficacy Outcomes in Children AADC Deficiency Treated with Eladocagene Exuparvovec Gene Therapy: Results From Three Clinical Trials–Wuh-Liang Hwu, Yin-Hsiu Chien, Ni-Chung Lee, Sheng-Hong Tseng, Chun-Hwei Tai, Anne Marie Conway, Mark Pykett 2:36 p.m. S27.009 Describing Neurologic and Neurodevelopmental Profiles of Pediatric Patients with Phelan McDermid Syndrome–Wilfreda Johnice Lindsey, Kristen Fisher, Andres Jimenez Gomez, Jimmy Holder, Sarah R. Risen, Sherry Vinson 2:48 p.m. S27.010 RNAseq Analysis for The Diagnosis of Lissencephaly–Hebah Qashqari, Hernan D. Gonorazky, Kimberly Amburgey, Sergey Naumenko, Arun Ramani, Michael Brudno, James Dowling

S28 Infectious Disease: Chronic Meningitis and the Immunosuppressed

CME

1:00 p.m. S28.001 Neurological Infections in Universal Health Care: Epidemiology, Incidence, and Outcomes–Wasan Abd Wahab, Jeffrey Bakal, Larry Svenson, Christopher Power 1:12 p.m. S28.002 Infectious Causes of Chronic Meningitis in HIV-Negative Patients–Kelly Baldwin, John Herbst, Jose Rivera, Eunice H. Bae, Tyler Crissinger 1:24 p.m. S28.003 Infectious Causes of Chronic Meningitis Among Neurosurgical Patients–Kelly Baldwin, John Herbst, Jose Rivera, Tyler Crissinger, Eunice H. Bae 1:36 p.m. S28.004 Neurologic Complications in the Boston Medical Center Endocarditis Registry, 2017-2019–Erin Barnes, Thiago Santos Carneiro, Anna Marisa Cervantes-Arslanian 1:48 p.m. S28.005 Role of Thalidomide as Immunomodulator in Management of Optochiasmatic Arachnoiditis in Patients of Tuberculous Meningitis–Manish Modi, Manoj Goyal, Kusum Sharma 2:00 p.m. S28.006 Improving Tuberculous Meningitis Diagnostics - A Combined Host and Pathogen Classifier–Prashanth Ramachandran, Akshaya Ramesh, Fiona Cresswell, Carson Quinn, Prashanth Ramachandran, Ananta Bangdiwala, Ananta Bangdiwala, Abdu Musubire, Abdu Musubire, Abdu Musubire, John Kasibante, Lillian Tugume, Ananta Bangdiwala, Charles Langelier, David Meya, Emily Crawford, David R. Boulware, Michael R. Wilson 2:12 p.m. S28.007 Regional Brain Volumes Associated with Neurocognitive Performance in Zambian Youth with Human Immunodeficiency Virus–Owen Dean, Alexandra Buda, Heather Adams, Sylvia MwanzaKabaghe, Michael Potchen, Esau G. Mbewe, Pelekelo Kabundula, Sarah Mohajeri, Gretchen L. Birbeck, David Bearden 2:24 p.m. S28.008 Conserved CSF HIV Antibody Response in Central Nervous System Escape–Isobel Anne Hawes, Ryan D. Schubert, Akshaya Ramesh, Gavin Sowa, Joanna Hellmuth, Magnus Gisslen, Richard W. Price, Michael R. Wilson 2:36 p.m. S28.009 Progressive Multifocal Leukoencephalopathy: A 25-Year Retrospective Cohort Study–Pria Anand, Gladia C. Hotan, Andre Vogel, Nagagopal Venna, Farrah J. Mateen 2:48 p.m. S28.010 Neurologic Features and Brain Imaging Findings of Immunosuppressed Individuals With West Nile Virus Meningoencephalitis: A Case Series of 4 Patients–Amir Abdallah, David Gritsch, Angela Parsons, Brian Chong, Marie Francisca Grill

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

TUESDAY, APRIL 28 1:00 p.m.–3:00 p.m.

3:30 p.m.–4:45 p.m.

S29 Multiple Sclerosis: Disease-modifying Therapy

2:12 p.m. S29.007 Variation in Time to First Disease Modifying Therapy in people with MS in the United States, United Kingdom, and Germany–Alexander Stahmann, David Ellenberger, Ruth-Ann Marrie, Rod Middleton, Richard St. John Nicholas, Jeff Rodgers, Amber Salter 2:24 p.m. S29.008 Impact of Switching from Natalizumab to a Moderate versus High Efficacy DMT in Clinical Practice at 24-Month Follow-Up–Carrie Michelle Hersh, Haleigh Claire Harris, Devon Conway, Le Hua 2:36 p.m. S29.009 BEST-MS: A Standardized and Prospective Study Comparing the Efficacy of Natalizumab versus Fingolimod in Active Relapsing Multiple Sclerosis.– Mikael Cohen, Lydiane Mondot, Florence Bucciarelli, Beatrice Pignolet, David Laplaud, Bruno Brochet, Gilles Defer, Nathalie Derache, Patrick Vermersch, Helene Zephir, Marc Debouverie, Eric Berger, Pierre Labauge, Xavier Ayrignac, Jerome De Seze, David Brassat, Christine Lebrun-Frenay 2:48 p.m. S29.010 Clinical Manifestation of Alemtuzumab-induced Autoimmune Thyroid Disease in People with Highly Active Multiple Sclerosis Is Dependent on Age and Presence of Early Brainstem Involvement–Siew Mei Yap, Mary Dillon, Rachel K Crowley, Christopher McGuigan

S30 Sports Neurology and Neuro Trauma

CME

3:30 p.m. S30.001 Prevalence of Medical Comorbidities Following Concussion – Experience at Two Academic Institutions over 19 years–Zabreen Tahir, Ali Al Jarrah, Ayaz M. Khawaja, Saksham Gupta, Saef Izzy 3:42 p.m. S30.002 Changes in Vestibular Ocular Motor Screen in Adolescents Treated with Vestibular Therapy after Concussion–Bara Alsalaheen, Andrea Almeida, Nicholas Samuel Streicher, Michael Popovich, Matthew T. Lorincz 3:54 p.m. S30.003 Arterial Hyperoxia Is Associated with Poor Functional Outcome and Cognitive Impairment After TBI: A Retrospective Multi-center Cohort Study–Fred Rincon, Mijail Serruya, Jack Jallo 4:06 p.m. S30.004 Amygdala Hypoconnectivity and Emotional Blunting in Pediatric Moderate/Severe TBI–Kevin Bickart, Alexander Olsen, Emily Dennis, Talin Babikian, Robert Asarnow, Christopher Giza 4:18 p.m. S30.005 Neurofilament Light-Chain Protein as A Potential Biomarker of Neurodegeneration and Progression in Former Contact Sports Athletes–Foad Taghdiri, Namita Multani, Miracle Ozzoude, Apameh Tarazi, Mozghan Khodadadi, Richard Wennberg, David J. Mikulis, Robin Green, Brenda Colella, Kaj Blennow, Henrik Zetterberg, Charles Tator, Carmela Tartaglia 4:30 p.m. S30.006 Concussion and Court: The Role Litigation Plays in Time to Recovery–Virginia Alexandria Headd, Mohammed Alwahaidy, Michael Lillis, Dilpreet Kaur, Said Shukri, Patrick Eugeni, Rebecca Alexandra Burgos, Jennifer McVige, Laszlo Mechtler

Tuesday, April 28

SCIENTIFIC SESSIONS

1:00 p.m. S29.001 Progressive Multifocal Leukoencephalopathy in a Patient on Ocrelizumab Monotherapy–James Sul, Arpan Patel, Marc L. Gordon, Jared Steinklein, Shayna Sanguinetti, Bidyut Pramanik, Zachary Orban, Igor J. Koralnik, Asaff Harel 1:12 p.m. S29.002 Evaluation of Risk Factors in Developing Lymphopenia and Hypogammaglobulinemia in AntiCD20 Treated Multiple Sclerosis Patients–Brandi L. Vollmer, Timothy L. Vollmer, John Corboy, Enrique Alvarez 1:24 p.m. S29.003 Identification of Therapeutic Lag in Multiple Sclerosis–Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo Ayuso, Sara Eichau Madueno, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, J M. Girard, Pierre Duquette, Serkan Ozakbas, Pierre Grammond, Patrizia Sola, Diana Ferraro, Roberto Bergamaschi, Cavit Boz, Elisabetta Cartechini, Maria Jose Sa, Murat Terzi, Raed Alroughani, Francois Grand-Maison, Franco Granella, Gerardo Iuliano, Raymond Hupperts, Jeannette LechnerScott, Daniele Litterio A. Spitaleri, Vincent Van Pesch, Aysun Soysal, Julie Prevost, Eduardo Aguera Morales, Francisco Javier Olascoaga Urtaza, Recai Turkoglu, Youssef Sidhom, Riadh Gouider, Bart Van Wijmeersch, Helmut Butzkueven, Charles Malpas, Sandra Vukusic, Tomas Kalincik 1:36 p.m. S29.004 Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis–Kristen M. Krysko, Jennifer Graves, Mary R. Rensel, Bianca Weinstock-Guttman, Alice Rutatangwa, Gregory S. Aaen, Anita L. Belman, Leslie A. Benson, Tanuja Chitnis, Mark Gorman, Manu S. Goyal, Yolanda C. Harris, Lauren B. Krupp, Timothy E. Lotze, Soe Soe Mar, Manikum Moodley, Jayne Ness, Moses Rodriguez, John W. Rose, Teri Schreiner, JanMendelt Tillema, Michael Waltz, Theron Charles Casper, Emmanuelle Waubant 1:48 p.m. S29.005 Disease Control Beyond NEDA: The Value of Nonclinical Disease Activity Measures to Determine Treatment Response to Natalizumab–Peter A. Calabresi, Ludwig Kappos, Gavin Giovannoni, Tatiana Plavina, Irene Koulinska, Michael R Edwards, Bernd C. Kieseier, Carl DeMoor, Elizabeth Fisher, Richard A. Rudick, Alfred W. Sandrock 2:00 p.m. S29.006 Lower Long-Term Disability with Early Start of High-Efficacy Therapies in Multiple Sclerosis–Anna He, Bernd Merkel, J William L. Brown, Lana Zhovtis Ryerson, Ilya Kister, Charles Malpas, Dana Horakova, Eva Havrdova, Guillermo Izquierdo Ayuso, Sara Eichau Madueno, Alessandra Lugaresi, R.M.M. Hupperts, Patrizia Sola, Diana Ferraro, Helmut Butzkueven, Francois Grand-Maison, Alexandre Prat, J M. Girard, Pierre Duquette, Thor Petersen, Pierre Grammond, Franco Granella, Vincent Van Pesch, Roberto Bergamaschi, Tomas Kalincik

CME

AAN.com/view/20AM 97

TUESDAY, APRIL 28 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m.

S31 Epilepsy/Clinical Neurophysiology (EEG) 3

Tuesday, April 28

SCIENTIFIC SESSIONS

3:30 p.m. Dreifuss-Penry Epilepsy Award Presentation This award recognizes physicians in the early stages of their careers who have made an independent contribution to epilepsy research. Recipient: Vikram Rao, MD San Francisco, CA

CME

5:18 p.m. S31.010 The Logitudinal Effects of HOBSCOTCH - A Selfmanagement Program for People with Epilepsy– Nicholas Streltzov, Samantha Schmidt, Wenyan Zhao, Lindsay Schommer, Felicia Chu, Heidi L. Henninger, Robert Roth, Elaine T. Kiriakopoulos, Morgan Mazanec, Barbara C. Jobst

3:42 p.m. S31.002 Clinical and EEG Determinants of Electroencephalographic Seizures in Critically Ill Children–France W. Fung, Jiaxin Fan, Lisa Vala, Darshana Parikh, Marin Jacobwitz, Maureen Donnelly, Alexis Topjian, Rui Xiao, Nicholas Scott Abend 3:54 p.m. S31.003 Recognition and Treatment of New Onset Focal Seizures in Emergency Departments–Jacob Pellinen, Erica Tafuro, Annie H. Yang, Dana Price, Jacqueline French 4:06 p.m. S31.004 Long-term Safety and Efficacy of Cannabidiol (CBD) for the Treatment of Seizures in Patients with Tuberous Sclerosis Complex (TSC) in an Openlabel Extension (OLE) Trial (GWPCARE6)–Elizabeth Thiele, E Martina Bebin, Francis M. Filloux, Patrick KL Kwan, Rachel Loftus, Farhad SahebkarMoghaddam, Steven Paul Sparagana, James W. Wheless 4:18 p.m. S31.005 Presurgical Evaluation and Surgical Outcomes in Medically Refractory Epilepsy and Temporal Encephalocele–Kiran M. Kanth, Jeffrey W. Britton, Gregory D. Cascino, Karl Krecke, Jamie Van Gompel, Robert Witte, Lily Wong-Kisiel 4:30 p.m. S31.006 Improving Detection of Hippocampal Epileptiform Activity Using Magnetoencephalography (MEG)–Ellie Paige Sidler, Hansel Greiner, Francesco Mangano, Jesse Skoch, Ravindra Arya, Katherine Dana Holland, Gewalin Aungaroon, Todd Arthur, Hisako Fujiwara, Paul Horn, Jeffery R. Tenney 4:42 p.m. S31.007 Long-Term (2-Year) Safety and Efficacy of Adjunctive ZX008 (Fenfluramine Hydrochloride Oral Solution) for Dravet Syndrome: Interim Results of an Ongoing Open-Label Extension Study–Joseph Sullivan, Auvin Stephane, Milka Pringsheim, Kelly G. Knupp, Elaine C. Wirrell, Gail M. Farfel, Bradley Galer, Glenn Morrison, Michael Lock, Arnold Gammaitoni, Elizabeth Thiele 4:54 p.m. S31.008 Comparison of Responsive Neurostimulation System Efficacy Between Different Electrographic Seizure Onset Patterns–Paulina Henriquez-Rojas, Tara Torabi, Pue Farooque, Lawrence J. Hirsch, Robert B. Duckrow, Aline Herlopian, Dennis Spencer, Jason Lee Gerrard, Imran H. Quraishi 5:06 p.m. S31.009 Safety and Tolerability Associated With Chronic Intermittent Use of Diazepam Buccal Film in Pediatric, Adolescent, and Adult Patients With Epilepsy–Syndi Seinfeld, Michael Gelfand, Allen H Harevy Heller, Carla Buan, Gary Slatko

98 2020 AAN Annual Meeting

S32 Neuro-ophthalmology/ Neuro-otology

CME

3:30 p.m. S32.001 The Brain and Optic Nerve Study with Artificial Intelligence (BONSAI): A Deep Learning System to Detect Papilledema on Ocular Fundus Photography– Valerie Biousse, Raymond Najjar, Jiang Zhubo, Caroline Vasseinex, Daniel Ting, Yong Liu, Tien-Yin Wong, Nancy J. Newman, Dan Milea 3:42 p.m. S32.002 Human vs. Machine: The Brain and Optic Nerve Study with Artificial Intelligence (BONSAI)–Nancy J. Newman, Raymond Najjar, Caroline Vasseinex, Jiang Zhubo, Daniel Ting, Yong Liu, Valerie Biousse, Tien-Yin Wong, Dan Milea 3:54 p.m. S32.003 Predicting Optic Neuritis Outcomes–Lindsey Blake DeLott, James F. Burke, Chris Andrews, Fiona Evann Costello, Wayne T. Cornblath, Jonathan D. Trobe, Paul Lee, Kevin A. Kerber 4:06 p.m. S32.004 Utility of Magnetic Resonance or Computed Tomography Venography in the Evaluation of Overweight Women with Papilledema–Anna Kabanovski, Jovi CY Wong, Edward A Margolin, Jonathan A Micieli 4:18 p.m. S32.005 rAAV2/2-ND4 for the Treatment of Leber Hereditary Optic Neuropathy (LHON): Final Results from the RESCUE and REVERSE Phase III Clinical Trials and Experimental Data in Nonhuman Primates to Support a Bilateral Effect–Mark L. Moster, Alfredo Sadun, Thomas H. Klopstock, Nancy J. Newman, Catherine Vignal-Clermont, Valerio Carelli, Patrick Yu-Wai-Man, Valerie Biousse, Robert C. Sergott, Barrett Katz, Adam DeBusk, Laure Blouin, Caroline Chevalier, Pierre Burguiere, Magali Taiel, Jose-Alain Sahel 4:30 p.m. S32.006 Deficiency of Mkk4 and Mkk7 Together Prevents Both Retinal Ganglion Cell Death and Axonal Degeneration After Axonal Injury–Stephanie B. SycMazurek, Rebecca Rausch, Olivia Marola, Kimberly Fernandes, Richard Libby 4:42 p.m. S32.007 Functional and metabolic changes in visual snow syndrome: a combined BOLD fMRI and MRspectroscopy study–Francesca Puledda, Dominic Ffytche, David Lythgoe, Owen O’Daly, Christoph J. Schankin, Steve CR Williams, Peter Goadsby 4:54 p.m. S32.008 Transient Vestibular Symptoms Preceding Posterior Circulation Stroke: A Prospective, Multicenter, Observational Study–Hyun Ah Kim, Seo-Young CHOI, Jae-Hwan Choi, Ji-Yun Park, Hyung Lee, Kwangdong CHOI 5:06 p.m. S32.009 Benign paroxysmal positional vertigo: The “Sémont PLUS maneuver” is more effective than the Sémont maneuver – a prospective multinational randomized single-blinded trial–Michael Strupp, Anne-Sophie Vinck, Otmar Bayer, Anita Hennig, Dominik Obrist, Marco Mandala

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

TUESDAY, APRIL 28 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m. S32 Neuro-ophthalmology/ Neuro-otology

CME

5:18 p.m. S32.010 Diagnostic Impact of a Device-enabled Remote “Tele-Dizzy” Consultation Service–David S. Zee, David E. Newman-Toker, Roksolyana Romana Tourkevich, Anthony Joseph Brune, Kemar Earl Green, Susan Peterson, Mehdi Fanai, Jorge OteroMillan, Daniel R. Gold

S33 Aging and Dementia: Non-Alzheimer Dementia

Rexach, Aaron Ritter, Erik Roberson, Julio C. Rojas -Martinez, Marwan N. Sabbagh, David P. Salmon, Rodolfo Savica, William Seeley, Adam Staffaroni, Jeremy Syrjanen, Carmela Tartaglia, Nadine Tatton, Joanne Taylor, Arthur Toga, Sandra Weintraub, Diana Wheaton, Bonnie Wong, Zbigniew K. Wszolek 4:18 p.m. S33.005 Deep Grey Matter and Hippocampal Involvement in Genetic Cases of Frontotemporal Lobar Degeneration–Federica Agosta, Edoardo G. Spinelli, Alma Ghirelli, Nilo Riva, Giuseppe Magnani, Francesca Caso, Paola Caroppo, Sara Prioni, Tremolizzo Lucio, Ildebrando H. Appollonio, Vincenzo Silani, Paola Carrera, Massimo Filippi 4:30 p.m. S33.006 Highly Frequent MAPT p.R406W Carriers with a Nonconforming FTD Phenotype in the Belgian Flemish Population–Helena Gossye, Sara Van Mossevelde, Julie Van Der Zee, Karin Peeters, Lubina Dillen, Marleen Van Den Broeck, Yannick Vermeiren, Annelies Laureys, Naomi de Roeck, Patrick Cras, Sebastiaan Engelborghs, Peter P. De Deyn, Christine Van Broeckhoven 4:42 p.m. S33.007 Spinal Cord MRI for Early Detection of Presymptomatic Pathology in c9orf72 Mutation Carriers: A Longitudinal Neuroimaging Study– Giorgia Querin, Peter Bede, Mounir El Mendili, Melanie Pellegrini-Issac, Daisy Rinaldi, Martin Catala, Dario Saracino, Francois Salachas, Agnes Camuzat, Veronique Marchand-Pauvert, Julien Cohen-Adad, Olivier Colliot, Isabelle Le Ber, PierreFrançois Pradat 4:54 p.m. S33.008 Right Temporal Degeneration and Conceptual Loss of Emotions: Semantic-variant Frontotemporal Dementia?–Kyan Younes, Maxime Montembeault, Valentina Borghesani, Ariane E Welch, Salvatore Spina, Lea Grinberg, Bill Seeley, Zachary Miller, Bruce L. Miller, Maria Gorno Tempini 5:06 p.m. S33.009 Automatic Analysis of Lexical Features in Speech of Patients with Primary Progressive Aphasia–Sunghye Cho, Naomi Nevler, Sharon Ash, Mark Liberman, Murray Grossman 5:18 p.m. S33.010 Pick’s Disease: Clinicopathologic Characterization of 21 Cases–Parichita Choudhury, Eugene L. Scharf, Michael Paolini, Jonathan Graff-Radford, David T. Jones, Julie A. Fields, Melissa Murray, Neill R. Graff-Radford, Dennis W. Dickson, Ronald C. Petersen, David S. Knopman, Mary M. Machulda, Eva Alden, Joseph Duffy, Keith A. Josephs, Ross Reichard, Joseph E. Parisi, Bradley F. Boeve

AAN.com/view/20AM 99

Tuesday, April 28

4:06 p.m. S33.004 The ARTFL LEFFTDS Frontotemporal Lobar Degeneration (ALLFTD) Protocol: Preliminary Data and Future Plans–Bradley F. Boeve, Adam L. Boxer, Howard J. Rosen, Leah Kathleen Forsberg, Hilary Heuer, Danielle Brushaber, Brian Appleby, Joanna Biernacka, Yvette Bordelon, Hugo Botha, Patrick Brannelly, Bradford Dickerson, Susan Dickinson, Dennis W. Dickson, Kimiko Domoto-Reilly, Kelley Faber, Anne Fagan, Julie A. Fields, Ann Fishman, Tatiana Foroud, Douglas Galasko, Ralitza H. Gavrilova, Tania F. Gendron, Daniel H. Geschwind, Nupur Ghoshal, Jill S. Goldman, Jonathan Graff-Radford, Neill R. Graff-Radford, Ian Michael Grant, Murray Grossman, Ging-Yuek R. Hsiung, Eric Huang, Edward D. Huey, David Irwin, David T. Jones, Kejal Kantarci, Anna Karydas, Daniel Kaufer, David S. Knopman, Joel Kramer, Walter Kremers, John Kornak, Walter A. Kukull, Emma Lagone, Irene Litvan, Peter A. Ljubenkov, Diane Lucente, Ian R.A. Mackenzie, Masood Manoochehri, Joseph C. Masdeu, Scott McGinnis, Mario F. Mendez, Bruce L. Miller, Toji Miyagawa, Kevin R. Nelson, Chiadi Uchendu Onyike, Alexander Pantelyat, David Pasquale, Rodney Pearlman, Leonard Petrucelli, Rosa Rademakers, Eliana Marisa Ramos, Katherine P. Rankin, Katya Rascovsky, Jessica E.

SCIENTIFIC SESSIONS

3:30 p.m. S33.001 Validity of Traumatic Encephalopathy Syndrome Clinical Research Criteria for Chronic Traumatic Encephalopathy Pathology: The Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) Study–Jesse B. Mez, Michael Alosco, Daniel Daneshvar, Nicole Saltiel, Zachary Baucom, Yorghos Tripodis, Bobak Abdolmohamadi, Madeline Uretsky, Raymond Nicks, Brett Martin, Joseph N. Palmisano, Philip H. Montenigro, Todd M Solomon, Victor E Alvarez, Brigid C. Dwyer, Lee Goldstein, Douglas I. Katz, Neil W. Kowall, Robert Cantu, Yorghos Tripodis, Bertrand Huber, Thor D. Stein, Robert Stern, Ann C. McKee 3:42 p.m. S33.002 Age of Onset of Cognitive Impairment and the Core Features of Dementia with Lewy Bodies–Parichita Choudhury, Tanis J. Ferman, Jonathan GraffRadford, Jeremiah Aakre, Danielle Brushaber, David T. Jones, David S. Knopman, Kejal Kantarci, Rodolfo Savica, Neill R. Graff-Radford, Daniel A. Drubach, Julie A. Fields, Mary M. Machulda, Leah Kathleen Forsberg, Laura Andelman Allen, Toji Miyagawa, Otto Pedraza, E M. St Louis, Michael H. Silber, Walter Kremers, Ronald C. Petersen, Bradley F. Boeve 3:54 p.m. S33.003 Clinical and Pathologic Features of Patients with REM Sleep Behavior Disorder and Parkinsonism in the Mild Cognitive Impairment Stage of Lewy Body Disease–Toji Miyagawa, Tanis J. Ferman, Neill R. Graff-Radford, David S. Knopman, Jonathan Graff-Radford, Rodolfo Savica, David T. Jones, Otto Pedraza, Julie A. Fields, Mary M. Machulda, Leah Kathleen Forsberg, Laura Andelman Allen, Kejal Kantarci, Erik Kent St. Louis, Michael H. Silber, Melissa Murray, Joseph E. Parisi, Dennis W. Dickson, Ronald C. Petersen, Bradley F. Boeve

CME

TUESDAY, APRIL 28 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m.

Tuesday, April 28

SCIENTIFIC SESSIONS

S34 Clinical Trials and Therapeutics in Autoimmune Neurology 3:30 p.m. S34.001 MuSK Chimeric Autoantibody Receptor (CAAR) T Cells for Antigen-specific Cellular Immunotherapy of Myasthenia Gravis–Sangwook Oh, Kevin O’Connor, Aimee Payne 3:42 p.m. S34.002 Inhibition of C1q, Initiator of the Classical Complement Cascade, by ANX005 for the Treatment of Guillain-Barré Syndrome: Results from a Phase 1b Study–Zhahirul Islam, Nowshin Papri, Israt Jahan, Khan Abul Kalam Azad, Henk-Andre Kroon, Eric Humphriss, Sethu Sankaranarayanan, Ted Yednock, Sanjay C. Keswani, Quazi Deen Mohammad 3:54 p.m. S34.003 Safety of Satralizumab Based on Pooled Data from Phase 3 Studies in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)–Benjamin M. Greenberg, Jerome De Seze, Edward J. Fox, Albert Saiz, Takashi Yamamura, Carole Marcillat, Xiujing Kou, Kristina Weber, Brian G. Weinshenker 4:06 p.m. S34.004 Long-term Efficacy and Safety of Inebilizumab for Neuromyelitis Optica Spectrum Disorder in the Randomized, Double-blind N-MOmentum Study and Extension–Bruce A. C. Cree, Jeffrey L. Bennett, Ho Jin Kim, Brian G. Weinshenker, Sean J. Pittock, Dean M. Wingerchuk, Kazuo Fujihara, Friedemann Paul, Gary Raymond Cutter, Romain Marignier, Ari Green, Orhan Aktas, Hans-Peter Hartung, Fred D. Lublin, Maureen Anne Mealy, Jorn Drappa, G. Barron, Soraya Madhani, Dewei She, Daniel M. Cimbora, W. Rees, John Ratchford, Eliezer Katz 4:18 p.m. S34.005 Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study–Michael Levy, Achim Berthele, Ho Jin Kim, Kazuo Fujihara, Ichiro Nakashima, Celia Oreja Guevara, Jacqueline Palace, Sean J. Pittock, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Marcus Yountz, Diane Lawson, Eva-Laudon Meyer, Dean M. Wingerchuk 4:30 p.m. S34.006 Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder–Dean M. Wingerchuk, Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Kerstin Allen, Kenji P Fujita, Marcus Yountz, Roisin Armstrong 4:42 p.m. S34.007 Neurological Complications and Neural Autoantibody Profiles Associated with Immune Checkpoint Inhibitors–Elia Sechi, Svetomir N. Markovic, Andrew McKeon, Divyanshu Dubey, Teerin Liewluck, Vanda A. Lennon, Alfonso Sebastian Lopez, Christopher J. Klein, Michelle L. Mauermann, Sean J. Pittock, Eoin P. Flanagan, Anastasia Zekeridou

100 2020 AAN Annual Meeting

CME

4:54 p.m. S34.008 A Clinical Characterization of Stiff Person Syndrome Spectrum Disorders–Yujie Wang, Fan Tian, Salman Aljarallah, Kathryn Fitzgerald, Scott Douglas Newsome 5:06 p.m. S34.009 Long term outcomes in Myelin Oligodendrocyte Glycoprotein-IgG (MOG-IgG) Associated Disorders– Alfonso Sebastian Lopez, Marina Buciuc, Elia Sechi, Sean J. Pittock, John Chen, Brian G. Weinshenker, Divyanshu Dubey, Amy Kunchok, Jan-Mendelt Tillema, Eoin P. Flanagan 5:18 p.m. S34.010 LGI1 Antibody Encephalitis: Treatments and Longterm Outcome–Andrew Ernest Rodriguez, Sean J. Pittock, Andrew McKeon, Jeffrey W. Britton, Christopher J. Klein, Divyanshu Dubey, Alfonso Sebastian Lopez, Anastasia Zekeridou, Nicholas L. Zalewski, Eoin P. Flanagan

S35 Amyotrophic Lateral Sclerosis

CME

3:30 p.m. S35.001 Polyglutamine (CAG) Intermediate Repeat Expansions in ATXN2 is Associated with a More Aggressive Form of ALS Across Multiple Independent Cohorts–Corey McMillan, Ellen Tsai, Jessica Hurt, Joanne Wuu, Alice Ford, Vivianna Van Deerlin, Lauren B. Elman, Colin Quinn, Leo McCluskey, Mei Liu, Ih Chang, Rosa Rademakers, Marka Maria Van Blitterswijk, Chao Sun, Michael G. Benatar, Genomic Translation Consortium, Michael G. Benatar, Matthew Harms, Nicolas Currier 3:42 p.m. S35.002 Mutational Analysis of Known ALS Genes in a Large Italian Population-based Cohort–Maurizio Grassano, Andrea Calvo, Sonja Waltraud Scholz, Bryan Traynor, Chun-yiu Law 3:54 p.m. S35.003 Tofersen, a SOD1 Antisense Oligonucleotide in Participants with ALS – Results From a Multiple Dose Study–Merit E. Cudkowicz, Timothy M. Miller, Pamela Jean Shaw, Frank Bennett, Roger Lane, Ih Chang, Ying Liu, Weiping Chen, Ivan Nestorov, Danielle Graham, Laura Fanning, Manjit McNeill, Stephanie Fradette, Toby A. Ferguson 4:06 p.m. S35.004 The Rasch-Built Overall ALS Disability Scale: ROADS to a better ALS outcome measure–Christina N. Fournier, Richard S. Bedlack, Colin Quinn, James A. Russell, Diane Beckwith, Kathleen Kaminski, William R. Tyor, Vicki Hertzberg, Virginia James, Meraida Polak, Jonathan D. Glass 4:18 p.m. S35.005 CC100 Phase 1 Multiple Dose Study in Patients with ALS–Robert M. Pascuzzi, Cynthia Bodkin, Riley J. Snook, Martin R. Farlow, Sandra Guingrich, Angela Micheels, Huiying Gu, Sisi Yang, Brian Johnstone, Yansheng Du 4:30 p.m. S35.006 Radicava/Edaravone Findings in Biomarkers from ALS (REFINE ALS): Interim Analysis–James D. Berry, Benjamin R. Brooks, Angela L. Genge, Terry D. Heiman-Patterson, Stanley H. Appel, Michael G. Benatar, Robert P. Bowser, Merit E. Cudkowicz, Clifton L. Gooch, Jeremy M. Shefner, Stephen Apple, Wendy Agnese, Charlotte A. Merrill, Sally K. Nelson 4:42 p.m. S35.007 Cognitive dysfunction in pre-symptomatic C9orf72 carriers–Marie Ryan, Emmet Costello, Mark A Doherty, Caroline A. McHutchison, Mark Heverin, Russell L. McLaughlin, Sharon Abrahams, Niall Pender, Orla Hardiman 4:54 p.m. S35.008 Teleheath for ALS: Utilization and Predictors of Use by Patients–Zachary Simmons, Anne Haulman, Amit Chahwala, Andrew Geronimo 5:06 p.m. S35.009 Multivariate Analysis of Survival in an Amyotrophic Lateral Sclerosis Clinic Population–Jaimin Shailesh Shah, Marka Maria Van Blitterswijk, Rosa Rademakers, Otto Pedraza, Beth K. Rush, Jany Paulett, Janay Caradonna, Leonard Petrucelli, Bjorn E. Oskarsson

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

TUESDAY, APRIL 28 3:30 p.m.–5:30 p.m. S35 Amyotrophic Lateral Sclerosis

CME

5:18 p.m. S35.010 Real-world Evidence of Radicava® (Edaravone) for Amyotrophic Lateral Sclerosis from a National Infusion Center Database in the United States–Terry D. Heiman-Patterson, Johnna Perdrizet, Barbara Prosser, Wendy Agnese, Stephen Apple

SCIENTIFIC SESSIONS Tuesday, April 28

AAN.com/view/20AM 101

WEDNESDAY, APRIL 29 1:00 p.m.–3:00 p.m.

1:00 p.m.–2:00 p.m. S36 History of Neurology

CME

1:24 p.m. S36.003 From Shadow to Spotlight: The (Re)discovery of Trepanned Skulls in France During the 19th Century–Manon Auffret, Marc Verin 1:36 p.m. S36.004 Harvey Cushing’s Birthday Book and the Genre of Medical Festschrift–Michael Patrick Harlan Stanley 1:48 p.m. S36.005 Describing the Usage of Neurological Eponyms Over Time–Christopher James Becker, Margaret Leslie McDermott, Zachary N. London

Wednesday, April 29

SCIENTIFIC SESSIONS

1:00 p.m. Lawrence C. McHenry Award: An Award for the History of Neurology Presentation This award recognizes excellence in research in the history of neurology. Recipient: Elizabeth Coon, MD Rochester, MN

102 2020 AAN Annual Meeting

S37 Stroke Epidemiology: Risk Factors, Incidence, and Unique Populations 1:00 p.m. S37.001 Re-analysis of Acute Stroke Trials Using Utilityweighted Modified Rankin Scales–Alexander Rebchuk, Zoe O’Neill, Elena Szefer, Michael D. Hill, Thalia S. Field 1:12 p.m. S37.002 Traditional Vascular Risk Factors Account for Different Proportions of Ischemic Stroke Within Different Gender and Race Groups–Elizabeth M. Aradine, Yan Hou, Kathleen Ryan, Prachi Mehndiratta, Seemant Chaturvedi, Carolyn Cronin, Michael Phipps, Marcella A. Wozniak, Jose G. Merino, Tara McColgin Dutta, John Cole, Steven J. Kittner 1:24 p.m. S37.003 First-ever Ischemic Stroke and Incident Major Adverse Cardiovascular Events in 93,627 Older Women and Men–Luciano A. Sposato, Melody Lam, Britney Allen, Salimah Shariff, Gustavo Saposnik 1:36 p.m. S37.004 Cerebrovascular Disease in Perinatally-infected Children with HIV in Zambia–Colleen Louise Schneider, Owen Dean, Alexandra Buda, Sarah Mohajeri, Michael Potchen, Sylvia MwanzaKabaghe, Deanna Saylor, Esau G. Mbewe, Pelekelo Kabundula, Heather Adams, Gretchen L. Birbeck, David Bearden 1:48 p.m. S37.005 Epidemiology of Acute Ischemic Stroke in Pediatric Age Group: A National Perspective–Prerna Agrawal, Achint Patel, Reshmi Adupa, Rinu Varghese, Ivan Wudexi, Shakumar Patel, Gowthami Ramineni, Sukrut Pagad, Abhishek Lunagariya 2:00 p.m. S37.006 Clinical Outcomes in Acute Ischemic Stroke Treatment during Pregnancy in the Nationwide Inpatient Sample from 2005-2015–Emily Rachel Grodinsky, Bichum Ouyang, Yuanqing Liu, Sarah Song 2:12 p.m. S37.007 Incidence and Predictors of Cerebral Venous Thrombosis (CVT) in Pregnancy: National Inpatient Sample Study 2012-2015–Huy Q. Nguyen, Mohammad Rauf A. Chaudhry, Saqib A. Chaudhry, Shayan Ul Haque, Jiaqi Yao, Harathi Bandaru, Arada Wongmek, Jorge Humberto Moreno, Paisith Piriyawat, Salvador Cruz-Flores 2:24 p.m. S37.008 Outcomes of Hospitalizations related to Child Birth in Women with Unruptured Intracranial Aneurysms– Tapan Mehta, Devashish Desai, Pushti Varshang Khandwala, Shailesh Male, Louise D. McCullough, Andrew Grande, Bharathi Jagadeesan, Ramachandra P. Tummala 2:36 p.m. S37.009 Exploring Health Behaviors, Cultural Beliefs, and Technological Usage in Chinese and KoreanAmerican Seniors: The Cardiovascular Health in Asian Elderly Study–Sarah Song, Moses Koo, Ashley Adams, Victor Lei, Keiko Aun Fukuda, Richard Seto, Soo IN Lee, Eunki Kim, Yicklun Mo, Eliza Chan

CME

2:48 p.m. S37.010 Immigration Status and Outcomes Following Ischemic Stroke: A 16-year Retrospective Cohort Study–Manav Vyas, Peter Austin, Jimming Fang, Andreas Laupacis, Frank L. Silver, Moira Kapral

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

WEDNESDAY, APRIL 29 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m. S38 Child Neurology and Developmental Neurology: Acquired Brain Injury: BrainBehavior Relationships

CME

2:36 p.m. S39.009 Clinical/ Immunopathological Presentations and Antigen-specific CD8+ T Cell Responses in Paraneoplastic Autoimmune KLHL11 Encephalitis–Divyanshu Dubey, Michael R. Wilson, Caterina Giannini, Manish Gandhi, John Cheville, Vanda A. Lennon, Benjamin Clarkson, Scott D. Eggers, Michelle Devine, Caleigh Mandel-Brehm, Thomas Kryzer, Patrick Andrews, Chad Hales, Jorge C. Kattah, James Everett Eaton, Jiraporn Jitprapaikulsan, John R. Mills, Eoin P. Flanagan, Anastasia Zekeridou, Bradley Leibovich, James Fryer, Shannon Hinson, Matthew Torre, Charles E. Kaufman, James Thoreson, Jessica Ann Sagen, Jenny Linnoila, Joseph DeRisi, Andrew McKeon, Sean J. Pittock 2:48 p.m. S39.010 Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis: Clinical Presentation and Misdiagnosis–Cristina Valencia Sanchez, Sean J. Pittock, Divyanshu Dubey, Eoin P. Flanagan, Sebastian Lopez, Nicholas L. Zalewski, Anastasia Zekeridou, Andrew McKeon

Wednesday, April 29

1:00 p.m. S39.001 Prospective Assessment of Neuronal Autoimmunity in First Episode of Psychosis–Mar Guasp, Eloi Gine, Virginia Casado Ruiz, Nicolau Guanyabens, Eduard Parellada, Josep O. Dalmau 1:12 p.m. S39.002 Genetics of Anti-NMDAR Encephalitis Implicates NK Cells–Aditya Ambati, Ling Lin, Sergio MunizCastrillo, Hanna Ollila, Anne Laurie Pinto, Veronique Rogemond, NMDAR-Ab Working Group, Carsten Finke, Frank Leypoldt, Maarten Jan Titulaer, Jerome Honnorat, Emmanuel Mignot 1:24 p.m. S39.003 Clinical and Immunological Investigations in Patients with Suspected Autoimmune Post-Herpes Simplex Encephalitis–Juntaro Kaneko, Takahiro Iizuka, Ryoko Iwase, Toshiyuki Nagai, Atsushi Kaneko, Eiji Kitamura, Hitomi Tomita, Susumu Igarashi, Takashi Irioka, Motomi Arai, Naomi Kanazawa, Kazutoshi Nishiyama 1:36 p.m. S39.004 Sleep Disorders In Anti-NMDAR Encephalitis– Helena Ariño, Amaia Munoz, Eugenia MartinezHernandez, Thais Armangue, Joan Santamaria, Josep O. Dalmau 1:48 p.m. S39.005 Clinical Significance of Anti-NMDAR Concurrent with Glial or Neuronal Surface Antibodies–Eugenia Martinez-Hernandez, Mar Guasp, Anna GarciaSerra, Estibaliz Maudes, Thais Armangue, Albert Saiz, Francesc R. Graus, Josep O. Dalmau 2:00 p.m. S39.006 Population-based Incidence Estimate of AntiNMDA Receptor Encephalitis in New York City–Anusha Yeshokumar, Jacqueline Gofshteyn, Parul Agarwal, Kiran Thakur, Natasha Basma, Mary Claire Tuohy, Jyoti Ankam, Sarah Torres, Shelley Sisemore Varnado, Britany Klenofsky, Elissa Yozawitz, Nicole Luche, Dale C. Hesdorffer, Aaron Lane Nelson, Steven M. Wolf, Patricia E. McGoldrick, Zachary Grinspan, Nathalie Jette 2:12 p.m. S39.007 Delirium With Catatonic Signs: A Neuropsychiatric Phenotype Associated With Autoimmune Encephalitis?–Cynthia Arely Juarez Jaramillo, Jesús Ramírez-Bermúdez, Heraclides Gomez, Ángela Medina, Mariana Espinola-Nadurille, Patricia Arias-Garro, Andres Perez-Gonzalez 2:24 p.m. S39.008 Paraneoplastic Cerebellar Ataxia and Antibodies to Metabotropic Glutamate Receptor 2–Raquel Ruiz-Garcia, Eugenia Martinez-Hernandez, Bastien Joubert, Mar Petit-Pedrol, Lidia Sabater, Josep O. Dalmau, Francesc R. Graus

CME

SCIENTIFIC SESSIONS

1:00 p.m. S38.001 Magnetic Resonance Imaging Abnormalities in the Splenium of the Corpus Callosum Is Specific and Predictive for Seizure in Neonates with Hypoxic Ischemic Encephalopathy: A Retrospective Chart Review–Linda Nguyen, Dillon Yungyi Chen, Jeffrey J. Gold 1:12 p.m. S38.002 Older Age Is Associated with a First Clinical Demyelinating Event in Children with the Radiologically Isolated Syndrome–Naila Makhani, Christine Lebrun-Frenay, Aksel Siva, Evangeline Wassmer, Sona Narula, Soe Soe Mar, Jonathan Santoro, Nusrat Ahsan, Silvia Tenembaum, James Nick Brenton, Philippe Cabre, Clarisse Carra-Dalliere, Jonathan Ciron, Jerome De Seze, Kumaran Deiva, Francoise Durand Dubief, Matilde Inglese, Megan M. Langille, Guillaume Mathey, Rinze F Neuteboom, Filipe Palavra, Jean Pelletier, Daniela Pohl, Daniel Reich, Juan Ignacio Rojas, Veronika Shabanova, Eugene Shapiro, Robert Ian Thompson-Stone, Eric Thouvenot, Mar Tinore, Ugur Uygunoglu, Wendy Sulina Vargas, Sunita Venkateswaran, Helene Verhelst, Patrick Vermersch, Christina Azevedo, Orhun H. Kantarci, Darin T. Okuda, Daniel Pelletier, Naila Makhani, Observatoire Francop (OFSEP), Naila Makhani, Naila Makhani 1:24 p.m. S38.003 Anterior Horn T2-Hyperintensity: A Novel Outcome Measure in Acute Flaccid Myelitis–Olwen Murphy, Ruth Andrea Salazar Camelo, Janet Dean, Cristina Sadowsky, Carlos A. Pardo-Villamizar 1:36 p.m. S38.004 Intrathecal Chemotherapy-Associated Vasospasm in Children with Leukemia–Lisa Sun, Patrick Charles Brown, Rebecca F. Gottesman, Adriana Gonzalez Torriente, Wendy C. Ziai, Ryan Felling 1:48 p.m. S38.005 Is MRI Always Necessary in Pediatric Patients with Papilledema Without Atypical Features?–Travis Larsh, Gary Hsich 2:00 p.m. S38.006 Inhibitory Control Deficits in Children with Tourette Syndrome Revealed by Object-hit-and-avoid Task–Nicholas Cothros, Alex Medina, Davide E. Martino, Sean Dukelow, Rachel Hawe, Adam Kirton, Elaheh Nosratmirshekarlou, Tamara M. Pringsheim 2:12 p.m. S38.007 Parental Perception of ADHD Symptoms and Initiation of Medication–Maryam Aletan, Charles Borgen, Jeffrey M. Kornitzer 2:24 p.m. S38.008 Video-based Eye Tracking Distinguishes Follow Up OMAS Patients from Controls–Kaajal Parbhoo, Brian J White, Donald C Brien, Effie Viguiliouk, Douglas P Munoz, E. Ann Yeh 2:36 p.m. S38.009 Childhood Seizures: Knowledge and Attitudes of Caregivers in a Rural Nigerian Community–Adaobi Bisi-Onyemaechi 2:48 p.m. S38.010 Differential Behavioral Outcomes of Cerebellar Disruption in Early Mouse Development–Jason Singh Gill, Roy Sillitoe

S39 Autoimmune and Paraneoplastic Neurological Disorders: Clinical Characteristics and Diagnosis

AAN.com/view/20AM 103

WEDNESDAY, APRIL 29 1:00 p.m.–3:00 p.m.

Wednesday, April 29

SCIENTIFIC SESSIONS

S40 Multiple Sclerosis: Clinical Trials 1:00 p.m. S40.001 Clinical and Disability Characteristics of Patients with Multiple Sclerosis Over Age 60 in a Large Multi-Center Database.–Le Hua, Fan Tian, Carrie Michelle Hersh, Ellen M. Mowry, Kathryn Fitzgerald 1:12 p.m. S40.002 Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS–Bruce A. C. Cree, Gary Raymond Cutter, Jerry S. Wolinsky, Mark S. Freedman, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Frederic Sedel, Fred D. Lublin 1:24 p.m. S40.003 Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years–Ludwig Kappos, Gavin Giovannoni, Ralf Gold, Robert J. Fox, Patrick Vermersch, Ralph H. B. Benedict, Amit Bar-Or, Nicolas Rouyrre, Daniela Piani Meier, Shannon Ritter, Ajay Kilaru, Frank Dahlke, Goeril Karlsson, Bruce A. C. Cree 1:36 p.m. S40.004 Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis–Xavier Montalban, Jeffrey Alan Cohen, Giancarlo Comi, Patricia K. Coyle, Ludwig Kappos, Bingbing Li, Nicolaos Sfikas, Roman Willi, Dieter Haering, Martin Merschhemke, Stephen L. Hauser 1:48 p.m. S40.005 Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study–Robert J. Fox, Douglas L. Arnold, Gavin Giovannoni, Bruce A. C. Cree, Patrick Vermersch, Amit Bar-Or, Ralf Gold, Ralph H. B. Benedict, Daniela Piani Meier, Sophie Arnould, Shannon Ritter, Frank Dahlke, Goeril Karlsson, Ludwig Kappos 2:00 p.m. S40.006 Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study–Douglas L. Arnold, Bruce A. C. Cree, Amit Bar-Or, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Daniela Piani Meier, Sophie Arnould, Shannon Ritter, Goeril Karlsson, Ludwig Kappos, Robert J. Fox 2:12 p.m. S40.007 Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies–Ralph H. B. Benedict, Jerome De Seze, Stephen L. Hauser, Hans-Peter Hartung, Ludwig Kappos, James Overell, Harold Koendgen, Qing Wang, Annette Sauter, Marianna Manfrini, Stanley L. Cohan

104 2020 AAN Annual Meeting

1:00 p.m.–3:00 p.m. CME

2:24 p.m. S40.008 B Cells, T Cells and Inflammatory CSF Biomarkers in Primary Progressive MS and Relapsing MS in the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Trial–Amit Bar-Or, Jeffrey L. Bennett, H. Christian Von Budingen, Robert L. Carruthers, Keith R. Edwards, Robert J. Fallis, Damian Fiore, Jeffrey Marc Gelfand, Paul Giacomini, Benjamin M. Greenberg, David A. Hafler, Erin Longbrake, Beverly Assman, Carolina Ionete, Ulrike Kaunzner, Christopher Lock, Xiaoye Ma, Bruno C. Musch, Gabriel Pardo, Jinglan Pei, Fredrik L. Piehl, Martin Weber, Tjalf Ziemssen, Ann Herman, Christopher Harp, Anne H. Cross 2:36 p.m. S40.009 Design of a Phase 2b Dose-finding Trial to Evaluate Safety and Efficacy of the CNS-penetrant BTK Inhibitor SAR442168 in Patients with Relapsing Forms of Multiple Sclerosis–Anthony Traboulsee, Christopher C. LaGanke, Xavier Montalban, Sibyl E. Wray, Xinyan Zhang, Andre P. Matta, Timothy Turner, Erik Wallstrom 2:48 p.m. S40.010 Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study–Robert J. Fox, Ludwig Kappos, Michel Burcklen, Mark S. Freedman, Eva Havrdova, Brian Hennessy, Reinhard Hohlfeld, Fred D. Lublin, Xavier Montalban, Carlo Pozzilli, Tatiana Scherz, Philippe Linscheid, Magdalena Pirozek-Lawniczek, Hilke Kracker, Till Sprenger

S41 Parkinson’s Disease Interventions and Clinical Trials

CME

1:00 p.m. S41.001 A Phase 1 Study of PBT434, a Novel Small Molecule Inhibitor of a-Synuclein Aggregation, in Adult and Older Adult Volunteers–David A. Stamler, Margaret Bradbury, Cynthia Wong, Elliot Offman 1:12 p.m. S41.002 Efficacy of Opicapone Compared to Entacapone in Parkinson’s Patients with Motor Fluctuations and ON Hoehn & Yahr = 2.5: A Post Hoc Analysis of BIPARK-1–Mark F. Lew, Robert A. Hauser, Stuart H. Isaacson, Joaquim Ferreira, Michael Serbin, Khodayar Farahmand, Kurt Olson, Olga Klepitskaya, Francisco Rocha, Patricio Soares-da-Silva, Grace Lin Liang 1:24 p.m. S41.003 Safety and Tolerability During a 4-Week Continuous Subcutaneous Infusion of ABBV-951, a New Drug Formulation for the Treatment of Parkinson’s Disease: Final Results of a Phase 1b Study–Maurizio F. Facheris, Susan Criswell, Nirav Pavasia, Rajesh Pahwa, Charles Locke, Weining Robieson, David Shprecher 1:36 p.m. S41.004 Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes–Aaron Ellenbogen, Fabrizio Stocchi, Alberto J. Espay, Werner Poewe, Sheila Oren, Ryan J. Case, C. Warren Olanow 1:48 p.m. S41.005 Varenicline for the Treatment of Imbalance in Parkinson’s Disease–Jacob Hawkins, Glenn Thurston Stebbins, Sachin Kapur, Christina L. Vaughan, Deborah Hall 2:00 p.m. S41.006 Rock Steady Boxing (RSB) participants with Parkinson’s disease have better quality of life and lower burden of non-motor symptoms than nonparticipants–Danielle Larson, Chen Yeh, Miriam R. Rafferty, Danny Bega 2:12 p.m. S41.007 Pimavanserin for Treatment of Comorbid Depression in Patients With Parkinson’s Disease–Michael T. Guskey, Gustavo Alva, Jason Lamar Aldred, Bruce Coate, Victor Abler, Marc Cantillon, James Norton, Daryl DeKarske 2:24 p.m. S41.008 Use of Multimodal Imaging in a Phase 2 Study in Participants with Parkinson’s Disease (SPARK)–R. Matthew Hutchison, Karleyton Evans, Minhua Yang, Zhen Xiao, Tara Fox, Beth Hirschhorn, Adriane KischHancock, David Scott, Barry Bedell, Vincent Auclair, Jesse M. Cedarbaum, Miroslaw Brys 2:36 p.m. S41.009 Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the CSF of individuals with Parkinson’s disease–Alan Fowler, Yasar Alejandro Torres-Yaghi, Fernando L. Pagan, Michaeline Hebron, Barbara Wilmarth, Abigail Catherine Lawler, Elizabeth E. Mundel, Nadia Yusuf, James N. Starr, Muhammad Waseem Anjum, Shahnaz Miri, Steven Wayne Nakano, Amelia Carwin, Sara Matar, Jaeil Ahn, Charbel E H Moussa

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

WEDNESDAY, APRIL 29 1:00 p.m.–3:00 p.m. S41 Parkinson’s Disease Interventions and Clinical Trials

3:30 p.m.–4:30 p.m. CME

2:48 p.m. S41.010 The lessebo effect in Parkinson’s disease: insights from individual patient data meta-analyses–Tiago Mestre, Raquel Lobo, Nilza Goncalves, Joaquim Ferreira, Anthony E. Lang

CME

3:30 p.m. S42.001 Pre-Specified Interim Analysis of the STEMTRA Trial: Clinical Outcomes in Chronic Traumatic Brain Injury Patients–Peter J. McAllister, Alan Weintraub, Satoshi Ikeda, Benjamin M. Frishberg, Albert Lai, Yusuke Shinoda, Steven C. Cramer, Michael C Munin, Neil E. Schwartz, Bijan Nejadnik, Damien Bates 3:42 p.m. S42.002 Mapping the Imaging Correlates of Hand Motor Performance in Multiple Sclerosis: Focus on Structural and Functional Motor Networks–Claudio Cordani, Paola Valsasina, Alessandro Meani, Federica Esposito, Bruno Colombo, Elisabetta Pagani, Massimo Filippi, Maria Assunta Rocca 3:54 p.m. S42.003 Cerebellar Inhibition Using Low-Intensity Focused Ultrasound–Jean-Francois Nankoo, Anton Fomenko, Julianne Baarbe, Yangui Wang, Andres M. Lozano, Robert E. Chen 4:06 p.m. S42.004 Integrated Upper Limb Spasticity Management Including Botulinum Toxin A on Patient-centred Goal Attainment: The ULIS-III Study–Lynne TurnerStokes, Stephen Ashford, Klemens Fheodoroff, Jorge Jacinto, Allison Brashear, Pascal Maisonobe, Andreas Lysandropoulos 4:18 p.m. S42.005 Clinical Characteristics that Impact OnabotulinumtoxinA Treatment Adherence in Patients with Spasticity from the ASPIRE Study–Alberto Esquenazi, Wayne W. Feng, George F. Wittenberg, Philippe Gallien, Alessio Baricich, Kristina Fanning, Aleksej Zuzek, Gerard Francisco, Daniel Bandari

S43 Stroke Recovery and Outcomes

CME

AAN.com/view/20AM 105

Wednesday, April 29

3:30 p.m. S43.001 Quality Of Life And Caregiver Burden With Medical Application Based Post Stroke Care Strategy (MAPSS): A Pilot Study–Dheeraj Khurana, Ashok Kumar, Smita Pattnaik, Manish Modi 3:42 p.m. S43.002 Assessment and Patterns of Early Cognitive Function in Primary Intracerebral Hemorrhage– Jennifer Meeks, Arvind Bambhroliya, Katie Alex, Cole Chapman, Farhaan S. Vahidy 3:54 p.m. S43.003 Trends in case fatality after acute stroke: A 15-year population based study–Raed Joundi, Mohammed Rashid, Joan Porter, Amy Yu, Eric E. Smith, Moira Kapral 4:06 p.m. S43.004 Predictors of Post-stroke Death in the Veterans Affairs Hospital System–Seemant Chaturvedi, Laura Myers, Anthony Perkins, Dawn M. Bravata 4:18 p.m. S43.005 Primary Outcome and Intrapatient Stability of the Modified Rankin Scale Between Day 90 and 365 After Stroke Onset: A Secondary Analysis of the NINDS tPA and IMS III Trials–Adam De Havenon, David L. Tirschwell, Laura Heitsch, Vivek Reddy, Jennifer J. Majersik, Bradford B. Worrall 4:30 p.m. S43.006 Right Hemispheric Homologous Language Pathways and Aphasia Recovery After Stroke– Zafer Keser, Rajani Sebastian, Khader Hasan, Argye E. Hillis 4:42 p.m. S43.007 Profile of Cognitive Outcomes Among Young Stroke Survivors–Indira Priya Done, Rajeswari Aghoram, Sunil K. Narayan 4:54 p.m. S43.008 Relationship of Depression to Cognitive Impairment in Stroke Survivors at the Lagos University Teaching Hospital and Irrua Specialist Teaching Hospital– Cyril O. Erameh 5:06 p.m. S43.009 BMI and Diabetes Do Not Influence Post-stroke Fatigue–Juliana Gabbay, Seung Jae Moon, Tanveen Dhallu, Nadege Gilles, Yelena Ilyasova, Susan W. Law, Jeremy Weedon, Steven R. Levine 5:18 p.m. S43.010 Change in Thyroid Hormones in Acute and Chronic Stage of Ischemic Stroke (IS) and Their Association with Stroke Severity–Aruna Paul, Claire Emmanuelle Delpirou Nouh, Alexander Mdzinarishvili, Chao Xu, Allshine Chen, Albina Gosmanova, Niyaz Gosmanov, Blair Apple, Chanel Seraphin, Juliane Chainakul, Evgeny Sidorov

SCIENTIFIC SESSIONS

S42 Neuro-rehabilitation

3:30 p.m.–5:30 p.m.

WEDNESDAY, APRIL 29 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m.

Wednesday, April 29

SCIENTIFIC SESSIONS

S44 Research Methodology and Education

CME

3:30 p.m. S44.001 Disclosure of Medical Errors in Stroke Patients: Development of a Simulation-based Curriculum for Neurology Residents–Diana M. Barratt, Jill S. Liebman, Farah Fourcand, Sheryl Strasser, Mark MacGowan, Diana Nallely Rodriguez, Hyder Tamton, Robert Craig Coppola, Maryam Shakir, Shedrick Boren, Adnan Subei 3:42 p.m. S44.002 Implementation of an Online, Interactive Curriculum in Movement Disorders at 9 Neurology Residency Programs: A Randomized Controlled Study–Sara Maguire Schaefer, Zachary N. London, Heather Rigby, Raymond Price, Joseph M. Ferrara, Emily Poole Pharr, Matthew A. McCoyd, Scott Vota, Carolyn Cronin, Molly C. Cincotta, Jeremy Moeller 3:54 p.m. S44.003 Neurology Resident Diagnostic Accuracy in Critical Care Scenarios: Analysis of the Close-the-Loop Resident Clinical Acumen Project–Daniel Santos, Emily Schorr, Rachel Brandstadter, Stephen Krieger 4:06 p.m. S44.004 The Brain in Mixed Reality: Migraine Education in Motion–Lily Zurkovsky, Rolando Brual 4:18 p.m. S44.005 Increasing Resident Satisfaction with Continuity Clinic in Adult Neurology and Internal Medicine Residency Programs through Block Scheduling– Dougan McGrath, Rita Menapace, Amanda Young, Lauren DiMarino, Kelly Baldwin 4:30 p.m. S44.006 Simulation-based Mastery Learning Improves Residents’ Identification and Management of Status Epilepticus–Yara Mikhaeil-Demo, George Wesley Culler, Jessica Warady Templer, Danny Bega, David Salzman, Amar Bhatt, Neelofer Shafi, Elaine Cohen, Elizabeth Gerard, Jeffrey Barsuk 4:42 p.m. S44.007 Team is Brain: An Interdisciplinary Educational Initiative to Improve Stroke Care in the Emergency Department–Erin Rebecca Fiedler, Michael Teitcher, Rick R. Gill, Matthew A. McCoyd, Sean D. Ruland 4:54 p.m. S44.008 Actor and Patient Scoring in Neurology OSCEs: A Valuable Dimension in the Assessment of Communication Skills and Professionalism of Medical Students.–Gina Louise Hadley, Gabriele C. De Luca 5:06 p.m. S44.009 Attracting Neurology’s Next Generation: A Qualitative Study of Career Choice and Perceptions– Justin T. Jordan, Carolyn Cahill, Tasha Ostendorf, Laurie Gutmann, Anita Navarro, Charlene Gamaldo, Veronica E. Santini, Imran I. Ali, Madhu Soni, Rujuta Bhatt Wilson, Rana R. Said, Barry M. Czeisler, Maggie Rock, A. Gordon Smith 5:18 p.m. S44.010 Gender’s Influence on Career Success of PhysicianScientists in Neurology–Jenna Leigh Brownrout, Wyatt Peter Bensken, Taylor Gordon, Catherine Squirewell, John Heiss, Avindra Nath, Omar Iqbal Khan

106 2020 AAN Annual Meeting

S45 Multiple Sclerosis: Imaging 3:30 p.m. S45.001 MRI Changes Over the Disease Course in a Large Multiple Sclerosis Clinical Cohort–Gabrielle Macaron, Kunio Nakamura, Kedar Mahajan, Ryan Honomischl, Scott Husak, Nicholas Thompson, Robert A. Bermel, Jeffrey Alan Cohen, Daniel Ontaneda 3:42 p.m. S45.002 New/Enlarging T2 Lesion Identification: Semiautomated vs. Human–Alexandra Jeanne White, Paola Raska, Douglas L. Arnold, Jay Costantini, Stephen Jones, Robert J. Fox 3:54 p.m. S45.003 Cortical Surface Area and Subcortical Volume Imaging Differences Between African Americans and Caucasians with Relapsing Remitting Multiple Sclerosis–Melody Gilroy, Fen Bao, Carla E. Santiago-Martinez, Evanthia Bernitsas 4:06 p.m. S45.004 Diffusion Tensor Imaging Reveals Greater Microstructure Damage in Multiple Sclerosis Lesions that Shrink into Cerebrospinal Fluid (Atrophied Lesion Volume)–Niels Bergsland, Michael G. Dwyer, Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov 4:18 p.m. S45.005 QSM Rim+ Lesions Are Associated with Physical Disability and Cognitive Function–Melanie Marcille, Abhishek Jaywant, Sandra Hurtado Rua, Charles D. Tyshkov, Ulrike Kaunzner, Nancy M. Nealon, Jai Perumal, Timothy K. Vartanian, Lily Zexter, Thanh Nguyen, Yi Wang, Susan Gauthier 4:30 p.m. S45.006 Patterns of Grey Matter Atrophy in Patients with MS: A Multivariate Analysis Using Source-based Morphometry–Maria Assunta Rocca, Paola Valsasina, Alessandro Meani, Claudio Gobbi, Chiara Zecca, Alex Rovira, Xavier Montalban, Hugh Kearney, Olga Ciccarelli, Lucy Matthews, Jacqueline Palace, Antonio Gallo, Alvino Bisecco, Carsten Lukas, Barbara Bellenberg, Frederik Barkhof, Hugo Vrenken, Paolo Preziosa, Massimo Filippi 4:42 p.m. S45.007 Automated Lesion Segmentation and Image Synthesis of MS Brain MRI Scans Using Deep Learning–Manpreet Singh, Amirhossein Jaberzadeh, Daniel Pelletier 4:54 p.m. S45.008 Artificial Intelligence Applied on Conventional Magnetic Resonance Images Improves the Correct Diagnosis of CNS Diseases Mimicking Multiple Sclerosis–Massimo Filippi, Loredana Storelli, Nicoletta Anzalone, Anna Del Poggio, Paolo Preziosa, Laura Cacciaguerra, Maria Assunta Rocca

CME

5:06 p.m. S45.009 Cognitive Impairment and MRI-based Disease Progression in MS PATHS: Variable Susceptibility Across the Lifespan–Leigh Elkins Charvet, Carl DeMoor, Kathryn Fitzgerald, Rachel Galioto, Carrie Michelle Hersh, Le Hua, Megan Hyland, Lauren B. Krupp, Shirley Liao, Xavier Montalban, Ellen M. Mowry, Jacqueline Ann Nicholas, Carlos Nos, Mary R. Rensel, Stephen M. Rao, Richard A. Rudick, Lana Zhovtis Ryerson, Mar Tinore, Tjalf Ziemssen, Elizabeth Fisher, James Rhys Williams 5:18 p.m. S45.010 Artificial Intelligence-based Thalamic Volumetry Is Fast, Reliable, and Generalizable to Large, Heterogeneous Datasets Using Only Clinical Quality T2-FLAIR MRI–Michael G. Dwyer, Daniel Brior, Cassondra Lyman, Hannah Ferrari, Niels Bergsland, Tom Fuchs, Dejan Jakimovski, Bianca WeinstockGuttman, Ralph H. B. Benedict, Jon V. Riolo, Diego Silva, Robert Zivadinov

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

WEDNESDAY, APRIL 29 3:30 p.m.–5:30 p.m. S46 Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron/ Charcot Marie Tooth

5:18 p.m. S46.010 Results of a Phase 2 Double-Blind PlaceboControlled Study of a Local Muscle Therapeutic, ACE-083, in Subjects with Charcot-Marie-Tooth (CMT) Disease–Florian P. Thomas, Michael E. Shy, Colin Quinn, Urvi G. Desai, David N. Herrmann, Jeffrey Statland, S H. Subramony, Thomas H. Brannagan, Ali A. Habib, Chafic Y. Karam, Alan Pestronk, David Walk, Russell Butterfield, Nicholas Elwood Johnson, Ashley Leneus, Barry Miller, Marcie Fowler, Marc Jeffrey Van De Rijn, Kenneth M. Attie

Wednesday, April 29

SCIENTIFIC SESSIONS

3:30 p.m. S46.001 CuATSM Phase 2a Study Confirms DiseaseModifying Effects in Patients with Sporadic ALS Observed in the Phase 1 Study–Dominic B. Rowe, Susan Mathers, Kay Noel, Craig Rosenfeld 3:42 p.m. S46.002 Beyond the Upper Motor Neuron: Extra-motor Involvement in Primary Lateral Sclerosis–Eoin Finegan, Stacey Li Hi Shing, Rangariroyashe Chipika, Mark A Doherty, Jennifer C Hengeveld, Alice Vajda, Colette G. Donaghy, Russel McLaughlin, Siobhan Hutchinson, Orla Hardiman, Peter Bede 3:54 p.m. S46.003 WITHDRAWN 4:06 p.m. S46.004 Characterising Progressive Brainstem Pathology in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis: In Vivo Insights Based on Computational Imaging–Peter Bede, Rangariroyashe Chipika, Eoin Finegan, Stacey Li Hi Shing, Mark A Doherty, Jennifer C Hengeveld, Alice Vajda, Siobhan Hutchinson, Colette G. Donaghy, Russell L. McLaughlin, Orla Hardiman 4:18 p.m. S46.005 Natural History of Hereditary Spastic Paraplegias on Functional Gait Parameters and Electromyography During 18 Months Followup–Diana Maria Cubillos Arcila, Valeria Feijó Martins, Gustavo Dariva Machado, Ana Paula Janner Zanardi, Lauren Herberts Sehnem, Leonardo Alexander Peyre Tartaruga, Jonas Alex Morales Saute 4:30 p.m. S46.006 The Canadian Neuromuscular Disease Registry: A National Spinal Muscular Atrophy (SMA) Registry for Real World Evidence–Maryam Oskoui, Jiri Vajsar, Victoria Hodgkinson, Bernard Brais, Alex MacKenzie, Hugh John McMillan, Craig Gordon Campbell, Lawrence Korngut 4:42 p.m. S46.007 Reduced Spinal Motor Neuron Expression of Insulin-like Growth Factor-2 and Insulin-like Growth Factor Binding Protein 5 in Spinal Muscular Atrophy Type 1–Crystal Jing Jing Yeo, Shi Yan Ng, Basil T. Darras 4:54 p.m. S46.008 Modeling the Human Corticospinal Tract-on-a-chip with Regionally-specific hiPSC-derived Neurons and Astrocytes–Arens Taga, Labchan Rajbhandari, Raha Dastgheyb, Christa Habela, Sarah Gross, Norman Haughey, Arun Venkatesan, Nicholas J. Maragakis 5:06 p.m. S46.009 Charcot Marie Tooth Disease Type 4C: Genotype Phenotype Correlation and Natural History–Tyler A. Rehbein, Simona Treidler, Michael E. Shy, David N. Herrmann, Michael E. Shy

CME

AAN.com/view/20AM 107

THURSDAY, APRIL 30 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m.

Thursday, April 30

SCIENTIFIC SESSIONS

S47 Headache II

CME

1:00 p.m. S47.001 Exploring the Boundaries Between Episodic and Chronic Migraine: Results from the CaMEO Study–Aubrey Manack Adams, Michael L. Reed, Kristina Fanning, Dawn C. Buse, Peter Goadsby, Jes Olesen, David W. Dodick, Richard B. Lipton 1:12 p.m. S47.002 Impact of Depression and Anxiety Symptoms on Patient-reported Outcomes in Patients with Migraine: Results from the American Registry for Migraine Research (ARMR)–Talia Pearl, Gina Dumkrieger, Catherine Daniela Chong, Todd J. Schwedt, David W. Dodick 1:24 p.m. S47.003 Measuring Headache Severity Using Multiple Features in Daily Diary Designs–James McGinley, RJ Wirth, Carrie R. Houts 1:36 p.m. S47.004 Impact of an Employer-Provided Migraine Coaching Program on Burden and Patient Engagement: Results from Interim Analysis–Leonhard Schaetz, Timo Rimner, Purnima Pathak, Juanzhi Fang, Deepak Chandrasekhar, Jelena Mueller 1:48 p.m. S47.005 Gender Dichotomy in Headache Medicine and Other Fellowships Within United Council for Neurologic Subspecialties (UCNS)–Nasima D. Shadbehr, Payal Patel Soni, Michelle K. Lee, Olivia Hogue, Jennifer S. Kriegler, Zubair Ahmed, Maryann Mays 2:00 p.m. S47.006 Migraine Polygenic Risk Score Is Associated with Severity of Migraine – Analysis of Genotypic Data from Four Placebo-controlled Trials of Erenumab– Daniel D. Mikol, Hernan Picard, Jan Klatt, Andrea Wang, Cheng Peng, Kari NULL Stefansson 2:12 p.m. S47.007 Higher Health Care Resource Utilization and Costs Among Patients With Potentially Insufficient Response to Triptans–Steven C. Marcus, Anand R. Shewale, Stephen D. Silberstein, Richard B. Lipton, William B. Young, Hema Viswanathan, Jalpa Doshi 2:24 p.m. S47.008 Melanopsin and Cone Stimulation Both Contribute to Interictal Light Sensitivity in Migraine–Eric Kaiser, Harrison McAdams, Aleksandra “Sasha” Igdalova, Brett L. Cucchiara, David H. Brainard, Geoffrey Karl Aguirre 2:36 p.m. S47.009 Economic Burden Increased with Number of Treatment Failures in Migraine Patients - A Retrospective Claims Database Analysis in the United States–Lawrence C. Newman, Jasper Huels, Pamela Vo, Lujia Zhou, Cristina Lopez Lopez, Andy Cheadle, Melvin Olson, Juanzhi Fang 2:48 p.m. S47.010 Health-Related Quality of Life Based on Response to Triptans in People With Migraine: Analysis of Real-World Data–Stephen D. Silberstein, Anand R. Shewale, Sarah Baradaran, Richard B. Lipton, Sarah Cotton, James Jackson, Hema Viswanathan

108 2020 AAN Annual Meeting

S48 Neurocritical Care: Traumatic Brain Injury and Goals-of-care Decisionmaking 1:00 p.m. S48.001 Glycemia as a Key Determining Factor for Survival and Neurological Recovery After Acute Traumatic Spinal Cord Injury–Julio C. Furlan 1:12 p.m. S48.002 High-sensitivity C-reactive protein as a prognostic biomarker for traumatic brain injury (TBI): A TRACK-TBI Study–Linda Xu, Frederick Korley, Ava Puccio, Adam Ferguson, Shelly Sun, Pratik Mukherjee, Kevin Wang, David Chinedu Okonkwo, Geoffrey Manley, Sonia Jain, Ramon R. Diaz-Arrastia 1:24 p.m. S48.003 The MortalitY in Moderate-Severe TBI plus ICU-Complications (MYSTIC)-Score to Predict InHospital Mortality in Maximally Treated ModerateSevere TBI Patients Including ICU Complications– Michelle Chang, Julie Flahive, Kelsey Goostrey, Marcey L. Osgood, Raphael A. Carandang, Wiley Hall, Robert J. Goldberg, Susanne Muehlschlegel 1:36 p.m. S48.004 How Physicians Disclose Prognostic Information to Surrogates of Patients with Critical Neurologic Illness – a Pilot Multi-center Qualitative Analysis–Anne-Marie Shields, Connie Ge, Kelsey Goostrey, Beshoy Armanios, Anne-Marie Shields, Praewpannanrai Buddadhumaruk Sun, Catherine L Hough, Jay Steingrub, Douglas White, Susanne Muehlschlegel 1:48 p.m. S48.005 Clinicians’ Goals-of-care Communication Patterns for Critically Ill Neurologic Patients: A Pilot Multi-center Qualitative Study–Connie Ge, Adeline Lindsay Goss, Kelsey Goostrey, Beshoy Armanios, Anne-Marie Shields, Praewpannanrai Buddadhumaruk Sun, Catherine L Hough, Jay Steingrub, Douglas White, Susanne Muehlschlegel 2:00 p.m. S48.006 Subtypes of Insecure Psychological Attachment Styles as Predictors of Neuro ICU Goals-of-care Decisions–Qiang Johnson Zhang, Andrea Knies, Prerak Juthani, Stephanie Tu, Jolanta Pach, Aida Martinez, David Y. Hwang 2:12 p.m. S48.007 Trends and Predictors of In-hospital Mortality for Status Epilepticus: National Inpatient Sample Study 2005-2014–Huy Q. Nguyen, Mohammad Rauf A. Chaudhry, Shayan Ul Haque, Mushtaq H. Qureshi, Harathi Bandaru, Ihtesham A. Qureshi, Jorge Humberto Moreno, Guillermina Alicia Nelson, Mohtashim Arbaab Qureshi, Anantha Vellipuram, Paisith Piriyawat, Alberto Maud, Gustavo J. Rodriguez, Salvador Cruz-Flores 2:24 p.m. S48.008 Advanced Predictive Modeling of Children with Neurological Injury in the PICU: A Machine Learning Approach–Neil K. Munjal, Robert Clark, Dennis Simon, Patrick M. Kochanek, Christopher Horvat

CME

2:36 p.m. S48.009 Improving the Safety of Neurocritical Care Transitions through Failure Mode and Effects Analysis (FMEA)–Priyanka Chilakamarri, Emily Finn, John Sather, Kevin N. Sheth, Charles Matouk, Vivek Parwani, Andrew Ulrich, Melissa Davis, Laura Pham, Sarwat Chaudhry, Arjun Venkatesh 2:48 p.m. S48.010 Anisocoria and Poor Pupil Reactivity in the Neuro ICU–Charlene Jennifer Ong, Brenton Prescott, Hanife Saglam, David M. Greer

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

THURSDAY, APRIL 30 1:00 p.m.–3:00 p.m. S49 Multiple Sclerosis: Basic Science 1:00 p.m. Alliance Awards: S. Weir Mitchell Presentation This award is designed to encourage basic research in neuroscience by physicians in clinical neurology training programs. Recipient: Amir Hadi Maghzi, MD Boston, MA

2:36 p.m. S49.009 Evaluating the Correlation Between Spinal Fluid and Blood Levels of Neurofilament Light, GFAP, Tau, and UCHL1: Do We Need a Correction Factor in Evaluating Blood Levels?–Enrique Alvarez, Alanna Ritchie, Kavita Nair, Robert H. Gross, Amanda Lee Piquet, Courtney Knapp, Sean Selva, Stefan Sillau, Jeffrey L. Bennett, Gregory Owens, Timothy L. Vollmer 2:48 p.m. S49.010 Genetic Variation Modulates Risk for Multiple Sclerosis Among Smokers–Farren Briggs, Corriene Sept

S50 Ataxia, Dystonia, and Atypical Parkinsonism

CME

1:00 p.m. Alliance Awards: Founders Presentation This award is designed to encourage clinical and translational research in neuroscience by physicians in clinical neurology training programs. Recipient: Abhimanyu Mahajan, MD, MHS Cincinnati, OH 1:12 p.m. S50.002 Gene Therapy in the Shaker Rat Model of Cerebellar Degeneration and Ataxia–Collin James Anderson, Karla Patricia Figueroa, Sharan Paul, Warunee Dansithong, Stefan M. Pulst 1:24 p.m. S50.003 Japan Consortium of Ataxias (J-CAT): A National Registry to Elucidate Landscape for Degenerative Ataxias in Japan–Yuji Takahashi, Hidetoshi Date, Yuka Hama, Shinji Oda, Kinya Ishikawa, Yoshikazu Ugawa, Osamu Onodera, Jun-ichi Kira, Satoshi Kuwabara, Hidenao Sasaki, Masahisa Katsuno, Gen Sobue, Hiroshi Takashima, Yoshihisa Takiyama, Atsushi Takeda, Shoji Tsuji, Ritsuko Hanajima, Kenji Nakashima, Ichiro Miyai, Kunihiro Yoshida, Hidehiro Mizusawa 1:36 p.m. S50.004 Results from the Long-Term Open Label Extension Phase Analyses of BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia–Victoria Wirtz, Gilbert J. L’Italien, Robert Berman, Melissa Beiner 1:48 p.m. S50.005 Homozygous BZRAP1 Mutations Cause Autosomal Recessive Dystonia–Niccolo Emanuele Mencacci, Marisa Brockmann, Sander Pajusalu, Burcu Atasu, Paulina Gonzalez Latapi, Michael Schwake, Bettina Balint, Apostolos Papandreou, Alan Pittman, Javier Simon-Sanchez, Sarah Wiethoff, Thomas T. Warner, Manju Kurian, Thomas Gasser, Ebba Lohmann, Katrin Ounap, Kailash P. Bhatia, Christian Rosenmund, Thomas C. Sudhof, Nicholas W. Wood, Dimitri Krainc, Claudio Acuna 2:00 p.m. S50.006 The Classification of Autosomal Recessive Cerebellar Ataxias: A Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force–Marie Beaudin, Antoni MatillaDuenas, Bing-Wen Soong, Jose Luiz Pedroso, Orlando Graziani Povoas Barsottini, Hiroshi Mitoma, Shoji Tsuji, Jeremy D. Schmahmann, Mario Manto, Guy A. Rouleau, Nicolas Dupre 2:12 p.m. S50.007 The Role of Inferior Parietal Lobule in Task Specific Dystonia–Shabbir Hussain I. Merchant, Mark Hallett, Shabbir Hussain I. Merchant, Silvina Horovitz

AAN.com/view/20AM 109

Thursday, April 30

CME

SCIENTIFIC SESSIONS

1:12 p.m. S49.002 Detection of Microglia Activation in the Theiler’s Murine Encephalomyelitis Virus Model of Chronic Demyelination Using UltraSmall Superparamagnetic Iron Oxides (USPIO) Nanoparticle Enhanced High-Field Imaging–Robert Zivadinov, Ferdinand Schweser, Michael G. Dwyer, Suyog U. Pol 1:24 p.m. S49.003 Central Effects of BTK Inhibition in Neuroinflammation–Ross C. Gruber, Nathalie Chretien, Michael R Dufault, Jonathan Proto, Mindy Zhang, Michael J. LaMorte, Evis Havari, Tarek Samad, Timothy Turner, Anthony Chomyk, Emilie Christie, Bruce D. Trapp, Dimitry Ofengeim 1:36 p.m. S49.004 RNA-Binding Protein Altered Expression and Mislocalization in Multiple Sclerosis–Katsuhisa Masaki, Yoshifumi Sonobe, Ghanashyam Ghadge, Peter Pytel, Paula Lepine, Stephanie Zandee, Alexandre Prat, Raymond P. Roos 1:48 p.m. S49.005 CLOCK-MS: Evaluating the Mechanism of Action of Cladribine Tablets via CNS and Blood Biomarkers in MS–Gregory F. Wu, Ursula Boschert Shafaatian, Brooke Hayward, John Walsh, Daniel Jones, Anne H. Cross 2:00 p.m. S49.006 Bruton’s Tyrosine Kinase (BTK) Inhibition Promotes Myelin Repair in Two Different Models of Demyelination–Marie-Stephane Aigrot, Elodie Martin, Roland Grenningloh, Bruno Stankoff, Catherine Lubetzki, Ursula Boschert Shafaatian, Bernard Zalc 2:12 p.m. S49.007 Medullary Lesions as a Specific Neuropathological Basis for Sleep Disturbance in Early RelapsingRemitting Multiple Sclerosis–James F. Sumowski, Andrew W. Varga, Stephen Krieger, Rachel Brandstadter, Ilana B. Katz Sand, Victoria Leavitt, Michelle Fabian, Korhan Buyukturkoglu, Claire Riley, Sylvia Klineova, Fred D. Lublin, Aaron E. Miller, Sam H. Horng 2:24 p.m. S49.008 Familial Monophasic Acute Transverse Myelitis Due to a Pathogenic Variant in VPS37A–Michael Levy, Maureen Anne Mealy, Tai-Seung Nam, Santiago Pardo, Carlos A. Pardo-Villamizar, Nara Sobreira, Dimitrios Avramopoulos, David Valle, Kathleen Burns

1:00 p.m.–3:00 p.m.

THURSDAY, APRIL 30 1:00 p.m.–3:00 p.m. CME

2:24 p.m. S50.008 Fampridine and acetazolamide for the treatment of episodic ataxia type 2 (EAT2TREAT): a randomised, double-blind, placebo-controlled, three-period crossover trial–Michael Strupp, Carolin Muth, Ulrich Mansmann 2:36 p.m. S50.009 Divergent Patterns of Grey and White Matter Tau Histopathology in Clinically Similar LBD and PSP–David Gerhard Coughlin, Lucia Giannini, Claire Shan Peterson, Rebecca Lobrovich, David A. Wolk, Andrew D. Siderowf, Daniel Weintraub, Edward Lee, John Q. Trojanowski, Murray Grossman, David Irwin 2:48 p.m. S50.010 Multiple System Atrophy Patients Might Develop Nocturnal Urinary Concentration Failure Prior to Orthostatic Hypotension Early in the Disease Course–Yusuke Sakata, Masato Kanazawa, Masahiro Hatakeyama, Takuya Konno, Tetsutaro Ozawa, Osamu Onodera

Thursday, April 30

SCIENTIFIC SESSIONS

S50 Ataxia, Dystonia, and Atypical Parkinsonism

1:00 p.m.–3:00 p.m.

110 2020 AAN Annual Meeting

3:30 p.m.–4:45 p.m.

S51 General Neurology: Models of Clinical Care and Disease

CME

1:00 p.m. S51.001 Improving the Comfortability of Neurology Residents in Providing Care for Spanish-Speaking Monolingual Patients during Neurologic Emergencies–Jennifer Smith, Fan Caprio 1:12 p.m. S51.002 MIN-102 (leriglitazone), a Brain Penetrant PPAR gamma Agonist, Decreases Neuroinflammation and Neurodegeneration and Promotes ReMyelination in Preclinical Models of X-linked Adrenoleukodystrophy (X-ALD)–Sonia Poli, Anna Vilalta, Laura Rodriguez-Pascau, Marc CerradaGimenez, Johannes Berger, Sonja Forss-Petter, Isabelle Weinhofer, Patricia Musolino, Marc Martinell, Pilar Pizcueta 1:24 p.m. S51.003 Short-term Post Discharge Care, Long-term Benefits - A Transitional Model of Care–Melissa ReiderDemer, Jeffrey L. Saver, Inna Keselman 1:36 p.m. S51.004 Clinical, Biological, Imaging and Genetic Repository C-BIGR; An Integrated Approach to Biobanking in the Context of Open Science–Marie-Noelle Boivin, Mahdieh Tabatabaei Shafiei, Sonia Lai Wing Sun, Jason Karamchandani 1:48 p.m. S51.005 Newsworthiness Of Neurological Research–Isha Snehal, Appaji Rayi, Vineet Punia 2:00 p.m. S51.006 NeuroBytes: A new rapid, high-yield, nationwide e-Learning platform for continuing professional development in neurology–Laura Elizabeth Lavette, Alexandra M. Miller, Zachary N. London, Veronica E. Santini, Ilana Marie Ruff, Jeff Kraakevik, Amanda Chamberlain, Beth Rogers-Baggett, Calli Leighann Cook, Alexander Merkler, Robert A. Rook, Don B. Smith, Wayne E. Anderson, Stacy Lynne Johnson, Joan Sweeney, Richard S. Isaacson, Roy E. Strowd 2:12 p.m. S51.007 Establishment of Chronic Alcoholic Neuropathy Model in Rat–Toshiki Fujioka, Tsunehiko Imai, Masao Amari, Takafumi Uchi, Hideo Kihara, Sumihisa Urita 2:24 p.m. S51.008 MIN102 (Leriglitazone), a Brain Penetrant PPAR Gamma Agonist for the Treatment of Friedreich’s Ataxia–Sonia Poli, Laura Rodriguez-Pascau, Elena Britti, Joaquim Ros, Pilar Gonzalez-Cab, David R. Lynch, Marc Martinell, Pilar Pizcueta 2:36 p.m. S51.009 Clioquinol Elicits Cytotoxic Effects on Cultured Astrocytes Through the Impairment of the Autophagy-Lysosome Pathway–Yasuaki Mizutani, Tatsuro Mutoh 2:48 p.m. S51.010 Src Inhibition Attenuates Polyglutaminemediated Neuromuscular Degeneration in Spinal and Bulbar Muscular Atrophy–Madoka Iida, Kentaro Sahashi, Naohide Kondo, Hideaki Nakatsuji, Genki Tohnai, Masahisa Katsuno

S52 From Bench to Bedside with CME Novel Treatments for Pain 1.25 3:30 p.m. Mitchell B. Max Award for Neuropathic Pain Presentation This award recognizes an individual for outstanding work in the field of neuropathic pain for either a single contribution or for lifetime achievement. Recipient: Anne Louise Oaklander, MD, PhD, FAAN, FANA Boston, MA 3:42 p.m. S52.002 Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis : Neurological Safety in a Randomized, Double-Blind, Active-Controlled, 80Week Phase 3 Study–Paola Sandroni, Kenneth C. Gorson, Phillip A. Low, David Hunter, Glenn Pixton, Robert Fountaine, Mark T. Brown, Lars Viktrup, Christine R. West, Kenneth M. Verburg 3:54 p.m. S52.003 Randomized, Double-masked, Placebocontrolled Trial of Botulinum Toxin for Chronic Pelvic Pain in Women–Barbara P. Karp, Hannah Tandon, Hannah Tandon, Jacqueline Aredo, Ninet Sinaii, Jay Shah, Pamela Stratton 4:06 p.m. S52.004 Decoy Peptide Disruption of Neuronal Signaling Suggests a Novel Pharmacologic Target for Pain States–Yohance Mandela Allette, Youngsook Kim, Jared Smith, Matthew Ripsch, Fletcher White 4:18 p.m. S52.005 Pilot of Trigger-based Palliative Care Referral Among Individuals with Parkinson Disease– Christopher Tarolli, Grace A. Zimmerman, E. Ray Dorsey, Robert Horowitz, Benzi Kluger, Robert G. Holloway 4:30 p.m. S52.006 Analgesic Nutraceutical Salts and Co-crystals of Pentoxifylline, Clonidine and Linsidomine for the Topical Treatment of Complex Regional Pain Syndrome-1–Oli Abate Fulas, Andre Laferriere, Ghada Ayoub, Cristina Mottillo, Hatem Titi, Robin S Stein, Tomislav Friþcic, Terence Coderre

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

THURSDAY, APRIL 30 3:30 p.m.–5:30 p.m. S53 Stroke Prevention

5:06 p.m. S53.009 Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis: CREST-2 Update–James F. Meschia, Brajesh K. Lal, George Howard, Wayne M. Clark, Fayaz Shawl, Tanya N. Turan, Gary Roubin, Robert D. Brown, Kevin M. Barrett, Seemant Chaturvedi, Marc I. Chimowitz, Bart M. Demaerschalk, Virginia J. Howard, John Huston, Ronald M. Lazar, Wesley Moore, Claudia Moy, Jenifer Voeks, Thomas G. Brott 5:18 p.m. S53.010 Frequency and Predictors of Disease in other Vascular Beds in Patients with Asymptomatic Carotid Stenosis: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis (CREST 2)–Seemant Chaturvedi, James F. Meschia, Brajesh K. Lal, George Howard, Gary Roubin, Tanya N. Turan, Philip A. Teal, Robert D. Brown, Kevin M. Barrett, Marc I. Chimowitz, Bart M. Demaerschalk, Virginia J. Howard, John Huston, Ronald M. Lazar, Wesley Moore, Claudia Moy, Jenifer Voeks, Thomas G. Brott

S54 Multiple Sclerosis: Disease Progression, Diseasemodifying Therapy, and Clinical Considerations

CME

3:30 p.m. S54.001 Onset of Progressive Motor Impairment in Patients with Critical CNS Demyelinating Lesions–Roman Mehari Kassa, Elia Sechi, Eoin P. Flanagan, Timothy Kaufmann, Orhun H. Kantarci, Brian G. Weinshenker, Jayawant Narayan Mandrekar, William F. Schmalstieg, M. Mateo Paz Soldan, Mark Keegan 3:42 p.m. S54.002 Modeling Subject-Level Disease Progression for Multiple Sclerosis Clinical Trials with Machine Learning–Jonathan Walsh, Aaron Smith, Yannick Pouliot, David Li-Bland, Anton Loukianov, Charles Fisher 3:54 p.m. S54.003 Confirmed Disability Progression Provides Limited Predictive Information Regarding Future Disease Progression–Brian Curran Healy, Bonnie Glanz, Elyse Swallow, James Signorovitch, Kaitlin Hagan, Diego Silva, Corey Pelletier, Tanuja Chitnis, Howard L. Weiner 4:06 p.m. S54.004 Remotely Monitored Ambulatory Activity Correlates with Disability in Progressive MS: A Baseline Analysis from the SPI2 Phase 3 Clinical Trial of MD1003 (High Dose Pharmaceutical Grade Biotin)–Valerie A J Block, Amber M. Alexander, Nico Papinutto, Anand Rajesh, Tristan Gundel, Jeffrey Marc Gelfand, Roland G. Henry, Frederic Sedel, Bruce A. C. Cree 4:18 p.m. S54.005 Mapping Vibratory Sensory Loss Across MS Disease Course–Nigar Dargah-Zada, Sonya Ulrike Steele, Ikesinachi Osuorah, Gina Norato, Jenifer Dwyer, Frances Andrada, Joan M. Ohayon, Zongqi Xia, Philip De Jager, Daniel Reich, Irene CM Cortese 4:30 p.m. S54.006 Evaluation of Disability Improvement in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Cladribine Tablets as Measured by the Expanded Disability Status Scale Score–Maria Pia Sormani, Alessio Signori, Gavin Giovannoni, Nektaria Alexandri 4:42 p.m. S54.007 Depression in MS is Associated with Worsening Neuroperformance, Relapses, and New Brain Lesions–Jenny J. Feng, Jeffrey Alan Cohen, Daniel Ontaneda 4:54 p.m. S54.008 Updated Incidence of Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) and Its Relationship with Natalizumab Exposure Over Time–Gavin Giovannoni, Ludwig Kappos, Joseph R. Berger, Gary Raymond Cutter, Robert J. Fox, Heinz Wiendl, Ih Chang, Veronica Englishby, Lily Lee, Stephanie Licata, Pei-Ran Ho

AAN.com/view/20AM 111

Thursday, April 30

CME

SCIENTIFIC SESSIONS

3:30 p.m. S53.001 Poor Atrial Fibrillation Management Leads to Avoidable Thrombectomies in Elderly Patients– Nicole Beaton Sur, Vasu Saini, Luis F. Torres, Nastajjia Krementz, Sishir Mannava, Kunakorn Atchaneeyasakul, Amer Malik, Dileep R. Yavagal, Seemant Chaturvedi 3:42 p.m. S53.002 Factors Associated with Oral Anticoagulant Non-use in Patients with Atrial Fibrillation-related Stroke–Nicole Beaton Sur, Sebastian Koch, Kefeng Wang, Marco R. Di Tullio, Carolina M. Gutierrez, Chuanhui Dong, Hannah Gardener, Enid Garcia, Juan Carlos Zevallos, William Scott Burgin, David Z. Rose, Jeffrey Goldberger, Jose Gabriel Romano, Ralph L. Sacco, Tatjana Rundek 3:54 p.m. S53.003 Utility of Pre-sepsis P-wave Terminal Force in Lead V1 (PTFV1) as a Predictor of Atrial Fibrillation and Ischemic Stroke in Patients with Sepsis–Aisha Elfasi, Frederick Moore, Robert Mankowski, Gabriela Ghita, Katelyn Villani, Stephen Anton, Scott Brakenridge, Babette Brumback, Philip Efron, Marie-Carmelle Elie-Turenne, Christiaan Leeuwenburgh, Lyle Moldawer, Alexis N. Simpkins 4:06 p.m. S53.004 The Use of Dual Therapy vs Triple Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome: A Network Meta-analysis of Randomized Clinical Trials–Aaron Desai, Cesar Escamilla-Ocanas, Parisa Asgarisabet, Rahul Damani 4:18 p.m. S53.005 Candidates for Long Term Anticoagulation Among Hospitalized Patients with Atrial Fibrillation in United States–Nitish Kumar, Vamshi Balasetti, Iryna Lobanova, Wei Huang, Nitish Kumar, Brandi R. French, Farhan Siddiq, Camilo Ramiro Gomez, Adnan I. Qureshi 4:30 p.m. S53.006 Emergency Medicine Physicians’ Perceptions of Initiating Anticoagulants in the Emergency Department for Patients with Atrial Fibrillation– Hope Hua, Lilly Lee, Seemant Chaturvedi, Nicole Beaton Sur 4:42 p.m. S53.007 Biochemical Aspirin Resistance and Clinical Outcome in Indian Patients with Ischemic Stroke–Rohit Bhatia, Pranjal Sisodia, M.V.Padma Srivastava, Renu Saxena, Sreenivas Vishnubhatla, Kameshwar Prasad, Gautam Sharma, Mamta Bhushan Singh 4:54 p.m. S53.008 Physician Approaches to Anti-thrombotic Management of Patients with Acutely Symptomatic Carotid Stenosis Awaiting Endarterectomy or Stenting: A Mixed Methods Study–Aravind Ganesh, Gordon Jewett, David JT Campbell, Ravinder Jeet Singh, Abdulaziz Sulaiman Al Sultan, John Wong, Bijoy Menon

3:30 p.m.–5:30 p.m.

THURSDAY, APRIL 30 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m. CME

5:06 p.m. S54.009 Neurogenic Pain in Multiple Sclerosis: A Single Center Comprehensive Pain Assessment–Sheila Steiner, Giovanna Durman, M. Mateo Paz Soldan, Sara Woltz, Ka-Ho Wong, John W. Rose 5:18 p.m. S54.010 Defining the Neuroimmunology/Multiple Sclerosis Subspecialty: Surveys of Fellowship Training in the United States–Erin Longbrake, Ahmed Z. Obeidat, Jeffrey E. Dunn, Nancy L. Sicotte, Le Hua

Thursday, April 30

SCIENTIFIC SESSIONS

S54 Multiple Sclerosis: Disease Progression, Diseasemodifying Therapy, and Clinical Considerations

112 2020 AAN Annual Meeting

S55 Movement Disorders: Neuromodulation, Circuits, and Management 3:30 p.m. Jon Stolk Award in Movement Disorders for Young Investigators Presentation This award recognizes young investigators who have made significant contributions to movement disorders research. Recipient: Aasef Shaikh, MD, PhD Cleveland, OH 3:42 p.m. S55.002 Differences in Subthalamic Oscillatory Neurons Associated with Severity in Parkinson’s Disease– Ping Zhuang, Mark Hallett, Xuemin Zhao, Yuqing Zhang, Jiping Li, Yongjie Li 3:54 p.m. S55.003 Subthalamic-Cortical Connectivity and Motor Improvement In Parkinson’s Disease Following Magnetic Resonance-Guided Focused Ultrasound Subthalamotomy–Rafael Rodriguez-Rojas, Jorge Uriel Manez Miro, Jose A Pineda-Pardo, Raul Martinez-Fernandez, Alicia Sanchez-Turel, Marta del Alamo, Frida Hernandez-Fernandez, Mariana Monje, Beatriz Fernandez-Rodriguez, Jose A. Obeso 4:06 p.m. S55.004 Focused Ultrasound Subthalamotomy in Parkinson’s Disease: Lesion Topography and Motor Improvement.–Jorge Uriel Manez Miro, Rafael Rodriguez-Rojas, Raúl Martinez-Fernandez, Marta del Alamo, Jose A Pineda-Pardo, Frida HernandezFernandez, Esther De Luis-Pastor, Mariana Monje, Beatriz Fernandez-Rodriguez, Fernando AlonsoFrech, Lydia Vela, Jose A. Obeso 4:18 p.m. S55.005 Can Tele-Monitored transcranial Direct Current Stimulation (tDCS) Help Manage Fatigue and Cognitive Symptoms in Parkinson’s disease?–Kush Sharma, Shashank Agarwal, Daniella Mania, Alberto Cucca, Steven Frucht, Andrew S. Feigin, Milton Biagioni 4:30 p.m. S55.006 Symptomatic Relief in Essential Tremor with Home Use of Non-Invasive Neuromodulation Therapy– Rajesh Pahwa, Elizabeth L. Ulrich Peckham, Winona Tse, Olga Waln, Christopher Young Way, Melita Talene Petrossian, Nabila Dahodwala, Michael Soileau, Mark F. Lew, Cameron LG Dietiker, Nijee Sharma Luthra, Stuart H. Isaacson 4:42 p.m. S55.007 Gait Measures from Videos Detect Parkinsonian Gait in Older Adults with Dementia–Andrea Sabo, Kimberley-Dale Ng, Sina Mehdizadeh, Babak Taati, Andrea Iaboni 4:54 p.m. S55.008 Cholinergic Degeneration is Associated with Slower Gait in Parkinson’s Disease–William Alexander Dalrymple, William Alexander Dalrymple, Jamie Blair, Joseph Flanigan, Scott A. Sperling, Binit Shah, Madaline B. Harrison, Matthew J. Barrett

CME

5:06 p.m. S55.009 Directional versus omnidirectional Deep Brain Stimulation: Results of a Multi-Center Prospective Blinded Crossover Study–Leonard Verhagen Metman, Jan Vesper, Pablo Mir, Matthew A. Brodsky, Sergiu Groppa, Ramiro Alvarez, Andrew Howard Evans, Marta Blazquez Estrada, Sean Nagel, Witold Libionka, Julie Pilitsis, Monica Pötter-Nerger, Winona Tse, Leonardo B. Almeida, Nestor Tomycz, Joohi Jimenez-Shahed, Fatima Carrillo, Christian J. Hartmann, Florence Defresne, Edward Karst, Binith Cheeran, Alfons Schnitzler 5:18 p.m. S55.010 Coping with Parkinson’s Disease: A Mexican Study–Cynthia Guadalupe Sarabia-tapia, Susana Lopez, Oscar Esquivel, Yazmin Rios, Amin Cervantes-Arriaga, Mayela De Jesus Rodriguez Violante

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

THURSDAY, APRIL 30 3:30 p.m.–5:30 p.m.

3:30 p.m.–5:30 p.m. S56 Neuromuscular Therapeutics

CME

4:54 p.m. S57.008 Prevalence of White Matter Hyperintensities in Young Adults With and Without Mild Traumatic Brain Injury–Teena Shetty, Eric Miller, Manoj Tanwar, Matthew Garvey, Caitlin Miller, Esther Kim, Vikas K. Agrawal, Luca Marinelli, Apostolos Tsiouris 5:06 p.m. S57.009 Neurological Diagnostic Testing in Elderly Patients with Acute Altered Mental Status–Hsien Lee Lau, Lixandra Gonzalez, Melissa Bailey, Joshua Lukas, Whitney E. Mayberry, Matthew Feldman, Neeta Garg 5:18 p.m. S57.010 Neurofilament Light Chain (NfL) as a Potential Biomarker in Hereditary Transthyretin-Mediated (hATTR) Amyloidosis–Paul Nioi, Simina Ticau, Gautham Sridharan, Shira Tsour, William Cantley, Amy Chan, Jason Gilbert, David Erbe, Kevin Fitzgerald

Thursday, April 30

3:30 p.m. S57.001 Association of Serum Uric acid with Amyotrophic lateral sclerosis–Md Raknuzzaman 3:42 p.m. S57.002 Incidental Findings on Brain Magnetic Resonance Imaging–Sarah Elisabeth Keuss, Thomas Parker, Christopher Lane, Chandrashekar Hoskote, Sachit Shah, David Cash, Ashvini Keshavan, Sarah Buchanan, Heidi Murray-Smith, Andrew Wong, Sarah James, Kirsty Lu, Jessica Collins, Daniel Beasley, Ian Malone, David Thomas, Anna Barnes, Marcus Richards, Nick Fox, Jonathan Schott 3:54 p.m. S57.003 Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy–Madeline Merkel, Martha Grogan, Philip N Hawkins, Arnt Kristen, John L. Berk, Ole Suhr, Hollis Lin, Anastasia McManus, Christine Powell, John Vest, Verena Karsten, Daniel Judge 4:06 p.m. S57.004 Echocardiographic Abnormalities and Determinants of 1-month Outcome of Stroke Among West Africans in the SIREN Study–Mayowa Owolabi, Abiodun Adeoye, Joshua O. Akinyemi, Okechukwu S. Ogah, Rufus O. Akinyemi, Mulugeta Gebregziabher, Kolawole W. Wahab, Adekunle Fakunle, Adeseye Akintunde, Oladimeji Adebayo, Akinyemi Aje, Hemant Tiwari, Donna Arnett, Francis Agyekum, Lambert Appiah, Ganiyu Amusa, Taiwo Olunuga, Onoja M Akpa, Fred Sarfo, Albert K. Akpalu, Carolyn Jenkins, Daniel Thomas Lackland, Lukman Femi Owolabi, Morenikeji Komolafe, Mercy Faniyan, Oyedunni Arulogun, Reginald Obiako, Bruce I. Ovbiagele 4:18 p.m. S57.005 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Biomarkers of MIN-102 (Leriglitazone)–Uwe Meya, Guillem Pina, Silvia Pascual, Marc Cerrada-Gimenez, Pilar Pizcueta, Marc Martinell, David Eckland, Jeroen v.d. Wetering de Rooij 4:30 p.m. S57.006 Association Between Adverse Childhood Experiences and a Diagnosis of Functional Neurological Disorder–Jennifer McCombe, Samiha Rahman, Hilda Cruz, Yan Yuan, Janis Miyasaki 4:42 p.m. S57.007 Plasma Phosphorylated Neurofilament Heavy Chain Levels Over Time in Participants With Infantile- and Later-onset SMA: Data from the SHINE Study– Basil T. Darras, Charlotte J. Sumner, Francesco Muntoni, Thomas O. Crawford, Richard S. Finkel, Eugenio Mercuri, Madhu Nagappa, Maryam Oskoui, Eduardo Tizzano, Monique M. Ryan, Ying Liu, Marco Petrillo, Boris Kandinov, Janice Chun Yee Wong, Wildon Farwell

CME

SCIENTIFIC SESSIONS

3:30 p.m. S56.001 Zilucoplan, a Peptide Inhibitor of Complement Component 5, Prevents Weakness in a Passive Transfer Model of Immune-Mediated Necrotizing Myopathy–Olivier Boyer, Laurent Drouot, Alonso Ricardo, Camil Sayegh 3:42 p.m. S56.002 Immune Checkpoint Inhibitor-associated Myopathies Define a Distinct Subtype of Immunemediated Myopathies–James Douglas Triplett, Margherita Milone, Marcus Vinicius Rocha Pinto, Anastasia Zekeridou, Teerin Liewluck 3:54 p.m. S56.003 PROMISE-MG: Comparative Effectiveness Study of MG Treatments- Baseline Data–Pushpa Narayanaswami, Donald B. Sanders, Jeff Guptill, PROMISE-MG Study Group 4:06 p.m. S56.004 Analysis of the Duke Myasthenia Gravis (MG) Clinic Registry: Demographic and Clinical Characteristics– Donald B. Sanders, Shruti M. Raja, Jeff Guptill, Lisa Hobson-Webb, Vern C. Juel, Janice M. Massey 4:18 p.m. S56.005 IVIG Refractory CIDP: Clinical Characteristics, Antibodies, and Response to Alternative Treatment–Jamila Godil, Nizar Chahin, Thomas E. Ragole, Amy C. Visser, Matthew J. Barrett, Orly Moshe-Lilie, Chafic Y. Karam 4:30 p.m. S56.006 Clinical Trial Readiness Study of Distal Myopathy and Dysphagia in Nephropathic Cystinosis–Reza Seyedsadjadi, Stacey Sullivan, Natalie Grant, Camille Corre, Nicholas Mello, William S. David, Florian Eichler 4:42 p.m. S56.007 NeuroREACH™ Platform for Expanded Access Program (EAP) Trials as the Foundation for Clinical Research of the Future–Alexander Sherman, Amanda Podesta, Jason Walker, Hong Yu, Derek D’Agostino, Natalia Tarasenko, Ervin Sinani, Sarah Luppino, Jennifer Scalia, Sabrina Paganoni, Merit E. Cudkowicz 4:54 p.m. S56.008 Oculopharyngeal Muscular Dystrophy Patients with Treatment-responsive, Statin-associated Autoimmune Necrotic Myopathy–Khalid Mohammed Alrasheed, Bernard Brais, Jan Schulz, Theodore Wein, Jason Karamchandani, Erin K. O’Ferrall 5:06 p.m. S56.009 Quantitative Reduction of Sialorrhea After Unilateral Parotid Electron Beam Radiotherapy in Debilitating Neurological Disorders–Edward J. Kasarskis, Carter Baughman, William St. Clair, Bhaswanth Dhanireddy, Meghann Bruno, Meha Joshi, Richard J. Kryscio 5:18 p.m. S56.010 Plasma Deoxydihydroceramides are Elevated in People with Diabetic Neuropathy and Correlate with Neuropathy Severity–Vera Fridman, Simona Zarini, Stefan Sillau, Kathleen Harrison, Bryan Bergman, Eva Feldman, Brian Callaghan, Jane Reusch

S57 General Neurology: Diagnostic Testing and Disease Biomarkers

AAN.com/view/20AM 113

FRIDAY, MAY 1 1:00 p.m.–3:00 p.m.

Friday, May 1

SCIENTIFIC SESSIONS

S58 Headache Therapeutics

1:00 p.m.–3:00 p.m. CME

1:00 p.m. S58.001 Clinically Meaningful Responses to Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medications in the Randomized, Placebocontrolled FOCUS Study–Sait Ashina, Verena Ramirez Campos, Joshua M. Cohen, Lindsay Janka, Egilius L H Spierings 1:12 p.m. S58.002 Prednisone in Short-term Prevention of Episodic Cluster Headache–Mark Obermann, Dagny Natascha Holle 1:24 p.m. S58.003 Mindfulness as an Adjunctive Treatment Strategy for Reduction of Migraine Pain During a Single Office Visit–Virginia Baker, Andrew Robert Garrett, Nawaz Hack 1:36 p.m. S58.004 Acute Treatment Patterns Among New Triptan Treatment Users and Potential Triptan Insufficient Responders–Anand R. Shewale, Steven C. Marcus, Richard B. Lipton, David W. Dodick, Hema Viswanathan, Jalpa Doshi 1:48 p.m. S58.005 Lasmiditan Inhibits Trigeminal-Autonomic Reflex Activation in a Preclinical Model of Trigeminal Autonomic Cephalalgias.–Marta Vila Pueyo, Peter Goadsby, Philip R. Holland 2:00 p.m. S58.006 Extracranial Injections of OnabotulinumtoxinA in Combination with Intravenous Injection of Atogepant Attenuates Activation and Sensitization of HT and WDR Neurons by CSD–Agustin Melo Carrillo, Andrew Strassman, Aaron Schain, Aubrey Manack Adams, Mitchell F. Brin, Rami Burstein 2:12 p.m. S58.007 Efficacy of Ubrogepant in a Preclinical Model of Medication Overuse Headache–Edita Navratilova, Janice Oyarzo, David W. Dodick, Pradeep Banerjee, Frank Porreca 2:24 p.m. S58.008 Adverse Event Profiles of Therapies that Target the Calcitonin Gene-Related Peptide (CGRP) Pathway, During the First Six Months After Launch: A Realworld Data Analysis Using the FDA Adverse Events Reporting System (FAERS)–Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen, Sanjay Gandhi, Michael Seminerio, Verena Ramirez Campos, Yoel Kessler, Stephen Thompson, Andrew M. Blumenfeld 2:36 p.m. S58.009 Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201)–Robert Croop, Gary D. Berman, David B. Kudrow, Kathleen B. Mullin, Elyse Stock, Alexandra Thiry, Charlie Conway, Christopher Jensen, Meghan Lovegren, Vlad Coric, Richard B. Lipton 2:48 p.m. S58.010 Cardiovascular Safety of Erenumab in Patients with Migraine and Aura–Messoud Ashina, Peter Goadsby, David W. Dodick, Stewart J. Tepper, Fei Xue, Feng Zhang, Jeffrey Olearczyk, Gabriel Paiva da Silva Lima

114 2020 AAN Annual Meeting

S59 Epilepsy/Clinical Neurophysiology (EEG) 4

1:00 p.m.–3:00 p.m. CME

1:00 p.m. S59.001 Association Between Status Epilepticus and Cardiovascular Risk–Takafumi Kubota, Guadalupe Fernandez-Baca Vaca, Guadalupe Fernandez-Baca Vaca 1:12 p.m. S59.002 Associations Over Time Among Albendazole Treatment, Cyst Evolution, and Seizures Outcomes in Neurocysticercosis–Arturo Carpio, Mindy Chang, Hongbin Zhang, Matthew Romo, Alex Jaramillo, W. Allen Hauser, Elizabeth A. Kelvin 1:24 p.m. S59.003 Frontal Lobe Glucose Hypometabolism in Patients with High Risk for Sudden Unexplained Death in Epilepsy (SUDEP): An Objective PET Study– Ananyaa Kumar, Hani Alhourani, Csaba Juhasz, Maysaa Merhi Basha 1:36 p.m. S59.004 Prevalence of Medical Comorbidities and Cardiovascular Diseases in Patients with Epilepsy.– Takafumi Kubota, Takahiro Tsushima, Guadalupe Fernandez-Baca Vaca 1:48 p.m. S59.005 Sleep-related Seizure Onset and Peri-ictal Arousals in Refractory Focal Epilepsy–Garima Shukla, Pooja Narang, Anupama Gupta, Mamta Bhushan Singh, Achal K. Srivastava 2:00 p.m. S59.006 Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome (DS): 3-Year Interim Results of an Open-Label Extension (OLE) Trial (GWPCARE5)–Jonathan J. Halford, Ingrid E. Scheffer, Rima Nabbout, Rocio SanchezCarpintero, Yael Shiloh-Malawsky, Matthew H. Wong, Daniel Checketts, Eduardo Dunayevich 2:12 p.m. S59.007 Treatment Complacency Among Patients Living With Epilepsy, Caregivers, and Health Care Professionals–Patricia E. Penovich, John M. Stern, Danielle Becker, Lucretia Long, Nancy Santilli, Eugenia Peck 2:24 p.m. S59.008 Early Stages of Lafora Progressive Myoclonus Epilepsy–Antonio V. Delgado-Escueta, Viet-Huong Nguyen, Reyna M. Duron, Cesia Garrido, Alenoush M. Aramian, Julia N. Bailey, Deborah Holder, Arthur Partikian, Nancy Allison Mcnamara, Rene Silva 2:36 p.m. S59.009 Long-term Efficacy and Safety of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures: Open-label Extension of a Randomized Clinical Study–Pavel Klein, Gregory L. Krauss, Sami M. Aboumatar, Marc Kamin 2:48 p.m. S59.010 Real-world Experience with ZX008 (Fenfluramine HCl) for the Treatment of Seizures in Dravet Syndrome: Initial Report from United States Expanded Access Program–Scott Perry, Elaine C. Wirrell, David B. Burkholder, Bradley Galer, Arnold Gammaitoni

S60 Cerebrovascular Imaging and Biomarkers

CME

1:00 p.m. S60.001 Deployment of Portable, Bedside, Low-field Magnetic Resonance Imaging for Evaluation of Stroke Patients–Bradley Cahn, Jill T. Shah, Hadrien Dyvorne, Rafael O’Halloran, Michael Poole, Matthew Yuen, Mercy Mazurek, Adrienne Ward, Sam Payabvash, Rachel Beekman, Stacy C. Brown, Guido Jose Falcone, Kevin Gobeske, Nils Petersen, Adam S. Jasne, Richa Sharma, Joseph Schindler, Lauren Hachmann Sansing, Emily Jean Gilmore, Charles R. Wira, Charles Matouk, Gordon Sze, Matthew Rosen, W. Taylor Kimberly, Kevin N. Sheth 1:12 p.m. S60.002 Small-vessel Vasculopathy Harboured Within Intracranial Large-artery Atherosclerosis–Thomas Wai Hong Leung, Xinyi Leng, Yannie Ol-Yan Soo, Hing Lung Ip, Ma Sze Ho, Bonaventure Ip, Simon Yu 1:24 p.m. S60.003 Prevalence, Predictors, and Prognosis of Intracranial Stenosis in Patients with TIA and Minor Stroke: Population-based Study Versus Randomized Trials–Robert Hurford, Frank Wolters, Linxin Li, Gary KK Lau, Wilhelm Kuker, Peter Rothwell 1:36 p.m. S60.004 ASPECTS Scoring Applied to CTA Source Images is Predictive of Final Infarct Volume and Good Functional Recovery–Joseph F. Carrera, Joseph Donahue, Prem Batchala, Andrew Mebane Southerland, Bradford B. Worrall 1:48 p.m. S60.005 The Presence of Arterial Stenosis in Posterior Reversible Encephalopathy Syndrome–Monica Scarsella, Meghan Purohit, Naresh Mullaguri, Dinesh V. Jillella, Ken Uchino 2:00 p.m. S60.006 The Dynamic Progression of Hyperintensity Ratio as a Marker of Cerebral Autoregulatory Failure in Large Vessel Occlusion Stroke–Karan Tarasaria, Amre Nouh 2:12 p.m. S60.007 The Association Between Notch3 Mutations and Cerebral Small Vessel Disease Burden in a Chinese Population-based Sample–Jingyi Liu, Yi Dai, DingDing Zhang, Fei Han, Feifei Zhai, Lixin Zhou, Ming Yao, Jun Ni, Zheng-Yu Jin, Li-Ying Cui, Shu-Yang Zhang, Yi-Cheng Zhu 2:24 p.m. S60.008 Apolipoproteins, Lipoprotein(a) and Risk of Intracranial Atherosclerosis and Ischemic Stroke: A Secondary Analysis of the ARIC Study–Adam De Havenon, Jennifer J. Majersik, Nazanin Sheibani, Ka-Ho Wong

= Clinical Knowledge

= Technology

= Research

= Abstract of Distinction

FRIDAY, MAY 1 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m. S60 Cerebrovascular Imaging and Biomarkers

CME

2:36 p.m. S61.009 Association of Frailty Patterns with Long-Term Neurological Recovery in Cardiac Arrest Survivors– Wendy Tong, Brianna Cocuzzo, Jennifer W Allen, Elizabeth Matthews, David J. Roh, Soojin Park, Jan Claassen, Daniel Brodie, Mitchell S. V. Elkind, Sachin Agarwal 2:48 p.m. S61.010 Long-term Opioid Use in Patients with Aneurysmal Subarachnoid Hemorrhage–Idrees Azher, Matthew Anderson, Katarina B. Dakay, Brian Mac Grory, Scott Moody, Ashutosh Kaushal, Bradford B. Thompson, Linda C. Wendell, Shyam Sudarshan Rao, Nicholas S. Potter, Leana Mahmoud, Shawna M. Cutting, Michael E. Reznik, Shadi Yaghi, Karen L. Furie, Ali Mahta

Friday, May 1

1:00 p.m. S61.001 First Deployment of a Portable, Bedside, LowField Magnetic Resonance Imaging Solution for Artificial Intelligence Based Application–Kevin N. Sheth, Bradley Cahn, Sadegh Salehi, Jill T. Shah, Samantha By, E Brian Welch, Michael Sofka, Laura Sacolick, Matthew Yuen, Mercy Mazurek, Charles Matouk, Barbara S. Gordon, Adrienne Ward, Sam Payabvash, Guido Jose Falcone, Nils Petersen, Joseph Schindler, Emily Jean Gilmore, David Y. Hwang, Kevin Gobeske, Jennifer A. Kim, Lauren Hachmann Sansing, Gordon Sze, Matthew Rosen, W. Taylor Kimberly, Prantik Kundu 1:12 p.m. S61.002 Cerebral Autoregulation-guided Parameters for Predicting Midline Shift After Large-vessel Occlusion Ischemic Stroke–Andrew Silverman, Anson Wang, Sreeja Kodali, Sumita Strander, Alexandra Kimmel, Cindy Khanh Phuong Nguyen, Krithika Umesh Peshwe, Charles Matouk, Kevin N. Sheth, Randolph S. Marshall, Can Tan, Nils Petersen 1:24 p.m. S61.003 Characterization of Blood Pressure Trajectories in the Hyperacute Phase of Large Vessel Occlusion Ischemic Stroke–Krithika Umesh Peshwe, Cindy Khanh Phuong Nguyen, Sreeja Kodali, Sumita Strander, Alexandra Kimmel, Anson Wang, Charles Matouk, Lauren Hachmann Sansing, Kevin N. Sheth, Charles R. Wira, Andrew Silverman, Nils Petersen 1:36 p.m. S61.004 TCD and EEG Combined Better Predicts DCI After SAH–Hsin Yi Chen, Manohar Ghanta, Eric Rosenthal, Sahar Fatima Zafar, M. Brandon Westover, Jennifer A. Kim 1:48 p.m. S61.005 Dialysis in Acute Intracerebral Hemorrhage is Associated with Worsening Perihematomal Edema–Alireza Shirazian, Louis Cannizzaro, Namir Khandker, Doan Nguyen, Billie Hsieh, Vi Tran, Andres Felipe Peralta-Cuervo, Maria P AguileraPena, Ifeanyi Obianyo Iwuchukwu 2:00 p.m. S61.006 Comparison of Neurologic Complications of Veno-arterial Versus Veno-venous Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-analysis–Aaron Shoskes, Ibrahim Migdady, Abhishek Deshpande, Carrie Price, Catherine Hassett, Adrian Hernandez, Sung Min Cho 2:12 p.m. S61.007 Understanding Characteristics of Acute Brain Injury in Adult ECMO: An Autopsy Study–Giorgio Caturegli, Liam Chen, Sung-Min Cho 2:24 p.m. S61.008 Acute Brain Injury in Neonatal and Infant ECMO: An Autopsy Study–Giorgio Caturegli, Liam Chen, Sung-Min Cho

CME

SCIENTIFIC SESSIONS

2:36 p.m. S60.009 The Association of SUR1 Polymorphisms with Acute Infarct Size: The MRI-GENIE Study–Arlinda Deng, Huichun Xu, Anne-Katrin Giese, Markus D. Schirmer, Kathleen L. Donahue, Polina Golland, Robert Irie, Elissa McIntosh, John Cole, Patrick McArdle, Joseph P. Broderick, Jordi JimenezConde, Christina Jern, Robin Lemmens, Arne Lindgren, James F. Meschia, Jonathan Rosand, Pankaj Sharma, Tatjana Rundek, Ralph L. Sacco, Reinhold Schmidt, Agnieszka Slowik, Vincent Thijs, Daniel Woo, Bradford B. Worrall, Braxton Mitchell, Ona Wu, Natalia Sana Rost, Steven J. Kittner 2:48 p.m. S60.010 The Endocannabinoid 2-arachidonoylglycerol (2-AG) Is Elevated In Acute Ischemic Stroke–Marina Buciuc, Vlad C Vasile, Gian Marco Conte, Eugene L. Scharf

S61 Neurocritical Care: Cerebrovascular Disease

AAN.com/view/20AM 115

Your Annual Meeting in One Touch Download the easy-to-use AAN Conferences mobile app for iOS® and Android® today.

Get the App and Simplify Your Annual Meeting Experience Add your interests to your profile to get tailored program recommendations Find your way in the Metro Toronto Convention Centre to programs and vendors with turn-by-turn directions View the most up-to-date information on speakers and talks Build your personalized program schedule or take advantage of our specially curated program tracks Discover Annual Meeting highlights and can’t-miss events Tap into information about Toronto, including the hotel map and local attractions Read what’s being said at the Annual Meeting and join the conversation using #AANAM on Facebook, Twitter, and Instagram Live stream select courses and sessions Access program materials, submit your program evaluations, and claim CME post-Annual Meeting Sponsored by:

POSTER SESSIONS This year, the Poster Hall is going all digital. Visit the Poster Hall multiple times per day to catch all the latest abstract presentations with an interactive, touchscreen experience. Posters on related topics are grouped together in “neighborhoods” (noted by the numbers in the map on the following page) for easy navigation. Authors will be available to present their research and answer questions, and be sure to check out the special Poster Session on neuroinflammation as part of the Friday Grand Finale Innovation Lunch.

Saturday, April 25 12:00 p.m.–1:00 p.m. P1 Poster Session 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118

Sunday, April 26 8:00 a.m.–9:00 a.m. P2 Poster Session 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124 12:00 p.m.–1:00 p.m. P3 Poster Session 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130 5:30 p.m.–6:30 p.m. P4 Poster Session 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136

Monday, April 27 8:00 a.m.–9:00 a.m. P5 Poster Session 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141 12:00 p.m.–1:00 p.m. P6 Poster Session 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 5:30 p.m.–6:30 p.m. P7 Poster Session 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153

Tuesday, April 28 8:00 a.m.–9:00 a.m. P8 Poster Session 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 12:00 p.m.–1:00 p.m. P9 Poster Session 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165 5:30 p.m.–6:30 p.m. P10 Poster Session 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171

Wednesday, April 29 8:00 a.m.–9:00 a.m. P11 Poster Session 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176 12:00 p.m.–1:00 p.m. P12 Poster Session 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182 5:30 p.m.–6:30 p.m. P13 Poster Session 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188

Thursday, April 30 8:00 a.m.–9:00 a.m. P14 Poster Session 14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194 12:00 p.m.–1:00 p.m. P15 Poster Session 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200 5:30 p.m.–6:30 p.m. P16 Poster Session 16 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206

Friday, May 1 11:30 a.m.–1:00 p.m. P17 Poster Session 17: Neuroinflammation. . . . . . . . . . . . . . . . . . . . . . 211

AAN.com/view/20AM 117

POSTER SESSION 1

CME

0 Saturday, April 25

12:00 p.m.–1:00 p.m.

Saturday, April 25

POSTER SESSIONS

Poster Session 1 1. Multiple Sclerosis: Neuroimaging 1: 1-001 to 1-022 2. Autoimmune Neurology 1: 2-001 to 2-011 3. Surgical Therapies in Movement Disorders 1: 3-001 to 3-008 Parkinson’s Disease: Exercise, Mental Health, and Social Determinants 1: 3-009 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Surgery and Co-morbidities 1: 4-001 to 4-011 5. General Neurology: Clinical Case Reports 1: 5-001 to 5-013 6. Headache: Therapeutics 1: 6-001 to 6-013 7. Neuromuscular and Clinical Neurophysiology (EMG): Imaging, Neurophysiology, and Outcome Measures 1: 7-001 to 7-014 8. Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 1: 8-001 to 8-009 9. Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 1: 9-001 to 9-021 10. Basic Science and Clinical Neuro-oncology 1: 10-001 to 10-015 11. Sleep Medicine: Covering New Grounds 1: 11-001 to 11-012

Multiple Sclerosis: Neuroimaging 1

P1.1-001 Reappraisal of Old Assumptions: Patient-Reported Memory (But Not Objective Memory) is Linked to Hippocampal Volume in Early Multiple Sclerosis–Lisa Glukhovsky, Rachel Brandstadter, Victoria Leavitt, Stephen Krieger, Korhan Buyukturkoglu, Michelle Fabian, Ilana B. Katz Sand, Sylvia Klineova, Claire Riley, Fred D. Lublin, Aaron E. Miller, James F. Sumowski P1.1-002 T2 Lesion Burden Modifies The Association Between Serum Neurofilament And Clinical Outcomes In MS PATHS (Partners Advancing Technology And Health Solutions)–Kathryn Fitzgerald, Elias S. Sotirchos, Matthew Smith, Elizabeth Fisher, Carol Singh, Tatiana Plavina, James Rhys Williams, Carl DeMoor, Richard A. Rudick, Ellen M. Mowry, Peter A. Calabresi P1.1-003 Decreased Activation of Deep Grey Matter Structures in Patients with Multiple Sclerosis Without Cognitive Deficits–Martin Berghoff, Clara Haerig, Jens Sommer, Bertram Walter, Gebhard Sammer, Bianca Gunther

P1.1-004 Multi-center Characterization of Brain Atrophy and Lesion Accrual Rates in Pediatric Multiple Sclerosis Assessed on Clinicalroutine T2-FLAIR MRI Using the NeuroSTREAM and SCLV Techniques–Michael G. Dwyer, Niels Bergsland, Svetlana Eckert, Rebecca Campbell, Jesper Hagemeier, Dejan Jakimovski, Kresimir Dolic, Eugenija Maruþic, Tanuja Chitnis, Anat Achiron, Shay Menascu, Shmuel Miron, Bianca Weinstock-Guttman, Robert Zivadinov P1.1-005 Determining the Impact of Ocrelizumab on Chronic Active Lesions in Multiple Sclerosis Utilizing Quantitative Susceptibility Mapping–Neha Safi, Sneha Pandya, Thanh Nguyen, Weiyuan Huang, Ulrike Kaunzner, Nancy M. Nealon, Jai Perumal, Timothy K. Vartanian, Yi Wang, Susan Gauthier P1.1-006 3T vs. 7T MRI Scan Protocols to Assess Deep Grey Matter Lesions and Atrophy in Relapsing-remitting Multiple Sclerosis–Youmna Jalkh, Renxin Chu, Shahamat Tauhid, Brian Curran Healy, Howard L. Weiner, Rohit Bakshi, Jonathan D. Zurawski P1.1-007 Magnetic Resonance Imaging (MRI) Metrics in Routine

118 2020 AAN Annual Meeting

Clinical Practice: Proof of Concept in MS PATHS (Multiple Sclerosis Partners Advancing Technology for Health Solutions)–Elizabeth Fisher, Tobias Kober, Adrian Tsang, Ricardo Corredor-Jerez, Shirley Liao, Tammie Benzinger, Maria Laura Blefari, Peter A. Calabresi, Mario J. Fartaria, Carrie Michelle Hersh, Till Huelnhagen, Stephen Jones, Hagen H. Kitzler, Lauren B. Krupp, Nicholas Levitt, Yvonne W. Lui, Sara J. Makaretz, Robert T. Naismith, Kunio Nakamura, Daniel Ontaneda, Rodrigo Perea, Stephen M. Rao, Alex Rovira, Madalina Tivarus, James Rhys Williams, Richard A. Rudick P1.1-008 Clinical Disability Worsening Correlates Preferentially with Atrophy of Thalamic Subregions in Patients with Multiple Sclerosis–Kedar Mahajan, Kunio Nakamura, Daniel Ontaneda P1.1-009 Medulla Oblongata Atrophy in Early Stage Multiple Sclerosis–Laura Sander, Antal Horvath, Simon Pezold, Michael Amann, Simon Andermatt, Oezguer Yaldizli, Jens Wuerfel, Ludwig Kappos, Cristina Granziera, Claudio Gobbi, Jens Kuhle, Philippe Cattin, Regina Schlaeger P1.1-010 Hippocampal Regional Vulnerability to Damage Differs

Between MS and Neuromyelitis Optica–Laura Cacciaguerra, Gianna Carla Riccitelli, Marta Radaelli, Elisabetta Pagani, Massimo Filippi, Maria Assunta Rocca P1.1-011 Achieving Human Level Performance for Automatic Lesion Segmentation in Multiple Sclerosis with Deep Learning–Zhuang Song, David Clayton, Alex De Crespigny, Thomas Bengtsson, Richard Carano P1.1-012 Foveal Shape Differs Between Neuromyelitis Optica and Multiple Sclerosis Patients– Seyedamirhosein Motamedi, Frederike Oertel, Sunil Yadav, Ella Kadas, Klemens Ruprecht, Judith Bellmann-Strobl, Hanna Zimmermann, Friedemann Paul, Alexander U. Brandt P1.1-013 MRI-Based Clustering of Multiple Sclerosis Patients in the Perspective of Personalized Medicine–Raffaello Bonacchi, Alessandro Meani, Camilla Bassi, Elisabetta Pagani, Massimo Filippi, Maria Assunta Rocca P1.1-014 White Matter Tractometry Correlates with Fatigue Severity in Young Adults with Multiple Sclerosis–AnnMarie Beaudoin, Francois Rheault, Guillaume Theaud, Kevin Whittingstall, Albert Lamontagne, Maxime Descoteaux = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number With Active Systemic Lupus Erythematosus–David Gritsch, Amir Abdallah, Brian Chong, Marie Francisca Grill, Dean M. Wingerchuk

Autoimmune Neurology 1

Surgical Therapies in Movement Disorders 1

P1.3-008 Case Report: Deep Brain Stimulation targeting the Globus Pallidus internus for Parkinson’s disease and Tourette syndrome– Qiang Johnson Zhang, Teri R. Thomsen

2 3 3

P1.2-001 Mercuryinduced Neurotoxicity and Neuroinflammation: A Role for Heavy Metal Intoxication in the Pathogenesis of Autoimmune Diseases of the Nervous System– Ekta Gaurang Shah, Ian J. Butler, Pedro Mancias, Kelly Lauren Block, Carlos Alberto Perez P1.2-002 Case Report: The Use of Tocilizumab in Down Syndrome Disintegrative Disorder–Alexander Sandweiss, Eyal Muscal, Timothy E. Lotze P1.2-003 Effects of EphB4HAS on Human Microglial Cell Line–Sami Souayah, Hongxin Chen, Nizar Souayah P1.2-004 Stiff-Person Spectrum Disorders Can Be Highly Underdiagnosed in Russia: a Retrospective Analysis–Yury Seliverstov, Evgenya Melnik, Vera Fominykh, Anastasia Skalnaya, Lev Brylev P1.2-005 Susac Syndrome Revisited: A Novel Presentation– Zoya Zaeem, Gregg G. Blevins, Imran Jivraj, Wasif Hussain P1.2-006 Two Cases of Susac Syndrome Mimicking Multiple Sclerosis.–Shitiz K. Sriwastava, Melanie D. Ward, Kumar Rajamani P1.2-007 Hypothalamic Relapse in Neuromyelitis Optica–Mary Clare McKenna, David Bradley P1.2-008 Neuromyelitis Optica Spectrum Disorder Presenting as Symmetric, Bilateral Cranial Nerve Palsies–Alise Kathryn Carlson, Ahmad Mahadeen, Catherine Hassett, Andrew Blake Buletko P1.2-009 Pruritus as initial symptom of Neuromyelitis Optica Spectrum Disorder. A Peruvian case report–Andrea Rivera-Valdivia, Maria Meza-Vega, Darwin Segura Chavez, Sheila Castro Suarez P1.2-010 Paraneoplastic Parkinsonism-Dysautonomia Due To Anti-Hu Antibodies–Vito Antonio Gerardo Ricigliano, Barbara Fossati P1.2-011 Fulminant Transverse Myelitis and Reversible Cerebral Vasculopathy in an Aquaporin4-Antibody Positive Patient

P1.3-001 Blood-Brain Barrier Opening with Focused Ultrasound in Parkinson´s Disease Dementia: A Safety and Feasibility Study– Carmen Gasca-Salas, Beatriz Fernandez-Rodriguez, Jose A Pineda-Pardo, Rafael RodriguezRojas, Frida Hernandez-Fernandez, Ignacio Obeso, David Mata Marin, Pasqualina Guida, Marta del Alamo, Carlos Ordas Bandera, Itay Rachmilevitch, Jose A. Obeso P1.3-002 Outcomes of a Prospective, Multicenter, International Registry of Deep Brain Stimulation for Parkinson’s Disease–Guenther Deuschl, Roshini Jain, Heleen Scholtes, Alex Wang, Michael Barbe, Steffen Paschen, Andrea Kuehn, Jens Volkmann, Monica Pötter-Nerger, Jan Vesper P1.3-003 Patient-Selected Goal Achievement and Satisfaction After Bilateral STN-DBS in Parkinson’s Disease–Seon Kyung Nam, Dallah Yoo, Beomseok Jeon P1.3-004 Real-World Clinical Outcomes Using a Novel Directional Lead from a DBS Registry for Parkinson’s Disease– Guenther Deuschl, Roshini Jain, Heleen Scholtes, Alex Wang, Michael Barbe, Steffen Paschen, Andrea Kuehn, Jens Volkmann, Monica Pötter-Nerger, Jan Vesper P1.3-005 Neuro-Anatomical Volumetric Changes in Deep Brain Stimulation of Parkinson’s Disease Patients–Drew S. Kern, Daniel Uy, Remy Rhoades, Steven Ojemann, Aviva Abosch, John Thompson P1.3-006 Clinical Outcomes from Directional Deep Brain Stimulation in Parkinson’s Disease Patients: A Retrospective Analysis–Alina Shub, Yarema B Bezchlibnyk, Donald P. Smith, Teresita Malapira, Wai Wai Miller, Yangxin Huang, Stephen Aradi, Theresa A. Zesiewicz P1.3-007 Real-World Assessment of DBS Outcomes Using a 16-Contact Device Capable of Multiple Independent Current Control–Corneliu C. Luca, Jonathan Jagid, Francesca Macaluso, Roshini Jain

Parkinson’s Disease: Exercise, Mental Health, and Social Determinants 1

P1.3-009 High Mortality in Early Onset Parkinson`s Disease (EOPD) Patients–Eldbjorg Hustad, Tor age Myklebust, Jan O. Aasly P1.3-010 Impact of Race and Socioeconomic Status on the Utilization of Advanced Therapies in Parkinson’s Disease–Jennifer Smith, Yichao Yu, Guanhong Miao, Tanya Simuni P1.3-011 Anticholinergic Use in Parkinson’s Disease: Practice Patterns in Patients with Cognitive Impairment–Neil Kanta Shetty, Ornella Maria Dubaz, Yichao Yu, Hanzi Gao, Tanya Simuni P1.3-012 Assessing Knowledge and Awareness of Parkinson’s Disease through a Community Farmer’s Market–Lynda Nwabuobi, Elizabeth Delaney, Hiral Shah P1.3-013 Social Determinants of Health in African Americans with Parkinson’s DIsease–Meagan O. Bailey, Modupeola Arojojoye, Jessica Wilson, Sharlet Anderson P1.3-014 The Relationship between Serum Vitamin Levels and Dietary Vitamin Intakes in Parkinson’s Disease–Jenna Paseka, John M. Bertoni, Danish Bhatti, Lindsey Wess, Morgan Brummels, Corrine Hanson, Erin Smith P1.3-015 Carepartner Communication on Parkinson Disease Psychosis–Sneha Mantri, Emily Klawson, Steven M. Albert, Madeline Lepore, Catherine Kopil, Margaret Daeschler, Michelle Whitman, Eugenia Mamikonyan, Robyn Rapoport, Chelle Precht, Sarah Glancey, Steven Kahl, Connie C. Marras, Lana Chahine P1.3-016 Underserved Patient Access to Multidisciplinary Rehabilitation for Movement Disorders in a Single Tertiary Academic Referral Center.–Ka Loong Kelvin Au, Alaina Giacobbe, Emily Dinh, Oliver Nguyen, Kathryn P.L. Moore, Adolfo Ramirez Zamora, Michael S. Okun, Leonardo Brito De Almeida

AAN.com/view/20AM 119

Saturday, April 25

Transfer Ratios: A 2-Year Study–Maria Assunta Rocca, Paolo Preziosa, Loredana Storelli, Lucia Moiola, Mariaemma Rodegher, Giancarlo Comi, Massimo Filippi

POSTER SESSIONS

P1.1-015 Thalamus Atrophy is Not a Predictor of Cognitive Performance in Multiple Sclerosis Patients with Previous Optic Neuritis–Ana Margarida Novo, Claudia Lima, Otilia C d’Almeida, Ana Afonso, Maria Macário, Livia Diogo Sousa, Miguel CasteloBranco, Isabel Santana, Sonia Batista P1.1-016 MRI Features of Progressive Multifocal Leukoencephalopathy: Cortical Susceptibility Changes–Moein Amin, Robert J. Fox, Stephen Jones, Daniel Ontaneda P1.1-017 The Association Between MRI Brain Volumes and Computerized Cognitive Scores of People with Multiple Sclerosis–Daniel Golan, Jared Srinivasan, Myassar Zarif, Barbara Bumstead, Marijean Buhse, Lori Fafard, Jeffrey A. Wilken, Cynthia L. Sullivan, Timothy Fratto, Eline VanVlierberghe, Diana Sima, Wim Van Hecke, Mark Gudesblatt P1.1-018 Cortical and Deep Gray Matter Perfusion is Associated with Physical and Cognitive Performance in Multiple Sclerosis Patients–Dejan Jakimovski, Niels Bergsland, Michael G. Dwyer, John Traversone, Jesper Hagemeier, Deepa Ramasamy, Murali Ramanathan, Jens Kuhle, Bianca Weinstock-Guttman, Ralph H. B. Benedict, Robert Zivadinov P1.1-019 Quantitative MRI in Multiple Sclerosis Patients with Hypertension–Justin Abbatemarco, Kunio Nakamura, Scott Husak, Daniel Ontaneda, Robert A. Bermel, Devon Conway P1.1-020 Measurement of White Matter Atrophy in Multiple Sclerosis Using Diffusion Weighted Imaging–Loredana Storelli, Elisabetta Pagani, Paolo Preziosa, Federica Esposito, Laura Cacciaguerra, Massimo Filippi, Maria Assunta Rocca P1.1-021 Differences in Functional Connectivity Assessed by Graph Measures in Primary and Secondary Progressive Multiple Sclerosis Patients–Giulia Bommarito, Maria Giulia Preti, Maria Petracca, Amgad Droby, Mohamed-Mounir El Mendili, Matilde Inglese, Dimitri Van De Ville P1.1-022 Effects of Fingolimod and Natalizumab on Brain T1/ T2-Weighted and Magnetization

POSTER SESSION 1 P1.3-017 Mindfulness Training for People with Parkinson’s: Emotional Well Being, Social Support and Group Effect–Barbara Anne Pickut

Saturday, April 25

POSTER SESSIONS

Epilepsy/Clinical Neurophysiology (EEG): Surgery and Co-morbidities 1

P1.4-001 Withdrawal of Antiepileptic Drugs After Stereotactic Laser Amygdalohippocampotomy–Arjun Athreya, Jon T. Willie, Robert Gross, Rebecca E. Fasano, Ioannis Karakis P1.4-002 3D Printed Models of Brain and Intracranial Electrodes for Epilepsy Education and Surgical Planning–Pooneh Memar Ardestani, Kyle Gifford, Kristy Bogart, Shannon Walters, Michael Zeineh, Dominik Fleischmann, Babak Razavi P1.4-003 Aura Semiology as a Predictor of Outcomes Following Epilepsy Surgery–Christina Maria Boada, Scott Grossman, Patricia C. Dugan, Jacqueline French P1.4-004 Utility of MEG for Functional Language Mapping– Gabriel Biondo, Gamaleldin M. Osman, Travis Hamilton, Sarah Madani, Muhammad O. Salim Khan, Amanda Brown, Gregory L. Barkley, Jason Schwalb, Ellen Air, Susan M. Bowyer P1.4-005 Cognitive and Psychiatric Outcomes Following Epilepsy Surgery–Chang Brian Hoon Jung, Sumeet Vadera, Jack J. Lin, Mona Sazgar, Lilit Mnatsakanyan P1.4-006 Stereotactic Radiosurgery of Corpus Callosum in a Patient with Refractory Seizures: A Case Report–Bahareh Sianati, Arthur Alcantara Lima, James P. Valeriano P1.4-007 Case Series: Temporal Lobe Encephalocele (TE) in AdultOnset Drug Resistant Mesial Temporal Lobe Epilepsy (MTLE)– Joseph Francis Imbs, Mark Girgis, Andrea Abousamra, Christopher Murray Parres, Anant Krishnan, Karol Zakalik, Jason Schwalb, Andrew J. Zillgitt P1.4-008 Predicting Depression Following Temporal Lobe Epilepsy Surgery in Adults–Christine Marie Doherty, Amy Nowacki, Lara Jehi, Robyn Busch P1.4-009 Demographic and Neuropsychological Predictors of Declining Employment Following

CME

Standard Anterior Temporal Lobectomy for the Treatment of Focal Epilepsy–Patrick William Kerns, Kathryn Devlin, Anna Graefe, Maromi Nei, Ashwini Sharan, Mitra Dehghan Harati, Michael R. Sperling P1.4-010 Can We Accurately Lateralize the Epileptogenic Zone in Patients Who Have Seizure Clusters? A Study Using Stereoelectroencephalography (SEEG)–Miguel Arevalo Astrada, Ana Suller Marti, Rick McLachlan, David C. Diosy, Seyed M. Mirsattari, David Steven, Jorge G. Burneo P1.4-011 Stereo-EEG Seizure Localization in Patients with Medically Intractable Focal Epilepsy Associated with Schizencephaly–Irina Podkorytova, Bradley Lega, Ryan Hays, Mark A. Agostini, Sasha Alick, Rohit Das, Hina N. Dave, Marisara Dieppa, Kan Ding, Alexander G. Doyle, J. H. Harvey, Rodrigo Zepeda Garcia, Ghazala Perven General Neurology: Clinical Case Reports 1

P1.5-001 A Case of Non-alcoholic Wernicke’s Encephalopathy and Dry Beri-beri with GI Involvement Following a Period of Prolonged Gastrointestinal Illness–Christina Lineback, Nupur Brahmbhatt, Sabra M. Abbott P1.5-002 Wernicke-Korsakoff Syndrome And Catatonia: A Case Report–Caroline Bittar Braune, Osvaldo J M Nascimento, Gabriel R. Freitas, Marcia Cristina Antu Ribas, Thiago Rodrigues, Viviane Tavares Carvalho, Thiago Pinheiro, Arthur Ramalho Monfredinho, Ivan Abreu, Raisa Saron Wanderley Murari, Marcos Ravi Cerqueira Ferreira Figueiredo, Rodrigo Queiroz, Matheus Castro, Lucas De Almeida Peixoto P1.5-003 Imaging and Neuropsychological Findings in Chronic Wernicke-Korsakoff Syndrome with Isolated Involvement of the Periaqueductal Gray Matter–Meredith Wicklund P1.5-004 Reversible Lesion of the Splenium of the Corpus Callosum Associated with Postpartum Thiamine Deficiency–Rutvij J. Shah, Alan Little P1.5-005 Machiava Bignami: A Case of a 62 Year Old Woman with

120 2020 AAN Annual Meeting

0 Saturday, April 25 Malnutrition Who Presents with Altered Mental Status, Vision Loss with Acute Restricted Diffusion of the Splenium of the Corpus Callosum–Ephrem Teklemariam, Ryna Then P1.5-006 Tongue Fasciculations Presenting as an Early Clinical Sign of Cobalamin Deficiency–Anuradha Singh, Jane Shaji, Danielle Bazer, Agnes Kowalska P1.5-007 Thyrotoxic Hypokalemic Periodic Paralysis (TPP) - A hidden diagnosis–Hemani Ticku, Mhd. Omar Subei, Michael W. Devereaux P1.5-008 Thyrotoxicosis from Graves’ Disease Presenting with Ocular Myasthenia Gravis, Thymoma, and Demyelination– Brittany Marie Kasturiarachi, Julia Cook, Jordan Infield, Muhammad Fawad Ishfaq, Aneel Kumar P1.5-009 Grave’s Disease Mimicking a Structural Myelopathy–Andre Granger, Arielle Marisa Kurzweil P1.5-010 Hemichorea as the Presenting Symptom of Severe Hyperglycemia–Rena Sukhdeo, Hafiz Elahi, Aman Deep, Andrew Schroeder, Hafiz Elahi P1.5-011 Superficial Siderosis: A Case Of No Return–Jennifer Hung, Raymond CS Seet P1.5-012 An Unusual Presentation of Superficial Siderosis–Jinesh Shah, Yi Jing Zhao, Ling Ling Chan P1.5-013 Establishing Ammonia Levels in Acute Onset Encephalopathy May Provide Rapid Diagnosis of Treatable Causes– Karlo Toljan, Ahmad Mahadeen, Sumit Parikh Headache: Therapeutics 1

P1.6-001 Changes in Work Productivity and Interictal Burden: Results from a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Galcanezumab in Adults with Treatment-Resistant Migraine (CONQUER)–David Garcia-Azorin, Janet Ford, Dawn C. Buse, Austin L Hand, Linda Wietecha, Holland Detke P1.6-002 Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials–

12:00 p.m.–1:00 p.m. Jelena Pavlovic, David W. Dodick, Lawrence C. Newman, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charlie Conway, Christopher Jensen, Beth Morris, Vlad Coric, Robert Croop P1.6-003 Rimegepant 75 mg Is More Effective for Migraine Than Nonsteroidal Anti-inflammatory Drugs: Post Hoc Analysis of Data From 2 Phase 3 Trials–Ira M. Turner, Dawn C. Buse, Andrew M. Blumenfeld, Elyse Stock, David Stock, Charlie Conway, Christopher Jensen, Beth Morris, Vlad Coric, Robert Croop P1.6-004 The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine–Piero Barbanti, Cinzia Aurilia, Sabina Cevoli, Bruno Colombo, Fabio Frediani, Francesco Bono, Licia Grazzi, Domenico D’Amico, Antonio Salerno, Bruno Mercuri, Antonio Carnevale, Catello Vollono, Gabriella Egeo, Luisa Fofi, Claudia Altamura, Carmen Costa, Nicoletta Brunelli, Adriana Fallacara, Giulia Pierangeli, Valentina Favoni, Roberta Messina, Massimo Filippi, Paola Di Fiore, Domenico Santangelo, Fabrizio Vernieri P1.6-005 Early Onset of Efficacy With Fremanezumab in Patients With Medication Overuse and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Double-blind FOCUS Study–Zaza Katsarava, Martina Machkova, Verena Ramirez Campos, Joshua M. Cohen, Lindsay Janka, Egilius L H Spierings P1.6-006 Results of a Phase 1, Open-label, Single-dose, Parallelgroup Study of Rimegepant 75 mg in Subjects with Hepatic Impairment–Andrea Ivans, Joseph Stringfellow, Vlad Coric, Robert Croop P1.6-007 Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201)–Christopher Jensen, Robert Croop, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charlie Conway, Meghan Lovegren, Vlad Coric, Gilbert J. L’Italien = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

P1.7-001 Evidence that Advanced Motor Cortex Pathology in Amyotrophic Lateral Sclerosis Causes Whole Brain Systemic Effects–Anson Wang, Sumit Niogi P1.7-002 A Trial of Blood-Brain Barrier Opening in ALS using MR-Guided Focused Ultrasound– Agessandro Abrahao, Ying Meng, Meheleth Llinas, Yuexi Huang, Clement Hamani, Todd Mainprize, Isabelle Aubert, Chinthaka Heyn, Sandra E. Black, Kullervo Hynynen, Nir Lipsman, Lorne H. Zinman P1.7-003 Brain Metabolic Correlates of Apathy in an ALS Cohort: A 18F-FDG PET Study– Adriano Chio, Andrea Calvo, Cristina Moglia, Marco Pagani, Veria Vacchiano, Rosario Vasta, Umberto Manera, Vincenzo Arena, Antonio Canosa P1.7-004 Observing Patterns in MRI with QSM in Patients with SOD1 Genetic ALS–Robin Warner, Apostolos Tsouris, Andrew Schweitzer, Mona Shahbazi, Dale J. Lange P1.7-005 Quantifying Cerebral Degeneration in Amyotrophic Lateral Sclerosis Using Texture Analysis of Multimodal MRI–Ekhlas Assaedi, Pedram Parnianpour, Andrew Wu, Muhammad Khan, Annie Dionne, Angela L. Genge, Lawrence Korngut, Lorne H. Zinman, Sanjay Kalra P1.7-006 Impedance Pharyngography to Evaluate Swallowing in Patients with Amyotrophic Lateral Sclerosis– Hilda Victoria Gutierrez, Fu Zhang, Akashleena Mallick, Badria Munir, Sarah MacKenzie, Hawa Yusuf, Seward B. Rutkove P1.7-007 Electrical Impedance Tomography as a Quantitative Measure of Pulmonary Function in ALS Patients–Badria Munir, Ethan K Murphy, Akashleena Mallick, Hilda Victoria Gutierrez, Fu Zhang, Christy Smith, Sean Levy, Courtney E. McIlduff, Hawa Yusuf, Ryan J Halter, Seward B. Rutkove P1.7-008 EEG ß-power and ß-synchrony in the Sensorimotor Network as a Potential Biomarker for Disease Severity and

Progression of Motor Symptoms in ALS–Antonio Fasano, Stefan Dukic, Amina Coffey, Teresa Buxó, Roisin Mc Mackin, Rangariroyashe Chipika, Mark Heverin, Peter Bede, Muthuraman Muthuraman, Madeleine Lowery, Richard Carson, Bahman Nasseroleslami, Orla Hardiman P1.7-009 Failure of Transcranial Magnetic Stimulation of the Primary Motor Cortex to Induce a Motor evoked Potential Response in Primary Lateral Sclerosis–Jeffrey Barrett Joseph Schachter, Adel Marei, Mona Shahbazi, Shara Holzberg, Sabrina Paganoni, James P. Wymer, Dale J. Lange P1.7-010 The Voice of Silence - The Impact of Augmentative / Alternative Communication on the Quality of Life of Patients Diagnosed with Amyotrophic Lateral Sclerosis–ANA KUSEL P1.7-011 A Clinical Bulbar Assessment Scale for ALS (C-BAS)–Gary L. Pattee, Elizabeth H. Burton, Laura Ball P1.7-012 State of the Healthrelated Quality of Life Evidence in Amyotrophic Lateral Sclerosis (ALS): A Systematic Literature Review–Eleanor Paul, Johnna Perdrizet, Stephen Apple, Terry D. Heiman-Patterson, Tomas H. Holmlund, Markeya Martin, Lauren Webb, Kabirraaj Toor P1.7-013 Development of a Patient-Centered Tool for the Assessment of Muscle Cramps– Hans D. Katzberg, Meg Mendoza, Evelyn Sarpong, Eduardo Ng, Vera Bril, Carolina Barnett Tapia P1.7-014 Electrodiagnostic Correlations with Gene Mutations in Congenital Disorders of Glycosylation (CDG): An Observational Study–Noushin Jazebi, Lynne Wolfe, William Gahl, David Adams, Tanya Jarca Lehky Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 1

P1.8-001 Disentangling the Neuroanatomical Basis of Olfactory Dysfunction in the General Population–Ran Lu, N. Ahmad Aziz, Martin Reuter, Tony Stoecker, Monique M B Breteler P1.8-002 Incidence of Traumatic Brain Injury and Fall Among

Patients with Alzheimer’s Disease and Impact on Mortality–Zabreen Tahir, Ali Al Jarrah, Ayaz M. Khawaja, Saef Izzy P1.8-003 Alzheimer’s Disease as a Disorder of Tryptophan Metabolism–Donald F. Weaver, Mayuri Gupta, Autumn Meek, Yanfei Wang, Fan Wu P1.8-004 Apathy is Associated with Risk of Incident Dementia Among Community-Dwelling Older Adults–Meredith Bock, Feng Xia, Tina Hoang, Kristine Yaffe P1.8-005 Association of Nighttime Behaviours with Rate of Cognitive Decline in Pathologically Confirmed AD Patients: Role of Gender and Comorbidities–Yunxi Wang, Corinne Fischer, Tom Schweizer, David G. Munoz P1.8-006 Real World Evidence For Cognitive Impairment in the Long Term Care Insurance Population– Anitha Rao, Karuna Relwani, Neelum T. Aggarwal P1.8-007 Impact of a National Dementia Research Program – the CCNA (Canadian Consortium on Neurodegeneration in Aging)– Howard M. Chertkow, Nathalie Belanger, Jennifer Bethell, Sandra E. Black, Michael Borrie, Roger Dixon, Gillian Einstein, Howard Feldman, Serge G. Gauthier, David B. Hogan, Mario Masellis, Colleen Maxwell, Katherine McGilton, Manuel Montero-Odasso, Natalie Phillips, Randi Pilon, Julie Robillard, Kenneth Rockwood, Jennifer Walker, Victor Whitehead P1.8-008 Prevalence of Cerebral Microbleeds in Patients with Idiopathic Normal Pressure Hydrocephalus and their Impact on Post-Shunt Outcome–Lukas Sveikata, Alma Lingenberg, Tiberiu Laticevschi, Anand Viswanathan, Gilles Allali P1.8-009 Oldest Olds in Latin America: A Naturalistic Analysis Over Normal Aging and Superaging–Ismael Calandri, Lucia Crivelli, Maria Eugenia Martin, Noelia Egido, Ricardo F. Allegri

AAN.com/view/20AM 121

Saturday, April 25

Neuromuscular and Clinical Neurophysiology (EMG): Imaging, Neurophysiology, and Outcome Measures 1

POSTER SESSIONS

P1.6-008 A Randomized, Placebo-Controlled Study of Galcanezumab in Patients with Treatment-Resistant Migraine: Double-Blind Results from the CONQUER Study–W. M. Mulleners, Byung-kun Kim, Miguel JA Lainez, Michel Lanteri-Minet, Sheena K Aurora, Russell Nichols, Shufang Wang, Antje Tockhorn-Heidenreich, Holland Detke P1.6-009 Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study–Andrew M. Blumenfeld, Lei Luo, Larisa Yedigarova, Richard B. Lipton P1.6-010 Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP-targeted Monoclonal Antibodies Examining Monthly Migraine Days in the Treatment of Migraine–Evan Popoff, Karissa Johnston, Robert Croop, Alexandra Thiry, Linda Harris, Vladimir Coric, Gilbert J. L’Italien P1.6-011 Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable antiCGRP Monoclonal Antibodies (mAb) Examining Health-related Quality of Life (HRQoL).–Evan Popoff, Karissa Johnston, Linda Harris, Alexandra Thiry, Robert Croop, Vladimir Coric, Gilbert J. L’Italien P1.6-012 Rimegepant 75 mg Exposure, Safety, and Tolerability are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, SingleDose Study–Andrea Ivans, Joseph Stringfellow, Vlad Coric, Robert Croop P1.6-013 Safety and Tolerability of Fremanezumab in Patients With Episodic and Chronic Migraine: a Pooled Analysis of Phase 3 Studies–Bert B. Vargas, Xiaoping Ning, Yoel Kessler, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Peter J. McAllister

POSTER SESSION 1 Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 1

Saturday, April 25

POSTER SESSIONS

P1.9-001 Investigation of S-Nitrosoglutathione in Stroke: A Systematic Review and MetaAnalysis of Literature in Pre-clinical and Clinical Research–Shimeng Liu, Haiqing Zheng, Wengui Yu, Viswanathan Ramakrishnan, Shreyansh Shah, Louis Fernando Gonzalez, Inderjit Singh, Carmelo Graffagnino, Wayne W. Feng P1.9-002 Mesenchymal Stem Cells (MSCs) Protect Hypoxic Neuronal Cells by Mitochondrial Transfer–Deepaneeta Sarmah, Anne-Marie Rodriguez, Kiran Kalia, Dileep R. Yavagal, Pallab Bhattacharya P1.9-003 A Therapeutic Approach Using Peripheral Blood Mononuclear Cells Preconditioned by Oxygen-glucose Deprivation in Ischemic Rats–Masato Kanazawa, Masahiro Hatakeyama, Tetsuya Takahashi, Kaoru Omae, Yasuko Kimura, Tetsuya Takahashi, Osamu Onodera, Masanori Fukushima, Takayoshi Shimohata P1.9-004 Biomarkers of Coagulation and Hemostatic Activation in the Post-Acute Period Effectively Rule Out Hypercoagulable States in Patients with Embolic Stroke of Undetermined Source–Michael Liu, Srikant Rangaraju, Deandrea Ellis, Alexander Duncan, Samir Belagaje, Trina Belair, Laura Bamford, Fadi B. Nahab P1.9-005 Hyperviscosity in Acute Ischemic Stroke with Large Artery Steno-occlusive Disease–Si Baek Lee, Sung-Hoon Kim, Dong-Woo Ryu, Yun Jeong Hong, Jung-Wook Park P1.9-006 Role of Blood Based Biomarkers for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: Multi-Centric Prospective Cohort Study– Kameshwar Prasad, Amit Kumar, Bhavna Kaul, Kuljeet Singh Anand, Sankar Prasad Gorthi, Surekha Dabla, Chandrashekhar Agrawal, Ram Sagar P1.9-007 Systemic Inflammation Indexes Associated with the Severity and Functional Prognosis of Ischemic Stroke–Luis Fernández, Alejandro Gonzalez Aquines, Juan Fernando Gongora Rivera

CME

P1.9-008 Human plasma proteomics for biomarker discovery for ischemic stroke and TIA–Supriya Ramesha, Michael Liu, Briana Richardson, Michael R. Frankel, Srikant Rangaraju P1.9-009 Border-zone Infarcts Predict Early Recurrence in Patients with Large Artery Atherosclerotic Subtype Despite Medical Treatment–Alexandra Kvernland, Shyam Prabhakaran, Pooja Khatri, Adam De Havenon, Sharon Yeatts, Erica Scher, Jose L. Torres, Koto Ishida, Denis Vezina, Aaron S. Lord, David S. Liebeskind, Shadi Yaghi P1.9-010 Lower Coated-Platelet Levels, RANTES and Fibrinogen Correlate with the Number of Cerebral Microbleeds in Carotid Stenosis–Sergio Ramirez-Salazar, Angelia Kirkpatrick, Andrea Vincent, Bappaditya Ray, Anna Csiszar, Zoltan Ungvari, Andriy Yabluchanskiy, George Dale, Calin I. Prodan P1.9-011 Increased Total Bilirubin Levels are Associated with Hemorrhagic Transformation in Patients with Acute Ischemic Stroke–Gui-Qian Huang, Jin-Cai He P1.9-012 Association of Admission Serum Low-densityLipoprotein With Stroke Etiology Of Large-Vessel-Disease And Functional Outcome At Discharge– Taha Nisar P1.9-013 Role of Glial Fibrillary Acidic Protein as a Biomarker in Differentiating Intracerebral Hemorrhage From Ischemic Stroke And Stroke Mimics: A MetaAnalysis–Amit Kumar, Shubham Misra, Kameshwar Prasad P1.9-014 Neutrophil-ToLymphocyte Ratio Predicts Large Vessel Occlusion Stroke–Shashvat Desai, Ashutosh P. Jadhav P1.9-015 Cavernous Malformations Secondary to PDCD10 Gene Mutation–Marion Oliver, Samantha R. Cencer, Angelique Maria Manasseh, Muhib Khan P1.9-016 Clinical Features and Genetic Testing in Multivessel Cervical Artery Dissection–Collin Culbertson, Neil E. Schwartz, Sarah Lee P1.9-017 Intravenous Dimethyl Fumarate Promotes Hemoglobin Clearance in a Preclinical Hemorrhagic Stroke Model–Sharon

122 2020 AAN Annual Meeting

0 Saturday, April 25 O’Neill, YeQing Pi, Kyle Ferber, Jen Tavares, Balakrishnan Ganapathy, Stanley Goldstein, Ashley Nelson, Ankur Thomas, Bin Wang, Xi Zhan, Fengmei Zheng, Moore Arnold, Linda Burkly, Michael Rooney, Jacob S. Elkins P1.9-018 Role of Cytokines in Acute Ischemic Stroke Patients: Preliminary Analysis of a Prospective Database–Sajid Suriya, Mudassir Farooqui, Asad Ikram, Dania Qaryouti, Syed Quadri, Santiago Ortega Gutierrez, Fares Qeadan, Atif Zafar P1.9-019 Predict the Ischemic Volumes of Acute Stroke by Using Visual Assessment on CT Perfusion Source Imaging–Wenjie Cao, Wenjie Cao, Lumeng Yang, Qiang Dong P1.9-020 White Matter Hyperintensity Pattern Predicts Stroke Etiology–Piotr Bzdyra, Bichum Ouyang, Laurel Jean Cherian, Rima Dafer, Nicholas D. Osteraas, James Conners, Sarah Song, Alejandro Vargas P1.9-021 Cerebral Microbleeds And White Matter Hyperintensities Are Not Associated With Increased Risk of Hemorrhagic Transformation In Acute Ischemic Stroke Without Intravenous Thrombolysis–Amreen Farooqui, Abdullah Bin Zahid, Nandakumar Nagaraja Basic Science and Clinical Neuro-oncology 1

P1.10-001 Large Retrospective Institutional Review Identifies Novel Integrated Imaging and Clinical Markers as Early Independent Negative Prognostic Indicators of Glioblastoma Progression and Survival: A Proposed Supplement to RANO–Na Tosha N. Gatson, Shane Bross, Vinaykumar Puduvalli, Anand Mahadevan, Michel Lacroix, Syed Kazmi, Gino Mongelluzzo P1.10-002 Outcomes and Correlations Between Legacy Quality of Life Measures (EORTC-C30/EORTC-BN20) and the Electronic Quality of Life Measuring System (NIH PROMIS) in Glioblastoma Patients–Tobias Walbert, Lonni Schultz, Aarushi Suneja P1.10-003 Underrepresentation of Women and Older Patients in U.S. Glioblastoma Clinical Trials–Liu

12:00 p.m.–1:00 p.m. Yang, Andrea C. Wasilewski, Nimish A. Mohile P1.10-004 The Effects of Dexamethasone on Mitogen Activated Protein Kinase-14 Signaling in Diffuse Intrinsic Pontine Glioma (DIPG) Cells–Collin Vinson, Pinki Chowdhury, Christopher Waker, Chanel Keoni, Kallol Kumar Set, Rob Lober P1.10-005 Calebin-A Induced Death of Malignant Peripheral Nerve Sheath Tumor Cells by Inactivation of Histone Acetyltransferase–Ming-Jen Lee, Yi-Jane Tsai, May-Yao Lin, Huey-Ling You, Nagabhushanam Kalyanam, Chi-Tang Ho, Min-Hsiung Pan P1.10-006 Efficacy and Toxicity of Radiation Regimens With or Without Temozolomide for CNS Lymphoma–Katherine Elizabeth Selwa, Anna Laucis, Yilun Sun, Theodore Lawrence, Kyle Cuneo, Michelle Kim, Daniel Wahl, Yoshie A. Umemura, Larry Junck P1.10-007 Use Of Non-Ablative Dose Of Radiation To Enhance Delivery Of Unmodified Morpholino Oligonucleotides In A Brain Tumor Model To Silence MGMT And Enhance The Efficacy Of ChemoRadiation–Prakash Ambady, Jeffrey Wu, Joshua Walker, Cymon Kersch, DreeAnna Morris, Jessica Bills, Samantha Holland, MIchael Pagel, Leslie Muldoon, Edward A. Neuwelt P1.10-008 Editing of IDH1 R132H Mutation in Human Induced Pluripotent Stem Cells to Investigate Tumor Genesis in Glioma–Alexander Kopp, Matthias Preussler, Susan Richter, Michael Heide, Anne Scholer, Lara Marrone, David Capper, Evelin Schrock, Barbara Klink P1.10-009 Estrogen Hormone Replacement Therapy in Incidental Meningioma - A Growth Rate Analysis–Ryan T. Merrell, Laura Castillo-Saavedra, Carlen Amy Yuen, Andrew Wilmington, Mary Tilley Jenkins Vogel, Matthew Walker, David Olayinka Kamson P1.10-010 Longitudinal Perception of Prognosis of Patients with High Grade Glioma Compared to their Caregivers and Clinicians–Akanksha Sharma, Eric Wolfe, Celina Barrera, Samantha Williamson, Hannah Farfour, Maciej M. Mrugala, Mark Edwin, Jeff Sloan, Alyx B. Porter = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Sleep Medicine: Covering New Grounds 1

Saturday, April 25

P1.11-001 Pediatric Upper Airway Resistance Syndrome: A Usually Missed Suspect–Victor Daescu, Mohsin Maqbool P1.11-002 Sleep Disordered Breathing in Pediatric Multiple Sclerosis–Michelle Jasmin Jaeggi, Stephanie Grover, Tara Feltham, Tara Berenbaum, Samantha Stephens, Shelly K. Weiss, E. Ann Yeh P1.11-003 Sleep Disturbances and Idiopathic Intracranial Hypertension in Men–Arina Bingeliene, Trevor Jairam, Arun Sundaram, Mark Boulos P1.11-004 Comorbidities of Patients with Restless Legs Syndrome–Kevin Senanayake, Daniel Krashin, Natalia Murinova P1.11-005 Prevalence of Restless Leg Syndrome in Skin Biopsy Proven Small Fiber Neuropathy– Urvi G. Desai, Benjamin R. Brooks P1.11-006 Sleep Characteristics in Active Duty Service Members with PTSD: Novel Findings and

Implications–Brent Jacobus, Adam M. Willis, Vincent Mysliwiec, Matthew S. Brock P1.11-007 Diffusion Tensor Imaging Evidence of Hypothalamic Injury in Traumatic Brain Injury Warfighters with Sleep Dysfunction–Brian Gerstenslager, Ping Hong Yeh, John Ollinger, Kimbra L. Kenney, John Kent Werner P1.11-008 Traumatic Brain Injury Warfighters with Poor Sleep have Increased Plasma Biomarkers of Neurodegeneration–John Kent Werner, Pashtun-Poh Shahim, Jessica Gill, Risa N. Richardson, Kimbra L. Kenney P1.11-009 Is it Time to Pay Attention to Circulating MicroRNAs as a Diagnostic Biomarker in REM Behavior Disorder?–Arturo Garay, Stella Valiensi, Verónica Barrachina, Daniela Giardino, Verónica Barrachina, Arturo Garay P1.11-010 Sleep Problems and Risk of All-cause Cognitive Decline or Dementia: An Updated Systematic Review and Metaanalysis–Wei Xu P1.11-011 Feasibility of a Home Sleep Apnea Test in a Cognitively Impaired Population–David Robert Colelli, Sandra E. Black, Mario Masellis, Andrew Lim, Mark Boulos P1.11-012 The Relationship between Sleep Disorders and Nonarteritic Anterior Ischemic Optic Neuropathy–Trevor Jairam, Arina Bingeliene, Arun Sundaram, Mark Boulos

POSTER SESSIONS

P1.10-011 Hormone Levels Are Associated with Altered Brain Structure and Functional Connectivity in Prolactinomas– Shun Yao, Wenli Chen, Haijun Wang P1.10-012 Caregiver Perceptions of End of Life Care in Patients with High Grade Glioma–John Thomas Fortunato, Lonni Schultz, Joel N. Phillips, Tobias Walbert P1.10-013 Finite Element Analysis Modeling of TTFields in Brain Metastasis According to Various Types of Cerebral Edema–Sindhu Reddy Pisati, Pyay San, Edwin Lok, Eric Tai-Lee Wong P1.10-014 Does the Location Matter? Characterization of the Anatomic Locations, Molecular Profiles, and Clinical Features of Gliomas–Christopher Patrick Mackintosh, Richard Butterfield, Nan Zhang, Julia Lorence, Bernard Bendok, Richard Zimmerman, Kristin Swanson, Alyx B. Porter, Maciej M. Mrugala P1.10-015 Trends in Radiotherapeutic Management and Outcomes in Esophageal Brain Metastases–Aaron Ravelo, Stephen Abel, Thomas F. Scott, Alexander Yu, Rodney E Wegner

AAN.com/view/20AM 123

POSTER SESSION 2

CME

0 Sunday, April 26

8:00 a.m.–9:00 a.m.

Sunday, April 26

POSTER SESSIONS

Poster Session 2 1. Multiple Sclerosis: Neuroimaging 2: 1-001 to 1-022 2. Autoimmune Neurology 2: 2-001 to 2-011 3. Surgical Therapies in Movement Disorders 2: 3-001 to 3-007 Parkinson’s Disease: Exercise, Mental Health, and Social Determinants 2: 3-008 to 3-014 Parkinson’s Disease Genetics and Imaging 1: 3-015 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Surgery and Co-morbidities 2: 4-001 to 4-011 5. General Neurology: Clinical Case Reports 2: 5-001 to 5-013 6. Headache: Therapeutics 2: 6-001 to 6-011 7. Neuromuscular and Clinical Neurophysiology (EMG): Imaging, Neurophysiology, and Outcome Measures 2: 7-001 to 7-014 8. Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 2: 8-001 to 8-010 9. Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 2: 9-001 to 9-020 10. Basic Science and Clinical Neuro-oncology 2: 10-001 to 10-014 11. Sleep Medicine: Covering New Grounds 2: 11-001 to 11-006 Sleep Medicine: Focus on Therapies 1: 11-007 to 11-013

Multiple Sclerosis: Neuroimaging 2

P2.1-001 Characterization of Whole Brain Axonal Pathology in Multiple Sclerosis Using HighGradient Diffusion MRI–Susie Y. Huang, Qiuyun Fan, Natalya Machado, Andrew Russo, Chanon Ngamsombat, Aapo Nummenmaa, Thomas Whitzel, Maya Polackal, Eric Klawiter P2.1-002 Identifying The Role Of A Hippocampal-thalamic Memory Network In Ms Using A Machine Learning Approach–Korhan Buyukturkoglu, Ceren Tozlu, Srinidhi Bharadwaj, Amy Kuceyeski, James F. Sumowski, Victoria Leavitt P2.1-003 Cognitive Impairment in Multiple Sclerosis: A Multiparametric Structural and Functional MRI Study–Carmen Vizzino, Gianna Carla Riccitelli, Elisabetta Pagani, Paola Valsasina, Paolo Preziosa, Massimo Filippi, Maria Assunta Rocca P2.1-004 Evaluating the Performance of an AtlasFree Automated Method of Brain Classification for Lesion Segmentation in Progressive Multifocal Leukoencephalopathy– Hadar Kolb, Daniel Reich, Irene CM Cortese, Govind Nair

P2.1-005 Characterizing Dynamic Functional Connectivity in the Main Clinical Phenotypes of Multiple Sclerosis–Milagros Hidalgo de la Cruz, Paola Valsasina, Francesca Sangalli, Federica Esposito, Massimo Filippi, Maria Assunta Rocca P2.1-006 Diffusion Tensor Imaging of the Nucleus Basalis of Meynert Reveals Associations with Cognitive State in Patients with Multiple Sclerosis–Niels Bergsland, Ralph H. B. Benedict, Michael G. Dwyer, Tom Fuchs, Dejan Jakimovski, Bianca WeinstockGuttman, Robert Zivadinov P2.1-007 MS Subjects with Vascular Disease Risk Factors (VDRF) Show Persistent Dysmetabolism in Brain Phosphate Metabolites and Brain Volume Loss–Vijayshree Yadav, Michael A. Lane, Allison Fryman, Frank Bittner, Valerie Anderson, Manoj K. Sammi, William Rooney P2.1-008 Long-standing Multiple Sclerosis Neurodegeneration: Volumetric MRI Comparison to Parkinson’s Disease, Mild Cognitive Impairment, Alzheimer’s Disease and Elderly Healthy Controls–Dejan Jakimovski, Niels Bergsland, Michael G. Dwyer, Jesper

124 2020 AAN Annual Meeting

Hagemeier, Deepa Ramasamy, Kinga Szigeti, Thomas J. Guttuso, David G. Lichter, David Hojnacki, Bianca Weinstock-Guttman, Ralph H. B. Benedict, Robert Zivadinov P2.1-009 Multiplex Imaging of Immune Cells in the Multiple Sclerosis Brain–Valeria Ramaglia, Salma Sheikh-Mohamed, Karen Legg, Calvin Park, Olga Rojas, Stephanie Zandee, Fred Fu, Olga Ornatsky, Eric Swanson, David Pitt, Alexandre Prat, Trevor McKee, Jennifer L. Gommerman P2.1-010 Systematic Assessment of Common Error Modes in Using FIRST for MRI-based Thalamic Volumetry in People with Multiple Sclerosis–Cassondra Lyman, Hannah Ferrari, Tom Fuchs, Daniel Brior, Niels Bergsland, Dejan Jakimovski, Bianca WeinstockGuttman, Robert Zivadinov, Michael G. Dwyer P2.1-011 Alteration of Restingstate Functional Connectivity in Response to Structural Disruption Differs Between Well-Established Functional Networks in Multiple Sclerosis–Alexander Bartnik, Tom Fuchs, Kira Ahton, Xian Li, Matthew Richard Mallory, Devon Oship, Zachary Weinstock, Niels Bergsland, Deepa Ramasamy,

Bianca Weinstock-Guttman, Ralph H. B. Benedict, Robert Zivadinov, Michael G. Dwyer P2.1-012 Higher HDL and ApoA Apolipoproteins are Associated with Better Cerebral Perfusion in Multiple Sclerosis Patients–Dejan Jakimovski, Murali Ramanathan, Michael G. Dwyer, Niels Bergsland, Deepa Ramasamy, Richard Browne, Bianca Weinstock-Guttman, Robert Zivadinov P2.1-013 Effect of AntimuCD52 antibody on Brain and Spinal Cord Imaging Markers of Neurodegeneration, Microglia, and Macrophage Activation in the Theiler’s Murine Encephalomyelitis Virus Model of Chronic Demyelination–Robert Zivadinov, Ferdinand Schweser, Michael G. Dwyer, Suyog U. Pol P2.1-014 Longitudinal Progression of Cortical Thinning Differs Across MS Phenotypes and is Clinically Relevant: A Multicentre Study–Milagros Hidalgo de la Cruz, Maria Assunta Rocca, Paola Valsasina, Claudio Gobbi, Antonio Gallo, Chiara Zecca, Alvino Bisecco, Massimo Filippi

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

P2.2-001 Functional Role of Antibodies to Herpes Simplex Virus (HSV1) in Infection of the Nervous System and Autoimmunity– Marianna Spatola, Thais Armangue, Josep O. Dalmau, Galit Alter P2.2-002 Clinical Characteristics of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy in Japan– Akio Kimura, Nobuaki Yoshikura, Yuichi Hayashi, Takayoshi Shimohata P2.2-003 Status Epilepticus Suspected Autoimmune: Antibody Frequency and Main Clinical Features–Hiroki Suga, Takahiro Iizuka, Juntaro Kaneko, Atsuko Yanagida, Atsushi Kaneko, Eiji Kitamura, Naomi Kanazawa, Tsugio Akutsu, Josep O. Dalmau, Kazutoshi Nishiyama P2.2-004 Evaluation of the Prevalence of Headache and Pain of Unknown Cause in Patients with Common Variable Immunodeficiency (CVID) Evaluate the Prevalence of Headache and Pain in Patients with Common Variable Immunodeficiency (CVID)–Lawanda Esquibel, Bruno Ivo De Almeida, Leah Millsap, Jonathan Ross Galli, Adi Gundlapalli, M. Mateo Paz Soldan, Julia Klein, Melissa M. Cortez, John W. Rose, John E. Greenlee, Harry Haydon Hill, Ka-Ho Wong, Stacey Clardy P2.2-005 A Retrospective, Crosssectional Study Evaluating Plasma Neurofilament Light Levels in Autoimmune Encephalitis–Amanda Lee Piquet, Enrique Alvarez, Jeffrey L. Bennett, Courtney Knapp, Stefan Sillau, Kavita Nair, Timothy L. Vollmer P2.2-006 Clinical Features, Immunotherapy, and Outcome in Patients with Cryptogenic NORSE– Takahiro Iizuka, Atsuko Yanagida, Ryoko Iwase, Hiroki Suga, Juntaro Kaneko, Naomi Kanazawa, Yutaka Nonoda, Kenzo Koizumi, Takashi Nakamura, Hiroki Ueno, Takeo Shishido, Masamune Sakamoto, Keisuke Imai, Yuka Terasawa, Yuya Itagaki, Kasumi Hattori, Mizuki Ayano, Yasushi Hosoi, Hiroya Ohara, Kazutoshi Nishiyama P2.2-007 Longer Term Seizure Outcomes in a Retrospective Autoimmune Epilepsy Cohort–Sahar Noorani, Divyanshu Dubey, Kan Ding, Ryan Hays, Steven Vernino, Rohit Das P2.2-008 The Use of Rituximab in Neurological Diseases; Real

World Data from a Neuroscience Centre–Alexandra Kondratiuk, Paolo Muraro, Michael Johnson, Victoria Sing-Curry, Jane Pritchard, Rachel Dorsey, Richard St. John Nicholas, Antonio Scalfari P2.2-009 Real-world Experience with Ocrelizumab - A Safety Analysis–Jamie Bolling, Matthew Vasquez, Carlos Eduardo Vervloet Sollero, Aaron M. Carlson, Tirisham Gyang P2.2-010 Influence of Autoimmune Antibody Testing on Neurohospitalists’ use of Immunotherapy–Kristin Marissa Galetta, Amy Rosen, Galina Gheihman, Joshua P. Klein, Shamik Bhattacharyya P2.2-011 Driving Out of Coma: Treatment of Anti-NMDA Receptor Encephalitis with Bortezomib– Maryam Hosseini, Shadi Milani, Xiao-Tang Kong

Legacy, Kathryn P.L. Moore, Nicole Herndon, Karen Hegland, Adolfo Ramirez Zamora, Kelly D. Foote, Michael S. Okun, Leonardo B. Almeida P2.3-006 Patient-Adjusted Deep Brain Stimulation Programming is Time-Saving in Dystonia Patients– Julien François Bally, Mohammad Rohani, Marta Ruiz-Lopez, Suneil Kalia, Moji Hodaie, Andres M. Lozano, Renato Puppi Munhoz, Alfonso Fasano P2.3-007 Cultural Disparities in Deep Brain Stimulation (DBS) Decision Making in Patients with Parkinson Disease (PD)–Risako Shirane, McKenna Nisson, Eileen Moran, Vicki Shanker, Christina Palmese Parkinson’s Disease: Exercise, Mental Health, and Social Determinants 2

3 3

Surgical Therapies in Movement Disorders 2

P2.3-001 Sex Disparities in Patients with Essential Tremor Referred for Deep Brain Stimulation–Lisa Marie Deuel, Drew S. Kern, Michelle Fullard P2.3-002 Vertically-Stacked Single Segment Activation (V-SSA) as a Programming Approach for Directional DBS in Globus Pallidus Internus (GPi) in Parkinson’s Disease (PD) Patients: First Clinical Case Series–Muhammad Waseem Anjum, Islam Fayad, Yasar Alejandro Torres-Yaghi, Srivatsan Pallavaram, Christopher Kalhorn, Fahd Amjad, David Zhang, Fernando L. Pagan P2.3-003 High-Frequency VNS Attenuates Symptom Severity and Neurodegeneration in a Rat Model of Parkinson’s Disease–Ryan Verner, Ariana Farrand, Ryan McGuire, Vanessa K. Hinson, Heather Boger P2.3-004 Natural History of Caregiver Burden After Deep Brain Stimulation for Parkinson Disease–Eric Jackowiak, Amelia Louise Heston, Carol Persad, Amanda Maher, Parag Patil, Kelvin L. Chou, Vikas Kotagal P2.3-005 Unique speech change pattern in Parkinson’s disease after GPi deep brain stimulation– Shannon Chiu, Takashi Tsuboi, Matthew Robert Burns, Joseph

P2.3-008 Improved Dual-Task Performance During Turning After a Single Session of Action Observation Training in Parkinson’s Disease Patients–Elisabetta Sarasso, Federica Agosta, Alessia Cristiano, Andrea Gardoni, Maria Volonté, Andrea Tettamanti, Alberto Sanna, Diana Trojaniello, Massimo Filippi P2.3-009 Impact of Mental Health Services and Exercise in Parkinson’s Disease–Clarissa Martinez Rubio, Fernando Cubillos, Samuel Wu, Hanzi Gao, Nicole Lessard Yarab, Miriam R. Rafferty P2.3-010 Table tennis exercise for patients with Parkinson disease: a prospective pilot study–Kenichi Inoue P2.3-011 Clinically Important Change in the Fahn-Marsden Dystonia Rating Scale (FMDRS) Movement Subscale–Joan Miravite, Sara Calvo, Leon Meytin, Hwai Yin Ooi, Harini Sarva, Susan B. Bressman, Rachel J. SaundersPullman, Esther Cubo Delgado P2.3-012 Effect of Non-contact Boxing on Non-motor Symptoms in Parkinson’s Disease–Atif Ghaffar, Rosemary Gallagher, Laura Ketigian, Lily Rubin, Zachary Scheid, Jennifer Zhu, Crystal Michaelides, Adena Leder

AAN.com/view/20AM 125

Sunday, April 26

Autoimmune Neurology 2

POSTER SESSIONS

P2.1-015 Three Distinct Myelin Water Fraction (MWF) Clusters Identified within Chronic Multiple Sclerosis (MS) Lesions–Ulrike Kaunzner, Sneha Pandya, Nancy M. Nealon, Jai Perumal, Timothy K. Vartanian, Thanh Nguyen, Yi Wang, Sandra Hurtado Rua, Susan Gauthier P2.1-016 MRI Activity in Secondary Progressive Multiple Sclerosis–Daniella Zohar, Anat Achiron P2.1-017 Quantum – Quantitative and Standardized Imaging in Daily Clinical Routine of MS Patients– Katrin Schuh, Roland Opfer, Lothar Spies, Sven Schippling P2.1-018 The Gender Role in Early Multiple Sclerosis Utilizing Optical Coherence Tomography–Melody Gilroy, Madeline Bross, Carla E. Santiago-Martinez, Evanthia Bernitsas P2.1-019 The Role of 7T MRI to Assess Atrophy of the Subcortical Deep Gray Matter in Relapsingremitting Multiple Sclerosis– Jonathan D. Zurawski, Renxin Chu, Yanmei Tie, Shahamat Tauhid, Brian Curran Healy, Howard L. Weiner, Rohit Bakshi P2.1-020 Correlation Analysis of MRI Lesion Load and Clinical Measures in Multiple Sclerosis Cohort Using Structured Clinical Documentation Support Toolkit–Afif Hentati, Tiffani Stroup Franada, John Pula, Darryck Maurer, Bryce Hadsell, Alexander Epshteyn, Samuel Tideman, Anna Pham, Roberta Frigerio, Demetrius M. Maraganore, Susan M. Rubin P2.1-021 A Longitudinal Assessment of Fingolimod on White Brain Matter and Disease Disability in Relapsing Remitting Multiple Sclerosis–Melody Gilroy, Hayley VanSickle, Fen Bao, Carla E. Santiago-Martinez, Evanthia Bernitsas P2.1-022 Quantitative MRI Brain Atrophy and IgG Subclass Profile: Cross Sectional Relationship In A Population of People with MS (PwMS)–Jared Srinivasan, Christopher Dasaro, Olivia Kaczmarek, Barbara Bumstead, Kaitlyn Jaenicke, Marijean Buhse, Daniel Golan, Myassar Zarif, Mark Gudesblatt

Sunday, April 26

POSTER SESSIONS

POSTER SESSION 2 P2.3-013 Disparities in Access to Care and Research Participation in Advanced Parkinson’s Disease: Differences between a Home Visit Study and Outpatient Clinic Population–Jori Fleisher, Ellen Klostermann, Erica Myrick, Serena Hess, Jeanne Lee, Bichum Ouyang, Deborah Hall, Joshua Chodosh P2.3-014 Community mobility is affected by balance and related aspects in Parkinson’s disease: preliminary results–Ana Carolina Leonardi Dutra, Nayron Soares, Gabriela Pereira, Nathalie Ribeiro Artigas, Julia Schneider Krimberg, Angelica Cristiane Ovando, Artur Francisco Schumacher Schuh, Carlos Roberto de Mello Rieder Parkinson’s Disease Genetics and Imaging 1

P2.3-015 Recruitment of a Virtual Nationwide Cohort of LRRK2 G2019S Carriers–Taylor Myers, Ruth Schneider, Stella JensenRoberts, Helen Rowbotham, Marie Luff, Eli Chanoff, Katherine D. Amodeo, Saloni Sharma, Roy Alcalay, Paul Cannon, E. Ray Dorsey, Robert G. Holloway P2.3-016 PARK2, PINK1, and DJ1 in patients with earlyonset Parkinson’s disease in four European countries.– Lukasz Milanowski, Jennifer Lindemann, Maria Barcikowska, Magdalena Boczarska-Jedynak, Krzysztof Czyzewski, Angela B. Deutschlander, Gabriela Duda, Lyuda Fedoryshyn, Andrzej Friedman, Dorota HoffmanZacharska, Zygmunt Jamrozik, Katherine Karpinsky, Dariusz Koziorowski, Anna KrygowskaWajs, Barbara Myga, Grzegorz Opala, Aleksander Pulyk, Irena Rektorova, Monika Rudzinska-Bar, Yanosh Sanotsky, Joanna Siuda, Jaroslaw Slawek, Katarzyna Smilowska, Lech Szczechowski, Cezary Zekanowski, Alexandra Beasley, Owen A. Ross, Zbigniew K. Wszolek P2.3-017 The Challenge of Genetic Counselling in Early Onset Parkinsonian Disorders–Maria J. Molnar, Peter Balicza, Dora Csaban, Viktor Molnar, Renata Bencsik, Aniko Gal, Zoltan Grosz, Anett Illes

CME

Epilepsy/Clinical Neurophysiology (EEG): Surgery and Co-morbidities 2

P2.4-001 Accelerated Forgetting in Patients with Epileptic and NonEpileptic Seizures–Rebecca L. Tom, Erin D’Agostino, Barbara C. Jobst P2.4-002 Improving Cognitive Assessment of Adult Epilepsy Monitoring Unit Patients–Wendy Chen, Victoria Deardon Liu, Kimford J. Meador, Scheherazade Le P2.4-003 Study of Interrelationship between Quality of Life and Cognition in People with Epilepsy - Cross Sectional Study from North Coastal Andhrapradesh–Sateesh T P2.4-004 Sleep Dependent Memory Consolidation in People With Epilepsy–Fatemeh Khadjevand, Tal Pal Attia, Laura C. Miller, Erik Kent St. Louis, Gregory A. Worrell P2.4-005 Polysomnographic Study of Sleep Architecture in Unselected Patients with Epilepsy: A Multicenter Study–Songtam Ngodngamtaweesuk, Kanitpong Phabphal, Pasiri Sithinamsuwan, Krongthong Wongsritrang, Tabtim Chongsuvivatwong, Kanokrat Suwanlaong, Thanyalak Amornpojnimman, Nichanan Ekpitakdamrong, Alan Geater, Sumonthip Leelawai, Anongtip S.A., Sasinat Makkaew, Faisol Chamroonsil P2.4-006 Is Youth Wasted on the Young? Determining Quality of Life in Older Patients with Epilepsy–Heather Heiser, Travis Stoub, Michael C. Smith, Michele Packard, Rebecca O’Dwyer P2.4-007 Psychosis and Seizures in the Veteran Population–Yarden Bornovski, Stephanie Argraves, Ebony Jackson-Shaheed, Benjamin David Tolchin, Joseph Goulet, Kei Cheung, Adrianna Hitchins, Hamada Hamid Altalib P2.4-008 Systematic Literature Review on Psychiatric Comorbidities in Patients with Epilepsy–Elaine Lu, Nataliya Pyatka, Martha Sajatovic P2.4-009 Anti-Epileptic Drug Psychiatric Adverse Events in Focal Epilepsy-A Cohort Study–Amany Marey, Zhiyuan Zhang, Alma Rechnitzer, Sarah Barnard, Jacqueline French, Andres M. Kanner, Hamada Hamid Altalib

126 2020 AAN Annual Meeting

0 Sunday, April 26 P2.4-010 Are We Following Best Practices for Evaluation of Psychogenic Non-epileptic Seizures (PNES)– We Shouldn’t Need to Reinvent the Wheel–Angela Wabulya, Michael B. Tennison, William J. Powers, Manisha Chopra, Bradley V. Vaughn P2.4-011 Interactions of Mood Disorders and Episodic Event Frequency in Transgender Patients– Julie Randall, Matthew McCaskill, Holly E. Hinson General Neurology: Clinical Case Reports 2

P2.5-001 Sever Hyperammonemic Encephalopathy Post Sleeve Gastrectomy–Lubna Ebn Omer El Sheikh, Ali M. Kh. Al-Salahat, Boulenouar Mesraoua, Musab Ali, Rasha Abumustafa, Vasgen Mnatsakayan, Rola Khodair, Gayane Robert Melikyan P2.5-002 Cortical Laminar Necrosis Following the Rapid Correction of Hyponatremia- A Case Report–Volkan Tasdemir, Tuncay Gunduz, Murat Kurtuncu P2.5-003 Osmotic Demyelination Syndrome Without Significant Sodium Fluctuation in a Patient with NASH Cirrhosis–Terese Gullo, Hera Ashraf Kamdar, Gaurav Thakur, Yasushi Kisanuki, Bader Alhafez P2.5-004 A Rare Case of AdultOnset Isolated HypothalamicPituitary Langerhans Cell Histiocytosis Presenting with Encephalopathy due to Hypercalcemia–Nilufer Yalcin, Allison Osen, Edith Graham, Starane Anthony Shepherd, Torrey Boland Birch P2.5-005 Hypercalcemiaassociated PRES and Status Epilepticus–Fransisca Indraswari, Hai Chen P2.5-006 ImPRESsively Challenging Case of PRES–Arpan Patel, Prateeka Koul, Pankti Shah, Mariel Deutsch P2.5-007 The Overlap of Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome– Meghan Purohit, Monica Scarsella, Naresh Mullaguri, Dinesh V. Jillella, Ken Uchino, Dolora R. Wisco P2.5-008 Case Report Of Malignant Hypertension With Thrombotic Microangiopathy

8:00 a.m.–9:00 a.m. Masquerading As Thrombotic Thrombocytopenic Purpura With Neurological Features–Sri Raghav Seshu Sista, Luis Guillermo Manrique, Swetha Vennavaram P2.5-009 Rapidly Cognitive Decline Secondary to CSF Venous Fistula with Post-Operative Rebound Intracranial Hypertension and a Hyperintense Paraspinal Vein Sign Seen Retrospectively–Peter Sherman Tatum, Emily Anderson, Alina Kravtsova, Osamah Alnasser, Chinoso Nduaguba, Deborah M. Green-LaRoche, Neel Madan P2.5-010 Spontaneous Cerebrospinal Fluid Leak Secondary to a High Auditory Stimulus: A Variant of Tullio’s Phenomenon– Roberto Cruz, Cristina Chavez, Elliot M. Frohman, Teresa Frohman P2.5-011 Pulsatile Tinnitus Secondary to Dehiscent Right Sigmoid Sinus–Abinayaa Ravichandran, Laura Berman, Hussam A. Yacoub, Jay D. Varrato P2.5-012 Syringomyelia with Coexistent Spinal Arachnoid Cyst in a 25-year-old-male: A Case Report–Artemio A. Roxas, Princi Demaisip P2.5-013 Normal Brain with an ‘abnormal’ MRI–Ajaz Sheikh, Nurose Karim Headache: Therapeutics 2

P2.6-001 An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine–Jessica Ailani, Andrew M. Blumenfeld, Bradley Marc Klein, Michelle Finnegan, Lawrence Severt, Chengcheng Liu, Joel M. Trugman P2.6-002 Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study–Stephen D. Silberstein, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Maja Galic, Xiaoping Ning, Adelene E. Jann P2.6-003 Rimegepant is Effective for the Acute Treatment of Migraine in Patients Who Have Discontinued or Currently Use

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Neuromuscular and Clinical Neurophysiology (EMG): Imaging, Neurophysiology, and Outcome Measures 2

P2.7-001 Cyst Can’t be the Case? A Unique Presentation of Multiple Tarlov Cysts–Scott Speelziek, Derek William Stitt P2.7-002 The Benefits of Neuromuscular Ultrasound Immediately After Surgery: A Case Example–Laura Danielson, David C. Preston P2.7-003 Muscle Thickness Measured by Ultrasound is Reduced in Neuromuscular Disorders and Correlates with Clinical and Electrophysiological findings–Alon Abraham, Vivian E. Drory, Yaara Feinmesser, Avi Asher Algom, Leif Erik Lovblom, Vera Bril P2.7-004 Miller-Fisher Syndrome (MFS) with Delayed Bilateral Facial Nerve Palsy: Imaging and Electrodiagnostic Findings, Treatment and Outcome–Charles Port, Anahit C. Mehrabyan, Victor Lin P2.7-005 The Utility of Inpatient Electromyography/Nerve Conduction Studies: Quality Over Quantity Saves Quite a Quota– Derryl Miller, Cynthia Bodkin P2.7-006 Electromyographic Assessment of Motor Fatigue in Acute and Early Sub-Acture Stroke Patients: A Preliminary Study–Yiyun Wang, Nathan Pinnette, Kevin Andrew Mazurek, Ania Busza P2.7-007 Guillain-Barre Syndrome with Dysautonomia Presenting as Posterior Reversible Leukoencephalopathy Syndrome– Emilia Raimondo, Mayra Montalvo Perero, Kara Stavros P2.7-008 Quantitative Gait Analysis in Patients with Diabetic Polyneuropathy–Kyong Jin Shin, Hong Ki Song

P2.7-009 A Wearable Sensory Neuroprosthesis to Improve Gait and Balance Function in Persons with Sensory Peripheral Neuropathy–The walk2Wellness Trial–Lars Oddsson, Teresa Bisson, Helen Cohen, Ikechukwu Iloputaife, Sara Koehler-McNicholas, Doris Kung, Lewis Lipsitz, Brad Manor, Patricia McCracken, Diane Wrisley P2.7-010 Early Electrophysiological Prediction of Long-Term Disability in Chronic Inflammatory Demyelinating Polyneuropathy–A 14 Year FollowUp Study–Ali Al-Zuhairy, Johannes Jakobsen, Christian Krarup P2.7-011 Home-Based Electrical Impedance Myography in LateOnset Pompe Disease–Lisa Hobson-Webb, Paul Zwelling, Ashley Pifer, Priya Kishnani P2.7-012 Development of an Optimized Timed Up and Go (oTUG) for Measurement of Changes in Mobility Impairment in Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trials– Vicky Chan, Maya Hatch, Greforij Kurillo, Jay Han, Diego Cadavid P2.7-013 Validation of the Upper Extremity Reachable Work Space (RWS) as a clinical outcome assessment for FSHD Clinical Trials–Jay Han, Greforij Kurillo, Diego Cadavid P2.7-014 Involuntary Movements, Fasciculations, and Ion Channel Dysfunction in Multifocal Motor Neuropathy (MMN)–Christian Krarup, Nils Wolfram, Tina Jeppesen, Mihai Moldovan Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 2

P2.8-001 Cerebellar Atrophy Associated With Gait Abnormalities in Older Adult Fallers–Amgad Droby, Mounir El Mendili, Inbal Maidan, Nir Giladi, Jeffrey Hausdorff, Anat Mirelman P2.8-002 Adult Onset Genetic Leukoencephalopathy: Practical Guide to Investigation and Results from an International Referral Centre–David S Lynch, Thomas James Williams, Nevin Alex John, Nick Fox, Matthew Adams, Henry Houlden, Elaine Murphy, Indran Davagnanam, Jeremy S. Chataway

P2.8-003 Exacerbation of Alzheimer’s Disease Neuropathology and Cognitive Deficits by Seizures–Sarah Gourmaud, David Stewart, Delia Maria Talos, Frances E. Jensen P2.8-004 Magnetic Resonance Imaging Measurement of Hippocampal Volume Using VoxelBased Morphometry Analysis in Early Alzheimer’s Disease– Nobutoshi Morimoto, Yoshiaki Takahashi, Motonori Takamiya, Mizuki Morimoto, Akihiko Shiino P2.8-005 Impact of Cerebral Microbleeds on Cognition in Patients with Alzheimer’s Disease–Yaohua Sophie Chen, Gregory Kuchcinski, Christine Delmaire, Emilie Skrobala, Julien Dumont Romain Barus, Sandrine Bergeron, Regis Bordet, Sophie Gautier, Florence Pasquier P2.8-006 Quantitative Neuroimaging of Volume Loss in Persons with Alzheimer’s Dementia–Somayeh Meysami, Cyrus A. Raji, Mario F. Mendez P2.8-007 Braak Neurofibrillary Tangle Staging Prediction Using In Vivo MRI Metrics–Caroline Dallaire-Théroux, Iman Beheshti, Olivier Potvin, Louis Dieumegarde, Stephan Saikali, Simon Duchesne P2.8-008 [11C]MK-6884 PET Tracer for M4 Muscarinic Cholinergic Receptors in Alzheimer’s Disease: Comparison with [18F]FDG PET–Joseph C. Masdeu, Belen Pascual, Paolo Zanotti Fregonara, Meixiang Yu, Quentin Funk, Victoria Arbones, Elijah Rockers, Yuchuan Wang, Wenping Li, Amy Cheng, Matt Anderson, Eric Hostetler, Anthony S. Basile P2.8-009 Quantitative Susceptibility Mapping MRI to Assess the Relationship Between Iron Accumulation and Hippocampal Atrophy as a Measure of the N Aspect of the A/T/N Alzheimer’s Disease Definition– Ronald J. Killiany, Andrew Ellison, Yansong Zhao, Eric Steinberg, Michael Alosco, Jesse B. Mez, Robert Stern P2.8-010 Free-Water Diffusion Tensor Imaging (DTI) Improves the Accuracy and Sensitivity of White Matter Analysis in Alzheimer’s Disease–Ryan R. Walsh, Maurizio Bergamino, Ashley Stokes

AAN.com/view/20AM 127

Sunday, April 26

P2.6-010 Impact of Eptinezumab Treatment on Migraine Frequency, Duration, and Severity in Patients with Migraine–Paul Winner, Peter Goadsby, Abigail Lim Chua, Deborah I. Friedman, Yufan Zhao, Roger Cady P2.6-011 Galcanezumab in the Prevention of Chronic Migraine in Patients on Botulinum Toxin Therapy–Shivangi Singh, Harsh Singh, Raghav Govindarajan

POSTER SESSIONS

Triptans: Results from 3 Phase 3 Clinical Trials–Robert Croop, Christopher Jensen, Alexandra Thiry, Elyse Stock, Charlie Conway, Beth Morris, Vlad Coric, Richard B. Lipton P2.6-004 Sustained Benefits of OnabotulinumtoxinA Treatment in Chronic Migraine: Results from a PREEMPT Pooled Analysis– Stephen D. Silberstein, H. Christoph Diener, David W. Dodick, Larisa Yedigarova, Richard B. Lipton P2.6-005 Effects of Galcanezumab on Acute Medication Use, Time to Response, and Total Pain Burden in Patients with Episodic Cluster Headache: Post hoc Outcomes from a Phase 3, Randomized, Doubleblind, Placebo-controlled Study– David B. Kudrow, J Scott Andrews, Mallikarjuna Rettiganti, Tina Oakes, Jennifer Bardos, Chunmei Zhou, Sheena K Aurora, Dulanji Kuruppu, Richard Wenzel, Robert Riesenberg, Charly Gaul, James Martinez P2.6-006 Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO)–Stewart J. Tepper, Richard B. Lipton, Stephen D. Silberstein, David B. Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Feng Zhang, Sunfa Cheng, Daniel D. Mikol P2.6-007 Eptinezumab Demonstrated Early and Sustained Reductions in HIT-6 Total and Item Scores Over Time in Patients with Chronic Migraine in the PROMISE-2 Trial–RJ Wirth, James McGinley, Carrie R. Houts, Joe Hirman, Roger Cady, Richard B. Lipton P2.6-008 Duration of Consecutive Migraine-Free Days Experienced After Treatment with Eptinezumab in Patients with Migraine–Peter Goadsby, Paul Winner, Brian Grosberg, Jan Lewis Brandes, Yufan Zhao, Roger Cady P2.6-009 Early Onset of Response to Fremanezumab in Migraine Patients With Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebocontrolled FOCUS Study–Andrew M. Blumenfeld, Ronghua Yang, Joshua M. Cohen, Verena Ramirez Campos, Patricia Pozo-Rosich

POSTER SESSION 2 Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 2

Sunday, April 26

POSTER SESSIONS

P2.9-001 Flair Hyperintense Vessels Do Not Correlate with MRI Perfusion Deficit–Idrees Azher, Katarina B. Dakay, Mahesh Jayaraman, Ryan A McTaggart, Ali Mahta, Karen L. Furie, Shadi Yaghi, Shawna M. Cutting P2.9-002 Caveats to Consider for CT Angiography and Perfusion Weighted Imaging for Stroke Management in the Setting of Venoarterial Extracorporeal Membrane Oxygenation–Manuel Aurelio Viamonte, Lidia Nagae, Teddy Si Youn, Alexis N. Simpkins P2.9-003 Radiologic Characteristic Of Perioperative Large Vessel Occlusions In Patients Who Underwent Transcatheter And Surgical Valve Replacement–Lucy Zhang, Joshua Santucci, Lacy Samuel Handshoe, Bhageeradh Mulpur P2.9-004 Accuracy of Magnetic Resonance Angiography for Identifying Moderate to Severe Internal Carotid Artery Stenosis: Analysis of Crest trial–Maryum Shoukat, Adnan I. Qureshi P2.9-005 Treatment Strategy Based on Carotid Plaque Vulnerability Identified by Simultaneous Non-contrast Angiography and IntraPlaque Hemorrhage (SNAP) Imaging–Yi Shen, Jian Wu P2.9-006 Collateral Strength on CT Angiography can Predict MRI Infarct Growth, but not Clinical Outcomes in Patients Treated with Mechanical Thrombectomy– Kristopher Southard, Bhageeradh Mulpur, Nirmal Andrapalliyal, Lacy Samuel Handshoe, Muhammad Shazam Hussain, Christopher Karakasis P2.9-007 Cerebral Small Vessel Disease Score and Atherosclerosis Burden: A Population-based Study in Rural Ecuador (The Atahualpa Project)–Victor J. Del Brutto, Robertino Mera, John Hill, Andrew Torpey, Leslie Peralta, Laura Generale, Gautam Matcha, Aldo Costa, Bettsy Recalde, Mark Sedler, Oscar H. Del Brutto P2.9-008 e-ASPECTS predicts Decompressive Hemicraniectomy– Danielle L. Weiss, Dennis Chuang, Ali Abbas Fadhil, Kelsey Duncan,

CME

Mickey Smith, Alexa Weiss, Sophia Sundararajan P2.9-009 Functional MRI in Ischemic Stroke Patients Treated with IV Thrombolysis and Mechanical Thrombectomy–Marco A. Gonzalez Castellon, Praveen Hariharan, Connor Phipps, David Warren P2.9-010 WITHDRAWN P2.9-011 Corneal Confocal Microscopy: An Imaging Endpoint for Neuro-Immune Alterations in Acute Stroke–Adeeb Mohd Narangoli, Adnan Khan, Saadat Kamran, Naveed Akhtar, Ioannis Petropoulos, Georgios Ponirakis, Hoda Gad, Hamad Almuhannadi, Abdulrahman Al-Mohamedi, Ashfaq Shuaib, Rayaz Ahmed Malik P2.9-012 RAPID CT Perfusion Use in Acute Stroke; A Piece in a Puzzle–Faisal Abdelaziz Ibrahim, Matthew James Hileman, Ahmed Abbas, Hayan Dayoub, Sajjad Mueed, Robert Burke P2.9-013 Does Brain Imaging Help in the Diagnosis And Management of Stroke in Antiphospholipid Antibody Syndrome?–Sanskriti Mishra, Steven R. Levine P2.9-014 Acute Ischemic Stroke (AIS) Due to Cerebral Lipiodol Embolization (CLE) from Diagnostic Lymphangiography–Michael Jang, May A. Kim-Tenser P2.9-015 Diagnostic Imaging Workup of Acute Ischemic Stroke in Glioblastoma Patients–Ashley Becker, Alexandra L. Czap, Kristin Alfaro-Munoz, Liang Zhu, James C. Grotta, Louise D. McCullough, John F. De Groot P2.9-016 Cerebral Hemodynamics in Acute Anterior Circulation Lacunar Stroke: a Transcranial Doppler Ultrasound Study–Fei Wu, Chun Yu, Haiyan Tang, Hui Zhang, Wenjie Cao, Qiang Dong P2.9-017 Change of Vascular Stenosis According to the Pathology on High Resolutional Vessel Wall Images–HeeKwon Park, Cindy Yoon, Jun-Yong Choi, Joung-Ho Rha P2.9-018 Inflammatory Markers Correlate with Functional Outcomes in Large Hemispheric Infarctions–Nandini Abburi, Andrea Sterenstein, Hannah Breit, Ivan Da Silva, Sarah Song, Sayona John, Lauren Koffman

128 2020 AAN Annual Meeting

0 Sunday, April 26 P2.9-019 Study of Clinical, Radiological, and Electroencephalographic Features in Posterior Reversible Encephalopathy Syndrome (PRES)– Mahadevappa Mahadevappa P2.9-020 Varicella Zoster Vasculopathy Causing Stroke: Utility of Hi-res Vessel Wall MR Imaging in Diagnosis & Management–Elham Khalilidehkordi, Peter Bailey, Sandeep Bhuta, Anthony Foat, Gaurav Singh, Arman Sabet Basic Science and Clinical Neuro-oncology 2

P2.10-001 Unifying Variability in T2-FLAIR Mismatch Sign for Diagnosing IDH-mutant Astrocytomas and Characterizing Evolution After Treatment–Patrick Throckmorton, Jerome J. Graber P2.10-002 Brain MRI findings in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) during Severe Neurotoxicity– Weizhe Li, Sepideh Mokhtari, John Arrington, Frederick locke, Aleksandr Lazaryan P2.10-003 Examining the Impact of Isocitrate Dehydrogenase (IDH) Gene Status on the Development of Venous Thromboembolism in Glioma Patients–Jacob Mandel, Michael N. Youssef, Shlomit YustKatz, Akash J. Patel, Ali Jalali, Jimin Wu, Ethan Ludmir, John F. De Groot P2.10-004 Temozolomide does not meaningfully reduce seizure frequency in elderly glioblastoma patients–Seth Andrew Climans, Alba Brandes, J Gregory Cairncross, Keyue Ding, Michael Fay, Normand Laperriere, Johan Menten, Ryo Nishikawa, Christopher O’Callaghan, David Osoba, James R. Perry, Claire Phillips, Wilson Roa, Chad Winch, Warren P. Mason P2.10-005 Scores and Performance of Patient Reported Outcome Measures in Patients with High Grade Glioma at Diagnosis–Samantha Myers, Peggy Auinger, Gretchen L. Birbeck, Joy Ellen Burke, Chinazom Uchenna Ibegbu, Nimish A. Mohile, Andrea C. Wasilewski, Jennifer N. Serventi, Thomas Wychowski

8:00 a.m.–9:00 a.m. P2.10-006 Neurotoxicity as Surrogate Marker for CAR T-cell Therapy Treatment Response– Carlen Amy Yuen, Peter Riedell, Andrew Artz, Satyajit Kosuri, Thomas J. Kelly, Shasha Wu, Anthony Reder, Kourosh Rezania, Betty C. Soliven, Tao Xie, Ali Saad, James A. Mastrianni, Deric M. Park, Wesley Klejch, Michael Bishop P2.10-007 A New Model of Care for Patients with Central Nervous System Cancers: Final Results of a Pilot Study–Elena Pentsova, Kathryn S. Nevel, Franchesca KonigToro, Katherine Panageas, Maryann Sibilla, Anne S. Reiner, Eli Diamond, Anastasia Zankowsky, Dominique Jean-Charles, Gayle RawlinsPeters, Brian Kelly, Judy Gilman, Alan C. Carver, Lisa Ruppert P2.10-008 Molecular Profile and Outcomes of Young Patients with Glioblastoma Multiforme. A Single Institutional Retrospective Case Series Review–Tigran Khachatryan, Pawan K. Singh P2.10-009 A Pilot Study to Assess the Integration of a Unique PROQOL Tool and Early Palliative Care Intervention in the Care of High Grade Glioma Patients and their Caregivers–Akanksha Sharma, Eric Wolfe, Celina Barrera, Samantha Williamson, Hannah Farfour, Maciej M. Mrugala, Mark Edwin, Jeff Sloan, Alyx B. Porter P2.10-010 Clinical Prognostic Factors of Survival in Glioblastoma Multiforme–Kartik R, Guan Rong Lee, Chia Ching Lee, Po-Yin Tang, Kusumawidjaja Grace, Lee Min Kevin Chua, Hwee Yee Lee, Wee Yao Koh, Chee Kian Tham, Wai Hoe Ng, Xuling Lin P2.10-011 Treatment Strategies for Glioblastoma in Older Patients: Age is Just a Number–Jacob Mandel, Michael N. Youssef, Ethan Ludmir, Akash J. Patel, Ali Jalali, Jeffrey Treiber, Jimin Wu, Mary Frances McAleer, John F. De Groot P2.10-012 Combined Necrosis and Brain Invasion Predict Radioresistance and Tumor Reoccurrence in Atypical Meningioma–Monica Emili Garcia-Segura, Rishi Jairath, David G. Munoz, Sunit Das

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number P2.10-013 Stroke in Cancer Patients–Marilou I. Ching, Edina Komlodi-Pasztor P2.10-014 Avelumab in Newly Diagnosed Glioblastoma Multiforme-the SEJ Study– Francois H. Jacques, Ian Lorimer, Garth Nicholas, Victorine Sikati Foko, Nathalie Dumais, Erik Apedaile Sleep Medicine: Covering New Grounds 2

Sunday, April 26

P2.11-007 A Pilot, Placebocontrolled Clinical Trial of Cereset Research for Insomnia–Catherine Tegeler, Charles H. Tegeler, Lindsay Joanna Howard, Kenzie Brown, Dawn Kellar, Lee Gerdes, Hossam Shaltout P2.11-008 Brainwave Entrainment through External Sensory Stimulus: A Therapy for Insomnia–Avathvadi V. Srinivasan, Karuppathal E, Karthik Raghavendran Venkatesan, Kalpana R P2.11-009 Efficacy and Safety of Lemborexant vs Zolpidem Extended Release and Placebo in Elderly Subjects with Insomnia: Results from SUNRISE-1–Gary Zammit, David Mayleben, Dinesh Kumar, Margaret Moline P2.11-010 Effectiveness and Safety of Lemborexant Over 12 Months in Adults with Insomnia Disorder: Long-term Results From the Phase 3 SUNRISE-2 Study–Jane Yardley, Mikko Karppa, Yuichi Inoue, Kate Pinner, Carlos Perdomo, Gleb Filippov, Naoki Kubota, Margaret Moline P2.11-011 Impact of Lemborexant Treatment on Insomnia Disease Severity and Fatigue: Results from the 12-Month Phase 3 Study SUNRISE-2–Margaret Moline, Mikko Karppa, Jane Yardley, Dinesh Kumar, Kate Pinner, Carlos Perdomo, Gleb Filippov, Norman Atkins P2.11-012 Efficacy and Safety of Lemborexant in Elderly Subjects with Insomnia Disorder: Pooled Analyses from SUNRISE-1 and SUNRISE-2–Margaret Moline, Jane Yardley, Kate Pinner, Dinesh Kumar, Mohammed Bsharat, Mikko Karppa, Gary Zammit, Carlos Perdomo, Russell Rosenberg P2.11-013 Doxepin in Children and Adolescents with Insomnia: A Single Center Experience–Yash Shah, Virginia Stringel, Ivan M. Pavkovic, Sanjeev V. Kothare

POSTER SESSIONS

P2.11-001 Relationship of Sleep-Related Complaint Load to Quality of Life in Epilepsy–Garik Yeganyan, Lusine Vardanyan, Lilit Ghahramanyan, Samson Khachatryan P2.11-002 Comparison of Screening Instruments for Obstructive Sleep Apnea in Adults with Epilepsy–Maeve Margaret Pascoe, Noah Andrews, James Bena, Irene L. Katzan, Nancy R. Foldvary-Schaefer P2.11-003 Screening for Obstructive Sleep Apnea in Stroke and TIA Patients using a Home Sleep Apnea Test vs. In-laboratory Polysomnography: A Randomized Controlled Trial–Mark Boulos, Maneesha Kamra, David Robert Colelli, Nardin Kirollos, David J. Gladstone, Karl Boyle, Arun Sundaram, Julia J. Hopyan, Richard H. Swartz, Muhammad Mamdani, Wanrudee Isaranuwatchai, Kevin Thorpe, Brian James Murray P2.11-004 Low Respiratory Arousal Threshold (LRAT) in African Americans with Obstructive Sleep Apnea (OSA)–Onyedika Moghalu, Peter Whitesell, John Kwagyan P2.11-005 Comorbidity Burden of Obstructive Sleep Apnea in a Large Academic Health Center–Kevin Senanayake, Daniel Krashin, Natalia Murinova P2.11-006 The Impact of Physical Activity on Sleep Quality in Strokefree in Adults. The Three Villages Study–Pablo R. Castillo, Robertino Mera, Victor J. Del Brutto, Katarzyna Slota, Oscar H. Del Brutto

Sleep Medicine: Focus on Therapies 1

AAN.com/view/20AM 129

POSTER SESSION 3

CME

0 Sunday, April 26

12:00 p.m.–1:00 p.m.

Sunday, April 26

POSTER SESSIONS

Poster Session 3 1. Multiple Sclerosis: Immunology and Basic Science 1: 1-001 to 1-022 2. Autoimmune Neurology 3: 2-001 to 2-011 3. Parkinson’s Disease Genetics and Imaging 2: 3-001 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 1: 4-001 to 4-012 5. General Neurology: Health Services: 5-001to 5-010 6. Headache: Therapeutics 3: 6-001 to 6-013 7. Neuromuscular Junction Disorders 1: 7-001 to 7-014 8. Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 3: 8-001 to 8-010 9. Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 3: 9-001 to 9-004 Stroke Epidemiology, Disparity, and Quality Improvement 1: 9-005 to 9-021 10. Basic Science and Clinical Neuro-oncology 3: 10-001 to 10-003 Neuro-oncology: Clinical Cases and More 1: 10-004 to 10-015 11. Sleep Medicine: Focus on Therapies 2: 11-001 to 11-013

Multiple Sclerosis: Immunology and Basic Science 1

P3.1-001 B Cells Selectively Induce CD8+ MAIT Cell Effector Functions: Implications for Multiple Sclerosis–Ayman Rezk, Koji Shinoda, Rui Li, Amit Bar-Or P3.1-002 Minocycline modifies circulating matrix metalloproteinases in Clinically Isolated Syndrome–Carlos Rodrigo Camara-Lemarroy, Luanne Metz, V. Wee Yong P3.1-003 Human Gut-Derived Commensal Bacterium Suppresses Neuroinflammation via MicrobeAssociated Molecular Patterns– John Michael Sanchez, Daniel Doty, Ana Beatriz DePaula-Silva, Jane Libbey, Robert Fujinami P3.1-004 Age Related Responses to Injury and Ensheathment Capacity of Human Oligodendrocytes–Jack P. Antel, Qiao Ling Cui, Milton Fernandes, YKT. Xu, Julia XiaoXuan Luo, Florian Pernin, Roy Dudley, Jeffery A. Hall, Timothy Kennedy P3.1-005 Siponimod Hinders the Formation of meningeal Ectopic Lymphoid Tissue in a Mouse Model of Multiple Sclerosis–Rosa Brand,

Monika Pfaller, Jolien Diddens, Katja Steiger, Klaus Lehmann-Horn P3.1-006 Filtration of Primary Progressive MS CSF Attenuates Reactive Astrogliosis In Vitro and In Vivo–Taylor Shue, Joseph Beaty, Anna Roselle, Jamie Wong, Saud A. Sadiq P3.1-007 Tumefactive Demyelination: Clinical Outcomes, Lesion Evolution and Treatments– Staley A. Brod, John William Lindsey, Flavia Nelson P3.1-008 Impact of Oxysterols on the Gut-brain Axis During Experimental Autoimmune Encephalomyelitis–Donovan Duc, Solenne Vigne, Benjamin Peter, Yannick Yersin, Florian Ruiz, Caroline Pot Kreis P3.1-009 Herpes Simplex Virus 1 Induces Brain Inflammation and Multifocal Demyelination in Cotton Rats Sigmodon Hispidus–Marina Boukhvalova, Emma Mortensen, Aissatou Mbaye, Diego Lopez, Lorne F. Kastrukoff, Jorge CG Blanco P3.1-010 IgG3+ Switched Memory B Cells are Elevated in Active Relapse-remitting Multiple Sclerosis–Felix Marsh-Wakefield, Pierre Julliard, Thomas Ashhurst, Helen McGuire, Simon Hawke, Georges Grau, Scott N Byrne

130 2020 AAN Annual Meeting

P3.1-011 RAM-589.555 favors neuroprotective/anti-inflammatory profile of CNS-resident glial cells in EAE affected mice–Rina Ilsna Falb, Tanya Rachutin-Zologin, Lakota Klever, Michael Gurevich, Anat Achiron P3.1-012 Effects of Prophylactic Glatiramer Acetate Treatment in the Spontaneous Opticospinal Encephalomyelitis Mouse Model–Ummugulsum Koc, Steffen Haupeltshofer, Ralf Gold, Simon Faissner P3.1-013 Oligodendroglial Specific Deletion of FGFR1 Protects Myelin in C57BL/6 Mice–Vinothkumar Rajendran, Franziska Kissel, Ranjithkumar Rajendran, Martin Berghoff P3.1-014 Complement-associated Synaptic Reorganization in the Hippocampal CA2 Subfield in Multiple Sclerosis and Cuprizoneinduced Myelin Loss–Valeria Ramaglia, Mohit Dubey, Alfonso Malpede, Naomi Petersen, Sharon de Vries, Dennis SW Lee, Geert Schenk, Inge Huitinga, Jennifer L. Gommerman, Jeroen JG Geurts, Maarten HP Kole P3.1-015 Analysis of the Methylome in Multiple Sclerosis

Patients from an Underrepresented Minority Population–Neda Sattarnezhad Oskouei, Jeremy Bingen, Mohamed Gaballa, Michael D. Carrithers P3.1-016 The Bruton’s Tyrosine Kinase Inhibitor Evobrutinib Ameliorates Meningeal Inflammation in Experimental Autoimmune Encephalomyelitis (EAE)–Sol Kim, Ursula Boschert, Roland Grenningloh, Pavan Bhargava P3.1-017 A Role for Dysfunctional RNA Binding Proteins in the Pathogenesis of Neurodegeneration in MS–Michael C. Levin, Hannah Salapa, Cole Libner, Catherine Hutchinson, Bogdan F. Popescu P3.1-018 IgG Depletion Ameliorates Pathogenic Effects of Primary Progressive MS CSF–Joseph Beaty, Taylor Shue, Anna Roselle, Jamie Wong, Saud A. Sadiq P3.1-019 Metabolic Stress Induces the Mislocalization of RNA Binding Protein TDP-43 in Human Oligodendrocytes in Vitro–Florian Pernin, Qiao Ling Cui, Katsuhisa Masaki, Raymond P. Roos, Jack P. Antel

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Autoimmune Neurology 3

Parkinson’s Disease Genetics and Imaging 2

P3.3-001 Addressing Challenges of Clinical Comprehensive Genetic Testing in Parkinson’s Disease–Emily J. Hill, Jennifer Marie Deger, Laurie Robak, Sindhu Rao, Hiba Saade, Brittany Ripperger, Lisa M. Shulman, Joseph M. Savitt, Neeja Vivek Desai, Rami Al-Ouran, Christina Griffin, Jamie Fong, Joseph Jankovic, Joshua M. Shulman P3.3-002 Glial Genes Influence Parkinson’s Disease Pathogenesis– Abby Lauren Olsen, Mel Feany P3.3-003 Evaluation of longitudinal changes in white matter structural integrity and grey matter volume in Parkinson’s disease–Ryan R. Walsh, Maurizio Bergamino, Elizabeth Keeling, Ashley Stokes P3.3-004 Prodromal Parkinson Disease in a Canadian Gaucher Disease Cohort–Priti Gros, Graeme Nimmo, Dominick Amato, Lorraine Kalia P3.3-005 Understanding the Effects of Free-Water Corrected diffusion MRI in Parkinson’s disease with Freezing of Gait–Virendra R.

Mishra, Jason Longhurst, Karthik Sreenivisan, Xiaowei Zhuang, Zhengshi Yang, Dietmar Cordes, Jeffrey L. Cummings, Zoltan Mari, Aaron Ritter, Jessica Caldwell, Irene Litvan, Brent Robert Bluett P3.3-006 Interrogating Whole Genome Sequences for Repeat Expansion Diseases in the NIH Undiagnosed Diseases Program– Camilo Toro, Bruce Hayward, Karen Usdin, May Malicdan, William Gahl P3.3-007 Quantitative susceptibility mapping in Parkinson’s disease shows increased iron content in the pulvinar compared to healthy controls–Nabeela Nathoo, Myrlene Gee, Krista Nelles, Jacqueline Burt, Peter Seres, Alan Wilman, Christian Beaulieu, Richard M. Camicioli P3.3-008 Decreased LAMP2 mRNA levels in CD45+ blood cells in patients with GBA-associated Parkinson’s disease–Konstantin Senkevich, Tatiana Usenko, Anastasia Bezrukova, Daria Bogdanova, Mikhael Nikolaev, Irina Miliukhina, Sofya Pchelina P3.3-009 Longitudinal Evolution of White Matter Damage in Parkinson’s Disease–Edoardo G. Spinelli, Federica Agosta, Pietro Giuseppe Scamarcia, Tanya Stojkovic, Elisabetta Pagani, Iva Stankovic, Vladana pica, Igor Petrovic, Elka Stefanova, Vladimir S. Kostic, Massimo Filippi P3.3-010 Resting-state connectivity in Levodopa responsive and unresponsive Parkinson’s disease patients with Freezing of Gait–Virendra R. Mishra, Karthik Sreenivisan, Xiaowei Zhuang, Jason Longhurst, Zhengshi Yang, Dietmar Cordes, Aaron Ritter, Jessica Caldwell, Jeffrey L. Cummings, Zoltan Mari, Irene Litvan, Brent Robert Bluett P3.3-011 Radiologic Overlap between Idiopathic Normal Pressure Hydrocephalus and the Parkinsonian Syndromes–Christina Martin, Guy Schwartz, Ruth Reinsel P3.3-012 Prevalence of GBA K198E Mutation in Colombian and Hispanic Populations–Philip W. Tipton, Alexandra Beasley, Owen A. Ross, Ronald Walton, Silvia SolerRangel, Óscar Romero-Osorio, Cindy Diaz, Claudia Lucia Moreno-López, Catalina Cerquera Cleves, Zbigniew K. Wszolek

P3.3-013 Striatal dopamine motor and non-motor network and cortical activity in Parkinson disease: a correlation study between 123I-FPCIT SPECT and FDG PET–Stuart McCarter, Hoon-Ki Min, Val John Lowe, Eduardo E. Benarroch, David T. Jones, Bradley F. Boeve, Rodolfo Savica P3.3-014 In-vitro Profile of a Novel Long Lasting Dopamine Agonist Designed to Optimize Efficacy and Safety–Miguel Guzman, Thomas Armer, Scott W. Borland, Robert Fishman P3.3-015 Early Onset Parkinson’s Disease Caused by Complete Uniparental Isodisomy of Chromosome 1–Changrui Xiao, Thomas Markello, Catherine Groden, William Gahl, Camilo Toro P3.3-016 Motor scores and sleep survey in GBA1 mutation carriers at risk for Parkinson Disease–Andrea Isabel Otero Rios, Alta Steward, Nishka Patel, Taylor Lindstrom, Raya Seid, Nahid Tayebi, Ellen Sidransky, Grisel J. Lopez P3.3-017 Distinct Effects of Motor Training on Brains’ Resting-State Functional Networks in Parkinson’s Disease–Amgad Droby, Inbal Maidan, Yael Jacob, Nir Giladi, Jeffrey Hausdorff, Anat Mirelman Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 1

P3.4-001 First Onset of any Treatment-emergent Adverse Event Over the Course of Repeated Midazolam Nasal Spray (MDZ-NS) use for the Treatment of Seizure Clusters: a Post hoc Analysis– Michael Gelfand, Svetlana Dimova, Eun Jung Choi, Aliceson King, Jody Cleveland P3.4-002 Pharmacokinetics of Intravail® A3 (n-dodecyl-beta-Dmaltoside), a Mucosal Absorption Enabler, After Intranasal Administration of NRL-1 in Patients with Epilepsy–Pavel Klein, Michael R. Sperling, R. Edward Hogan, Daniel C. Tarquinio, Ian Miller, Eric Segal, Adrian L. Rabinowicz, Enrique J. Carrazana

AAN.com/view/20AM 131

Sunday, April 26

P3.2-001 Autoimmunity in 1st and 2nd Degree Relatives of Children with Opsoclonus-Myoclonus Syndrome–Jonathan Santoro, Lauren Kerr, Sek Won Kong, Kenneth Mandl, Mark Gorman P3.2-002 Prevalence of Neurological Anti-GAD Autoimmunity in Martinique– Sophie Duclos, Philippe Cabre, Christophe Deligny, Aissatou Signate P3.2-003 Benefits of IVIG in Pediatric Acute-Onset Neuropsychiatric Syndrome–Isaac Melamed, Roger Kobayashi, Maeve O’Connor, Ai Lan Kobayashi, Andrew Schechterman, Melinda Heffron, Sharon Canterberry, Holly Miranda, Nazia Rashid P3.2-004 Beyond the Extreme Delta Brush: EEG as a Vital Adjunct in Diagnosing Autoimmune Encephalitis–Meenal Reddy Thadasina, Ashley Mary Paul, Preston J. Eibling, Miesty Woodburn, Alex Mirzoev P3.2-005 Anti-IgLON5 Encephalopathy: A Case Report– Phuongthao Quan, Ann Oh, Liang Wang, Srivadee Oravivattanakul P3.2-006 Pachymeningeal Enhancement in Anti-NMDA Receptor Encephalitis–Guillermo Delgado-García, Jesús RamírezBermúdez, Jose Jesus FloresRivera, Veronica Rivas, Jose Ignacio Munoz-Lopez, Leo Bayliss, Mariana Espinola-Nadurille

P3.2-007 GAD65 Antibody Encephalitis Presenting as Treatment Resistant Temporal Lobe Epilepsy and Peripheral Neuropathy in a Pediatric Patient–Maryam Nabavi Nouri, Michelle Chiu, Dewi Victoria Schrader, Osama Al-Jawadi P3.2-008 A Case of OpsoclonusMyoclonus Syndrome with Positive Serum Antibody Against Ganglionic (Alpha-3) Acetylcholine Receptor– Hadi Mohammad-Khanli, Eric C. Strong, Perry K. Richardson P3.2-009 Two Cases of Paroxysmal Dyskinesia Associated with Anti-GAD Antibody–Arpan Patel, Katherine Eacobacci, Pankti Shah, Prateeka Koul, Simona Vasilica Proteasa, Fred A. Lado P3.2-010 A Rare Case of Cerebral Tuberculosis and Autoimmune Encephalitis–Bhavika Kakadia, Larisa Syrow P3.2-011 Worsening of AntiHu Paraneoplastic Neurological Syndrome related to Anti-PD-1 Treatment: Case Report and Literature Review–Pooja Santosh Raibagkar, Doreen Ho, Krishna Gunturu, Jayashri Srinivasan

POSTER SESSIONS

P3.1-020 IFN- Is Essential For The Generation Of Type 1 Regulatory T Cells–Farinaz Safavi, Rodolfo Thome, Zichen Li, Javad Rasuli, Bogoljub Ciric, Guang-Xian Zhang, Mohamad Rostami P3.1-021 MSC-NTF Cell Immunomodulation: Effects on T and B Regulatory Cells–Revital Aricha, Natalie Abramov, Jonathan Semo, Haggai Kaspi, Chaim Lebovits, Ralph Kern P3.1-022 Retinal Pathology is Characterized by Retrograde Degeneration and Gliosis in a Mouse Model of Multiple Sclerosis–Praveena Manogaran, Marijana Samardzija, Anaïs Nura Schad, Carla Andrea Wicki, Christine Walker-Egger, Markus Rudin, Christian Grimm, Sven Schippling

Sunday, April 26

POSTER SESSIONS

POSTER SESSION 3 P3.4-003 Safety and Tolerability of NRL-1, an Intranasal Formulation of Diazepam, in Relationship to Usage Frequency in Subjects With Epilepsy: Interim Results From a Phase 3, Open-label, Repeat Dose Study–Ian Miller, James W. Wheless, R. Edward Hogan, Dennis J. Dlugos, Victor Biton, Gregory D. Cascino, Michael R. Sperling, Kore K. Liow, Blanca R. Vazquez, Ricardo Ayala, Eric Segal, Daniel C. Tarquinio, Weldon Mauney, Jay D. Desai, Enrique J. Carrazana, Adrian L. Rabinowicz, P3.4-004 Safety and Tolerability of NRL-1, an Intranasal Formulation of Diazepam, in Subjects with Epilepsy in a Phase 1, OpenLabel Study: Focus on Adverse Events Relevant to Clinicians and Patients–Daniel C. Tarquinio, R. Edward Hogan, Michael R. Sperling, James W. Wheless, Dennis J. Dlugos, Ian Miller, Adrian L. Rabinowicz, Enrique J. Carrazana, for the DIAZ.001.04 Study Group P3.4-005 Low Rate of Medication Errors Supports the Ability of Patients and Caregivers to Administer NRL-1, an Intranasal Formulation of Diazepam: Interim Results from a Phase 3, OpenLabel, Repeat Dose Study–Patricia Dean, Nancy Santilli, James W. Wheless, Blanca R. Vazquez, Eric Segal, Ian Miller, R. Edward Hogan, Enrique J. Carrazana, Adrian L. Rabinowicz, P3.4-006 Pharmacokinetics and Safety of Valtoco® (NRL-1; diazepam nasal spray) in Patients With Epilepsy During Seizure (Ictal/ Peri-ictal) and Non-seizure (Interictal) Conditions: Results from a Phase 1, Open-Label Study–R. Edward Hogan, Daniel C. Tarquinio, Michael R. Sperling, Pavel Klein, Ian Miller, Eric Segal, Adrian L. Rabinowicz, Enrique J. Carrazana, P3.4-007 Effectiveness and Safety of Valtoco® (NRL-1; diazepam nasal spray) in Patients With Epilepsy and a History of Seasonal Allergies: Interim Results From a Phase 3, Open-Label, 12-Month Repeat Dose Study– Blanca R. Vazquez, Michael R. Sperling, James W. Wheless, Kore K. Liow, Eric Segal, Ian Miller, R. Edward Hogan, Daniel C. Tarquinio, Weldon Mauney, Jay D. Desai, Dennis J. Dlugos, Ricardo Ayala, Victor Biton, Gregory D. Cascino,

CME

Enrique J. Carrazana, Adrian L. Rabinowicz, P3.4-008 A Two-Part, Phase 2b Efficacy Study of Staccato® Alprazolam Inhaler in Patients with Epilepsy with a Predictable Seizure Pattern: Topline Results from Part 2–Jacqueline French, Victor Biton, Hina N. Dave, Kamil Detyniecki, Michael Gelfand, Hui Gong, Kore K. Liow, Terence John O’Brien, Ahmed H. Sadek, Jouko Isojarvi P3.4-009 Cryptogenic new-onset refractory status epilepticus (NORSE) following blood transfusion in a patient with severe anemia–Connie Kang-Ling Wu, Erica Leah Von Stein, Collin Culbertson, Sandeep Songh Walia, Prashanth Krishnamohan, Zachary D. Threlkeld P3.4-010 A Three Year Retrospective Chart Review of Patients in Convulsive Status Epilepticus Presenting to the Emergency Department–Dana Louise Vanino, Trenton J. Tollefson, Inna Hughes, Lynn Liu P3.4-011 Status Epilepticus per se Did Not Lead to CSF Pleocytosis within the First 24 Hours–Sargun Bajaj, Donald Griesdale, Yahya Aghakhani, Farzad Moien Afshari P3.4-012 Can Consensus be Obtained on Preferred Practices for Rescue Therapies for Seizures and Seizure Clusters?–Lawrence J. Hirsch, Patricia Shafer, Jeffrey R. Buchhalter, Janice M. Buelow, Mary Nasuta, Andrea Tanner, Jacqueline French General Neurology: Health Services

P3.5-001 Assessing the Reliability of Reported Medical History in Older Adults–Gregory S. Day, Allison Long, John C. Morris P3.5-002 Integrating Advanced Practice Providers (APPs) in an academic Department of Neurology: perspectives and experiences of current APPs–Galina Gheihman, Angeliki Vgontzas, Jordan Paulson, David M. Pilgrim, Tracy T. Batchelor, Mary Angela O’Neal, Christopher T. Doughty P3.5-003 Needle in the Neuro Clinic: Access to an Intervention Pain Physician in Outpatient Neurology, a 1-year Sample.–

132 2020 AAN Annual Meeting

0 Sunday, April 26 Steven Soler, Alexis Ariel Clay, Katie McMillen, Michael D. Perloff P3.5-004 Proactive Ochsner Encounters: engaging all members of the neurology clinical care team in reminding patients of their overdue cancer screenings and immunisations.–Alexander Maslov, Caitlin Ernst, Julia I. Deyeva, Mohona Reza, Ravi Chilukuri, Jose H. Posas P3.5-005 Bridging the Divide: The Role of Neurologists in Reducing Reproductive Health Inequity in Women with Neurological and Other Disabling Health Conditions– Annette Wundes, Dagmar Amtmann, Claire Kalpakjian P3.5-006 Implementation of self-reported questionnaires to assess feasibility and adoption of 3D printing (3DP) and 3D virtual reality (VR) patient models in three complex spinal surgical cases–Alexander Maslov, Stephen Fletcher, Caleb Stewart, Jack McGee, Alec Slayden, James Kalyvas, Korak Sarkar P3.5-007 Tele Neurology-Cost Effective and Convenient–Melissa Reider-Demer, Dawn Eliashiv, Marc R. Nuwer, Inna Keselman P3.5-008 Fast Neuro = Expedited Access–Melissa Reider-Demer, Shuvro Roy, Timothy Edward Ryan, Marc R. Nuwer, Inna Keselman P3.5-009 An Evaluation of Patient Satisfaction of Telehealth Neurology Compared to In-person Neurology Consultations–Kelly Harper, Maxim Turchan, David Ezana, Claire Hanson, P. David Charles P3.5-010 Developing a Local Teleneurology Programme With Global Implications in Africa–N. Abimbola Sunmonu, Rufus O. Akinyemi, Bradford B. Worrall, Mayowa Owolabi, Nina J. Solenski Headache: Therapeutics 3

P3.6-001 First-Hand Impressions of the monoclonal Antibody in Migraine Prevention from Patients treated with Erenumab in Germany–Charly Gaul, Heike IsraelWillner, Katrin Schuh, Mirja Koch P3.6-002 Sustained Reduction of Migraine Headache Days in Patients with Episodic Migraine During Months 4 to 6 of Treatment with Galcanezumab–Stewart J. Tepper, Dustin Ruff, Linda Wietecha

12:00 p.m.–1:00 p.m. P3.6-003 Patient Preference for Dosing Regimen and Perception of Dosing Flexibility With Fremanezumab for Migraine: Results From a Patient Survey Following Completion of a 1-Year Extension Study–Robert Cowan, Sanjay Gandhi, Blaine Cloud, Joshua M. Cohen, Dawn C. Buse, Verena Ramirez Campos, Andrew H. Ahn, Richard B. Lipton P3.6-004 Onabotulinumtoxin A improves psychological aspects in chronic migraine patients–Hasan Ashkanani, Samar Farouk Ahmed, Ohood Almutairi, Fajer Bokubar, Shahad Mubarak, Sawsan Alwazzan, Raed Alroughani, Jasem Yousef Al-Hashel, Doaa Youssry P3.6-005 First one–year real world evidence data with the monoclonal antibody Erenumab in Germany–Andreas Straube, Phillip Stude, Charly Gaul, Mirja Koch, Katrin Schuh P3.6-006 Treatment Patterns and Comorbidities Among Patients Diagnosed with Post-Traumatic Headache at an Academic Medical Center–Sathvik Kakanuru, Daniel Krashin, Natalia Murinova P3.6-007 Ischemic Colitis Associated with Erenumab Use for Migraine–Shamik Bhattacharyya, Marie Gerhard-Herman P3.6-008 Anti-CGRP Class Reduces Migraine Burden Regardless of Concomitant Therapies in US Clinical Practice– Christopher Gottschalk, Kristen Henn, Jennifer Robinson, Virginia Schobel P3.6-009 Headache and Analgesic use following Aneurysmal Subarachnoid Hemorrhage– Brandon Lucke-Wold, Vyas Viswanathan, Chad Jones, Gabrielle Aiello, Youlei Li, Nicholas Nelson, Alexandra Ayala, Marc Alain Babi, Christopher Paul Robinson, Carolina B. Maciel, Katharina M. Busl P3.6-010 Oral Rimegepant Produces No Significant Effect on Blood Pressure When Administered Concomitantly with SC Sumatriptan–Michael Hanna, Andrea Ivans, Joseph Stringfellow, Christopher Jensen, Vlad Coric, Robert Croop P3.6-011 Effect of Yoga as add on Therapy in Migraine: A Randomized controlled study–Anand Kumar, Rohit Bhatia, Gautam Sharma, = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Neuromuscular Junction Disorders 1

Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 3

P3.8-001 Cortical amyloid-beta burden is associated with faster weight loss in cognitively normal individuals in late-life: a 6-year longitudinal study–Wei Xu P3.8-002 Principal component analysis of brain metabolism in symptomatic Alzheimer’s disease patients: A PET-FDG study.–Ignacio Demey, Ismael Calandri, Yanina Bergamo, Patricio Chrem Mendez, Leandro Urrutia, German Falasco, Jorge Campos, Gustavo Sevlever, Silvia Vazquez, Ricardo F. Allegri

P3.8-003 Structural Brain Patterns in Bilingual Versus Monolingual Persons with Alzheimer’s Disease– Cyrus A. Raji, Somayeh Meysami, Mario F. Mendez P3.8-004 Cerebellar Volume Is Associated With Cognitive Function in Mild Cognitive Impairment: Results from ADNI–Chi-Ying Lin, Sarah Tom, Chi-Hua Chen, ShengHan Kuo P3.8-005 Preserved Cholinergic Forebrain Integrity Reduces Structural Connectome Vulnerability in Mild Cognitive Impairment–Rok Berlot, Blaz Koritnik, Zvezdan Pirtosek, Nicola Ray P3.8-006 Semantic Network Assessment in Mild Cognitive Impairment and Alzheimer’s Disease–Maria Paula Maziero, Ariella Fornachiari Belan, Marina von Zuben de Arruda Camargo, Orestes Vicente Forlenza, Marcia Radanovic P3.8-007 Risk estimation of Amyloid Beta positivity on PET with Cognitive, CSF Biomarkers, volumetric MRI, APOE, and Demographic information.–Ali Ezzati, Danielle Harvey, Ashkan Golzar, Christian Habeck, Irfan Qureshi, Andrea R. Zammit, Jinshil Hyun, Monica Truelove-Hill, Charles B. Hall, Christos Davatzikos, Richard B. Lipton P3.8-008 White Matter Hyperintensities Relate to Activities of Daily Living More Strongly in Dementia with Lewy Bodies than in Alzheimer’s disease-The Sunnybrook Dementia Study–Saira Mirza, Usman Saeed, Joel Ramirez, Donald Stuss, Sandra E. Black, Mario Masellis P3.8-009 Brain Changes and Fast Decline in Cognition and Gait Speed: Findings from the SNACK-MRI Study–Giulia Grande, Davide Liborio Vetrano, Gregoria Kalpouzos, Anna-Karin Welmer, Anna Marseglia, Laura Fratiglioni, Debora Rizzuto P3.8-010 A Data-driven Approach for Estimating the Spatial Resolution of Brain PET images– Felix Carbonell, Alex P. Zijdenbos, Barry Bedell

Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 3

P3.9-001 Volumetric Analysis of Infarct on Brain Magnetic Resonance Imagining and Clinical Outcome in Ischemic Stroke after Mechanical Thrombectomy– Ahmad Sweid, Mahdi Alizadeh, Reid Gooch, Nikolaos Mouchtouris, Pascal Jabbour, Stavropoula Tjoumakaris, Robert H. Rosenwasser, Joshua Weinberg, Nabeel Herial P3.9-002 Developmental Venous Anomaly Inside a Glioblastoma– Jose Danilo Bengzon Diestro, Thomas Marotta, Julian Spears P3.9-003 Champagne MRI postTPA: An unusual case in a pediatric stroke patient with a large vessel occlusion–Irfan Sahail Sheikh, Nasar Ali, Khaled Gharaibeh, Ehad Afreen, Syed F. Zaidi P3.9-004 Stroke Patients with Coexisting Coronary Artery Disease and Antiplatelet Use at the Time of Stroke Harbor Increased Risk of a Further Vascular Event: A ClinicalBiomarker Analysis–Ei Zun The, Mei Yen Ng, Geelyn Ng, Bernadette Er, Amy May Lin Quek, Raymond CS Seet Stroke Epidemiology, Disparity, and Quality Improvement 1

P3.9-005 Make Kids StrokeSmart: A Community Based Interventional study.–Dipali P. Nemade, Mitzi Beckett, Justin Michael Nolte, Vikram Shivkumar P3.9-006 The Kansas Initiative for Stroke Survival. A Grass-Roots Effort to Improve Stroke Care in the State of Kansas.–Colleen Grace Lechtenberg, Yunxia Wang P3.9-007 Development of a Post-Stroke Transition Telehealth Program using Community Engagement - Survey Results– Maninder Sohi, Chad Aldridge, Ted Sindlinger, Justin Smith, Maya Lezzam, Amber Botkin, Leslie Gladney, Nina J. Solenski, Sherita Chapman P3.9-008 Developing a process for IV tPA door-to-needle administration in 30 minutes or less; a multidisciplinary approach– Sumaiya Khondker, Marc A. Lazzaro

AAN.com/view/20AM 133

Sunday, April 26

P3.7-001 Distribution of mutations associated with congenital myasthenic syndromes (CMS): results from the first 54 specimens tested at a clinical reference laboratory–Sat Dev Batish, Lebron Lebron, Marc Meservey, Jeff S Radcliff, Zhenyuan Wang, Vivekananda Datta P3.7-002 Targeting the neuromuscular junction to treat congenital myasthenic syndromes and inherited motor neuropathies– Hanns Lochmuller, Sally Spendiff, Denisa Hathazi, Armin Maeder, Stefan Hettwer, Andreas Roos, Rita Horvath P3.7-003 Recessive Congenital Myasthenic Syndrome Caused by a Homozygous Mutation in SYT2 Altering a Highly Conserved C-terminal Amino Acid Sequence– Ricardo A. Maselli, Helio Van Der Linden, Michael Ferns P3.7-004 Respiratory Assessments in the Neuromuscular Clinic in Patients with Myasthenia Gravis–Hans D. Katzberg, Carolina Barnett Tapia, Shabber Mannan, Eduardo Ng, Clodagh Ryan, Vera Bril P3.7-005 MuSK Antibody Positive Myasthenia Gravis Presenting with Bilateral Vocal Cord Abduction Paralysis: A Case Report and Literature Review–Ashley Santilli, Derek William Stitt P3.7-006 Myasthenia Gravis, Myocarditis, and Pericarditis in a Patient with Thymoma–Ryan Fogg, Lillian Flashner, William Jimenez, Rabia Choudry, Anishee Undavia, Aparna M. Prabhu

P3.7-007 Effect of Ramadan fasting on Myasthenia Gravis– Ismail I. Ibrahim, Walaa Elsayed, Fathi Massoud, R Khan, Jasem Yousef Al-Hashel P3.7-008 Familial MuSK Myasthenia Gravis–Janice M. Massey, E. Wayne Massey P3.7-009 Long-term risk of generalization in patients with pure ocular myasthenia gravis– Mohammed Said Alharbi, Anas Al-Dehailan, Mohammed Alqwaifly, Hans D. Katzberg, Vera Bril, Carolina Barnett Tapia P3.7-010 A Simple Question to Self-Report Myasthenia Gravis Severity Can Predict Patient Acceptable States–Deepak Menon, Carolina Barnett Tapia, Vera Bril P3.7-011 Case Series: Adding Intravenous Immunoglobulin Therapy in Steroid Refractory Ocular Myasthenia Gravis.–Hannah C. Machemehl, Jamie Morrell, Sami L. Khella P3.7-012 Comparison of Different Criteria for Refractory Myasthenia Gravis–Christopher Tran, Aishani Biswas, Meg Mendoza, Hans D. Katzberg, Vera Bril, Carolina Barnett Tapia P3.7-013 Eculizumab in the Treatment of Seronegative Refractory Generalized Myasthenia Gravis–Shivangi Singh, Harsh Singh, Sorabh Datta, Raghav Govindarajan P3.7-014 Reversible tongue atrophy in Seronegative Myasthenia Gravis following treatment–Janice M. Massey, E. Wayne Massey

POSTER SESSIONS

Dhanlika Dhanlika, Sreenivas Vishnubhatla, Manjari Tripathi, Deepa Dash, Rajesh Kumar Singh, Padma Vasantha Hadakasira P3.6-012 Prophylactic Treatment Patterns Among Patients Diagnosed with Migraine at Tertiary Medical Center and in Tertiary Headache Clinic.–Amita Singh, Daniel Krashin, Natalia Murinova P3.6-013 Switching and Discontinuation Patterns Among Triptan Users: A Systematic Literature Review–Alison Deighton, Karissa Johnston, Parisa Dabirvaziri, Linda Harris, Gilbert J. L’Italien, Richard B. Lipton

Sunday, April 26

POSTER SESSIONS

POSTER SESSION 3 P3.9-009 Door-In to Door-Out time in Emergent Large Vessel Occlusion: retrospective review informs targeted improvement strategies–Marek Cierny, Susan Fuhrman, Marc A. Lazzaro P3.9-010 Improving Performance Metrics in Acute Stroke Care by Use of Standardized Stroke Templates–Liang Wang, Phuongthao Quan, Yazan Al-Hasan, Xiao Weng, Justin Hoskin, Shane Root, Melissa Rene Balbuena-Root, Michael F. Waters P3.9-011 Quality Improvement Project: Factors for Stroke Clinic ‘No Shows’–Carmela San Luis, Shreyas Gangadhara, Shashank Shekhar, Christa O’hana San Luis Nobleza P3.9-012 Evaluating the Impact of Language Barriers on Management of Ischemic Stroke.–Tamar Berger, Elle Rathbun, Bardia Abbasi, Elle Rathbun, Jillian Tellier P3.9-013 Cardiovascular Events in LGBT (Lesbian, Gay, Bisexual, Transgender): An Overlooked Disparity and a Call to Action– Shivani Naik, Sahil Naik, Gopika Kutty, Tamour Khan Tareen, Murali K. Kolikonda, Kerri S. Remmel, Wei Liu P3.9-014 Understanding Cultural and Knowledge Barriers to Acute Stroke Care in the Los Angeles Filipino American Community– Antonio Moya, Eric M. Cheng, Vincent Grospe, Julia Brock, Linh Vo P3.9-015 Language Proficiency is a Marker of Vascular Risk and Ischemic Stroke Severity–Ryan Thomas Muir, Arunima Kapoor, Krista Lanctot, Megan L Cayley, Michelle Sicard, Karen Lien, Dariush Dowlatshahi, Demetrios James Sahlas, Gustavo Saposnik, Jennifer Mandzia, Leanne Casaubon, Ayman Emam H. Hassan, Yael Perez, Brian James Murray, Kevin Thorpe, Moira Kapral, Stephen Strother, Amy Ying Xin Yu, Peter Austin, Susan Bronskill, Nathan Hermann, Richard H. Swartz P3.9-016 The Association between Immigration Status and Acute Stroke Care: A Retrospective Study–Manav Vyas, Andreas Laupacis, Peter Austin, Jimming Fang, Frank L. Silver, Moira Kapral P3.9-017 No difference in tPA treatment times between whites and blacks in acute ischemic stroke

CME

patients–Sami Bajwa, Anand Vilaschandra Patel, Sneh Preet Munder, Karalyn Pappas, Jeffrey M. Katz, Richard Libman P3.9-018 Gender Differences In Etiologies Of Stroke-related Deaths In An Era Of Availability For Stroke Intervention–Alyssa Bautista, Sai Prasant Polineni, Seemant Chaturvedi P3.9-019 Increased occurrence of migraine in perimenopausal aged women with stroke–Morgan Figurelle, Crystal Sosa, Rebecca E. Wells, Amy K. Guzik P3.9-020 Gender Disparities in the Neurologic Management of Acute Stroke at a Military Treatment Facility–Morgan Christina Jordan, Jeffrey C. McClean P3.9-021 Young African Americans With Stroke Have A Greater Burden Of Multiple Risk Factors Than Their White Counterparts–Prachi Mehndiratta, Kathleen Ryan, John Cole, Marcella A. Wozniak, Seemant Chaturvedi, Carolyn Cronin, Michael Phipps, Jose G. Merino, Tara McColgin Dutta, Steven J. Kittner Basic Science and Clinical Neuro-oncology 3

P3.10-001 Reliability of Quantitative Brain Imaging Biomarkers–Fatemeh Hajighasemi, Kamran Paynabar, Kourosh JafariKhouzani, Bruce R. Rosen P3.10-002 Temozolomide Treatment in Patients with Refractory Pituitary Adenomas; A Case Series–Kelsey Duncan, Bahaudden Arafah, Lisa R. Rogers P3.10-003 Geriatric Syndromes and Treatment Toxicities in Older Patients with Malignant Gliomas– Ahmar Alam, Andrea C. Wasilewski, Nimish A. Mohile Neuro-oncology: Clinical Cases and More 1

P3.10-004 Neurosarcoidosis as a Mimic of Perineural Invasion– Sushma Kola, Daniel H. Lachance P3.10-005 A Rare Case of Plasma Cell Leukemia Meningitis–Mahsa Sadeghi, Jay Liuhong Liu, Ghadeer Fatani, Geoffrey R. Barger P3.10-006 Intravascular Lymphoma Presenting as Internal Border-zone Infarcts–Shweta Goswami, Yunxia Wang, John Leever

134 2020 AAN Annual Meeting

0 Sunday, April 26 P3.10-007 A Rare Case of Ecchordosis Physaliphora Presenting with Headache, Abducens Nerve Palsy and Intracranial Hypertension–Ruiqing Sun, Yousaf Ajam, Todd Masel P3.10-008 Paraneoplastic Opsoclonus-Myoclonus Syndrome As Presenting Symptom of Primary Gallbladder Adenocarcinoma– Lauren Brandes, Megan M. Mantica P3.10-009 Extrapituitary Manifestations of Xanthomatous Hypophysitis–Justin Hoskin, Yazan Al-Hasan, Stephen Coons, Jennifer Eschbacher, Christopher Dardis P3.10-010 Adult-onset CNS Langerhans Cell Histiocytosis: Mystery Cases–Aarushi Suneja, Anza Memon, Abir Mukherjee P3.10-011 What’s Shining in Your Spine? – An Unusual Case of Locked-in Syndrome–Jordan C. Gargiulo, Prashant Natteru, Shashank Shekhar, Hartmut Uschmann P3.10-012 Rapidly Progressive Dementia Prompting Histopathological Confirmation: An Unusual Case of CNS Intravascular Lymphoma–Belen Lawless, Gregory M. Blume, Diana P. Londono, Luis Guillermo Manrique, Hope Olszewski P3.10-013 Neuroleukemiosis Presenting as Mononeuritis Multiplex–Michael N. Youssef, Ellen Schlette, Sudhakar Tummala P3.10-014 A Case Report of Recurrent Longitudinally Extensive Holocord Transverse Myelitis After Combination Immune Checkpoint Inhibitor Therapy with Nivolumab and Ipilimumab–Nupur Brahmbhatt, Karan S. Dixit P3.10-015 A Rare Case of Burkitt’s Lymphoma Presenting with Features Mimicking Vogt Koyanagi Harada Disease–Ramya Tadipatri, Daniel Gonzalez, Suraj Muley

12:00 p.m.–1:00 p.m. Sleep Medicine: Focus on Therapies 2

P3.11-001 Effects of Pitolisant on Nighttime Sleep–Annika Triller, Annika Hof zum Berge, Benedicte Finger, Ulf Kallweit P3.11-002 Safety and Tolerability of Pitolisant in the Treatment of Adult Patients With Narcolepsy: An Open-Label, Expanded Access Program in the United States–Eric Bauer, Craig Davis, Albena Ilieva Patroneva, Jeffrey M. Dayno, Michael J. Thorpy P3.11-003 Efficacy of Pitolisant in Patients With High Burden of Narcolepsy Symptoms–Craig Davis, Lois Krahn, Ben Vaughn, Michael J. Thorpy P3.11-004 Long-Term Effects of Solriamfetol on Functioning and Work Productivity in Participants With Excessive Daytime Sleepiness Associated With Narcolepsy– Nancy R. Foldvary-Schaefer, Terri E Weaver, Richard Schwab, Colin Shapiro, Jan Hedner, Mansoor Ahmed, Patrick Strollo, Geert K. Mayer, Michelle Baladi, Morgan Bron, Patricia Chandler, Lawrence Lee, Atul Malhotra P3.11-005 Clinically Relevant Effects of Solriamfetol on Excessive Daytime Sleepiness: A Post-Hoc Analysis of the Magnitude of Change in a Clinical Trial of Adults With Narcolepsy– Russell Rosenberg, Michelle Baladi, Diane Menno, Morgan Bron P3.11-006 Pharmacokinetics and Formulation Selection of FT218, a Once-Nightly Sodium Oxybate Formulation for the Treatment of Narcolepsy–Jordan Scott Dubow, David Monteith, Julien Grassot, David J. Seiden P3.11-007 The PharmacokineticAdverse Event Relationship For FT218, a Once-Nightly Sodium Oxybate Formulation–David J. Seiden, Julien Grassot, David Monteith, Jordan Scott Dubow P3.11-008 Pharmacokinetics and Dose Proportionality of FT218, a Once-Nightly Sodium Oxybate Formulation for the Treatment of Narcolepsy–Jordan Scott Dubow, Julien Grassot, David Monteith, David J. Seiden P3.11-009 The Pharmacokinetics of Once-Nightly Sodium Oxybate FT218: Food Effect and Relative

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

Biovailability Compared to TwiceNightly Sodium Oxybate–David J. Seiden, Jordan Scott Dubow, David Monteith, Jordan Scott Dubow P3.11-010 Sodium Oxybate Treatment Effects on Sleep Architecture in Pediatric Patients With Narcolepsy With Cataplexy–Emmanuel Mignot, Richard K. Bogan, Jed Black, Rupa Parvataneni, Diane Menno, Y. Grace Wang, Yves Dauvilliers P3.11-011 Changes in Cataplexy Frequency by Therapy at Study Entry in a Phase 3, PlaceboControlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults With Narcolepsy With Cataplexy–Michael J. Thorpy, Karel Sonka, Richard K. Bogan, Markku Partinen, Rafael del Rio Villegas, Nancy R. FoldvarySchaefer, Roman Skowronski, Lihua Tang, Franck Skobieranda, Yves Dauvilliers P3.11-012 Cataplexy-Free Days With Sodium Oxybate Treatment in Children/Adolescents With Narcolepsy With Cataplexy– Emmanuel Mignot, Carol L. Rosen, Diane Menno, Y. Grace Wang, Judi Profant, Yves Dauvilliers P3.11-013 Concomitant Evolution of Treatment and Symptoms of Narcolepsy in a Longitudinal Study–Maurice Moyses Ohayon, Andrew Krystal, Todd J. Swick, Jed Black, Shannon Sullivan, Colin Shapiro, Charles C. Wells

Sunday, April 26

AAN.com/view/20AM 135

POSTER SESSION 4

CME

0 Sunday, April 26

5:30 p.m.–6:30 p.m.

Sunday, April 26

POSTER SESSIONS

Poster Session 4 1. Multiple Sclerosis: Immunology and Basic Science 2: 1-001 to 1-008 Multiple Sclerosis: Epidemiology 1: 1-009 to 1-020 2. Autoimmune Neurology 4: 2-001 to 2-003 Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 1: 2-004 to 2-012 3. Parkinson’s Disease Biomarkers and Pathophysiology: 3-001 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 2: 4-001 to 4-008 Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 1: 4-009 to 4-012 5. Medical Student Essay Award Recipients: 5-001 to 5-004 Neuroscience Research Prize Recipients: 5-005 to 5-007 6. Headache: Therapeutics 4: 6-001 to 6-013 7. Neuromuscular Junction Disorders 2: 7-001to 7-012 8. Aging and Dementia: Basic Science, \Biomarkers, and Genetics 1: 8-001 to 8-011 9. Stroke Epidemiology, Disparity, and Quality Improvement 2: 9-001 to 9-015 Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 1: 9-016 to 9-021 10. Neuro-oncology: Clinical Cases and More 2: 10-001 to 10-015 11. Neuro-ophthalmology/Neuro-otology 1: 11-001 to 11-013

Multiple Sclerosis: Immunology and Basic Science 2 P4.1-001 In depth analysis of B cells in multiple sclerosis patients after long-term treatment with Alemtuzumab–Felix MarshWakefield, Pierre Juillard, Thomas Ashhurst, Helen McGuire, Scott N Byrne, Georges Grau, Simon Hawke P4.1-002 Finding New Targets for the Understanding and Treatment of Multiple Sclerosis: Modeling Multiple Sclerosis through DiseaseSpecific Neural Stem Cells–Paul Martin Elsbernd, Jon P. Williams, Marcel Daadi P4.1-003 Immunoglobulins Modulated Oxidative Stress and Cytokines Expression in Human Microglial Cells Induced by Ketone Bodies–Hongxin Chen, Nizar Souayah P4.1-004 Expression Profiles of Novel Noncoding RNAs in the CSF and Blood Samples of Multiple Sclerosis Patients–Anna Iacoangeli, Clara Arndtsen, Julia Granato, Saud A. Sadiq P4.1-005 Single Cell Analysis of MS CSF B-Cells Show Significant Differences in Expansion Patterns and Gene Family Usage Between MS Subtypes–Jonah Vernejoul,

Francesca Marie Cali, Jerry Lin, Saud A. Sadiq P4.1-006 Ingested ACTH Blocks Th17 Production by Inhibiting GALT IL-6–Staley A. Brod P4.1-007 Demyelinated White Matter Exhibits Upregulated DNA Damage Response and Cellular Senescence in Progressive Multiple Sclerosis–Richard St. John Nicholas, Sara Bandiera, Richard Reynolds, Lesley Probert, Roberta Magliozzi, Dimitrios Papadopoulos Multiple Sclerosis: Epidemiology 1

P4.1-008 The Role of Metabotropic Glutamate Receptors in Cerebellar Dysfunction in Multiple Sclerosis– Julia Granato, Clara Arndtsen, Anna Iacoangeli, Saud A. Sadiq P4.1-009 Bone health, fracture risk, and Multiple Sclerosis: a UK Biobank study–Sara Leddy, Benjamin Jacobs, Gavin Giovannoni, Ruth Dobson P4.1-010 Clinical profile of AfricanAmerican and Caucasian patients with Multiple Sclerosis–Maria Petracca, Amgad Droby, MohamedMounir El Mendili, Swetha Paduri, Nicole Graziano, Natalie Saba, Arielle Falcone, Daniel Peter Kurz, Claire Riley, Jonathan Howard, Sylvia Klineova, Matilde Inglese

136 2020 AAN Annual Meeting

P4.1-011 Comparison of the proportions of Secondary Progressive Multiple Sclerosis between three registries within the SPMS Research Collaboration Network–Lars Forsberg, Alexander Stahmann, Rod Middleton, David Ellenberger, Jeff Rodgers, Richard St. John Nicholas, Ryan Ramanujam, Ali Manouchehrinia, Natasha Pillai, Pamela Dobay, Carol Lines, Thomas Hach, Anna Glaser, Jan A. Hillert P4.1-012 Obesity is associated with Optic Neuritis severity in Male patients with Multiple Sclerosis– Duong Chu, Mattia Rosso, Cindy Gonzalez, Shrishti Saxena, Brian Curran Healy, Howard L. Weiner, Tanuja Chitnis P4.1-013 Environmental exposures associated with Multiple Sclerosis: a UK Biobank study–Benjamin Jacobs, Gavin Giovannoni, Ruth Dobson P4.1-014 Late Onset Multiple Sclerosis: an Epidemiologic Study from the First Brazilian MS Center–Keila Narimatsu, Luiza Ramos De Freitas, Natalia Mendes, Ronney Lopes, Lohana Silva, Tamara Albuquerque, Paulo Freitas, Guilherme Olival

P4.1-015 A seasonal pattern of clinical activity remains in untreated MS patients in Montpellier and CLIMB cohort.– Pauline Prin, Virginia Rinaldi, Swetha Mandala, James Zheyong, Miklos Palotai, Clarisse CarraDalliere, Xavier Ayrignac, Nicolas Menjot de Champfleur, Pierre Labauge, Charles R.G. Guttmann P4.1-016 Epilepsy and multiple sclerosis: a comorbidity in Argentinian cohort patients without progressive forms–Guido Vazquez, Judith Diana Steinberg, Celeste Curbelo, Fatima Pagani Cassara, Anibal Chertcoff, Vladimiro Sinay, Adriana Carra P4.1-017 Tracking cognitive change in people with multiple sclerosis – 5 year follow up of the original Irish BICAMS validation cohort.–Maria Gaughan, Ruth Monaghan, Karen O’Connell, Fiadhnait O’Keeffe, Christopher McGuigan P4.1-018 Decreasing RTX Doses are associated with Stable Disease in Patients with Multiple Sclerosis– Claudio Gobbi, Gianna Riccitelli, Jens Kuhle, Rosaria Sacco, Chiara Zecca

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number P4.1-019 Increasing Trends of Cancer Diagnoses in People with Multiple Sclerosis–Claudio Gobbi, Giulio Disanto, Rosaria Sacco, Sharon MacLachlan, Sreeram Ramagopalan, Chiara Zecca P4.1-020 Timing is Everything: Comorbid Conditions Diagnosed after Multiple Sclerosis have Greater Effect on Disability, Participation and Quality of Life Among Older People with Multiple Sclerosis–Megan Christine Kirkland, Elizabeth M. Wallack, Michelle Ploughman

Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 1

Parkinson’s Disease Biomarkers and Pathophysiology

P4.3-001 CSF biomarkers in Parkinson patients with and without freezing of gait–Johnathan Lucas McKay, Jaime HatcherMartin, J. Christina Howell, William T. Hu, Stewart A. Factor P4.3-002 Cortical Responses to Balance Perturbation are Abnormal in Parkinson’s Disease–Aiden Payne, Lena Ting P4.3-003 Exploring the Parkinson’s disease phenome in the UK Biobank population–Daniel Belete, Benjamin Jacobs, Anette E. Schrag, Alastair John Noyce

P4.3-012 Role of uric acid and Apo A1 as biomarkers in Idiopathic Parkinson’s Disease and Parkinson Plus Syndromes in North Indian population–Tanish Modi, Jasbinder Kaur, Ritu Shree, Missamma Mulagala, Sahil Mehta P4.3-013 High Serum Cortisol levels are associated with fatigue and verbal fluency in Parkinson’s Disease: preliminary results– Gabriela Magalhães Pereira, Nayron Soares, Ana Carolina Leonardi Dutra, Nathalie Ribeiro Artigas, Julia Schneider Krimberg, Artur Francisco Schumacher Schuh, Rosa Maria Martins de Almeida, Carlos Roberto de Mello Rieder P4.3-014 GBA and ATP13A mutation and PD: clinical phenotype and pathogenic implications–Giulietta Riboldi, William T. Dauer, Steven Frucht P4.3-015 An Inconsistency Investigated: Parkinson’s Retrospective Autopsy Series and Clinicopathologic Correlation–Ali Rada Eltatawy, Mehmood Rashid P4.3-016 Brain Functional Plasticity of the Limbic Circuit in Parkinson’s Disease Patients with Freezing of Gait–Elisabetta Sarasso, Federica Agosta, Noemi Piramide, Elisa Canu, Maria Volonté, Massimo Filippi P4.3-017 Relationship of Cerebrospinal Vitamin B12 Indicators with Outcomes in a Large, Early Parkinson’s Disease Cohort (DATATOP)–Chadwick W. Christine, Peggy Auinger, Nasrin Saleh, Erland Arning, Teodoro Bottiglieri, Nam Tran, Per Ueland, Ralph Green Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 2

P4.4-001 EEG Patterns Predicting Poor Prognosis In Elderly Patients With Generalised Convulsive And Non-Convulsive Status Epilepticus– DEVAVRAT NENE, Raghavendra Kenchaiah, Ravindranadh Chowdary Mundlamuri, Parthasarathy Satishchandra, Madhu Nagappa, Parayil Sankaran Bindu, Prathyusha Parthipulli Vasuki, Kandavel Thennarasu, Jitender Saini, Rose Dawn Bharath, Arun Taly, Sanjib Sinha

AAN.com/view/20AM 137

Sunday, April 26

P4.2-004 Profile Of Patients With Guillain- Barre Syndrome During Pregnancy In A Tertiary Care Hospital In South India.–Namrata Jayaharan, Balasubramanian Samivel, Lakshmi N. Ranganathan, Shanmugasundaram N, Uma Maheswari E P4.2-005 Can Certain Baseline Characteristics in Patients with Stiff Person Syndrome (SPS) Predict Disease Burden and Functional Outcomes?–Loulwah Mukharesh, Kathryn Fitzgerald, Yujie Wang, Scott Douglas Newsome P4.2-006 Determination of sensitivity and specificity of live clustered cell based acethylcholine antibody assay in a well characterized cohort of adult myasthenia gravis patients–Jeff Guptill, Hans Frykman, Anna Fronda, Ebrima Gibbs

P4.3-004 Inhibiting the Depalmitoylase APT1 Protects Against Alpha-synuclein Neurotoxicity: A Novel Target for Disease-modifying Therapy in Human Synucleinopathies–Gary Ho, Nagendran Ramalingam, Erin C Wilkie, Thibaut Imberdis, Ulf Dettmer, Dennis J. Selkoe P4.3-005 Neuroinflammation Genomic Markers in Genome-wide Association Study of Parkinson’s Disease–Sun Ju Chung, Nari Choi, Juyeon Kim, Kiju Kim, Mi-Jung Kim, Young Jin Kim, Ho-Sung Ryu, Kye Won Park P4.3-006 Cortical High-Beta EEG Response to Dopaminergic Therapy in Parkinson’s Disease–Stephanie Tran, Karlo J. Lizarraga, Julianne Baarbe, James Saravanamuttu, Robert E. Chen P4.3-007 Lower Vitamin B12 Level at Parkinson’s Disease Diagnosis is Associated with Higher Risk of Dementia in the Future–Stuart McCarter, Cole Stang, Pierpaolo Turcano, Michelle M. Mielke, James H. Bower, Rodolfo Savica P4.3-008 Low serum Uric Acid levels are related to dyskinesia and postural instability/gait difficulty in Parkinson’s Disease–Nayron Soares, Gabriela Pereira, Ana Carolina Leonardi Dutra, Nathalie Ribeiro Artigas, Julia Schneider Krimberg, Artur Francisco Schumacher Schuh, Rosa Maria Martins de Almeida, Carlos Roberto de Mello Rieder P4.3-009 Abnormal intracortical facilitatory-inhibitory circuit interactions in patients with Parkinson’s disease–James Saravanamuttu, Natasha Radhu, Kaviraja Udupa, Carolyn Gunraj, Julianne Baarbe, Robert E. Chen P4.3-010 Antibody Synthesis in the CNS is Associated with Cognition in Parkinson’s disease– Marian Shahid, Patricia Linortner, Li Zhu, Cyrus P. Zabetian, Joseph F. Quinn, Brenna Cholerton, Thomas J. Montine, Lu Tian, Marion S. Buckwalter, Kathleen Poston P4.3-011 Neurofilament Light Chain as a Fluid Biomarker of Disease Progression and Disease Modification by PBT434 in a Mouse Model of MSA–Violetta Refolo, Amanda Heslegrave, Margaret Bradbury, Henrik Zetterberg, David A. Stamler, Nadia Stefanova

POSTER SESSIONS

Autoimmune Neurology 4 P4.2-001 Clinical and Immunological Investigation of Glial Fibrillar Acidic Protein Astrocytopathy in China—A Single Center Study of 11 Cases–Lei Liu, Jiawei Wang P4.2-002 Case of Concurrent Herpes simplex Encephalitis and Leucine-Rich Glioma Inactivated 1 Encephalitis–John Peters, Sarah Flanagan Wesley P4.2-003 Concomitant Chorea, Head Tremor and Cerebellar Degeneration; a Rare Combination in a Case of CRMP-5 Encephalitis– Harsh Patel, Hina Aslam, Robert Glenn Smith

P4.2-007 Validation of live clustered cell based acethylcholine antibody assay and utility in children with myasthenia gravis– Hans Frykman, Anna Fronda P4.2-008 Validation of a Surface Plasmon Resonance Assay for the Diagnostic Detection and Characterization of Muscle-specific Kinase (MuSK) Antibodies in Myasthenia Gravis Patients–Hans Frykman, Ebrima Gibbs P4.2-009 Additional Analyses of the Phase 2 Efgartigimod Study in Myasthenia Gravis–James F. Howard, Vera Bril, Renato Mantegazza, Said R. Beydoun, Fancisco Javier De Rivera Garrido, Fredrik L. Piehl, Maria Rosa Rottoli, Philip Van Damme, Tuan Hoang Vu, Peter Ulrichts, Antonio Guglietta, Jon Beauchamp, Hans de Haard, Jan Verschuuren P4.2-010 Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)–Sumit Verma, Raj Razdan, Ghazal Ahmad P4.2-011 Effect of Complement Inhibition on Lymphocytes in Treatment Refractory Myasthenia Gravis Patients–Jeff Guptill, James F. Howard, Melissa Russo, Doug Emmett, Manisha Chopra, Vern C. Juel, Janice M. Massey, Lisa Hobson-Webb, John Yi P4.2-012 B cell subsets and T follicular helper cells in myasthenia gravis thymus–Yohei Yamamoto, Naoko Matsui, Fumiko Oda, Yukiko Ozawa, Tetsuya Kanai, Akiyuki Uzawa, Izumi Ohigashi, Takashi Yamamura, Satoshi Kuwabara, Yuishin Izumi, Ryuji Kaji

Sunday, April 26

POSTER SESSIONS

POSTER SESSION 4 P4.4-002 Assessing the Value of Interhospital Transfer for Patients with Suspected Status Epilepticus (SE)–Ian Cossentino, Neha Dangayach, John Liang, Cappi C Lay, Alexandra S. Reynolds, Christopher Kellner, Kaitlin Johanna Reilly, on Behalf of the Mt Sinai NEMAT Research Group P4.4-003 Marked Response to Lidocaine Plus MgSO4 Treatment in a New Onset Febrile InfectionRelated Refectory Status Epilepticus–Helen Burks, Barlas Benkli, Mahsa Khayatkhoei, Yigit Karasozen, Shaun O. Smart P4.4-004 Pregabalin As Adjunctive Treatment For Symptomatic Cyclic Seizures In Neurocritically Ill Patients–Zachary M. Newcomer, Mitesh Patel, Katharina M. Busl, Jiang Meilin, Li Zhigang, Katherine Thomspson, Marc Alain Babi, Christopher Paul Robinson, Maria J. Bruzzone, Maria Hella, Stephan Eisenschenk, Carolina B. Maciel P4.4-005 Patient and Caregiver Preference for Route of Administration of a Benzodiazepine for Control of Increased Seizure Activity in Stable Patients–Gary Slatko, Ayanna Santos P4.4-006 NORSE (New Onset Refractory Status Epilepticus) due to ANNA-2 associated paraneoplastic encephalitis– Carolina Cuello-Oderiz, Irine Siraj, Elena Schmidt, Luis J. Mejico, Julius Latorre P4.4-007 A case of isolated and prolonged aphasic status epilepticus–Chen Chen, David A. Marks P4.4-008 Cardiology Perspective on Seizure Related Bradyarrhythmias and SUDEP: A Survey Study–Mark Farrenburg, Aniket Rali, Anna Grodzinsky, Y. Madhu Reddy, Patrick Landazuri Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 1

P4.4-009 Frequency and Types of Electrocardiogram Abnormalities Found During Electroencephalogram Recordings– Khalid I. El-Salem, Ahmed Moh’d Yassin, Abdel-Hameed AlMistarehi, Sumayyah Abumurad, Mohammad Qasaimeh, Raid M.

CME

Kofahi, Kefah Adnan Al-Hayk, Majdi Al Qawasmeh, Salma Yahya Bashayreh, Mohamad Jarrah P4.4-010 Fixation of sensitivity and other Eye condition related epileptiform discharges, an institutional cohort–Smitha Chandran, Praveen Kumar, Archana Netto Becket, Smitha Chandran, Smitha Chandran, Janardhan DC P4.4-011 Utility of Continuous Video EEG in patients with Cardiac Arrest–Ritika Suri, Lonni Schultz, Gregory L. Barkley, Jules Constantinou, Shailaja Gaddam, Marianna V. Spanaki-Varelas, Vibhangini Wasade P4.4-012 Continuous EEG for Seizure Detection in Neonates after Cardiac Bypass without Deep Hypothermic Cardiac Arrest– Rebecca Jeannette Levy, Amanda Sandoval Karamian, Elizabeth Mayne, Mehreen Iqbal, Natasha Purington, Kathleen Ryan, Courtney Wusthoff Medical Student Essay Award Recipients

P4.5-001 Sleep Restriction Therapy for Drosophila Models of Neurodegenerative Disease– Samuel Belfer P4.5-002 Comparison of Different Criteria for Refractory Myasthenia Gravis–Christopher Tran P4-5.003 Eponyms Are Here to Stay: Usage in the Literature and Among Current Neurology Trainees– Jimmy Zheng P4-5.004 Responding to the Needs for Rapid, High-yield eLearning Content in Neurology–Laura Lavette Neuroscience Research Prize Recipients

P4-5.005 Interactions Between Hippocampal Features and Sleep Spindle Architecture in Cognitively Normal Elderly–Abe Baker-Butler P4-5.006 A Novel Epigenetic Factor Regulates Mammalian Peripheral Nervous System Axon Regeneration–Bryan Dong P4-5.007 A Novel PCA-based fMRI Noise Reducing Wishart Filter to Improve Diagnosis of Neurodegeneration–Nikhil Boddu

138 2020 AAN Annual Meeting

0 Sunday, April 26 Headache: Therapeutics 4

P4.6-001 Effects of Lasmiditan on Cardiovascular Parameters in Healthy Subjects Receiving Oral Doses of Propranolol–Darren Wilbraham, Michael G. Case, M Tsai P4.6-002 The Aimovig “WearOff”: A Retrospective Case Series of Response to 14 day Dosing– Naveen George, Daniel Isaac Feldman, Deborah Reed P4.6-003 A Comparison of Efficacy, Tolerability and Safety in Subjects with Hemicrania Continua Responding to Indomethacin and Specialized Boswellia Serrata Extract–Eric J. Eross P4.6-004 Effect of Dihydroergotamine Infusion Rate on Inpatient Headache Treatment Outcomes–Nina Yakovlevna Riggins, Annika Ehrlich, Janet Corroo, Sarah R. Ahmad, Andrew Breithaupt, Mira Parekh, Morris Levin P4.6-005 Pterygopalatine Fossa Blockade: a novel, narcotic-sparing Treatment for Headache in Patients with Aneurysmal Subarachnoid Hemorrhage–Katharina M. Busl, Carolina B. Maciel, Marc Alain Babi, Christopher Paul Robinson, Erica Lobmeyer, Michael Pizzi, Alberto Bursian, Christopher J. Fox, Cameron Smith P4.6-006 Management of Childhood Migraine by Headache Specialist versus Non-Headache Specialists–Kelly Valentini, Radhika Gutta, Gunjanpreet Kaur, Ahmad Farooqi, Lalitha Sivaswamy P4.6-007 Post marketing experiences with erenumab (Aimovig) for the treatment of chronic migraine in a real-life clinical setting–Carolyn Zyloney, Catherine Barker, Yuedi Yu, Raissa Villanueva, Heidi B. Schwarz P4.6-008 Building a Case for Magnesium in Reversible Cerebral Vasoconstriction–Mallory Roberts, Elizabeth Pedowitz, Anna Pace P4.6-009 Utility of “Migraine Cocktail” in the Pediatric Emergency Department–Ankita Ghosh, Robert Lapus, Karly Flemmons, Mary Kay Koenig, Anand Gourishankar P4.6-010 Evaluation of Behavioral Insomnia Treatment in Shared Medical Visit Setting for Migraineurs with Comorbid

5:30 p.m.–6:30 p.m. Insomnia: Application of the RE-AIM Framework–Sau Mui Chan-Goh, Renee Hoeksel, John Sturgeon, Natalia Murinova P4.6-011 A Pilot Randomized Controlled Study of a Smartphone Delivered Progressive Muscle Relaxation Intervention for Migraine in Primary Care–Mia T. Minen, Samrachana Adhikari, Jane Padikkala, Eric J. Goldberg, Scott Powers, Sumaiya Tasneem, Ashley Bagheri, Richard B. Lipton P4.6-012 Time Trends in Opiate use for Headaches after Aneursymal Subarachnoid Hemorrhage–Vyas Viswanathan, Brandon Lucke-Wold, Gabrielle Aiello, Youlei Li, Chad Jones, Alexandra Ayala, Nicholas Nelson, Marc Alain Babi, Christopher Paul Robinson, Carolina B. Maciel, Katharina M. Busl P4.6-013 Are People with Migraine Willing to Engage in Digitally Based Behavioral Therapies: A look at recruitment statistics for a mobile health study–Mia T. Minen, Sarah Corner Neuromuscular Junction Disorders 2

P4.7-001 Extended Duration Plasmapharesis does not Improve Outcomes in Myasthenic Crisis– Lee Einar Neilson, Michael Hansen, Melanie Parikh, Bashar Katirji P4.7-002 Interactions Between Myasthenia Gravis and Pregnancy– Mohammed Said Alharbi, Carolina Barnett Tapia, Hans D. Katzberg, Vera Bril P4.7-003 Survey to assess variability in management of myasthenic crisis among neurologists–Neil Manering, Manisha Kak Korb, Namita Goyal, Tahseen Mozaffar, Ali A. Habib P4.7-004 Positive Acetylcholine Receptor Antibody - A Subtle Sign of An Occult Endometrial Cancer–Abinayaa Purushothaman Ravichandran, Alissa Eileen Romano P4.7-005 Anti-MuSK Antibody Positive Myasthenia Gravis Patient Demographics, Symptomatology, and Treatment Responsiveness in the University of Southern California Neuromuscular Clinic: A Retrospective Analysis–Victoria A. Cannon, Said R. Beydoun, Leila Darki = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Aging and Dementia: Basic Science, Biomarkers, and Genetics 1

Stroke Epidemiology, Disparity, and Quality Improvement 2

P4.9-001 National Institute of Neurological Disorders and Stroke (NINDS) Common Data Elements (CDEs): Updates to the Stroke V1.0 Recommendations–Katelyn Elizabeth Gay, Damon Collie, Muniza Sheikh, Joy R. Esterlitz, Jeffrey L. Saver, Steven Warach, Clinton B. Wright, Carolina Mendoza-Puccini, Scott Janis P4.9-002 An Exploratory Study to Investigate the Association between Short-term Exposure to Air-Pollution on the Occurrence of Ischemic or Hemorrhagic Stroke in a Case-crossover Design–Awadh K. Pandit, Kameshwar Prasad, Amit Kumar, Shubham Misra, Pumanshi Talwar, Mona Pathak P4.9-003 Cost of Hospitalization for Stroke in a Low-Middle Income Country: Findings from a Public Tertiary Hospital in the Philippines–Jose Danilo Bengzon Diestro, Abdelsimar Omar, Robert Joseph Sarmiento, Clare Angeli Guinto Enriquez, Lennie Lynn ChuaDe Castillo, Beverly Lorraine Ho, Kathleen Joy Khu, Jose Leonard R Pascual P4.9-004 Epidemiological profiling for stroke in Nepal: A need for establishing a stroke database in low income nations–Avinash Chandra, Basant Pant P4.9-005 Temporal Trends in Hemicraniectomy Utilization–Sai Prasant Polineni, Fadar Oliver Otite, Seemant Chaturvedi P4.9-006 National Trends In Utilization And Outcomes Of Endovascular Treatment In Acute Ischemic Stroke Patients In PreAnd Post-stent Retriever Era In The United States–Saqib A. Chaudhry, Ameer Hassan, Iqra N Akhtar, Mohammad-Rauf A. Chaudhry, Sairah Bashir, Wei Huang, Lakshmi Digala, Muhammad Fareed Suri, Werdah Zafar, Camilo Ramiro Gomez, Farhan Siddiq, Adnan I. Qureshi P4.9-007 Real World Prevalence and Treatment of Large Vessel Occlusion Stroke–John H Erdman, Parul Agarwal, Danielle Wheelwright, Nathalie Jette, Madhu Mazumdar, Mandip Singh Dhamoon, Laura Stein P4.9-008 Characteristics of Stroke in the Young in a Diverse Urban

County–Joseph Dardick, Natalie Tintin Cheng, Ava L. Liberman, Daniel L. Labovitz, Charles Esenwa P4.9-009 Epidemiology of Cerebral Ischemic Stroke in Southern Region in Saudi Arabia And Expected Role of Neurosurgery–Mona Alkhayri P4.9-010 Do Gender and Race/ Ethnicity Affect the Timing to CT-Head in Acute Stroke Patients?– Sara Shapouran, Roberto Gomez, Andrea Hidalgo P4.9-011 Delaying tPA Decision Impacts Overall Stroke Alert Efficiency: A Quality Improvement Initiative to Improve tPA Door to Needle Times–Daniel Cristancho, Hannah C. Machemehl P4.9-012 Ongoing Quality Improvement for Acute Ischemic Stroke at Comprehensive Stroke Center–Shimeng Liu, Zhu Zhu, Mohammad Shafie, Hermelinda Abcede, Jay Shah, Shuichi Suzuki, Li-Mei Lin, Kiarash Golshani, Dana Stradling, Wengui Yu P4.9-013 The E-ASPECTS Improves The Performance Of Emergencists In The Evaluation Of Early Signs Of Ischemia–Bernardo Teixeira, Lucas Ferreti, Bernardo Teixeira, Viviane H.F. Zetola, Marcos Christiano Lange P4.9-014 An Interdisciplinary Intervention to Improve Time to Systemic Thrombolysis for Inpatient Acute Ischemic Strokes–Harn Shiue, Andrew Pines, Devika Das, Vanesa Vanderhye, Shubhang Bhatt, Sara Dawit, Kara A. Sands P4.9-015 Points of In-Hospital Delays in Thrombolytic Therapy among Patients with Acute Ischemic Stroke: A Single Center 5-Year Retrospective Study–Glenn Anthony Constantino, Jo Ann Soliven Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 1

P4.9-016 Identifying Predictors for Final Diagnosis of Ischemic Events in an Emergency Department Observation Unit–Arooshi Kumar, Cen Zhang, Ava L. Liberman, Ava L. Liberman, Jose L. Torres, Sara Kate Rostanski

AAN.com/view/20AM 139

Sunday, April 26

P4.8-001 Aberrant accumulation of BRCA1 in Alzheimer’s disease and other tauopathies.–Masataka Nakamura, Satoshi Kaneko, Dennis W. Dickson, Hirofumi Kusaka P4.8-002 Activation of mGluR1 enhances C1q-Dependent Microglial Phagocytosis of Glutamatergic Synapses in Alzheimer’s Rodent Models–Sophia Wu, Bihua Bie, Mohamed Naguib P4.8-003 Expression of VGF in T-lymphocytes is age dependant and increased in patients with Alzheimer’s disease–Eva Christina Meyer, Mandy Busse, Stefan Busse P4.8-004 Increased Lamin A expression and heterochromatin changes in the hippocampus

at early Alzheimer’s disease stages–Ildefonso RodriguezLeyva, Laura Gil, Erika Chi, Sandra Nino, Carmen Guerrero-Marquez, Ana Belen Rebolledo-Poves, Jose Antonio Arias, Maria Esther Jimenez-Capdeville P4.8-005 Reduction of Astrocytic Glutamate Transporter Contributes to Amyloid-induced phagocytosis– Sophia Wu, Bihua Bie, Mohamed Naguib P4.8-006 Galectin 3 binding protein suppresses Aß production by modulating ß-cleavage of amyloid precursor protein–Tsuneyoshi Seki, Motoi Kanagawa, Kazuhiro Kobayashi, Hisatomo Kowa, Naoki Yahata, Kei Maruyama, Nobuhisa Iwata, Haruhisa Inoue, Tatsushi Toda P4.8-007 A novel small molecule tyrosine kinase inhibitor (GUtinib) preferentially targets discoidin domain receptors and reduces toxic proteins in neurodegeneration– Alan Fowler, Michaeline Hebron, Yasar Alejandro Torres-Yaghi, Fernando L. Pagan, Jaeil Ahn, Charbel E H Moussa P4.8-008 Prelimbic Cortex Inactivation Alters Prospective Reward Representation in Male Fischer 344 × Brown Norway F1 Hybrid Rats–Chase Labiste, Caesar Hernandez, Sara Betzhold, Noelle Wright, Alexa-Rae Wheeler, Tyler Ten Eyck, Barry Setlow, Jennifer Bizon P4.8-009 FDG PET Illustrates Hypometabolism in a Mouse Model of Alpha-Synucleinopathy–Kristina Deduck, Elodie Brison, Simone P. Zehntner, Kelvin Luk, Barry Bedell P4.8-010 Rab GTPase Proteins in Tauopathy–Nikolaus McFarland, Mayur Parmar, Shon Koren, Gina Bae, Nathaniel Ma, Michael Filoramo P4.8-011 The Effects of Stimulation of Innate Immunity with CpG-ODN in a Tauopathy Mouse Model, rTg4510–Jennifer L. Dobson

POSTER SESSIONS

P4.7-006 Validation of the Spanish Version of the 15-Item Myasthenia Gravis Quality of Life Scale (MGQOL15)–Marcus Cimino, Margaret Adler, Bhavesh Trikamji, Namita Goyal, Frank Lin, Luis A. Chui P4.7-007 Retrospective Analysis of Comorbidities Associated with Myasthenia Gravis–Brian Blankenship, Raghav Govindarajan P4.7-008 Effects of Medication Adjustment on Myasthenia Gravis Patients and Time to Readmission in an Academic Center–Connie Gwendolyn Tang, Nathanael Lee, Mina C Youn, Goran Rakocevic P4.7-009 Autoimmune Myocarditis Associated to Seropositive Myasthenia Gravis– Sonia M. Caraballo-Cartagena, David Q. Atkins, Migdoel CruzRodriguez, Gishlaine Alfonso P4.7-010 Pseudomyasthenia Gravis: An uncommon and potentially hazardous mimicker of mitochondrial disease–Prompan Mingbunjerdsuk, Mamatha Pasnoor, Jeffrey Statland, Omar Jawdat, Duaa Jabari, Richard J. Barohn, Mazen M. Dimachkie, Constantine Farmakidis P4.7-011 Refractory Myasthenia Responsiveness to Eculizumab in a Tertiary Care Setting in Challenging Cases–Uzma Usman, Erik L. Ortega, Shafeeq Ladha, Suraj Muley P4.7-012 When My-“asthenia” is NOT due to Myasthenia Gravis– Richard A. Lewis, Volkan Granit, Michael G. Benatar

Sunday, April 26

POSTER SESSIONS

POSTER SESSION 4 P4.9-017 Evolution of Decompressive Hemicraniectomy Practice at a Single Academic Institution: Inclusion of Elderly Patients–Amanda Opaskar, Reyanna Massaquoi, Saad I. Yazdani, Michael A. De Georgia, Cathy A. Sila, Sophia Sundararajan P4.9-018 Comparison of Existing and New Heparin Nomograms for the Treatment of Cerebrovascular Disease–Shadi V. Barbu, Justine K. Chan, Roy X. Zhang, Kenneth Griffin, Amanda W. Fletcher, Robert S. Hamilton, Steven Yuen, Joseph Thanh-Phu Duong, Michael F. Waters P4.9-019 Outcomes of Ischemic Stroke amongst patients on Long-term Current Use of Dual Anti-platelet Therapy Versus Aspirin Monotherapy.–Urvish K. Patel, Dhaivat Janakbhai Shah, Preeti Malik, Khush Patel, Abhishek Lunagariya P4.9-020 Comparative effectiveness of dual antiplatelet therapy with aspirin and clopidogrel versus aspirin monotherapy in acute mild-to-moderate ischemic stroke according to the recurrent stroke risks: An analysis of 15000 patients from a nationwide, multicenter registry–JOONTAE KIM, Seung-Han Lee, Jae-Myung Kim, Jae-Hwan Im, Hee-Joon Bae P4.9-021 Loading dose of aspirin and clopidogrel prior to carotid artery stenting reduces cerebral ischemic events compared to the historic CREST trial.–Yahia M. Lodi, Varun V. Reddy, Sumeet Singh Multani, Ji Young Lee, Andrew Hao Neuro-oncology: Clinical Cases and More 2

P4.10-001 Intrathecal Methotrexate Induced Dorsal Column Syndrome–Christopher S. Nance P4.10-002 Leptomeningeal Carcinomatosis- A case with a mismatch of clinical and radiological picture.–Varun Kumar Pala, Andrea S. Synowiec P4.10-003 Paraneoplastic Opsoclonus-Myoclonus Syndrome and Prostate Cancer: First Reported Case–Ariel Fromowitz, Ranita Sharma, Michael Nissenblatt, Tabitha Copeland P4.10-004 Initial and follow up imaging in paraneoplastic

CME

rhombencephalitis from Hodgkin’s lymphoma–Rebecca L. Hurst, Tigran Kesayan P4.10-005 Persistent Aglycorrhachia in Leptomeningeal Carcinomatosis–Yongyao Kong, Abraham Jian Qing Lee, Kim En Lee P4.10-006 Autoimmune diseaserelated primary CNS lymphoma: Review of literature and metaanalysis.–Leon Kaulen, Philipp Karschnia, Jorg Dietrich, Joachim M. Baehring P4.10-007 A Neurologists role in Gamma Knife: Time for a paradigm shift?–Glen H J Stevens P4.10-008 Brainstem Anaplastic Astrocytoma, IDH-Mutant, WHO Grade III Presenting with Multiple Cranial Nerve Palsies and Diffuse Neuroaxis Leptomeningeal Involvement–Yasmin Aziz, Laurie E. Knepper, Frank S. Lieberman, Jan Drappatz, Thomas Pearce, Clayton A. Wiley, Joseph Mettenburg P4.10-009 Initial Presentation of Papillary Craniopharyngioma with BRAF Mutation Treated with Adjuvant Chemotherapy–Mangala Gopal, Gaurav Thakur, Vinaykumar Puduvalli P4.10-010 Treatment of Cisplatin Induced Neurotoxicity with High Dose Pyridoxine and Pyridostigmine–Nicole Thomason, Lindsey Schwartz, Zafer Keser, Yvo Andres Rodriguez-Linares, Haris Kamal, Shivika Chandra P4.10-011 Correlation of fiber tracts with speech outcome in brain glioma–Fereshteh Naderi Behdani, S.Amir Javadi, Rastegar Rahmani, S.morsal Aghili P4.10-012 Standardizing care of leptomeningeal carcinomatosis (LMC): Impact on survival and the role for advanced practitioners in developing Ommaya clinics–Erika Leese, Anand Mahadevan, Andrew Conger, Na Tosha N. Gatson P4.10-013 Neuroimaging Characteristics in Neoplastic Chronic Meningitis–John Herbst, Kelly Baldwin P4.10-014 Severe, Persistent Methotrexate-Related Neurotoxicity in Pediatric Patients with ALL–Sarah Dabagh, Henry David, Andrew Doan, Deepa Bhojwani P4.10-015 Intravascular Lymphoma of the Central Nervous

140 2020 AAN Annual Meeting

0 Sunday, April 26 System: A Case Series Describing Clinical and Radiographic Characteristics–Megan Richie, Maulik Shah, Elan Guterman Neuro-ophthalmology/Neurootology 1

P4.11-001 Baseline Near Point of Convergence and Concussion Test Scores in a Cohort of Collegiate and Professional Athletes–Nicholas Moehringer, Shirley Z. Wu, Sayak Ghosh, Natalie Dahan, Lisena Hasanaj, Binu Joseph, Steven Galetta, Laura J. Balcer P4.11-002 The SUN Test of Vision: Investigation in Healthy Volunteers and Comparison to the Mobile Universal Lexicon Evaluation System (MULES)–Shirley Z. Wu, Natalie Dahan, Lisena Hasanaj, Liliana Serrano, Binu Joseph, Janet C. Rucker, Steven Galetta, Laura J. Balcer P4.11-003 Analysis of Rapid Sideline Tests and Mechanism of Injury From a Multidisciplinary Concussion Center Registry– Christopher Hernandez, Nicholas Moehringer, Julie Giles, Lisena Hasanaj, Binu Joseph, Janet C. Rucker, Steven Galetta, Laura J. Balcer P4.11-004 Visual snow syndrome - a clinical and phenotypical description of over 1000 cases– Francesca Puledda, Christoph J. Schankin, Peter Goadsby P4.11-005 Visual Search for Complex Objects in Healthy Subjects and Individuals with Developmental Prosopagnosia– Hyeongmin Kim, Andrea Albonico, Jennifer Hemstrom, Jason Barton P4.11-006 Cerebral blindness resulting from bilateral optic radiation infarction; a case report– Andrew Dugue, Richard Libman P4.11-007 Reversal of vision metamorphopsia (upside-down vision)–Joshua Yap, Kirsty Maclure, Timothy J. Young P4.11-008 Anisocoria? No Sweat! A Case Series of Anticholinergic Mydriasis–Inna Potekhina, Cameron Holicki, Lina Nagia, Aileen Antonio, Christopher Glisson P4.11-009 A Rare Case of Transient Horner Syndrome After Rotator Cuff Repair Surgery– Ruiqing Sun, Lalitha Battineni, Ahmad A. Shawagfeh

5:30 p.m.–6:30 p.m. P4.11-010 B-Mode Ultrasound: a novel tool for evaluation of pupillary function - in healthy and in pathological conditions–Felix Schmidt, Matthew B. Maas, Lutz Harms, Friedemann Paul, Stefan Schreiber, Klemens Ruprecht P4.11-011 Assessing Illness Perception Factors Associated with Educational Needs in NeuroOphthalmology–Rem Aziz, Robert T Chang, Heather Moss P4.11-012 Evaluating the Incidence and Neuro-Ophthalmic Manifestations of CarotidCavernous Fistulas–Devon Cohen, M. Tariq Bhatti, John Chen P4.11-013 Ocular Myasthenia Gravis – How Effective is Low Dose Prednisone Long Term?–Rashmi Verma, Mark J. Kupersmith

= Research

POSTER SESSION 5

CME

0 Monday, April 27

8:00 a.m.–9:00 a.m.

Poster Session 5

Multiple Sclerosis: Epidemiology 2

Multiple Sclerosis: Prognosis

P5.1-007 Evolving Diagnosis and Treatment of Secondary Progressive Multiple Sclerosis in the United States–Robert T. Naismith, Jennifer Robinson, Virginia Schobel P5.1-008 Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting

Multiple Sclerosis–Tomas Kalincik, Ibrahima Diouf, Charles Malpas, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo Ayuso, Sara Eichau Madueño, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, J M. Girard, Pierre Duquette, Pierre Grammond, Francois Grand-Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad, Raed Alroughani, R.M.M. Hupperts, Murat Terzi, Cavit Boz, Jeannette Lechner-Scott, Elisabetta Cartechini, Vincent Van Pesch, Gerardo Iuliano, Franco Granella, Roberto Bergamaschi, Ricardo Fernandez Bolanos, Daniele Litterio A. Spitaleri, Mark lee, Ostoja (Steve) Vucic, Radek Ampapa, Pamela Ann McCombe, Cristina M. Ramo, Thor Petersen, Freek Verheul, Julie Prevost, Francisco Javier Olascoaga Urtaza, Edgardo Cristiano, Helmut Butzkueven P5.1-009 Predictors of Falls, Emergency Department Visits, and Hospitalizations in an Advanced Multiple Sclerosis Population– Tania Bruno, Artee Srivastava, Laura Langer, Mark Bayley P5.1-010 What are the predictors of disease progression in Turkish Multiple Sclerosis patients.–Nuri Onat Demirci, Melih Tutuncu, Ugur

Uygunoglu, Sabahattin Saip, Aksel Siva P5.1-011 Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis–Sifat Sharmin, Francesca Bovis, Charles Malpas, Dana Horakova, Eva Havrdova, Guillermo Izquierdo Ayuso, Sara Eichau Madueño, Maria Trojano, Alexandre Prat, J M. Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Francois Grand-Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Murat Terzi, R.M.M. Hupperts, Raed Alroughani, Cavit Boz, Vahid Shaygannejad, Vincent Van Pesch, Ludwig Kappos, Jeannette Lechner-Scott, Roberto Bergamaschi, Recai Turkoglu, Claudio Solaro, Cristina M. Ramo, Gerardo Iuliano, Franco Granella, Bart Van Wijmeersch, Daniele Litterio A. Spitaleri, Ricardo Fernandez Bolanos, Mark Slee, Pamela Ann McCombe, Julie Prevost, Radek Ampapa, Serkan Ozakbas, Jose Luis Sanchez Menoyo, Aysun Soysal, Ostoja (Steve) Vucic, Thor Petersen, Freek Verheul, Ernest G. Butler, Suzanne J. Hodgkinson, Youssef Sidhom, Riadh Gouider, Edgardo Cristiano, Francisco Javier Olascoaga Urtaza, Maria Laura Saladino, Michael Barnett, Norma Deri, Fraser Moore,

AAN.com/view/20AM 141

Monday, April 27

P5.1-001 Observed differences in characteristics of secondaryprogressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry–Daniel Kantor, Bruce Frank Bebo, Patricia K. Coyle, Edward J. Fox, Robert A. Bermel, Jeffrey Greenberg, Wendi Malley, Robert McLean, Sabrina Rebello, Nicholas LaRocca, Aaron E. Miller P5.1-002 First Full Analysis of the ESSENCE Data Set Presents a Cross Section of the SPMS Patient Management in Germany–Markus W. Heibel, Santiago Manrique P5.1-003 A nationwide study of secondary progressive multiple sclerosis in the Danish population–Melinda Magyari, Tine Iskov Kopp, Stephan Bramow, Jette Lautrup Frederiksen Battisti, Claudia Christina Pfleger, Peter Vestergaard Rasmussen, Finn Sellebjerg P5.1-004 The Hardships of Hidden Disease: Impact of public perception in people with low disability multiple sclerosis–Megan Christine Kirkland, Caitlin J Newell, Michelle Ploughman

P5.1-005 Alemtuzumab-induced thyroid dysfunction - follow up data from the Northern Irish cohort– Fiona Kennedy, Sinead Kiernan, Fiona Magill, Tom Ormston, Kelechi Ike, Rachael Kee, Philip Johnston, Orla Gray, Jamie H. Campbell, Aidan G. Droogan, Stella Elaine Hughes, Gavin V. McDonnell P5.1-006 Estimating brain atrophy in clinical settings: linear measures of ventricular enlargement for evaluation of disease activity and long-term disability progression in Multiple Sclerosis–Maria Petracca, Giuseppe Pontillo, Sirio Cocozza, Martina Di Stasi, Antonio Carotenuto, Chiara Paolella, Maria Cipullo, Teresa Perillo, Elena Vola, Camilla Russo, Marco Masullo, Marcello Moccia, Roberta Lanzillo, Enrico Tedeschi, Andrea Elefante, Vincenzo Brescia Morra, Mario Quarantelli, Arturo Brunetti

POSTER SESSIONS

1. Multiple Sclerosis: Epidemiology 2: 1-001 to 1-006 Multiple Sclerosis: Prognosis: 1-007 to 1-016 Multiple Sclerosis: Therapeutics MOA and Safety 1: 1-017 to 1-023 2. Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 2: 2-001 to 2-012 3. Huntington’s Disease and Tardive Syndromes 1: 3-001 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 3: 4-001 to 4-005 Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 2: 4-006 to 4-012 5. General Neurology: Clinical Case Reports 3: 5-001 to 5-013 6. Headache: Therapeutics 5: 6-001 to 6-013 7. Autonomic Disorders 1: 7-001 to 7-007 Amyotrophic Lateral Sclerosis 1: 7-008 to 7-015 8. Aging and Dementia: Basic Science, Biomarkers, and Genetics 2: 8-001 to 8-011 9. Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 2: 9-001 to 9-021 10. Medical Education: Expansion and Outreach 1: 10-001 to 10-007 Undergraduate Medical Education 1: 10-008 to 10-015 11. Child Neurology and Developmental Neurology: Developmental Disabilities and Movement Disorders 1: 11-001 to 11-015

POSTER SESSIONS

POSTER SESSION 5 Csilla Rozsa, Bassem I. Yamout, Olga Skibina, Orla Gray, Jamie H. Campbell, Angel Perez Sempere, Bhim S. Singhal, Yara D. Fragoso, Cameron Shaw, Allan G. Kermode, Tatjana Petkovska-Boskova, Bruce Taylor, Magdolna Simo, Norbert R. Vella, Neil Shuey, Jabir Alkhaboori, Talal Muteb Al-Harbi, Richard A L Macdonell, Jose Andres Dominguez, Ilya Kister, Tunde Csepany, Carlos Alejandro Vrech, Krisztina Kovacs, Carmen Adella Sirbu, Stella Elaine Hughes, Maria Pia Sormani, Helmut Butzkueven, Tomas Kalincik P5.1-012 Confirmed Progression independent of Relapse Activity in Multiple Sclerosis Patients under long-term Natalizumab Treatment.– Jonas Graf, Verena Leussink, Giulia Soncin, Klaudia Lepka, Ingrid Meinl, Tania Kuempfel, Hans-Peter Hartung, Joachim Havla, Orhan Aktas, Philipp Albrecht P5.1-013 Progression to Secondary Progressive Multiple Sclerosis and its Early Risk Factors: A Population-based Study–Mahdi Barzegar, Vahid Shaygannejad, Julianna Tomlinson, Alireza Afshari P5.1-014 Late-onset Multiple Sclerosis is associated with an increased rate of reaching Disability Milestones–Mads Albrecht Andersen, Mathias Buron, Melinda Magyari P5.1-015 Clinical And Paraclinical Markers Of Disability Progression After A First Neurological Event: A Long Term Follow-Up Study–Gloria Dalla Costa, Vittorio Martinelli, Francesca Sangalli, Bruno Colombo, Lucia Moiola, Mario Risi, Letizia M. Leocani, Massimo Filippi, Giancarlo Comi P5.1-016 Race, Resilience and Multiple Sclerosis Outcomes– Rachel Darling, Jeremy Grant, Lisa Rapport, Evanthia Bernitsas

Monday, April 27

Multiple Sclerosis: Therapeutics MOA and Safety 1

P5.1-017 Cladribine Modulates the Function of Murine Microglia–Line Jorgensen, Kirsten Hyrlov, Maria Louise Elkjaer, Anders Elm Pedersen, Asa F Svenningsen, Zsolt Illes P5.1-018 Increased John Cunningham Virus Seroconversion Rates Seen in a Southern Hemisphere International Cohort

CME

of Natalizumab Treated Patients– Chris Dwyer, Vilija Jokubaitis, James Stankovich, Josephine Baker, John T. Carey, Trevor J. Kilpatrick, Kylie Fryer, Ernest G. Butler, Jodi Haartsen, Helmut Butzkueven, Adriana Cartwright, Neil Shuey, Jennifer Coleman, Richard A L Macdonell, Louise Rath, Yara D. Fragoso, Anneke Van Der Walt P5.1-019 Early preferential repopulation of anti-inflammatory B cells following an initial treatment of ocrelizumab in patients with multiple sclerosis–Koji Shinoda, Ayman Rezk, Rui Li, Amit Bar-Or P5.1-020 Effect of Alemtuzumab (LEMTRADA®) Treatment on the Peripheral Immune Repertoire in Multiple Sclerosis Patients– Sumanta Barman, Armin Scheffler, Tobias Ruck, Christoph Lehrich, Vera Balz, Heinz Wiendl, Sven G. Meuth, Hans-Peter Hartung, Nico Melzer, Norbert Goebels P5.1-021 Safety and Tolerability of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study–Till Sprenger, Michel Burcklen, Mark S. Freedman, Robert J. Fox, Eva Havrdova, Brian Hennessy, Reinhard Hohlfeld, Fred D. Lublin, Xavier Montalban, Carlo Pozzilli, Andrea Vaclavkova, Tatiana Scherz, Philippe Linscheid, Magdalena Pirozek-Lawniczek, Hilke Kracker, Ludwig Kappos P5.1-022 Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH® Prescribing Program database–Lana Zhovtis Ryerson, John F. Foley, Ih Chang, Ilya Kister, Gary Raymond Cutter, Ryan Metzger, Judith Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Zheng Ren, Christophe Hotermans, Pei-Ran Ho, Nolan Campbell P5.1-023 Herpes Zoster Virus (HZV) Infections among Multiple Sclerosis Patients Treated with Various Disease Modifying Therapies–Nicola Carlisle, Sam Hooshmand, Michelle Maynard, Leah Hoffman, Ahmed Z. Obeidat

142 2020 AAN Annual Meeting

0 Monday, April 27 Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 2

P5.2-001 Anti-MOG and AntiAQP4 Positive Neuromyelitis Optica Spectrum Disorder in a Patient with Myasthenia Gravis–Molly Bates, Jason Timothy Chisholm, Eric Miller, Zain Guduru P5.2-002 Characteristics of Patients with Anti-MAG Associated Neuropathy who Respond to Rituximab–David Chaar, Mihir Kakara, Shitiz K. Sriwastava, Sasan Moshirzadeh, Michal Romuald Halon, Robert P. Lisak P5.2-003 Paraneoplastic Myeloneuropathies: characterization of a distinguishable phenotype and clinical outcomes–Shailee Samir Shah, Rocio Vazquez Do Campo, Sean J. Pittock, Andrew McKeon, Neeraj Kumar, Eoin P. Flanagan, Christopher J. Klein, Divyanshu Dubey P5.2-004 Inflammatory Myopathy with Superimposed Myasthenia Gravis – A Rare Overlap Syndrome–Anthony John Propson, Shakaib Qureshi, Muhammad Farooq P5.2-005 Patient and Treatment Characteristics of a Large US Sample of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Initiating Intravenous Immunoglobulin (IVIG) Therapy– Colin Anderson-Smits, J. Bradley Layton, Mary E Ritchey, Vanessa Hayden, Ihor Sehinovych, Shailesh Chavan, Nizar Souayah P5.2-006 Clinical Correlates of Neurofascin Autoantibody Seropositivity–Anson Wilks, Alan Pestronk, Bob Bucelli P5.2-007 Chronic inflammatory demyelinating polyneuropathy associated with Neurofascin-155 antibodies in a child : a diagnosis that must not be ignored–Salma Sakka, Sirine Belghuith, HDIJI Olfa, Nouha Farhat, Khadija Sonda Moalla, Sawsan Daoud, Mariem Damak, Chokri Abdellaziz Mhiri P5.2-008 A unique neurological presentation of Granulomatosis with polyangiitis (Wegener’s granulomatosis) with

8:00 a.m.–9:00 a.m. polyneuropathy, myopathy and small vessel stroke.–Azima Shaji, Sruthi Devarinti, Richard Leung, Divisha Raheja P5.2-009 Rationale and Design of a Phase 3b Study of the Long-Term Tolerability and Safety of HyQvia in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): ADVANCE-CIDP 3–Shabbir Hasan, Kimberly Duff, Steve Wisseh, Ashraf Youssef, Shailesh Chavan P5.2-010 Facial Diplegia with Preserved Reflexes: An Unusual Case of Anti-GD1b IgG Positive Guillain-Barre Syndrome–Riwaj Bhagat P5.2-011 Differentiating GBS and CIDP in the Hospital Setting: Knowledge and Behavior Changes from Continuing Education–Anne C. Roc, Wendy Turell, Lisa Butler, Peter D. Donofrio P5.2-012 A novel treatment for autoimmune autonomic ganglionopathy?–Priyanka Shekhawat, Alice Tang, Roy L. Freeman, Christopher H. Gibbons Huntington’s Disease and Tardive Syndromes 1

P5.3-001 Transfer of Therapeutic miRNAs Within Extracellular Vesicles Secreted from Huntington’s Disease iPSC-derived Neurons–Marina Sogorb-Gonzalez, Jana Miniarikova, Astrid Vallessanchez, Sander van Deventer, Pavlina Konstantinova, Melvin Evers P5.3-002 Central Cognitive Processing Speed Is an Early Marker of Huntington’s Disease Onset–Jody Corey-Bloom, McKenna Williams, Charlotte Wong, Sameer Aboufadel, Chase Snell, Brenton A. Wright, Paul Gilbert P5.3-003 Huntington Disease: Systemic Manifestations–Swati Sathe, Amrita Mohan, Cristina Sampaio P5.3-004 Microglia activation in basal ganglia is a late event in Huntington’s disease pathophysiology–Erin FurrStimming, Leigh Latham, Odelin Charron, Gabriela D. Colpo, Paolo Zanotti Fregonara, Leorah Aude Emmanuelle Freeman, Antonio Teixeira, Natalia Pessoa Rocha

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 3

P5.4-001 Sudden Unexpected Death in Epilepsy (SUDEP), the SUDEP-7 inventory and other clinical risk factors–Ahmed Reda Muhammed Abdelkader, Hani Alhourani, Ananyaa Kumar, Maysaa Merhi Basha P5.4-002 The Association Between the SUDEP Biomarker and Obstructive Sleep Apnea in an Unselected patients with Epilepsy– Prut Koonalintip, Kanitpong Phabphal, Pasiri Sithinamsuwan, Krongthong Wongsritrang, Paemrak Phabphal, Thanyalak Amornpojnimman, Sumonthip

Leelawai, Anongtip S.A. P5.4-003 Epilepsy in nonhuman primates–Leah Croll, Charles Akos Szabo, Noha Abou-Madi, Orrin Devinsky P5.4-004 Role of Cerebellar Disinhibition in the Development of Seizures–Venkatraman Thulasi, Veeresh Kumar Nanjangud Shivamurthy, Xue Ming P5.4-005 The Paradoxical Hippocampal Interneurons in a Rat Model of Cortical Dysplasia–Yang Zheng, Yi Wang, Zhong Chen, Meiping Ding Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 2

P5.4-006 EEG-Based Functional Connectivity in Infantile Spasms Progression to Lennox Gastaut Syndrome–Virginia Liu, Rachel Alicia Smith, Beth Lopour, Daniel Walter Shrey P5.4-007 Neonatal Seizure Burden during Therapeutic Hypothermia: Predictive value of EEG in the first 24 hrs–Kshama Ojha, Abhinav Pal, Gregory N. Barnes, Dan Stewart P5.4-008 The Utility of Electroencephalography on Stroke Service: A Single Center Experience–Brittany Claire Turner, Mark Douglas Johnson, Ryan Hays, Jennifer Cross, Sondra Perez, Kan Ding P5.4-009 Yield of Continuous Electroencephalography in Acute Ischemic Stroke–Valerie Jeanneret Lopez, Eric Christopher Lawson, Polly Kumari, Dhaval P. Desai, Zubeda B. Sheikh, Hiba Arif Haider, Andres Rodriguez-Ruiz, Monica B. Dhakar P5.4-010 Diagnostic Utility of Reduced Electroencephalography for Seizure Detection: A Systematic Review–Kapil Gururangan, Babak Razavi, Rita A. Popat P5.4-011 EEG reactivity predicts outcomes in cardiac arrest patients.–Vikram Bhinder, Stephen Hantus, Vineet Punia, Christopher R. Newey P5.4-012 Prognostic and clinical value of continuous EEG monitoring in patients undergoing therapeutic hypothermia after cardiac arrest–Olivia Rose Ryder, Loredana Rammage, Aimen Vanood, Vikas Ravi, Andrew J. Zillgitt, Christopher Murray Parres

General Neurology: Clinical Case Reports 3

P5.5-001 Navigating The Diagnostic Maze of Pathogens in a Patient with Rapidly Ascending Paralysis–Batool Akhlaq Hussain, Maya Hrachova, Xiao-Tang Kong P5.5-002 Acute Flaccid Myelitis in a Non-Pediatric Patient–Stephanie Kazi, Justin A.C. Persson P5.5-003 Cavernous Malformation: An Elusive Mimicker of Transverse Myelitis–Aqsa Ullah, Michelle Serpa Nunes, Amna Imran, Afra Janarious, Saif Ullah P5.5-004 Stroke-like Presentation with Acute Spastic Quadriparesis Revealing Adult Polyglucosan Body Disease (APBD)–Jaspreet Johal, Ramiro Gabriel Castro Apolo, Nathan Paul Fenstermacher, Michael W Johnson, Adam B. Edwards, Preet M. Varade P5.5-005 Late Presentation of Seizures in a 54 year old male with Sturge Weber Syndrome–Joshua Rim, Joshua Santucci, Chen Yan, John A. Morren P5.5-006 An Irish family with autosomal recessive SPG7associated hereditary spastic paraparesis with a wide clinical spectre–Eimear Joyce, Siobhan Kelly, Kevin Murphy, Salman Mansoor P5.5-007 Cerebrotendinous Xanthomatosis: case report in Perú–Cintia Margoth ArmasPuente, Andrea Rivera-Valdivia, Jeny Bazalar-Montoya, Elison Sarapura-Castro, Maryenela Illanes-Manrique, Andrea DeBarber, Mario R. Cornejo Olivas P5.5-008 Lhermitte-Duclos Disease Associated with Cowden Syndrome: a Case Report of a Rare Genetic Hamartomatous Disorder–Vanessa Dias Veloso, Viviane Tavares Carvalho, Nathane Braga Da Silva Rezende, Osvaldo J M Nascimento, Caroline Bittar Braune P5.5-009 Charcot Marie Tooth Disease Type 2Q with DHTKD1 Mutation- A Report of the First Case from India–Hemanth Kumar K P5.5-010 A Case Report of Episodic Lingual Raynaud’s Phenomenon with Focal Neurologic Deficits in a Patient with Cystic Fibrosis–Timothy Richard Malone, Zachary Jeremiah Craig, Nathan Tagg

AAN.com/view/20AM 143

Monday, April 27

Considerations for Real-World Use–Blair Leavitt, Edward J. Wild, Jee Bang, Anne Smith, Valerie Schlegel, Scott Schobel, Alessia Nicotra, Bernhard G. Landwehrmeyer, Sarah J. Tabrizi, Mark Guttman P5.3-014 Translation of AMT130 Preclinical Data to Inform the Design of the First FDA-approved Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest Huntington’s Disease–Ralf Reilmann, Christopher Ross, Claudia M. Testa, Samuel A. Frank, Melvin Evers, Martin de Haan, Astrid Valles-sanchez, Pavlina Konstantinova, Sander van Deventer, Joseph J. Higgins P5.3-015 Case Report: Expanded Access Treatment of a mid stage Huntington’s Disease (HD) Patient with a Novel Stabilized Polyunsaturated Fatty Acid Drug (RT001)–Susan L. Perlman, Peter Milner, Harry Saal, Frederic Heerinckx P5.3-016 Prevalence of Huntington’s Disease in the US– George Yohrling, Karina Raimundo, Valerie Crowell, Debra Lovecky, Louise Vetter, Lauren Seeberger P5.3-017 Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease–Samuel A. Frank, Christina L. Vaughan, David A. Stamler, David Oakes, Mat D. Davis, Nicholas Gross, Mark Forrest Gordon, Juha-Matti Savola, Maria Wieman, Shirley Eberly, Elise Paulin Kayson, Jacquelyn Whaley, Jody Goldstein, Claudia M. Testa

POSTER SESSIONS

P5.3-005 Stereopure Oligonucleotides for the Selective Silencing of Mutant Huntingtin–Elena Dale, Maria Frank-Kamenetsky, Kristin Taborn, Kidist Aklilu, Yuanjing Liu, Shaunna Berkovitch, Jeffrey Brown, Pachamuthu Kandasamy, Jayakanthan Kumarasamy, Steven Mathieu, Naoki Iwamoto, Yuan Yin, Hailin Yang, Stephany Standley, Frank Favaloro, Kenneth Longo, Michael Byrne, Chandra Vargeese P5.3-006 Epidemiology of Huntington’s Disease (HD) in the US Medicare Population–Alex Exuzides, Valerie Crowell, Sheila Reiss Reddy, Eunice Chang, George Yohrling P5.3-007 The Digital-HD study: Smartphone-Based Remote Testing to Assess Cognitive and Motor Symptoms in Huntington’s Disease–Rosanna Tortelli, Cedric Simillion, Florian Lipsmeier, Timothy Kilchenmann, Filipe B Rodrigues, Lauren M Byrne, Atieh Bamdadian, Christian Gossens, Scott Schobel, Michael Lindemann, Edward J. Wild P5.3-008 Using the Huntington’s Disease-Behavioral Questionnaire (HD-BQ) as a Screening Tool for Behavioral Disturbances in HD–Jody Corey-Bloom, Charlotte Wong, Sameer Aboufadel, Chase Snell, Jordan Castleton, Haileigh Smith, Brenton A. Wright, Paul Gilbert P5.3-009 Changes in Brain Activity with Antisense Oligonucleotide RG6042 Treatment in Early Manifest Huntington’s Disease (HD)–David J. Hawellek, Pilar Garces, Amir H. Meghdadi, Shani Waninger, Anne Smith, Marianne Manchester, Scott Schobel, Joerg F Hipp P5.3-010 Clinical correlates of high cardiovascular risk in Parkinson’s disease: an observational study– Sergio Andrés Castillo-Torres, Christopher Cerda-Contreras, Denisse G Martinez Roque, Carlos Soto-Rincón, Beatriz Chávez, Ingrid Estrada-Bellman P5.3-011 Sleep complaints are associated with anxiety symptoms and poorer quality of life in Huntington’s Disease–Erin FurrStimming, Will Tanigaki, M. Agustina Rossetti, Sudha S. Tallavajhula, Natalia Pessoa Rocha P5.3-013 Intrathecal Drug Delivery of Antisense Oligonucleotides in Huntington’s Disease: Experience of Ionis/Roche RG6042 Development Programme and Best Practice

POSTER SESSION 5

Monday, April 27

POSTER SESSIONS

P5.5-011 Melkerrson Rosenthal Syndrome: A Rare Neurologic Disorder–Neeharika Thottempudi, Diaa Hamouda, Laura J. Wu P5.5-012 Anticoagulation Failure with Supratherapeutic International Normalized Ratio in Malignancy and Ischemic Stroke–Swaroopa Pulivarthi, Salman Assad, Mehar Zahid, Shuja Assad, Salman Assad P5.5-013 Cerebellar Hemorrhage as an Enantiopathy to Ipsilateral Stereotypy–Harkaveer Boyal, Alan R. Hirsch, aneeta wadhawan, harmeet wadhawan Headache: Therapeutics 5

P5.6-001 Trajectory of migrainerelated disability over 12 months with lasmiditan for acute treatment of migraine in the GLADIATOR Study–Li Shen Loo, Dawn C. Buse, Louise Lombard, Dustin Ruff, John H. Krege, Andy Buchanan, Richard B. Lipton P5.6-002 Acute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201)–Linda Harris, Gilbert J. L’Italien, Robert Croop, Elyse Stock, Alexandra Thiry, Kate Cowrie, Meghan Lovegren, Christopher Jensen, Vlad Coric, Richard B. Lipton P5.6-003 Patient Functioning and Disability among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study–Peter J. McAllister, Janet Ford, Virginia L. Stauffer, Matthew Sexson, David Ayer, Shufang Wang P5.6-004 Assessment to Identify Predictors of 2-Hour Pain Freedom among Patients Enrolled in 2 Phase 3 Studies of Lasmiditan for Acute Treatment of Migraine–Bert B. Vargas, Delphine Magis, Erin G. Doty, Dustin Ruff, Raghavendra Vasudev, John H. Krege, Ann M. Hake P5.6-005 Very Early Onset of Action of Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the International, Multicenter, Randomized, Placebo-controlled FOCUS Study–Jan Lewis Brandes, Verena Ramirez Campos, Ronghua

CME

Yang, Joshua M. Cohen, Maja Galic, Xiaoping Ning, Christina Treppendahl P5.6-006 Efficacy of Fremanezumab in Male Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medication Classes: Results of the Randomized, Placebo-controlled FOCUS Study–Antoinette MaassenVanDenBrink, G.M. Terwindt, Joshua M. Cohen, Ronghua Yang, Verena Ramirez Campos, Maja Galic, Xiaoping Ning, Mikko Karppa P5.6-007 Acute and Preventive Treatment Use in a Phase 3 Randomized Trial of Galcanezumab in Chronic Cluster Headache– Michel Lanteri-Minet, Kavita Kalidas, Tina Oakes, Jennifer Bardos, Chunmei Zhou, Richard Wenzel, Jeff Yang P5.6-008 Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine–Jessica Ailani, J Scott Andrews, Mallikarjuna Rettiganti, Robert Nicholson P5.6-009 Acute Treatment of Migraine with Oral Rimegepant 75 mg Confers Robust Improvement in Absenteeism, Presenteeism and Productivity: Results from a One Year, Open-Label, Safety Study (BHV3000-201)–Gilbert J. L’Italien, Robert Croop, Elyse Stock, Alexandra Thiry, Hana Rosenthal, Meghan Lovegren, Christopher Jensen, Vlad Coric, Richard B. Lipton P5.6-010 Efficacy and Safety of Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications During the Open-label Period of the Phase 3b FOCUS Study–Messoud Ashina, Joshua M. Cohen, Maja Galic, Verena Ramirez Campos, Ronghua Yang, Xiaoping Ning, H. Christoph Diener P5.6-011 Clinically Meaningful Responses to Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2–4 Migraine Preventive Medication Classes in the Open– label Period of the International, Multicenter Phase 3b Focus

144 2020 AAN Annual Meeting

0 Monday, April 27 Study–Jonathan P. Gladstone, Xiaoping Ning, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Egilius L H Spierings P5.6-012 Acute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, OpenLabel Safety Study (BHV3000201)–Gilbert J. L’Italien, Robert Croop, Elyse Stock, Alexandra Thiry, Meghan Lovegren, Kate Cowie, Christopher Jensen, Vlad Coric, Richard B. Lipton P5.6-013 Ubrogepant is Effective in the Acute Treatment of Migraine with Mild Pain–Richard B. Lipton, David W. Dodick, Peter Goadsby, Rami Burstein, Aubrey Manack Adams, Jeff Lai, Sung Y. Yu, Michelle Finnegan, Joel M. Trugman Autonomic Disorders 1

8:00 a.m.–9:00 a.m. Vernino, Lucy Norcliffe-Kaufmann, Gregor K. Wenning, Horacio C. Kaufmann P5.7-005 Intrathecal Autologous Mesenchymal Stem Cells in Multiple System Atrophy – Finding the Optimal Dose–Wolfgang Singer, Allan Dietz, Anita Zeller, Ann M. Schmeichel, Prashanthi Vemuri, Anna Castillo, Tonette Gehrking, James Schmelzer, Jade Gehrking, Elizabeth A. Coon, Paola Sandroni, Phillip A. Low P5.7-006 Cutaneous phosphorylated a-synuclein as a biomarker for the a-synucleinopathies: a metaanalysis–Alice Tang, Sharika Rajan, Ana Isabel Penzlin, Valentina Galvis, Roy L. Freeman, Christopher H. Gibbons P5.7-007 Does Orthostatic Hypotension Affect Cognition in Parkinson Disease? A Longitudinal Pilot Study–Katherine Longardner, Ece Bayram, Irene Litvan

7 7

P5.7-001 An Open-Label Phase 2 Study to Explore the Durability of Effect, and Safety of Once-Daily Oral Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, for the Symptomatic Treatment of Neurogenic Orthostatic Hypotension in Subjects With Synucleinopathies–Horacio C. Kaufmann, Italo Biaggioni, Whedy Wang, Brett Haumann, Ross Vickery P5.7-002 Patients with a History of Mild Traumatic Brain Injury have Altered Autonomic Responses to Happy and Fearful Music.–Max Josef Hilz, Ruihao Wang, Dafin Muresanu, Mao Liu P5.7-003 Anticipatory Autonomic responses in Patients with Postural Tachycardia Syndrome–Lucy Norcliffe-Kaufmann, Jose-Alberto Palma, Jose Martinez, Celeste Camargo, Horacio C. Kaufmann P5.7-004 Cerebellar and parkinsonian phenotypes of multiple system atrophy: differences and similarities at baseline from the Natural History Study of the Synucleinopathies– Patricio Millar Vernetti, JoseAlberto Palma, Alessandra Fanciulli, Florian Krismer, Wolfgang Singer, Phillip A. Low, Maria Teresa Pellecchia, Han-Joon Kim, Cyndya Shibao, Amanda C. Peltier, Italo Biaggioni, Maria J. Marti, Cinthia Terroba-Chambi, Marcelo Merello, David S. Goldstein, Roy L. Freeman, Christopher H. Gibbons, Steven

Amyotrophic Lateral Sclerosis 1

P5.7-008 Accelerating clinical therapeutic trials in ALS through frequent at-home data collection.– Seward B. Rutkove, Sarbesh Pandeya, Kristin Qi, Jeremy M. Shefner P5.7-009 Amyotrophic Lateral Sclerosis (ALS) patients experience with Edaravone in Argentina– Cecilia Quarracino, Mariana Bendersky, Natalia Bohorquez Morera, Roberto D. Rey, Gabriel Rodriguez P5.7-010 Distribution of Serum Creatine Kinase Levels in Amyotrophic Lateral Sclerosis– Devin Elizabeth Prior, Elijah Stommel, Victoria Lawson, Jason Kandel, Nathaniel Michael Robbins P5.7-011 Effects of Mexiletine on Cortical and Peripheral Nerve Hyperexcitability in Sporadic ALS– Michael D. Weiss, Eric A. Macklin, Courtney E. McIlduff, Ostoja (Steve) Vucic, Brian Wainger, Matthew Colm Kiernan, Stephen Goutman, Namita Goyal, Seward B. Rutkove, Shafeeq Ladha, I-Hweii Amy Chen, Matthew Harms, Thomas H. Brannagan, David Lacomis, Sasha Zivkovic, Maxwell T. Ma, Leo Hong-Li Wang, Zachary Simmons, Michael H. Rivner, Jeremy M. Shefner, Merit E. Cudkowicz, Nazem Atassi = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Aging and Dementia: Basic Science, Biomarkers, and Genetics 2

Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 2

P5.9-001 Which antiplatelet is the right choice for the secondary prevention of ischemic stroke or transient ischemic attack: A meta-analysis.–Ammad Ishfaq, Muhammad Fawad Ishfaq, Reza Bavarsad Shahripour, Aman Deep, Ana Hossein Zadeh Maleki, Fnu Abhi Pandhi P5.9-002 Use of anticoagulant therapy and cerebral microbleeds: a systematic review and metaanalysis–Yajun Cheng, Yanan Wang, Quhong Song, Ke Qiu, Liu Ming P5.9-003 Therapeutic Anticoagulation in Patients with Large Hemispheric Infarctions– Hannah Breit, Andrea Sterenstein, Nandini Abburi, Sarah Song, Sayona John, Ivan Da Silva, Lauren Koffman P5.9-004 Ischemic Strokes in Anticoagulated Patients: Treatment Failure or Alternate Etiology?–Irvin Nasseri, Alina Khan, Jay Patel, Chanda Mullen, Patrick Gallegos, Ahmed Itrat P5.9-005 Combination Antithrombotic Treatment for prevention of recurrent Ischemic Stroke in IntraCranial Atherosclerotic Disease: CATIS-ICAD–Danielle De Sa Boasquevisque, Mukul Sharma, Michael D. Hill, John W. Eikelboom, Kelvin Ng, Robert G. Hart, Kanjana Perera P5.9-006 Anticoagulation Therapy in the Very Old–Robert W. Stein, Sarah Grzebinski, Carolline Knight P5.9-007 Treatment of Hypercoagulability-Induced New Neurovascular events using Enoxaparin vs DOACs (THINNED)– Sakinah Sabadia, Danielle Golub, Shadi Yaghi, Christopher Hernandez, Jose L. Torres P5.9-008 Difference of Stroke Subtype Under Anticoagulation Therapy between Direct Oral Anticoagulant (DOAC) Only and DOAC Plus Antiplatelet Agent–Taizen Nakase, Junta Moroi, Tatsuya Ishikawa, Hiroaki Shimizu P5.9-009 Is Arrival Blood Pressure Indicative of Stroke Type To Optimize Premixing tPA? An

Analysis of Two National Institute of Neurological Disorders And Stroke Trials–Russell E. Bartt, Kristin Salottolo, Ann Wyborny, Kathryn L McCarthy, David Bar-Or P5.9-010 Intensive vs. Standard Blood Pressure Control in White Matter Disease Progression: Systematic Review and Metaanalysis–Michelle P. Lin, Fnu Sameeullah, James F. Meschia, Nilufer Taner, Erik Middlebrooks, Neethu Gopal, Thomas G. Brott P5.9-011 Impact of Initial Emergency Department Blood Pressure on Ischemic Stroke Severity and Disposition–Amanda Webb, Rohan Mangal, Michelle Wallen, Paul Banerjee, Latha Ganti P5.9-012 The role of left heart factors in the embolic stroke of undetermined source (ESUS) and ESUS recurrence. A multiethnic Asian and North African ESUS study.–Saadat Kamran, Maria Siddiqi, Naveed Akhtar P5.9-013 Implantable Loop Recorder Effectiveness in Cryptogenic Stroke - Lessons Learned–Tejeswi Suryadevara, Husitha Reddy Vanguru, Rashid Ali Ahmed, Danielle Hawley, Stephanie Loveless, Julius Latorre, Karen C. Albright, Claribel Danielle Wee, Avneet Singh P5.9-014 Cardioembolic stroke caused by bi-atrial thrombus and treated with intracardiac thrombectomy; a case report.– Hisham Alhajala, Iyad Isseh, Daniel Miller P5.9-015 Ischemic stroke after cardiovascular surgery–Franco Emanuel Appiani, Jesica Pszenyckyj, Carla Florencia Bolano Diaz, Guido Vazquez, Carlos Santiago Claverie, Roberto Favaloro, Francisco Klein P5.9-016 Recurrent Cerebrovascular Events Secondary to Atrial Myxoma Undetected by Transthoracic and Transesophageal Echocardiograms–Rashid Ali Ahmed, Husitha Reddy Vanguru, Neil Suryadevara, Karen C. Albright P5.9-017 UTility of echocardiograM in the workup Of ischemic STroke patients (UTMOST)–Meagan Maree Guay, Michael Daniel DeDominicis, Aadil Bharwani, Connor Lewicki, Anjali Shroff, Kanjana Perera

AAN.com/view/20AM 145

Monday, April 27

P5.8-001 Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer’s Disease–Lenora A. Higginbotham, Lingyan Ping, Eric Dammer, Duc Duong, Maotian Zhou, Marla Gearing, Erik C B Johnson, Ihab Hajjar, James J. Lah, Allan I. Levey, Nicholas Seyfried P5.8-002 Cerebrospinal Fluid Biomarkers in Normal Pressure Hydrocephalus–Foad Taghdiri, Namita Multani, Alfonso Fasano, Musleh Abdullah Algarni, Catalina Ramirez, David F. Tang-Wai, Carmela Tartaglia P5.8-003 Role for Specific Inflammatory Pathway Analytes Predicting Clinical Progression in MCI Stage of Alzheimer’s Disease–

Jagan Pillai, Gurkan Bebek, James Bena, Lynn Bekris, Stephen M. Rao, Bruce Lamb, James B. Leverenz P5.8-004 A Super Series of Extracellular Non-coding RNA in Cerebrospinal Fluid Reveals Broad Patterns Associated with Neurologic Diseases–Andrew Dhawan, Jacob Scott P5.8-005 miRNA from Exosomes in Older Adults that have Asymptomatic White Matter Hyperintensities Suggest Role for Brain Inflammation in Precursor Stage to Cognitive Impairment– Alexis N. Simpkins, Emanuel Boutzoukas, Andrew O’Shea, Asha Rani, Thomas Elliott Foster, Ronald A. Cohen, Adam Woods P5.8-006 Markers of Vitamin B12 Status in Relation to Cerebrospinal Fluid Biomarkers and Cognitive Performance–Babak Hooshmand, Franziska Koch, Patrick Fissler, Markus Otto, Hayrettin Tumani, Miia Kivipelto, Christine A F Von Arnim P5.8-007 More punctures, more CSF, less results–Guido Vazquez, Franco Emanuel Appiani, Carla Florencia Bolano Diaz, jesica Pszenyckyj, Macarena Gonzalez, Gonzalo Javier Gomez-Arevalo, Santiago O’Neill, Galeno Rojas, Alfredo Thomson P5.8-008 Plasma sex hormonebinding globulin is a potential biomarker of prodromal Alzheimer’s disease–Wei Xu P5.8-009 Relative Importance of Biomarkers in Alzheimer’s disease: Predicting Neurodegeneration by Apolipoprotein E-e4 Carrier Status–Shraddha Sapkota, Saira Mirza, Christopher Scott, Joel Ramirez, Donald Stuss, Mario Masellis, Sandra E. Black P5.8-010 Do deficits in Mitochondrial Spare Respiratory Capacity contribute to Neuropsychological changes seen in Alzheimer’s disease?–Simon Michael Bell, Matteo De Marco, Katy Barnes, Pamela Jean Shaw, Laura Ferraiuolo, Daniel Blackburn, Heather J. Mortiboys, Annalena Venneri P5.8-011 Validation of Sleep EEG-based Brain Age Index for Dementia-related Diseases–Elissa Ye, Haoqi Sun, Luis Paixao, Robert J. Thomas, Alice D. Lam, M. Brandon Westover

POSTER SESSIONS

P5.7-012 Structural and Functional Brain Reorganization Related to Cognitive Impairment in Amyotrophic Lateral Sclerosis– Massimo Filippi, Edoardo G. Spinelli, Camilla Cividini, Silvia Basaia, Elisa Canu, Veronica Castelnovo, Nilo Riva, Yuri Falzone, Federica Agosta P5.7-013 Genetic Testing for ALS: The Incidence of Pathogenic, Likely Pathogenic, and Uncertain Variants in a Clinic-Based Population– Jennifer A. Roggenbuck, Marilly Palettas, Radha Patel, Adam Quick, Stephen J. Kolb P5.7-014 Early Treatment Effects of Riluzole in ALS: Isometric Strength Improvement in Sentinel Muscles Correlates with Improved Survival–Benjamin R. Brooks, Elena Bravver, Urvi G. Desai, Navid Jalali, William B. Dawson, William Bockenek, Scott C Lindblom, Fawn Paling, Stephanie Hawkins, Patricia Antunez, Tiffany Williamson, Nicole Lucas, Scott Holsten, Amber L. Ward, Lisa Ranzinger, Johnny Jones, Allison Newell-Sturdivant, Cynthia Lary P5.7-015 Edaravone Utilization and Outcomes within a Nationally Integrated Health System–Kathryn Tortorice, Michelle Vu, Xiang Ming Wei, Diane Dong, Kwan Hur, Jennifer Zacher, Francesca Cunningham, Peter M. Glassman, Chester Good

Monday, April 27

POSTER SESSIONS

POSTER SESSION 5 P5.9-018 The Association Between The Infarct Pattern And Transthoracic Echocardiographic Changes In Cryptogenic Stroke Patients With Patent Foramen Ovale–Hui Zhang, Fei Wu, Haiyan Tang, Chun Yu, Qiang Dong, Wenjie Cao P5.9-019 Comparative Utility of Transthoracic Echocardiography (TTE) versus Transesophageal Echocardiography (TEE) in Young Patients with Acute Ischemic Stroke.–Rohini Bhole, Issa PourGhaz, E Jeffery Metter, Lauren A. Knight, Timothy Woods, Andrei V. Alexandrov P5.9-020 A case demonstrating the role of transesophageal echocardiography in Embolic Strokes of Undetermined Source– Melissa Ng, Adina Wise, Carolyn D. Brockington, John Liang P5.9-021 Temporal trends of atrial fibrillation and/or rheumatic heart disease-related ischemic stroke, and anticoagulant use in Chinese population: an 8-year study–Junfeng Liu, Yanan Wang, Wen Guo, Yajun Cheng, Lu Wang, Wendan Tao, Shihong Zhang, Bo Wu, Ming Liu Medical Education: Expansion and Outreach 1

P5.10-001 3D Model Simulation is more effective in teaching Functional Neuroanatomy to APPs–Karima Benameur, Bona Kim P5.10-002 Advanced Practice Providers versus Neurology Residents: similar stroke code quality metrics and functional outcomes–Muhib Khan, Heather Martin, Laurel Packard, Danielle Gritters, Hattie LaCroix, Tricia Tubergen, Joseph Zachariah, Elysia James, Jordan Andrew Combs, Michelle Del Castillo DeJesus Brazitis, Bashar Zleik, Nabil Wees, Nadeem I. Khan, Jiangyong Min, Justin Singer, Paul Mazaris P5.10-003 Evaluation of Multiple Sclerosis Education in the Curriculum of Colleges of Pharmacy Across the United States–Kristin Kollecas, Vannary Chhay, Jennifer Cardone, Darren M. Stam P5.10-004 Assessing and Enhancing Non-Neurology Resident Education on Acute Stroke Identification and Intervention– Rebecca Stainman, Arielle Marisa Kurzweil

CME

P5.10-005 Gender Bias in Honorific Use During Speaker Introductions at Department of Neurology Grand Rounds– Alexandra Pincus, Alexandra Hernandez, Mollie Marr, Karen Brasel P5.10-006 “Neurology for Non-Neurologists” Lecture Series for Internal Medicine Residents– Lauren Patrick, Megan Richie P5.10-007 Overcoming Neurophobia for Non Neurologists : A Novel Teaching Approach–Noore-ain Shahid, Paola Martinez, Michael L. Palm Undergraduate Medical Education 1

P5.10-008 Neuro Day: An Innovative Curriculum to Connect Medical Students with Patients– Jessica Frey, Brandon Chase Neeley, Gauri V. Pawar, Ann Murray P5.10-009 The Impact of VideoBased Versus In-Person OSCEs on Medical Student Clinical Reasoning–Sunitha Santhakumar, Maurice Kavanagh, Joseph Vercellone P5.10-010 Correlation of an OpenEnded Neurology Case Reasoning Exam (NeuroCaRE) to the NBME and Core Competencies Evaluation in a Neurology Clerkship–Miguel Chuquilin Arista P5.10-011 Non-Technical Factors Affecting Student’s Status Epilepticus Simulation Experience in a Neurology Clerkship–Miguel Chuquilin Arista, Maria Hella, Christopher Paul Robinson P5.10-012 Perceptions of Functional Neurological Disorders Among Medical Students–Molly C. Cincotta, Kelly Anne Boylan, Laura Ashley Stein, Thomas F. Tropea P5.10-013 Exposure to a Free Neurology Clinic Increases Empathy in Medical Students–Jaime Toro, Juan Sebastian Rivera Perez, Daniel Noriega, Juan Manuel Potes P5.10-014 Facilitated Learning Of Medical Students For Short Rotations In Neurology: An Experience In The EMG Lab In An Academic Institution–Sankar Bandyopadhyay P5.10-015 The Neurolympics: A Student Centered Tool in Neurology Clerkship Education–Jeffrey Barrett Joseph Schachter, Elizabeth Waterhouse

146 2020 AAN Annual Meeting

0 Monday, April 27 Child Neurology and Developmental Neurology: Developmental Disabilities and Movement Disorders 1

P5.11-001 ADHD and Spatial Attention in Children–Georgia Barbayannis, Xue Ming, A. M. Barrett, Jacklyn Johnson, Sarah Nessah Silverstein, Jeffrey M. Kornitzer P5.11-002 Correlations of possible TMS biomarkers of cognitive and emotional dysfunction in ADHD–Alonso Zea Vera, Paul Horn, Stewart H. Mostofsky, Donald Gilbert P5.11-003 A Machine-Based Prediction Model of ADHD Using CPT Data–Itai Berger, Inbal Yahav Shenberger, Ortal Slobodin P5.11-004 Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain: A Randomized Clinical Trial–Negin Badihian, Omid Yaghini, Shervin Badihian, Armindokht Shahsanai, Hossein Saneian P5.11-005 Screening for Social Determinants of Health to Assess Risk of Medical Utilization in an Urban Pediatric Neurology Clinic– Elizabeth Victoria Wilson, Heping Sheng, Hannah Mumber, Megan Sandel, Howard Cabral, Cristina Camayd, Laurie M. Douglass P5.11-006 Dystonic Reactions Among Pediatric Patients Treated for Headache with Metoclopramide Versus Prochlorperazine–Laura Anne Kirkpatrick, Yoshimi Sogawa, Catalina Cleves P5.11-007 Anxiety symptoms in youth with and without tic disorders–Jennifer Anne Vermilion, Carolina Pedraza, Erika Fullwood Augustine, Heather Adams, Amy Vierhile, Adam Lewin, Alyssa Thatcher, Michael McDermott, Tom O’Connor, Roger M. Kurlan, Edwin van wijngaarden, Tanya Murphy, Jonathan W. Mink P5.11-008 High Practice Variability in Cerebral Palsy Diagnosis: Need for clarification of the consensus definition?–Bhooma Rajagopalan Aravamuthan, Darcy L. Fehlings, Michael C. Kruer P5.11-009 The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions–

8:00 a.m.–9:00 a.m. Judith Jaeger, Anna Lee, Geetha Pudussery, Alexander Kolevzon P5.11-010 The National Institute of Neurological Disorders and Stroke (NINDS) Updates to the Cerebral Palsy Common Data Elements Version 1.0 Recommendations–Robin Sadja Feldman, Muniza Sheikh, Ilar Edun, Joy R. Esterlitz, Joline Brandenburg, Sarah McIntyre, Carolina MendozaPuccini P5.11-011 Efficacy and Safety of AbobotulinumtoxinA in Pediatric Lower Limb Spasticity: Interim Results from a Phase IV, Prospective, Observational, Multicenter Study–Mark Gormley, Edward R. Dabrowski, Mauricio R. Delgado, Ann H. Tilton, Asare Christian, Sarah Ann Evans, Pascal Maisonobe, Stefan Wietek, Bruce S. Rubin P5.11-012 Reduction of Upper Limb Spasticity Following AbobotulinumtoxinA Injections in Children with Cerebral Palsy: Results from an International, Phase 3, Pivotal Study–Ann H. Tilton, Jorge Carranza, Nigar Dursun, Marcin Bonikowski, Resa Aydin, Iwona MaciagTymecka, Joyce Oleszek, Edward R. Dabrowski, Anne-Sophie Grandoulier, Philippe Picaut, Mauricio R. Delgado P5.11-013 Multi-level and Multi-pattern Lower- and Upperlimb Spasticity Treatment with IncobotulinumtoxinA in Children and Adolescents with Cerebral Palsy–Edward R. Dabrowski, Henry G. Chambers, Florian Heinen, Petr Kanovsky, Sebastian Schroeder, H. Kerr Graham, Marta Banach, Hanna Dersch, Thorin Geister, Francisco Martinez-Torres, Irena Pulte, Deborah Gaebler-Spira P5.11-014 Neuropsychiatric burden of Adult Polyglucosan Body Disorder: A Patient Survey–Dinesh Lulla, Leslie Higuita, Daniel Silverstein, Heather Lau P5.11-015 A First Case of Noonan Syndrome SOS2 related with Leukodystrophy, Disseminated Neurofibromas and Polyneuropathy–Claudie Gauvreau, Yvan Labrie, Rachel Laframboise, Baiba Lace, Serge Rivest, Nicolas Chrestian

= Research

POSTER SESSION 6

CME

0 Monday, April 27

12:00 p.m.–1:00 p.m.

Poster Session 6

Multiple Sclerosis: Therapeutics MOA and Safety 2

Martin Weber, Richard W. Hughes, Chien-Ju Lin, Jianmei Wang, Annette Sauter, Harold Koendgen, Licinio Manuel Craveiro, Stephen L. Hauser, Tobias Derfuss P6.1-009 Improvement in PatientReported SymptoMScreen Scores Among Ocrelizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 1-Year Results From the CASTING Clinical Trial– Ilya Kister, Gary Raymond Cutter, Regine Buffels, Susanne Clinch, Wei Wei, Patrick Vermersch P6.1-010 It’s Not Always An Infection: Pyoderma Gangrenosum of the Urogenital Tract in Two Patients with Multiple Sclerosis Treated with Rituximab–Erica Hailey Parrotta, Lana Zhovtis Ryerson, Lauren B. Krupp P6.1-011 Immunomodulatory Effects of DMF Treatment on the Peripheral Lymphocyte Compartment: A Focus on Older MS Patients–Fabrizio Giuliani, Erin Longbrake, Yang Mao-Draayer, Derrick Robertson, Amit Bar-Or, Oksana Mokliatchouk, Eris Bame, Dongxia Xing, Becky J. Parks, Chongshu Chen, Catherine Miller P6.1-012 Overall Safety and Efficacy Through 10 Years of Treatment with Delayed-Release

Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis–Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Amit Bar-Or, Robert J. Fox, Chongshu Chen, Becky J. Parks, Shivani Kapadia P6.1-013 Interim analysis of peginterferon beta-1a in the breast milk of lactating patients with multiple sclerosis–Maria K. Houtchens, Maria Claudia Manieri, Tatenda Mahlanza, Andrea Ines Ciplea, Nancy Ramia, Yuan Zhao, Sarah England, Robin L. Avila, Kerstin Hellwig P6.1-014 Transition to non-active secondary progressive multiple sclerosis (SPMS) after up to 9.5 years of natalizumab treatment in the real-world TYSABRI Observational Program (TOP)– Ludwig Kappos, Helmut Butzkueven, Maria Trojano, Heinz Wiendl, Timothy Spelman, Shibeshih Belachew, Ray Su, Nolan Campbell, Pei-Ran Ho, Stephanie Licata

AAN.com/view/20AM 147

Monday, April 27

P6.1-001 Analysis of Reported Deaths While Exposed to DiseaseModifying Therapies for Multiple Sclerosis–Sam Hooshmand, Nicola Carlisle, Michelle Maynard, Leah Hoffman, Ahmed Z. Obeidat P6.1-002 In depth analysis of T cells in multiple sclerosis patients after treatment with Cladribine–Felix Marsh-Wakefield, Simon Hawke, Georges Grau, Pierre Juillard, Thomas Ashhurst, Helen McGuire, Scott N Byrne P6.1-003 Absolute Lymphocyte Counts Are Not a Biomarker of Clinical Response in Patients Treated With Delayed-Release Dimethyl Fumarate–Erin Longbrake, Yang Mao-Draayer, Paul Matthews, John F. Foley, Tomasz Zielinski, Chongshu Chen, Oksana Mokliatchouk, Becky J. Parks, Ankur Sharma, Dongxia Xing, Shivani Kapadia, Eris Bame P6.1-004 Dimethyl fumarate treatment alters T cell metabolism in multiple sclerosis–Marie Liebmann, Claudia Janoschka, Alexander M. Herrmann, Lisanne Korn, Andreas SchulteMecklenbeck, Nicholas Schwab,

Stjepana Kovac, Catharina Groß, Simone Konig, Sven G. Meuth, Heinz Wiendl, Luisa Hildegard Klotz P6.1-005 Change in cognitive processing speed is associated with cortical grey matter and thalamic volume loss in patients with relapsing-remitting multiple sclerosis–Ralph H. B. Benedict, Douglas L. Arnold, John W. Rose, Stanley L. Cohan, Sharon G. Lynch, Ludwig Kappos, Eva Havrdova, Bhupendra O. Khatri, Ray Su, Maria Naylor, Bernd C. Kieseier, Gavin Giovannoni P6.1-006 Efficacy and safety of fingolimod and dimethyl fumarate for management of multiple sclerosis: A single center retrospective study.–Anza Memon, Lara Fahmy, Janet Kandrevas, Mirela Cerghet P6.1-007 Cerebral Bioavailability of Cladribine : Influence of Metabolism and Mechanism of Transport across Brain Barriers–Nathalie Strazielle, Sandrine Blondel, Jean-Francois Ghersi-Egea P6.1-008 Serum Ig Levels and Risk of Serious Infections by Baseline Ig Quartile in the Pivotal Phase III Trials and Open-Label Extensions of Ocrelizumab in Multiple Sclerosis– Amit Bar-Or, Robert A. Bermel,

POSTER SESSIONS

1. Multiple Sclerosis: Therapeutics MOA and Safety 2: 1-001 to 1-022 2. Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 3: 2-001 to 2-004 Autoimmune Neurology 5: 2-005 to 2-012 3. Huntington’s Disease and Tardive Syndromes 2: 3-001 to 3-015 4. Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 3: 4-001 to 4-012 5. General Neurology: Drugs and Therapeutics 1: 5-001 to 5-011 6. Headache: Therapeutics 6: 6-001 to 6-013 7. Autonomic Disorders 2: 7-001 to 7-010 Amyotrophic Lateral Sclerosis 2: 7-011 to 7-015 8. Aging and Dementia: Basic Science, Biomarkers, and Genetics 3: 8-001 to 8-007 Behavioral and Cognitive Neurology: Other 1: 8-008 to 8-011 9. Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 3: 9-001 to 9-020 10. Medical Education: Expansion and Outreach 2: 10-001 to 10-006 Undergraduate Medical Education 2: 10-007 to 10-010 Graduate Medical Education: Pedagogy 1: 10-011 to 10-014 11. Neuro-ophthalmology/Neuro-otology 2: 11-001 to 11-013

Monday, April 27

POSTER SESSIONS

POSTER SESSION 6 P6.1-015 Multiple sclerosis-like CNS inflammation following allogeneic haematopoietic stem cell transplantation treated with a ‘domino’ autologous haematopoietic stem cell transplantation–Joyutpal Das, Atta Gill, Christine Jiaying Lo, Natalie Chan-Lam, Sian Price, Stephen Wharton, Helen Jessop, Basil Sharrack, John Snowden P6.1-016 In Vitro Assessment of the Binding and Functional Reponses of Ozanimod and Its Circulating Metabolites Across Human Sphingosine 1-Phosphate Receptors–Julie Selkirk, Grace Yan, Nathan Ching, Kate Paget, Morgan Brand, Richard Hargreaves P6.1-017 Effects of Ozanimod on Information Processing Speed: Findings From the Phase 3 SUNBEAM and DAYBREAK Extension Trials–John DeLuca, Jeffrey Alan Cohen, Bruce A. C. Cree, Hongjuan Liu, James K. Sheffield, Diego Silva, Giancarlo Comi, Ludwig Kappos P6.1-018 Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis–Stephen L. Hauser, Ludwig Kappos, Xavier Montalban, Xavier Montalban, Richard W. Hughes, Kalpesh Prajapati, Harold Koendgen, Ashish Pradhan, Jerry S. Wolinsky P6.1-019 Severe Reactivation of Rheumatic Cardiopathy During Treatment with Ocrelizumab.–Luis Hernandez-Echebarria, Adrian AresLuque, Elena Rodriguez Martinez, Lidia Binela Lara Lezama, Carlos Javier Martinez P6.1-020 Rapid onset drug induced neutropenia associated with Ocrelizumab in Multiple Sclerosis– Varun Kumar Pala, Bahareh Sianati, Thomas F. Scott P6.1-021 Ocrelizumab real-world safety in the treatment of multiple sclerosis (MS): Differences between investigator-reported and patient-reported safety–Jost Leemhuis, Richard W. Hughes, Julius Eggebrecht, Petra Dirks, Stefanie Hieke-Schulz, Klara Keine, Tjalf Ziemssen P6.1-022 Safety and Effectiveness of Dimethyl Fumarate Maintained Over 4 Years in Multiple Sclerosis Patients Treated in Routine Medical Practice–Krupa Shah Pandey,

CME

Kathryn Giles, Konstantin E. Balashov, Richard A L Macdonell, Jorg Windsheimer, Oksana Mokliatchouk, Becky J. Parks, Filipe Branco, Cynthia C. Jones Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 3

P6.2-001 Validation of a Live Cell-Based Assay For Antibodies to Clustered Acetlycholine Receptor Antibodies in Myasthenia Gravis– Anna Fronda, Hans Frykman P6.2-002 Validation of a Surface Plasmon Resonance Assay for the Diagnostic Detection and Characterization of Muscle-specific Kinase (MuSK) Antibodies in Myasthenia Gravis (MG) Patients– Ebrima Gibbs, Tariq M. Aziz, Hans Frykman P6.2-003 Use of Subcutaneous Immunoglobulin in Stiff Person Syndrome–Salman Aljarallah, Scott Douglas Newsome P6.2-004 Circulating B Cell Subsets and Cytokine Gene Expression Levels in Peripheral Blood and Skin Biopsy in Chronic Inflammatory Demyelinating Polyneuropathy–Ayse Nur Ozdag Acarli, Vuslat Yilmaz, Nermin Sirin, Arman Cakar, Aysun Soysal, Fikret Aysal, Hacer Durmus, Erdem Tuzun, Fatma Yesim Parman Autoimmune Neurology 5 P6.2-005 Presentation and Long-term Neurologic and Neurodevelopmental Profiles in Pediatric Patients with Febrile Infection-Related Epilepsy Syndrome (FIRES): A Single Institution Review–Kristen Fisher, Kimberly Davis, Nikita Shukla, Monica Martinez, Karen Evankovich P6.2-006 Feasibility & Safety of Plasma Exchange in Pediatric Neuro-immunology: A Single Center Experience–Padmavati Rajdatta Eksambe, Yash Shah, Katayoun Fomani, James Louie, Shefali Karkare, Sanjeev V. Kothare P6.2-007 Presence of P/Q Voltagegated Calcium Channel (VGCC) Antibodies in Pediatric Autoimmune Encephalitis–Kristen Fisher, Nikita Shukla P6.2-008 Pediatric anti-NMDA Receptor Encephalitis–Lydia Robinson Marcus, Jayne Ness

148 2020 AAN Annual Meeting

0 Monday, April 27 P6.2-009 Performance Evaluation of a Radioimmunoprecipitation Assay for the Detection of N-Type Voltage-gated Calcium Channel Antibodies in Patient and Control Groups–Bucky K Lozier, Thomas Haven, Morgan Reynolds, Christopher Grow, Anne Tebo, Lisa Kay Peterson P6.2-010 Improving the Identification and Diagnosis of Autoimmune Encephalitis Patients: A Departmental Quality Improvement Project.–Raffaella Umeton, Joshua D. Claunch, Daniela Arantxa Pimentel Maldonado, Carolina Ionete P6.2-011 Broken heart in Morvan’s syndrome–Amit Shankar Singh, Jeenendra Prakash Singhvi, Arun Kaul, Arshdeep Singh P6.2-012 Neuronal uptake, antibody binding, and injury by anti-Ma2 antibodies in organotypic cultures of rat brain: a possible role for anti-Ma2 antibody in production of neurological disease–Jonathan Ross Galli, Kenneth E. Hill, Susan Clawson, Blair Wood, Stacey Clardy, Noel Carlson, John E. Greenlee Huntington’s Disease and Tardive Syndromes 2

P6.3-001 Minimal Clinically Important Difference in AIMS Score Based on Clinical and Patient Global Impression of Change in Patients With Tardive Dyskinesia Treated With Deutetrabenazine–Hadas Barkay, Amanda Wilhelm, Maria Wieman, Mark Forrest Gordon, Robert A. Hauser, Juha M. Savola P6.3-002 Analyzing Sex Differences in Huntington’s Disease using Enroll-HD–Erin Furr-Stimming, Samantha Hentosh, Liang Zhu, Joseph Weldon Furr, Natalia Pessoa Rocha P6.3-003 Patient and Physician Perspectives on the Care and Assistance Needs in Huntington’s Disease (HD)–Karina Raimundo, Ruoding Tan, Tu My To, Jonathan de Courcy, Umang Ondhia, Hugh Rickards, Martha A. Nance P6.3-004 Using Functional Status to Aid Interpretation of Composite Unified Huntington’s Disease Rating Scale (cUHDRS) Scores in Patients with Huntington’s Disease (HD)–Dylan Trundell, Giuseppe Palermo, Jeffrey Long, Blair Leavitt, Scott Schobel, Sarah J. Tabrizi

12:00 p.m.–1:00 p.m. P6.3-005 Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia–Martha Sajatovic, Amanda Wilhelm, Stacy Finkbeiner, Hadas Barkay, Nayla Chaijale, Nicholas Gross, Mark Forrest Gordon P6.3-006 GEORGE® – The First Smartphone Application for Huntington Disease: A Pilot Study–Jamie Lynn Adams, Emma Waddell, Karthik Dinesh, Kelsey Spear, Christopher Tarolli, Molly Elson, Michael Curtis, David Mitten, Gaurav Sharma, E. Ray Dorsey P6.3-007 Discovering Dominant Features Associated with Disease Progression in Huntington’s Disease (HD): A Data-driven Approach Using the Enroll-HD Database–Naghmeh Ghazaleh, Richard Houghton, Giuseppe Palermo, Scott Schobel, Peter Wijeratne, Jeffrey Long P6.3-008 Treatment Responses with Long-Term Valbenazine in Patients with Tardive Dyskinesia– Carlos Singer, Cynthia L. Comella, Stephen Marder, Khodayar Farahmand, Roland Jimenez P6.3-009 Impact of Caring for Patients with Huntington’s Disease (HD) on Work Status–Karina Raimundo, Ruoding Tan, Tu My To, Jonathan de Courcy, Umang Ondhia, Hugh Rickards, Martha A. Nance P6.3-010 Chart Extraction/ Clinician Survey Shows Symptom Impact and Favorable Treatment Outcomes with VMAT2 Inhibitors in Patients with Tardive Dyskinesia– Leslie Lundt, Ericha Franey, Chuck Yonan P6.3-011 Comorbidities and Medications in Huntington’s Disease, Parkinson’s Disease and the General Population in a US Claims Database–Lianna S. Ishihara, Edward J. Wild, David Oliveri P6.3-012 Late-onset Huntington’s Disease: A Retrospective Review of 38 Cases–Kristina Hart, Alexandra O’Neill Duffy P6.3-013 Clinical correlates of Body Mass Index in Mexican patients with Huntington’s disease–Cynthia Lopez-Botello, Sergio Andres Castillo Torres, Denisse G Martinez Roque, Javier Duarte Bravo, Beatriz Chávez, Ingrid Estrada-Bellman, Patricia Rosalia Ancer Rodriguez = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number P6.3-014 Parkinsonism secondary to use of valbenazine and reversal with the addition of levodopa: A Case Report–Rani Priyanka Vasireddy, Zain Guduru P6.3-015 Chorea as an Uncommon Adverse Reaction to Ertapenem– Shweta Varade, Abinayaa Purushothaman Ravichandran, Dmitry Khaitov, Hussam A. Yacoub Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 3

P6.5-001 Functional studies and therapeutic strategies for SLC20A2-associated primary brain calcification–Isao Hozumi, Hisaka Kurita, Masatoshi Inden, Megumi Yamada, Yuichi Hayashi, Takayoshi Shimohata, Takashi Inuzuka P6.5-002 L-Methylfolate Calcium Supplementation in Adolescents and Children: A Retrospective Analysis–Michelle Rainka, Traci Aladeen, Erica S. Westphal, Jessica Greger, Jacqueline Meaney, Rachael Wojcik, Francis Michael Gengo, Horacio Capote P6.5-003 Long-Term Impact of Inotersen on Health-Related Quality-of-Life for Hereditary Transthyretin Amyloidosis with Polyneuropathy: NEURO-TTR Open-Label Extension at Two Years–Aaron Yarlas, Andrew Lovley, Michael Pollock, Montserrat Vera Llonch P6.5-004 A Potential Cure in Adult Onset Subacute Sclerosing Panencephalitis–Samhita Panda P6.5-005 The role of different therapeutic approaches to neurological Wilson´s disease in

Hidenao Sasaki, Hitoshi Warita, Masashi Aoki, Gen Sobue, Hidehiro Mizusawa, Yutaka Matsuyama, Shin Kwak P6.5-012 Longer-term Experience with Nusinersen in Teenagers and Young Adults with Spinal Muscular Atrophy: Results from the CS2/ CS12 and SHINE Studies–John W. Day, Kathryn J. Swoboda, Basil T. Darras, Claudia A. Chiriboga, Susan T. Iannaccone, Madhu Nagappa, Nicholas Deconinck, Richard S. Finkel, Mar Tulinius, Kyoko Saito, Jacqueline Montes, Peng Sun, Ishir Bhan, Boris Kandinov, Janice Chun Yee Wong, Wildon Farwell Headache: Therapeutics 6

P6.6-001 10-Year Costeffectiveness Analyses of Fremanezumab Compared to Erenumab as Preventive Treatment in Episodic Migraine for Patients With Inadequate Response to Prior Preventive Treatments–Lee Smolen, Joshua M. Cohen, Timothy M. Klein, Sanjay Gandhi, Stephen Thompson P6.6-002 Comparative Efficacy and Safety of Rimegepant Versus Ubrogepant and Lasmiditan for Acute Treatment of Migraine: A Network Meta-analysis (NMA)– Karissa Johnston, Evan Popoff, Alison Deighton, Parisa Dabirvaziri, Linda Harris, Alexandra Thiry, Robert Croop, Vladimir Coric, Gilbert J. L’Italien P6.6-003 Rimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects–Michael Hanna, Vlad Coric, Joseph Stringfellow, Andrea Ivans, Robert Croop P6.6-004 OnabotulinumtoxinA Treatment Improved HealthRelated Quality of Life in Adults with Chronic Migraine: Results from a Prospective, Observational Study (PREDICT)–Guy Boudreau, Ian Finkelstein, Corrie Graboski, May Ong-Lam, Suzanne N. Christie, Katherine Sommer, Meetu Bhogal, Goran Davidovic, Werner J. Becker

AAN.com/view/20AM 149

Monday, April 27

General Neurology: Drugs and Therapeutics 1

homozygotic twins with clinical phenotypic variability: case report and literature review–Theo Kruschel, Sara Samadzadeh, Max Novak, Harald Hefter P6.5-006 Serotonin Receptor Activity Profiles for Nine Commercialized Ergot Alkaloids Correspond to Known Risks of Fibrosis and Hallucinations–Robert Fishman, Miguel Guzman, Thomas Armer, Scott W. Borland, Matthew Leyden, Alan M. Rapoport P6.5-007 Longer-term Treatment With Nusinersen: Results in Lateronset Spinal Muscular Atrophy From the SHINE Study–Claudia A. Chiriboga, Basil T. Darras, Michelle Farrar, Eugenio Mercuri, Jan Kirschner, Nancy L. Kuntz, Gyula Acsadi, Mar Tulinius, Jacqueline Montes, Giulia Gambino, Richard Foster, Ishir Bhan, Janice Chun Yee Wong, Boris Kandinov, Wildon Farwell P6.5-008 Responder Analysis for the Modified Neuropathy Impairment Score + 7 and the Norfolk-Quality of Life-Diabetic Neuropathy Questionnaire in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy–Aaron Yarlas, Andrew Lovley, Montserrat Vera Llonch P6.5-009 Relevance of the Therapeutic Copper Compound Cu(atsm) to the Treatment of Sporadic ALS–James Hilton, Kai Kysenius, Paul Donnelly, Jeffrey Liddell, Peter Crouch P6.5-010 Safety Profile of Nusinersen in Presymptomatic and Infantile-Onset Spinal Muscular Atrophy (SMA): Interim Results From the NURTURE and ENDEARSHINE Studies–Basil T. Darras, Darryl C. De Vivo, Michelle Farrar, Eugenio Mercuri, Richard S. Finkel, Richard Foster, Wildon Farwell, Ishir Bhan P6.5-011 Perampanel for Sporadic Amyotrophic Lateral Sclerosis–Hitoshi Aizawa, Haruhisa Kato, Koji Oba, Takuya Kawahara, Yoshihiko Okubo, Tomoko Saito, Makoto Urushitani, Akira Tamaoka, Kiyotaka Nakamagoe, Kazuhiro Ishii, Takashi Kanda, Masahisa Katsuno, Naoki Atsuta, Yasushi Maeda, Makiko Nagai, Kazutoshi Nishiyama, Hiroyuki Ishiura, Tatsushi Toda, Akihiro Kawata, Koji Abe, Ichiro Yabe, Ikuko Takahashi,

POSTER SESSIONS

P6.4-001 Using Machine Learning to Augment Differentiation of Epileptic and Psychogenic NonEpileptic Seizures Recorded with sEMG–Damon Philip Cardenas, Luke Whitmire, Jonathan J. Halford P6.4-002 Accuracy of Automated Machine Learning Software in Identifying EEGs with Prolonged Seizures–Rebecca T. Lin, Destiny Lee Marquez, Mercedes P. Jacobson, Hannah Castaldi, Samuel Buckland, Vinit Shah, Joseph Picone P6.4-003 Indication and Yield of Ambulatory EEG Recordings–Yara Mikhaeil-Demo, Karina A. Gonzalez Otarula, Elizabeth Bachman, Stephan Schuele P6.4-004 Effects of an EvidenceBased Continuous EEG Triage Protocol on Seizure Detection in Hospitalized Adults: A Quality Improvement Analysis–Jessie Jacobson, Brent Jacobus, Daniel B. Simmons P6.4-005 Introducing New Technologies in a Training Program: Lessons from Implementing a Stat Electroencephalography Program at a Major Academic Medical Center–Erin Barnes, Anuj Patel, K. H. Vincent Lau P6.4-006 Intra-burst Theta During Burst-suppression Pattern in Comatose Post-cardiac Arrest Patients Correlates with Outcome; a Prospective Study–Ryka Sehgal, Kurt Yuqin Qing, Nicholas D. Schiff, Peter B. Forgacs P6.4-007 Prevalence of Pulmonary Diseases in Patients with a History of Epilepsy/Seizures–AbdelHameed Al-Mistarehi, Ahmed Moh’d Yassin, Saba Sari Mohadat, Ahmad al Omari, Ehab Yaser Khaled Harahsheh, Omar Telfah, Christina Hanania, Raya Abughanmi, Yara Abukariem, Majd mo’adi, Basheer Khassawneh

P6.4-008 Evaluation of Epilepsy Classification and Optimal Treatment Plan in Post-Stroke Epilepsy: A Single Center Experience–Lilly fagatele, Ka-Ho Wong, Cecilia Peterson, Mugdha Jaitpal, Amir Manzoor Arain, Adam De Havenon, Blake Newman P6.4-009 Patterns of Referral to a Comprehensive Epilepsy Program Iin An Urban Tertiary Care Center–Meghana Srinivas, Kristen Lucas, Rohit Ajay Marawar P6.4-010 Long term outcome of Epilepsy camps in rural India– Nirmal Surya P6.4-011 Evaluating a Data Quality and Safety Protocol for Epilepsy Monitoring Units: Two Years of Experience.–Marino Bianchini, Leonardo Cordenonzzi, Carolina M Torres, Debora RMF Cunha, Carlos Alves Batista, Luiza de Castro, Jorge WJ Bizzi P6.4-012 Prevalence and Risk Factors for Post-Stroke Epilepsy–Sofia Farina, Maria Sol Pacha, Guillermo Povedano, Franco Santajuliana, Walter Toledo, Ignacio Albornoz

Monday, April 27

POSTER SESSIONS

POSTER SESSION 6 P6.6-005 Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials–Morris Levin, Dawn C. Buse, Andrew M. Blumenfeld, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charlie Conway, Christopher Jensen, Beth Morris, Vlad Coric, Robert Croop P6.6-006 Rimegepant 75 mg Provides Early and Sustained Relief of Migraine With a Single Dose: Results from 3 Phase 3 Clinical Trials–Jelena Pavlovic, David W. Dodick, Deborah I. Friedman, Stewart J. Tepper, Lawrence C. Newman, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charlie Conway, Christopher Jensen, Beth Morris, Vlad Coric, Robert Croop P6.6-007 Impact of Fremanezumab on Migraine-associated Symptoms in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications During the Open-label Period of the Phase 3b FOCUS Study–Laszlo Mechtler, Xiaoping Ning, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang P6.6-008 Changes in Depression and Anxiety in a Randomized, Double-blind, Placebo-controlled Study of Galcanezumab in Adults with Treatment-resistant Migraine: Results from the CONQUER Study–Morris Maizels, Dawn C. Buse, Jakub Jedynak, Austin L Hand, Janet Ford, Holland Detke P6.6-009 Lasmiditan in Patients with Common Migraine Comorbidities: A Post hoc, Safety, and Efficacy Analysis of Two Phase 3 Randomized Clinical Trials–David Clemow, Simin Baygani, Paula M Hauck, Cory Hultman P6.6-010 Impact of Fremanezumab on Headache-related Disability in Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medication Classes in the Open–label Extension of the Phase 3b Focus Study–Amaal J. Starling, Verena Ramirez Campos, Xiaoping Ning, Joshua M. Cohen, Ronghua Yang P6.6-011 Is Botulinum Toxin Effective in Treating Menstrually Related Migraine?–Brin Freund, Natalie Castro, Almer Mendoza

CME

P6.6-012 Efficacy Is Maintained With Long-term Intermittent Use of Ubrogepant for the Acute Treatment of Migraine–Joel M. Trugman, Jessica Ailani, Susan Hutchinson, Kerry Louise Knievel, Kaifeng Lu, Sung Y. Yu, Michelle Finnegan, Lawrence Severt, Armin Szegedi, Richard B. Lipton P6.6-013 High Frequency Episodic Migraine Shift to Low Frequency Episodic Migraine in Patients Treated with Galcanezumab– Virginia L. Stauffer, Jakub Jedynak, Astrid Gendolla, Eric J. Eross, Leah Jin Autonomic Disorders 2

P6.7-001 Nerve Conduction Studies in Familial Dysautonomia– Joel Gutierrez, Bhumika Balgobin, Jose-Alberto Palma, Lucy NorcliffeKaufmann, Horacio C. Kaufmann P6.7-002 Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis–Alejandra GonzalezDuarte, Daniel Judge, Angela Dispenzieri, Hollis Lin, Madeline Merkel, Yue Wang, Michael J. Polydefkis P6.7-003 Establishment of Normative Data for Cardiovascular Autonomic Function Tests in Indian Population–Vineeth Jaison, Silky Adya, Himani Khatter, Bharat Singh, Jeyaraj Durai Pandian, Sheena Singh P6.7-004 Autonomic Dysfunction in Diabetic and Non-diabetic Lumbosacral Radiculoplexus Neuropathy–Kamal Shouman, Marcus Vinicius Rocha Pinto, Mariana Suarez, Wolfgang Singer, Peter J. Dyck, Phillip A. Low, P. James B. Dyck P6.7-005 Association of GAD65 Antibodies with Autonomic Dysfunction in non-Type I diabetic patients–Nina Bozinov, Lucas Kipp, Linda Nguyen, Safwan S. Jaradeh P6.7-006 The V122I Mutation in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy– Paul Nioi, Meg M Parker, Scott M Damrauer, Daniel J Rader, Simina Ticau, David Erbe, Greg Hinkle P6.7-007 Establishment of Normative Data for Quantitative Sudomotor Axon-Reflex Test from North India–Silky Adya, Himani

150 2020 AAN Annual Meeting

0 Monday, April 27 Khatter, Bharat Singh, Jeyaraj Durai Pandian, Sheena Singh P6.7-008 Cognitive performances in a cohort of Pure Autonomic Failure patients–Ilaria Cani, Luisa Sambati, Giulia Giannini, Giovanna Calandra-Buonaura, Gianmaria Asioli, Federico Oppi, Roberto Poda, Francesco Mignani, Federica Provini, Pietro Guaraldi, Pietro Cortelli P6.7-009 Pediatric onset postural orthostatic tachycardia syndrome in a single tertiary care center–Anthony Staples, Nicholas Thompson, Manikum Moodley P6.7-010 Establishment of Normative Data for Thermoregulatory sweat test in Indian Population–Himani Khatter, Silky Adya, Bharat Singh, Jeyaraj Durai Pandian, Sheena Singh Amyotrophic Lateral Sclerosis 2 P6.7-011 Cutaneous Silent Periods in Patients with Early-stage ALS–Joel Gutierrez, Rachel PerezLalana, Tatiana Zaldivar Vaillant, Gloria Lara-Ferandez, Astrubal Arias, Yodeisy Ferrer, Orla Hardiman P6.7-012 A Retrospective Review of Radicava Experience Across US ALS Centers–John Furey, John Furey, Ezri Yuen, NEALS Clinical Studies Group P6.7-013 Predicting Survival in ALS Using Machine Learning Algorithms - a Preliminary Analysis–Bill Jacobsen, Shafeeq Ladha P6.7-014 Open-label Pilot Study of Ranolazine for Cramps in Amyotrophic Lateral Sclerosis (ALS).–Swathy Chandrashekhar, Anai C. Hamasaki, Ayla McCalley, Laura Herbelin, Mamatha Pasnoor, Omar Jawdat, Mazen M. Dimachkie, Richard J. Barohn, Jeffrey Statland P6.7-015 The Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS (CAPTURE ALS)–Sanjay Kalra, Nicolas Dupre, Angela L. Genge, Janice Robertson, Christine Vande Velde, Claire Magnussen

12:00 p.m.–1:00 p.m. Aging and Dementia: Basic Science, Biomarkers, and Genetics 3

P6.8-001 The Relationship Between EEG Characteristics During Critical Illness and LongTerm Cognitive Impairment– Shawniqua Williams Roberson, Shawniqua Williams Roberson, Randip Singh Taneja, Brenda T Pun, James Jackson, Pratik P Pandharipande, E. Wesley Ely P6.8-002 Comparison of EEG utilization patterns in Dementia with Lewy Bodies versus Alzheimer Disease–Jakob Mrozewski, Peter Pressman, Samantha K. Holden P6.8-003 Genetic Architecture Drives Differences in RNA Editing Rates between Alzheimer Disease Cases and Controls in Diverse Populations–Olivia Gardner, Lily Wang, Derek Van Booven, Patrice Whitehead, Kara Hamilton-Nelson, Larry D. Adams, Takiyah Starks, Natalia Hofmann, Jeffery M. Vance, Michael L. Cuccaro, Eden R. Martin, Goldie S. Byrd, Jonathan Haines, William Bush, Gary W. Beecham, Margaret A. Pericak-Vance, Anthony J. Griswold P6.8-004 Meta-analysis of Gene Expression in Early-onset Alzheimer’s Disease–Daniela Lozano, Leena Raza, Jihad Aljabban, Dexter Hadley P6.8-005 Melatonin Receptor-1B Genotype, KIBRA Genotype, and Possibly a-Klotho Plasma Level in Women are Associated with Incident Delirium in Elderly Postsurgical Patients–Mark Anthony Terrelonge, Dan Wang, Chris Chengke Tang, Irina Movseyan, Clive Pullinger, Jacqueline Leung, Dena Dubal, Vanja C. Douglas P6.8-006 Long-read Sequencing Identifies GGC Repeat Expansions in NOTCH2NLC as the Cause of Neuronal Intranuclear Inclusion Disease–Jun Sone, Satomi Mitsuhashi, Atsushi Fujita, Hiroshi Takashima, Hiroshi Sugiyama, Yoshihisa Takiyama, Kengo Maeda, Fumiaki Tanaka, Yasushi Iwasaki, Mari Yoshida, Naomichi Matsumoto, Gen Sobue P6.8-007 A novel T567M mutation outside the tyrosine kinase domain of CSF1R with

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number clinical and radiological features of HDLS–Jonathan Yexian Lai, Haitao Tu, Jayne Yi Tan, Weng Khong Lim, Li Zeng, Adeline Su Lyn Ng Behavioral and Cognitive Neurology: Other 1

Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 3

Medical Education: Expansion and Outreach 2

Medicine–Aileen Cangiano-Heath, Chineze Nwebube, Jheison Giraldo, Cara E. Harth P6.10-003 A Novel Opportunity to Engage Underrepresented Youth in Neuroscience Education and Research–Nicte I. Mejia, Alazar Ayele P6.10-004 Identifying Strategies in Patient Recruitment for Acute Stroke Clinical Trials–Mehnaaz Ali, John Brooks Terry, Angie Shoen, Loren Friedman P6.10-005 A Bibliometric Analysis of Publication Patterns of Neurology Articles in General Medicine Journals–Mitchell Wilson, Margaret Sampson, Asif Doja P6.10-006 Qualitative Analysis of Neurology Consulting Services in a Pediatric Emergency Department– Matthew Hiller, Jan A. Martin, Janice Hanson Undergraduate Medical Education 2 P6.10-007 The Narrative Evaluation Quality Instrument: Development of a Tool to Assess the Assessor–Robert Ian Thompson-Stone, Michael Kelly, Christopher Mooney, Melanie Braun, Justin Rosati P6.10-008 Why Neurology (or Not)? Understanding Career Decision-Making of First-Year Medical Students–Rachel J. Gottlieb-Smith, Dorene Balmer, Douglas J. Gelb P6.10-009 A Stroke of Genius: Using Gaming to Reinforce Learning in Neurology Education–Ruchi Dhyani, Ann Helms P6.10-010 Neurology Problem Based Learning with Limited Neurologist Resources is Feasible– Irma Nora Duncan, Xiaoqian Fang, Norma Lopez, Michael Dobbs

10 10

P6.10-001 The Effectiveness of Video Teaching of the Neurological Examination for Surgical and Neurosciences Nurses–Thomas James Williams, Brittany Elyce Bolduc, Yorghos Tripodis, Saleh Abbas, Sherida Padilla, David M. Greer, Anna Marisa CervantesArslanian, Courtney Takahashi P6.10-002 The Impact of Early Introduction to Neurology for Underrepresented Minorities (URM) on Decision in Careers in

Graduate Medical Education: Pedagogy 1

P6.10-011 A Novel Goals of Care Communication Curriculum for Neurology Residents Improves Confidence and Skills–Tarini Goyal, Sylvia Bereknyei Merrell, Barbette Weimer-Elder, Merisa Kline, Carl Aaron Gold

AAN.com/view/20AM 151

Monday, April 27

P6.9-001 Anticoagulation with DOAC or Heparin Bridging in Acute Cardioembolic Stroke: Nationwide Retrospective Cohort Study Analysis in Japan–Takahisa Mikami, Norihiko Inoue, Mizuho Asada, Kiyohide Fushimi P6.9-002 Stroke Rates in Centrifugal Flow Left Ventricular Assist Devices: A Device-Specific Comparative Analysis–Catherine Hassett, Sung Min Cho, Tracey Huijun Fan, Ibrahim Migdady, Randall Starling, Ken Uchino P6.9-003 The “Natural History” of Stroke secondary to Atrial Fibrillation: two weeks without therapeutic anticoagulation.–Xiyan Yi, David Z. Rose, Arthur J Labovitz, Michael G Fradley, Nhi Tran, William Scott Burgin, Swetha Renati P6.9-004 Timing of Anticoagulation Post Atrial Fibrillation Related Ischemic

P6.9-014 High Dose Aspirin Versus Clopidogrel After a Breakthrough Ischemic Event While on Low Dose Aspirin–Saurav Das, Rachael Swisher, Shivani Naik, Chelsey Mcpheeters, Amy Braden, Michael Haboubi P6.9-015 The Relationship of Continous 24-Hour Admission Blood Pressure To Severity and Short-Term Outcome Amongst Stroke Patients At The University of Abuja Teaching Hospital, Abuja, Nigeria.–Ifeyinwa Ani-Osheku, Mustapha A. Danesi, Njide Okubadejo, Peter Alabi P6.9-016 Relative Changes in Blood Pressure as a Predicative Measure of Ischemia in Inpatient Code Strokes–Jacob Didion, Tina Mariko Burton, Anusha Boyanpally P6.9-017 PFO and Push-Ups: A Case Series of Valsalva Before Cryptogenic Stroke–Elle Wade, Martha Robinson, Atul Singla, Justin A. Salerian P6.9-018 Cangrelor as a bridging antiplatelet therapy in a patient with recent intracranial and cardiac stenting: A case report and review of literature–Subin Mathew, Katleen Wyatt, Feras Akbik, Vishal Patel, Jonathan Ratcliff, Ofer Sadan P6.9-019 Characterization of Unfractionated Heparin Infusions in a Comprehensive Stroke Center– Houman Khosravani, Cindy Shen, Peter Pham, Vincent Teo, Courtney Wong P6.9-020 Simultaneous Hemorrhagic And Ischemic Strokes- A rare but vexing entity– Abdulrahman Bukhari, Fransisca Indraswari, Mithilesh Siddu, Eduard Shaykhinurov, Soha Sadeghikhah, Christopher Leon Guerrero

POSTER SESSIONS

P6.8-008 Heat Shock Protein A12A Is Essential for Hippocampal Spinogenesis, Neurogenesis and Affective Behavior Development in Mice–Yali Gui, Hao Cheng, Yulian Duan, Xiaojin Zhang, Jiali Liu, Chuanfu Li, Zhengnian Ding, Li Liu P6.8-009 Using a Multimodal Biomarker Approach to Identify Functional Target Engagement of the Novel NMDA Positive Allosteric Modulator SAGE-718–Aaron Koenig, Harald Murck, Jason Berlin, Yi Luo, Sigui Li, Brandon Farley, David Nguyen, Irena Webster, Michael Quirk, Steve Kanes, James Doherty P6.8-010 Differential expression of neurexin genes in the mouse brain–Amy Cheung, Kensuke Futai P6.8-011 Role of NOX2 in the BDNF dysregulation and cognitive deficits after sepsis–Wan-Yu Huang, Ting-Yu Chen, Ko-Hung Liu, Ya-Ping Chen, Shankung Lin, HungMing Wu

Stroke–Alyson Rylie Plecash, Sahil Mann, Oscar R. Benavente, Samuel Yip P6.9-005 Ischemic and Hemorrhagic Strokes after Left Atrial Appendage Occlusion (LAAO): A Mayo Clinic Case Series–Chia-Chun Chiang, Chieh-Ju Chao, Reza Arsanjani, Cumara Barahona O’Carroll, Holmes David, Paul Friedman, Thomas Munger, Mohamad Alkhouli, Peter Pollak, Eric Yang P6.9-006 Prevalence of Symptomatic and Asymptomatic Cerebrovascular Disease in Patients Undergoing Left Atrial Appendage Closure: A Three-Site 9-Year Review–Najiyah Salwa, James F. Meschia, Demilade Adedinsewo, Peter Pollak, Fnu Sameeullah, Rocco Joseph Cannistraro, Kevin M. Barrett, Pragnesh P. Parikh, Michelle P. Lin P6.9-007 The Fasting for Brain and Heart Health Study: Preliminary results–Eugene L. Scharf, Toshia Myers, Su-Yeon Hwang, Patricia Kolbe P6.9-008 Measurement of Left Atrial Appendage Flow Velocity to Enhance Risk Assessment for Stroke in Atrial Fibrillation Patients–Eric Zhou, Andrew D. Chang, Nikhil Panda, Antony Chu, Karen L. Furie, Michael Atalay, Christopher Song, Shadi Yaghi P6.9-009 Left Atrial Enlargement and Reduced Ejection Fraction are Independently Associated with Cardiomebolic Stroke–Maryam Hosseini, Shadi Milani, Mohammad Shafie P6.9-010 The Growing Challenge of Post-TAVR Strokes–Kenneth Han, Prachi Mehndiratta, Michael Phipps, Seemant Chaturvedi P6.9-011 Predictors of neurological deterioration in patients with cerebellar stroke– Thanyalak Amornpojnimman P6.9-012 Recovered Neurological Worsening in Hospitalized Patients with Acute Ischemic Stroke– Jeong-Hoon Kim, Tai Hwan Park, Hye-Yun Kim, Moo-Seok Park, Min Ky Kim P6.9-013 In-Hospital Stroke: Risk Factors and Outcomes amongst Active Cancer Patients–Adriana Sari, Nathan Muntz, Zachary Benjamin Bulwa, Shyam Prabhakaran

Monday, April 27

POSTER SESSIONS

POSTER SESSION 6 P6.10-012 Assessing Impact of Evidence-Based Pedagogic Techniques in Resident-Led Neurology Didactics–Adeolu Oluwaseun Morawo, Chichun Sun, Gloriel Flores-Caban, Max R. Lowden P6.10-013 The Validity of the National In-training Examination for Canadian Pedatric Neurology Residents (NITECaP)–Sunita Venkateswaran, Serena Orr, Jonathan Dupre, Farhan Bhanji, Timothy Wood, Susan HumphreyMurto, Debra Pugh, David Callen P6.10-014 Stroke Simulation during a Neurology Bootcamp– Alexandra Kvernland, Brandon Giglio, Marco Joseph Russo, Sara Kate Rostanski Neuro-ophthalmology/Neurootology 2

P6.11-001 Risk of generalization in ocular myasthenia gravis after 10 years.–Antoine Gueguen, Benoit Hijazi, Kevin Zuber, Romain Deschamps, Cedric Lamirel, Catherine Vignal-Clermont, Olivier F. Gout P6.11-002 Myasthenia Gravis in Monozygotic Twins–Robert Craig Coppola, Matthew Kay, Mason Daniel Dyess P6.11-003 Predictive value of radiographic signs of raised intracranial pressure for the postoperative risk of recurrence of spontaneous cerebro-spinal fluid (CSF) leaks–Bryce Buchowicz, Amit Saindane, Samuel Bidot, Benson Chen, Nancy J. Newman, Valerie Biousse P6.11-004 Neuro-Imaging Evidence for Reversible Collapsibility of the Distal Transverse Sinuses in Spontaneous CSF Leak–Leanne Stunkel, Amit Saindane, John DelGaudio, Nancy J. Newman, Valerie Biousse P6.11-005 Abducens Nerve Palsy and Vision Loss Secondary to Erdheim-Chester Disease–Christina Yuen, John G. Kelsey, Eric Tamrazian, Margaret Adler P6.11-006 Sudden Severe Vision Loss And Persistent Vomiting: From A Suspicion Of Neuromyelitis Optica To A Diagnosis Of Acute Thinner Intoxication–Emerson de Paula Santos, Belisa Lopes Alvares, Ana Paula Costa

CME

0 Monday, April 27

12:00 p.m.–1:00 p.m.

P6.11-007 Sildenafil Induced Headache and Blurry vision–Yin Allison Liu, Jose Davila, Heather Moss P6.11-008 Determining the Best Functional and Structural Outcome to Measure the Deficits After an Episode of Optic Neuritis–Mark J. Kupersmith, Sylvia Klineova P6.11-009 Causes of Homonymous Macular Ganglion Cell Complex Atrophy on Optical Coherence Tomography without Significant Visual Field Changes–Mark Lukewich, Matthew Schlenker, Jonathan Micieli P6.11-010 TITLE: Role for OCT in detecting homonymous ganglion cell layer thinning in patients with multiple sclerosis–Rachel Nolan, Marissa Catherine Ilardi, Steven Galetta, Laura J. Balcer P6.11-011 Identification of a novel mutation in Bosch-BoonstraSchaaf Optic Atrophy Syndrome: Case Report and A Review of Literature–Sushant Puri, Peter Macintosh, James A. Goodwin, Brooke Johnson P6.11-012 Complex I Deficiency due to a Nuclear Mitochondrial DNA Mutation of the NDUFAF5 Gene Causing a Leber Hereditary Optic Neuropathy “Plus” Phenotypic Expression–Dev Mehta, Sasha Mansukhani, Mark A. Whealy, Deborah L. Renaud, John Chen, M. Tariq Bhatti P6.11-013 Atypical Presentation of Leber’s Hereditary Optic Neuropathy–Sara Rubenstein, Asif Hilmi, Xue Ming

152 2020 AAN Annual Meeting

= Research

POSTER SESSION 7

CME

0 Monday, April 27

5:30 p.m.–6:30 p.m.

Poster Session 7

Multiple Sclerosis: Therapeutics MOA and Safety 3

P7.1-010 Improved clinical outcomes for relapsing remitting multiple sclerosis (RRMS) patients treated with first line natalizumab vs first line injectable therapies– Carlos Acosta, Khalil Jomaa, Ray Su, Eddie Jones, Joseph Husbands, James Pike, Mia Berry P7.1-011 Short term efficacy and safety outcomes after switching from Anti-CD20 DMTs to Cladribine in a real-world setting–Daniel TD O’Neill, Suzanne J. Hodgkinson Multiple Sclerosis: Clinical Trials and Therapeutics 1

P7.1-012 Assessing myelin loss in the white matter near to and distant from chronic black holes in multiple sclerosis.–Dhairya Lakhani, Sijin Wen, Si Gao, Karina Ciccone, Seth A. Smith, Junzhong Xu, Richard Darrell Dortch, Francesca Bagnato P7.1-013 B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials–Stephen L. Hauser, Amit Bar-Or, Jeffrey Alan Cohen, Giancarlo Comi, Jorge D. Correale, Patricia K. Coyle, Anne H. Cross, Jerome De Seze, David Leppert, Xavier Montalban, Krzysztof Selmaj, Heinz Wiendl, Algirdas Kakarieka, Bingbing Li,

Roman Willi, Dieter Haering, Martin Merschhemke, Ludwig Kappos P7.1-014 Effect of teriflunomide on brain volume loss in patients with relapsing multiple sclerosis of differing ages in TEMSO–Jiwon Oh, Jens Wuerfel, Bhupendra O. Khatri, Aaron E. Miller, Jihad Said Inshasi, Byoung Joon Kim, Albert Saiz, Alex Lublin, Elizabeth Poole, Till Sprenger P7.1-015 Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets– Gavin Giovannoni, Giancarlo Comi, Kottil W. Rammohan, Peter Rieckmann, Patrick Vermersch, Fernando Dangond, Birgit Keller, Dominic Jack P7.1-016 Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets–Patrick Vermersch, Gavin Giovannoni, Per Soelberg Sorensen, Kottil W. Rammohan, Stuart D. Cook, Birgit Keller, Sanjeev Roy P7.1-017 Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and postapproval data–Stuart D. Cook, Gavin Giovannoni, Thomas Leist, Giancarlo Comi, Sana Syed, Axel Nolting, Doris Damian, Regina Schick

AAN.com/view/20AM 153

Monday, April 27

P7.1-001 Characterizing disability improvement among patients with early relapsing-remitting multiple sclerosis (RRMS) using functional systems (FS): results from the multicenter, observational STRIVE study–Jai Perumal, Robert J. Fox, Roumen D. Balabanov, Laura J. Balcer, Steven Galetta, Paula Read, Kuangnan Xiong, Menglan Pang, Denise I. Campagnolo, Christophe Hotermans, Lily Lee P7.1-002 Cerebrovascular Reactivity in Patients with Multiple Sclerosis Related to Fingolimod Treatment–Nevzat Uzuner, Gulnur Uzuner P7.1-003 Blood pressure changes during Alemtuzumab infusion for persons with MS–Eslam Hamdy Shosha, Courtney S. Casserly, Christine Tomkinson, Sarah Anne Morrow P7.1-004 Interrogating the Influence of the Multiple Sclerosis Modifying Drug Cladribine (2-Chlorodeoxyadenosine) Upon Primary Human Monocytes and Macrophages–Tiago Medeiros Furquim Mendonca, Sinan Ayoub, Laura Johnson, Andrea Aprico, Michele Binder, Trevor J. Kilpatrick

P7.1-005 Low Rate of Infections With Long-term Use of Ozanimod in Relapsing Multiple Sclerosis Trials–Hans-Peter Hartung, Bruce A. C. Cree, Krzysztof Selmaj, Eva Havrdova, Giancarlo Comi, James K. Sheffield, Neil Minton, Anne Janjua, Ning Ding, Amit Bar-Or P7.1-006 Extramedullary Plasmacytoma in a Patient Treated with Dimethyl Fumarate–Whitney E. Mayberry, Neeta Garg P7.1-007 Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study–Joel Corbett, Stefan Blum, Mike Boggild, Simon Broadley, Pamela Ann McCombe P7.1-008 Recurrent Intracerebral Hemorrhage Due to Alemtuzumab Treatment in a Patient with Multiple Sclerosis: Case Report–Meltem Inci, Tuncay Gunduz, Murat Kurtuncu, Mefkure Eraksoy P7.1-009 Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS)–Vicki Maltby, Amanda Lydon, Mastura Monif, Trevor J. Kilpatrick, Helmut Butzkueven, Bruce Taylor, Pamela Ann McCombe, Suzanne J. Hodgkinson, Marzena Pedrini, Allan G. Kermode, Michael Barnett, Tomas Kalincik, Jeannette LechnerScott

POSTER SESSIONS

1. Multiple Sclerosis: Therapeutics MOA and Safety 3: 1-001 to 1-011 Multiple Sclerosis: Clinical Trials and Therapeutics 1: 1-012 to 1-022 2. Neuro-rehabilitation 1: 2-001 to 2-012 3. Aytpical Parkinsonism and Ataxia 1: 3-001 to 3-015 4. Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 4: 4-001 to 4-012 5. History of Neurology: 5-001 to 5-012 6. Headache: Therapeutics 7: 6-001 to 6-013 7. Amyotrophic Lateral Sclerosis 3: 7-001 to 7-007 Spinal Muscular Atrophy/Motor Neuron Disorders 1: 7-008 to 7-014 8. Behavioral and Cognitive Neurology: Aging and Neurodegenerative Disease 1: 8-001 to 8-011 9. Cerebrovascular Disease: Telestroke, Pre-hospital, and Emergent Stroke Evaluation and Treatment 1: 9-001 to 9-021 10. Graduate Medical Education: Pedagogy 2: 10-001 to 10-016 11. TRANSCENDS: 11-001 to 11-010

Monday, April 27

POSTER SESSIONS

POSTER SESSION 7 P7.1-018 Autologous hematopoietic stem cell transplantation versus alemtuzumab in aggressive MS: a retrospective real-word study–Caterina Lapucci, Giacomo Boffa, Elvira Sbragia, Elisabetta Capello, Daniela Curro, Alice Laroni, Luca Roccatagliata, Antonio Uccelli, Francesca Gualandi, Giovanni Luigi Mancardi, Matilde Inglese P7.1-019 Early Treatment with Natalizumab Is Associated with Improved Long-Term Cognitive and Physical Performance in Multiple Sclerosis: Results from MS PATHS–Daniel Ontaneda, Ellen M. Mowry, Scott Douglas Newsome, Robert T. Naismith, Jacqueline Ann Nicholas, James Rhys Williams, Elizabeth Fisher, Carl DeMoor, Justin Bohn, Pei-Ran Ho, Alfred W. Sandrock, Richard A. Rudick P7.1-020 Longitudinal Assessment of Optical Coherence Tomography in Patients with Relapsing-Remitting Multiple Sclerosis on Three Disease Modifying Therapies–Ka-Ho Wong, Rae E. Bacharach, Julia Klein, M. Mateo Paz Soldan, John W. Rose P7.1-021 Cladribine at all stages of multiple sclerosis: Up to five years follow-up–Kimberley Allen-Philbey, Stefania De Trane, Andrea Stennett, Ozlem Yildiz, Ashok Adams, Benjamin Turner, Monica Marta, Sharmilee Gnanapavan, Lucia Bianchi, Joela Teresa Marianne Mathews, Daniel Altmann, Gavin Giovannoni, David Baker, Klaus Schmierer P7.1-022 Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CAREMS II Follow-up (TOPAZ Study)–Ann D. Bass, Raed Alroughani, Simon Broadley, Giancarlo Comi, Yang Mao-Draayer, Hans-Peter Hartung, Eva Havrdova, Ho Jin Kim, Kunio Nakamura, Carlos Alberto Navas, Alex Rovira, Krzysztof Selmaj, Patrick Vermersch, Sibyl E. Wray, Zia Choudhry, Nadia Daizadeh, Salman Afsar, Barry A. Singer

CME

Neuro-rehabilitation 1

P7.2-001 Investigating Bulbar Motor and Cognitive-Linguistic Impairment in ALS–Amanda Martino, Dennell Mah, Miriam Garrido-Clua, Agessandro Abrahao, Lorne H. Zinman, Sanjay Kalra, Yana Yunusova P7.2-002 Evaluation of Staff Communication Before and After Implementation of a Training Protocol for Inpatients with Memory Impairments–Lauren Riley Nelson, Tessa Hart, Amanda Rabinowitz, Mary Ferraro, Lyn Turkstra P7.2-003 Estimating Digital Therapy Progress Using Large-Scale Speech and Cognitive Rehabilitation Data–Shaheen E. Lakhan, Veera Anantha, Ehsan Dadgar, Michael Munsell P7.2-004 Effect of Transcranial Direct Current Stimulation on Severely Affected Arm-Hand Motor Function in Patients After An Acute ischemic Stroke–Meheroz H. Rabadi, Christopher Aston P7.2-005 Upper Extremity Telerehabilitation for Progressive Multiple Sclerosis–Martin Malik, Matthew Lustberg, Ashwin Kumar, Lauren B. Krupp, Kathleen Sherman, Vikram Kapila, Preeti Raghavan, Leigh Elkins Charvet P7.2-006 Social Factors Related to Home-Based Telerehabilitation After Stroke–Sophia Raefsky, Lucy Dodakian, Vu Le, Alison McKenzie, Jill See, Robert Zhou, Thalia Nguyen, Benjamin Vanderschelden, Gene Wong, Laila Nazarzai, Jutta Heckhausen, Steven C. Cramer, Amar Dhand P7.2-007 Transcranial Direct Current Stimulation (tDCS) can Reduce Fatigue and Improve Sleep Quality in Multiple Sclerosis– Giuseppina Pilloni, Claire Choi, Michael Shaw, Lauren B. Krupp, Leigh Elkins Charvet P7.2-008 Telerehabilitation for Neurological Disability with Remotely Supervised Transcranial Direct Current Stimulation (RStDCS)–Kelly Lee, Amy Ro, Matthew Lustberg, Michael Shaw, Nabil Khan, Pamela Best, Martin Malik, Kelly Lee, Allan George, Abhishek Datta, Marom Bikson, Kathleen Sherman, Lauren B. Krupp, Leigh Elkins Charvet P7.2-009 Effectiveness of neurofeedback using near-infrared

154 2020 AAN Annual Meeting

0 Monday, April 27 spectroscopy to enhance the efficacy of motor imagery-based rehabilitation in stroke patients: A Randomized trial–Shakthi KJS, Kameshwar Prasad P7.2-010 Foix-Alajouanine Syndrome Mimicking Longitudinally Extensive Transverse Myelitis– Anirudha Swaminathan Rathnam, Iram Zaman, Anza Memon P7.2-011 Characterizing Changes in Sensorimotor Integration after Chronic Stroke Based on Neural Activity and Movement Kinematics–Kevin Andrew Mazurek, Suzan Hoffman, Soma Mizobuchi, Eleni Patelaki, David Paul Richardson, Nicholas Abraham, Ania Busza, Edward Freedman, John Foxe P7.2-012 An International, Multicenter, Observational, Longitudinal Study to Assess the Effectiveness of AbobotulinumtoxinA Injections for Adult Lower Limb Spasticity: The AboLiSH Study–Alberto Esquenazi, Stephen Ashford, Allison Brashear, Pascal Maisonobe, Andreas Lysandropoulos Atypical Parkinsonism and Ataxia 1

P7.3-001 Frequency of red flags and other associated symptoms in multiple system atrophy–Yu Jin Jung, Han-Joon Kim, Dallah Yoo, JiHyun Choi, Hui-Jun Yang, Beomseok Jeon P7.3-002 Methods and Utility of Quantitative Brainstem Measurements in Progressive Supranuclear Palsy versus Parkinson’s Disease in a Routine Clinical Setting–Jessica Cooperrider, Brent Robert Bluett, Stephen Jones P7.3-003 Augmenting BK Channel Function as Therapy for Spinocerebellar Ataxia (SCA)– Sharan Srinivasan, David Bushart, Vikram Shakkottai P7.3-004 “Putaminal hypointensity (PUT-hypo)” on Susceptibility-Weighted Imaging (SWI) in Parkinsonism Predominant Multiple System Atrophy (MSA-P): Comparison between Parkinson’s Disease (PD) and Age-matched Controls without Parkinsonism–Aki Arai P7.3-005 Prevalence of RFC1Mediated Spinocerebellar Ataxia in a United States Ataxia Cohort– Dona Aboud Syriani, Darice Wong,

5:30 p.m.–6:30 p.m. Claudio Melo DeGusmao, Sameer Andani, Yuanming Mao, Giacomo Glotzer, Paul Lockhart, Sharon Hassin-Baer, Vikram Khurana, Soma Das, Christopher Gomez, Susan L. Perlman, Brent L. Fogel P7.3-006 Is Ataxia in Huntington’s Disease, an Underestimated Symptom?–Gustavo Leite Franklin, Sibele Milano, Giovanna Pavanelli, Nayra Lima, Salmo Raskin, Francisco M. Branco Germiniani, Orlando Graziani Povoas Barsottini, Jose Luiz Pedroso, Fernanda Maggi, Iscia Lopes-Cendes, Paula Christina Azevedo, Pedro Manzke, Vitor Tumas, Helio Afonso Ghizoni Teive P7.3-007 Channelopathies are a frequent cause of genetic ataxias associated with cerebellar atrophy–Laurence Gauquelin, Taila Hartley, Mark Tarnopolsky, David Dyment, Bernard Brais, Michael T Geraghty, Martine Tetreault, Sohnee Ahmed, Samantha Rojas, Karine Choquet, Jacek Majewski, Francois Bernier, A. Micheil Innes, Guy A. Rouleau, Oksana Suchowersky, Kym Boycott, Grace Yoon P7.3-008 Expression of Mutant Human a-synuclein in Oligodendrocytes during Myelination Period Induces Remarkable Glial Inflammation and Demyelination in the Spinal Cord and Brainstem/Cerebellar White Matter: a Novel Model of Multiple System Atrophy-Cerebellar Type and Primary Progressive Multiple Sclerosis–Katsuhisa Masaki, Dai Matsuse, Hiroo Yamaguchi, Toru Saiga, Yuji Nishimura, Tatsunori Tanaka, Mitsuru Watanabe, Ryo Yamasaki, Kenji Tanaka, Jun-ichi Kira P7.3-009 Improving Episodic Ataxia Diagnosis by Combination of Genomic and Transcriptomic Sequencing–Sebastien Audet, Annie Laplante, Camille Michaud, Vincent Ferraro, Eric Bareke, Lahoud Touma, Antoine Duquette, Martine Tetreault P7.3-010 Gray Matter Changes in Spinocerebellar Ataxias SCA3 and SCA10–Walter O. Arruda, Alex Meira, Sergio Ono, Arnolfo Carvalho Neto, Salmo Raskin, Carlos Camargo, Helio Afonso Ghizoni Teive P7.3-011 Ioflupane 123I (DaTscan) SPECT Identifies Dopamine Receptor Dysfunction Early In The Disease Course In Progressive Apraxia of Speech–Zeynep Idil = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Headache–Noah Rosen, Robert A. Duarte P7.5-003 White hellebore (Veratrum album): A new old friend in the pharmacological management of epilepsy?–Guillermo DelgadoGarcía, Carolina Rodríguez-Návarez, Bruno Estanol Vidal, Teresa V. Corona Vazquez P7.5-004 Origins of Electrocortical Stimulation in Localizing Seizure Foci for Excision–Edward J. Fine, Felix Cheng P7.5-005 On the Seat of the Soul: Descartes’ Pineal Gland–Rahul Dilip Abhyankar P7.5-006 Layer –specific Map of the Cortical Surface: the Differences in Cytoarchitecture Properties Across Lobes–Marufjon Salokhiddinov, Vesna Vuksanovic P7.5-007 Taking a Strohl Through History: Putting Strohl Back in Guillain-Barré-Strohl Syndrome– Steven Paul Bondi, Elizabeth Eleanor Carroll, Jaydeep M. Bhatt P7.5-008 The ANA’s book “Eugenical Sterilization: A Reorientation of the Problem” through the lens of contemporaneous book reviews– Pedro Weisleder P7.5-009 The Neurological Study Unit: “A Combined Attack on a Single Problem from Many Angles”– Elan D. Louis P7.5-010 Historical Perspective of Progressive Supranuclear Palsy (Steele-Richardson-Olszewski Syndrome)–Shrikant Mishra, Shaweta Khosa, Kolar N. Murthy P7.5-011 Wallace William Tourtellotte (WWT), M.D. PhDA Quintessential Neurologist, Scientist, Teacher, Educator, Residency Program Transformer and Humanist - Profile at Time of His Recent Demise–Kolar N. Murthy, Shri Kant Mishra, Shaweta Khosa P7.5-012 Applicability of Fisher’s Rules in Alleviating Resident Burnout–Saurav Das, Vinay Puri

5 6

Headache: Therapeutics 7

P7.6-001 Efficacy With Fremanezumab in Migraine Patients With Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of

the Randomized, Placebo-controlled FOCUS Study–Dawn C. Buse, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Xiaoping Ning, Maja Galic, Richard B. Lipton P7.6-002 Effectiveness of Erenumab-aooe, Fremanezumabvfrm and Galcanezumab- gnlm in Migraine Patients at Tertiary Headache Clinic with Emphasis on High-Frequency Migraine Patients– Roxanne McCurry, Daniel Krashin, Melissa Schorn, Sau Mui Chan-Goh, Marcel Budica, Natalia Murinova P7.6-003 Rimegepant 75 mg Demonstrates Safety and Tolerability Similar to Placebo With No Effects of Age, Sex, or Race in 3 Phase 3 Trials–Jack D. Schim, Susan Hutchinson, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charlie Conway, Christopher Jensen, Beth Morris, Vlad Coric, Robert Croop P7.6-004 Safety and tolerability of erenumab in older migraine patients: A subgroup analysis of randomised trials–Christian Lampl, Josefin Snellman, Shannon Ritter, Jan Klatt P7.6-005 Consistency of Galcanezumab Efficacy Throughout a Month over Time–Karen Samaan, Patricia Pozo-Rosich, Robert Nicholson, Suchitrita Rathmann, Eric M. Pearlman P7.6-006 Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study– John F. Rothrock, Lei Luo, Eric J. Eross, Katherine Sommer, Andrew M. Blumenfeld P7.6-007 Safety and Efficacy of Ubrogepant in Participants With Moderate to High Cardiovascular Risk–Lawrence Severt, Stephen D. Silberstein, Andrew M. Blumenfeld, Richard B. Lipton, Kaifeng Lu, Sung Y. Yu, Susan Hutchinson P7.6-008 Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication–Andrew M. Blumenfeld, Kerry Louise Knievel, Aubrey Manack Adams, Lawrence Severt, Matthew Butler, Jeff Lai, David W. Dodick

AAN.com/view/20AM 155

Monday, April 27

Ravichandran, Shweta Varade, Preet M. Varade P7.4-007 Reliable Count of Seizures using Diaries versus Video Electroencephalography for Seizures of KCNQ2-DEE–Cynthia Harden, Celene Grayson, Constanza Luzon, Noam Butterfield, Ernesto Aycardi, Simon Pimstone, John J. Millichap P7.4-008 Seizures in the ED: Significance of Asymptomatic Bacteriuria in Patients Presenting with Breakthrough Seizures–Omer Waqar Naveed, Maria Kristina Casanova Dorotan, Brian Michael Flynn, Wayne Satz, Mercedes P. Jacobson P7.4-009 Use of Anakinra in a Patient with a History of Posttraumatic Epilepsy (PTE) Presenting with Epilepsia Partialis Continua (EPC)–Krishna Bikkasani, Madeline Cara Fields P7.4-010 Unit Cost of Epilepsyrelated Healthcare Encounters in the US–Simon Borghs, Silky Beaty, Witesh Parekh, Linda Kalilani, Nada Boudiaf, Andrea Loewendorf P7.4-011 Prevalence of Cardiovascular Diseases and Vascular Risk Factors in Patients Epilepsy/Clinical with History of Epilepsy/ Neurophysiology (EEG): EEG, Seizures–Ahmed Moh’d Yassin, Clinical Epilepsy, and Genetics Abdel-Hameed Al-Mistarehi, Khalid 4 I. El-Salem, Abdallah Almegdadi, Mohammad Ennab, Mohammad P7.4-001 Biological markers for Jamil Ahmad, Ali Kareem, differentiating seizure–Yoojin Lee, Amr Tashtoush, Sama Almasri, Won-Joo Kim, Youngje Heo, Yun Mohammed Kana’an, Belal Adel Ho Choi Aldabbour, Suha Awwad Aqaileh P7.4-002 Music therapy as an P7.4-012 Prevalence and adjunctive treatment for refractory association factors of obstructive epilepsy–Anna Babaie, Shirley Ju, sleep apnea in unselected adult Sami Bajwa P7.4-003 Epileptic seizure induced patients with epilepsy: a multicenter polysomnographic study–Paemrak by tilt-table testing: a case report– Phabphal, Kanitpong Phabphal, Sheela Toprani, Jessica Walter Pasiri Sithinamsuwan, Krongthong P7.4-004 Symptomatic Ictal Wongsritrang, Thanyalak Bradycardia, An Important Amornpojnimman, Tabtim Consideration in the Workup of Syncope in Temporal Lobe Epilepsy– Chongsuvivatwong, Kanokrat Suwanlaong, Sasinat Makkaew, Sara Rubenstein, Siddharth Gupta, Faisol Chamroonsil Martha Mulvey, David A. Marks P7.4-005 Clinical Features and History of Neurology Profile of Epilepsy in Elderly; Preliminary Experience from an P7.5-001 Ancient Representations Epilepsy Center–Sidra Saleem, of Neurological Diseases in the Anum Hamid Riaz, Vicki A. RamseyPre-Columbian Era–Joyce Antonella Williams, Naeem Mahfooz, Hongyan Jimenez-Zambrano, Luis Bejar Li, Imran I. Ali, Ajaz Sheikh Saona P7.4-006 Tacrolimus Neurotoxicity P7.5-002 A History of Non Oral Masked by Daily Cannabis Treatments For Management of Use–William Ueng, Abinayaa

POSTER SESSIONS

Seckin, Jennifer Louise Whitwell, Rene Utianski, Hugo Botha, Farwa Ali, Joseph Duffy, Heather Clark, Mary M. Machulda, Lennon Jordan, Val John Lowe, Keith A. Josephs P7.3-012 Ataxia with Vitamin E Deficiency: Widening the Phenotypic Spectrum–Sarah Wrigley, Sean S. O’Sullivan, Aisling Ryan P7.3-013 The second case of dystonia associated with an autosomal recessive spinocerebellar ataxia type 16-the phenotype expanded.–Diana Angelika Olszewska, Sean O’Riordan, Justin Kinsella P7.3-014 Joubert’s Syndrome with dystonic-ataxic tremor: a novel phenotypic variant–Danielle Larson, Lisa Kinsley, Joanna Sarah Blackburn, Niccolo Emanuele Mencacci P7.3-015 RT001 to Treat Progressive Supranuclear Palsy (PSP)—Altered Progression of Disease in 3 Patients–Kristin Andruska, Frederic Heerinckx, Robert James Molinari, Carrolee Barlow, Mark Midei, Peter Milner

POSTER SESSIONS

POSTER SESSION 7 P7.6-009 Clinically Meaningful Benefits of OnabotulinumtoxinA Beyond Headache Days in Chronic Migraine: Analysis of the COMPEL and Pooled PREEMPT Studies–Andrew M. Blumenfeld, H. Christoph Diener, Richard B. Lipton, David W. Dodick, Ronald DeGryse, Aubrey Manack Adams, Stephen D. Silberstein P7.6-010 Safety and Tolerability of Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results From the Open-label Period of the Phase 3b FOCUS Study–David B. Kudrow, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Xiaoping Ning P7.6-011 Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Longterm Safety Study of Rimegepant for the Acute Treatment of Migraine–James McGinley, Gilbert J. L’Italien, Alexandra Thiry, Robert Croop, Vlad Coric, Richard B. Lipton P7.6-012 Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine–Peter J. McAllister, Gary D. Berman, David B. Kudrow, Timothy Smith, Richard B. Lipton, Elyse Stock, David Stock, Charlie Conway, Christopher Jensen, Beth Morris, Vlad Coric, Robert Croop P7.6-013 Galcanezumab Shows Efficacy as Early as Day 1 After Initial Treatment vs. Placebo for the Prevention of Episodic and Chronic Migraine–Anna Andreou, Peter D. Wright, Holland Detke, Dustin Ruff, Uwe Reuter

Monday, April 27

Amyotrophic Lateral Sclerosis 3

P7.7-001 Is a Personalized N-of-1 Trial Feasible to Test Shakuyakukanzoto (SKT), a Kampo (Japanese Herbal Medicine) for ALS Patients with Muscle Cramps?–Hiroshi Mitsumoto, Ken Cheung, Madison Gilmore, Bjorn E. Oskarsson P7.7-002 The Cause of Death in Pathologically Confirmed Amyotrophic Lateral Sclerosis with Mechanical Ventilation Assist,

CME

a Retrospective Hospital-based Study–Kiyonobu Komai, Chiho Ishida, Kazuya Takahashi, Atsuro Tagami, Yuko Motozaki, Atsuhiro Kawashima P7.7-003 When the Timing is Right: Is There an Association Between Willingness to Discuss Palliative Care and the Severity of ALS?–Lalanthica Yogendran, Bradley Shane, Dominique Mortel, Bradley Shane, Briana Ibarra, Holli Ann Horak, Catherine Johnston, Katalin Scherer P7.7-004 FUS Associated Familial Amyotrophic Lateral Sclerosis Mimicking a Limb Girdle Muscular Dystrophy Phenotype–Hera Ashraf Kamdar, Allison Jordan, Miriam L. Freimer, Bakri Elsheikh, Jennifer A. Roggenbuck, Adam Quick P7.7-005 Screening SOD1Gene Among Tunisian Patients With Amyotrophic Lateral Sclerosis–Imen Kacem, Ikram Sghaier, Amina Nasri, Saloua Mrabet, Ben Djebara Mouna, Maher Kharrat, Amina Gargouri, Riadh Gouider P7.7-006 Connectivity in ALS (CoALS) - A Pilot Study–Vijay Renga P7.7-007 Canadian ALS Best Practice Recommendations– Christen L. Shoesmith, Agessandro Abrahao, Timothy J. Benstead, Marvin C. Chum, Nicolas Dupre, Aaron E. Izenberg, Wendy Johnston, Sanjay Kalra, Desmond Leddin, Colleen M. O’Connell, Kerri Schellenberg, Anu Tandon, Lorne H. Zinman Spinal Muscular Atrophy/ Motor Neuron Disorders 1

P7.7-008 Effect of Nusinsersen in an Adult SMA Cohort: CSF Biomarkers and RULM–Colin Quinn, Giulia Fadda, Corey McMillan, Sara-Claude Michon, Elizabeth Anne Kichula, Ling Zhao, Brenda Banwell, Amit Bar-Or, Lauren B. Elman P7.7-009 Improving NMJ Transmission Fidelity: An Additional Target in SMA?–Greg Owendoff, Martin B Skov, Nikki Losievski, Kaitlyn M Corlett, Deepti Chugh, Vicki McGovern, Thomas H Pedersen, Arthur H M Burghes, William D. Arnold P7.7-010 Quality of Life in Adults with Spinal Muscular Atrophy– Carlos Enrique Arias Bermudez, Samuel Frank, Stephen J. Kolb, William D. Arnold, Steven Severyn,

156 2020 AAN Annual Meeting

0 Monday, April 27 Matt Linsenmayer, Kristina Kelly, Amy M. Bartlett, Marco Tellez, Sarah Heintzman, Gary Sterling, Bakri Elsheikh P7.7-011 Assessing Clinical Meaningfulness in Teen and Young Adults with Spinal Muscular Atrophy: Cure SMA Survey–Allison Mazzella, Rosangel Esperanza Cruz, Jill Jarecki, Chad R. Heatwole P7.7-012 Positive response to nusinersen in a patient with motor neuron disease and 1 copy of SMN1–Daniel Calame, Farida Abid P7.7-013 Nusinersen Initiation in Adults with Spinal Muscular Atrophy–Maha Daimee, Shakti Nayar P7.7-014 Cortico-Muscular Coherence Patterns in Spinal Muscular Atrophy–Amina Coffey, Saroj Bista, Matthew Mitchell, Rosie Giglia, Richard Carson, Madeleine Lowery, Mark Heverin, Peter Bede, Bahman Nasseroleslami, Orla Hardiman Behavioral and Cognitive Neurology: Aging and Neurodegenerative Disease 1

P7.8-001 The Montreal Cognitive Assessment-Basic B: A Screening Tool for Cognitive Impairment in Parkinson Disease–Glenda Herbozo, Daniella Alejandra Bustamante P7.8-002 Predicting DRS-2 total scores from the MoCA–Meghan Zorn, Kevin M. Duff, John Rolston, Camila Henriques De Aquino, D. James Ballard, Paolo M. Moretti P7.8-003 Validation of MoCA– MMSE conversion scales in Korean Patients with Cognitive Impairments–Junghee Seo, HeeJin Lee, Mun Kyung Sunwoo P7.8-004 Superior test-retest reliability of cognitive assessment with Cognivue® vs SLUMS during an 18-month longitudinal study–John C. Andrefsky, Diego Cahn-Hidalgo, Reina Benabou P7.8-005 A Phase II, Single Center, Randomized, Double-Blind, PlaceboControlled Study of the Safety and the Therapeutic Effectiveness of Rapid Acting Insulin in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer’s Disease– Michael Rosenbloom, Terry R. Barclay, Lauren Erickson, Maria Pyle, Lyndsay Hage, Emily Green, Aleta Svitak, Bhavani Kashyap, William H. Frey, Leah R. Hanson

5:30 p.m.–6:30 p.m. P7.8-006 Impaired holistic processing of facial recognition in patients with mild Alzheimer’s disease–Chen-Wen Fang, Yang-Kun Ou, Chao-chih Wang P7.8-007 The Presenting Symptoms of Posterior Cortical Atrophy or “Benson’s Disease”: The UCLA Experience–Oleg Yerokhin Yerstein, Leila Parand, Mario F. Mendez P7.8-008 Brief Smell Identification Test Performance in RBD, DLB and AD–Leah Kathleen Forsberg, Jeremy Syrjanen, Tanis J. Ferman, Bradley F. Boeve, Toji Miyagawa, Neill R. Graff-Radford, David S. Knopman, Jonathan Graff-Radford, Rodolfo Savica, David T. Jones, Daniel A. Drubach, Julie A. Fields, Mary M. Machulda, John A. Lucas, Laura Andelman Allen, Erik Kent St. Louis, Michael H. Silber, Ronald C. Petersen P7.8-009 Figure Copy and Recall Profiles Help Distinguish Alzheimer’s Disease, Frontotemporal Degeneration, and Dementia with Lewy Bodies–Amalia Peterson, Adrian Boltz, Matthew Harris, Alexander Eisenstein, Daniel Kaufer P7.8-010 Data-driven Approach identifies the Cholinergic CinguloOpercular Task Control Network as a Key Driver of Cognitive Impairment in PD–Nicolaas I. Bohnen, Sygrid van der Zee, Martijn Muller P7.8-011 Voice of Unreason: An Unusual Case of Dysprosody in TDP43 Positive Frontotemporal Dementia–Emma Troy, Michael A. Farrell, Colin Doherty Cerebrovascular Disease: Telestroke, Pre-hospital, and Emergent Stroke Evaluation and Treatment 1

P7.9-001 Mobile Stroke Unit Operation in a Topographically Variable County–Ilana Spokoyny, Joey English, Jenny Im, Jorge Delgadillo, Eric Pancoska, Trish Entsminger, Nobl Barazangi P7.9-002 Prevalence and reasons for pre-hospital delay after acute ischemic stroke: Data from a single tertiary care centre in Coimbatore, South India.–Rajesh Shankar Iyer P7.9-003 Novel Large Vessel Occlusion Stroke Identification Scale in the Pre-hospital Setting–Torolira Daniel, Sara Brown, Fen-Lei F. Chang = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number Suspected TIA–Arooshi Kumar, Koto Ishida, Ava L. Liberman, Cen Zhang, Shadi Yaghi, Jose L. Torres, Sara Kate Rostanski P7.9-021 Characteristics of wakeup stroke through the timing – An experience from a north African cohort–Khadija Sonda Moalla, Mariem Damak, Mariem Damak, Nouha Farhat, Salma Sakka, HDIJI Olfa, Sawsan Daoud, Hanen Hadj Kacem, Noureddine Rekik, Chokri Abdellaziz Mhiri Graduate Medical Education: Pedagogy 2

P7.10-001 Electronic learning in clinical neuroscience: Does e-learning facilitate resident education?–Brittany Curry, Hugh John McMillan, Richard Webster, Deepti Reddy, Aleksandra Mineyko, Hilary Writer, Heather Jean MacLean, Sara Ieradi, Daniela Pohl P7.10-002 Enhancing Comfort and Readiness of Physicians Treating Patients with Intellectual and Developmental Disabilities by Facilitating Meaningful Interactions–Jessica Sanders, Hannah Johnson P7.10-003 Clinical Skills Evaluation in Neurology, Child Neurology and Psychiatry: Program Directors’ Perspective and Future Opportunities–Justin Abbatemarco, Dorthea Juul, Patti Vondrak, Maryann Mays, Mary Alissa Willis, Larry R. Faulkner P7.10-004 The Daily Fact Pile: A Resident-Driven Open Forum of Shared Clinical Experiences–Kasser Saba, Benjamin Jiang, Rabia Yasin, Chad Hoyle P7.10-005 Enhancing Resident Exposure to Outpatient General Neurology through an Ambulatory Urgent Care Rotation–Nicole Morgan, Helen Badu, Harold J. Weinberg, Arielle Marisa Kurzweil P7.10-006 Development and Evaluation of a Child Neurology Residency Curriculum for Delivering Bad News–Jan A. Martin, Fiona Horgan, Craig A. Press, Ricka Messer, Megan M. Barry, Allison Feldman, Paritosh Kaul P7.10-007 Improving Learning with a Neurology Question of the Day–Corey Goldsmith P7.10-008 Encouraging and Measuring Practice Improvements Via Sequential Continuing

Education–Katie Robinson, Jennifer Frederick, Jenna Gentile, Robert Esgro, Patricia K. Coyle P7.10-009 Project Neurotransmission: Improving Neurology Communication and Teaching with a Rounding Tool–Maria El-Hallal, Grace Fisler, Shefali Karkare, Ivan M. Pavkovic, Sanjeev V. Kothare P7.10-010 Strategic considerations for applying the flipped classroom to neurology education–Stefano Sandrone, Jimmy V. Berthaud, Chad Carlson, Jacquelyne Cios, Neel Dixit, Amtul Farheen, Jessica B. Kraker, James W. M. Owens, Gustavo A. Patino, Harini Sarva, Daniel Weber, Logan D. Schneider P7.10-011 Challenges in Establishing Neurology Scholarly Residency Tracks: Global Health, Research and Education–Kate Daniello, Anindita Deb P7.10-012 Flipped classroom in neurology: principles, practices, and perspectives–Stefano Sandrone, Jimmy V. Berthaud, Chad Carlson, Jacquelyne Cios, Neel Dixit, Amtul Farheen, Jessica B. Kraker, James W. M. Owens, Gustavo A. Patino, Harini Sarva, Daniel Weber, Logan D. Schneider P7.10-013 Communication Skills in Child Neurology Residency: an OSCE Pilot–Margie A. Ream, Pedro Weisleder, Dara V. Albert P7.10-014 Implementing Neurology EPAs in Singapore using the Consolidated Framework for Implementation Research–Nigel CK Tan, Yee Cheun Chan, Kevin Tan P7.10-015 Neurology Rounding Practices and Barriers to Bedside Rounding–Jacqueline Schulman, Shamik Bhattacharyya, Tracey A. Milligan P7.10-016 Neurology Morning Rounds: Return to the Bedside?– Jacqueline Schulman, Shamik Bhattacharyya, Robert Boxer, Ahya Sajawal Ali, Liam Cleary, Tracey A. Milligan

Monday, April 27

Tkach, Adam De Havenon, Jaleen Smith, Peter Hannon, Lee Shan Chung, Jennifer J. Majersik P7.9-012 Inpatient Telestroke Coverage Improves Guideline-Based Secondary Stroke Prevention: Results from the TELECAST Trial–Amelia Solei, Kathryn Bard, Matthew Keith Ronck, Eric Jaton, Leah Stinson, Monica Ngo, Apameh Salari, Sarah A. Engkjer, Andrew Jiahao Zhang, Jae H. Kim, Christine Elizabeth Yeager, Oladi Sedjio Bentho, Benjamin Robert Miller, Christopher Streib P7.9-013 Emergency Department Factors that Negatively Impact Door To Needle Time In Acute Stroke– Andrew Hanna, Joshua Tsau, Tej Stead, Ankur Garg, Mohammed S. Khan, Paul Banerjee, Latha Ganti P7.9-014 Re-examining the Exclusion Criterion of Early Recurrent Ischemic Stroke in Intravenous Thrombolysis: a Metaanalysis–Katrina Hannah Ignacio, Jose Danilo Bengzon Diestro, Adrian Isidoro Espiritu, Julian Spears, Maria Cristina San Jose P7.9-015 Thrombolytic Therapy with rt-PA for Acute Ischemic Stroke in Thailand: A Detailed Comparison of Community Hospitals with Regional Hospitals and Tertiary Care Hospitals.–Nisa Vorasoot, Kannikar Kongbunkiat, Udomlack Peansukwech, Kittisak Sawanyawisuth, Somsak Tiamkao, Narongrit Kasemsp P7.9-016 Delays in Recognition and Management of In-hospital Strokes–Ariane Carpentier, Yan Deschaintre P7.9-017 Evaluation of Acute Stroke and Stroke Mimics in the Emergency Department–Yasser Tajali, Julian Paul Agin-Liebes, Varsha Kurup, Kevin Spiegler, Nora Montealrgre, Tina Lulla, Carly Ray, Prateeka Koul, Anusha Boyanpally, Francisco Eduardo Gomez, Andrea Hidalgo P7.9-018 Crying patients Impact Trainees Treatment IN Stroke alerts (CITTINS)–Jeanne Feuerstein, Chad Kendall Bush, Cameron Ludt, Sharon Poisson P7.9-019 External Validation of the Diagnosis of TIA (DOT) Score for Identification of TIA in a Chinese Population–Junliang Yuan, Wenli Hu P7.9-020 Diagnostic Evaluation of Patients Admitted to Emergency Department Observation Unit for

POSTER SESSIONS

P7.9-004 Prehospital Los Angeles Motor Scale for Triage and Predicting Stroke Severity–Tej Stead, Latha Ganti, Paul Banerjee P7.9-005 Successful Implementation of a County-Wide Mobile Stroke Unit Clinical and Research Program by a Community Hospital–Ilana Spokoyny, Nobl Barazangi, Jenny Im, Jorge Delgadillo, Eric Pancoska, Greg Gilbert, Joey English P7.9-006 Inpatient Telestroke Coverage Improves Guideline-based Diagnostic Stroke Evaluation: Results from the TELECAST trial–Matthew Keith Ronck, Monica Ngo, Eric Jaton, Leah Stinson, Kathryn Bard, Amelia Solei, Apameh Salari, Sarah A. Engkjer, Andrew Jiahao Zhang, Jae H. Kim, Christine Elizabeth Yeager, Oladi Sedjio Bentho, Benjamin Robert Miller, Christopher Streib P7.9-007 Factors Contributing to Door to Telestroke Request Times–Nicholas Fuller, Chris Hackett, Robert Fishman, David G. Wright, Sandeep S. Rana, Russell Mitesh Cerejo, Konark Malhotra, Ashis H. Tayal P7.9-008 Telestroke Utilization and Practice Before and After Extending the Call Window to 24 hours–Chris Hackett, Nicholas Fuller, Rahul Haridas Rahangdale, David G. Wright, Sandeep S. Rana, Robert Fishman, Rebekah Heintz, Russell Mitesh Cerejo, Konark Malhotra, Ashis H. Tayal P7.9-009 Inpatient Teleneurology Follow-up Has Similar Outcomes to In-Person Neurology and Provides an Alternative to Transfer–Alyssa Trevino, Alicia Zha, Christy Ankrom, Kristie Chu, Michele Joseph, Liang Zhu, Rene Malazarte, Tiffany Cossey, Sean I. Savitz, Tzu-Ching Wu, Amanda L. Jagolino-Cole P7.9-010 Improved Adherence to AHA Acute Stroke Treatment Guidelines Through Telestroke (TELECAST Trial)–Matthew Keith Ronck, Apameh Salari, Eric Jaton, Leah Stinson, Monica Ngo, Kathryn Bard, Amelia Solei, Sarah A. Engkjer, Andrew Jiahao Zhang, Jae H. Kim, Christine Elizabeth Yeager, Oladi Sedjio Bentho, Benjamin Robert Miller, Christopher Streib P7.9-011 Telestroke Consultation Can Accurately Diagnose Ischemic Stroke Mimics–Jason Tsun-Yin Poon, Knut Hoversten, Aleksander

AAN.com/view/20AM 157

POSTER SESSION 7

CME

0 Monday, April 27

5:30 p.m.–6:30 p.m.

TRANSCENDS Recipients

Monday, April 27

POSTER SESSIONS

P7-11.001 Psychiatric Comorbidities in Multiple Sclerosis among Different Racial and Ethnic Groups: A Nationwide Survey– Daniel Pimental Maldonado P7-11.002 Attitudes and Preferences on Mental Health and Care Delivery Among Patients with Multiple Sclerosis: Racial/Ethnic Considerations–Daniel Pimental Maldonado P7-11.003 Impact of Race and Socioeconomic Status on the Utilization of Advanced Therapies in Parkinson’s Disease–Jennifer Adrissi P7-11.004 Characterization of HIV-associated neurocognitive impairment in older persons with HIV in Lima, Peru: Preliminary Findings–Monica Diaz P7-11.005 Crossover trial of asymmetric subthalamic stimulation for axial dysfunction in Parkinson’s disease–Karlo Lizarraga P7-11.006 Risk factors for cerebrovascular complications in patients with left ventricular assist device: Experience in a single comprehensive stroke center– Jorge Ortiz Garcia P7-11.007 Lipid metabolomics in catamenial epilepsy: looking into the underlying mechanisms of cyclic seizures–Maria Jose Bruzzone Giraldez P7-11.008 Cerebral Amyloid Angiopathy related Intracerebral Hemorrhage is Associated with Higher Risk of Seizures–Clio Rubinos

158 2020 AAN Annual Meeting

= Research

POSTER SESSION 8

CME

0 Tuesday, April 28

8:00 a.m.–9:00 a.m.

Poster Session 8

Multiple Sclerosis: Clinical Trials and Therapeutics 2

P8.1-008 Economic Burden of Multiple Sclerosis in Employees with and without Suboptimal Treatment Outcomes to DiseaseModifying Drugs: An Employer Perspective–Carrie Michelle Hersh, Richard A. Brook, Nicholas Rohrbacker, Ian Beren, Lori Lebson, Christian Henke, Amy L. Phillips P8.1-009 Treatment-emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in Two Phase 3 Trials in Multiple Sclerosis–Jiwon Oh, Bryan D. Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori Lebson, Thomas Leist P8.1-010 RENEWED: Long-Term Electrophysiological and Clinical Outcomes in Participants Previously Enrolled in the Opicinumab Phase 2 Study RENEW–Orhan Aktas, Focke Ziemssen, Tjalf Ziemssen, Giancarlo Comi, Helmut Butzkueven, Guillermo Izquierdo Ayuso, Alexander Klistorner, Wenting Cheng, Maria Naylor, Sarah Gheuens, Bing Zhu P8.1-011 An analysis of the relationship between cladribine dose and risk of malignancies in patients with multiple sclerosis–

Stuart D. Cook, Gavin Giovannoni, Thomas Leist, Giancarlo Comi, Axel Nolting, Elke Sylvester, Dominic Jack, Doris Damian, Andrew Galazka P8.1-012 Stopping disease modifying therapy in patients over age 50 with presumed benign multiple sclerosis–Derek Justin McFaul, Nektar Hakopian, Jessica Betty Smith, Annette M. LangerGould P8.1-013 MS disease modifying therapy (DMT) sequencing – natalizumab to cladribine tablets – experience in 67 patients–Nora Moehn, Tatjana Mihalova, David Rog, Iris Katharina Penner, Tjalf Ziemssen, Torsten Wagner, Michael Huebschen, Sylvia Menck, Elke Voss, Martin Stangel P8.1-014 Glatiramer Acetate Depot (extended-release) phase IIa study in patients with primary progressive multiple sclerosis: safety and efficacy snapshot– Shlomo Flechter, Laura Popper, Nadav Bleich Kimelman, Inna Demender, Shai Rubnov, Uri Danon, Ehud Marom, Ron E. Milo, Ronit Gilad, Boaz Weller, Adi VakninDembinsky, Mark Hellman, Arnon Karni

AAN.com/view/20AM 159

Tuesday, April 28

P8.1-001 Onset of B-cell Depletion and Suppression of MRI Activity with Ofatumumab Treatment in Relapsing Multiple Sclerosis: The APLIOS Study–Amit Bar-Or, Edward J. Fox, Alexandra L. Goodyear, Inga Ludwig, Morten Bagger, Dieter Haering, Harald Kropshofer, Martin Merschhemke, Heinz Wiendl P8.1-002 Bright White Light Therapy for the Treatment of Multiple Sclerosis (MS) Associated Fatigue: A Randomized, Controlled Trial–Farrah J. Mateen, Andre Vogel, Tamara B. Kaplan, Gladia C. Hotan, Natalie C. Manalo, Sara Grundy, Kathryn Holroyd, Matthew Stauder, Aleksandar Videnovic P8.1-003 Real-world experience of oral cladribine use in the MSBase Registry–Helmut Butzkueven, Timothy Spelman, Sara Eichau Madueno, Francois Grand-Maison, Tomas Kalincik, Suzanne J. Hodgkinson, Olga Skibina, Ernest G. Butler P8.1-004 Effect of Ocrelizumab on Thalamic Atrophy in Patients with Relapsing and Primary Progressive Multiple Sclerosis–Douglas

L. Arnold, Till Sprenger, Amit Bar-Or, Jerry S. Wolinsky, Ludwig Kappos, Shannon Kolind, Marianna Manfrini, Stefano Magon, Johan Van Beek, Harold Koendgen, Corrado Bernasconi, Laura Gaetano, Anthony Traboulsee P8.1-005 Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data–Jerry S. Wolinsky, Bruno Brochet, Hans-Peter Hartung, Robert T. Naismith, Laura Airas, Karine Coutant, Harold Koendgen, Marianna Manfrini, James Overell, Annette Sauter, Kalpesh Prajapati, Ludwig Kappos P8.1-006 A Year and Half of Real World Efficacy and Safety of Ocrelizumab in the Treatment of Multiple Sclerosis–Brandi L. Vollmer, Samuel Gendelman, Kavita Nair, Stefan Sillau, John Corboy, Timothy L. Vollmer, Enrique Alvarez P8.1-007 Alemtuzumab Depletion Failure and Neutralizing Anti-Drug Antibodies: a Case Report and Call for Monitoring–Kathleen Munger, Angray Kang, David Baker, Andrew D. Goodman, Lawrence M. Samkoff

POSTER SESSIONS

1. Multiple Sclerosis: Clinical Trials and Therapeutics 2: 1-001 to 1-022 2. Neuro-rehabilitation 2: 2-001 to 2-013 3. Aytpical Parkinsonism and Ataxia 2: 3-001 to 3-011 Parkinson’s Disease Clinical Trials and Methodology 1: 3-012 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 5: 4-001 to 4-004 Epilepsy/Clinical Neurophysiology: Antiseizure Medications 1: 4-005 to 4-011 5. General Neurology: Drugs and Therapeutics 2: 5-001 to 5-010 General Neurology: Clinical Case Reports 4: 5-011 to 5-013 6. Advocacy, Alzheimer’s Disease, and the Unconventional 1: 6-001 to 6-013 7. Amyotrophic Lateral Sclerosis 4: 7-001 to 7-006 Spinal Muscular Atrophy/Motor Neuron Disorders 2: 7-007 to 7-014 8. Behavioral and Cognitive Neurology: Aging and Neurodegenerative Disease 2: 8-001 to 8-009 9. Cerebrovascular Disease: Telestroke, Pre-hospital, and Emergent Stroke Evaluation and Treatment 2: 9-001 to 9-020 10. Graduate Medical Education: Wellness and Value: 10-001 to 10-015 11. Child Neurology and Developmental Neurology: Developmental Disabilities and Movement Disorders 2: 11-001 to 11-006 Child Neurology and Developmental Neurology: Neuromuscular Disease 1: 11-007 to 11-015

Tuesday, April 28

POSTER SESSIONS

POSTER SESSION 8 P8.1-015 Transcriptional Landscape and TCR Diversity of ATA188, a Pre-manufactured, Allogeneic Epstein-Barr Virusspecific T-cell Immunotherapy for Patients with Multiple Sclerosis (MS)–Philippe Foubert, Sriganesh Srihari, Laetitia Le Texier, Rhine R Shen, Farahnaz Forozan, Corey Smith, Rajiv Khanna, Blake T Aftab P8.1-016 Utilization of Health Resources and Disease Modifying Therapy Use in a High Risk, Underserved Multiple Sclerosis Patient Population and Associated Impact on Disease Progression and Disability–Lauren Tardo, Benjamin M. Greenberg, Lindsay A. Horton P8.1-017 Effect of Ibudilast on Thalamus and Spinal Cord in Progressive MS: Analysis from a Phase II Trial–Kunio Nakamura, Paola Raska, Christopher Goebel, Robert J. Fox P8.1-018 A Real-World, SingleCenter, Retrospective Cohort Analysis of Alemtuzumab Clinical and Safety Outcomes in Persons with Relapsing Multiple Sclerosis– Jorge Acevedo Herman, Farnaz Khalighinejad, David Alfego, Jomal Mathews, Christopher Hemond P8.1-019 Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered AntiCD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis–Lawrence Steinman, Edward J. Fox, Hans-Peter Hartung, Bruce A. C. Cree, Enrique Alvarez, Peiqing Qian, Sibyl E. Wray, Derrick Robertson, Deren Huang, Krzysztof Selmaj, Daniel R. Wynn, Michael S. Weiss, Jenna Bosco, Sean Power, Koby Mok P8.1-020 Pilot randomized activeplacebo controlled double-blind trial of low dose ketamine for the treatment of multiple sclerosisrelated fatigue–Kathryn Fitzgerald, Bridget Morris, Aurash Soroosh, Alexandra Balshi, Adam Kaplin, Bardia Nourbakhsh P8.1-021 Comparison of Efficacy and Safety Outcomes of Generic Versus Original Fingolimod Products in Patients with Multiple Sclerosis from Buenos Aires, Argentina– Anibal Chertcoff, Judith Diana Steinberg, Adriana Carra

CME

P8.1-022 Efficacy of Alemtuzumab in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting–Rocco Totaro, Luana Evangelista, Giovanna De Luca, Maura Danni, Maurizio Maddestra, Matteo Di Giuseppe, Elisabetta Cartechini, Eugenio Pucci, Barbara Maccarone, Samuele Arabi, Alessio Signori, Maria Pia Sormani Neuro-rehabilitation 2

P8.2-001 Machine Learning for Rehabilitation Exercise “Dose” Measurement: protocol description and feasibility of inpatient rehabilitation data collection– Jeronimo Cardona, Ania Busza, Noah Balestra, Linda Riek P8.2-002 Neuroimaging Indicates Response to Transcranial Direct Current Stimulation Treatments in Multiple Sclerosis–Lillian Walton Masters, Marco Muccio, Peidong He, Claire Choi, Abhishek Datta, Marom Bikson, Lauren B. Krupp, Yulin Ge, Leigh Elkins Charvet P8.2-003 Amantadine as a potential treatment for Marchiafava-Bignami disease: case series and possible mechanism– Tigran Kesayan, Martin Anthony Myers P8.2-004 The Pediatric Evaluation of Disability Inventory Computer Adaptive Test in Individuals with HNRNPH2-Related Disorders– Rachel Salazar, Sara Beenders, Olivia Thornburg, Nicole LaMarca, Jennifer M. Bain P8.2-005 The Use of Exergames in Neurorehabilitation–Paola Santos, Bianca Simone Zeigelboim, Helio Afonso Ghizoni Teive, Paola Santos, Paola Santos, Paola Santos, Paola Santos P8.2-006 Barriers for Utilization of Institutional Rehabilitation Services by Stroke Patients in a Developing Country–Sudhindra Vooturi, Praveen Kumar Yada, Subhash Kaul P8.2-007 Attitudes and Perceptions of Cardiac Arrest Survivors Towards Physical Activity after Hospital Discharge–Michelle Chee, Alexandra Alberto, Donald Edmonson, Sachin Agarwal P8.2-008 Patient Perspectives on the Impact of Adult Spasticity on Daily Life and its Management with Botulinum Toxin Type A–Alberto Esquenazi, Jorge Jacinto, Andreas Lysandropoulos

160 2020 AAN Annual Meeting

0 Tuesday, April 28 P8.2-009 Clinical spectrum of stiff person syndrome associated with glutamic acid decarboxylase antibodies–Anza Memon, Anirudha Swaminathan Rathnam, Iram Zaman, Naganand Sripathi P8.2-010 Spatial-motor “Aiming” and sitting balance with prism adaptation in spatial neglect–A. M. Barrett, Peii Chen, Peii Chen, Andrew Abdou P8.2-011 The Impact of Motor Function on the Depressive State in Multiple Sclerosis Patients–Cintia Ramari, Carlos Bernardo Tauil, Erica Brasil, Flavia Da Silva, Ana De David, Leonilda M. B. Santos, Leopoldo Dos Santos-Neto P8.2-012 Cervical Spontaneous Spinal Epidural Hematoma and Spinal Manipulation Therapy: Case Report and Review–Arthur Alcantara Lima, Alexander Yu, Russell Mitesh Cerejo P8.2-013 Resting-State Cerebral Connectivity Changes during Comprehensive Treatment of Post-Stroke Spasticity–Petr Hlustik, Tomas Veverka, Pavel Hok, Pavel Otruba, Petr Kanovsky Atypical Parkinsonism and Ataxia 2

P8.3-001 The Upper Limb Cardiopulmonary Exercise Test in Friedrich Ataxia Patients–Francesco Sacca, Chiara Pane, Andrea Salzano, Rossella vastarella, Claudia del Prete, Assunta Trinchillo, Giuseppe De Michele, Alessandro Filla, Antonio Cittadini P8.3-002 Prospective Characterization of Genetically Confirmed X-linked Dystonia Parkinsonism patients and their families: A 1 year longitudinal feasibility study–Patrick Acuna, Jan Kristoper Palentinos De Guzman, Niecy Ganza-Bautista, John Benedict Lagarde, Criscely L. Lanzuela Go, Nutan Sharma P8.3-003 Neurological Findings In The Most Prevalent Hereditary Ataxias In Southern Brazil– Bernardo Teixeira, Bianca Simone Zeigelboim, Helio Afonso Ghizoni Teive, Lucas Ferreti, P8.3-004 Cancer Frequency in Spinocerebellar Ataxia Type 10 (SCA10) Patients–Debora Bauer Schultz, Joao M Marcon, Daniel Balaban, Erika Nakagawa, Camila Fujiwara Murakami, Carlos Camargo, Helio Afonso Ghizoni Teive

8:00 a.m.–9:00 a.m. P8.3-005 Are balance scales affected by fear of falling? – a Delphi methodology study–Diego Torres-Russotto, James Y. Shou, Nabeel M. Syed, Venkata Bendi, L Schmaderer, Jennifer McKune, Amy Hellman, Luis E. Zayas, Rebecca Jane Thompson, Pamela May, Ryan T. Brennan, John M. Bertoni, Dawn Venema, Joseph Siu, Vivien Marmelat, Danish Bhatti P8.3-006 Heterozygous Variant in DNM1L Manifesting as Tremor and Ataxia–Vadim Dushkin, Joseph M. Ferrara, Sarika Srivastava, Konark Mukherjee P8.3-007 Role of University of Pennsylvania Smell Identification Test (UPSIT) in Diagnosis of Parkinsonian Syndromes in a Real World Setting–Nicole Pulley, Brittany Liebenow, Kenneth Kishida, Mustafa S. Siddiqui P8.3-008 Can the Evaluation of Cramps Help in the Differential Diagnosis of Spinocerebellar Ataxias (SCAs)?–Daniel Balaban, Joao M Marcon, Camila Fujiwara Murakami, Erika Nakagawa, Debora Bauer Schultz, Carlos Camargo, Helio Afonso Ghizoni Teive P8.3-009 Optical Coherence Tomography of Patients with Parkinson’s Disease and Progressive Supranuclear Palsy–Samir Alkabie, Alex Lange, Praveena Manogaran, A Jon Stoessl, Fiona Evann Costello, Jason Barton P8.3-010 Characteristics of Progressive Supranuclear Palsy Progression – a Longitudinal Cohort Study with Neuropathology– Duncan Street, James Rowe P8.3-011 A Novel Late-onset Dominant Episodic Ataxia in a Large French Canadian Kindred–David Pellerin, Mathilde Renaud, Karine Choquet, Martine Tetreault, Sylvie Provost, Marie-Josee Dicaire, Roberta La Piana, Rami Massie, Colin H. Chalk, Anne Louise Lafontaine, Marie-Pierre Dube, Antoine Duquette, Bernard Brais Parkinson’s Disease Clinical Trials and Methodology 1

P8.3-012 PF-QII Analysis of Deep Brain Stimulation versus Levodopa-carbidopa Intestinal Gel: Real-world Differences in Patient Characteristics and Quality of Life Outcomes.–Neil Kanta Shetty, Cindy

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

P8.4-001 Phenytoin Toxicity in Elderly Patient in the Presence of CYP2C9 Mutation–Suman Bharath, Diosely Castro Silveira P8.4-002 Allelic Variants of PAX5 and MEF2C-AS2 Genes are Associated with Depression in Temporal Lobe Epilepsy–Marino Bianchini, Luiza de Castro, Debora RMF Cunha, Suelen Mota, Talissa Bianchini, Jorge WJ Bizzi P8.4-003 The diagnostic yield of next generation sequencing panels for epilepsy in clinical practice– Leslie Scarffe, Sarah Alsubhi, Andrea Accogli, Myriam Srour P8.4-004 An Unusual Presentation of a Progressive Myoclonic Syndrome–Chang Brian Hoon Jung, Joseph Lu, Lilit Mnatsakanyan Epilepsy/Clinical Neurophysiology: Antiseizure Medications 1

P8.4-005 Perampanel in Patients with a History of Psychiatric Illness: Post Hoc Analysis of Four Randomized Phase III Studies (304, 305, 306, and 335) and their OpenLabel Extensions (307 and 335 OLEx)–Andres M. Kanner, Anna Patten, Manoj Malhotra P8.4-006 Adverse Event (AE) Profile with Perampanel as First Adjunctive Therapy in Patients with Partial-Onset Seizures: Analysis of the FAME Study–Hugh Jiwoong Lee, Dong Ik Kim, Ji Hyun Kim, Amitabh Dash P8.4-007 Long-term Safety and Efficacy of Adjunctive Perampanel in Pediatric Patients (Aged 4 to–Robert Flamini, Anna Patten, Leock Y. Ngo P8.4-008 Perampanel in RealWorld Clinical Care of Patients with Epilepsy: Results from the Retrospective, Phase IV PROVE Study 506–James W. Wheless, Anna Patten, Manoj Malhotra P8.4-009 Perampanel and Pregnancy–Blanca R. Vazquez, T. Tomson, Cindy Dobrinsky, Edgar Schuck, Terrence O’Brien P8.4-010 Effect of Concomitant Enzyme-Inducing Antiepileptic Drugs (EIAEDs) on the Efficacy and Safety of Adjunctive Perampanel 4

mg/day in Patients Aged =12 Years with Partial-Onset Seizures in AsiaPacific Study 335–Takuji Nishida, Amitabh Dash, Anna Patten, Leock Y. Ngo, Manoj Malhotra P8.4-011 Perampanel as an add -on reduces seizure frequency.– Randhi Venkata Narayana, Nalin Chaudhary General Neurology: Drugs and Therapeutics 2

P8.5-010 Neurological Manifestations Associated with Synthetic Cannabinoid Use – A Case Series–Marwa A. Elnazeir, Siddharth Narayanan, Riwaj Bhagat, Pradeepthi Badugu, Abid Hussain, Tamour Khan Tareen, Adriana Elena Palade General Neurology: Clinical Case Reports 4

5 5

P8.5-001 Comparison of Newer Second Generation Antipsychotics (SGAs) in Regards to Metabolic Profile–Jessica Greger, Traci Aladeen, Emily Lewandowski, Rachael Wojcik, Erica S. Westphal, Jonathan Beecher, Michelle Rainka, Horacio Capote P8.5-002 Recurrent Intracranial Hypertension in a Transgender Female-to-Male on Testosterone Therapy: A Case Report–Shakaib Qureshi, Kasim Qureshi, Adam Hassan, Aileen Antonio P8.5-003 Motor Neuron Disease: Cellular or Molecular Experimental Therapy. What Works Better?– Dmitriy Labunskiy, Olga Ignatieva, Irina Boynova, Tatyana Usanova, Guljeren Khudaiberenova P8.5-004 Reversible splenial lesion from abrupt withdrawal of Oxcarbazepine–Sri Raghav Seshu Sista, Julia Ann Szmanda, Michael Zagardo, Jorge C. Kattah P8.5-005 Hidden in plain sight: a rationale for repurposing apomorphine in addiction disorders–Manon Auffret, Marc Verin, Andrew John Lees P8.5-006 Brown-Sequard Syndrome Caused by a CocaineInduced Spinal Cord Infarct: A Case Report–Sabeena Iqbal Malik, Maher Fakhouri P8.5-007 Mononeuritis multiplex secondary to MDMA–Shameer Rafee, Sarah Wrigley, Sean Connolly, Niall Tubridy P8.5-008 Heroin vapor inhalation induced toxic leukoencephalopathy acute and follow-up brain imaging: inflammation and atrophy from “chasing the dragon”–Tigran Kesayan P8.5-009 Neurological Comorbidities in Hospitalized Patients with Opioid Abuse–Kevin R. Nelson, Katelyn Dolbec, William D. Watson, Hanwen Yuan, Mam Ibraheem

P8.5-011 Mount Fuji Sign After Glioblastoma Multiforme Resection–Gina Susana PerezGiraldo, Ahmad Al-Awwad P8.5-012 Primary Histiocytic Sarcoma of the Central Nervous System: A case report with an unusual initial presentation and rapid progression–Mehnaaz Ali, Nicholas Anthony Ressa, Michael Kentris P8.5-013 T-cell-rich B-cell lymphoma presents as Numb Chin Syndrome–Natalie Ann Majors, Anita M. Fletcher, Michael K. Sowell Advocacy, Alzheimer’s Disease, and the Unconventional 1

P8.6-001 Neurology Morbidity and Mortality Conferences Across US Academic Medical Centers– Sophia Ryan, Kathleen McKee, Lizbeth Londono-Sanchez, Aneesh B. Singhal P8.6-002 Advocacy Training in Medical Education: Results of a Novel Curriculum for Neurology Residents–Vincent LaBarbera, Kara Stavros, Jonathan Cahill P8.6-003 Attitudes and Preferences on Mental Health and Care Delivery Among Patients with Multiple Sclerosis: Racial and Ethnic Considerations–Daniela Arantxa Pimentel Maldonado, Carolina Ionete, Christopher Hemond, Idanis Berrios Morales, Raffaella Umeton, Justin Eusebio P8.6-004 Diversity and Inclusion: a Snapshot of the Academic Neurology Workforce–Camilo A. Gutierrez, Alyx B. Porter, Norman Ajiboye, Jennifer Armstrong, Nicte I. Mejia, Karen A. Spencer, Nicole Beaton Sur, Shawniqua Williams Roberson, Dylan P. Wint, Fernando Testai

AAN.com/view/20AM 161

Tuesday, April 28

Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 5

POSTER SESSIONS

Zadikoff, Samuel Wu, Yue Wu, Tanya Simuni P8.3-013 Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in the Japanese and the Rest of the World Parkinson’s Disease Population With a GBA Mutation: Results from Part 1 of the MOVES-PD Study–M. Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, Thomas Gasser, Stuart H. Isaacson, Jaime Kulisevsky, Tanya Simuni, Yuji Takahashi, Anne-Marie Wills, Leonor Correia Guedes, Per Svenningsson, Ryosuke Takahashi, Cheryl H. Waters, Masahisa Katsuno, Allena Ji, Sebastian JM Gaemers, Pacal Minini, Blandine Nembo, S. Pablo Sardi, Stephane Saubadu, Jyoti Sharma, Tanya Fischer P8.3-014 Three-year Follow-up of a Prospective, Double-blinded, Multi-center Randomized Controlled Trial Evaluating Deep Brain Stimulation with Multiple Source, Constantcurrent Rechargeable System for Treatment of Parkinson’s Disease (INTREPID)–Jerrold L. Vitek, Roshini Jain, INTREPID Study Group, Philip Starr P8.3-015 Efficacy of Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: a Post-Hoc Analysis from DoubleBlind Combined BIPARK-I and II Data–Robert A. Hauser, Joaquim Ferreira, Werner Poewe, Angelo Antonini, Francisco Rocha, Diogo Magalhães, Patricio Soares-daSilva, Olga Klepitskaya, Grace Lin Liang P8.3-016 Safety and Efficacy of Continuous Apomorphine Infusion in Patients with Parkinson’s disease: Results from a Phase 3, Open-label Study–Stuart H. Isaacson, Alberto J. Espay, Rajesh Pahwa, Thomas Clinch, Peter A. LeWitt P8.3-017 ABBV-951 Maintains Stable Levodopa Exposure following Subcutaneous Infusion in Parkinson’s Disease Patients– Matthew Rosebraugh, Philip Kym, Wei Liu, Maurizio F. Facheris

POSTER SESSIONS

POSTER SESSION 8 P8.6-005 The Use of Medical Cannabis in African American and Caucasian Populations: A Comparative Study–Laszlo Mechtler, Chris Ralyea, Vincent Harry Bargnes, Paul B. Hart, Colin Begley, Alex Benyovszky, Alea Manzella P8.6-006 Automated Handoffs – Meaning in Medicine–Lindsay Marie Malatesta, Mitesh P. Lotia P8.6-007 Does Pseudobulbar Affect Influence Healthcare Conversations in patients with Amyotrophic Lateral Sclerosis?– Aditi Vian Varma-Doyle, Nicole Villemarette-Pittman, Brian Joseph Copeland P8.6-008 Effect of Improved Management Strategies on Study Retention Rates–Michael Dela Cruz, Kinga Aitken, Ka-Ho Wong, Theodore Rock, Lee Shan Chung, Adam De Havenon, L Dana DeWitt, Peter Hannon, Vivek Reddy, Jennifer J. Majersik P8.6-009 Investigating Electronic Communication of Neurologists and Patients–Kirby Heffrin, Tracey A. Milligan P8.6-010 Leadership Training in Neurology: Can we Stem the Tide of Physician Burnout?–Jillian MacDonald, Keith Argenbright, Drew Thodeson P8.6-011 Impact of a Dedicated Post-Stroke Hospitalization Clinic–Michelle Nguyen, Carolina Parker, Michael J. Lyerly P8.6-012 HCP Yo Self!–Will McKeen, Natalie Thom, Melissa Betts Pergakis, Katelyn Cecilia Klee Bird P8.6-013 Should Patients With Dementia Define Their Own Quality of Life: A Systematic Review– Helen Burks, Riya Chadha, Nahid Rianon

Tuesday, April 28

Amyotrophic Lateral Sclerosis 4

P8.7-001 Edaravone for Amyotrophic Lateral Sclerosis: Oral Formulation and Its Development Plan–Koji Takei, Tomoyuki Omura, Yoshinobu Nakamaru, Masae Kakubari, Tomoko Natori, Youichi Shiide, Yukiko Nishimura, Makoto Akimoto, Manabu Hirai P8.7-002 The Terminal Complement Pathway Is Markedly Activated in the Cerebrospinal Fluid and Plasma of Amyotrophic Lateral Sclerosis Patients–Camil Sayegh,

CME

Simon Read, Alonso Ricardo, GuoQing Tang, Yalan Tang, Xiangyang Xu P8.7-003 COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update–Bjorn E. Oskarsson, Joanna Dojillo, Malath Makhay, Kazuko Matsuda P8.7-004 Haplotype analysis among amyotrophic lateral sclerosis families with the p.A5VSOD1 mutation: two separate founders or a single common founder?–Josep Gamez, Jose Manuel Vidal-Taboada, Cecilia Garcia, Laura Zalba, Maria Maria Salvado, Alba Sierra, Consuelo Garcia-Carmona, Ana Belen Canovas P8.7-005 Structural and Neurometabolic Correlates of Motor Neuron Function in ALS: A Multimodal fMRI-MRS-DTI-Texture Intersection Study–Ojas Srivastava, Avyarthana Dey, Sneha Chenji, Angela L. Genge, Christopher Hanstock, Lawrence Korngut, Lorne H. Zinman, Sanjay Kalra P8.7-006 A Two-Year Retrospective Chart Review to Evaluate Demographics of Amyotrophic Lateral Sclerosis Patients Attending a Multidisciplinary Clinic–Arash Jalali-Sohi, Leila Darki, Lise Phan, Said R. Beydoun Spinal Muscular Atrophy/ Motor Neuron Disorders 2 P8.7-007 Cure SMA Care Center Network and SMA Clinical Data Registry with Electronic Health Record Integration–Mary K. Schroth, Jamie Shish, Teresa Stewart, Abigail Paras, Adrian Segura P8.7-008 Investigating NMJ transmission failure in Adults with Spinal Muscular Atrophy–Bakri Elsheikh, Stephen J. Kolb, Steven Severyn, Matt Linsenmayer, Kristina Kelly, Amy M. Bartlett, Marco Tellez, Sarah Heintzman, Gary Sterling, William D. Arnold P8.7-009 Structural Cardiac Malformations in Spinal Muscular Atrophy; A Case Series–Natalie Martins Manhica, Jaehyung Lim, Susan Matesanz, Russell Butterfield, Seth J. Perlman, Timothy E. Lotze, Elizabeth Anne Kichula, Bijoy Thattaliyath, Katherine D. Mathews

162 2020 AAN Annual Meeting

0 Tuesday, April 28 P8.7-010 Health Utility Index Scores in treated and untreated patients with Spinal Muscular Atrophy: Findings from the 2019 Cure SMA Community Update Survey–Lisa Belter, Rosangel Esperanza Cruz, Jill Jarecki P8.7-011 SMA Patient Experienced Aseptic Meningitis With Severe Hypoglycorrhachia After Nusinersen Infusion–Afra Janarious, Ali A. Habib, Tahseen Mozaffar, Manisha Kak Korb P8.7-012 A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with LaterOnset Spinal Muscular Atrophy (TOPAZ): An Introduction–Amy Place P8.7-013 Improvements in the definition of biomarkers for Spinal Muscular Atrophy (SMA) type III and IV: a multimodal longitudinal study.–Giorgia Querin, Jean-Yves Hogrel, Rabab Debs, Veronique Marchand-Pauvert, Tanya Stojkovic, Anthony Behin, Pascal Laforet, Pascal Laforet, Francois Salachas, Peter Bede, Timothee Lenglet, Pierre-François Pradat P8.7-014 Combination therapy with nusinersen and AVXS-101: a real-world clinical experience–Yohei Harada, Kapil Arya, Galia Napchan-Pomerantz, Rondi Kauffmann, Amit Kumar Agarwal, Vikki Stefans, Aravindhan Veerapandiyan Behavioral and Cognitive Neurology: Aging and Neurodegenerative Disease 2

7 8

P8.8-001 Acoustic Prosodic Measures in Natural Speech of Progressive Supranuclear Palsy and Corticobasal Spectrum Disorders–Natalia Parjane, Sharon Ash, Sunghye Cho, Mark Liberman, Murray Grossman, Naomi Nevler P8.8-002 Effect of Cognitive Reserve on Structural and Functional MR Imaging Measures in Adult Healthy Subjects–Lorenzo Conti, Gianna Carla Riccitelli, Carmen Vizzino, Paolo Preziosa, Maria Assunta Rocca, Massimo Filippi P8.8-003 Association of White Matter Integrity and Age on Cognitive Performance in U-2 Pilots–Kelsey Cacic, Bianca Cerqueira, John H. Sladky

8:00 a.m.–9:00 a.m. P8.8-004 Survey on Acceptance of Passive Technology Monitoring for Early Detection of Cognitive Impairment–Sylvia Josephy, Kara M. Smith P8.8-005 APOE-?4, White Matter Hyperintensities, and Cognition in Alzheimer and Lewy Body Dementia–Saira Mirza, Usman Saeed, Jo Knight, Joel Ramirez, Donald Stuss, Julia Keith, Sean Nestor, Di Yu, Walter Swardfager, Ekaterina Rogaeva, Peter H. St George-Hyslop, Sandra E. Black, Mario Masellis P8.8-006 Potential benefits of Masupirdine (SUVN-502) on Behavioral and Psychological symptoms in patients with moderate Alzheimer’s Disease– Ramakrishna Nirogi, Anil Shinde, Pradeep Jayarajan, Vinod Goyal, Gopi Bhyrapuneni, Ramkumar Subramanian, Satish Jeta, Jyothsna Ravula, Venkat Jasti P8.8-007 Feasibility and preferences of an advanced care planning model in patients with mild cognitive impairment and mild dementia–Joaquin Ojeda, Paloma Cutillas, Susana Lopez Gallardo, Javier Gomez Pavon, Alberto Alonso P8.8-008 Concurrent Alzheimer disease and primary lateral sclerosis associated with presenilin-1 gene mutation in a 30-year-old man–Erica Elise Lewis, Glen R. Finney, David Avila P8.8-009 Cerebrospinal Fluid TDP-43 is a Possible Predictor of Survival in Amyotrophic Lateral Sclerosis–Chiara Zecca, Maria Teresa Dell’Abate, Rosa Capozzo, Alessandro Introna, Roberta Barone, Maria Barulli, Petronilla Battista, Giancarlo Logroscino Cerebrovascular Disease: Telestroke, Pre-hospital, and Emergent Stroke Evaluation and Treatment 2

P8.9-001 Predictors for Critical Care Resource Utilization Following Intravenous Alteplase for Acute Ischemic Stroke–Ritwik Bhatia, Andres De Leon Benedetti, Vasu Saini, Kristine H. O’Phelan, Sebastian Koch P8.9-002 A Case Report of Recombinant Tissue Plasminogen Activator (t-PA) Use in an acute stroke patient with tuberous sclerosis (TS)–Reza Bavarsad = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number A. Elnazeir, Gopika Govindan Kutty, Shivani Naik, Tina Walsh, Lisa Smith, Tracy Ander, Jignesh J. Shah, Kerri S. Remmel, Wei Liu P8.9-018 Shorter Door-in Door-out Time and Higher ASPECTS Score is Associated with Higher Likelihood of Endovascular Therapy–Humza Ahmed, Keiko Aun Fukuda, Kavit Shah, Shashvat Desai, Benjamin Morrow, Pratit Dhirajlal Patel, Habibullah Ziayee, Bradley Marc Klein, Marcelo Rocha, Tudor G. Jovin, Ashutosh P. Jadhav P8.9-019 Outcomes After Thrombectomy for In-House Stroke – Hub Versus Spoke–Rahul Rao, Shashvat Desai, Jody Manners, Ashutosh P. Jadhav P8.9-020 Lower LDL is Not Associated With Increased Risk of Hemorrhagic Conversion after Mechanical Thrombectomy–Daniel Robert Kogan, Vasu Saini, Elizabeth Jordan, Sishir Mannava, Nastajjia Krementz, Mario Phillip Zamora, Luis Guada-Delgado, Melissa Bailey, Juan Sebastian Diaz, Amer Malik, Dileep R. Yavagal, Nicole Beaton Sur Graduate Medical Education: Wellness and Value

P8.10-001 Sleep-Deprived Residents and Rapid Picture Naming Performance Using the Mobile Universal Lexicon Evaluation System (MULES) Test–Jenna Conway, Luke Moretti, Omar Akhand, Liliana Serrano, Arielle Marisa Kurzweil, Steven Galetta, Laura J. Balcer P8.10-002 Improving work life balance and decreasing burnout among neurology and internal medicine residents through block continuity clinic curriculum.– Dougan McGrath, Rita Menapace, Amanda Young, Lauren DiMarino, Kelly Baldwin P8.10-003 Creation and utilization of a custom-built phone application in augmenting resident experience, education, and satisfaction– Nathanael Lee, Jeffrey B. Ratliff P8.10-004 Wellness Initiative in Neurology Residents, Fellows and Advanced Practice Clinicians– Chichun Sun, Nora Elfiky, Elise Ruth Hennessy, Gloriel Flores-Caban, Cathleen Adams

P8.10-005 Feasibility of a Wrist Biosensor to Characterize Exercise and Sleep Patterns in Neurology Residents–Kellyann Niotis, Nabeel Saif, Marialaura Simonetto, Xian Wu, Peter Z. Yan, Richard S. Isaacson P8.10-006 Institutional Value of Neurology Residents–Preston Erickson, Stefan M. Pulst, Wanda I. Penovich, Steven Hayworth P8.10-007 Neurology Resident Well-Being: Program Implementation Outcome Assessment–Elizabeth Spurgeon, Justin Abbatemarco, Payal Patel Soni, Monica Scarsella, Megan Allison Nieuwoudt, Maryann Mays, Kerry H. Levin, Mary Alissa Willis P8.10-008 The Rush Neurology Wellness Initiative: A Three-Part Approach to Burnout–Teresa Lee, Emily Rachel Grodinsky, Rebecca O’Dwyer, Amar Bhatt P8.10-009 Improving Neurology Resident Well-Being Using a Data-Guided Approach–Vijay K. Ramanan, Jery Inbarasu, Lauren Jackson, Lyell K. Jones, James P. Klaas P8.10-010 Neurology Residency Subspecialty Block Continuity Clinic Curriculum and Departmental Contribution–Kelly Baldwin, Neil R. Holland, David Avila P8.10-011 Wellness Initiative Societies Empowering Residents (WISER): Reflections on Establishing a Wellness Curriculum in a Child Neurology Residency Program–Mariam Hull, Timothy E. Lotze P8.10-012 A Preliminary Report on “The Human Connection: Investigating The Effect of Enhanced Patient Connection on Provider Burnout”–Yaowaree Leavell, Jessica Hong-My Tran, Mary Sun, Michelle Fabian, Laura Stein P8.10-013 Longitudinal Assessment of Burnout In Neurology Residents–Jeffrey B. Ratliff, Joseph F. Carrera, Andrew Mebane Southerland, Cormac A. O’Donovan, Ted Arthur Weissfeld, Vicki Shanker P8.10-014 Combating Resident and Fellow Obesity Through Intensive Meal Plan Coaching: A GMEC wellness subcommittee quality improvement pilot project.– Kelly Baldwin, Rita Menapace

AAN.com/view/20AM 163

Tuesday, April 28

Claude Beaulieu, Francis Fortin, Nicole Daneault, Yan Deschaintre, Laura C. Gioia, Gregory Jacquin, Alexandre Y. Poppe, Christian Stapf, Celine Odier P8.9-012 Stroke Outcomes and Palliation in Interhospital Transfer Thrombectomy Candidates with Large Vessel Occlusion Following Extension of the Interventional Treatment Window–Christopher Kyper, Melanie R. F. Greenway, Maisha T. Robinson, Josephine F. Huang P8.9-013 Factors Associated with Prolonged Hospitalization and Inhospital Mortality in Patients with Large Vessel Occlusion following Endovascular Treatment–Vasu Saini, Nastajjia Krementz, Vasu Saini, Melissa Bailey, Juan Sebastian Diaz, Elizabeth Jordan, Mario Phillip Zamora, Luis GuadaDelgado, Daniel Robert Kogan, Nastajjia Krementz, Dileep R. Yavagal P8.9-014 Short-term Outcome of Mechanical Thrombectomy for Acute Ischemic Stroke Patients on Therapeutic Anticoagulation– Klaudia Nowak, Justyna Derbisz, Ewa Wlodarczyk, Michal Paykart, Roman Pulyk, Pawel Brzegowy, Bartlomiej Lasocha, Tadeusz Popiela, Agnieszka Slowik P8.9-015 Outcomes in Treatment of Acute Carotid Occlusions with and without Bridging Thrombolysis–Keiko Aun Fukuda, Kavit Shah, Daniel Tonetti, Shashvat Desai, Bradley Gross, Ashutosh P. Jadhav P8.9-016 Association Between Functional Outcomes of Stroke Patients Receiving Mechanical Thrombectomy and CT Perfusion Imaging Acquisition–Shashank Agarwal, Eva Mistry, Erica Scher, Sun Kim, Matthew D. Sanger, Kelley Humbert, Koto Ishida, Jose L. Torres, Sara Kate Rostanski, Cen Zhang, Karthikeyan M. Arcot, David Turkel-Parrella, Jeffrey Farkas, Eytan Raz, David Gordon, Howard Riina, Maksim Shapiro, Omar Tanweer, Erez Nossek, Peter Nelson, Aaron S. Lord, Denis Vezina, Shadi Yaghi P8.9-017 Mechanical Thrombectomy Could Still be Beneficial in Acute Large Vessel Occlusion with Large Core Infarction–Riwaj Bhagat, Marwa

POSTER SESSIONS

Shahripour, Ana Hossein Zadeh Maleki, Balaji Krishnaiah P8.9-003 Higher Intracerebral Hemorrhage Rates and Poor Outcome from tPA treatment among Nursing Home Patients– Shivani Naik, Saurav Das, Riwaj Bhagat, Lisa Smith, Ruolan Liu, Tracy Ander, Michael Haboubi, Jignesh J. Shah, Kerri S. Remmel, Wei Liu P8.9-004 Sudden Neurologic Deterioration after Thrombolysis of Vertebral Artery Occlusion–Sina Marzoughi, Ankur Banerjee, Tomoyuki Ohara, MacKenzie Horn, Charlotte Zerna, Ericka Teleg, Bijoy Menon, Andrew M. Demchuk P8.9-005 Safety and efficacy of thrombolysis in Ischemic stroke in Coastal Andhra Pradesh, India: A single centre experience– Kumaravelu Somasundaram, Tirupathi Rajeswari, Hima Bindu Bolla, Balakrishna Sanampudi, Budda Sai sandeep, Pothineni Ramesh Babu P8.9-006 Clinical Improvement Despite post-rtPA Subarachnoid Hemorrhage–Claribel Danielle Wee, Karen C. Albright P8.9-007 Safety and Efficacy of Tirofiban Among Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy: A Systematic Review and Metaanalysis–Hongchen Zhao, Qiang Dong, Wenjie Cao P8.9-008 Frequency and Outcome of Perioperative Ischemic Strokes from Large Vessel Occlusions Associated with Transcatheter Aortic Valve Replacement–Joshua Santucci, Lucy Zhang, Ghulam Abbas Kharal, Ken Uchino P8.9-009 Telestroke Call Volume and Mechanical Thrombectomy after Dawn and Defuse 3 Trials– Ashik Shrestha, Sami Alkasab, Eyad Almallouhi, Christine Holmstedt P8.9-010 Influence of renal impairment on hemorrhagic transformation and outcome in stroke patients undergoing reperfusion therapy: a systematic review and meta-analysis–Yanan Wang, Yajun Cheng, Ke Qiu, Quhong Song, Ming Liu P8.9-011 Non-Contrast Enhanced CT and Angio-CT Might Allow Selection of Late Window Ischemic Stroke Endovascular Treatment Candidates–Ahmad Nehme, Marie-

POSTER SESSION 8 P8.10-015 Is Bronfenbrenner’s Ecological Systems Theory useful for understanding Interprofessional Collaboration?–Kevin Tan, Nigel CK Tan, Jai Rao, Yang Yann Foo

Tuesday, April 28

POSTER SESSIONS

Child Neurology and Developmental Neurology: Developmental Disabilities and Movement Disorders 2

P8.11-001 Preliminary Report of Open Label Extension of Trial of Propranolol in Autism Spectrum Disorder–David Q. Beversdorf, Bradley Ferguson, Samantha Hunter, Kathy Hirst, Bridget Lolli, Nicole Takahashi P8.11-002 Medical Cannabis in the Treatment of Patients with Autism Spectrum Disorder–Jennifer McVige, Virginia Alexandria Headd, Mohammed Alwahaidy, Dylan Lis, Dilpreet Kaur, Brianna Albert, Laszlo Mechtler P8.11-003 Rett syndrome: A more Heterogeneous group than previously thought?–Ola H. Skjeldal, Mari Wold Henriksen P8.11-004 CASK related Pontocerebellar Hypoplasia: A rare cause of infantile microcephaly– Surabhi Kaul, Shivika Chandra P8.11-005 Congenital Mirror Movements: Case Report–Nishad Shaheid, Savitra M. Bandari, Diosely Castro Silveira, Mahindra Bandari P8.11-006 Improving Pediatric Resident Confidence and Competence in Communication with Patients with Disabilities– Megan Bone, Tyler Alexander Terrill, Kimberly Goodspeed Child Neurology and Developmental Neurology: Neuromuscular Disease 1

P8.11-007 Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy Through Newborn Screening–Jacqueline Glascock, Jacinda B. Sampson, Anne M. Connolly, Basil T. Darras, John W. Day, Richard S. Finkel, Rodney Howell, Katherine Klinger, Nancy L. Kuntz, Thomas Prior, Perry Shieh, Thomas O. Crawford, Douglas A. Kerr, Jill Jarecki P8.11-008 Natural History of Type 2 and 3 Spinal Muscular Atrophy (SMA): Longitudinal 2-year NatHis-SMA Study–Laurent

CME

Servais, Andreea Mihaela Seferian, Aurore Daron, Yann Pereon, Claude Cances, Carole Vuillerot, Liesbeth MH De Waele, Vincent Laugel, Ulrike Schara, Teresa Gidaro, Charlotte Lilien, Jean-Yves Hogrel, Pierre-Yves Baudin, Pierre Carlier, Emmanuel Fournier, Linda Pax Lowes, Ksenija Gorni, Myriam Ly-Le Moal, Nicole Hellbach, Timothy Seabrook, Christian Czech, Ricardo Hermosilla, Melanie Annoussamy on behalf of the Na P8.11-009 One-Time Intrathecal (IT) Administration of AVXS-101 IT Gene-Replacement Therapy for Spinal Muscular Atrophy: Phase 1 Study (STRONG)–Richard S. Finkel, John W. Day, Basil T. Darras, Nancy L. Kuntz, Anne M. Connolly, Thomas O. Crawford, Russell Butterfield, Perry Shieh, Gihan Tennekoon, Susan T. Iannaccone, Matthew N. Meriggioli, Sitra TauscherWisniewski, John Shoffner, Francis Ogrinc, Sarah Kavanagh, Elaine Kernbauer, JoAnn Whittle, Douglas M. Sproule, Douglas Feltner, Jerry R. Mendell P8.11-010 SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA)–Eugenio Mercuri, Nina Barisic, Odile Boespflug-Tanguy, Nicholas Deconinck, Anna Kostera-Pruszczyk, Ricardo Masson, Elena Mazzone, Andres Nascimento Osorio, Kyoko Saito, Dmitry Vlodavets, Carole Vuillerot, Sabine FuerstRecktenwald, Sibylle Fuhrer, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Carmen Martin, Wai Yin Yeung, John W. Day P8.11-011 FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA)–Laurent Servais, Giovanni Baranello, Ricardo Masson, Maria Bronislawa Mazurkiewicz-Beldzin, Kristy Rose, Dmitry Vlodavets, Hui Xiong, Edmar Zanotelli, Muna ElKhairi, Sabine Fuerst-Recktenwald, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Renata Scalco, Basil T. Darras P8.11-012 JEWELFISH: Safety and Pharmacodynamic Data in Non-Naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam

164 2020 AAN Annual Meeting

0 Tuesday, April 28

8:00 a.m.–9:00 a.m.

(RG7916)–Claudia A. Chiriboga, Claudio Bruno, John W. Day, Tina Duong, Dirk Fischer, Jan Kirschner, Francesco Muntoni, Sabine FuerstRecktenwald, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Francis Warren, Wai Yin Yeung, Eugenio Mercuri P8.11-013 Preference of Treatment Characteristics Among Patients with Spinal Muscular Atrophy (SMA): A Discrete Choice Experiment–Er Chen, Alisha Monnette, Alessandra Bazzano, Dongzhe Hong, Stacy E. Dixon, William D. Arnold, Lizheng Shi P8.11-014 Thrombotic Microangiopathy (TMA): A potential adverse reaction post Zolgensma (onasemnogene abeparvovec-xioi) therapy for Spinal Muscular Atrophy (SMA)– Nayana Prabhu, Ezgi Saylam, Cassandra Louis, Michelle Moss, Rachel Millner, David Douglass, Aravindhan Veerapandiyan, Amit Kumar Agarwal, Vikki Stefans, Kapil Arya P8.11-015 Pooled Safety Data from the Risdiplam (RG7916) Clinical Trial Development Program–Giovanni Baranello, Enrico Silvio Bertini, Claudia A. Chiriboga, Basil T. Darras, John W. Day, Nicholas Deconinck, Dirk Fischer, Nathalie M. Goemans, Jan Kirschner, Andrea Klein, Ricardo Masson, Maria Bronislawa Mazurkiewicz-Beldzin, Laurent Servais, Yi Wang, Sabine FuerstRecktenwald, Marianne Gerber, Ksenija Gorni, Birgit Jaber, Tammy McIver, Renata Scalco, Eugenio Mercuri

= Research

POSTER SESSION 9

CME

0 Tuesday, April 28

12:00 p.m.–1:00 p.m.

Poster Session 9

Multiple Sclerosis: Clinical Trials and Therapeutics 3

P9.1-008 Rationale and Design of two Phase 3 Randomized Controlled Trials (Evolution RMS 1&amp;2) Evaluating the Bruton&rsquo;s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis– Xavier Montalban, Douglas L. Arnold, Amit Bar-Or, Anne H. Cross, Eva Havrdova, Olaf Stuve, Martin Weber, Heinz Wiendl, Jerry S. Wolinsky, Sana Syed, Matt Mandel, Emily Martin, Patrick Vermesch P9.1-009 Clinical outcomes and treatment satisfaction in patients switching to teriflunomide in the real-world Teri-PRO and TAURUSMS I studies–Mark S. Freedman, Boris Alexander Kallmann, Jose Meca Lallana, Bhupendra O. Khatri, Jihad Said Inshasi, Pascal Laurent Rufi, Myriam Benamor, Philippe Truffinet, Elizabeth Poole, Patricia K. Coyle P9.1-010 Real-world outcomes with ocrelizumab compared with other disease-modifying therapies in US commercial claims databases–Natalie J. Engmann, Daniel Sheinson, Erru Yang, Damian Fiore, Enrique Alvarez, Kavita Nair, Timothy L. Vollmer

P9.1-011 Impact of drug diversity on patient care in RRMS in Germany between 2010 and 2018–Arnfin Bergmann, Stefan Braune, Heidi Dikow, Arnfin Bergmann P9.1-012 In-vivo B-cell activity predicts response to treatment with glatiramer acetate and interferons in patients with relapsing-remitting multiple sclerosis (RRMS)–Stefan Braune, Sabine Tacke, Tjalf Ziemssen, Paul Lehmann, Arnfin Bergmann, Stefanie Kuerten P9.1-013 Fingolimod Discontinuation Rate and Characteristics of Disease Activity in Real-world Cohort–Neda Zarghami Esfahani, Gloria Von Geldern, Meghan C. Romba, Michael J. Persenaire, Annette Wundes P9.1-014 Demographic, clinical and patient-reported characteristics of patients on ocrelizumab versus other diseasemodifying therapies in the Corrona Multiple Sclerosis Registry–Daniel Kantor, Natalie J. Engmann, Wendi Malley, Robert McLean, Angel Cronin, Blessing Dube, Aaron E. Miller

AAN.com/view/20AM 165

Tuesday, April 28

P9.1-001 Intravenous Immunoglobulins for the Prevention of Postpartum Relapses in Multiple Sclerosis–Alenka Horvat Ledinek, Gregor Jakob Brecl, Jana Jerse, Berislav Ruska, Tin Pavicic, Tereza Gabelic, Barbara Barun, Ivan Adamec, Uros Rot, Sasa Sega Jazbec, Magdalena Krbot Skoric, Mario Habek P9.1-002 Patterns and Trends of Healthcare Utilization among People with Multiple Sclerosis in the Age of Disease-Modifying Therapy: an Analysis of Administrative Claim Data from a Commercially Insured Population in the United States, 2004-2013–Wen Zhu, Xiaoyu Tang, Joan Landon, Michael Isfort, Jessica Franklin, Tianxi Cai, John Seeger, Zongqi Xia P9.1-003 Long-term Efficacy and Safety of Ponesimod, an oral S1P1 Receptor Modulator: Results from Randomized Phase II Core and Extension Studies in RelapsingRemitting Multiple Sclerosis–Mark S. Freedman, Carlo Pozzilli, Eva Havrdova, Patricia K. Coyle, Alexandre Lemle, Michel Burcklen, Anna Larbalestier, Brian Hennessy,

Tatiana Scherz, Andrea Vaclavkova, Tomas Olsson P9.1-004 Comparison of the efficacy of rituximab and glatiramer acetate in patients with active secondary progressive multiple sclerosis: A randomized clinical trial–Julianna Tomlinson, Masoume Cheshmavar, Negin Badihian, Shervin Badihian, Vahid Shaygannejad, Fereshteh Ashtari P9.1-005 Changes in immune cell profile, clinical and safety outcomes in fingolimod-treated patients with relapsing multiple sclerosis in the FLUENT study–Yang Mao-Draayer, Jeffrey Alan Cohen, Amit Bar-Or, May Han, Barry A. Singer, Nina Jaitly, Scott Kolodny, Chelsea Elam, Xiangyi Meng, Marina Ollervides Ziehn, Bruce A. C. Cree P9.1-006 Investigating the Safety and Efficacy of Elezanumab in Two Phase 2 Studies Enrolling Patients With Different Disease Courses of Multiple Sclerosis–Bruce A. C. Cree, Pfleeger Kimberly, Brittany Schwefel, Adam Ziemann P9.1-007 Efficacy and Tolerability of Disease Modifying Therapies in Late Onset Multiple Sclerosis– Smathorn Thakolwiboon, Amputch Karukote, GyeongMo Sohn, Dongkwan Jin, Mirla L. Avila

POSTER SESSIONS

1. Multiple Sclerosis: Clinical Trials and Therapeutics 3: 1-001 to 1-022 2. Autoimmune Neurology 6: 2-001 to 2-012 3. Parkinson’s Disease Clinical Trials and Methodology 2: 3-001 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 1: 4-001 to 4-009 5. Neuroepidemiology 1: 5-001 to 5-010 6. Advocacy, Alzheimer’s Disease, and the Unconventional 2: 6-001 to 6-006 Practice, Policy, and Ethics: Improving the Lives of Patients and Providers 1: 6-007 to 6-015 7. Spinal Muscular Atrophy/Motor Neuron Disorders 3: 7-001 to 7-011 Inherited Muscle Disorders 1: 7-012 to 7-015 8. Aging and Dementia: Retina and Non-alzheimer Dementia 1: 8-001 to 8-010 9. Cerebrovascular Disease: Telestroke, Pre-hospital, and Emergent Stroke Evaluation and Treatment 3: 9-001 to 9-021 10. Global Health: 10-001 to 10-013 Neurovirology 1: 10-014 to 10-018 11. Neuro-ophthalmology/Neuro-otology 3: 11-001 to 11-013

Tuesday, April 28

POSTER SESSIONS

POSTER SESSION 9 P9.1-015 Assessment and Follow-up of the Response to Disease Modifying Treatments in Multiple Sclerosis: Spanish Expert Consensus–Jordi I. Rio, Joaquin Pena Martinez, Luis Brieva Ruiz, Celia Oreja Guevara, Lucienne Costa-Frossard, Alfredo Rodriguez Antiguedad, Jose Manuel Garcia Dominguez, Mar Baz, Maria Jose Moreno Jimenez, Basilio Hernandez, Rafael Arroyo Gonzalez P9.1-016 Real-world evaluation of effectiveness and safety of cladribine tablets and patient reported outcomes in suboptimally controlled patients previously taking oral or intravenous diseasemodifying drugs for relapsing forms of multiple sclerosis (MASTER-2)– Edward J. Fox, Ann D. Bass, Brooke Hayward, John Walsh, Lori Lebson, Derrick Robertson P9.1-017 Quetiapine is Not Tolerable to People with MS in Doses Potentially Required to Enhance Myelin Repair–Luanne Metz, Yaser Almalik, Seraj Omar Makkawi, Adam Zedde, Graziela Cerchiaro P9.1-018 Adherence, persistence and switching patterns of patients initiating ocrelizumab compared to other disease-modifying therapies in the real world–Natalie J. Engmann, Erru Yang, Damian Fiore, Gabriel Pardo P9.1-019 Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in RelapsingRemitting Multiple Sclerosis– Robert J. Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Muehler P9.1-020 Reported Outcomes for DMTs in Multiple Sclerosis: Relatively Misleading–Brent Sokola, Wenxin Zhuo, Jagannadha R. Avasarala P9.1-021 Glatiramer Acetate Depot (extended-release) phase IIa study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (No Evidence of Disease Activity) subpopulation three-years analysis–Shlomo Flechter, Ariel L. Miller, Laura Popper, Nadav Bleich Kimelman, Shai Rubnov, Uri Danon, Ehud Marom, Ron E. Milo, Joab Chapman, Alla Shifrin, Ronit Gilad,

CME

Chen Hoffmann, Dimitrios Karussis, Arnon Karni P9.1-022 Analysis of First Line Therapy Criteria Responses in a Cohort of 1,300 Relapsing Remitting MS Patients–Pierre Labauge, Jerome De Seze, Jean Pelletier, Clarisse Carra-Dalliere, Safa Aouinti, Frederic Pinna, Kevin Bigaut, Adil Maarouf, Xavier Ayrignac, Marie Christinee Picot Autoimmune Neurology 6

P9.2-001 Anti-Yo associated non-paraneoplastic autoimmune neuropathy: Report of 2 cases–MICHAIL KOSMIDIS, Harry Alexopoulos, Sofia Akrivou, Marinos C. Dalakas P9.2-002 Clinical, diagnostic and therapeutic spectrum of seropositive and seronegative autoimmune encephalitis: Single center cohort study of 51 cases– Lara Fahmy, Muhammad Affan, Anza Memon, Mirela Cerghet P9.2-003 Neuronal Intermediate Filament (NIF) Antibody Positivity in a Patient with Glial Fibrillary Acidic Protein (GFAP) Astrocytopathy– Yongyao Kong, Odelia SQ Koh, Yi Rong Chiew, Eati Basal, Andrew McKeon, Adeline Su Lyn Ng P9.2-004 Tocilizumab in New Onset Refractory Status Epilpeticus (NORSE) - A Report of the First Case from India.–Manoj Bharath Alluru, Ramesh Patil, Srikanteshwara Praveen Kumar, Archana N.B, Janardhan DC, Rashmi S, Raghu Patil, Harisha K, Harisha K, Nirmala A.C. P9.2-005 SLE presenting with holocord myelitis–Anand Kumar, Mamta Bhushan Singh, Ajay Garg, Venugopalan Y. Vishnu, Vinay Goyal, Padma Vasantha Hadakasira P9.2-006 A Rare Case of Amphiphysin-associated Stiff Person Syndrome in a Male Patient with Breast Cancer–Loulwah Mukharesh, Scott Douglas Newsome P9.2-007 Autoimmune Dysautonomia and Ataxia due to Ganglionic Acetylcholine Receptor Autoantibodies–Duarte G. Machado, Alison Lori Carlson P9.2-008 Three Paraneoplastic Syndromes preceding an Occult Breast Cancer–Sidonie Elie Ibrikji, Tarek El Halabi, Raja Sawaya, Samir F. Atweh

166 2020 AAN Annual Meeting

0 Tuesday, April 28 P9.2-009 Seizure, fever, hallucinations, and vision loss: A circuitous route to dual diagnoses– Elizabeth Eleanor Carroll, Asya Izraelit Wallach, Arielle Marisa Kurzweil, Steven Frucht, Thomas Berk, Michael Boffa, Ilya Kister P9.2-010 Cognitive impairment and ophthalmoplegia: To increase awareness of early recognition of lupus meningoencephalitis– Ashmanie Mahatoo, Annie S. Daniel P9.2-011 A case of transient meningeal thickening on MRI with Anti-phospholipid syndrome–Alex Gunko, Orna O’Toole P9.2-012 Characterization of Retinal Nerve Fiber Layer Thickness in a Cohort with Anti-Glutamic Acid Decarboxylase and Anti-Glycine Receptor Autoimmunity–Robert Kadish, Ka-Ho Wong, Jonathan Ross Galli, John E. Greenlee, Julia Klein, M. Mateo Paz Soldan, Stacey Clardy, John W. Rose Parkinson’s Disease Clinical Trials and Methodology 2

P9.3-001 Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes–Jennifer S. Hui, Susan Fox, William Neeson, Parul Bhargava, Eric J. Pappert, David Blum, Bradford A. Navia P9.3-002 Effectiveness and Safety of Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: the OPTIPARK Study–Heinz Reichmann, Andrew John Lees, Francisco Rocha, Diogo Magalhães, Patricio Soares-da-Silva P9.3-003 The BouNDless Study: An Active-Controlled, Randomized, Double-Blind, Double-Dummy Phase 3 Study of Continuous ND0612 Infusion in Patients with Parkinson’s Disease Experiencing Motor Fluctuations–Alberto J. Espay, Olivier Rascol, Tamar Yardeni, Liat Adar, Olivia Rosenfeld, Ryan J. Case, C. Warren Olanow P9.3-004 Effect of Once-Daily Opicapone on the Pharmacokinetics of Repaglinide–Gordon Loewen, Grace Lin Liang, Roland Jimenez, Kurt Olson, Evan Smith, Haig Bozigian

12:00 p.m.–1:00 p.m. P9.3-005 Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV951: Design of a 52-Week Phase 3 Study–Maurizio F. Facheris, Janet Benesh, Janet Streit, Weining Robieson, Cindy Zadikoff, David G. Standaert P9.3-006 Assessment of safety and efficacy of Opicapone addon to levodopa in Parkinson´s disease.–Marta Ruiz-Lopez, Lola Diaz, Cici Feliz, Pedro J. Garcia-Ruiz P9.3-007 First Results for The BeyoND Study: An open-label international, multicenter study evaluating the long-term safety of ND0612 in patients with idiopathic Parkinson’s disease–Stuart H. Isaacson, Werner Poewe, Tanya Simuni, Sheila Oren, Ryan J. Case, C. Warren Olanow P9.3-008 Long-term Evaluation of Open-label Pimavanserin Safety and Tolerability in Parkinson’s Disease Psychosis–Clive G. Ballard, David Kreitzman, Stuart H. Isaacson, James Norton, George Demos, I-Yuan Liu, Hubert H. Fernandez, Tihomir V. Ilic, Jean Philippe Azulay, Joaquim Ferreira, Victor Abler, Srdjan Stankovic P9.3-009 Safety and Tolerability of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients–Mya C. Schiess, Jessika Suescun, MarieFrancoise Doursout, Christopher Adams, Charles Green, Jerome Saltarrelli, Timothy Michael Ellmore P9.3-010 Gocovri Reduces Disruptive Motor Episodes and Improves Function in Parkinson’s Disease Patients With OFF Episodes and Dyskinesia: Analysis of Phase 3 Trial Data–Robert A. Hauser, Dustin Chernick, Andrea Formella P9.3-011 A Prospective, Randomized, Placebo-Controlled Pilot Study of Mirabegron (Myrbetriq®) and Behavioral Modification for Overactive Bladder in Parkinson Disease–Pinky Agarwal, Theodore R. Brown, Sudeshna Ray, Arina Madan, Ina Roy-Faderman, Daniel J. Burdick P9.3-012 GLYCOPAR: A randomized, placebo-controlled, two-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

P9.4-001 Tiagabine-Induced Encephalpathy–Kiran M. Kanth, Nicholas M. Gregg, Kate Wills Hocquard, Cheolsu Shin, Jeffrey W. Britton P9.4-002 Efficacy of Eslicarbazepine Acetate as First Adjunctive Therapy with Levetiracetam or Lamotrigine, or as Later Adjunctive Therapy in Patients with Focal Seizures– Andrei Pikalov, Todd Grinnell, John David Hixson, Robert Tosiello, David Blum, David Cantu P9.4-003 Safety and Tolerability of Eslicarbazepine Acetate as First Adjunctive Therapy with Levetiracetam or Lamotrigine, or as Later Adjunctive Therapy in Patients with Focal Seizures–David Cantu, Barry E. Gidal, Robert Tosiello, David Blum, Andrei Pikalov, Todd Grinnell P9.4-004 Clinical Predictors of 12-Month Retention in Patients Treated with Eslicarbazepine Acetate: Real-World Evidence from the Euro-Esli Study–Francisco Sales, Rob McMurray, Rui Loureiro, Hélder Fernandes, Vicente Villanueva P9.4-005 Experience with Eslicarbazepine in the IDD/LongTerm Care Epilepsy Population– Jess Collins P9.4-006 Psychiatric Adverse Events According to Psychiatric History and Current Status: A Post-hoc Analysis of Three Phase III Trials of Adjunctive Eslicarbazepine Acetate in Adults with Focal Seizures–Hamada Hamid Altalib, Todd Grinnell, David Cantu, Fabio Ikedo, Mariana Vieira, Robert Tosiello, David Blum P9.4-007 Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study –the 2-year open-label extension of the ESL study (BIA-2093-311)–Eugen Trinka, Ana C. Pereira, Joana Moreira, Luis Magalhaes, Fabio Ikedo, Helena Gama P9.4-008 Long-term Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4–17 years) with Focal Seizures–Raman Sankar, Fenella J. Kirkham, Gregory L.

Holmes, Jesus Eric Pina-Garza, James W. Wheless, Todd Grinnell, David Cantu, Helena Gama, Joana Moreira, Robert Tosiello, David Blum P9.4-009 Efficacy and Safety of Eslicarbazepine Acetate as add-on Treatment in Adult Patients with Focal-Onset Seizures by Concomitant Antiepiletic Drug: Data from Four Double-Blind Pivotal Phase III Studies–João Chaves, Rui Loureiro, Joana Moreira, Fabio Ikedo, Hélder Fernandes Neuroepidemiology 1

P9.5-001 Differences in Pharmacovigilance Regulatory Requirements in Latin America countries (LATAM): impact in the real world experience–Judith Diana Steinberg, Adriana Carra, Yara D. Fragoso, Miguel Angel Macias-Islas, Claudia A. Carcamo Rodriguez, Ethel Ciampi, Edgar Patricio Correa Diaz, Juan Duran Quiroz, Juan Raul Garcia, Carolina Guerra, Nelson Novarro, Carlos Oehninger, Geraldine Orozco, Virginia Rodriguez, Irene Trevino Frenk, Darwin R. Vizcarra P9.5-002 Risk factors and Radiological findings of Sinus vein Thrombosis in all patients referring to Imam Hossein Hospital between 2007-2018–Farhad Assarzadegan, Saba Ilkhani, Arash Azhideh, Manuchehr Ilkhani P9.5-003 Gender, reproductive history, and early onset amyotrophic lateral sclerosis (ALS), Data from the National ALS Registry: 2010 – 2018–Jaime Raymond MPH, Paul Mehta, Theodore Larson, Erik P. J. Pioro, D. Kevin Horton P9.5-004 Chronic Pain in the PostDeployment Period: Results from the Warrior Strong Cohort–Ann Scher, Lisa Brenner, Wesley Cole, Heidi Terrio, Karen A. Schwab P9.5-005 Unraveling the Risk factors for Spontaneous Intracerebral Hemorrhage and its Severity among West Africans– Mayowa Owolabi, Fred Sarfo, Mulugeta Gebregziabher, Onoja M Akpa, Onoja M Akpa, Kolawole W. Wahab, Godwin Ogbole, Rufus O. Akinyemi, Morenikeji Komolafe, Reginald Obiako, Lukman Femi Owolabi, Daniel Thomas Lackland,

Donna Arnett, Hemant Tiwari, Hugh Markus, Bruce I. Ovbiagele P9.5-006 The impact of exogenous and nutritional lifestyle factors on ALS progression rate: a cross-sectional multicenter study.–Andrei Ivashynka, Aliona Cucovici, Vitalie Stelian Lisnic, Dafin Muresanu, Sergio Russo, Maurizio Leone P9.5-007 Occupational Exposition to Pesticides and Amyotrophic Lateral Sclerosis in Quebec and France–Marie Beaudin, AnneMarie Trudelle, Marie-Soleil Lamarre, Jacques Le Bouthillier, Pierre-François Pradat, Nicolas Dupre P9.5-008 Use of ALS cases from the ATSDR/CDC National ALS Registry and a population based control group to investigate ambient air pollution and suspected neurotoxicants as risk factors for ALS–Evelyn Talbott, Angela Malek, Judith Rager, Vincent Arena, Ravi sharma, Jeanine Buchanich, Fan Wu P9.5-009 A Comparison of Blood Metal Levels from Patients in the National Amyotrophic Lateral Sclerosis (ALS) Biorepository with Participants in the National Health and Nutrition Examination Survey– Theodore Larson, Tracy Peters, Maureen Orr, Stephen Goutman, Paul Mehta, D. Kevin Horton P9.5-010 Correlates of AntiAQP4 Autoantibody Serostatus Among NMOSD Participants in the CIRCLES Study–Lawrence Cook, Jessica Alvey, John W. Rose, Anna Jolley, Renee Kuhn, Brie Marron, Megan Kenneally, Judy Sheard, Jacinta Behne, Terrence F Blaschke, Terry Smith, Michael R. Yeaman Advocacy, Alzheimer’s Disease, and the Unconventional 2

P9.6-001 Advocacy and leadership curriculum integration in a neurology residency program: A way to combat burnout–Aileen Antonio, Christopher Morgan, Emily C. Johnson P9.6-002 Financial Relationships Between Neurologists and Industry- Payment Trends, 20152018–Aditi Ahlawat, Pushpa Narayanaswami

AAN.com/view/20AM 167

Tuesday, April 28

Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 1

POSTER SESSIONS

Parkinson’s disease–Tiago Mestre, Maria Eliza Thomaz D Freitas, Ahmed Saeed Basndwah, Marta Lopez, Heba Shinawi, Lais Oliveira, Duha Mohammed Al-Shorafat, Deborah Mancini, Jane Lui, Shawna Reddie, David A. Grimes, Susan Fox P9.3-013 Design of Phase 1/2a Study of AAV9-Based Gene Therapy for Parkinson’s Disease with Pathogenic GBA1 Mutations (PROPEL Trial)–Olga Uspenskaya, Erin Mahoney, Lynne Verselis, Mark Lowrey, Jenny Velaga, Jeffrey J. Sevigny P9.3-014 Improvements in Dyskinesia with LevodopaCarbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients in a ‘Real-World’ Study: Interim Results of the Multinational DUOGLOBE Study With up to 24 Months Follow-Up–Jason Lamar Aldred, Norbert Kovacs, Francesco Pontieri, David G. Standaert, Paul M. Bourgeois, Thomas L. Davis, Esther Cubo Delgado, Marieta Anca-Herschkovitsch, Robert Iansek, Mustafa S. Siddiqui, Mihaela A. Simu, Lars Bergmann, Pavnit Kukreja, Weining Robieson, Ray Chaudhuri P9.3-015 Dopamine Dysregulation Syndrome in Parkinson’s Disease and its Management with Advanced Therapies–Sanskriti Sasikumar, Roberto Matta, Renato Puppi Munhoz, Taline Naranian, Louis Liu, Andres M. Lozano, Suneil Kalia, Moji Hodaie, Alfonso Fasano P9.3-016 Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa-Treated Patients with Parkinson’s Disease–Nobutaka Hattori, Takanobu Nomura, Phyllis M. Salzman, Hiroki Kitabayashi, Masatake Ishiuchi, Keizo Toyama, Akihisa Mori P9.3-017 Nilotinib is reasonably safe and may halt the disease progression in moderately severe Parkinson’s disease patients– Fernando L. Pagan, Michaeline Hebron, Barbara Wilmarth, Yasar Alejandro Torres-Yaghi, Abigail Catherine Lawler, Elizabeth E. Mundel, Nadia Yusuf, James N. Starr, Muhammad Waseem Anjum, Shahnaz Miri, Steven Wayne Nakano, Amelia Carwin, Myrna Arellano, Sara Matar, Jaeil Ahn, Charbel E H Moussa

Tuesday, April 28

POSTER SESSIONS

POSTER SESSION 9 P9.6-003 Dementia, valuing, and advance directives–Benjamin Lin, David Merli P9.6-004 American Migraine Foundation: Patient Engagement Map–Nim Lalvani, Anna Quinn, Izabella D’Onofrio, Violetta Gerzen P9.6-005 Financial Relationship Between the Industry and Clinical Neurophysiology: Analysis of Open Payments Data from 2013 to 2018–Jolanta Marszalek, Gerald Chi, Fahimehalsadat Shojaei, Sisira Yadala, Karthika Durga Veerapaneni, Krishna Nalleballe P9.6-006 Quality Improvement and Clinical Innovation: Trial of an e-consult system in an outpatient tertiary care neurology practice for patients in an Accountable Care Organization model–Rohit Das, Ailing Eileen Yang, David Pool, Debra Clamp, Jaya Raghav Trivedi, Benjamin M. Greenberg, Padraig Eoin O’Suilleabhain Practice, Policy, and Ethics: Improving the Lives of Patients and Providers 1

P9.6-009 Automated Detection Software Improves Seizure Recognition in an Epilepsy Monitoring Unit–Brad Kenichi Kamitaki, Alma Yum, Stephen Wong P9.6-010 Utilization of systematic safety checklists to improve lengthof-stay, infection rates, preventable complications and mortality at the Neurointensive Care Unit of the Baylor Saint Luke’s Medical Center: A quality improvement study.– Cesar E Escamilla-Ocanas, Gabriel Torrealba Acosta, Mohammad I. Hirzallah, Eric Bershad, Chethan Venkatasubba Rao, Rahul Damani P9.6-011 Time Allowed Versus Time Needed for Complicated Patients: A Survey of Multiple Sclerosis Specialists–William A. Kilgo P9.6-012 Baclofen Toxicity The Importance of Medication Reconciliation–Christine Smith, Brenda Fahy, Jean E. Cibula P9.6-013 BBRAINS: Reducing Unnecessary Overnight Pages in the Neurology Unit via Improved Resident/Nurse Communication– Jumana Tariq A Alshaikh, Travis Gesell, Allison Norenberg, Changrui Xiao, Zachary Benjamin Bulwa, Faten El Ammar, Julia Bodnya, Helene Rubeiz, Vineet Arora

CME

P9.6-014 Standardized Documentation Improves Stroke Guideline Compliance–Micah Etter, Judy Dawod, Anna Kafka, Katalin Scherer P9.6-015 Reducing Prescribing Errors in Hospitalized Children on the Ketogenic Diet: A QuasiExperimental Quality Improvement Study–Benjamin Siegel, Meredith Johnson, Thomas Dawson, Emily Kurzen, Philip J. Holt, David Wolf, Evan Orenstein Spinal Muscular Atrophy/ Motor Neuron Disorders 3

P9.7-001 Incidence of Motor Neuron Disease Presenting with Isolated Fasciculations–Clover Youn, Stephen N. Scelsa P9.7-002 A Case of VRK1 Mutation Associated with Microcephaly and Childhood-Onset Motor Neuron Disease–Carlayne E. Jackson, Tiffany Ann Brown P9.7-003 NT5c1A Antibodies in Motor Neuron Disease–Michael Conrad Hunter, Manisha Kak Korb, Ali A. Habib P9.7-004 Mitochondrial Bioenergetic Profile in Platelets as a Biomarker for Amyotrophic Lateral Sclerosis (ALS)–Mohamed Kazamel, Balu Chacko, Peter H. King, Ikjae Lee, Victor Darley-Usmar P9.7-005 Progression of Brain Functional Connectivity Changes Associated with Altered Cognition in Amyotrophic Lateral Sclerosis–Elisa Canu, Federica Agosta, Veronica Castelnovo, Nilo Riva, Davide Calderaro, Yuri Falzone, Barbara Poletti, Vincenzo Silani, Massimo Filippi P9.7-006 The Return of Answer ALS Results Study (RoAR): Answering the Duty to Disclose– Leah Vicini, Amy M. Bartlett, Sarah Heintzman, MacKenzie Kaschalk, Ashley Fox, Amy Knapp, Matthew Harms, Stephen J. Kolb, Jennifer A. Roggenbuck P9.7-007 The Pathogenesis of Chlorovirus Infection in SOD1G93A Transgenic Mice and Clinical Implications for ALS–Gary L. Pattee, Tom Petro, David Dunigan, Irina Agarkova, James Van Etten P9.7-008 Clinical implications of MiToS in ALS patients using FORTITUDE-ALS data for 12 weeks follow up–Paulos Gebrehiwet,

168 2020 AAN Annual Meeting

0 Tuesday, April 28 Jenny Wei, Lisa Meng, Stacy A. Rudnicki, Phil Sarocco P9.7-009 Intersection of Prions and Amyotrophy: A Case Report– Clark Moser, Ligia Viorela Onofrei P9.7-010 Role of hnRNPA1 in an Italian ALS Population-Based Cohort–Maurizio Grassano, Andrea Calvo, Sonja Waltraud Scholz, Antonio Canosa, Umberto Manera, Rosario Vasta, Cristina Moglia, Bryan Traynor, Chun-yiu Law P9.7-011 Sequence of arm muscle weakness suggests cortical/ network influences over contiguous spread of neurodegeneration ALS spinal cord–Nimish J. Thakore, Brian Drawert, Brittany Lapin, Erik P. J. Pioro Inherited Muscle Disorders 1

P9.7-012 Singlecell Transcriptomes in Facioscapulohumeral Muscular Dystrophy–Lawrence J. Hayward, Dongsheng Guo, Kathryn Rae Wagner, Oliver King, Charles Emerson P9.7-013 Myofibrillar Myopathy 5: Clinical, Morphological and Genetic Studies of a Cohort of Chinese Patients with Novel Pathogenic FLNC Nonsense Mutation–Yuan Gao, Richard S.K. Chang, Siu-lun Ronnie Ho, Chun-yiu Law, Windsor Mak, Man-yu Mona Tse, Ching-wan Lam, Shu Leong Ho P9.7-014 Kinect-acquired Reachable Workspace correlates with patient-reported upper extremity Activities of Daily Living (ADLs) function in FSHD–Jay Han, Maya Hatch, Vicky Chan, Gregorij Kurillo P9.7-015 Modeling the Epidemiologic Burden of Duchenne Muscular Dystrophy (DMD) in the United States (US)–Alexa Klimchak, Karissa Johnston, Katherine Osenenko, Shelagh Szabo, Katherine Gooch Aging and Dementia: Retina and Non-alzheimer Dementia 1

P9.8-001 Accelerated neuroretinal thinning in Alzheimer’s disease reflects cognitive decline: a longitudinal study–Roberto Santangelo, Su-Chun Huang, Maria Paola Bernasconi, Monica Falautano, Massimo Filippi, Giancarlo Comi, Giuseppe Magnani, Letizia M. Leocani

12:00 p.m.–1:00 p.m. P9.8-002 Optical Coherence Tomography Reveals LightDependent Retinal Responses in Alzheimer’s Disease: A Reproducible Biomarker–David P. Bissig, Vy Le, Clarice Zhou, Jacqueline Bernard P9.8-003 Altered Pupil Dynamics in Patients with Neurodegenerative Diseases–Jeff Huang, Brian Coe, Matthew Smorenburg, Donald C Brien, Sandra E. Black, Elizabeth Finger, Morris Freedman, Anthony E. Lang, Michael J. Strong, Richard H. Swartz, Carmela Tartaglia, Lorne H. Zinman, Douglas P Munoz P9.8-004 Saccadic Behaviour in an Eye-Tracking Task is Differentially Altered by Neurodegenerative Diseases–Heidi Riek, Brian Coe, Don Brien, Sandra E. Black, Michael Borrie, Dariush Dowlatshahi, Elizabeth Finger, Morris Freedman, Donna Kwan, Anthony E. Lang, Connie C. Marras, Mario Masellis, Christen L. Shoesmith, Richard H. Swartz, Brian Tan, Carmela Tartaglia, Lorne H. Zinman, the ONDRI Investigators, Douglas P Munoz P9.8-005 Characterization of the retina of the triple-transgenic mice model of Alzheimer&#39;s disease: onset and progression of the disease–Rui Bernardes, Hugo Ferreira, João Martins, Paula Moreira, António Francisco Ambrósio, Miguel Castelo-Branco, Pedro Serranho P9.8-006 Retinal Vascular Tortuosity Correlates with Retinal Amyloid Count: a Cohort Study–Oana Maria Dumitrascu, Mazyiar Khansari, Yonggang Shi, Tania Torbati, Diana Emma Cristea, Steven Verdooner, Patrick D. Lyden, Keith Black, Yosef Koronyo, Maya Koronyo-Hamaoui P9.8-007 Cognitive Reserve and Vulnerability in Frontotemporal Dementia : Role of Bilingualism and Stressors–Ratnavalli Ellajosyula, Jwala Narayanan P9.8-008 Cognitively Complex Occupations Relate to Slower Cognitive and Functional Decline in Behavioral Variant Frontotemporal Degeneration–Jessica Bove, Nikolas Kinney, Corey McMillan, Lauren M. Massimo P9.8-009 Concordance among neuropsychological profile, functional neuroimaging and = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Cerebrovascular Disease: Telestroke, Pre-hospital, and Emergent Stroke Evaluation and Treatment 3

Marina Ivanov, Katie Kunze, Kara A. Sands P9.9-015 Thrombolysis versus Thrombaspiration in Acute Ischemic Stroke:A Prospective Observational Study from a Rural Tertiary Care Center in India–Ahamed Subir Humyum Kabir, Ahamed Subir Humyum Kabir, Fazal Ghafoor P9.9-016 Case Series of Protamine Followed by Thrombolysis in Heparinized Acute Ischemic Stroke Patients–Reid D. Taylor, Erika Prezas, Rylee Rankin, Joshua Lewis, Alexander T. Schneider P9.9-017 Immediate Response To Intravenous Recombinant Alteplase In Different Stroke Types–Taha Nisar P9.9-018 “Cortical” deficits at presentation do not influence treatment times among acute ischemic stroke patients.–Sneh Preet Munder, Anand Vilaschandra Patel, Sami Bajwa, Karalyn Pappas, Jeffrey M. Katz, Richard Libman P9.9-019 Positive HANG score predicts large vessel occlusion or severe stenosis in anterior circulation stroke–Harsh Singh, Ashish Nanda, Vikas Kumar, lauren polezogopoulos P9.9-020 Successful Use of Thrombolytic Therapy in a Pregnant Woman with Acute Ischemic Stroke–Jemima Akinsanya, Dinesh V. Jillella P9.9-021 Stroke and thrombosed vertebral artery associated with retained epicardial pacing wire–Yeonjung Kim, Ji Yon Kim, Seung Min Kim, Sun Uck Kwon Global Health

P9.10-001 Headache Among HIV-Infected Adults in Lusaka, Zambia–Curi Kim, Mashina Chomba, Arnold Phiri, Sombo Fwoloshi, Cassidy Claassen, Lottie Hachaambwa, Deanna Saylor P9.10-002 HIV central nervous system immune reconstitution inflammatory syndrome (CNS IRIS): Diagnostic challenges in resourcelimited settings–Allison P. Navis, Omar Siddiqi, Susan Morgello, Gretchen L. Birbeck P9.10-003 Initial Results from the Zambian Epidemiology of Parkinson’s Disease and Healthcare Registry (ZEPHyR)–Teresa

Lee, Omar Siddiqi, Masharip Atadzhanov, Deanna Saylor, Jori Fleisher P9.10-004 Where There Is No Neurologist: Developing a Curriculum for a New Neurology Training Program in Zambia– Deanna Saylor, Omar Siddiqi P9.10-005 HIV infection is associated with higher mortality in individuals presenting with reduced level of consciousness to a referral hospital in Uganda.–Amir Abdallah, Amir Abdallah, Bart M. Demaerschalk, Nan Zhang, Richard Butterfield, Cumara Barahona O’Carroll P9.10-006 Epilepsy in the Republic of Guinea: Social Determinants of Clinical Outcomes–Dylan R. Rice, Foksuna Sakadi, Nana Rahamatou Tassiou, Andre Vogel, Abdoul Bachir Djibo Hamani, Aissatou Kenda Bah, Alex Garcia, Bryan Patenaude, Fode Abass Cisse, Farrah J. Mateen P9.10-007 Smartphone EEG Utility and Quality for Epilepsy Patients in the West African Republic of Guinea–Elisaveta Sokolov, Abdoul Bachir Djibo Hamani, Foksuna Sakadi, Jennifer Williams, Andre Vogel, Mike Schaekermann, Nana Rahamatou Tassiou, Aissatou Kenda Bah, Vidita Khatri, Gladia C. Hotan, Neishay Ayub, Edward Chi Wai Leung, Tadeu Fantaneanu, Archana Anil Patel, Manav Vyas, Tracey A. Milligan, Mauricio Fernando Villamar, Daniel B. Hoch, Sherrill J. Purves, Behnaz Esmaeili, Jose Tellez-Zenteno, Ernesto Gonzalez-Giraldo, Illya Tolokh, Lauren Lahdan Heidarian, Lila Tracy Worden, Neville Jadeja, Sara Elizabeth Fridinger, Liesly Lee, Fode Abass Cisse, Farrah J. Mateen P9.10-008 Comprehensive Profile of Antiviral Antibody Responses in Zika-associated GBS During the Zika Epidemic in Colombia–Beatriz Parra, Matthew Robinson, Dyvia Mohan, Daniel Monaco, Lyda Osorio, H. Benjamin Larman, Carlos A. Pardo-Villamizar

AAN.com/view/20AM 169

Tuesday, April 28

P9.9-001 General Anesthesia for Thrombectomy in Extended Window Leads to Similar Outcomes as Compared to Conscious Sedation–Muhib Khan, Chantal Bhan, Lee Elisevich, Tracy J Koehler, Justin Singer, Paul Mazaris, Joseph Zachariah, Elysia James, Tricia Tubergen, Laurel Packard, Jiangyong Min, Nabil Wees, Nadeem I. Khan P9.9-002 Elevated Hemoglobin A1C Predicts Myocardial Infarction after Mechanical Thrombectomy for Acute Ischemic Stroke–Juan Sebastian Diaz, Vasu Saini, Nastajjia Krementz, Sishir Mannava, Melissa Bailey, Mario Phillip Zamora, Daniel Robert Kogan, Luis Guada-Delgado, Elizabeth Jordan, Nicole Beaton Sur, Dileep R. Yavagal P9.9-003 Differences in Presentation and Treatment Times of Patients With Large Vessel Occlusion–John H Erdman, Laura Stein, Danielle Wheelwright, Nathalie Jette, Madhu Mazumdar, Mandip Singh Dhamoon, Parul Agarwal P9.9-004 TIME IS BRAIN in mechanical thrombectomy Particularly in Those Arriving within 6 hours and have good ASPECTS score–Thomas Michael Snyder, Shashank Agarwal, Brent Lawrence Flusty, Sun Kim, Denis Vezina, Aaron S. Lord, Albert Samuel Favate, Kelley Humbert, Jose L. Torres, Matthew D. Sanger, Cen Zhang,

Koto Ishida, Sara Kate Rostanski, Shadi Yaghi P9.9-005 Thrombectomy in the Aged Population and Preadmission Elevated Disability (TAPPED): A Retrospective Chart Review– Robert Alan Hamilton, Hannah Wang, Claire Emmanuelle Delpirou Nouh, Chao Xu, Evgeny Sidorov P9.9-006 Cut-off Time for Intraarterial Therapy in Patients with Stroke–Kathryn L McCarthy, Stephanie Jarvis, Cynthia Dickerson, Benjamin Atchie, Alicia Erin Bennett, David Bar-Or P9.9-007 Cangrelor for NeuroInterventions–Hazem M. Shoirah, Sherif Elsayed, Nicole Davis, Nadine Musallam, Manisa Tanprayoon, Andrew Kaplan, Rick Knudson, Francesco Ciummo, Jay Mocco, Reade De Leacy, Thomas Oxley, Christopher Kellner, Inder Paul Singh, Tomoyoshi Shigematsu, Johanna Therese Fifi P9.9-008 Impact Of Stroke Severity Based EMS Bypass Protocol On Primary Stroke Centers.–Ehad Afreen, Hisham Raza Alim Salahuddin, Nurose Karim, Mouhammad A. Jumaa P9.9-009 Double Trouble: Successful Thombectomy for Recurrent, Contralateral M2 Occlusions–Jessica Frey, Amelia Karen Adcock P9.9-010 Describing Contraindications for Intraarterial Therapy at a Comprehensive Stroke Center–Kathryn L McCarthy, Stephanie Jarvis, Cynthia Dickerson, Benjamin Atchie, Alicia Erin Bennett, David Bar-Or P9.9-011 Predicting Neuroimaging Eligibility for Extended Window Endovascular Thrombectomy or tPA–Adam De Havenon, Kole Mickolio, Phil Taussky, Al-Wala Awad P9.9-012 Acute thrombocytopenia after tissue plasminogen activator for stroke: A Case Report– Jonathan Morena, Casey C May, Tamara Strohm P9.9-013 Novel Definition of Stroke “Good Responders” Predicts 90-Day Outcome for Thrombolysis– Alyssa Bautista, Dawn Meyer, Brett C. Meyer P9.9-014 Low Serum Calcium and Clinical Outcomes Following Systemic Thrombolysis in Acute Ischemic Stroke–Harn Shiue,

POSTER SESSIONS

pathological biomarkers in Primary Progressive Aphasia. A singlecentre experience–Salvatore Mazzeo, Cristina Polito, Sonia Padiglioni, Valentina Berti, Silvia Bagnoli, Gemma Lombardi, Irene Piaceri, Marco Carraro, Camilla Ferrari, Benedetta Nacmias, Sandro Sorbi, Valentina Bessi P9.8-010 Brain Functional Connectivity Associated with the Right Temporal Degeneration–Elisa Canu, Federica Agosta, Michela Leocadi, Davide Calderaro, Veronica Castelnovo, Paola Caroppo, Sara Prioni, Tremolizzo Lucio, Ildebrando H. Appollonio, Paola Valsasina, Massimo Filippi

Tuesday, April 28

POSTER SESSIONS

POSTER SESSION 9 P9.10-009 The Spectrum of Neuroinflammatory Disorders After the Outbreak of Zika Infection in Colombia: A Multi-center Observational Study–Lyda Osorio, Jose Vargas, Susana Dominguez, Jorge Andres Jimenez-Arango, Jairo Lizarazo, Reydmar Lopez, Guillermo Gonzalez-Manrique, Gustavo Eduardo Ramos, Andres Felipe Zea-Vera, Jorge A. Angarita Diaz, Julie Benavides, Viviana Martinez, Paula Barreras, Maria Alejandra Garcia-Dominguez, Luis Carlos Quintero, Katherine V Claros, Karina Luque, Linda Carolina Jaramillo Rojas, Fernando Rosso, Christian Rojas, Jonathan Urrego, Daniela Zuluaga, Carmen Ocampo, Monica Morales, Juan Pablo Rojas, Gonzalo Zuniga, Mario Llanos, Martha Moyano, Laura S. Munoz-Arcos, Beatriz Parra, Carlos A. Pardo-Villamizar P9.10-010 How Microcephaly Related to Zika Virus is Impacting on Brazilian Infant Mortality Rates?–Nilson Nogueira Mendes Neto, Jessika Thais da Silva Maia, Marcelo Rodrigues Zacarkim, Daniel Lucey, David Aronoff P9.10-011 Current Practice Habits and Educational Opportunities in the Evaluation and Management of Pediatric Seizures in Guatemala– Matilde Racancoj Sac, Eugenia Huix Ramos, Jose Molina Vail, Alicia Henriquez, Ryan Kammeyer, Diana J. Walleigh P9.10-012 Overview of Acute Flaccid Paralysis (AFP) in Children Aged–Xue Yi Chen, Maria Alejandra Garcia-Dominguez, Carlos A. Pardo-Villamizar P9.10-013 Socioeconomic status and stroke incidence, prevalence, mortality and worldwide burden: an ecological analysis from the Global Burden of Disease Study 2017–Abolfazl Avan, Hadi Digaleh, Mario Di Napoli, Saverio Stranges, Reza Behrouz, Golnaz Shojaeianbabaei, Amin Amiri, Reza Tabrizi, Naghmeh Mokhber, J David Spence, Mahmoud Reza Azarpazhooh

CME

Neurovirology 1

P9.10-014 Severe Tick-borne Myeloradiculitis despite Vaccination against the Disease: a Matter of Age?–Julia Feige, Tobias Moser, Larissa Irene Sellner, Slaven Pikija, Johann Sellner P9.10-015 Thrombolysis in Aseptic meningitis mimicking Acute Ischemic Stroke–Sachi Gianchandani, Vivien H. Lee P9.10-016 Acquired West Nile encephalitis with bifrontal epileptiform discharges and vasculitis-associated stroke in kidney and liver transplant recipient: a Case Report.–Annie Lee Hsieh, Stefan Gillen, Antonette Climaco, Radi Zaki, Amro Mohammed Abdulsattar, Steven Yang, Maria Virginia Diaz Rojas, Indira De Jesus-Alvelo P9.10-017 Case report of clinical improvement in a patient with neuroinvasive West Nile virus after late treatment with interferon alpha–Saher Suleman, Fawaz Philip Tarzi P9.10-018 West Nile Myelitis Disguised as Severe Compressive Myelopathy–Tejas Ranade, Xiao Weng, Huiam Mubarak, Liang Wang, Jiong Shi Neuro-ophthalmology/Neurootology 3

P9.11-001 Relationship Between Optic Nerve Angle, Intracranial Pressure, and Visual Outcomes in Patients with Idiopathic Intracranial Hypertension (IIH)–Benson Chen, Solmaz Asnafi, Mung Yan Lin, Beau Benjamin Bruce, Jane Lock, Rahul Sharma, Nancy J. Newman, Valerie Biousse, Amit Saindane P9.11-002 Differences in clinical characteristics of idiopathic benign paroxysmal positional vertigo according to the serum vitamin D status–Jae-Hwan Im, Jae-Myung Kim, Seung-Han Lee P9.11-003 Mal de Debarquement Syndrome and Anxiety–Jamie So, Jennifer L. Cox, Lixin Zhang P9.11-004 Radiographic Horizontal Conjugate Gaze Deviation in Acute Vestibular Syndrome–Shervin Badihian, Jorge C. Kattah, John Pula, David E. Newman-Toker P9.11-005 Acute Vertigo from a Unilateral Middle Cerebellar

170 2020 AAN Annual Meeting

0 Tuesday, April 28

12:00 p.m.–1:00 p.m.

Peduncle Demyelinating Lesion– Scott Grossman, Erica Hailey Parrotta, Catherine Cho, Stephen Krieger, Janet C. Rucker P9.11-006 Horizontal Aperiodic Alternating Nystagmus in Peripheral Vestibulopathy and Brainstem Lesion–Ji-Yun Park, Hyun Ah Kim, Kwang-Dong Choi P9.11-007 A Novel Case of CACNA1F Mutation Causing Congenital Nystagmus–Michael Doyle, Daniel G. Healy P9.11-008 Radiographic Horizontal Gaze Deviation in Stroke and Acute Peripheral Vestibulopathy: a Systematic Review–Shervin Badihian, Jorge C. Kattah, David E. Newman-Toker P9.11-009 Internuclear Ophthalmoplegia (INO) with Vertical Misalignment: Is it Skew or is it Trochlear Palsy?–Alexander Lewis, Junling Dong, Neel Fotedar, Alessandro Serra, Michael W. Devereaux P9.11-010 Saccadic Latencies in Progressive Supranuclear Palsy–Scott Grossman, Sayak Ghosh, Todd Hudson, John-Ross Rizzo, Janet C. Rucker P9.11-011 The Accuracy of Clinician Detection of Saccadic Slowing: A Corroboration with Eye Movement Recordings–Scott Grossman, Rachel Calix, Laura J. Balcer, Steven Galetta, Steven Frucht, John Ross Rizzo, Todd Hudson, Janet C. Rucker P9.11-012 Looking “cherry red spot myoclonus” in the eyes– Giulietta Riboldi, John Martone, John Ross Rizzo, Todd Hudson, Camilo Toro, Steven Frucht, Janet C. Rucker P9.11-013 Wall-Eyed Monocular Internuclear Ophthalmoplegia (WEMINO) and Millard-Gubler Syndromes in a Patient with Isolated Pontine Infarction: Topographic, Oculomotor, and Radiological Analysis of Two Very Uncommon Conditions.–Ricardo M. Ceballos-Lizarraga, Carlos Palomino-Diaz, Ángel RomeroFigueroa

= Research

POSTER SESSION 10

CME

0 Tuesday, April 28

5:30 p.m.–6:30 p.m.

Poster Session 10

Multiple Sclerosis: Symptom Assessment and Management

P10.1-010 The MSiDMT- a tablet based cognitive assessment tool for MS patients–Rod Middleton, Owen R. Pearson, Gillian Ingram, Lynne Watson, Hannah Wood, Christopher Roberts, Katherine Tuite-Dalton, Elaine Craig, Jeff Rodgers, David Ford, Richard St. John Nicholas P10.1-011 Group Cognitive Rehabilitation Therapy improves Cognitive Function in patients with Multiple Sclerosis–Hugo MarionMoffet, Julie Duval, Genevieve Morin, Emmanuelle Lapointe P10.1-012 Multiple Sclerosis Related Fatigue and Autonomic Dysfunction–Jason Tsun-Yin Poon, Leah Millsap, Preston Erickson, John W. Rose, Melissa M. Cortez P10.1-013 Screening Predictors of Psychological Reaction to Multiple Sclerosis Diagnosis–Jon Links, Tehila Eilam-Stock, Nabil Khan, Guadalupe Zuniga - Estrada, Tamar Bacon, Carrie Sammarco, Lisa Laing, Leigh Elkins Charvet P10.1-014 Correlations Between Four Common Measures of Cognition in Patients With Secondary Progressive Multiple Sclerosis–Ralph H. B. Benedict, Xiangyi Meng, Amit Bar-Or, Bruce A. C. Cree, Robert J. Fox, Patrick Vermersch, Wendy Su, Ludwig Kappos

P10.1-015 OCT Measures as Predictors of Cognitive Function in MS Using Artificial Intelligence– David Chaar, Mihir Kakara, Sara Razmjou, Evanthia Bernitsas P10.1-016 Validation Of Brief International Cognitive Assessment For Multiple Sclerosis In Tunisia– Saloua Mrabet, Amira Souissi, Amina Nasri, Wafa Ferchichi, Amina Gargouri, Ben Djebara Mouna, Imen Kacem, Riadh Gouider P10.1-017 Micro RNAs (miRNA) Disregulation in Multiple Sclerosis Related Cognitive Impairment; pilot study–Jesus F. Lovera, Deidre J. Devier, Yuhai Zhao, Vivian Jaber, Walter Lukiw P10.1-018 Single Digit Modality: What is a Clinically Significant Change in Multiple Sclerosis Patients–Francois H. Jacques, Adrian Schembri, Chantal Paquette P10.1-019 Psychiatric Comorbidities in Multiple Sclerosis among Different Racial and Ethnic Groups: A Nationwide Survey–Justin Eusebio, Carolina Ionete, Christopher Hemond, Idanis Berrios Morales, Raffaella Umeton, Daniela Arantxa Pimentel Maldonado

AAN.com/view/20AM 171

Tuesday, April 28

P10.1-001 Effect of Nabiximols Cannabinoid Oromucosal Spray on Spasticity and Muscle Strength in Patients with Multiple Sclerosis (MS) Across 3 Randomized Controlled Trials–Francois Bethoux, Kathryn Nichol, Joanne M. Wagner, Joris Berwaerts, Daniel Checketts, Karen Cartwright P10.1-002 Patterns of Cognitive and Physical Impairment In A Large, Heterogeneous MS Population: Results From MS PATHS–Tjalf Ziemssen, Mar Tinore, Carl DeMoor, Michael R Edwards, Elizabeth Fisher, Rachel Galioto, Carrie Michelle Hersh, Megan Hyland, Irene Koulinska, Marisa P. McGinley, Xavier Montalban, Ellen M. Mowry, Carlos Nos, Daniel Ontaneda, Stephen M. Rao, Mary R. Rensel, Lana Zhovtis Ryerson, Yujie Wang, James Rhys Williams, Kuangnan Xiong, Richard A. Rudick P10.1-003 Sex Differences in Cognitive Performance in Multiple Sclerosis–Tomas Uher, Manuela Vaneckova, Jan Krasensky, Jana Blahova Dusankova, Eva Havrdova, Dana Horakova

P10.1-004 Depression is Associated with Greater Declines in Cognition over time in MS–Ruth-Ann Marrie, Charles Bernstein, James Marriott, James Bolton, John David Fisk P10.1-005 Assessing sensorimotor and cognitive function in people with multiple sclerosis is feasible using robotics–Leif Simmatis, Stephen Scott, Moogeh Baharnoori P10.1-006 A Mindfulness group intervention in newly diagnosed persons with Multiple Sclerosis: a pilot study.–Sarah Anne Morrow, Nancy Vording, Jordan Ward, Heather Rosehart, Arlene MacDougall P10.1-007 Mild cognitive decline in people with relapsing-remitting multiple sclerosis: a major role of structural over functional brain alterations.–Riccardo Manca, Basil Sharrack, Annalena Venneri P10.1-008 Postprandial Somnolence in People with Multiple Sclerosis– Tatiana Christmas, Saul Reyes, Neena Singh, Kimberley AllenPhilbey, Gavin Giovannoni P10.1-009 eSupport and eFIT: Internet-based targeted behavioral interventions for persons with multiple sclerosis–Victoria Leavitt, Philip De Jager, Philip De Jager, Sharonna Bloom

POSTER SESSIONS

1. Multiple Sclerosis: Symptom Assessment and Management: 1-001 to 1-022 2. Autoimmune Neurology 7: 2-001 to 2-005 Autoimmune Neurology: Encephalitis 1: 2-006 to 2-011 3. Parkinson’s Disease Clinical Trials and Methodology 3: 3-001 to 3-009 Tools and Technology to Measure Parkinson’s Disease Symptoms 1: 3-010 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 2: 4-001 to 4-011 5. Neuroepidemiology 2: 5-001 to 5-009 6. Practice, Policy, and Ethics: Improving the Lives of Patients and Providers 2: 6-001 to 6-012 7. Inherited Muscle Disorders 2: 7-001 to 7-014 8. Aging and Dementia: Retina and Non-alzheimer Dementia 2: 8-001 to 8-010 9. Systemic Disease and Stroke, Unusual Stroke Etiologies, and Cerebral Venous Sinus Thrombosis 1: 9-001 to 9-021 10. Neurovirology 2: 10-001 to 10-012 NeuroHIV, Neurovirology, and Rare Bacteria 1: 10-013 to 10-018 11. Sports Neurology and Neuro Trauma 1: 11-001 to 11-012

POSTER SESSIONS

POSTER SESSION 10 P10.1-020 Multiple Sclerosis Related Pain with Magnetic Resonance Imaging Lesion Localization Correlation and Gender Differences: A Cohort Study–GyeongMo Sohn, Smathorn Thakolwiboon, Mirla L. Avila P10.1-021 Objective Measurement of Cognitive Impairment in Multiple Sclerosis Patients Using Novel Computerized Testing–Roberto Bomprezzi, Kerime Ararat, Kara M. Smith, Reina Benabou P10.1-022 A Prospective Observational Registry Study of Repository Corticotropin Injection for the Treatment of Multiple Sclerosis Relapse–Jeffrey Marc Kaplan, Tamara Miller, Matthew J. Baker, Bryan R. Due, Enxu Zhao Autoimmune Neurology 7

P10.2-001 A Rare Case of Autoimmune Encephalitis in a Patient After Treatment of Metastatic Melanoma with a Combination of Immune Checkpoint Inhibitors Nivolumab and Ipilimumab–Ramya Tadipatri, Fawaz Philip Tarzi P10.2-002 Sleep disorder, bulbar symptoms and abnormal eye saccades: a case report of antiIgLON5 antibody syndrome–Shameer Rafee, Niall Tubridy, Sean O’Riordan P10.2-003 Steroid Responsive Encephalopathy with Associated Thyroiditis Presenting with Acute Transient Aphasia–Ashley Weng, Pooja Santosh Raibagkar, Barbara Voetsch, Ritu Bagla P10.2-004 Acute Inflammatory Myelitis: a pragmatic approach– Micaela Hernandez, Mariano Marrodan, Alejandro Kohler, Jorge D. Correale P10.2-005 Rare Case of Myasthenia Gravis, Parkinsonism, and GAD-65 Antibody Associated Ataxia– Pranusha Pinna, Natalie P. Witek, Madhu Soni

Tuesday, April 28

Autoimmune Neurology: Encephalitis 1

P10.2-006 Brazilian autoimmune encephalitis network (BrAIN): preliminary results from a nationwide multicentric study–Fabio Fieni Toso, Rene De Araújo Gleizer, Bruna Dias, Maria Eduarda Slhessarenko, Alessandra Dellavance, Luiz Eduardo Andrade, Romana Hoeftberger, Orlando Graziani Povoas Barsottini, Livia Almeida Dutra Antonio

CME

P10.2-007 Autoimmune encephalitis timing and incidence: the Manitoba experience–Dung Hoang Nguyen, Cynthia Yang Xu, Marcus Ng P10.2-008 Anti-NMDA Receptor Encephalitis and Brain Volume Loss–Ann Oh, Frederick Bassal, Justin Hoffman, Matthew Harwood, Patricia Cornejo, Jeremy Hughes, Ram Narendra Narayan P10.2-009 REM Sleep Without Atonia and Sleep Disturbances in Patients with LGI1 and CASPR2 Autoimmunity–Michelle Devine, John Craig Feemster, Elizabeth Lieske, Stuart McCarter, David James Sandness, Tyler Steele, Bradley F. Boeve, Michael H. Silber, Andrew McKeon, Erik Kent St. Louis P10.2-010 Specific Psychiatric Features Identify Anti-NMDAR Encephalitis Before Neurological Deterioration–Nicola Warren, Cullen Mark O’Gorman, Andrew Swayne, Dan Siskind, Stefan Blum P10.2-011 Frequency and clinical significance of seronegative anti-NMDAR encephalitis–Mar Guasp, Yasmina Módena-Ouarzi, Thais Armangue, Josep O. Dalmau, Francesc R. Graus Parkinson’s Disease Clinical Trials and Methodology 3

P10.3-001 Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advance Parkinson’s Disease–Kalpana Merchant, Tanya Simuni, Brian Fiske, Christopher Coffey, Helen Matthews, Richard Wyse, Patrik Brundin, David K. Simon, Michael Schwarzschild, David Weiner, Jamie Lynn Adams, Charles Stanley Venuto, Laura Trusso, Liana Baker, Melissa Kostrzebski, Tina Ward, Gary Rafaloff P10.3-002 Modeling PD Progression in the PPMI Cohort: Implications for Clinical Trial Design–Christopher Coffey, Michael Brumm, Andrew D. Siderowf, Tanya Simuni, Douglas Galasko, Brit Mollenhauer, Lana Chahine, Vanessa Arnedo, Mark Frasier, Caroline M. Tanner, Kathleen Poston, Daniel Weintraub, Samantha J. Hutten, Karl D. Kieburtz, Kenneth L. Marek, Nichole Daegle P10.3-003 Validation of Fox Insight Cohort via Virtual Research Visits–Ruth Schneider, Taylor Myers, Margaret Daeschler, Christopher Tarolli, Jamie Lynn Adams, Richard

172 2020 AAN Annual Meeting

0 Tuesday, April 28 L. Barbano, Lindsey Riley, Ninad Amondikar, Peggy Auinger, Maria Cristina Gil Diaz, E. Ray Dorsey, Connie C. Marras, Caroline M. Tanner P10.3-004 Minority enrollment in Parkinson’s Disease clinical trials: meta-analysis and systematic review of studies evaluating treatment of neuropsychiatric symptoms.–Daniel Garbin Di Luca, Jacob Sambursky, Anthony Diaz, Joacir Graciolli Cordeiro, Danielle Spengler Shpiner, Jason H. Margolesky, Carlos Singer, Corneliu C. Luca P10.3-005 Achieving an optimal profile for immunotherapy of alpha-synucleinopathies: Rational generation of monoclonal antibodies selective for pathogenic forms of alpha-synuclein–Johanne M. Kaplan, Ebrima Gibbs, Beibei Zhao, Jing Wang, Clay Shyu, Steven S. Plotkin, Neil R. Cashman P10.3-006 Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment– Jessica Powell, Esther Rawner, Sakura Minami, Erin Newman, Bruce Morimoto, Jonas Hannestad P10.3-007 PPMI 2.O New Science/ New Cohorts - Transforming PPMI–Kenneth L. Marek, Andrew D. Siderowf, Karl D. Kieburtz, Christopher Coffey, Tatiana Foroud, Lana Chahine, Kathleen Poston, Brit Mollenhauer, Douglas Galasko, Vanessa Arnedo, Tanya Simuni, Caroline M. Tanner P10.3-008 Baseline Characteristics of Participants of the SPARK Trial, a Phase 2 Study of the anti-alphasynuclein antibody Cinpanemab (BIIB054) in Parkinson’s Disease–Tara Fox, Andrew D. Siderowf, Hubert H. Fernandez, Caroline M. Tanner, Ronald Postuma, David K. Simon, Michael Byrne, Anthony E. Lang, David J. Brooks, Olivier Rascol, Eduardo S. Tolosa, Werner Poewe, Fabrizio Stocchi, Brit Mollenhauer, Nir Giladi, Beth Hirschhorn, Jesse M. Cedarbaum, George Nomikos, Laura Fanning, Minhua Yang, Zhen Xiao, Miroslaw Brys P10.3-009 CVT-301 (Inhaled Levodopa) Utilization by Patients With Parkinson’s Disease (PD) in Clinical Studies–William G. Ondo, Marie-Helene Saint-Hilaire, Michael Klingler, Christopher Kenney

5:30 p.m.–6:30 p.m. Tools and Technology to Measure Parkinson’s Disease Symptoms 1

P10.3-010 Characterization of Idiopathic Parkinson’s Disease Subgroups Using Quantitative Gait Analysis and Corresponding Subregional Striatal Uptake Visualized Using 18F-FP-CIT Positron Emission Tomography–Seung Min Kim, Sangjoon Kang, Yeonjung Kim P10.3-011 Upper Extremity Motor Symptoms’ Severity Estimation with Ecologically Valid Data Arising from Smartphone Touchscreen–Sevasti Bostantjopoulou-Kambouroglou, Stelios Hadjidimitriou, Vasileios Charisis, Anastasia Ntracha, Ioannis Dagklis, Sevasti BostantjopoulouKambouroglou, Zoe Katsarou, Dhaval Trivedi, K Ray Chaudhuri, Lisa Klingelhoefer, Heinz Reichmann, Leontios Hadjileontiadis P10.3-012 Multi-Dimensional, Short-Timescale Tablet-Based Quantification of Movement Disorder Symptomatology–John Sanderson, James Yu, David Liu, Shane Lee, Peter Lauro, Umer Akbar, Anelyssa D’Abreu, Wael Asaad P10.3-013 Visualizing Cutaneous Phosphorylated alpha-Synuclein Improves Diagnostic Accuracy in Parkinson’s Disease–Todd D. Levine, Bailey Bellaire, Christopher H. Gibbons, Roy L. Freeman P10.3-014 Evaluation of Gastric Motility of Parkinson’s Disease Patients Based on a Novel Wearable Device and Time-Frequency Analysis–Vasileios Charisis, Stelios Hadjidimitriou, Dimitrios Iakovakis, Hugo Placido da Silva, Sevasti Bostantjopoulou-Kambouroglou, Zoe Katsarou, Leontios Hadjileontiadis P10.3-015 Dopaminergic Neuronal Imaging in Parkinson’s disease parkin mutation patients and potential pathophysiologic insights of simple heterozygous patients: A clinical DAT-SPECT study–Mario Sousa, Mario Sousa, Mario Sousa, Maria Rosario G. Almeida, Mario Sousa, Francisco Oliveira, Maria Rosario G. Almeida, Ana Sofia Morgadinho, Cristina Januario P10.3-016 Archimedes Spiral Drawing in Idiopathic Parkinson’s Disease Patients Showed More Variability in Jerkiness in Patients with Freezing of Gait–Lakshmi Pillai, Aliyah Glover, Hafsa Bareen Syeda, Tuhin Virmani = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number P10.3-017 Is the UPDRS a Reliable Tool for Detecting the Worse Side in Parkinson’s Disease?–Erin Smith, John M. Bertoni, Danish Bhatti, Diego Torres-Russotto Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 2

Practice, Policy, and Ethics: Improving the Lives of Patients and Providers 2

5 6

P10.5-001 Development of an algorithm to identify individuals with Neurofibromatosis type 1 within administrative data.–Carolina Barnett Tapia, Elisa Candido, Branson Chen, Patricia Parkin, Priscila Pequeno, Karen Tu P10.5-002 Reliability of a questionnaire on lifestyle prooxidant and antioxidant factors in a multicenter cross-sectional study on ALS–Aliona Cucovici, Andrei Ivashynka, Valeria Alexa, Vitalie Stelian Lisnic, Maurizio Leone P10.5-003 Burden of disease due to stroke and risk factors in Latin America: an analysis of the Global Burden Disease Study–Kevin Pacheco-Barrios, Stefano GianonniLuza, Ana Balbuena, Carlos Alva-Diaz P10.5-004 Genetic and epidemiological study of hereditary ataxia and spastic paraplegia in eastern Quebec–ikhlass HAJ SALEM, Francis Brunet, PierreOlivier Cote, ikhlass HAJ SALEM, Nicolas Dupre P10.5-005 High Education Better Protects Non-Hispanic than Hispanic Americans against Risk of Stroke: National Health Interview Survey–Golnoush Akhlaghipour, Mohsen Bazargan, Shervin Assari

P10.6-001 Shifting the Balance from Indirect to Direct Patient Care in a Non-Surgical Residency Training Program: a Comprehensive Needs Assessment Study in Neurology Residents–K. H. Vincent Lau, Lucia Ryll P10.6-002 Impact of the Patient Protection and Affordable Care Act on One-year Mortality Risk in Glioblastoma–Nuriel Moghavem, Debby Oh, Eduardo SantiagoRodriguez, Scarlett Lin Gomez, Reena Parada Thomas P10.6-003 The First Graduate Medical Education-led Quality and Safety Team in the Military at the Largest Health Care System in the United States–Erick Michael Roff, Steven M. McKnight, Virginia Baker, Nawaz Hack P10.6-004 Improving Utilization of ICU care: Development of ICH Admission Protocol at a Comprehensive Stroke Center– Parneet Kaur Grewal, Deborah Lynch, Anjali Asthana, Rhea Shrivastava, James Conners P10.6-005 Patient Characteristics Associated with Readmissions in Three Neurology Services at New York University Langone Health (NYULH)–Steven Paul Bondi, Dixon Yang, Leah Croll, Jose L. Torres

P10.6-006 Stress Management and Resiliency Training Decreases Stress and Burnout in Neurologists–Leah R. Hanson, Lauren Erickson, Aleta Svitak, Samantha Sherman, Jane Oh P10.6-007 Work-Life Factors, Attitudes, and Wellness Behaviors in Neurology Trainees–Hsien Lee Lau, Leticia Tornes, Teshamae Monteith P10.6-008 Acceptance of Telemedicine within an Academic Neurology Department–Meena R. Kannan, Nina J. Solenski P10.6-009 A novel method for facilitating concussion care in a large health system–Kate M. Essad P10.6-010 Providing an easily accessible online resource for physician wellness advocates– Crystal Jing Jing Yeo, Heidi B. Schwarz, Cormac A. O’Donovan, Neil A. Busis, Anindita Deb, Janice F. Wiesman, Suzanne Powell, Jennifer Rose Molano P10.6-011 Scope and Adequacy or Disclosure of Conflicts of Interest Between Academic Neurologists and Industry–Jade Smith, Charlotte Wahle, Nathaniel Michael Robbins P10.6-012 Improving Stroke Response and Education at the Southern Arizona Veterans Affairs Health Care System (SAVAHCS)– Veronika Solnicky, Katalin Scherer, Sanchari Datta, Jaehyun Kim, Jennifer Tay, Tanya Lin Inherited Muscle Disorders 2

P10.7-001 Factors that Influence Progression of Respiratory Dysfunction in Myotonic Dystrophy Type 1–Leigh Hartog, William D. Arnold, Samantha Jo LoRusso P10.7-002 Mechanism of Disease in Novel Dominant Skeletal and Cardioskelatal Titinopathies– Jennifer A. Roggenbuck, Johan Lindquist, Kelly Rich, Zaynab Hourani, William D. Arnold, Henk Granzier P10.7-003 CLIA laboratory genetic testing of facioscapulohumeral muscular dystrophy: a retrospective analysis.–Autumn Rieken, Aaron Bossler, Katherine D. Mathews, Steven A. Moore P10.7-004 Duchenne Muscular Dystrophy (DMD) and Vitamin D deficiency–Tyler Tribble, Raj Razdan, Saila Upadhyayula, Karen Loechner, Sumit Verma

AAN.com/view/20AM 173

Tuesday, April 28

Neuroepidemiology 2

P10.5-006 Benchmarking Performance on Administration of Dexamethasone for Bacterial Meningitis–Shefali Dujari, Santosh Gummidipundi, Zihuai He, Carl Aaron Gold P10.5-007 Physical Activity and early onset amyotrophic lateral sclerosis (ALS), Data from the National ALS Registry: 2010 – 2018–Jaime Raymond MPH, Paul Mehta, Theodore Larson, D. Kevin Horton P10.5-008 Associations Between Outpatient Neurology Dementia Care and Healthcare Utilization– Shaun Ajinkya, Nicholas Milano P10.5-009 Challenges and Limitations of Ascertaining Amyotrophic Lateral Sclerosis (ALS) Cases in the United States–Paul Mehta, Bryn Davis, Jaime Raymond MPH, Theodore Larson, D. Kevin Horton

POSTER SESSIONS

P10.4-001 Relative bioavailability, pharmacokinetic and food effect assessment of two immediaterelease formulations of the NaV1.6-selective sodium channel blocker XEN901: Pediatric Granules and Adult Tablets–Rostam Namdari, Gregory N. Beatch, Jay A Cadieux, Ernesto Aycardi P10.4-002 Assessment of Potential Pharmacokinetic and Pharmacodynamic Interactions between XEN901 (a Novel NaV1.6 Selective Sodium Channel Blocker) and Phenytoin (a non-selective NaV Blocker) in Adult Healthy Subjects– Rostam Namdari, Gregory N. Beatch, Jay A Cadieux, Ernesto Aycardi P10.4-003 A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Two Formulations of a Novel Nav1.6 Sodium Channnel Blocker (XEN901) in Healthy Adult Subjects.–Gregory N. Beatch, Rostam Namdari, Jay A Cadieux, Heather Kato, Ernesto Aycardi P10.4-004 Behavioral Complications from Levetiracetam in the Epilepsy Monitoring Unit–Angela Parsons, Amy Z. Crepeau P10.4-005 A comparative analysis of licensing and reimbursement of anti-epileptic drugs in Canada and Australia–Joshua Tam, Christian Gericke P10.4-006 Efficacy of clobazam as an add-on therapy in brain tumorrelated epilepsy.–Nupur Brahmbhatt, Jessica Warady Templer P10.4-007 Initial Data From the Ongoing ENDYMION Open-label Extension Trial of Soticlestat (TAK935/OV935) in Participants With Developmental and/or Epileptic Encephalopathies (DEE)–Jonathan J. Halford, Dimitrios Arkilo, Mahnaz Asgharnejad, Celia Zinger, Shijie Chen, Matthew During, Jacqueline French P10.4-008 A Phase 1b/2a Study of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Adults With Developmental and/or Epileptic

Encephalopathies (DEE)–Jonathan J. Halford, Michael R. Sperling, Dimitrios Arkilo, Mahnaz Asgharnejad, Celia Zinger, Rengyi Xu, Matthew During, Jacqueline French P10.4-009 Post Hoc Analysis of Rufinamide Study 022: Adverse Events in Titration vs Maintenance Periods in Patients with LennoxGastaut Syndrome–Auvin Stephane, Carlos Perdomo, Manoj Malhotra P10.4-010 Efficacy, Safety and Need for Dosing Change of Zonisamide During Pregnancy in Women with Epilepsy–Paige Sutton, Meriem K. Bensalem Owen, Sally Valentina Mathias P10.4-011 Pooled Post Hoc Analysis of Treatment-Emergent Adverse Events (TEAEs) by Treatment Period in Patients Aged =12 to–Sanjeev V. Kothare, Jay Salpekar, Anna Patten, Manoj Malhotra, Kimford J. Meador

Tuesday, April 28

POSTER SESSIONS

POSTER SESSION 10 P10.7-005 Abnormal Gyrification in Brain of early onset Myotonic Dystrophy patients–Elena Pinzan, Luca Weis, Corrado Angelini P10.7-006 Scapuloperoneal Myopathy and Cardiomyopathy with a Novel MYH7 Mutation: A Case Report–Sara Jasmin Hooshmand, Raghav Govindarajan P10.7-007 BAG3 Myopathy in Patient with Prominent Neuropathic Phenotype and no Cardiac or Respiratory Involvement–Lindsay Marie Malatesta, Aravindhan Veerapandiyan, Kapil Arya, Murat Gokden, Vikki Stefans P10.7-008 Distinctive pathological features of inherited and sporadic late-onset nemaline myopathies– Stefan Nicolau, Aneesha Dasgupta, Duygu Selcen, Andrew G. Engel, Jason Doles, Margherita Milone P10.7-009 Second Report of Dominantly Inherited Distal Myopathy Caused by Large Deletion in the Nebulin Gene–Franclo Henning, Clair Engelbrecht, Stefan Dan Zaharie, Hannah White, Thomas L. Winder P10.7-010 Two patients with phosphaturic neuromuscular presentations–Rahul Dilip Abhyankar, Chunyu Cai, Helena Hwang, Jeffrey L. Elliott, Jaya Raghav Trivedi P10.7-011 Pathophysiology, Diagnosis and Management of Primary Periodic Paralysis: Identification of Gaps in Knowledge and Competence Among Neurologists–Deborah Susulka, Thomas Finnegan, Pakinam Aboulsaoud, Stephen C. Cannon P10.7-012 A novel heterozygous mutation in the C-terminal region of HSPB8 leads to limb-girdle rimmed vacuolar myopathy–Stefan Nicolau, Teerin Liewluck, Jeffrey L. Elliott, Andrew G. Engel, Margherita Milone P10.7-013 An In-Home Study of Facioscapulohumeral Muscular Dystrophy (FSHD) Patients using Contactless Wireless Sensing and Machine Learning–Zachary Kabelac, Hariharan Rahul, Rumen Hristov, Vicky Chan, Maya Hatch, Jay Han, Diego Cadavid, Aaron Chang, Dina Katabi P10.7-014 Clinical ,microRNAs,Morphological clues in LGMD D2 (TNPO3-related )Disease Progression.–Valentina Pegoraro, Corrado Angelini, Roberta Marozzo

CME

Aging and Dementia: Retina and Non-alzheimer Dementia 2

P10.8-001 Brain Functional Connectivity Disruption in a Large Cohort of Patients with Primary Progressive Aphasia–Federica Agosta, Elisa Canu, Michela Leocadi, Davide Calderaro, Giuseppe Magnani, Paola Caroppo, Sara Prioni, Tremolizzo Lucio, Ildebrando H. Appollonio, Vincenzo Silani, Vladimir S. Kostic, Paola Valsasina, Massimo Filippi P10.8-002 Flortaucipir and Neuroinflammation PET in Semantic Dementia–Joseph C. Masdeu, Belen Pascual, Neha Pal, Elijah Rockers, Quentin Funk, Meixiang Yu, Paul E. Schulz, Gustavo C. Roman, Paolo Zanotti Fregonara P10.8-003 The Role of Alzheimer’s Pathology in Frontotemporal Lobar Degeneration: Resting-State Functional Connectivity Analysis of the Default Mode Network–Emily Snook, Namita Multani, Foad Taghdiri, Cassandra Anor, Anna Vasilevskaya, Brenda Varriano, Karen Misquitta, David F. Tang-Wai, Carmela Tartaglia P10.8-004 Diagnostic Utility of Volumetric Brain MRI Quantification for Distinguishing Frontotemporal Dementia from Alzheimer’s Disease–Somayeh Meysami, Cyrus A. Raji, Mario F. Mendez P10.8-005 A Comparison of Automated and ManuallySegmented White Matter Lesions in Primary Progressive Aphasia– Sachin Patel, Erin Meier, Andreia Vasconcellos Faria, Argye E. Hillis P10.8-006 The Effect of Social and Leisure Activity Engagement on Cortical Thickness in bvFTD–Nikolas Kinney, Jessica Bove, Jeffrey Scott Phillips, Daniel Wakeman, Corey McMillan, Lauren M. Massimo P10.8-007 [18F]THK-5351 PET Imaging Distinctively Demonstrates Neurodegenerative Changes in Progressive Supranuclear Palsy Concomitant with Cerebellar Ataxia Patient and Amyotrophic Lateral Sclerosis Patient; Case Reports–Yuji Saitoh, Taiji Mukai, Asami Tasaki, Etsuko Imabayashi, Kanako Komatsu, Yuko Saito, Hiroshi Matsuda, Yuji Takahashi P10.8-008 Association of Serum Homocysteine Level with White Matter Microstructural Integrity in a

174 2020 AAN Annual Meeting

0 Tuesday, April 28 Non-demented Elderly Population– Mei-Jun Shu, Fei-Fei Zhai, Fei Han, Lixin Zhou, Jun Ni, Ming Yao, ShuYang Zhang, Zheng-Yu Jin, Li-Ying Cui, Yi-Cheng Zhu P10.8-009 Transcranial Cerebral Blood Flow differences in Alzheimer’s Dementia and Vascular Dementia– Joby Thomas Mammen, Lakshmi N. Ranganathan, Jawahar Marimuthu P10.8-010 Irregular Diurnal Rhythmicity and Cerebrovascular Pathology in Older Adults–Rosa Sommer, Lei Yu, Julie A. Schneider, David A. Bennett, Aron S. Buchman, Andrew Lim Systemic Disease and Stroke, Unusual Stroke Etiologies, and Cerebral Venous Sinus Thrombosis 1

P10.9-001 Deep cerebral venous thrombosis: A meta-summary of different treatments–Zhi Xuan Quak, Priscilla Lye, Benjamin Yong Qiang Tan, Cunli Yang, Raymond CS Seet, Stella Tsermentseli, Anil Gopinathan, Leonard Leonard Yeo P10.9-002 Safety of Pregnancy After Cerebral Venous Thrombosis: Results From a National Comprehensive Hospital–Yating Wu, Lixin Zhou, Ming Yao, Yicheng Zhu, Jun Ni, Liying Cui, Bin Peng P10.9-003 Cerebral Venous Thrombosis in Argentina: Clinical Characteristics, Epidemiology, Prognosis and Treatment–Miguel A. Saucedo, Fabio Gonzalez, Marta Bala, Lucrecia Bandeo, Anibal Chertcoff, Marcela Uribe Roca, Pablo Bonardo, Oscar Martinez, Luciana Vanesa Leon Cejas, Maria Sol Pacha, Ricardo C. Reisin P10.9-004 Prescription of Direct Oral Anticoagulants following Cerebral Venous Sinus Thrombosis–Mariyam Humayun, Barrie Schmitt, Maheen Humayun, Sana Somani, Chen Lin, Toby I. Gropen, Ekaterina Bakradze, Michael J. Lyerly P10.9-005 Difference of cerebral flows in uremia as a cause of encephalopathy. Follow-up by Transcranial Doppler–Leticia Alejandra Olguín-Ramírez, Dali Hernandez-Guajardo, Joan Stephanie Celis Jasso, Jose Franco-Garcia, Denisse G Martinez Roque, Horacio Chapa-Martinez, Beatriz Chávez, Fernando Gongora P10.9-006 Giant Cell Arteritis Presenting with Lingual Artery

5:30 p.m.–6:30 p.m. Infarction–Andres De Leon Benedetti, Luis F. Torres, Sishir Mannava, Jason H. Margolesky P10.9-007 Hyponatremia as an independent predictor of mortality and functional outcome in stroke– Maliha Hakim, Mashfiqul Hasan P10.9-008 Frequency and Predictors of Cancer After an Ischemic Stroke: A Systematic Review and MetaAnalysis–Bastien Rioux, Lahoud Touma, Ahmad Nehme, Genevieve Gore, Laura C. Gioia, Mark Robert Keezer P10.9-009 Underlying Infection is Probably Linked to an Increased Risk of Intrathecal Methotrexate Induced Leukoencephalopathy Mimicking Ischemic Stroke: A Case Series– Maya Hrachova, David Jordan Adams, Xiao-Tang Kong P10.9-010 Clinical Features of Headaches in Ischemic Stroke. A Mexican Series.–Alejandro R. MarfilRivera, Juan Fernando Gongora Rivera, Luis Fernández, Mario Cristobal Nino, Aldo Garcia-Heredia P10.9-011 Amyloid-Beta Related Angiitis of the Central Nervous System: A Case series–Julianne Hall, Nicholas D. Osteraas, Rima Dafer P10.9-012 Multifocal intracranial stenosis associated with Nilotinib– Bhavika Kakadia, Richa Thakkar, Tudor G. Jovin, Ryna Then P10.9-013 Rare Case of Diffuse Cerebral Microhemorrhages from Methotrexate Toxicity in Patient with Acute Lymphoblastic Leukemia– Veronika Solnicky, Chelsea S. Kidwell P10.9-014 Reversal of Serotonergic Induced Vasospasm with Cyproheptadine: A Case ReportTo report a case of cyproheptadine used to reverse vasospasm precipitated by Imitrex in a patient with Reversible Cerebral Vasospasm Syndrome (RCVS).–Jennifer Chima, Tracey Huijun Fan, Christopher R. Newey P10.9-015 Posterior Sternoclavicular Subluxation - A Rare Mechanism of Stroke–Leighton Mohl, Christopher Streib, Ryan Cusic P10.9-016 Association Between Spontaneous Cervical Artery Dissection and Changes in Barometric Pressure–Ilana Green, Debra Owens, Phillip Stenger, Bradford B. Worrall, Andrew Mebane Southerland P10.9-017 Re-Thinking the ‘Posterior’ in Posterior Reversible = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Neurovirology 2

NeuroHIV, Neurovirology, and Rare Bacteria 1

P10.10-013 Association of Insomnia and Antiretroviral Treatment in a cohort of HIV-seropositive Women– Ernesto Borrero-Quintana, Raissa Menendez, Miriam Matos, Yisel Cantres, Elaine Rodriguez, Estefania Medina, Yamil Gerena, Valerie Wonja P10.10-014 Progressive Multifocal Leukoencephalopathy Associated with Idiopathic CD4+ Lymphocytopenia in a Patient with Heterozygous STAT4 Mutation–Ayse Nur Ozdag Acarli, Can Tuzer, Tuncay Gunduz, Rashad Ismayilov, Erhan Pariltay, Asude Alpman, Ayca Aykut, Semra Demir, Figen Soylemezoglu, Murat Kurtuncu, Mefkure Eraksoy

P10.10-015 HIV-Associated Neurocognitive Disorders at Moi Teaching and Referral Hospital, Eldoret, Kenya.–Amina Mohamed, Daniel Kinyanjui, Chrispine Oduor P10.10-016 Long term survival and 9-year follow-up of 14 HIV-infected adults with Progressive Multifocal Leucoencephalopathy–Mahmoud A. AbdelRazek, Golnaz Yadollahikhales, Rabab Elsadek, Aya A. Ouf, Nagagopal Venna P10.10-017 Effect of teriflunomide on JCPyV infection in primary astrocytes and choroid plexus epithelial cells–Walter J Atwood, Timothy J Turner, Jeffrey Chavin, Ben Guikema, Bethany A O’Hara P10.10-018 Reversible Small Vessel Vasculitis and Encephalitis in the Context of Anti-Retroviral Resistance: A Manifestation of Central Nervous System HIV Escape– Ryan Thomas Muir, Suradech Suthiphosuwan, Aditya Bharatha, Amy Lin, David G. Munoz, Mario Ostrowski, Raphael Schneider Sports Neurology and Neuro Trauma 1

P10.11-001 Mild Traumatic Brain Injury and Neuropsychiatric Sequelae in the Pediatric Population–Pavan Patel, Khaled Abdalla, Maryamnaz Hosseinzadeh Zaribaf, Max Shmidheiser P10.11-002 A Supervised Exercise Challenge Detects Dizziness More Frequently Than Symptom Reporting and Vestibular/Ocular-Motor Screening in Adolescent Concussion Patients–Michael Popovich, Andrew R. Sas, Andrea Almeida, Jeremiah Freeman, Bara Alsalaheen, Matthew T. Lorincz, James T. Eckner P10.11-003 The prevalence of concentration deficits in pediatric concussion patients–Avy Ronay P10.11-004 Baseline Concussion Symptom Score Differences Comparing Collision, Contact, and Noncontact Sports and Comparison of Between Sexes–Andrew R. Sas, Chelsea Herbert, Michael Popovich, Melvin Darwin, Andrea Almeida, Matthew T. Lorincz P10.11-005 Orthostatic Vitals as a Diagnostic Tool for Sport-Related Concussion–Andrew R. Sas, Aleah Gillenkirk, Michael Popovich, Andrea Almeida, James T. Eckner, Ingrid Ichesco, John Grant, Matthew T. Lorincz

P10.11-006 Reflex syncope as cause and effect of concussion related dysautonomia in a collegiate athlete–Paige Buddenhagen, Kate M. Essad P10.11-007 The 5 Modifying Factors of Concussion–Said Shukri, Michael Lillis, Dilpreet Kaur, Rebecca Alexandra Burgos, Patrick Eugeni, Brianna Albert, Jennifer McVige P10.11-008 Effects of Pre-Accident History of Migraine on Acute Concussion Symptoms and Recovery: The Toronto Concussion Study–Laura Langer, Mark Bayley, David Lawrence, Paul Comper, Tharshini Chandra, Evan Foster, Jonathan P. Gladstone P10.11-009 Convergence Insufficiency in the Division I Athlete–Nicholas Samuel Streicher P10.11-010 Association of MULES performance and S3SE Symptom Domains in College Students–Hunaid Hasan, Charles C Moreno, George N. Ansoanuur, Zachary Houck, Russell M. Bauer, James Clugston P10.11-011 Precision-Medicine in Post-Concussion Syndrome by Relating Subject Specific StructuralFunctional Connectomes and Neuropsychological Measures– Melisa Gumus, Michael Mack, Robin Green, Mozghan Khodadadi, Richard Wennberg, David J. Mikulis, Brenda Colella, Apameh Tarazi, Adrian P. Crawley, Ruma Goswami, Ahmed Ebraheem, Charles Tator, Carmela Tartaglia P10.11-012 Utility of Automated Pipeline for Assessment of Regional Brain Volumes in Chronic Traumatic Brain Injury (TBI)–Emily Xu, Andrew Gene Kim, Lisa Kjonigsen, Sebastian Magda, James Joseph Rock, Kodiak Carb, Megan Teresa Moyer, Danielle Sandsmark, Ramon R. Diaz-Arrastia

Tuesday, April 28

P10.10-001 Opsoclonus-myoclonus Syndrome associated with West Nile Encephalitis–Neisha Patel, Arpan Patel, Alanna Mary Rose Balbi, Ritesh Ramdhani P10.10-002 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) and Transverse Myelitis: A Tale of West Nile Virus Infection–Jaspreet Johal, Ramiro Gabriel Castro Apolo, Abinayaa Purushothaman Ravichandran, Keithan Sivakumar, Shweta Varade, Alison L. Walsh P10.10-003 What’s hiding in the hair? – An Unusual Case of Ascending Paralysis.–Prashant Natteru, Zachary Goodwin, Saurabh G. Shukla, Hartmut Uschmann P10.10-004 Herpes Simplex Virus-1 Encephalitis Mimicking an Acute Stroke–Benjamin Ted Alwood, Usaamah Mahmood Khan P10.10-005 A Case of Hemorrhagic Encephalitis due to Powassan Virus in Pennsylvania–Hunter Ryan Hewitt, Shweta Varade, Dmitry Khaitov, Preet M. Varade P10.10-006 Powassan Virus: A Diverse Appearing Encephalitis–

Christopher Bentley Traner, Firas Kaddouh, Guido Jose Falcone P10.10-007 Chikungunya Virus Meningoencephalitis: A Case Report–Gabriela Accioly Lopes, Daiane Botelho, Gabriela de Souza, Caroline Bittar Braune, Raphael Breder, Camila Pupe, Thiago Pinheiro, Ana Maria Fillipis P10.10-008 Rapidly progressive dementia and Zika virus infection– Osvaldo J M Nascimento, Lucas Masiêro Araujo, Felipe Araujo Rocha, Ana Maria Bispo, Ivan Da Silva P10.10-009 Neuroinfectious Disease Inquiries within the Emerging Infections Network: Prevalence and Characteristics–Elizabeth Matthews, Luisa Diaz-Arias, Susan E Beekman, Philip Polgreen, Greer Waldrop, Vivian Yang, Kathryn Rimmer, Arun Venkatesan, Kiran Thakur P10.10-010 Varicella-Zoster Virus-associated Longitudinally Extensive Transverse Myelitis in an immunocompetent adult: An unusual and rare complication of Herpes Zoster.–Daniel Alejandro Crespo, Amrita Amanda Vuppala, David Semerad, John M. Bertoni P10.10-011 A presentation of disseminated VZV causing polyneuritis cranialis without clinical evidence of meningoencephalitis in an immunocompromised patient– Jessica Bloomfield, Michelle Bravo, Alexa Cohen, Anila Thomas P10.10-012 Neurosyphilis and VZV Encephalitis Coinfection Presenting as a Stroke Mimic–Christopher Trent Brewer, Reza Bavarsad Shahripour, Talal Aboud

POSTER SESSIONS

Encephalopathy Syndrome: A Single Center Chart Review of 95 Patients–Molly Bates, Kyle Darpel, Jessica Doyle Lee P10.9-018 Atrio-Esophageal Fistula Associated with Stroke: 2 Case Reports Of Rare But Fatal Complication–Ghada Ashraf Ahmed Mahmoud Mohamed, Hassan Osama Mostafa Aboul Nour, Panayiotis N. Varelas P10.9-019 Magnetic Resonance Vessel Wall Imaging in Central Nervous System Vasculitides: a Case-Series–Matthew Padrick, Marcel Maya, Shlee S. Song, Kyle Ogami, Nicholas Szumski, Zhaoyang Fan, Oana Maria Dumitrascu P10.9-020 Serial Vessel Wall Enhancement Change on HighResolution MRI Vessel Wall Imaging in Primary Angiitis of the Central Nervous System.–Takashi Shimoyama, Ken Uchino, Leonard Calabrese, Rula Hajj-Ali P10.9-021 Prevalence And Associations of Ischemic Stroke with Pulmonary Arteriovenous Fistulas–Ninad Desai, Karan Kaushik Topiwala, Karan Tarasaria, Mubashir Pervez

AAN.com/view/20AM 175

POSTER SESSION 11

CME

0 Wednesday, April 29 8:00 a.m.–9:00 a.m.

Wednesday, April 29

POSTER SESSIONS

Poster Session 11 1. Multiple Sclerosis Special Populations: Pregnancy and Pediatrics: 1-001 to 1-014 Multiple Sclerosis: Clinical Practice and Decision-making 1: 1-015 to 1-021 2. Autoimmune Neurology: Encephalitis 2: 2-001 to 2-012 3. Tools and Technology to Measure Parkinson’s Disease Symptoms 2: 3-001 to 3-009 Motor and Non-motor Features of Parkinson’s Disease 1: 3-010 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 3: 4-001 to 4-002 Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/Neurostimulation and Diet Therapies 1: 4-003 to 4-012 5. Improving Delivery of Care and Novel Treatments for Pain and Palliative Patients 1: 5-001 to 5-012 6. Headache: Migraine 1: 6-001 to 6-012 7. Inherited Muscle Disorders 3: 7-001 to 7-008 Peripheral Neuropathy 1: 7-009 to 7-015 8. Aging and Dementia: Retina and Non-alzheimer Dementia 3: 8-001 to 8-010 9. Systemic Disease and Stroke, Unusual Stroke Etiologies, and Cerebral Venous Sinus Thrombosis 2: 9-001 to 9-021 10. NeuroHIV, Neurovirology, and Rare Bacteria 2: 10-001 to 10-014 Fungi, Parasites, and Spirochetes 1: 10-015 to 10-018 11. Sports Neurology and Neuro Trauma 2: 11-001 to 11-013 Multiple Sclerosis Special Populations: Pregnancy and Pediatrics

P11.1-001 Menarche and Relapses in Girls with Pediatric Multiple Sclerosis–Kristen M. Krysko, Michael Waltz, Tanuja Chitnis, Bianca Weinstock-Guttman, Gregory S. Aaen, Leslie A. Benson, Yolanda C. Harris, Lauren B. Krupp, Timothy E. Lotze, Soe Soe Mar, Jayne Ness, Mary R. Rensel, Moses Rodriguez, John W. Rose, Alice Rutatangwa, Teri Schreiner, Emmanuelle Waubant, Theron Charles Casper, Jennifer Graves P11.1-002 The Clinical Spectrum of Non-Traumatic Myelopathies in Childhood: 10 Years’ experience at a specialized center–Maria Alejandra Garcia-Dominguez, Eliza M. Gordon-Lipkin, Laura S. Munoz-Arcos, Sergio Gomez, Olwen Murphy, Carlos A. Pardo-Villamizar P11.1-003 A Retrospective Chart Review of the Safety and Tolerability in Ocrelizumab in Pediatric and Young-Adult Onset Multiple Sclerosis–Carolyn Goldschmidt, Mary R. Rensel, Kedar Mahajan, Moein Amin P11.1-004 Pregnancy of MS patients treated with cladribine

tablets–Kerstin Hellwig, Sandra Thiel, Andrea Ines Ciplea, Andrew Galazka, Axel Nolting, Michael Huebschen P11.1-005 Effects of Disease Modifying Therapy (DMT) Exposure on infant birth weight and birth length: Interim Data from Prospective PREG-MS Cohort.–Maria K. Houtchens, Maria Claudia Manieri, Tatenda Mahlanza, Eric Klawiter, Andrew Solomon, Ellen S. Lathi, Carolina Ionete, Idanis Berrios Morales, Christopher Severson, James M. Stankiewicz, Ann C. Cabot, Joshua D. Katz, Dessa Sadovnick, Claudia J. Chaves, Shamik Bhattacharyya, Dorlan J. Kimbrough, Ursela Baber, Biljana Beretich, Syed Rizvi, Salvatore Napoli, Tanuja Chitnis, Tarun Singhal, Tamara B. Kaplan, Maria K. Houtchens P11.1-006 A new activation assay reveals abnormal myelin and EBV antigen-reactivities superimposed on abnormal ‘autoactivation’ in pediatric multiple sclerosis–Ina Mexhitaj, Rui Li, Julia O’Mahony, Brenda Banwell, Amit Bar-Or P11.1-007 Paediatric Primary Progressive Multiple Sclerosis: fact or fiction?–Yael Hacohen, Omar Abdel-Mannan, Rosa

176 2020 AAN Annual Meeting

Cortese, Evange Wassmer, Cheryl Hemingway, Alan J. Thompson, Wallace Brownlee, Olga Ciccarelli P11.1-008 Pregnancy and obstetrical outcomes in women with RRMS–Irene Gomez Estevez, Judit Diaz-Diaz, Ines Gonzalez Suarez, Monica Luque Alarcon, Elena Miñano-Guillamón, Celia Oreja Guevara P11.1-009 Rituximab and Pregnancy in Neuroimmunological Disorders: A Retrospective Study– Lily Ge, Ilya Kister, Robert William Charlson, Jonathan Howard, Lauren B. Krupp, Lana Zhovtis Ryerson P11.1-010 Gender Identity and Sexual Orientation Affect Healthcare Satisfaction, but not Utilization, in Persons with Multiple Sclerosis–Shahin Khayambashi, Amber Salter, Tuula Tyry, Gary Raymond Cutter, Robert J. Fox, Ruth-Ann Marrie P11.1-011 Differences by Sex in the Workup of Children at High Risk for Multiple Sclerosis–Naila Makhani, Christine LebrunFrenay, Aksel Siva, Evangeline Wassmer, Sona Narula, Soe Soe Mar, Jonathan Santoro, Nusrat Ahsan, Silvia Tenembaum, James Nick Brenton, Philippe Cabre,

Clarisse Carra-Dalliere, Jonathan Ciron, Jerome De Seze, Kumaran Deiva, Francoise Durand Dubief, Matilde Inglese, Megan M. Langille, Guillaume Mathey, Rinze F Neuteboom, Filipe Palavra, Jean Pelletier, Daniela Pohl, Daniel Reich, Juan Ignacio Rojas, Veronika Shabanova, Eugene Shapiro, Robert Ian Thompson-Stone, Eric Thouvenot, Mar Tinore, Ugur Uygunoglu, Wendy Sulina Vargas, Sunita Venkateswaran, Helene Verhelst, Patrick Vermersch, Christina Azevedo, Orhun H. Kantarci, Darin T. Okuda, Daniel Pelletier, Naila Makhani, Naila Makhani, Naila Makhani, Pediatric Radiologic Consortium (PARIS) P11.1-012 Anterior and Posterior Visual Pathway Injury in Pediatric-Onset Multiple Sclerosis as Measured by Visual Evoked Potentials and Magnetoencephalography–John Rainer Sollee, Ritobrato Datta, Amy Lavery, Geraldine Liu, Brenda Banwell, William Gaetz, Amy T. Waldman P11.1-013 Prevalence of Serious Adverse Pregnancy Outcomes After Exposure to Interferon Beta Before or During Pregnancy: Stratification by Characteristics of Pregnant = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Multiple Sclerosis: Clinical Practice and Decision-making 1

Autoimmune Neurology: Encephalitis 2

P11.2-001 Longitudinal Changes in Driving Behavior Following Antibody-Mediated Encephalitis– Gregory S. Day, Ganesh Babulal, Ganesh Rajasekar, Sarah Stout, Catherine M. Roe P11.2-002 Electroencephalographic (EEG) Findings in N-Methyl-D-Aspartase (NMDA) Encephalitis–Dustin M. Anderson, Nabeela Nathoo, Jeffrey Dennis Jirsch P11.2-003 Autoimmune Dementia – A Prospective Hospital-Based Study From A Tertiary Care Center In North India–Suman Kushwaha, Aldrin Anthony, Siddharth Dr P11.2-004 DPPX autoimmune encephalitis presenting with chronic diarrhea, multidirectional nystagmus, opsoclonus and prominent hyperekplexia–Karissa Arca, Amir Abdallah, David Gritsch, Benzion Blech, Andrew McKeon, Jonathan L. Carter P11.2-005 A challenging case of rapidly progressive dementia: cryptococcal meningitis patient with co-existing positive antiNMDA receptor antibody in CSF–Kyle Matthew Hodges, Diaa Hamouda, Ruiqing Sun, Xianping Li P11.2-006 Generalised Epileptiform Activity in Anti-Glycine Receptor Antibody Autoimmune Limbic Encephalitis–Reuben Beer, Gaurav Singh, Stefan Blum, Arman Sabet P11.2-007 Zic4 Antibody Positive Autoimmune Encephalitis Responding to Rituximab After Failing First Line Therapies: A Case Report–Mays Alani, Fabian H. Rossi, Michael Hoffmann, Lourdes Benes-Cases, Umesh K. Sharma, Nina Tsakadze

P11.2-008 Autoantibody Prevalence in Cerebrospinal Fluid in Autoimmune Encephalitis and Related Disorders: The Need for a More Targeted Screening Approach–Thomas Haven, Joshua M Klonoski, Lisa Kay Peterson P11.2-009 Antibody screening using a tissue-based assay facilitates prompt induction of immunotherapy for autoimmune encephalitis–Makoto Hara, Hideto Nakajima, Satoshi Hirose, Tomotaka Mizoguchi, Takayoshi Akimoto, Yuki Yokota, Masaki Ishihara, Akihiko Morita, Katsuhiko Ogawa, Satoshi Kamei P11.2-010 Integration of an Evidence-Based Algorithm for Inpatient Autoimmune and Paraneoplastic Neurologic Syndrome Autoantibody Panel Ordering Practice to Improve Diagnostic Evaluation Quality– Anita M. Fletcher, Cierra Sharp, Michael Sweeney P11.2-011 Endophenotypes of Non-Paraneoplastic Limbic Encephalitis in Childhood and Possible Underlying Immune Deficiencies/Dysregulations: A Case Series and Literature Review–Abdulla Alawadhi, Nagwa Wilson, Reza Alizadehfar, Guillaume Sebire P11.2-012 Autoimmune Glial Fibrillary Acidic Protein (GFAP) Astrocytopathy Resulting in Treatment-refractory Flaccid Paralysis–Juan Pablo Pauta Martinez, Unsong Oh Tools and Technology to Measure Parkinson’s Disease Symptoms 2

P11.3-001 Detecting Bradykinesia in Early Morning Off: A Large Database Study using the Personal KinetiGraph® (PKG®)–Stuart H. Isaacson, Rajesh Pahwa, Eric J. Pappert, Diego Torres-Russotto P11.3-002 Objective Markers of Finger Tapping in Idiopathic Parkinson’s Disease with Freezing of Gait–Hafsa Bareen Syeda, Lakshmi Pillai, Aliyah Glover, Aaron Kemp, Horace Spencer, Mitesh P. Lotia, Linda Larson-Prior, Tuhin Virmani P11.3-003 Motion analysis of the pendulum test to assess rigidity in people with Parkinson’s disease– Giovanni Martino, Johnathan Lucas McKay, Friedl De Groote, Stewart A.

Factor, Lena Ting P11.3-004 Qualitative and quantitative measurement of skin surface fatty acids in Parkinson’s disease-the results of the first casecontrol study in any neurological condition.–Diana Angelika Olszewska, Siona Ni Raghallaigh, Lorraine Brennan, Allan McCarthy, Owen A. Ross, Peter Barrett, Mary Codd, Frank C Powell, Timothy Lynch P11.3-005 Parkinson’s disease Significantly Increases Variability of Day-to-Day activity patterns–Danish Bhatti, Vivien Marmelat P11.3-006 Impact of Medical Education on Knowledge of OFF-symptom Recognition and OnDemand Treatment Options Among Neurologists–Thomas Finnegan, Piyali Chatterjee, Cate Murray, Daniel Kremens, Robert A. Hauser P11.3-007 Development of a Multivariable Proxy Model for Six-Minute Walk Distance (6MWD) in Duchenne Muscular Dystrophy (DMD) Using Machine Learning Methods–Nicolae Done, Joel Iff, James Signorovitch, Dimitris Bertsimas, Erik K. Henricson, Jimmy Royer, Craig McDonald P11.3-008 Cognitive loading during walking increases stride-tostride randomness in people with Parkinson’s disease–Shane Meltz, Danish Bhatti, Ryan Meidinger, Carolin Curtze, Michael Cortese, John M. Bertoni, Amy Hellman, Vivien Marmelat P11.3-009 Objective Markers of Foot Tapping in Idiopathic Parkinson’s Disease with Freezing of Gait–Aliyah Glover, Lakshmi Pillai, Hafsa Bareen Syeda, Aaron Kemp, Mitesh P. Lotia, Linda Larson-Prior, Tuhin Virmani Motor and Non-motor Features of Parkinson‚Äôs Disease 1 P11.3-010 Effect of Dopaminergic Medication on Adenosine 2A Receptor Availability in Patients with Parkinson’s Disease–Imran Ali Waggan, Jouni Tuisku, Markus Matilainen, Helin Semi, Riitta Parkkola, Eero Rissanen, Juha O. Rinne, Laura Airas

AAN.com/view/20AM 177

Wednesday, April 29

P11.1-015 Film as a Health Communication Tool in Hispanics to Understand Perceptions and Attitudes in Multiple Sclerosis– Andrea Martinez, Astrid Diaz, Clara Manrique, Chanchan Zhu, Steven Cen, Michael Vincent Robers, Ivonne Vicente, Margaret E. Burnett, Angel R. Chinea, Jacob L. McCauley, Lilyana M. Amezcua P11.1-016 Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine Treated Patients at the 96 Week Timepoint (CLARITY) Using Deconvolution Algorithms– Irinia Kalatskaya, Gavin Giovannoni, Thomas Leist, Per Soelberg Sorensen, Ursula Boschert, Julie E. Demartino, Alex Rolfe P11.1-017 Hypertension is Undertreated in Patients with Multiple Sclerosis–Sunakshi Bassi, Devon Conway P11.1-018 Disrupted Copper Homeostasis is a Treatable Feature of Progressive Multiple Sclerosis–Peter Crouch, James Hilton, Kai Kysenius, Paul Donnelly, Jeffrey Liddell P11.1-019 Therapeutic status quo in multiple sclerosis: a sign of hopelessness?–Gustavo Saposnik, Angel Perez Sempere, Yolanda Aladro, Javier Sotoca Fernandez, Fabien S. Bakdache, Maria Terzaghi, Jorge Maurino P11.1-020 Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over

8 Years–Elisabeth Gulowsen Celius, Jiwon Oh, Anat Achiron, Alastair Compston, Virginia A. Devonshire, Kerstin Hellwig, George J. Hutton, Pamela Ann McCombe, Marie M. Moore, Renata Simm, Livia Diogo Sousa, Stephen G. Vincent, Luke Chung, Nadia Daizadeh, Colin Mitchell, David Rog P11.1-021 Effect of MS Disease Modifying Treatment Prices on the Day-to-Day Lives of People with MS–Bari Talente

POSTER SESSIONS

Women with MS in a Registerbased Cohort study in Finland and Sweden–European Interferon Group, Katja Hakkarainen, Sarah Burkill, Yvonne Geissbuhler, Meritxell Sabidó Espin, Achint Kumar, Kiliana Suzart-Woischnik, Riho Klement, Jan A. Hillert, Auli Verkkoniemi-Ahola, Shahram Bahmanyar, Scott Montgomery, Pasi Korhonen, Marta Korjagina, the Nordic MS Pregna group P11.1-014 An International Registry Tracking Pregnancy Outcomes in Women Treated with Dimethyl Fumarate–Kerstin Hellwig, David Rog, Christopher McGuigan, Kun Chen, Becky J. Parks, Cynthia C. Jones

Wednesday, April 29

POSTER SESSIONS

POSTER SESSION 11 P11.3-011 Clinical Characteristics of Patients with Parkinson’s Disease and Cognitive Impairment–Julie Chandler, Erin Ferries, Radhika Nair, Leanne Munsie, Tich Changamire, Lee Wilson, Nick Patel, Kevin M. Biglan P11.3-012 The UCSD Performancebased Skills Assessment Primarily Measures Attention, Executive Function, and Memory in Parkinson’s Disease–Samantha K. Holden, Abigail Simpson, Luis Daniel Medina P11.3-013 Intrinsic Brain Functional Network Dynamics in Parkinson´s Disease Patients with Depression– Maria Diez-Cirarda, Inigo Gabilondo Cuellar, Naroa Ibarretxe-Bilbao, Juan C Gomez-Esteban, Jinhee Kim, Olaia Lucas, Sang Soo Cho, Rocío Del Pino, Javier Peña, Natalia Ojeda, Marian Acera, Alexander Mihaescu, mikaeel Valli, Alberto Cabrera-Zubizarreta, Marian GomezBeldarrain, Antonio Strafella P11.3-014 Are Cognitive Deficits in Parkinson’s Disease Associated with Dopaminergic Dysfunction: A Graph Theory Analysis–Alexander Mihaescu, Jinhee Kim, Ariel GraffGuerrero, Mario Masellis, Sang Soo Cho, Mikaeel Valli, Maria DiezCirarda, Antonio Strafella P11.3-015 Gender Disparities in Treatment of Dysautonomia in Parkinson’s Disease–Cameron Miller-Patterson, Kyle Edwards, Lana Chahine P11.3-016 The Effects of Medication and Parkinson’s Disease Severity on Proprioceptively Encoded Memory Guided Reaching–Yessenia Rivera, Tara Entezar, Miranda Munoz, Gian D. Pal, Leonard Verhagen Metman, Lisa Goelz, Daniel Corcos, Fabian David P11.3-017 Blepharoclonus in Parkinson’s Disease: a prevalent and meaningful finding?–Jason H. Margolesky, Nicholas James Fleming, Danielle Spengler Shpiner, Corneliu C. Luca, Henry Paul Moore, Carlos Singer

CME

Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 3

P11.4-001 Attitudes Towards the Pharmacy Switch of Antiepileptic Medications: Patient’s Perspective–Halina SienkiewiczJarosz, Katarzyna Karas-Ruszczyk, Iwona Kurkowska-Jastrzebsk, Ewa Krzystanek, Magdalena Konopko, Przemyslaw Bienkowski P11.4-002 Evaluating the implementation of a pharmacistdriven epilepsy education and adherence program–Magdalena Siodlak, Andrew Cannon, Ryan Simonet, Amanda Margolis, Barry E. Gidal, Robert Joseph Kotloski Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/ Neurostimulation and Diet Therapies 1 P11.4-003 Safety, Tolerability, and Pharmacokinetics of ET-105, Lamotrigine for Oral Suspension, Under Fasting and Fed Conditions– Nishant Shah, Danielle Boyce, Lixin Gong, Enxian Lu, Shoufeng Li P11.4-004 Administration of Lamotrigine Formulation for Oral Suspension (ET-105) Through Gastrostomy Feeding Tubes–Nishant Shah, Danielle Boyce, Prexa Patel, Lixin Gong, Enxian Lu, Shoufeng Li P11.4-005 Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events (AEs) in the Tuberous Sclerosis Complex (TSC) Phase 3 Randomized Controlled Trial (GWPCARE6)–Joyce Y. Wu, Hannah Cock, Orrin Devinsky, Charuta N. Joshi, Ian Miller, Colin M. Roberts, Rocio SanchezCarpintero, Daniel Checketts, Farhad Sahebkar-Moghaddam P11.4-006 Quality of Life and Qualitative Caregiver Assessments in Children and Adolescents with Developmental and Epileptic Encephalopathies Treated with Cannabidiol Transdermal Gel: An Open-label Clinical Trial–Lynette Sadleir, Joseph Hulihan, John A. Messenheimer, Shayma Ali, Donna Gutterman, Terri Sebree, Ingrid E. Scheffer P11.4-007 Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Openlabel Clinical Trial–Ingrid E.

178 2020 AAN Annual Meeting

0 Wednesday, April 29 8:00 a.m.–9:00 a.m. Scheffer, Joseph Hulihan, John A. Messenheimer, Shayma Ali, Suzanne L. Davis, Donna Gutterman, Terri Sebree, Lynette Sadleir P11.4-008 A Review of the Pharmacokinetic Properties of Cenobamate (YKP3089), a Novel Antiepileptic Drug for the Treatment of Uncontrolled Focal Seizures in Adults–Stephen Greene, Laurent Vernillet P11.4-009 Cenobamate Adverse Events by Time of Onset and Dose From Two Randomized Clinical Studies in Patients With Uncontrolled Focal Seizures–Louis Ferrari, William E. Rosenfeld, Marc Kamin P11.4-010 Efficacy of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures Based on Number of Concomitant Antiepileptic Drugs, Seizure Frequency, and Epilepsy Duration at Baseline–William E. Rosenfeld, Arkady Nisman, Jeong Woo Cho, Louis Ferrari P11.4-011 Safety of Cenobamate for the Treatment of Focal Seizures, Following 1-Week vs 2-Week Titration Schedules–Marc Kamin, William E. Rosenfeld, Louis Ferrari P11.4-012 Population Pharmacokinetics Of Levetiracetam In Mexican Adult Patients With Epilepsy–Maria Patricia Hernández Mitre, Susanna E. Medellin Garibay, Ildefonso Rodriguez-Leyva, Herlinda Castillo-Ibarra, Cristian Jazmín Rodríguez Pinal, Sergio Zarazua Guzman, Helgi Helene Jung Cook, Silvia Romano Moreno, Rosa del Carmen Milán Segovia Improving Delivery of Care and Novel Treatments for Pain and Palliative Patients 1

P11.5-001 Does Early Initiation of Palliative Care (PC) Consult of Neurocritical Care Patients Provide Added Value?–Katlynn Van Ogtrop, Adriana Calosso, Santiago Lopez, Jeffrey M. Katz, Kayla Finuf, Christian Nouryan, Ashley Panzone P11.5-002 Non-Invasive Neuromodulation in Diabetic Peripheral Neuropathy: a metaanalysis–Kevin Pacheco-Barrios, Huiyan Zeng, Ying Cao, Ying Li, Jimming Zhang, Caifeng Yang, Felipe Fregni P11.5-003 10 kHz Spinal Cord Stimulation for Treatment of Painful

Diabetic Neuropathy-A Multicenter Randomized Controlled Trial–Erika Petersen, Thomas Stauss, James Scowcroft, Judith A. White, Shawn Sills, Kasra Amirdelfan, Maged Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Vincent Galan, Richard Bundschu, Neel Mehta, Dawood Sayed, Shivanand Pramod Lad, David DiBenedetto, Khalid Sethi, Paul Wu, Charles E. Argoff, Christian Nasr, Rod Taylor, Lisa Brooks, Jeyakumar Subbaroyan, Brad Gliner, David Caraway, Nagy Mekhail P11.5-004 A Common Data Language for Clinical Research Studies: Development of the National Institutes of Health Common Data Elements for Pain–Robin Sadja Feldman, Robin Sadja Feldman, Jane Atkinson, Linda L. Porter, Laura Wandner, Danielle Haney, Barbara P. Karp, Carolina Mendoza-Puccini, Andrew Franklin, Joy R. Esterlitz P11.5-005 ALS Patient and Caregiver Attitudes toward Physician-Assisted Death in California–Anna Hauswirth, Hannah George, Catherine Lomen-Hoerth P11.5-006 Improvements in Physical Function in Patients with Osteoarthritis Receiving Subcutaneous Tanezumab in Randomized Controlled Trials– Steven P Stanos, Wilson J Chang, Cory Hultman, Mojgan Sadrarhami, Peter Park P11.5-007 A Palliative Care Education Needs Assessment Survey of Neurology Residents–Tara Cook, Robert Arnold, Julie Childers P11.5-008 Subcutaneous Tanezumab Versus Tramadol for Chronic Low Back Pain: Efficacy and Safety Results from a 56-Week Phase 3 Study with a 24-Week Follow Up Period–John Markman, Robert Bolash, Timothy McAlindon, Alan Kivitz, Manuel Pombo-Suarez, Seiji Ohtori, David Li, Lars Viktrup, Candace Bramson, Christine R. West, Kenneth M. Verburg P11.5-009 Improvement in Pain and Physical Function following Subcutaneous Tanezumab Treatment in Patients with Osteoarthritis–Asya Gutman, Charles E. Argoff, Erik Shaw, Yvonne D’Arcy, Evan Ekman, Jerry Hall, Leslie Tive, David Semel

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number P11.5-010 Online Case Challenges Demonstrate the Need for Continued Education Relating to the Assessment and Management of Chronic Pain Among Neurologists– Deborah Susulka, Thomas Finnegan, George Boutsalis, Lee Radosh P11.5-011 Diagnostic pudendal nerve blocks followed by Pulsed Radiofrequency treatments in refractory chronic pelvic pain: A case series–Saugat Dey P11.5-012 Medical Cannabis in the Treatment of Neuropathy–Laszlo Mechtler, Chris Ralyea, Paul B. Hart, Vincent Harry Bargnes

Peripheral Neuropathy 1

P11.7-009 Novel Pathogenic Variant in the SCN10A Gene Associated with Autosomal Dominant Small Fiber Neuropathy.– Swathy Chandrashekhar, Mamatha Pasnoor, Constantine Farmakidis, Duaa Jabari, Omar Jawdat, Jeffrey Statland, Richard J. Barohn, Mazen M. Dimachkie P11.7-010 Tissue Response to Change in Oxygen Conditions: Potential Role in Chemotherapy Induced Peripheral Neuropathy– Kendra Hebert, Wilson Schreiber, Harold Swartz, Mary Chamberlin, Stacy Kovatch, Nicholas Streltzov, Victoria Lawson P11.7-011 Pyridoxine-Containing Nutritional or “Natural” Supplements: A Potential Cause of Worsening Neuropathy Symptoms–Miguel Angel SantiagoCruz, Janice Vargas, Lizmarie Tirado-Castro, Sonia M. CaraballoCartagena, Carlos A. Luciano P11.7-012 Daratumumab as First Line Therapy in a POEMS Syndrome Patient Demonstrating Atypical Features–Bo Carl Leung, Thomas Anthony Nelson, Matthew Burford P11.7-013 Intermittent Acute Porphyria as a Differential Diagnosis of Peripheral Neuropathy: a Case Report Series– Karina L. Pires, Mariana Beiral Hammerle, Debora Coelho de Souza

Oliveira, Eduarda Mendes Mello, Raquel Libanesa Rosario Beltre P11.7-014 Focal leg weakness and sensory loss in a patient with neuroendocrine carcinoma of the lung–Eliz H. Agopian P11.7-015 Chemotherapy-induced Peripheral Neuropathy in Young Adults Treated with VincaAlkaloids–Aneta Rajdova, Eva Vlckova, Lenka Šmardova, Josef Bednarik Aging and Dementia: Retina and Non-alzheimer Dementia 3

P11.8-001 Comparing frequency of vascular risk factors in dementia with Lewy bodies and Alzheimer’s disease: A meta-analysis of observational cohort studies–Yinka Read, Laura Brennan, Abigail Lyon, Hela Saidi, Carol F. Lippa P11.8-002 Long-term Exposure to Air Pollution and the Risk of Dementia: the Role of Cardiovascular Disease–Giulia Grande, Petter Ljungman, Kristina Eneroth, Tom Bellander, Debora Rizzuto P11.8-003 Impact of Race, Ethnicity and White Matter Hyperintensity on Incident Mild Cognitive Impairment at One Year after Lacunar Stroke: a Secondary Analysis of the SPS-3 Trial–Cecilia Peterson, Ka-Ho Wong, Adam De Havenon P11.8-004 Mortality and stroke risk in patients with dementia treated with renin-angiotensin system (RAS) blocking drugs. A longitudinal nationwide cohort study from the Swedish Dementia Registry–Marta Villa, Hong Xu, Bojana Petek, Irena Kalar, Maria Eriksdotter, Sara Garcia-Ptacek P11.8-005 Clinical Profiles of Arteriosclerosis and Alzheimer’s Disease at Mild Cognitive Impairment and Early Dementia in a National Neuropathology Cohort–Dixon Yang, Arjun Vijay Masurkar P11.8-006 Behavioral Markers for Processing Speed Deficits in a Vascular Cognitive Impairment Cohort–Ying Chen, Kelly Sunderland, Paula McLaughlin, Julia Fraser, Joel Ramirez, Donna Kwan, Yuelee Khoo, Malcolm Binns, Stephen Strother, Manuel MonteroOdasso, Leanne Casaubon, Richard H. Swartz, Douglas P Munoz

AAN.com/view/20AM 179

Wednesday, April 29

Inherited Muscle Disorders 3 P11.7-001 A Novel Missense Mutation In The MYH7 Gene Causes An Uncharacteristic Phenotype Of Myosin Storage Myopathy: A Case Report–Alier Marrero, Jean Mamelona, Louisa Filice, Youcef Oussedik, Nicolas Crapoulet P11.7-002 A Novel Missense Mutation Causing Fascioscapulohumeral Dystrophy Type 2: A Case Report–Ali Ebrahim, Mahsa Sadeghi, Sabeena Iqbal Malik, Sadaf Saba, Wan Yee Kong, Maher Fakhouri, Jun Li P11.7-003 Examining the Frequency of Follow-Up Clinical Assessments for Performance Status in Late-Onset Pompe Disease–David A. Shirilla, Mamatha Pasnoor, Omar Jawdat, Constantine Farmakidis, Duaa Jabari, Richard J. Barohn, Jeffrey Statland, Mazen M. Dimachkie P11.7-004 Genotype-Phenotype Variability in MTM1 Myopathy– Divya Rahul Shah, Veena Rajaram, Dennis Kendall Burns, Chunyu Cai, Diana Castro, Susan T. Iannaccone P11.7-005 A New Congenital Multicores Titinopathy with Myosin deficiency–Aurelie Perrin, Corinne

Metay, Marcello Villanova, Robert Carlier, Elena Pegoraro, Raul Juntas-Morales, Tanya Stojkovic, Isabelle Richard, Pascale Richard, Henk Granzier, Michel Koenig, Mireille Cossee, Edoardo Malfatti P11.7-006 Hypokalemic Periodic Paralysis: Clinical and Genetic Spectrum of a Pediatric Cohort– Alicia Henriquez, Alicia Henriquez P11.7-007 Unusual Presentation of a Dystrophinopathy–Chaitanya V. Amrutkar, Jeffrey Statland, Duaa Jabari, Mamatha Pasnoor, Mazen M. Dimachkie, Omar Jawdat, Richard J. Barohn, Constantine Farmakidis P11.7-008 Studying Clinical and Genetic Characteristics of Emery-Dreifuss Muscular Dystrophy–Gulshan Yunisova, Piraye Serdaroglu, Feza Deymeer, Arman Çakar, Fatma Yesim Parman, Hacer Durmus

POSTER SESSIONS

Headache: Migraine 1

P11.6-001 Changes in Acute Migraine-specific Medications After Initiating Erenumab: Results from a Real-world Retrospective Cohort Study in the United States–Dionne Hines, Shweta Shah, Jasjit Multani, Rolin Wade, Dawn C. Buse, Mark Bensink P11.6-002 Migraine: Another Health Disparity in Canada–Lizbeth Hernandez Ronquillo, Lilian Thorpe, Bonnie Janzen, Jose Francisco Tellez Zenteno, Punam Pahwa P11.6-003 Flunarizine Induced Parkinsonism in Migraine Group: A Nationwide Population-based Study–Wei Cheng-Yu, Wei Lin, Cheng-Li Lin P11.6-004 The Accuracy of the Diagnosis of Migraines and Prevalence of Prophylactic Care Prescribed–Joseph Sisti, Van Hellerslia, Paul M. Katz P11.6-005 Psychiatric Burden of Patients with Syncope and Migraine–Marissa Sakoda, Sathvik Kakanuru, Michael Flamm, Daniel Krashin, Ami Zarrillo Cuneo, Natalia Murinova P11.6-006 First insights in realworld effectiveness of erenumab in chronic migraine patients with high burden of disease in Germany from the NTD headache and migraine registry–Andreas Peikert, Monika Koerwer, Viola Tozzi, Heidi Dikow, Fabian Rossnagel, Silvio Schnabel, Stefan Braune, Arnfin Bergmann P11.6-007 The Role of Insomnia in Migraine and Tension-type Headaches: A Population-Based Study–Jiyoung Kim, Min Kyung Chu P11.6-008 A Multidisciplinary Approach to Psychiatric Comorbidities in a Military

Migraine Population–Virginia Baker, Nawaz Hack P11.6-009 Migraine and Functional Impairment Associated with Driving: Results of the OVERCOME Study–Richard B. Lipton, Li Shen Loo, Andre B Araujo, Robert Nicholson, Anthony J Zagar, Yongin Kim, Erin G. Doty, Hu Li, Dawn C. Buse, Robert E. Shapiro, Michael L. Reed, Eric M. Pearlman P11.6-010 I-BEAM: Impact and Burden of Episodic Acute Migraine – A Patient Experience Study– Stephen Bevan Shrewsbury, Sutapa Ray, Sutapa Ray P11.6-011 Acute Treatment Management Gaps in People With Migraine: Results of the CaMEO Study–Dawn C. Buse, Stephanie J. Nahas, Todd J. Schwedt, Michael L. Reed, Kristina Fanning, Aubrey Manack Adams, Richard B. Lipton P11.6-012 The Utility of the ID Migraine in Migraine Diagnosis in Calabar, Nigeria–Sidney Kelechi Oparah, Udeme Asibong, Emmanuel Olose, Ozomma Izuchukwu Simon

Wednesday, April 29

POSTER SESSIONS

POSTER SESSION 11 P11.8-007 Regional Reductions in the Frequency of Vascular Dementia Were Detected in the West Amongst Patients Included in the National Inpatient Sample Database from 2006-2014–Alexis N. Simpkins, Zhaoyi Chen, Teddy Si Youn, Adam Kelly, Anna Khanna, Christina Wilson, Jiang Bian, William Hogan, Nandakumar Nagaraja P11.8-008 Histopathological Staging of Salient Cerebrovascular Lesions Associated With Normal Aging–Caroline Dallaire-Théroux, Stephan Saikali, Simon Duchesne P11.8-009 Relationship between motoric cognitive risk syndrome, cardiovascular risk factors and diseases, and incident cognitive impairment: Results from a population-based cohort study– Olivier Beauchet, Harmehr Sekhon, Gilles Allali P11.8-010 High prevalence of stroke but low prevalence of Vascular dementia in a memory clinic from South India–Ratnavalli Ellajosyula, Jwala Narayanan, Uday Murgod, Murali Srinivasan, Vikram Kamath Systemic Disease and Stroke, Unusual Stroke Etiologies, and Cerebral Venous Sinus Thrombosis 2

P11.9-001 A Case Series: Acute ACA Stroke Presenting With Spasticity–Amy Wei-Hsin Yu, Chindhuri Selvadurai, Hardik Amin P11.9-002 Acute Onset of Internuclear Ophthalmoplegia, Upbeat Nystagmus, and Exotropia from Ponto-mesencephalic Infarction.–Steven Yang, Annie Lee Hsieh, Maria Virginia Diaz Rojas P11.9-003 Loeys-Dietz Syndrome and Ischemic Stroke–Michael Nahhas, Disha Kohli, Chirantan Banerjee P11.9-004 Seizure heralding the onset of acute stroke: Experience from a tertiary care center in Qatar.–Maria Siddiqi, Naim I. Haddad, Maher Saqqur P11.9-005 The Twitching Trunk: Etiology and Treatment of Truncal Myoclonus–Faraze Niazi, Jessica Frey, Meghana Raghavan, Ann Murray P11.9-006 Unraveling Moyamoyaa clinico-radio-etiological study from India–Shambaditya Das,

CME

Souvik Dubey, Mrinal Kumar Acharya, Goutam Gangopadhyay, Niladri Sarkar, Biman Kanti Ray P11.9-007 Case report: Diagnosis of Occult Cancer in Acute Ischemic Stroke Using Positron Emission Tomography Combined with Computed Tomography–Bastien Rioux, Mark Robert Keezer, Laura C. Gioia P11.9-008 A 47 F with multiple sclerosis presented with left MCA acute ischemic stroke and NSTEMI due to atypical thrombotic thrombocytopenic purpura.–Ronak Patel, Hartmut Uschmann P11.9-009 An Unusual Cause of Septic Emboli–Mariel Davila Martinez P11.9-010 CADASIL: a provable disorder, when diagnosed can dramatically change management.–Muhammad Hasanayn Jaffer, Martin Anthony Myers, Katie Bailey, Tigran Kesayan P11.9-011 Acute ischemic stroke as a result of paradoxical embolus in a patient with renal cell carcinoma, intravenous tumor thrombus extension, and patent foramen ovale–David Gritsch, Amir Abdallah, Abigail M. Taylor, Zhubene Mesbah, Bart M. Demaerschalk P11.9-012 Chronic Lymphocytic inflammation with Pontine perivascular enhancement responsive to steroids (CLIPPERS): A unique pathology and stroke mimic–Aman Deep, Rena Sukhdeo, Andrei V. Alexandrov P11.9-013 Isolated Infratentorial PRES; An Atypical Presentation of a Common Neurological Disorder.– Muhammad Waleed Zeb, Edward Michals P11.9-014 Balint’s syndrome presenting as the initial sign of occult breast cancer. Updating the diagnostic paradigm with recommendations for effective further management–Nara Michaelson P11.9-015 A Rare Case of Ischemic Strokes due to Sarcoidosis Related Cerebral Phlebitis–Sonia Kaur Singh, Rohini D. Samudralwar P11.9-016 Anarthria caused by a Lesion in the Quadrilateral Space of Pierre Marie–Rashid Ali Ahmed, Amr Hassan Ewida, Ekenedilichukwu Chidinma Nwoye, Antonio Culebras

180 2020 AAN Annual Meeting

0 Wednesday, April 29 8:00 a.m.–9:00 a.m. P11.9-017 Internal Carotid Artery Web as a Cause of Ischemic Stroke in a Young Adult: a Case Report– Emily Rachel Grodinsky, Nicholas D. Osteraas, Rima Dafer P11.9-018 Vanishing Beauty: A Case of a 59-Year-Old Woman with Iatrogenic Central Retinal Artery Occlusion After Cosmetic Facial Augmentation with Filler Injections–Joseph Conovaloff, Maya Hrachova, Anton Hasso, Hermelinda Abcede P11.9-019 Acute Ischemic Stroke due to Vasospasm after Daily Vaping of Tetrahydrocannabinol: a Case Report–Katherine Lam, Alison Caruana, Philip Yeung, Adrian Marchidann P11.9-020 Simultaneous Subarachnoid Hemorrhage and Transient Global Amnesia Secondary to Reversible Cerebral Vasoconstriction Syndrome– Reuben Beer, Peter Bailey P11.9-021 A Unique Mechanism of Acute Ischemic Stroke in a Patient Presenting with Pseudo-Pseudo Meigs’ Syndrome Secondary to Systemic Lupus Erythematous– Alok Patel, Starane Anthony Shepherd NeuroHIV, Neurovirology, and Rare Bacteria 2

P11.10-001 The Effect of Sex Hormones on the Secretion of the Insulin Receptor in HIV Infection– Miguel Angel Santiago-Cruz, Rafael Brito, Javier Brunet, Yisel Cantres, Yamil Gerena, Valerie E. Wojna P11.10-002 Atypical Spectrum of JC Virus Infection Syndrome: Report of Three Cases–William Souza Martins Ferreira, Rafael Gemaque Lima Bentes, André Luiz Guimarães de Queiroz, Karlla Danielle Ferreira Lima, Victor Mantelatto Bonsi, Christiane Monteiro Siqueira Campos, Carmen Lucia Penteado Lancellotti, Victor Hugo Rocha Marussi, Marcelo Schmid, Alex Machado Baêta P11.10-003 Determining the Neurocognitive status and the Functional Ability of patients to screen for HIV-Associated Neurocognitive Disorder (HAND)– Ritika Agarwal, Ravinder Singh Aujla, Amit Kumar Gupta, Mukesh Kumar

P11.10-004 Cryptococcal Infection Presenting with Upper and Lower Motor Findings–Jessica Lee, Rahul Rao P11.10-005 Tabes Dorsalis in an HIV-infected Patient: a Case Report–Caroline Lourenço Medeiros, Luis Felipe Haberfeld Maia, Leonardo Alves Araujo, Raisa Saron Wanderley Murari, Sandra Milena Torres, Naiade Couto, Arthur Ramalho Monfredinho, Caroline Bittar Braune P11.10-006 Facial Diplegia with distal paresthesias as variant of Guillain Barré Syndrome after Chikungunya infection: two case reports–Viviane Tavares Carvalho, Nathane Braga Da Silva Rezende, Thiago Pinheiro, Rodrigo Queiroz Silveira, Leonardo Alves Araujo, Ana Carolina Ferreira, Ana Filipis, Caroline Bittar Braune, Osvaldo J M Nascimento P11.10-007 Cytomegalovirus Infection – Not So (H)armless–Zara Togher, Eibhlin Higgins, Alex Gunko, Michael Doyle, Sarah Fullam, Niall Tubridy, Sean Connolly, Eoin Feeney, Christopher McGuigan P11.10-008 A pediatric case of Coxsackie A virus rhombencephalitis–Neel Fotedar, Kendall Wyllie, Peter Paul Lim, Bryony Jane Lucas, Megan Scruggs, Amy Edwards, Keith Ponitz, Jessica Helena Goldstein P11.10-009 The Role of Extracellular Vesicles (EVs) and EV-cargo in virally-mediated CNS diseases.–Setty Magana, Michelle Pleet, Maria Chiara Monaco, Nyater Ngouth, Marta Garcia Montojo, Fatah Kashanchi, Steven Jacobson P11.10-010 Heading West: An Uncommon Neurologic Presentation of West Nile Virus– Bianca Barcelo, Rachel Brown, Dominique Mortel, Anita Koshy P11.10-011 Idiopathic Spinal Epidural Abscess with Few Risk Factors causing Lumbosacral Radiculopathy–Michael Connerney, Erfanul Saker, Erfan Farno, Erfanul Saker, Michael Connerney P11.10-012 Streptococcus Constellatus and Actinomyces Brain Abscess Without Signs of Contiguous Spread: A Case Report–Rahim Shakoor, Alexander Agelidis, Muhammad Waleed Zeb, Ahmed Hassan

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number P11.10-013 Influenza Associated Acute Hemorrhagic Leukoencephalopathy with Favorable Response to Treatment– Micah Drew Yost, Stuart McCarter, Kelsey Christoffel, Nicholas L. Zalewski P11.10-014 Self Limiting Multiple Craniopathies secondary to Dengue Infection: A Case Report–Kimberly Geronimo, Artemio A. Roxas Fungi, Parasites, and Spirochetes 1

Sports Neurology and Neuro Trauma 2

Wednesday, April 29

P11.11-001 Resting State Functional Connectivity and White Matter Integrity as Biomarkers to Track Brain Changes in Former Athletes with Multiple Concussions–Anna Vasilevskaya, Foad Taghdiri, Charles Burke, Apameh Tarazi, Seyed Ali Naeimi, Mozghan Khodadadi, Ruma Goswami, Richard Wennberg, David J. Mikulis, Robin Green, Brenda Colella, Charles Tator, Carmela Tartaglia P11.11-002 Sulcal Cavitation During Head Impact and Correlating with Mild Traumatic Brain Injury Neuropathology–Jacob Lee Van Orman, Joseph Kerwin, Suhas Vidhate, Bianca Davila-Montero, Ricardo Mejia-Alvarez, Daniel P. Perl, Adam M. Willis P11.11-003 sLORETA Volumetric Quantitative EEG Analysis in High

nerve blocks from cranio-cervical trauma.–Brittany Brand- Poinson, Anthony Mercoli, Andrew Thomas Guidry, Kevin E. Crutchfield P11.11-012 Variations in Cause of Injury May Explain Disparities in In-Hospital Mortality after TBI–Sai Prasant Polineni, Enmanuel Perez Martinez, Neil Mehta, Christopher Chin, John Wiltshire, Praneet Polineni, Shyam Gajavelli, M. Ross Bullock P11.11-013 Effect of Therapeutic Hypothermia on Outcomes After Severe Traumatic Brain Injury: A Nationwide Inpatient Sample analysis–Harathi Bandaru, Harathi Bandaru, Ihtesham A. Qureshi, Mohtashim Arbaab Qureshi, Mohammad Rauf A. Chaudhry, Paisith Piriyawat, Alberto Maud, Gustavo Rodriquez, Salvador Cruz-Flores, Rakesh Khatri, Anantha Ramana Vellipuram

POSTER SESSIONS

P11.10-015 Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis– Pria Anand, Shibani Sharon Mukerji, Jesse Thon, Shauna Gunaratne, Tracey Cho, Nagagopal Venna P11.10-016 Medical Management of Intraventricular Neurocysticercosis–Karan Hingorani, Pria Anand, Anna Marisa Cervantes-Arslanian P11.10-017 A Rare Case Of Fulminant Cerebral Phaeohyphomycosis In A Transplanted Patient.–Daniel Garbin Di Luca, Andres De Leon Benedetti, Sakir H. Gultekin, Jason H. Margolesky P11.10-018 Rocky Mountain spotted fever presenting with meningoencephalitis and bilateral abducens nerve palsies–Melissa Ng, Sarah McCord, David Bekhor

School Athletes Shortly After Sport Concussion Injury: Dysfunction and Compensation–Harry G. Kerasidis, P. David Ims, Stacie Rector, Anastassia Kerasidis P11.11-004 A Scoping Review of Registered Clinical Studies on Concussion and Mild Traumatic Brain Injury (2000-2019) Shows an Encouraging Diversity of Research Initiatives, but a Problematic Variability of Injury Definitions.– Julio C. Furlan, Michael Radan, Charles Tator P11.11-005 Effects of Aerobic Exercise Training on Carotid Arterial Stiffness and Brain Health in Traumatic Brain Injury–Tran Bao Le, Tsubasa Tomoto, Rong Zhang, Munro Cullum, Kathleen R. Bell, Christopher Madden, Marisara Dieppa, Kan Ding P11.11-006 Skilled Motor Task Improvement using Alternative Auditory Feedback–Robert J. Giombetti P11.11-007 Cerebrovascular Reactivity: Subject-Level Classification Model for Acute Concussion.–Reema Shafi, Julien Poublanc, Runrun Wang, Larissa Mcketton, Lashmi Venkatraghavan, Adrian P. Crawley, Olivia Sobczyk, Runrun Wang, Charles Tator, James Duffin, Alan Mutch, Joseph A. Fisher, David J. Mikulis P11.11-008 Synthesis of Behavioral Health Outcomes in Mild Traumatic Brain Injury using Principal Component Analysis (PCA)–Teena Shetty, Radhika Madhavan, Suresh Joel, Caitlin Miller, Esther Kim, Matthew Garvey, Joseph T Nguyen, Joseph C. Masdeu, Luca Marinelli P11.11-009 Measurement of inflammatory cytokines and neurodegenerative/injury biomarkers in acute concussion/ mild traumatic brain injury (c/mTBI) serum and saliva samples–Ahmed Chenna, John Winslow, Christos John Petropoulos P11.11-010 Regional Variation in Sulfonylurea Receptor-1 Regulated Channel Expression after Repetitive Mild Traumatic Brain Injury in Mice: An Exploratory Study–Benjamin Zusman, Patrick M. Kochanek, Janesko-Feldman Keri, Vincent Vagni, Ruchira M. Jha P11.11-011 Balance and pain scores improve after occipital

AAN.com/view/20AM 181

POSTER SESSION 12

CME

0 Wednesday, April 29 12:00 p.m.–1:00 p.m.

Wednesday, April 29

POSTER SESSIONS

Poster Session 12 1. Multiple Sclerosis: Clinical Practice and Decision-making 2: 1-001 to 1-022 2. Autoimmune Neurology: Encephalities 3: 2-001 to 2-007 3. Motor and Non-motor Features of Parkinson’s Disease 2: 3-001 to 3-014 Functional Neurologic Disorders and Miscellaneous Movement Disorders Topics 1: 3-015 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/Neurostimulation and Diet Therapies 2: 4-001 to 4-012 5. Improving Delivery of Care and Novel Treatments for Pain and Palliative Patients 2: 5-001 to 5-012 6. Headache: Migraine 2: 6-001 to 6-013 7. Peripheral Neuropathy 2: 7-001 to 7-014 8. Behavioral and Cognitive Neurology: Other 2: 8-001 to 8-009 9. Systemic Disease and Stroke, Unusual Stroke Etiologies, and Cerebral Venous Sinus Thrombosis 3: 9-001 to 9-010 Cerebrovascular Disease: Intracerebral Hemorrhage, SAH, Aneurysms, and Vascular Malformations 1: 9-011 to 9-021 10. Fungi, Parasites, and Spirochetes 2: 10-001 to 10-011 Tuberculosis and Other Bacterial Infections 1: 10-012 to 10-019 11. Child Neurology and Developmental Neurology: Brain Injury: HIE, Stroke, Trauma, and Inflammation 1: 11-001 to 11-015

Multiple Sclerosis: Clinical Practice and Decision-making 2

P12.1-001 AAN 2018 Treatment Guidelines: US Payers’ Perspective–Zachary Contreras, Jeffrey D Dunn, Tamara Howerton, Kevin Duhrkopf, Louis Hudspeth, Daniel LM Kennedy, Manuel Nunez, Michael Raffaele, Aaron L. Boster P12.1-002 Determinants of Therapeutic Lag in Multiple Sclerosis–Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo Ayuso, Sara Eichau Madueno, Francesco Patti, Alexandre Prat, J M. Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Serkan Ozakbas, Patrizia Sola, Diana Ferraro, Roberto Bergamaschi, Elisabetta Cartechini, Maria Jose Sa, Cavit Boz, Francois GrandMaison, Jeannette Lechner-Scott, Murat Terzi, Franco Granella, Raed Alroughani, Gerardo Iuliano, Raymond Hupperts, Daniele Litterio A. Spitaleri, Vincent Van Pesch, Aysun Soysal, Julie Prevost, Francisco Javier Olascoaga Urtaza, Eduardo Morales, Recai Turkoglu, Mark Slee, Cristina M. Ramo, Youssef Sidhom, Riadh Gouider,

Pamela Ann McCombe, Helmut Butzkueven, Charles Malpas, Sandra Vukusic, Tomas Kalincik P12.1-003 The use of Autologous Haemopoetic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis after Alemtuzumab treatment failure: a case series–Simon Michael Bell, John Snowden, Helen Jessop, Joyutpal Das, Azza Ismail, Basil Sharrack P12.1-004 Treatment Patterns Among Patients With Multiple Sclerosis Newly Initiating DiseaseModifying Therapy–Leorah Aude Emmanuelle Freeman, Rina Mehta, Marc Tian, Corey Pelletier P12.1-005 Olfactory threshold as a biomarker predicting treatment response in relapsing multiple sclerosis–Gabriel Bsteh, Harald Hegen, Klaus Berek, Anne Zinganell, Sebastian Wurth, Michael Auer, Franziska Di Pauli, Florian Deisenhammer, Thomas Berger P12.1-006 Siponimod: From Understanding Mode of Action to Differentiation Versus Fingolimod–Marc Bigaud, Sarah Tisserand, Philipp Albrecht, Bernard Zalc, Thomas Hach, Frank Dahlke, Daniela Piani Meier

182 2020 AAN Annual Meeting

P12.1-007 Impact of Alemtuzumab on Work Capacity in Patients With RRMS: Pooled Analysis of CAREMS Core Studies–Brian Steingo, Regina Berkovich, Elisabeth Gulowsen Celius, Daniel Kantor, R.M.M. Hupperts, Celia Oreja Guevara, Mary Ann Picone, Jenny Ravenscroft, David Rog, Miriam Ross, Bernard M.J. Uitdehaag, Zia Choudhry, Nadia Daizadeh, Lobat Hashemi, Tjalf Ziemssen P12.1-008 Thalamic Volume and Axonal Density Correlates with Cognitive Function in Multiple Sclerosis Patients Treated With Fingolimod–Devon Conway, Sarah Marie Planchon Pope, Sehong Oh, Kunio Nakamura, Nicholas Thompson, Ken Sakaie, Daniel Ontaneda P12.1-009 Retinal layer thinning rate as a biomarker predicting treatment response in relapsing multiple sclerosis–Gabriel Bsteh, Harald Hegen, Klaus Berek, Patrick Altmann, Anne Zinganell, Sebastian Wurth, Michael Auer, Franziska Di Pauli, Barbara Teuchner, Berthold Pemp, Florian Deisenhammer, Thomas Berger P12.1-010 TREAT-MS Study of Real-World Effectiveness of Alemtuzumab in RRMS Patients in Germany: Subgroup Analysis by

Timing of Treatment Initiation–Tjalf Ziemssen, Robin White, Raimar Kern, Ulrich Engelmann, Rocco Haase, Ben Guikema, Katja Akgün P12.1-011 Comparison of Tolerability Between Rituximab and Ocrelizumab–Brandon P. Moss, Thomas Love, Laura Elizabeth Baldassari, Sarah Marie Planchon Pope, Jeffrey Alan Cohen, Daniel Ontaneda P12.1-012 Multiple sclerosis and MyChart® messaging: a retrospective chart review evaluating its use at an academic medical center–Nadia Khalil, Angela Aungst, Lise Casady, Kevin G. Allison, Ryann Fiascki, Christian Curbelo, Janice Y. Maldonado, Derrick Robertson P12.1-013 Comorbidity Pattern Among Adults With MS in the United States: A Propensity Score–Matched Study–Sandipan Bhattacharjee, Zufan Yegezu, Kristin Kollecas, Kevin Duhrkopf, Nupur Greene, Lobat Hashemi P12.1-014 Tumefactive Demyelinating Lesions: Followup Study and Treatment options from a Greek Single-Center.– AGLAIA VAKRAKOU, DIMITRIOS TZANETAKOS, Maria-Eleptheria Evangelopoulos, Georgios Velonakis, John S. Tzartos, Maria = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Autoimmune Neurology: Encephalitis 3

P12.2-001 Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy masquerading as tuberculosis of the central nervous system–David Tang, Amanda Xin Yi Chin, Amy May Lin Quek P12.2-002 Failure of IVIG in Steroid-responsive Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy–Amit Chaudhari, Chelsea Lam, Ateena Pirverdian, Sam Lai, Ardith M. Courtney P12.2-003 Case Report of Autologous Hematopoietic Stem Cell Transplant in a Patient with Anti-IgLON5 Associated Encephalitis–John A. Brooks, Pierre R. Bourque, Harold Atkins, Gregory S. Day, Carolina A.E. Rush P12.2-004 Ma2 paraneoplastic limbic encephalitis: Examination of potential prognostic factors and effects of various immunotherapeutic approaches– Mohammad Al Aladawi, Amber Salter, Michelle Maynard, Ahmed Z. Obeidat P12.2-005 Anti-NMDA Receptor Encephalitis Related to Renal Cell Carcinoma: a Case Report–Carlos Eduardo Vervloet Sollero, Christopher Paul Robinson, Tirisham Gyang, Aaron M. Carlson P12.2-006 Infant presenting with Autoimmune NMDA Positive encephalitis secondary to Herpes Simplex Encephalitis: A Case Report–Rani Priyanka Vasireddy, Zain Guduru, Qutubuddin G. Khan P12.2-007 AMPAR Autoimmunity: Neurological, Oncological and Serological Accompaniments.– Cecilia Zivelonghi, Andrew McKeon, Elia Sechi, Kevin O’Connor, Sean J. Pittock, Divyanshu Dubey, Vanda A. Lennon, Eoin P. Flanagan, Anastasia Zekeridou

Motor and Non-motor Features of Parkinson’s Disease 2

P12.3-001 Pharmacokinetics of CVT-301 (Inhaled Levodopa) CoAdministered With Oral Carbidopa in Subjects With Parkinson’s Disease (PD) Under Fed Conditions– Beth E. Safirstein, Aaron Ellenbogen, Ping Zhao, Herbert Henney, Deena M. Kegler-Ebo, Charles Oh P12.3-002 Is It Possible to Eliminate Hospital Administered Haloperidol For the Acute Management of Agitation in Patients with Parkinsonism? A Quality Improvement Initiative– Katelyn Cecilia Klee Bird, Taylor Francoeur, Betsy Thomas, Na Wang, Stephanie L. Bissonnette P12.3-003 Factors Associated With Depressive Symptoms Depression in a Multicentric Parkinson’s Disease Mexican Cohort–Jesus Eduardo GarciaBerlanga, David Garza Brambila, Amin Cervantes, Karla SalinasBarbosa, Sara Isais-Millan, Antonio Anaya-Escamilla, Edna VelazquezAvila, Alejandro Banegas-Lagos, Arnulfo Gonzalez-Cantu, Mayela De Jesus Rodriguez Violante, Daniel Martinez-Ramirez P12.3-004 Evolution of Cognition in Mild-Moderate Parkinson’s Disease–Ergun Y. Uc, Matthew Rizzo, Steven W. Anderson, Jeffrey Dawson P12.3-005 Longitudinal Clinical and Neuroanatomical Changes of PD-MCI Reverters–Giulia Donzuso, Federica Agosta, Elisa Canu, Tanya Stojkovic, Silvia Basaia, Iva Stankovic, Alexandra Tomic, Elka Stefanova, Vladana pica, Vladimir S. Kostic, Massimo Filippi P12.3-006 Onset of Action for RimabotulinumtoxinB in the Treatment of Adult Sialorrhea– Laxman Bhaqwan Bahroo, Stuart H. Isaacson, Rajesh Pahwa, Thomas Clinch, Mark F. Lew P12.3-007 The Effects of Medication and Parkinson’s Disease Severity on Visually Encoded Memory Guided Reaching–Tara Entezar, Yessenia Rivera, Miranda Munoz, Gian D. Pal, Leonard Verhagen Metman, Lisa Goelz, Daniel Corcos, Fabian David P12.3-008 Alexithymia a Prevalent, New Determinant of Quality of Life in Persons with Parkinson’s Disease–Alonso Alejandro Alvarado,

Amin Cervantes-Arriaga, Lorena Zuazua-Vidal, Angel Alcocer-Salas, Angel Alcocer-Salas, Mayela De Jesus Rodriguez Violante P12.3-009 Pain Syndromes: An Early Clinical Marker Of Prodromal Parkinsons Disease–Mrinal Kumar Acharya P12.3-010 Factors associated with psychosis in patients with Parkinson’s disease–Claudia Esparza, David Garza Brambila, Amin Cervantes-Arriaga, Karla Salinas-Barboza, Sara Isais, Antonio Anaya-Escamilla, Edna VelazquezAvila, Alejandro Banegas-Lagos, Arnulfo Gonzalez-Cantu, Mayela De Jesus Rodriguez Violante, Daniel Martinez-Ramirez P12.3-011 Trunk-pelvis coordination during gait in early denovo parkinson’s disease–Jinhee Kim, Seong-Ho Koh P12.3-012 Evaluating the Use of Oral Anti-Parkinsonian Medication in Patients with Advanced Parkinson’s Disease Who Are Treated with Deep Brain Stimulation and Are Receiving Levodopa-Carbidopa Intestinal Gel: Study Design and Interim Results– Jason Lamar Aldred, Fahd Amjad, Anita Johnson, Pavnit Kukreja, Irene Malaty, Sotirios A. Parashos, Junaid H. Siddiqui, Mustafa S. Siddiqui, Jorge Zamudio, Sandeep Thakkar P12.3-013 Social Cognition in Parkinson’s Disease- Emotion Recognition in Comparison to a Normal Indian Population– Sreenivas Umaiorubahan Meenakshisundaram, Lakshmi N. Ranganathan, Balasubramanian Samivel P12.3-014 Vitamin D Receptor Mutations Influence on Course of Parkinson’s Disease in Patients Treated with Levodopa–Olaf Chmura, Adrianna Wasinska, Jan Koper, Barbara Zapala Functional Neurologic Disorders and Miscellaneous Movement Disorder Topics 1

P12.3-015 Genotype-Phenotype Associations in Hereditary Spastic Paraplegia (HSP): A Systematic Review and Individual-level Data Meta-analysis–Seyed-Mohammad Fereshtehnejad, Philip Saleh, Neha Patel, Suvorit Subhas Bhowmick, Gerard Raimon Saranza, Melanie Anderson, Lorraine Kalia

AAN.com/view/20AM 183

Wednesday, April 29

P12.1-022 MOG Optic Neuritis: Atypical Presentations and Disease Spectrum at a Tertiary Centre, Calgary, Alberta–Jodie Burton, Katayoun Alikhani, Fiona Evann Costello

POSTER SESSIONS

Constantinos Anagnostouli, Elisavet Andreadou, Georgios Koutsis, Panagiotis Toulas, Leonidas Stefanis, Konstantinos Kilidireas P12.1-015 Early Real-World Safety, Tolerability, and Efficacy of Cladribine Tablets: A Single Center Experience–Julie Anne Bain, Ashley Jones, Sarah Overholt, Melanie Guenette, Daniel H. Selchen, Jiwon Oh P12.1-016 Factors associated with therapeutic status quo among patients with multiple sclerosis: the patient´s point of view–Gustavo Saposnik, Angel Perez Sempere, Javier Sotoca Fernandez, Luis Brieva Ruiz, Fabien S. Bakdache, Maria Terzaghi, Jorge Maurino P12.1-017 Demyelination-related Movement Disorders: Prospective Evaluation of 152 Patients and Comparative Analysis of Patients with and without Spinal Lesions– Hesham Ahmed Abboud, Hammad Khan, Konrad Knusel, Xin Xin Yu, Jeffrey Alan Cohen, Hubert H. Fernandez P12.1-018 Young Woman with weakness progressing to quadriplegia: Is this multiple sclerosis or something else? A Case Report–Maria E. Garcia Ayala, Carmen Serrano, Eduardo Labat P12.1-019 Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis–Per Soelberg Sorensen, Diego Centonze, Gavin Giovannoni, Xavier Montalban, Daniel H. Selchen, Patrick Vermersch, Heinz Wiendl, Bassem I. Yamout, Hashem Salloukh, Peter Rieckmann P12.1-020 Efficacy of Subcutaneous Interferon ß -1a in Patients with a First Clinical Demyelinating Event in Reflex is Maintained After Application of the 2017 McDonald Criteria–Mark S. Freedman, Ludwig Kappos, Giancarlo Comi, Nicola De Stefano, Sanjeev Roy, Delphine Issard P12.1-021 First Results from PANGAEA2.0 EVOLUTION: State of the Art Management of Patients with Secondary Progressive Multiple Sclerosis (SPMS) or at Risk for SPMS to Identify Key Parameters in Daily Clinical Practice for an Early and Unified Diagnosis–Benedict Rauser, Tjalf Ziemssen

POSTER SESSION 12

Wednesday, April 29

POSTER SESSIONS

P12.3-016 The role of the cerebellum in cortical myoclonus: a neurophysiological study–Anna Latorre, Lorenzo Rocchi, Kailash P. Bhatia P12.3-017 Effect of Paroxetine on the Pharmacokinetics of Valbenazine and its Active Metabolite–Evan Smith, Gordon Loewen, Rosa Luo, Shannon Ingersoll, Roland Jimenez, Haig Bozigian, Grace Lin Liang Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/ Neurostimulation and Diet Therapies 2

P12.4-001 Long-term Retention on Adjunctive Brivaracetam and Reasons for Discontinuation by Number of Lifetime AEDs in Adults With Focal Seizures: a Post hoc Analysis–Pavel Klein, Rick McLachlan, Cedric Laloyaux, Xavier Nondonfaz, Sami Elmoufti, Svetlana Dimova, Christian Brandt P12.4-002 Baseline Seizure Related Disability Assessment Scale (SERDAS) Scores in an Observational Study of Brivaracetam–Jacqueline French, Roger J. Porter, Julie Varner, AnneLiv Schulz, Ying Zhang, Melinda S. Martin P12.4-003 Real-world Study of Brivaracetam in the US: an Interim Analysis–Melinda S. Martin, Roger J. Porter, Julie Varner, Anne-Liv Schulz, Ying Zhang, Jacqueline French P12.4-004 Long-term Tolerability and Retention of Adjunctive Brivaracetam in Children With Primary Generalized or Mixed Seizure Types: Interim Subgroup Analysis of Pooled Data From two Open-label Trials–Anup D. Patel, Teresa De Jesus Gasalla, Xavier Nondonfaz, Sami Elmoufti, Jan-Peer Elshoff P12.4-005 Switching AntiEpileptic Drugs to Once a Day Regimen in Epilepsy Patients with Poor Adherence.–Sung Hyun Kim, Dong Wook KIM P12.4-006 Profound Reduction in Seizure Frequency (=75%) Leads to Improved Everyday Executive Function in Patients with Dravet Syndrome at 1 Year Post-treatment with ZX008 (Fenfluramine HCl Oral Solution): Analysis of Data From

CME

the Phase 3 Clinical Development Program–Kim I. Bishop, Peter Isquith, Gerard A. Gioia, Glenn Morrison, Douglas Haney, Arnold Gammaitoni P12.4-007 Gender and Racial Disparity in Antiepileptic Drug(AED) Trials– A metaanalysis and systematic review of AED randomized controlled trials and open labels studies–Wan Yee Kong, Hamidreza Saber, Maysaa Merhi Basha P12.4-008 Interim Safety and Effectiveness Outcomes from a Prospective Post-Approval Trial of the RNS® System–HaeWon Shin, Martha Morrell P12.4-009 Responsive Vagal Nerve Stimulation in Lennox Gastaut Syndrome (LGS) and Intractable Pediatric Epilepsy: URMC VNS Clinic Experience– Olivia Brumfield, Julie Socha, Inna Hughes P12.4-010 Generator Replacement with Cardiac Based VNS Device in Children with Drug-Resistant Epilepsy–Aristides Hadjinicolaou, Puneet Jain, Ivanna Yau, Robyn Whitney, James Rutka, Cristina Y. Go P12.4-011 Vagus Nerve Stimulation: Seizure Reduction in Medically Refractory Epilepsy–Ana Suller Marti, Rick McLachlan, Seyed M. Mirsattari, David Steven, Andrew Parrent, Andrea Andrade, Sandrine deRibaupierre, David C. Diosy, Keith MacDougall, Jorge G. Burneo P12.4-012 Outcome of Vagal Nerve Stimulation for Treatment of Primary Generalized Epilepsy–Ram Mohan R. Sankaraneni, Anuja R. Patil, Sanjay P. Singh Improving Delivery of Care and Novel Treatments for Pain and Palliative Patients 2

P12.5-001 Chronic Painin the Wearing Off Phase of Parkinson’s Disease–Matheus Gomes Ferreira, Marcelo Rezende Young Blood, Camila Medyk, Helio Afonso Ghizoni Teive, Marcelo Ferro, Carlos Camargo P12.5-002 Subcutaneous Tanezumab Versus Placebo or Tramadol in Patients with Chronic Low Back Pain: 16-Week Efficacy and Safety Results from a Phase

184 2020 AAN Annual Meeting

0 Wednesday, April 29 12:00 p.m.–1:00 p.m. 3 Study–John Markman, Robert Bolash, Timothy McAlindon, Alan Kivitz, Manuel Pombo-Suarez, Seiji Ohtori, David Li, Lars Viktrup, Candace Bramson, Christine R. West, Kenneth M. Verburg P12.5-003 Symptomatic Tarlov (Perineural) Cysts: Diagnostic Workup and Comparison of Outcomes by Treatment Modality– Keely Coxon, Gregory T. Carter, Thomas Stonecipher, Michael R. Chun, Julian Fohrman P12.5-004 Adverse Effects related to the Use of Prescription Opioids: A Public Health Challenge–Gabriel D. Pinilla Monsalve, Luis PinillaMonsalve P12.5-005 Palliative care and Parkinson’s disease: current practice, knowledge and barriers to referral. Insights from French palliative care units.–Manon Auffret, Jeanne Keromnes, Guillaume Robert, Vincent Morel, Marc Verin P12.5-006 Orthopedic Complications of Congenital Zika Syndrome May Predict Chronic Pain–Nilson Nogueira Mendes Neto, Jessika Thais da Silva Maia, David Aronoff, Daniel Lucey, Kalyane Fernandes, Tabata de Alcantara P12.5-007 Tramadol’s mystery withdrawal - should we worry about SNRI discontinuation syndrome?–Lena Eder P12.5-008 Stakeholder Feedback on Novel Behavioral Intervention Targeting Chronic Low Back Pain and Comorbid Depression in Older Adults–Ailing Eileen Yang, Wei Yuet, LaDonna Saxon, James LePage, Una Makris P12.5-009 Spinal Cord Stimulation can provide significant relief to patients with neuropathic pain caused by CIDP–Morad Nasseri, Ariel Majjhoo P12.5-010 WITHDRAWN P12.5-011 When Time is Short: Reducing delays for neurology patients seeking medical aid in dying–Lauren Treat, Christina L. Vaughan, Benzi Kluger P12.5-012 Opioid use for amyotrophic lateral sclerosis: a report on experiences in Japanese patients–Ryo Morishima, Kota Bokuda, Hideki Kimura, Toshio Shimizu

Headache: Migraine 2

P12.6-001 Annual Costs Associated with Patients with Migraine by Intensity of TreatmentSeeking Behavior–Ruslan Horblyuk, Oth Tran, Philip Chan, Gilwan Kim, David Smith, Chad Patel P12.6-002 A Brief Look at Urgent Care Visits for Migraine: the Care Received and Ideas to Guide Migraine Care in this Proliferating Medical Setting–Kina Zhou, Leslie Miller, Mia T. Minen P12.6-003 Presence of Stigma in the Treatment of Migraine Patients among Neurologists–Adeel Zubair, Jason J. Sico, Deena Kuruvilla P12.6-004 Migraine Patients Exhibit Increased Relative Risk for Medication Overuse Headache with Sustained Triptan Treatment – Results from a Real-World Claims Analysis–Linda Harris, Robert Croop, Vlad Coric, Gilbert J. L’Italien, Harsh Dandona, Ying Li P12.6-005 Competency and Knowledge of CGRP Blockade in Migraine Therapy: Influence and Continuing Need for Education– Anne C. Roc, Wendy Turell, Mark W. Green P12.6-006 Sensory Hypersensitivity Symptoms in Migraine with vs. Without Aura: Results from the American Registry for Migraine Research (ARMR)– Talia Pearl, Gina Dumkrieger, Catherine Daniela Chong, Todd J. Schwedt, David W. Dodick P12.6-007 Potential Clinical Evidence for Limbic System Sensitization in Migraine–Eric J. Eross P12.6-008 Patient-Identified Most Bothersome Symptom in Patients with Chronic Migraine: An Analysis of PROMISE-2–Richard B. Lipton, David W. Dodick, Jessica Ailani, Paul Winner, Nada A. Hindiyeh, Joe Hirman, Steven Snapinn, Lahar R. Mehta, Roger Cady P12.6-009 Gastrointestinal Comorbidities Representing a Relative Contraindication to NSAID Use: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study–

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Peripheral Neuropathy 2

Ladstatter, Florian Deisenhammer P12.7-013 Epstein-Barr virus driven acute motor axonal neuropathy with central demyelination following stem-cell transplant–Anila Kanna, Morad Nasseri, Mihir Kakara, Mona Elsayed P12.7-014 Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic Pitfalls in a Medically Underserved Community–Saurabh G. Shukla Behavioral and Cognitive Neurology: Other 2

P12.8-008 The Brain Medicine Approach to Complex Disorders of Affect, Cognition and Behaviour (ABC)–Sarah Levitt, Kenneth J. Shulman, Sara Mitchell P12.8-009 Validation of DSM V Diagnostic Criteria in Indian population–Sankar Prasad Gorthi, Jaydip Kumar Mangroliya, Sharma PSVN, Shweta Rai Systemic Disease and Stroke, Unusual Stroke Etiologies, and Cerebral Venous Sinus Thrombosis 3

8 9

P12.8-001 Effects of 5-HTTLPR Polymorphisms on Amygdalar Functional Connectivity and Emotional Regulation–Danielle Reynolds, Aimen Vanood, Douglas Gould P12.8-002 Dissociable Systems for Recognizing Places and Navigating through them: Causal and Developmental Evidence.– Stephanie Wahab, Frederik Kamps, Sama Radwan, Daniel Dilks P12.8-003 Cognitive Performance After Repeated Administration of the NMDA Positive Allosteric Modulator SAGE-718 in Healthy Volunteers–Aaron Koenig, Harald Murck, Yi Luo, Irena Webster, Michael Quirk, Steve Kanes, James Doherty P12.8-004 Phase-Amplitude Coupling and Long-Range Phase Synchronization in the Frontosubthalamic Circuit during Conflict Processing–Ke Zeng, Ayda Ghahremani, Neil Drummond, Robert E. Chen P12.8-005 Is a measure of dualtask performance better able to screen for cognitive impairment in patients with post-concussion syndrome?–Neda Anssari, David Gold, Apameh Tarazi, Carmela Tartaglia P12.8-006 Cognitive Effects of Limbic Deep Brain Stimulation in Patients with Refractory Chronic Neuropathic Pain–Gregory Chin, Heather Dawes, Edward F. Chang, Prasad Shirvalkar P12.8-007 Machine Learning on Drawing Tests of Cognition: A Systematic Review–Ryan James McGinn, Rana Kamhawy, Henry He, Jasper Ho, Mukul Sharma, Vinai Bhagirath

P12.9-001 Ischemic myelopathy as a perioperative complication of Percutaneous Coronary Intervention via Femoral Approach–Sri Raghav Seshu Sista, Hrachya Nersesyan P12.9-002 A Rare Presentation of Intracranial Vasculopathy in a Patient with Erdheim-Chester Disease–Catherine Hassett, Elizabeth Spurgeon, Sung Min Cho, Andrew Blake Buletko, Andrew Russman P12.9-003 Reversible ICA Stenosis Associated With Chronic Graft Versus Host Disease Related Vasculitis–Varalakshmi Ballur Narayana Reddy, Rebecca Jules, Nikolaus McFarland P12.9-004 Release Hallucinations as Harbinger Symptom of Posterior Cerebral Artery Infarction–Carlos M. Millan, Vasu Saini, Amer Malik P12.9-005 Sturge-Weber Syndrome and Head Trauma: Abnormal Cerebrovascular Hemodynamics–Jeetendra Sah, Jeetendra Sah, Yoshimi Hisamoto, Vinodkumar Velayudhan, Steven G. Pavlakis P12.9-006 Bilateral Internal Carotid Artery Agenesis in an Elderly Patient: An Extremely Rare Anatomical Variant.–Mauricio Perez Davila, Bhanu Gogia, Diaa Hamouda, Arun Chhabra, Karthikram Raghuram P12.9-007 An Unusual Case of Cerebral Air Embolism–Dana Ionel, Fred Odago, L Creed Pettigrew, Jessica Doyle Lee P12.9-008 Reversible Vasoconstriction Syndrome associated with Vaping Cannabis Oil–Florina Gabriela Kraiter, Preet M. Varade

AAN.com/view/20AM 185

Wednesday, April 29

P12.7-001 Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy (TopCSPN): Study Design and Baseline Characteristics–A. Gordon Smith, Cathy Revere, Robin A. Conwit, Robert H. Dworkin, Aaron Vinik, Tom Greene, Merit E. Cudkowicz, Christopher Coffey, Dixie Jean Ecklund, Marianne Chase, J. Robinson Singleton P12.7-002 Humoral Immune Microvasculopathy: Treatable Motor-Sensory Axonal Polyneuropathies with C5b9 Deposition on Endoneurial Microvessels–Bhavesh Trikamji, Alan Pestronk P12.7-003 Ixazomib, Lenalidomide, and Dexamethasone (Ixa-LenDex) for Patients with POEMS Syndrome–Michelle L. Mauermann, William J. Litchy, Peter J. Dyck, Wolfgang Singer, Jenny Davies, Angela Dispenzieri

P12.7-004 Evaluation of Clinical Presentation, Skin Biopsy Findings, and Immunologic Testing in Patients with Symptoms of Sensory Neuropathy–Norianne Pimentel, Leila Darki, Said R. Beydoun P12.7-005 AL-Amyloidosis presenting with painful mononeuropathy multiplex and bilateral cranial nerve 3 palsies– Jane Liao, Farah El-Sadi, Anna Nikonova, Stephanie Yang, Kiran Jakate, Jonathan Micieli, Charles Kassardjian P12.7-006 Natural history and treatment predictors in a cohort of IgM associated neuropathies– James Douglas Triplett, Elie Naddaf, Maria Torres, Shahar Shelly, Prabin Thapa, Christopher J. Klein, Michelle L. Mauermann P12.7-007 Increased Serum Neurofilament Light Chain Concentration Indicates Poor Outcome in Guillain-Barré Syndrome–Patrick Altmann, Desiree De Simoni, Alexandra Kaider, Birgit Ludwig, Jakob Rath, Fritz Leutmezer, Fritz Zimprich, Romana Hoeftberger, Michael P. Lunn, Amanda Heslegrave, Thomas Berger, Henrik Zetterberg, Paulus Stefan Rommer P12.7-008 Nonsystemic Vasculitic Neuropathy Masquerading as Guillain-Barre Syndrome–Joshua A. Budhu P12.7-009 A Case of PharyngealCervical-Brachial Variant of Guillain-Barré Syndrome Responsive to IVIG–Ryan Christopher Corn, Philip Yeung, Adrian Marchidann, Simona Treidler P12.7-010 Changing the game: New data on axonal GuillainBarré syndrome in Mexican adult patients–Roberto Cervantes Uribe, Guillermo Delgado-García, Juan Carlos Lopez, Luis Enrique Colunga-Lozano, Sofia Garcia Trejo, Anna Lisette Bazan, Jorge BurgosCenteno, Francisca FernandezValverde, Edwin S. Vargas P12.7-011 Predictive factors of Treatment-related fluctuations in patients with Guillain-Barre syndrome–Juan Castiglione, Lucas Alessandro, Patricio Brand, Veronica A. Bruno, Fabio Adrian Barroso P12.7-012 Cerebrospinal Fluid Protein in Guillain-Barré syndrome – Need of an Age-dependent Interpretation–Harald Hegen, Felix

POSTER SESSIONS

Stephanie J. Nahas, Dawn C. Buse, Kristina Fanning, Michael L. Reed, Aubrey Manack Adams, Richard B. Lipton P12.6-010 Burden of Comorbid Depression and Anxiety on Migraine-specific Health-related Quality of Life in Adult Migraine Patients in the United States– Dawn C. Buse, Ravi Iyer, Joshua M. Cohen, James Jackson, Verena Ramirez Campos, Sarah Cotton, Gary Milligan, Richard B. Lipton P12.6-011 Assessment of the Patient Experience Across All Phases of Migraine–Juliana VanderPluym, Verena Ramirez Campos, Alma Cortez, Joshua M. Cohen, Sanjay Gandhi, Sandra Lewis, Carolyn Sweeney, Carla Demuro, Richard B. Lipton P12.6-012 Creation of a National Real-World Data Pediatric Migraine Registry: Proof of Principle–Amy Gelfand, Christina Lynch Szperka, Tara Pezzuto, Alex Hammett, Shirley Kessel, Daniel Benjamin, Michael Cohen-Wolkowiez, Christoph Hornik P12.6-013 Psychiatric Comorbidity Burden in Chronic Migraine and Medication Overuse Headache in Pregnancy–Daniel Krashin, Ami Zarrillo Cuneo, Melissa Schorn, Sau Mui Chan-Goh, Marcel Budica, Natalia Murinova

Wednesday, April 29

POSTER SESSIONS

POSTER SESSION 12 P12.9-009 An Unusual Presentation of Concomitant Cervical Spinal Cord and Cerebellar Acute Ischemic Stroke in a Patient on Weight Loss Medications– Mushtaq H. Qureshi, Shayan Ul Haque, Usman Ghumman, Sheharyar Hakeem, Jose GavitoHiguera, Paisith Piriyawat, Alberto Maud, Salvador Cruz-Flores, Anantha Vellipuram P12.9-010 Cerebral Sinovenous Thrombosis (CSVT) – Tales Of Caution: Cerebro Spinal Fluid (CSF) analysis and Distinct Radiologic Pattern.–Anusha Mangalampalli, Sri Raghav Seshu Sista, Gregory M. Blume Cerebrovascular Disease: Intracerebral Hemorrhage, SAH, Aneurysms, and Vascular Malformations 1

P12.9-011 Middle Meningeal Artery Embolization for the Treatment of Chronic Subdural Hematoma: A Systematic Literature Review–Brandon Bond, Kamila Bond, Jorge C. Kattah P12.9-012 Predictors Of Length Of Hospitalization In Patients Admitted With Intracerebral Hemorrhage In The United States– Sairah Bashir, Saqib A. Chaudhry, Mohammad-Rauf A. Chaudhry, Iqra N Akhtar, Werdah Zafar, Adnan I. Qureshi P12.9-013 Timing of Diffusion Weighted Imaging Lesions after Primary Spontaneous Intracerebral Hemorrhage–Rajeev Garg, Mohammad Alberawi, Bichum Ouyang, Sayona John, Mehmet Kocak, Sudeep Bhabad, Miral Jhaveri, Thomas P. Bleck P12.9-014 Predictors and outcomes of Intra Cerebral Hemorrhage among End Stage Renal Disease patients: a national perspective–Achint Patel, Ivan Wudexi, Aaron Rodas, Mousa Dajjani, Shakumar Patel, Don Rajan, Abhishek Lunagariya P12.9-015 Risk Stratification by Hemorrhage Location for Intracerebral Hemorrhage Patients in Large Administrative Databases–Cole Chapman, Jennifer Meeks, Arvind Bambhroliya, Sheeba Sujit, Sunil Sheth, Sean I. Savitz, Wendy C. Ziai, Daniel F. Hanley, Farhaan S. Vahidy

CME

P12.9-016 Validation and comparison of prognostic scores for spontaneous intracerebral hemorrhage in an Argentine cohort–Maria Agustina Ruiz Yanzi, Julian Nicolás Acosta, Melanie Sanchez, Maximiliano Darakdjian, Guido Jose Falcone, Sebastian F. Ameriso P12.9-017 Predictive ability of intracerebral hemorrhage scales in minimally invasive hematoma evaluation–Terrence Tian, Rui Song, Kaitlin Johanna Reilly, Alexandra S. Reynolds, Cappi C Lay, Neha Dangayach, Christopher Kellner, John Liang P12.9-018 Serum NfL Predicts Hemorrhage Recurrence In Cerebral Amyloid Angiopathy-Related Hemorrhage–Ya Su, Xin Cheng, Qiang Dong P12.9-019 Hereditary Cerebral Amyloid Angiopathy, Piedmont Type Mutation–Mariel Kozberg, Susanne van Veluw, Matthew Frosch, Steven M. Greenberg P12.9-020 Prognostic value of Serum MatrixMetalloproteinases-9 level in patients spontaneous Intracerebral Hemorrhage in North Indian Population–Ritesh Raj, Ram Sagar, Amit Kumar, Kameshwar Prasad P12.9-021 Marijuana and Hemorrhagic Stroke: Does a Risk Exist?–Carol Swetlik, Ibrahim Migdady, Leen Hasan, Carrie Price, Sung Min Cho Fungi, Parasites, and Spirochetes 2

P12.10-001 New Onset Sensorimotor Epilepisa Partialis Continua as an initial presentation of Neurocysticercosis–Nicole Thomason, Mario Sandoval, Shivika Chandra P12.10-002 An Elusive Case of Chronic Meningitis due to Candida Dubliniensis in a Patient with Remote IV Drug Use–Robert McInnis, Albert Hung, Nagagopal Venna P12.10-003 Cryptococcal Fungemia Leading to Cerebral Venous Thrombosis in a Multiple Sclerosis Patient on Fingolimod.– Joel Kammeyer, Nicole Lehmann P12.10-004 Simultaneous presentation of Neurocysticercosis and Giant Perivascular Spaces– Yasar Sattar, Erfanul Saker

186 2020 AAN Annual Meeting

0 Wednesday, April 29 12:00 p.m.–1:00 p.m. P12.10-005 Cryptococcal meningitis complicated by cerebellar ischemic strokes and obstructive hydrocephalus in a patient with multiple sclerosis on fingolimod–Kelsey Anne Coleman, Joseph Eric Malone, Grant William Zeigler, Tiffany L. Fisher P12.10-006 Vertebrobasilar Insufficiency Caused by Disseminated Coccidioidomycosis with Central Nervous System Involvement - A Case Report– Amputch Karukote, Smathorn Thakolwiboon, Jie Pan, Henrik Wilms P12.10-007 Three cases of Creutzfeldt-Jakob Disease after Hurricane Maria in Puerto Rico: Is this a coincidence?–Maria E. Garcia Ayala, Rhaisa Castrodad- Molina, Ernesto Borrero-Quintana, David Blas-Boria, Viviana Ivonne Orozco, Eduardo Labat P12.10-008 A Family of Sporadic Creutzfeldt-Jakob Disease (sCJD).–Dipali P. Nemade, Jason Dean Adams, Samrina Hanif, Justin Michael Nolte, Dharampreet Singh P12.10-009 Neurosyphilis in Adult Patients Presenting with Meningoencephalitis to The University Teaching Hospital in Lusaka, Zambia–Mashina Chomba, Sombo Fwoloshi, Eugene Mubanga, Igor J. Koralnik, Omar Siddiqi, Deanna Saylor P12.10-010 When a Zebra Starts Galloping Like a Horse: A Case of Ocular Syphilis–Abigail Lofchie, Mark Milstein, Emma Wallace P12.10-011 Histoplasmosis of the central nervous system in an immunocompetent male–Sydney Moseley, Alexandra Nee, Kristina Maselli, Robert Fekete Tuberculosis and Other Bacterial Infections 1

P12.10-012 Mycobacteria avium complex (MAC) Brain Abscess in an AIDS Patient: Case Report and Literature Review–J. Clay Goodman, Shankar P. Gopinath, Wedad Alfarkh, Kenneth Muldrew, Andrew DiNardo P12.10-013 A critically ill patient with central nervous system tuberculosis and negative initial screening workup–Adeel Zubair, Mark Landreneau, Jens Witsch, Robert K. Fulbright, Anita J Huttner, Kevin N. Sheth, David Y. Hwang

P12.10-014 Brain Abscess Complicating a Closed-Head Traumatic Intracerebral Hemorrhagic Contusion–Earllondra Brooks, Lauren Kett, Joshua P. Klein P12.10-015 Brain Abscess Due to Yokenella regensburgei in a Patient with Primary CNS Lymphoma– Serendipity Zapanta Rinonos, Tiffany Sexton, Kimberly Nichols, Oveimar De La Cruz P12.10-016 Streptococcus Intermedius Acute Bacterial Myelitis: A Unique Case of Spinal Cord involvement with an unusual CNS Offender–Ahmed Abbas, Faisal Abdelaziz Ibrahim P12.10-017 An Unusual Case of TB-associated Acute Demyelinating Encephalomyelitis in a 7-month-old Infant–Jennifer H. Yang, Kimmy Vuong, Amaran Moodley, Dillon Yungyi Chen P12.10-018 A Case of Cerebral Vasculitis Due to Neurobartonellosis–Meryim Poursheykhi, Tanu Garg, Christian Cajavilca, Rajan Ramji Gadhia P12.10-019 Community Acquired Meningitis from Serratia Marcescens in an Adult: A Case Report–Mariyam Humayun, Shruti Prabodh Agnihotri Child Neurology and Developmental Neurology: Brain Injury: HIE, Stroke, Trauma, and Inflammation 1

P12.11-001 Transcriptional and Epigenetic Changes of Brain Derived Neurotrophic Factor Following Prenatal Stress: A Systematic Review of Experimental Studies–Negin Badihian, Shervin Badihian, Seyede Shahrbanoo Daniali, Roya Kelishadi P12.11-002 Death After Birth Asphyxia in the Cooling Era–Fatema Juma Al Amrani, Eric Racine, Michael I. Shevell, Pia Wintermark P12.11-003 Sarnat Staging as Clinical Prognostic Tool to Assess Neurodevelopmental Outcome at 24 months of Age in Full Term Infants Treated with Therapuetic Hypothermia for Hypoxic Ischemic Encephalopathy–Danielle Gordon, Ian Griffin, Harvey S. Bennett P12.11-004 Distinctive MRI Pattern of Perinatal Brain Injuries Arising from Placental Inflammation and Hypoxia-Ischemia in Term = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Wednesday, April 29

Mailo, Aleksandra Mineyko, Mahendranath Moharir, Sebastien Perreault, Jonathan Smith, Daniela Pohl P12.11-015 Use of anticoagulation does not increase hemorrhagic transformation following cardioembolic stroke in childhood– Pin-Yi Ko, Hedieh Khalatbari, Mark Wainwright, Catherine M. AmlieLefond

POSTER SESSIONS

Newborns–Fatema Juma Al Amrani, Guillaume Sebire, Moy Fong Chen, Pia Wintermark, Christine Saint-Martin P12.11-005 Intracranial hemorrhage in term and latepreterm neonates–Amanda Sandoval Karamian, Qian-Zhou Yang, Kristen Yeom P12.11-006 A rare presentation of perinatal spinal cord infarct–Gilad Muth, Devorah Segal P12.11-007 School Performance and Psychiatric Morbidity 6 Years after Pediatric Acute Disseminated Encephalomyelitis: A Nationwide Population-based Cohort Study– Magnus Spangsberg Boesen, Annika Langkilde, Alfred Peter Born, Melinda Magyari, Morten Bjorn Blinkenberg, Tanuja Chitnis, Lau Thygesen, Frank Eriksson P12.11-008 Pediatric MS Subjects Have Reduced Walking Capacity Compared to Healthy Controls– James Nick Brenton, Emma Woolbright, Sue Min, Hitoshi Gene Koshiya, Myla D. Goldman P12.11-009 Development of Silent Brain Lesions in Pediatric Patients with anti-MOG-Associated Demyelination–Giulia Fadda, Julia O’Mahony, Robert Allan Brown, Denise Castro, Giulia Longoni, Helen Branson, Leonard Herman Verhey, E. Ann Yeh, Ruth-Ann Marrie, Patrick Waters, Douglas L. Arnold, Brenda Banwell, Amit Bar-Or P12.11-010 Early magnetic resonance imaging as a predictor of outcome in pediatric traumatic brain injury–Anna Janas, Zachary D. Threlkeld, Max Wintermark, Sarah Lee P12.11-011 Outcomes in Acute Necrotizing Encephalopathy of Childhood–Nurin Chatur, Giulia Longoni, E. Ann Yeh P12.11-012 Mimickers of Autoimmune Encephalitis: Two Pediatric Cases–Jenny Lin, Grace Gombolay P12.11-013 Neurological Presentations Associated with Infectious Gastroenteritis in Children–Matthew Hiller, Kevin Messacar P12.11-014 Pediatric Stroke Protocols in Canada–Maria Gladkikh, Hugh John McMillan, Andrea Andrade, Ishvinder Bhathal, Cyrus Boelman, Janette Alexandra

AAN.com/view/20AM 187

POSTER SESSION 13

CME

0 Wednesday, April 29 5:30 p.m.–6:30 p.m.

Wednesday, April 29

POSTER SESSIONS

Poster Session 13 1. Multiple Sclerosis: Clinical Practice and Decision making 3: 1-001 to 1-015 Neuromyelitis Optica and Other Autoimmune Disorders 1: 1-016 to 1-022 2. Autoimmune Neurology: NMOSD and MOG 1: 2-001 to 2-011 3. Functional Neurologic Disorders and Miscellaneous Movement Disorders Topics 2: 3-001 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/Neurostimulation and Diet Therapies 3: 4-001 to 4-003 Epilepsy/Clinical Neurophysiology: Antiseizure Medications 2: 4-004 to 4-010 5. General Neurology: Clinical Case Reports 5: 5-001 to 5-011 6. Headache Science 1: 6-001 to 6-010 7. Peripheral Neuropathy 3: 7-001 to 7-014 8. Behavioral and Cognitive Neurology: Non neurodegenerative Disorders 1: 8-001 to 8-011 9. Cerebrovascular Disease: Intracerebral Hemorrhage, SAH, Aneurysms, and Vascular Malformations 2: 9-001 to 9-021 10. Fungi, Parasites, and Spirochetes 3: 10-001 to 10-005 Tuberculosis and Other Bacterial Infections 2: 10-006 to 10-017 11. Child Neurology and Developmental Neurology: Brain Injury: HIE, Stroke, Trauma, and Inflammation 2: 11-001 to 11-006 Child Neurology and Developmental Neurology: Neurogenetics 1: 11-007 to 11-015 Multiple Sclerosis: Clinical Practice and Decision-making 3

P13.1-001 Cladribine Decreases CD95-expressing CD4+ and CD8+ Cells in Lymphoid Organs in Naïve Marmosets (Callithrix Jacchus)– Yolanda Kap, Ursula Boschert, Bert t’Hart P13.1-002 Long-term Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis: Analysis of Real World Data From the Italian Multiple Sclerosis Registry (CLARINETMS)–Francesco Patti, Andrea Visconti, Antonio Capacchione, Maria Trojano P13.1-003 Adult-Onset Recurrent Fulminant Acute Disseminated Encephalomyelitis (ADEM) Requiring Hemicraniectomy – A Case Report–Maria Antonietta Mazzola, Nilufer Yalcin, Fatemeh Khadjevand, David P. Lerner, Claudia J. Chaves P13.1-004 Year 1 Performance of Adveva®, a Patient Support Program (PSP) for Patients Taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing

Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK)–Kate Morgan, Nadine Lott, Marco Lyons P13.1-005 A Real-World Retrospective Analysis of Outcomes in Multiple Sclerosis Patients Who Transitioned to Alemtuzumab After Rituximab or Ocrelizumab–Marie Coste, Miriam C Fenton, Zia Choudhry, Mark Ozog, Lobat Hashemi, Elizabeth Poole, Michael Behling, Kathleen Mortimer, Bill Aschenbach, Ben Guikema P13.1-006 The patients´ perspective in multiple sclerosis: the SymptoMScreen questionnaire correlates with clinical characteristics and clinicianassessed outcomes–Jose Meca Lallana, Miguel Angel Hernandez Perez, Angel Perez Sempere, Luis Brieva Ruiz, Elena Garcia-Arcelay, Maria Terzaghi, Gustavo Saposnik, Jorge Maurino, Javier Ballesteros P13.1-007 Pharmacodynamic Biomarkers of Interferon ß-1a: Assessment in Patients Receiving Long-Term Treatment with Subcutaneous Interferon ß-1a–Mark S. Freedman, Jerome

188 2020 AAN Annual Meeting

Wojcik, Mauro D’Antonio, Yann Hyvert, Sofia Stinchi, Vittorio D’Urso, Fernando Dangond P13.1-008 Dynamic Cohorts in Multiple Sclerosis: A Proactive Approach for Safety Monitoring and Comparative Effectiveness– Meritxell Sabidó Espin, Michael Batech, Caroline Foch, Emmanuelle Boutmy, Patrice Verpillat P13.1-009 Baseline Patient and Caregiver Characteristics From a Prospective, Noninterventional, Real-World Study (REALITY) on the Effect of Alemtuzumab on Fatigue and Other Patient- and Caregiver-Reported Quality-ofLife Outcomes in Patients With RRMS–Stig Eriksen, Job van Exel, Jette L Frederiksen, Helle Hvilsted Nielsen, Oivind Torkildsen, Augusto Rini, Luca Massacesi, Margaret Mondino, Massimiliano Mirabella, Alessandra Lugaresi, Giacomo Lus, Damiano Paolicelli, Maria Luisa Caniatti, Jon Tsai, Elio A. Scarpini P13.1-010 Which Brain Lesion Locations Differentiate Multiple Sclerosis (MS) from Neuromyelitis Optica Spectrum Disorders (NMOSD) and MOG Antibody Disorder (MOGAD)?–Jasmin Patel,

Antonio Pires, Anna Derman, Erik Charlson, Girish Fatterpekar, Ilya Kister P13.1-011 A Rare Case of Balos Concentric Sclerosis (BCS) in a Patient with Multiple Sclerosis (MS)–Bradley Shane, Melissa Ashley-Marie Martinez P13.1-012 Atypical myelitis in patients with multiple sclerosis: characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders–Kevin Bigaut, Mikael Cohen, Jonathan Ciron, Bertrand Bourre, Philippe Kerschen, Pierre Labauge, Nicolas Collongues P13.1-013 Two Cases with Acute Tumefactive non enhancing Demyelinating lesions; The Significance of Gadolinium Contrast enhancement in MRI–Faisal Abdelaziz Ibrahim, Syed Rizvi, Matthew Weber, Joshua Battley, Arooj Kohli, James M. Gilchrist P13.1-014 A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFYMS Baseline Analysis–Nicola De Stefano, Anat Achiron, Frederik = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number Barkhof, Andrew Chan, Tobias Derfuss, Suzanne J. Hodgkinson, Letizia M. Leocani, Xavier Montalban, Alexandre Prat, Klaus Schmierer, Finn Sellebjerg, Patrick Vermersch, Heinz Wiendl, Birgit Keller, Sanjeev Roy P13.1-015 Siponimod Penetrates, Distributes and Acts on the Central Nervous System: Translational Insights–Marc Bigaud, Bettina Rudolph, Emmanuelle Briard, Christian Beerli, Anna Schubart, Anne Gardin Neuromyelitis Optica and Other Autoimmune Disorders 1

P13.2-001 Increased Likelihood of Relapse in Pediatric AntiMOG Acute Disseminated Encephalomyelitis (ADEM) and Optic Neuritis (ON) vs. Seronegative ADEM and ON Patients–Kristen Fisher, Alfred Balasa, Nikita Shukla, Timothy E. Lotze P13.2-002 Optic Chiasm Involvement Associated with Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies–Deena Tajfirouz, Sean J. Pittock, Eoin P. Flanagan, Amy Kunchok, M. Tariq Bhatti, John Chen P13.2-003 Clinical Phenotypes, Predictors of Relapse, and Response to Treatment in Myelin Oligodendrocyte GlycoproteinAntibody Associated Disorders– Wendy Sulina Vargas, Anusha Yeshokumar, Seth Nathatn Levin, Christopher Langston, Claudiu Iulian Diaconu, Rebecca Gabrielle Straus Farber, Kiran Thakur, Libby Levine, Kaho Onomichi, Katherine Nelson, Michelle Fabian, Ilena George, Ilana B. Katz Sand, Sylvia Klineova, Rachel Brandstadter, Sam H. Horng, Fred D. Lublin, Nancy M. Nealon, Deepak Jyotindra Soneji, Kiersten Marie Dykstra, Zongqi Xia, Philip De Jager, Claire Riley P13.2-004 Treatment Strategies in anti-myelin oligodendrocyte glycoprotein (MOG) associated Demyelinating Disease in a Pediatric Cohort–Anita M. Fletcher, John M. Wright, Michael Sweeney P13.2-005 Myelin oligodendrocyte glycoprotein (MOG) antibodies: results from first 1,045 specimens tested at a clinical reference laboratory–Sat Dev Batish, Vivekananda Datta, Jeff S Radcliff, Emily Katzman, Brian Sansoucy P13.2-006 Neuromyelitis Optica Spectrum Disorders and Systemic Lupus Erythematosus: Case Series from an University Center–Vanessa Cristina Colares Lessa, Caroline Lourenço Medeiros, Luis Felipe Haberfeld Maia, Arthur Ramalho Monfredinho, Paola Teixeira Soria,

Functional Neurologic Disorders and Miscellaneous Movement Disorder Topics 2

P13.3-001 A Case of Two Brothers: Should we look beyond a Cerebral Palsy diagnosis?– Ihedinachi Ndukwe, Michael Hutchinson, Sean O’Riordan P13.3-002 A Case Report of Two Siblings Aicardi-Goutières Syndrome Type 2–Camila Fujiwara Murakami, Erika Nakagawa, Alex

Meira, Eduardo Pereira, Francisco Germiniani, Helio Afonso Ghizoni Teive P13.3-003 The association of gender, age of onset and phenotype in Functional Movement Disorders: The FMD-GAP Study–Sarah C. Lidstone, Michael Costa-Parke, Tommaso Ercoli, Samantha K. Holden, Michelle Fullard, Jon Stone P13.3-004 Quantitative oculomotor assessment in X-linked dystonia parkinsonism: a potential motor biomarker–Christopher D. Stephen, David Balkwill, Patrick Acuna, Susan King, Richard F. Lewis, Nutan Sharma P13.3-005 Treatment of Paroxysmal Kinesigenic Dyskinesia With Use of Low Dose Oxcarbazepine: Experience at a Pediatric Tertiary Care Center.– Mariam Hull, Farida Abid, Mered Parnes P13.3-006 A Novel SPAST/SPG4 Splice-Site Mutation in a Family with Dominant Hereditary Spastic Paraplegia–Nathaniel Michael Robbins, Thomas L. Winder, Pedro Gonzalez-Alegre, Nicky Wu, Sean Soorena Zadeh, Tanya Bardakjian P13.3-007 Newly Identified Dynactin Variant (DCTN1 p.Tyr78His) in a Patient with Perry Syndrome–Marek Cierny, Sam Hooshmand, Dominic B. Fee, Ryan T. Brennan P13.3-008 SANDO Syndrome associated with new POLG heterozygous gene mutation: Case Report.–Daniel Alejandro Crespo, Deepmala Nandanwar, Sachin Kedar, Danish Bhatti P13.3-009 Testing a Potential Marker for the Diagnosis of Functional Movement Disorders– Jessica Tom, Zakary Woods, Chen Yeh, Danny Bega P13.3-010 An Unusual Case of Untreated Galactosemia in an Adult Woman–Keith Groshans, James Price, Jason S. Hawley P13.3-011 Acute Onset Chorea in Profound Hypophosphatemia with Bilateral Basal Ganglia Lesions– Chaitanya Medicherla, Robert Staudinger P13.3-012 Mass Media and Mass Psychogenic Illness–Jennifer McVige

AAN.com/view/20AM 189

Wednesday, April 29

Autoimmune Neurology: NMOSD and MOG 1

Maria Luisa Rodrigues Prata, Rafael Lemos, Joao Marcos Campos Ferreira, Fernanda Cristina Rueda Lopes, Caroline Bittar Braune, Gabriel Rodriguez De Freitas, Marcia Cristina Antu Ribas, Osvaldo J M Nascimento P13.2-007 Neuromyelitis Optica Spectrum Disorder (NMOSD) Misdiagnosed as Spinal Cord Infarction–Odai Abdalla, Carlos Ynigo Dy Lopez, Irine Siraj, Rashid Ali Ahmed, Corey A. McGraw P13.2-008 Adding FUEL to the FLAMES: FLAIR-variable Unilateral Enhancement of the Leptomeninges (FUEL) in MOG-IgG-Associated Disease–Adrian Budhram, Amy Kunchok, Eoin P. Flanagan P13.2-009 Anti-MOG Antibody associated Encephalomyelitis in an HIV-Positive Patient–Karissa Arca, Marie Francisca Grill P13.2-010 Autologous haematopoietic stem cell transplantation in multiple sclerosis and other immune-mediated neurological diseases: guidelines and recommendations of the European Society for Blood and Marrow Transplantation and the Joint Accreditation Committee of the International Society for Cellular Therapy–Basil Sharrack, Riccardo Saccardi, Tobias Alexander, Badoglio Manuela, Joachim Burman, Dominique Farge, Raffaella Greco, Helen Jessop, Majid Kazmi, Kirill Kirgizov, Myriam Labopin, Giovanni Luigi Mancardi, Roland M G Martin, John Moore, Paolo Muraro, Montserrat Rovira, Maria Pia Sormani, John Snowden P13.2-011 Clinical Course and Treatment Response in a Cohort of Pediatric Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease– Xinran Xiang, Stephen Russell Deputy, Rashmi Rao

POSTER SESSIONS

P13.1-016 Improving individualized monitoring strategy for Rituximab treatment in patients with Neuromyelitis Optica Spectrum Disorders: development of a high sensitive ddPCR assay for CD19 mRNA quantification.–Antonio Bertolotto, Paola Valentino, Luca Mirabile, Jessica Bertolo, Benedetta Mussolin, Giulia Siravegna, Serena Martire, Fabiana Marnetto P13.1-017 Risk Stratification for Demyelinating Disease Secondary to TNF-Alpha Inhibitor Exposure– Amy Wei-Hsin Yu, Maggie Pecsok, Erin Longbrake, Sarah Flanagan Wesley P13.1-018 Functional Outcomes Differ Between Vascular and Inflammatory Myelopathies–Maria Alejandra Garcia-Dominguez, Xue Yi Chen, Olwen Murphy, Paula Barreras, Jose Alejandro Ramirez, Carlos A. Pardo-Villamizar P13.1-019 White Matter Myelin Alterations are Diffuse in Neuromyelitis Optica Spectrum Disorders and Prevail on Axonal Damage–Laura Cacciaguerra, Maria Assunta Rocca, Loredana Storelli, Marta Radaelli, Vittorio Martinelli, Massimo Filippi P13.1-020 Cladribine supresses the activity of neuromyelitis optica: two year follow up study–Konrad Rejdak, Ewa Papuc P13.1-021 A Rare Presentation of Biopsy-Proven Necrotizing Neurosarcoidosis in a Woman with Exposure to MDR-TB–John Peters, Bogdan Ioannis Patedakis Litvinov, Nicholas Blondin P13.1-022 Serum biomarkers and patient age in multiple sclerosis and aquaporin-4 antibody-positive

neuromyelitis optica spectrum disorders–Eun-Jae Lee, YoungMin Lim, Seungmi Kim, Lyn Kyung Choi, Hyunjin Kim, Seung Min Kim, Geonwoo Kim, Hyewon Kim, Seulki Lee, Kwang-Kuk Kim

Wednesday, April 29

POSTER SESSIONS

POSTER SESSION 13 P13.3-013 A Comparison of FND Diagnostic Criteria: Retrospective Chart Review–Kevin James Kyle, Allan Ding Wu, Federica Agosta P13.3-014 Characterization of a large retrospective cohort of functional movement disorders patients from the University of Colorado Health system–Zachary Macchi, Samantha K. Holden P13.3-015 Correlation Between Dysautonomic Symptoms and Severity in Patients with Hereditary Spastic Paraplegia–Erika Nakagawa, Camila Fujiwara Murakami, Daniel Balaban, Joao M Marcon, Debora Bauer Schultz, Carlos Camargo, Helio Afonso Ghizoni Teive P13.3-016 Partial Stiff Person Syndrome as a Stroke Mimic– Duarte G. Machado, Kendall Anne Hodges P13.3-017 Effects of ATP1A3 Mutations on Brain Functional Network Connectivity–Christopher Thomas Whitlow, Mohammad Kawas, Jared Cook, Jeongchul Kim, Kiran Sai, Beverly M. Snively, Ihtsham Haq, Kathleen J. Sweadner, Laurie J. Ozelius, Allison Brashear Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/ Neurostimulation and Diet Therapies 3

P13.4-001 Incidence of Leukopenia in Ketogenic diet: A single-center experience–Eric Segal, Juliann M. Paolicchi, Enrique A. Feoli, Nicole Dvorak, Bianca Amorese P13.4-002 Effect of Ketogenic Diet on Serum Levels of Interleukin-6 and Interleukin1ß in Pediatric Patients with Drug-resistant Epilepsy–Magith Thambi, Varsha Prabhu, Kurupath Radhakrishnan, MK Unnikrishnan, Janak Kanthimathi Nathan P13.4-003 Hyperperfusion in the cerebellum in patients with epileptic seizures–Masako Kinoshita, Kazuki Nakahara, Kaoru Obata, Ryota Matsunari, Hiromitsu Tabata

CME

Epilepsy/Clinical Neurophysiology: Antiseizure Medications 2

General Neurology: Clinical Case Reports 5

Hyperfamiliarity for Faces–Nishi Chandrasekaran, Alan R. Hirsch, Nehal Jain, Filza Vayani

4 5 6

P13.4-004 Perampanel May Improve Insomnia Through a Decrease in Anxiety in Patients with Epilepsy–Mina Jung, Sungyang Jo, Hyojae Kim, HyunWoo Kim, YoungSeo Koo, SangAhm Lee P13.4-005 Post Hoc Univariate and Multivariate Analyses to Identify Clinical Factors Associated with a 50% or 75% Response in a Phase III Trial of Adjunctive Perampanel in Patients with Primary Generalized Tonic-Clonic Seizures (PGTCS)–Christian Brandt, Gregory L. Krauss, Robert T. Wechsler, Anna Patten, Leock Y. Ngo, Manoj Malhotra P13.4-006 Efficacy and Safety of Adjunctive Perampanel 4 mg/day in Pediatric Patients (Aged 4 to– Katherine Moretz, Manoj Malhotra, Anna Patten, Leock Y. Ngo P13.4-007 Perampanel Exposure– Response Relationships for Cognition and Safety in Pediatric Patients (Aged 4 to–Oneeb Majid, Larisa Reyderman, Jim Ferry, Ziad Hussein P13.4-008 Pharmacokinetic and Food Effect Assessment of XEN496 (Pediatric Formulation of Ezogabine) in Healthy Adults and Relative Bioavailability Assessment with Potiga® (Adult Formulation of Ezogabine)–Jay A Cadieux, Rostam Namdari, Gregory N. Beatch, Ernesto Aycardi P13.4-009 Development of Pediatric Formulations of the Potassium Channel Opener Ezogabine and the NaV1.6Selective Sodium Channel Blocker XEN901 for the Treatment of Developmental and Epileptic Encephalopathies–Jay A Cadieux, Matthew D Tandy, Rostam Namdari, Ernesto Aycardi P13.4-010 Efficacy and Safety of Eslicarbazepine Acetate According to Epilepsy Etiology: A Post-hoc Analysis of Three Phase III Trials in Adults with Focal Seizures– David Cantu, Todd Grinnell, Luis Magalhaes, Rui Loureiro, Robert Tosiello, David Blum

190 2020 AAN Annual Meeting

0 Wednesday, April 29 5:30 p.m.–6:30 p.m.

P13.5-001 An Interesting twist in the diagnosis of intracranial lesions in an immunocompromised patient–Aparna M. Prabhu, Aparna M. Prabhu P13.5-002 Dysphagia as the Initial Presentation of Varicella Zoster Virus Meningitis: A Case Report– Daniel Minsuk Oh, Brian Scott LaGrant, Chi-Chang David Lin P13.5-003 A Thoracentesis with a Neurological Surprise–Sakinah Sabadia, Kaleb H. Yohay P13.5-004 Uhthoff’s Phenomenon in Amyotrophic Lateral Sclerosis– Madhusudan Patel, Karla Licona, Alan R. Hirsch P13.5-005 Prominent Corticospinal Tract Changes on MRI in Bulbar Onset Amyotrophic Lateral Sclerosis (ALS)–Derek Gerard Neupert, Casey R. Dunn, Aimee M. Aysenne P13.5-006 Longitudinal bulbar and respiratory declines in Amyotrophic Lateral Sclerosis (ALS)–Nnenna Asidianya, Lawrence Korngut, Angela L. Genge, Agessandro Abrahao, Sanjay Kalra, Lorne H. Zinman, Yana Yunusova P13.5-007 Ataxia and ophthalmoplegia: an atypical case of Miller Fisher Syndrome (MFS) with anti-GAD antibody–Ali Reza Shoraka, Diaa Hamouda, Bhanu Gogia, Xianping Li P13.5-008 PET Imaging in Rapidly Progressive Neurodegeneration – an Underutilised Resource?– Michael Doyle, Sean Connolly, Ronan Killeen, Niall Tubridy P13.5-009 Muscle Satellite Cell Ablation Leads to Disorganization of Muscle Microvasculature– Kyutae Kim, Kana Ishii, Yoko Asakura, Mayank Verma, Atsushi Asakura P13.5-010 Serum Neurofilament Light Chain Concentrations Withstand Delayed Freezing up to 24 Hours – a Pre-analytical Study.–Patrick Altmann, Fritz Leutmezer, Miranda Stattmann, Raphael Wurm, Heidemarie Zach, Henrik Zetterberg, Paulus Stefan Rommer, Thomas Berger, Gabriel Bsteh P13.5-011 No Need for Netflix; TV Rerun Syndrome: The Result of Concurrent Déjà vécu And

Headache Science 1

P13.6-001 Migraine-related disability and co-morbid depression among migraineurs in Ethiopia: a cross-sectional study–Biniyam Alemayehu Ayele P13.6-002 CGRP, PACAP, and VIP serum Levels in Chronic Migraine: are they Usefull in Clinical Practice? A Case-Control Study–Agustin Oterino Duran, Sara Perez-pereda, Maria Toriello, Vicente Quintanilla, Fernando Iglesias, Javier-Gonzalo Ocejo, Jesus Castillo P13.6-003 Development of a Novel Drug for the Prevention of Migraine based on Receptor Activity Mapping and Achievement of a Target Receptor Profile–Miguel Guzman, Thomas Armer, Scott W. Borland, Robert Fishman, Matthew Leyden P13.6-004 Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range–Charlie Conway, Gene Dubowchik, Robert Croop, Vlad Coric P13.6-005 Temporalis muscle thickness as surrogate marker of activation of motor component of trigemino-vascular system in Migraine patients–Amit Shankar Singh, Jeenendra Prakash Singhvi, Abhishek Prasad, Arshdeep Singh, Harpreet Singh Mann, Shehbaz Singh Sidhu P13.6-006 Novel Receptor Activity Mapping of Methysergide and its Metabolite, Methylergometrine, Provides a Mechanistic Rationale for both the Clinically Observed Efficacy and Risk of Fibrosis in Patients with Migraine–Miguel Guzman, Thomas Armer, Scott W. Borland, Robert Fishman, Matthew Leyden P13.6-007 Neural Correlates of Visuospatial Processing in Migraine Patients: Does the Pain Network Interfere?–Roberta Messina, Gianna Carla Riccitelli, Bruno Colombo, Alessandro Meani, Massimo Filippi, Maria Assunta Rocca

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Peripheral Neuropathy 3

Sotirios Tsimikas, Shiangtung W. Jung, Louis St. L. O’Dea, Eugene Schneider, Richard S. Geary, Brett Monia Behavioral and Cognitive Neurology: Nonneurodegenerative Disorders 1

P13.8-001 Determinants of aphasia recovery in early poststroke phase: Exploratory use of decision tree analysis–Durjoy Lahiri, Souvik Dubey, Alfredo Ardila, Debasish Sanyal, Biman Kanti Ray P13.8-002 Implicit identification of disability in right brain stroke survivors.–A. M. Barrett, William Graves, Marinos Pylarinos, Jenny Masmela, Olga Boukrina P13.8-003 Association of Stroke Health Literacy with Stroke Risk Factors and Post- Stroke Depression–Callista Clairmont, Amelia Karen Adcock, Amelia Karen Adcock P13.8-004 Transient global amnesia is related to aberrant higher functional activity in the salience network and lower functional activities in the default mode network–Seung-Ah Lee, Bori Kim, Kee-Duk Park, Soo Mee Lim, Jee Hyang Jeong, Geon Ha Kim P13.8-005 Chronotaraxis: An Underestimated Right Hemisphere Syndrome–Michael Hoffmann P13.8-006 Fregoli Delusion: A disorder of Misidentification with Temporal Lobe Metastasis Secondary to Lung Carcinoma– Danny Jayasuriya, Salman Assad, Cailtin Mulvihill, Justin Michael Nolte, Paul Brent Ferguson P13.8-007 Capgras syndrome in a 21-year-old patient with a chondrosarcoma compressing the right temporal lobe–Jodi Nelson P13.8-008 Witzelsucht or Compulsive Joking and Loss of the Right Frontal Lobe–Leila Parand, Golnoush Akhlaghipour, Oleg Yerokhin Yerstein, Mario F. Mendez P13.8-009 A Surgically Treated Case of Partial Kluver-Bucy Syndrome–Avalon O’Connor, Soliman Mohamed, Dimitar Saveski, Saba Shahab, Jacob Im, Sydney Eaton, Elise Quint, Soliman Mohamed P13.8-010 Intracranial solitary fibrous tumor presenting as Gerstmann syndrome: A double

rarity!–Jordan C. Gargiulo, Prashant Natteru, Gilbert Ochieng Mbeo, Hartmut Uschmann P13.8-011 From Kid to K-9: A Case of Benzodiazepine Withdrawal-Induced Zoopsic Intermetamorphosis–Hoda Seens, Alan R. Hirsch Cerebrovascular Disease: Intracerebral Hemorrhage, SAH, Aneurysms, and Vascular Malformations 2

P13.9-001 The Oldest Bleeds in the Oldest State: Hemorrhagic Stroke in the Nonagenarian Population–Robert Michaud, Michael Patrick Harlan Stanley, John Dziodzio, David Seder P13.9-002 National Estimates Of Recurrent Intracranial Hemorrhage Among Patients With Ruptured Intracranial Aneurysms– Mohammad-Rauf A. Chaudhry, Saqib A. Chaudhry, Iqra N Akhtar, Werdah Zafar, Yun Fang, Ameer Hassan, Sairah Bashir, Mohsain Gill, Adnan I. Qureshi P13.9-003 The impact of obstructive sleep apnea on ruptured intracranial aneurysm– Oleg Y. Chernyshev, Shyamal Chandra Bir, Hugo Cuellar-Saenz, Roger E. Kelley P13.9-004 Acute Multifocal Atraumatic Convexity Subarachnoid Hemorrhage–Katarina B. Dakay, Katarina B. Dakay, Ali Mahta, Karen L. Furie, Shadi Yaghi, Shawna M. Cutting P13.9-005 Incidence and Significance of EEG Abnormalities in Atraumatic Convexity Subarachnoid Hemorrhage– Katarina B. Dakay, Jacob Didion, Lisa Knopf, Ali Mahta, Shadi Yaghi, Shawna M. Cutting P13.9-006 A Case of Early Rupture Following Flow-Diversion with Quantification of Hemodynamics and Aneurysmal Wall Stress using Additive Manufacturing and Particle Tracking Velocimetry– Melissa Cook, Ricardo MejaAlvarez, Nikhil Mehta, David Chason, Adam M. Willis P13.9-007 Prognosis on Admission of Aneurysmal Subarachnoid Hemorrhage (PAASH) scale validation in Mexican Population– Raul Anwar Garcia Santos, Antonio Arauz, Raúl Eugenio Valdes Galvan, Raul rodriguez cruces

AAN.com/view/20AM 191

Wednesday, April 29

P13.7-001 Atypical CISP: A New Variant of Chronic Immune Sensory Demyelinating Polyradiculoneuropathy–Shahar Shelly, Peter J. Dyck, Pritikanta Paul, Christopher J. Klein, P. James B. Dyck P13.7-002 Skin Biopsy as a Biomarker in Chronic Inflammatory Demyelinating Polyneuropathy– Fatma Yesim Parman, Ayse Nur Ozdag Acarli, Gokcen Unverengil, Nermin Gorkem Sirin, Arman Cakar, Hacer Durmus P13.7-003 Health Utilities and Acceptable States in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Preliminary data–Meg Mendoza, Hans D. Katzberg, Vera Bril, Carolina Barnett Tapia P13.7-004 Triggers and Risk Factors in Lumbosacral Radiculoplexus Neuropathy– Marcus Vinicius Rocha Pinto, Peng Soon Ng, Peter J. Dyck, Prabin Thapa, Ruple S. Laughlin, P. James B. Dyck P13.7-005 Subcutaneous Immunoglobulin (SCIG) Therapy for Neuromuscular Conditions; A KU Experience–Chaitanya V. Amrutkar, Mazen M. Dimachkie, Richard J. Barohn, Constantine Farmakidis, Omar Jawdat, Duaa Jabari, Mamatha Pasnoor P13.7-006 Vasculitic Neuropathy in a Patient with IgG4-related Disease–Benjamin Jiang, Isabelle Ayoub, Zarife Sahenk, Miriam L. Freimer P13.7-007 Acute polyradiculoneuropathy due to small molecule protein kinase

inhibitors in cancer treatment–Sara Joan Doyle, Adrian Opala, Karan S. Dixit, Jinny O. Tavee P13.7-008 Population Characteristics and Progression to Disability Among Patients with Small Fiber Neuropathy–Stephen A. Johnson, Nathan P. Staff, E. Matthew Hoffman, Christopher J. Klein P13.7-009 Combined central and peripheral demyelination: a case serie–Nicolas Dubuisson, Stephan Goedee, Peter Y.K. Van den Bergh, Frank Diekstra, Alexander Vrancken, Ludo Van Der Pol, Leonard H. Van den Berg P13.7-010 Diagnostic Criteria for Idiopathic Distal Sensory Polyneuropathy and Idiopathic Small Fiber Polyneuropathy– Jennifer Gewandter, Roy L. Freeman, Robert H. Dworkin, Catharina Faber, David N. Herrmann, Ahmet Hoke, Noah A. Kolb, Giuseppe Lauria, Rayaz Ahmed Malik, Anne Louise Oaklander, Amanda C. Peltier, Michael J. Polydefkis, James W. Russell, A. Gordon Smith, Roi Treister, Nurcan Uceyler P13.7-011 Analysis Of Clinical Symptomatology In Patients With TS- HDS Polyneuropathy Via Clinical Questionnaire–Sri Raghav Seshu Sista, Gregory M. Blume, Ruth Arms, Stanca Iacob P13.7-012 Phrenic Neuropathy Water Immersion Dyspnea: Clinical Findings and Need for Patient Counseling–Rocio Vazquez Do Campo, Shahar Shelly, Pritikanta Paul, Hongyan Bi, Andrea Boon, Jayawant Narayan Mandrekar, Robert Vassallo, Christopher J. Klein P13.7-013 Hereditary Transthyretin Amyloidosis and Carpal Tunnel Syndrome: Update on Opportunities for Earlier Diagnosis of Amyloidosis–Shivkumar Bhadola, K. H. Vincent Lau, Michelle Kaku P13.7-014 Rationale and Design of NEURO-TTRansform, a Phase 3 Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx (ION-682884) in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy–Sami L. Khella, Morie A. Gertz, Teresa Coelho, Cecilia Monteiro, Li-Jung Tai, Nicholas Viney, Gustavo Buchele, Michela Brambatti,

POSTER SESSIONS

P13.6-008 MRI findings in Neurosarcoidosis Patients with Headache as a Primary Presenting Symptom–Yamin Sallowm, Muhammad Affan, Mirela Cerghet, Ashhar Ali P13.6-009 Variables Affecting Rates of Neuroimaging and Referral for Headache–Katherine Lin Berry, Juliette Preston P13.6-010 A Design Framework for the Creation of a User-centered Headache Diary App Through a Qualitative Analysis of App Reviews–Kaitlyn Toy, Tyler Gumpel, Fatoumata Sow, Seher Ali, Mia T. Minen

Wednesday, April 29

POSTER SESSIONS

POSTER SESSION 13 P13.9-008 Intraventricular and Intravenous Milrinone for Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage–Naresh Mullaguri, Christine Ahrens, Christopher R. Newey, Pravin George, Dhimant Dani P13.9-009 Aneurysmal subarachnoid hemorrhage: frequency and clinical evolution according to aneurysmal size–Mario Ricciardi, Maximiliano Alberto Hawkes, Julian Nicolás Acosta, Sebastian F. Ameriso P13.9-010 National Estimates Of Recurrent Intracranial Hemorrhage Among Patients With Unruptured Intracranial Aneurysms: Effect Of Treatment Modality–Iqra N Akhtar, Saqib A. Chaudhry, Ameer Hassan, Sairah Bashir, Werdah Zafar, Mohammad-Rauf A. Chaudhry, Adnan I. Qureshi P13.9-011 Use of Pipeline Flow Diversion in Acute Ruptured Fusiform Anterior Cerebral Artery Aneurysm–Yahia M. Lodi, Andrew Hao, Ji Young Lee P13.9-012 Hemodynamic Alterations and Reversible Cervicomedullary Edema after Embolization of Cranial Dural Arteriovenous Fistula–Jessica Daley White, Steven Tversky, John Pile-Spellman, Rajanandini Muralidharan P13.9-013 Case Report of an Acute Progressive Spinal Dural Arteriovenous Fistula after Multiple Prolonged Flights–Shirley Ju, Anna Babaie P13.9-014 Endovascular Reconstruction Utilizing Flow Diversion Stenting in a Patient with Bilateral Giant Cavernous Internal Carotid Artery Aneurysms–Keithan Sivakumar, Jaspreet Johal, Chun Chu, Casey James Judge, Hussam A. Yacoub P13.9-015 Exceptional case of rapid growth and ruptured of a very small asymptomatic unruptured intracranial aneurysm which was stable over years in a 72 years old active smoker–Yahia M. Lodi, Ji Young Lee, Andrew Hao, Leona Ramose P13.9-016 A Teenager with a Peridural Ring Giant Supraclinoid Aneurysm–Franklyn Rocha Cabrero, Vasu Saini, Dileep R. Yavagal, Amer Malik

CME

P13.9-017 Rapid Onset Cognitive Impairment and Unusual Bithalamic Lesions–Conrad Joshua Goerz, Mohamed Somji, Jai Jai Shankar, Zul Kaderali, Sean J. Udow P13.9-018 Ruptured Spinal Aneurysm as a Complication of Post-Partum Angiopathy–Ahmad Nehme, Laurent Letourneau-Guillon, Celine Odier, Alexandre Y. Poppe P13.9-019 Flow-Diverting Stent Placement in a Pediatric Patient Through Radial Artery Approach– Ivo Bach, Pratit Dhirajlal Patel, Neil Majmundar, Priyank Khandelwal P13.9-020 Multiple watershed infarcts confirming the existence of a vascular steal phenomenon established around a brain arteriovenous malformation– Gabriel Torrealba Acosta, Pedro Diaz Marchan, Cesar Escamilla Ocanas, Rahul Damani P13.9-021 Headache at Onset of Intracerebral Hemorrhage and Associations with Outcome– Michael E. Reznik, Scott Moody, Tracy E Madsen, Shadi Yaghi, Matthew Schrag, Ali Mahta, Shyam Sudarshan Rao, Christoph Stretz, Linda C. Wendell, Bradford B. Thompson, Karen L. Furie, Brian Mac Grory Fungi, Parasites, and Spirochetes 3

P13.10-001 Lyme Neuroborreliosis presenting as multiple bilateral cranial nerve palsies–Spurthi Surpur, Varun Kumar Pala, Ashis H. Tayal P13.10-002 The Great Mimicker: A Case of Bannwarth Syndrome– Bindi Akshay Patel P13.10-003 Lyme Neuroborreliosis Presenting with a Cytotoxic Lesion of the Corpus Callosum, Diffuse Cerebral Edema, and Multifocal Infarcts–Benjamin Jiang, Appaji Rayi P13.10-004 Nocardiosis of the Central Nervous System: Brain MR Imaging Finding And Outcome with review of the literature–Waad Alshammari P13.10-005 Combined Capnocytophaga spp. and Fusobacterium Nucleatum Brain Abscess with Vibrio Cholera Infection: a Case Report–Alexander John Senetar, Miguel Chuquilin Arista

192 2020 AAN Annual Meeting

0 Wednesday, April 29 5:30 p.m.–6:30 p.m. Tuberculosis and Other Bacterial Infections 2

Child Neurology and Developmental Neurology: Brain Injury: HIE, Stroke, Trauma, and Inflammation 2

10 11

P13.10-006 Skipped Multilevel Lesion as An Atypical Tuberculous Spondylitis Mimicking Spinal Metastasis: Case Report–Paulus Sugianto, Felisitas Farica Sutantoyo P13.10-007 Encephalitis By Bartonella Quintana, A Rare Entity In The Pediatric Age–Maria del Carmen Espinosa Sotero, Cynthia Arely Juarez Jaramillo P13.10-008 Sensorineural Hearing Loss as an Atypical Presentation of Typhoid Fever in Adult Patient–Khaled Al Khodari, Tehniyat Baig, Mohammad Al Khateeb, Muhammad Naeem P13.10-009 Scrub Typhus: Case of a Rare Etiology Behind Intracerebral Hemorrhage–Ahmad Ozair, Mudit Kotwal, Arjumand Faruqi P13.10-010 Bartonella Henselae Infection Manifesting with Multiple Cranial Neuropathies–Tiffany Lei, Candace B. Borders, An Hong Do P13.10-011 Bilateral Sensorineural Hearing Loss: A Unique Sequelae of Murine Typhus Aseptic Meningitis– Justin Samorajski, Madiha Khan, Prianka Gajula, Lindsay Euers, Lara Colton P13.10-012 Native-Valve Legionella Endocarditis with Devastating Neurological Complications–Meryim Poursheykhi, Rajeel Imran, Mahrukh Khalid, John J. Volpi P13.10-013 A Challenging Case of Progressive Pachymeningitis– Elizabeth Pedowitz, Fred D. Lublin, Ilana B. Katz Sand P13.10-014 Encephalopathy with restricted diffusion in the splenium of corpus callosum in a case of Legionella Pneumophilia infection– Magdalena Stepien P13.10-015 Streptococcus intermedius: an unusual culprit of simultaneous cerebral and cord intramedullary abscesses– Muhammad Hasanayn Jaffer, Tigran Kesayan P13.10-016 A Rare Case Of Guillain-Barre Syndrome Associated with Nontuberculous Mycobacterium Infection– Subhendu Rath, Francis J. DiMario P13.10-017 Bihemispheric Cortical Infarcts in a Patient with E.Coli Meningitis–Bhanu Gogia, Vinodh A Kumar, Barbara O’Brien

P13.11-001 A Series of Unfortunate Strokes–Steve Bibu, Vikram Bhise P13.11-002 Acute Hyperextension “Surfer’s” Myelopathy in a Gymnast: Bending over Backwards for Diagnosis–Rebecca Jeannette Levy, Carolina Guimaraes, Sonia Partap P13.11-003 The use of gadolinium based contrast agents in pediatric brain MRIs: The indications and yield.–Anila Kanna, Rima Ali Ahmad Aljundi, Amanda Berger Weber P13.11-004 Effect of Nutrition Support Therapy on Outcomes in Children with Moderate to Severe Traumatic Brain Injury–Chelsea Grace McElroy, Katrina Peariso, Paul Horn P13.11-005 Idiopathic Intracranial Hypertension in children: Are we missing something?–Lokesh Saini, Priyanka Madaan, Bvchaitanya Reddy, SUMEET Dhawan, Akshay Saxena, Rakesh Sharma, Arushi Gahlot Saini, Renu Suthar, Jitendra Sahu, Naveen Sankhyan P13.11-006 A Rare Case of Spontaneous Arachnoid Cyst Rupture Presenting as Right Hemiplegia and Expressive Aphasia in a Pediatric Patient–Natalie Ann Majors, Tamour Khan Tareen, Vinay Puri Child Neurology and Developmental Neurology: Neurogenetics 1

P13.11-007 Age-at-onset and Time-to-event of Core Features in CLN3 (Batten) Disease–Margaux Cecille Masten, Jennifer Anne Vermilion, Heather Adams, Amy Vierhile, Frederick J. Marshall, Christopher Beck, Erika Fullwood Augustine, Jonathan W. Mink P13.11-008 Quantitative Gait Analysis in CLN3 Disease–Grace A. Zimmerman, Amy Vierhile, Heather Adams, Jonathan W. Mink, Erika Fullwood Augustine P13.11-009 A Neurological Assessment Scale For Infantile Neuroaxonal Dystrophy–Paldeep Atwal, Frederic Heerinckx, Mark Midei, Peter Milner

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

P13.11-010 Atypical phenotypes caused by the ATP1A3 variant p.P775L–Daniel Calame, Marwan Shinawi, Julie Cohen, Richard Person, Richard Person, Timothy E. Lotze, Sho T. Yano, Debra Regier P13.11-011 Evidence of pharmacodynamic tolerance during repeated daily gaboxadol exposure in individuals with Angelman syndrome–Tom Parry, Amit Rakhit, Kiyoshi Egawa, Sheryl Smith P13.11-012 Physiologically based pharmacokinetic modeling (PBPK) for gaboxadol exposure in children with Angelman syndrome–Rakesh Gollen, Tom Parry, Amit Rakhit, Martin Graham P13.11-013 Caregiver insight on the core domains in Angelman syndrome–Anna Lee, Geetha Pudussery, Aaron Tansy, Alexander Kolevzon P13.11-014 Quality of Life in Adolescent and Adult Individuals with Angelman Syndrome: Baseline Results from the Phase 2 STARS Study–Raquel Cabo, Nasreen Khan, Rebecca Burdine, Christopher Keary P13.11-015 The pivotal Phase 3 NEPTUNE trial investigating gaboxadol in Angelman syndrome: Study design–Christopher Keary, Rebecca Burdine, Celine Saulnier, Shijie Chen, Geetha Pudussery, Amit Rakhit, Alexander Kolevzon

Wednesday, April 29

AAN.com/view/20AM 193

POSTER SESSION 14

CME

0 Thursday, April 30

8:00 a.m.–9:00 a.m.

Thursday, Apvril 30

POSTER SESSIONS

Poster Session 14 1. Neuromyelitis Optica and Other Autoimmune Disorders 2: 1-001 to 1-016 Multiple Sclerosis: Clinical Assessments and Outcome Measures 1: 1-001 to 1-022 2. Autoimmune Neurology: NMOSD and MOG 2: 2-001 to 2-013 3. Motor and Non-motor Features of Parkinson’s Disease 3: 3-001 to 3-007 Movement Disorders: Tremor 1: 3-008 to 3-017 4. Epilepsy/Clinical Neurophysiology: Antiseizure Medications 3: 4-001 to 4-003 Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 1: 4-004 to 4-009 5. General Neurology: Clinical Science: Cohorts and Case Series 1: 5-001 to 5-009 6. Headache Science 2: 6-001 to 6-010 7. Peripheral Neuropathy 4: 7-001 to 7-014 8. Behavioral and Cognitive Neurology: Non neurodegenerative Disorders 2: 8-001 to 8-011 9. Cerebrovascular Disease: Intracerebral Hemorrhage, SAH, Aneurysms, and Vascular Malformations 3: 9-001 to 9-007 Stroke Prevention, Risk Factors, Complications, and Recovery 1: 9-008 to 9-021 10. Neurocritical Care: Epilepsy and TBI 1: 10-001 to 10-018 11. Child Neurology and Developmental Neurology: Neurogenetics 2: 11-001 to 11-008 Child Neurology and Developmental Neurology: Seizures and Epilepsy 1: 11-009 to 11-014

Neuromyelitis Optica and Other Autoimmune Disorders 2

P14.1-001 Subcutaneous Anti-CD20 Antibody Treatment Delays Gray Matter Atrophy in Human Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis Mice–Suyog U. Pol, Serena Liang, Ferdinand Schweser, Anna Schubert, Marilena Preda, Michele Sveinsson, Deepa Ramasamy, Michael G. Dwyer, Gisbert Weckbecker, Robert Zivadinov P14.1-002 Effectiveness of Subcutaneous Tocilizumab therapy in Neuromyelitis Optica Spectrum Disorder–Itay Lotan, Robert William Charlson, Lana Zhovtis Ryerson, Michael Levy, Ilya Kister P14.1-003 Neurofilament Light Chain Levels in Patients with Antibodies to Myelin Oligodendrocyte Glycoprotein (MOG-Ab)–Sara Mariotto, Sergio Ferrari, Daniela Alberti, Serena Zanzoni, Kathrin Schanda, Salvatore Monaco, Markus Reindl, Alberto Gajofatto P14.1-004 Neuromyelitis Optica Spectrum Disorders Misdiagnosed as Multiple Sclerosis: Can Current

Diagnostic Guidelines Separate the Two Diseases?–Maria Alkhasova, Paige Sutton, L Creed Pettigrew, Zain Guduru, Jagannadha R. Avasarala P14.1-005 When Tissue is an Issue: “Trident Sign” Enhancement Helps Diagnose Sarcoid Myelopathy–Chris Hollen, Rebecca Spain P14.1-006 Predictors of Diagnosis and Outcome in Pediatric MOGantibody Associated Disorders– Duriel Isaiah Hardy, Jennifer McGuire, Brenda Banwell, Sarah E. Hopkins P14.1-007 Differential expression of soluble cerebrospinal fluid, serum, and cell surface markers in neuromyelitis optica spectrum disorder–Silva Markovic-Plese, Zina Versfeld, Morgan McSweeney, Nazanin Kiapour, Nazanin Kiapour, Tingting Zhan P14.1-008 Frequency of optic nerve lesions on MRI in acute optic neuritis associated with neuromyelitis optica spectrum disorders in a Latin American cohort–Juan Ignacio Rojas, Vanesa Toneguzzo, Juan Ignacio Rojas, Juan Ignacio Rojas, Juan Pablo

194 2020 AAN Annual Meeting

Pettinicchi, Maria C. Castillo, Edgar Carnero Contentti, Maria C. Castillo, Edgar Carnero Contentti, Veronica A. Tkachuk, Antonio Dos Santos, Vanesa Toneguzzo, Edgar Carnero Contentti, Liliana Beatriz Patrucco, Antonio Dos Santos, Alejandro E. Caride, Omaira Molina P14.1-009 Risk factors related to relapse after first immunosuppressive treatment in patients with neuromyelitis optica spectrum disorders–Fernando Morales-Ramírez, Irene Trevino, Vanessa Barriga Maldonado P14.1-010 Characterization of T cells in NMOSD patients - an emerging role for T cells in disease pathogenesis–Maren Lindner, Urvashi Bhatia, Andreas Schulte-Mecklenbeck, Timo Wirth, Catharina Groß, Tyge Schmidt, Melanie Korsen, Tilman SchneiderHohendorf, Nicholas Schwab, Sumanta Barman, Orhan Aktas, Norbert Goebels, Anne Winkler, Christine Stadelmann-Nessler, Wolfgang Brueck, Tania Kuempfel, Nadja Siebert, Friedemann Paul, Ingo Kleiter, Heinz Wiendl, Tanja D. Kuhlmann, Marius Ringelstein, Luisa Hildegard Klotz

P14.1-011 Bilaterally Synchronized Faciobrachial Dystonic Seizures in Anti-LGI1 Encephalitis: A Case Report–Takahisa Mikami, Eiichiro Amano, Takahiro Iizuka, Akira Machida P14.1-012 Natalizumab Maintains Remission in a Patient with MOG Antibody Disease–Rebecca L. Gillani, Robert Mallery P14.1-013 Menstrual and Reproductive History in Neuromyelitis Optica Spectrum Disorder (NMOSD): a crosssectional analysis using the EnvIMS questionnaire–Lindsay Waxman, Liesly Lee, Karly Stratos, Kathryn Taberner, Alyson Wong, Kathleen Carr, Dina Dababneh, Dalia Rotstein P14.1-014 Immigration, Childhood Sunlight Exposure, and Risk of Neuromyelitis Optica Spectrum Disorder (NMOSD)–Dina Dababneh, Liesly Lee, Karly Stratos, Kathryn Taberner, Lindsay Waxman, Alyson Wong, Kathleen Carr, Dalia Rotstein P14.1-015 An Unusual Presentation of Acute Psychosis in an Elderly Patient with Inflammatory Cerebral Amyloid Angiopathy–Leila Ghaffari, Taha Bali = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number P14.1-016 Rare Case of NeuroBehçet’s Syndrome in an Adult Male .–Shri Kant Mishra, Shaweta Khosa, Daniel E. Okobi, Frank Diaz, Catherine Yim, Emil Heinze Multiple Sclerosis: Clinical Assessments and Outcome Measures 1

Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study–Ho Jin Kim, Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Kenji P Fujita, Marcus Yountz, Roisin Armstrong, Dean M. Wingerchuk Motor and Non-motor Features of Parkinson’s Disease 3

P14.3-001 Predictive Factors Of Disease Progression In Parkinson’s Disease In A Tunisian Cohort–Amina Nasri, Arwa Rekik, Saloua Mrabet, Imen Kacem, Amina Gargouri, Ben Djebara Mouna, Riadh Gouider P14.3-002 Visual-Spatial Dysfunction in Parkinson’s Disease: an Exploratory Multimodal Biomarker Study–Alberto Cucca, Amgad Droby, Mahya Beheshti, Ikuko Acosta, Daniella Mania, Kush Sharma, Marygrace Berberian, Hilary C Bertish, Todd Hudson, Alessandro Di Rocco, Maria F. Ghilardi, Matilde Inglese, JohnRoss Rizzo, Milton Biagioni, Andrew S. Feigin P14.3-003 Trends in the Incidence of Parkinson’s disease diagnosis between 2006 and 2016: Analysis of a large UK Primary care database.–Olaitan Okunoye, Louise Marston, Kate Walters, Anette E. Schrag P14.3-004 Implications of Gut Microbiome Dysbiosis in Parkinson’s Disease: A Literature Review.–Mohamed Elfil, Serageldin Kamel, Mohamed Ibrahim Kandil, Nada Ahmed, Sara Maguire Schaefer, Brian Koo P14.3-005 Microbiome characterization and reversal of dysbiosis in Parkinson’s disease by Fecal Microbiota Transplantation– Herbert L DuPont, Jessika Suescun, Zhi-Dong Jiang, Eric L Brown, Tehseen Iqbal, Ashley S Alexander, Andrew W DuPont, Michael E. Newmark, Heather T Essigmann, Mya C. Schiess

AAN.com/view/20AM 195

Thursday, Apvril 30

P14.2-001 A Case of anti-MOG Associated Disease Presenting With Palatal Myoclonus And Extensive Bilateral Cortical-Based Inflammation–Jafar Hashem, Kyle Matthew Blackburn P14.2-002 Neuromyelitis Optica Spectrum Disorder (NMOSD): Epidemiology, Treatments, and Outcomes in a Single Center–Robert Kadish, Tavan Parker, Imran Tanvir, Minying Royston, Adrian Kielhorn, Joseph Biskupiak, Stacey Clardy P14.2-003 An aggressive presentation of aquaporin-4 neuromyelitis spectrum disorder in a 2-year-old girl: challenges in diagnosis and treatment.–Tuba Rashid Khan, Cynthia X. Wang P14.2-004 Comparative Immune Cell and Cytokine Phenotyping in Neuromyelitis Optica Spectrum Disorder Patients from the CIRCLES Cohort–Kevin O’Connor, Aditi Sharma, Elizabeth Cotzomi, Ruoyi Jiang, Lawrence Cook, Jessica Alvey, Terrence F Blaschke, Judy Sheard, Jacinta Behne, Terry Smith, Michael R. Yeaman P14.2-005 Harnessing the power of social media to learn about a very rare disorder: survey of Facebook group about paroxysmal symptoms in Neuromyelitis Optica Spectrum Disorder–Itay Lotan, Tamar Bacon, Michael Levy, Ilya Kister P14.2-006 Adolescents with NMOSD Achieved Similar Exposures and Favorable Safety Profile when Treated with the Adult Satralizumab Dosing Regimen–Cheryl Hemingway, Hanna Silber Baumann, Xiujing Kou, Daniela Stokmaier, Veronica Anania, Hajime Ito, H. Christian Von Budingen, Sian Lennon-Chrimes P14.2-007 Characterisation of the PK and PD of Satralizumab, a Recycling Antibody, to Support Q4W Dosing in Patients with NMOSD– Sian Lennon-Chrimes, Hanna Silber Baumann, Gaelle Klingelschmitt, Xiujing Kou, Veronica Anania, Hajime Ito, H. Christian Von Budingen P14.2-008 Infection Risk in Patients with Complement-Mediated Neurological Disorders Receiving Eculizumab: Findings from Two Phase 3 Studies and Their Extensions in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD) and

Acetylcholine-Receptor AntibodyPositive Refractory Generalized Myasthenia Gravis (AChR+ gMG)–Todd D. Levine, Renato Mantegazza, Celia Oreja Guevara, Cynthia Carrillo-Infante, Roger Kaprielian, Shulian Shang, Marcus Yountz, James F. Howard P14.2-009 The impact of relapses on quality of life in patients with neuromyelitis optica spectrum disorder: data from the phase 3 PREVENT study–Achim Berthele, Michael Levy, Karissa Johnston, Meagan Harwood, Adrian Kielhorn, Minying Royston, Guido Sabatella, Jacqueline Palace P14.2-010 Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study– Jacqueline Palace, Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, KaiChen Wang, Shulian Shang, Marcus Yountz, Roisin Armstrong, Dean M. Wingerchuk P14.2-011 Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 AntibodyPositive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study–Achim Berthele, Sean J. Pittock, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, KaiChen Wang, Shulian Shang, Marcus Yountz, Roisin Armstrong, Dean M. Wingerchuk P14.2-012 Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study–Kazuo Fujihara, Achim Berthele, Ho Jin Kim, Michael Levy, Ichiro Nakashima, Celia Oreja Guevara, Jacqueline Palace, Sean J. Pittock, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Marcus Yountz, Larisa Miller, Imran Tanvir, Roisin Armstrong, Dean M. Wingerchuk P14.2-013 Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-

POSTER SESSIONS

P14.1-017 Identifying Gaps in Knowledge, Skill and Confidence Among MS Specialists to Facilitate Appropriate Evolutions in MS Care–Klaus Schmierer, Morgan Peniuta, Jiwon Oh, Thomas Leist, Patrice Lazure, Sophie Peloquin P14.1-018 Multiple Sclerosis Disease-Modifying Therapy: Recent Switch Patterns Among United States Neurologists– Patricia K. Coyle, Jennifer Robinson, Jennifer Robinson P14.1-019 Study for the Validation of the FeetMe® Integrated Sensor Insole System Compared to GAITRite® System to Assess the Characteristics of the Gait in Patients with Multiple Sclerosis– Anabel Granja Domínguez, Anja Hochsprung, Susana Palao Duarte, Cristina Páramo Camino, Aurora Alemán Rodríguez, Carmen Duran, Navarro Guillermo, Ana Venegas, MARIA JOSE MORENO JIMENEZ, Basilio Hernandez, Guillermo Izquierdo Ayuso P14.1-020 Changing Patterns in Disease-Modifying Therapy Selection for Treatment-Naive Multiple Sclerosis in the United States–Patricia K. Coyle, Jennifer Robinson, Virginia Schobel P14.1-021 Association of Serum Neurofilament Biomarker Levels with Quality of Life and Healthcare Utilization in Patients with Multiple Sclerosis–Kristin Marissa Galetta, Chinmay Deshpande, Brian Curran Healy, Bonnie Glanz, Marina Ollervides Ziehn, Shristi Saxena, Anu Paul, Fermisk Saleh, Mikaela Collins, Patricia Gaitan-Walsh, Paola Castro-Mendoza, Howard L. Weiner, Tanuja Chitnis P14.1-022 Polypharmacy in MS: Correlations with pain, fatigue, and mood–Joan Thelen, Sara Baker, Jared Bruce, Amanda Thuringer, Muhammad Nashatizadeh, Sharon G. Lynch

Autoimmune Neurology: NMOSD and MOG 2

Thursday, Apvril 30

POSTER SESSIONS

POSTER SESSION 14 P14.3-006 Prevalence of Cognitive impairment in Mexican patients with Parkinson’s Diseases.–Oscar Esquivel, Susana Lopez, Cynthia Guadalupe Sarabia-tapia, Emmanuel Escobar-Valdivia, R Arturo Abundes-Corona, Omar Cardenas-Sanchez, Yazmin RiosSolis, Fanny Herrera-Rodriguez, Amin Cervantes-Arriaga, Mayela De Jesus Rodriguez Violante P14.3-007 Factors associated with Freezing of Gait in Parkinson’s Disease: A multi-centric Mexican cohort–David Garza Brambila, Amin Cervantes, Karla SalinasBarboza, Sara Isais-Millan, Antonio Anaya-Escamilla, Edna VelazquezAvila, Alejandro Banegas-Lagos, Arnulfo Gonzalez-Cantu, Mayela De Jesus Rodriguez Violante, Daniel Martinez-Ramirez Movement Disorders: Tremor 1

P14.3-008 How many adults in the US have essential tremor? Using data from epidemiological studies to derive age-specific estimates of prevalence.–Stephen Crawford, Cathy Lally, Jennifer Petrillo, James F. Paskavitz, Elan D. Louis P14.3-009 Efficacy and Safety of CX-8998 in T-CALM, a Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial in Participants With Essential Tremor: Subgroup Analysis by Baseline Tremor Severity–H. A. Jinnah, Spyros Papapetropoulos, Margaret S. Lee, Stacey Boyer, Evan Newbold, Rajesh Pahwa, Kelly E. Lyons, Rodger J. Elble, William G. Ondo, Theresa A. Zesiewicz, Peter Hedera, Adrian Handforth, Jenna Elder, Mark Versavel P14.3-010 The Clinical Role of Jaw Tremor in Movement Disorders–Sana Aslam, Nan Zhang, Charles H. Adler, Shyamal Mehta, Thomas Beach, Holly A. Shill P14.3-011 Clinical and neuropsychological correlates of the TETRAS score in DBS patients– Steven T. Bellows, Hannah Combs, Joohi Jimenez-Shahed P14.3-012 Are cerebellar signs seen in pre-manifest essential tremor cases? A study of unaffected first-degree relatives of cases–Elan D. Louis, Evan Hale, Hollie Dowd, Gina Liu, Deepti Varathan

CME

P14.3-013 Quantitative Tremor Analysis of Functional Tremor– Steven Zhang, Richa Tripathi, Douglas Bernhard, Christine Doss Esper, Stewart A. Factor P14.3-014 Characterizing Quality of Life Post-Deep Brain Stimulation (DBS) using EQ-5D-5L–Mya C. Schiess, Leonard Verhagen Metman, George M. Plotkin, Kenneth P. Martinez, Fernando L. Pagan, Todd Weaver P14.3-015 Primary Orthostatic Tremor Treated Successfully with Perampanel–Brett Travers, Christian Gericke P14.3-016 Patient-Reported “Good” Days During a Prospective Study of the Treatment of Neurogenic Orthostatic Hypotension With Droxidopa– Steven Kymes, Lawrence Hewitt, Clement Francois P14.3-017 Treatment of Medication-Refectory Holmes Tremor by Simultaneous Thalamic Ventral Intermediate (VIM) Nucleus and Subthalamic Nucleus (STN) Deep Brain Stimulation-A Case Report–Muhammad Waseem Anjum, Christopher Kalhorn, Yasar Alejandro Torres-Yaghi, Amelia Carwin, Fernando L. Pagan Epilepsy/Clinical Neurophysiology: Antiseizure Medications 3

P14.4-001 Efficacy and Safety of Adjunctive Perampanel in South Korean Patients with PartialOnset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Post Hoc Analysis of Phase II and III Double-Blind and Open-Label Extension (OLEx) Studies–Manoj Malhotra, Leock Y. Ngo, Anna Patten, Alejandro Salah P14.4-002 Efficacy and Safety of Perampanel Monotherapy in Patients with Newly Diagnosed or Currently Untreated Recurrent Partial-Onset Seizures (POS): Final Analysis of Study 342 (FREEDOM) 4 and 8 mg/day Core Data–Takamichi Yamamoto, Ji Hyun Kim, Sung Chul Lim, Hirotomo Ninomiya, Yuichi Kubota, Risa Matsunaga, Hidetaka Hiramatsu P14.4-003 Antiepileptic Drug (AED) Treatment in Juvenile Myoclonic Epilepsy (JME): a Population-based Study–Ahyuda Oh, Hyunmi Kim

196 2020 AAN Annual Meeting

0 Thursday, April 30 Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 1

P14.4-004 E-cigarette Use (Vaping) Causes Seizures on EEG detected by Responsive Neurstimulation : Evidence from Electrocorticography–Joel Michael Oster, Peter Sherman Tatum, Catherine Monigan, James Kryzanski P14.4-005 Patient, Caregiver, and Healthcare Professional Perspectives on Seizure Freedom, Seizure Control, and Treatment Goals–Danielle Becker, Lucretia Long, Nancy Santilli, Jane Babrowicz, Eugenia Peck P14.4-006 Transition from Pediatric to Adult Epilepsy Care: A Multi-Disciplinary Approach– Nassim Zecavati, Francis Tirol P14.4-007 Characterizing the Phenotype of Epilepsy in Children with Past Leukemia–Elham Abushanab, Elia Margarita Pestana Knight, Ahsan Moosa Naduvil Valappil P14.4-008 Readmissions for Cardiac and Non-cardiac Causes Among those with Epilepsy or Multiple Sclerosis–Hernan Nicolas Lemus Esquivel, Parul Agarwal, Churl-Su Kwon, Anusha Yeshokumar, Mandip Singh Dhamoon, Madhu Mazumdar, Nathalie Jette P14.4-009 Neuro Critical Care Models Improve Outcomes in Epilepsy & Certified Stroke Centers–Harold H. Morris, Angela M. Hawkins General Neurology: Clinical Science: Cohorts and Case Series 1

P14.5-001 Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): A Database Analysis–Cagdas Erdogan, Ayse Oytun Bayrak, Kayihan Uluc, Necdet H. Karli, Ayse Dikicibasi Koc, Serefnur Ozturk, Ihsan Sukru Sengun, Yaprak Secil, Melih Tutuncu, Mehmet Ali Akalin, Hilmi Uysal, Sevim Erdem Ozdamar, Yesim Parman P14.5-002 Genetic Testing for Hereditary ATTR Amyloidosis: Insights from the hATTR Compass Program–Sami L. Khella, Naresh Bumma, Aaron Gabriel, Michael Stevenson, Carol Cannon

8:00 a.m.–9:00 a.m. P14.5-003 High Prevalence of Transthyretin-Related Amyloidosis in Crete, Greece is Due to Three TTR Pathogenic Variants with Markedly Differing Phenotypic Presentations–Minas Tzagournisakis, Emanouil Foukarakis, Anastasios Marinis, Lambros Mathioudakis, Kleita Michaelidou, Cleanthe Spanaki, Miltiadis Tsilimbaris, Andreas J. Plaitakis, Panayiotis Mitsias, Zaganas Ioannis P14.5-004 Relationships Between Forced Vital Capacity and Respiratory Sub-domain Scale on the ALSFRS-R–Cuiping Zhao, Xiaotian Ma, James P. Wymer P14.5-005 Quantitative Magnetisation Transfer Brain Imaging Reveals Altered Biological Integrity of Motor Regions in Amyotrophic Lateral Sclerosis– Andrew Barritt, Rebecca Broad, Nicholas Dowell, Peter N. Leigh, Mara Cercignani P14.5-006 Clinical Characteristics of Patients with Motor Neuron Diseases in a Tertiary Health Care Centre in Abuja, Nigeria–Nkechi Obianozie, Gerald Awele Onwuegbuzie, Peter Alabi, Ifeyinwa Ani-Osheku, Fatima Ilemona Abdulai P14.5-007 Genetic testing utilization for patients with neurological disease: limitations of using claims data–Samuel Mackenzie, Chun Chieh Lin, Peter K. Todd, James F. Burke, Brian Callaghan P14.5-008 Machine Learning Model for Prognostication of 90day Patient Outcome Immediately after Thrombectomy in Acute Ischemic Stroke Patients–Srinivasa Rao Kundeti, Manikandakrishnan V, Priyanka M Shreedharan, Sankar Prasad Gorthi P14.5-009 Functional Outcome and Clinical Characteristics of Stroke survivors with earlyonset post stroke seizures in a semi-urban area in Kogi State, Nigeria.–Babatunde Ayodeji Ademiluyi, Olabisi Ademiluyi

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number Headache Science 2

Behavioral and Cognitive Neurology: Nonneurodegenerative Disorders 2

P14.8-001 Looking for Light: Paradichlorobenzene Toxicity in a 30 Year-Old Woman Following Long Term Ingestion of Mothballs– Abigail Lofchie, Kailie Eison, Ilirjan Gjombalaj, Reema Mehta, Peter C. Mabie

P14.8-002 Fatigue in Multiple Sclerosis: Relation with Clinical and Neuropsychological Variables, Brain MRI Lesions and Atrophy– Carmen Vizzino, Gianna Carla Riccitelli, Alessandro Meani, Paolo Preziosa, Maria Assunta Rocca, Massimo Filippi P14.8-003 Pilot Investigation of the Relationship Between Hippocampal Volumes and Memory Deficits in Progressive Multiple Sclerosis (pMS)–Julia Rybkina, Sonja Stojanovski, Asaf Gilboa, Tania Bruno, Zorry Belchev, Anne Wheeler, Robin Green P14.8-004 Predicting Longitudinal Cognitive Decline in MS Using Baseline Clinical Routine T2-FLAIR MRI–Tom Fuchs, Ralph H. B. Benedict, Hoan Tran, Daniel Brior, Niels Bergsland, Dejan Jakimovski, Deepa Ramasamy, Robert Zivadinov, Michael G. Dwyer P14.8-005 The Challenge of Maintaining Therapeutic Benefits over the Long Term: Example of Adding 4 Reactivation Sessions to a Cognitive-Behavioural Fatigue Management Program for People with Relapsing-Remitting Multiple Sclerosis.–Fanny Hamelin, Marie Claire Gay, Sarah Thomas, Peter Thomas, Olivier Heinzlef P14.8-006 Intake of high saturated fat foods predicts cognitive change in the Women’s Interagency HIV Study (WIHS)–Lakshmi Warrior, Deborah Gustafson, Kathleen Weber, Phyllis Tien, Audrey French, Amanda Spence, Anjali Sharma, Sheri Weiser, Leah H Rubin P14.8-007 Body mass index and leptin are associated with executive function over 10 years in women with and without HIV infection. The Women’s Interagency HIV Study (WIHS)– Francesca Macaluso, Kathleen Weber, Elaine Dellinger, Susan Holman, Howard Minkoff, Howard Minkoff, Sheila Keating, Deborah Gustafson P14.8-008 The Effects of Methylphenidate on Creativity in Individuals with Attention Deficit Hyperactivity Disorder–Alinna Julien Sam, David Q. Beversdorf, Bradley Ferguson

AAN.com/view/20AM 197

Thursday, Apvril 30

Peripheral Neuropathy 4 P14.7-001 Corneal Nerve Fiber Length In Hereditary Transthyretin Amyloidosis Polyneuropathy– Monica Alcantara, Shabber Mannan, Bruce A. Perkins, Vera Bril P14.7-002 Peripheral Neuropathy outcome after 2-years of treatment with tafamidis in patients with only small fiber symptoms and nonVal30Met hATTR amyloidosis.– Maria Alejandra Gonzalez Duarte, Xel-Ha Dominguez-Vega, Giovanni Cortes-Leon, Sandra PerezCastaneda, Karla Cardenas-Soto P14.7-003 Neurological Manifestations in Patients with Hereditary Transthyretin Amyloidosis: A Retrospective Database Study Based at a Major Multidisciplinary Amyloidosis Center–Shivkumar Bhadola, Michelle Kaku, K. H. Vincent Lau P14.7-004 TTR Knockdown Therapy in Patients with hATTR Amyloidosis Who Have Disease Progression despite Liver Transplant–Orly Moshe-Lilie, Diana Dimitrova, Stephen B. Heitner, Sasha Zivkovic, Chafic Y. Karam P14.7-005 Poor Yield of Routine Transthyretin Genetic Screening in Patients with Idiopathic Neuropathy–Dina Namiranian, Rami Massie, Colin H. Chalk P14.7-006 Reducing Axonal Firing Induces Sustained Pain Remission and Axonal Regrowth in SCN9A Variant Small-fiber Neuropathy– Madeleine Klein, Heather Downs, Anne Louise Oaklander P14.7-007 Episodic Psychosis, Ataxia, Motor Neuropathy Caused by a Novel Mutation in ADPRHL2–Hacer Durmus, Henrich Sticht, Serdar Ceylaner, Said Hashemolhosseini, Yesim Parman

P14.7-008 Case Series: Pediatric Patients with Concomitant Genetic Neuropathy Syndromes and Immune Mediated Polyneuropathy.–Norianne Pimentel, Emmanuelle R. Tiongson, Wendy G. Mitchell, Leigh RamosPlatt P14.7-009 NUDT2 Associated Syndrome with Developmental Delay and Peripheral Neuropathy.– Shrikant Mishra, Shaweta Khosa, Hane Lee, UCLA Clinical Site of the Undiagnos, Frank Diaz, Robert Freundlich, Undiagnosed Diseases Network, Julian Martinez Agosto, Christina Palmer, Stanley Nelson, Brent L. Fogel P14.7-010 A Mitochondrial tRNA Mutation Causes Axonal Charcot-Marie-Tooth Disease in a Large Family from the Venezuelan Andes–Alexander James Fay, Yngo Garcia, Marta Margeta, Ya Ming Hou, Sunita Maharjan, Tom McMahon, Laia Bassaganyas, YingHui Fu, Louis J. Ptacek P14.7-011 Respiratory Insufficiency as a Feature of MORC2 Gene-Related CharcotMarie-Tooth Disease Type 2: A Case Report–Gregory Fenton, Rabia Malik, Richard Dineen P14.7-012 A Novel SPG11 mutation causing Charcot- MarieTooth Disease Type 2–Nirav Sanghani, Leila Maybodi, Nizar Souayah P14.7-013 Conduction Block in Charcot-Marie Tooth Neuropathy Type 4J–Jacqueline Li, Mark G. Stefanelli P14.7-014 Acute Intermittent Porphyria Associated With Reversible Posterior Encephalopathy Syndrome: A Rare Presentation–Sandra Milena Torres, Naiade Couto, Caroline Lourenço Medeiros, Gabriel R. Freitas, Caroline Bittar Braune, Osvaldo J M Nascimento

POSTER SESSIONS

P14.6-001 Establishing Responder Definitions for Short-form Headache Impact Test (HIT-6) Total and Item Scores in Chronic Migraine–Carrie R. Houts, RJ Wirth, James McGinley, Richard B. Lipton, Joe Hirman, Roger Cady P14.6-002 Differences in Exposure Between Intravenously (IV) Administered Eptinezumab and Subcutaneously (SC) Administered CGRP Inhibitor Monoclonal Antibodies After Single Therapeutic Doses–Brian Baker, Martin Beliveau, Susan Pederson, Barbara Schaeffler P14.6-003 Correlation Analysis of the Change in SF-36 with Change in Patient-Identified Most Bothersome Symptom and Monthly Migraine Days (MMDs) in Patients with Chronic Migraine (CM): Results of the PROMISE-2 Study–William B. Young, Jessica Ailani, Dawn C. Buse, Ruslan Horblyuk, Joe Hirman, Roger Cady P14.6-004 Utilization of Smartphone Based Migraine Tracking with a Free Text Feature: A Retrospective Analysis–Talia Boyers, Jana Jaran, Sarah Corner, Mia T. Minen P14.6-005 Characterization of Transit Times in the Large Intestine of Mice Following Treatment with a CGRP Antibody, CGRP Receptor Antibody and a Small Molecule CGRP Receptor Antagonist–Kirk Willis Johnson, Xia Li, Baolin Li P14.6-006 Water-insoluble Mucoadhesive Formulation Enables Consistent and Rapid Intranasal Absorption of Drugs, Including Granisetron, Zolmitriptan and Dihydroergotamine–Fumiyoshi Iwashima P14.6-007 Psychometric Evaluation of the Functional Impact of Migraine Questionnaire Within the COMPEL Trial–Pranav Gandhi, Richard B. Lipton, Naomi Knoble, Donald M Bushnell, Xiaomeng Niu, Hema Viswanathan P14.6-008 Pharmacokinetic Comparison of STS101, an Intranasal Dry Powder Formulation of Dihydroergotamine, with Other Intranasal, Injectable and Oral Inhaled DHE Formulations–Detlef Albrecht, Detlef Albrecht, John Kollins

P14.6-009 Comparison of Early Plasma Exposure to DHE for Marketed and Development Stage Nasal, Inhalation, and Injectable Products–Kelsey Satterly, Stephen Bevan Shrewsbury, John Hoekman P14.6-010 Development of a Text Message-based Headache Diary in Adolescents and Children–Danielle Joy Kellier, Dana Haagen, Blanca Marquez de Prado, Philip Grabner, Lara Lechtenberg, Gerardo Velasquez, Nichelle Raj, John T. Farrar, Andrew D. Hershey, Christina Lynch Szperka

Thursday, Apvril 30

POSTER SESSIONS

POSTER SESSION 14 P14.8-009 A Novel Approach for Reducing Stress in Veterans with PTSD and Depression: Improving Awareness and Detection of Central Auditory Processing Disorder–Eliot A. Licht, Delia Karahalios, Kimberly L. Panizzon P14.8-010 SAGE-217 in Major Depressive Disorder: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial–Akanksha Mittal, Anita Clayton, Robert Lasser, Indrani Nandy, Abdul J. Sankoh, Andrew D. Campbell, Brian Werneburg, Christopher Silber, Jeff Jonas, Steve Kanes, Handan Gunduz-Bruce P14.8-011 Catatonia Misdiagnosed as Creutzfeldt– Jakob disease–Syeda Maria Muzammil, Eduardo Adonias De Sousa Cerebrovascular Disease: Intracerebral Hemorrhage, SAH, Aneurysms, and Vascular Malformations 3

P14.9-001 Long Term Outcome Of Patients With Unruptured Aneurysms Treated by Alteplase Due to Ischemic Stroke–Justyna Derbisz, Pawel Brzegowy, Roman Pulyk, Tadeusz Popiela, Agnieszka Slowik P14.9-002 Dural Arteriovenous Fistula Presenting as an Unusual Cause of Tongue Atrophy– Bhageeradh Mulpur, Erik P. J. Pioro P14.9-003 Tadalafil-Associated Recurrent Intracerebral Hemorrhage–Tyler Koehn, Kenneth Griffin, Jina Maria Youn P14.9-004 Spinal Dural ArterioVenous Fistula: A Masquerade as a Longitudinal Myelitis–Amardeep Saund, Saleem Mohamad Al Mawed, Brijesh Prakash Mehta, Adnan Subei P14.9-005 Predictors of good functional outcome after hemorrhagic stroke–Jessica Houck, Amanda Webb, Latha Ganti P14.9-006 Delayed Vasospasm in Traumatic Subarachnoid Hemorrhage–Rohan Sharma, Sen Sheng, Poornachand Veerapaneni, Hisham Gibriel Bakhiet Elkhider, Shilpa Haldal, Kelly-Ann Patrice, Vishank Arun Shah, Krishna Nalleballe, Nidhi Kapoor P14.9-007 Spontaneous intracranial hemorrhage and acute multiple bilateral subcortical

CME

infarcts, a case of possible CADASIL–Chen Chen, Jacklyn Johnson, Andrea Hidalgo, Nizar Souayah, Jayoung Pak, David A. Marks Stroke Prevention, Risk Factors, Complications, and Recovery 1

P14.9-008 Ischemic stroke as a complication of cannabis use: a systematic review–Ibrahim Migdady, Carol Swetlik, Leen Hasan, Carrie Price, Sung Min Cho P14.9-009 A Global First: Assessment of Sleep Apnoea and Select Sleep Disorders in an African Cohort–N. Abimbola Sunmonu, Rufus O. Akinyemi, Mayowa Owolabi, Nina J. Solenski, Bradford B. Worrall P14.9-010 Predictors of Stroke Mortality among Patients Admitted to a Hospital in Ethiopia–Yohannes Gelan, Amanuel Weldeab P14.9-011 Relationship between the severity of Obstructive Sleep Apnea syndrome and the intima media thickening of common carotid artery in patients with stroke–Horacio Chapa-Martinez, Denisse G Martinez Roque, Leticia Alejandra Olguín-Ramírez, Fernando Gongora, Francisco Guerrero Campos, Beatriz Chávez P14.9-012 Changing Face Of Carotid Revascularization Procedures In The United States–Adnan I. Qureshi, Saqib A. Chaudhry, Iqra N Akhtar, Wei Huang, Ameer Hassan, Sairah Bashir, Mohammad-Rauf A. Chaudhry, Farhan Siddiq, Camilo Ramiro Gomez, Muhammad Fareed Suri P14.9-013 Carotid Artery Stent Placement via Radial Arterial Route–Vamshi Krishna Sai Balasetti, Iqra N Akhtar, Nitish Kumar, Farhan Siddiq, Camilo Ramiro Gomez, Adnan I. Qureshi P14.9-014 Balloonless Carotid Stenting – a Novel Approach to Reducing Peri-Operative Stroke Risk–Hendrik Lintel, Aakash N. Bodhit, Varun Sampat, Paula Buchanan, Andre Guthrie, Ali Hamzehloo, Randall Edgell P14.9-015 Risk Factors for Recurrence of Vascular Events in Middle-Aged Stroke Survivors– Kevin Nhat Vanent, Audrey Leasure, Lindsey Ray Kuohn, Oscar R.

198 2020 AAN Annual Meeting

0 Thursday, April 30 Benavente, Ashkan Shoamanesh, Alessandro Biffi, Kevin N. Sheth, Guido Jose Falcone P14.9-016 GuidelineRecommended Cancer Screening in Adults with Stroke: A Nationwide Analysis–Stephanie Buchman, Hooman Kamel, Babak Navi, Neal S. Parikh P14.9-017 Baseline Differences in Risk Factor Control and Medication Use Between 2 Trials Employing Intensive Medical Management (SAMMPRIS & CREST2)–Tanya N. Turan, Jenifer Voeks, Kevin M. Barrett, Robert D. Brown, Seemant Chaturvedi, Marc I. Chimowitz, Bart M. Demaerschalk, Prabhu D. Emmady, George Howard, Virginia J. Howard, John Huston, Michael Jones, Brajesh K. Lal, Wesley Moore, Claudia Moy, Ana Roldan, Gary Roubin, Navdeep Sangha, Thomas G. Brott, James F. Meschia P14.9-018 Association Between Lipoprotein(a) Concentration and the Risk of Stroke in the Chinese Han Population: a Retrospective Case-control Study–Hanhui Fu, Ding-Ding Zhang, Rui Zhu, Liying Cui, Ling Qiu, Songbai Lin, Bin Peng P14.9-019 Diet Pattern in Acute Stroke Patients, a Semiquantitative Analysis–Laurel Jean Cherian, Thomas Holland, Puja Agarwal, Yamin Wang, Morgan Angotti, Martha Clare Morris, Neelum T. Aggarwal P14.9-020 Serum Alpha-1 Antitrypsin and atherosclerosis burden in patients with acute ischemic stroke–Ali Mahta, Shadi Yaghi, Michael E. Reznik, Bradford B. Thompson, Linda C. Wendell, Shyam Sudarshan Rao, N. Stevenson Potter, Katarina B. Dakay, Shawna M. Cutting, Brian Mac Grory, Tina Mariko Burton, Ali Saad, Daniel Sacchetti, Leana Mahmoud, Scott Moody, Kayla Murray, Samantha Costa, Frank Sellke, Hooman Kamel, Karen L. Furie P14.9-021 Intracranial Arterial Dolichoectasia in Patients with Ischemic Stroke: Preliminary Results From the IDEAS Study– Victor J. Del Brutto, Jonathan Amodio, Viviana Jimenez, Ralph L. Sacco, Tatjana Rundek, Jose Gabriel Romano

8:00 a.m.–9:00 a.m. Neurocritical Care: Epilepsy and TBI 1

P14.10-001 Introducing Highfidelity Acute Neurology Simulation for Medical Students–Ramdinal Aviesena Zairinal, Riwanti Estiasari P14.10-002 Early Electrographic Seizure Detection by Neuro ICU Nurses via Bedside Real-Time Quantitative EEG–Safa Kaleem, Jennifer Kang, Christa Brittany Swisher P14.10-003 Implementation of a Quantitative Electroencephalography Curriculum for Seizure Detection in the Pediatric Intensive Care Unit - A Quality Improvement Initiative–Daniel Davila-Williams, Agnieszka Kielian, Madeline Chiujdea, Alexandra Fialkow, Arnold J. Sansevere P14.10-004 EEG Monitoring for the Detection of Subclinical Seizures in the Pediatric Intensive Care Unit – A Quality Improvement Project–Jamie Ghossein, Richard Webster, Fuad Alnaji, Srinivas Bulusu, Daniela Pohl P14.10-005 Predictors of Functional Outcomes in Status Epilepticus–Matthew R. Woodward, Matthew R. Woodward, Nicholas Allen Morris, Neeraj Badjatia P14.10-006 Ictal-Interictal Continuum In Toxic Metabolic Encephalopathy: Prevalence and Outcomes–Maryum Shoukat P14.10-007 Adjunctive Perampanel in Refractory Status Epilepticus (RSE): A Report of Two Cases.–Xin Yang, Amin Marji, Wazim Mohamed, Mohammad Ibrahim, Maysaa Merhi Basha, Shishir K. Rao P14.10-008 Effect of seizures on outcomes in patient with cardiac surgery–Vishwanath Sagi, Jaimin Trivedi, Christine Williamitis, Kandis Adkins P14.10-009 Reliability of EEG Reactivity in the Assessment of Comatose Patients Under Standardized Protocol–Derek Debicki, Mashael Omar Khateeb, Loretta Norton, Teneille Gofton

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Child Neurology and Developmental Neurology: Neurogenetics 2

P14.11-001 Concomitant Medication in Adolescent and Adult Individuals with Angelman Syndrome: Baseline Results from the Phase 2 STARS Study–Lynne Bird, Raquel Cabo, Nasreen Khan, Wen-Hann Tan P14.11-002 The Neurodevelopmental and Motor Phenotype of SCA21 (ATXTMEM240)–Emma Burdekin, Brent L. Fogel, Shafali Jeste, Julian Martinez Agosto, Jessica E. Rexach, Charlotte Distefano, Carly Hyde, Tabitha Safari, Rujuta Bhatt Wilson P14.11-003 The Phase 2a ROCKET trial investigating gaboxadol in adolescents and young adults with Fragile X Syndrome: Study design–Dejan Budimirovic, Anna Lee, Kelli Dominick, Nicole R. Tartaglia, Elizabeth M. Berry-Kravis P14.11-004 Trofinetide: A Novel Approach to Rett Syndrome– Jeffrey Neul, Alan K. Percy, Timothy A. Benke, Elizabeth M. Berry-Kravis, Daniel Glaze, Nancy Jones, Joshua Corriveau, James M. Youakim P14.11-005 Alpha- mannosidosis masquerading as familial macrocephaly–Surabhi Kaul, Shivika Chandra P14.11-006 Uridine Supplementation for Treatment of Epileptic Encephalopathy from Carbamoyl-Phosphate Synthetase 2, Aspartate Transcarbamylase and Dihydroorotase (CAD) Gene Mutation–Aliya Frederick, Kimberly Sherer, Linda Nguyen, Michelle Sahagian, Richard H. Haas P14.11-007 A Case of progressive leukodystrophy and congenital

deafness associated with KARS mutation–Anuradha Singh, Jane Shaji, Emilio Rafael Garrido Sanabria, Agnes Kowalska, Simona Treidler, Saima Siddiqui P14.11-008 Expanding the phenotypic spectrum of dopamine transporter deficiency syndrome with a novel mutation–Bushra Tehreem, Jeffrey M. Kornitzer Child Neurology and Developmental Neurology: Seizures and Epilepsy 1

P14.11-009 Developing targeted therapies for epileptic encephalopathy due to SYNGAP1 mutations–Jimmy Holder, Lunhui Lin, Ridhima Vij P14.11-010 Evaluation of the association between the age of onset and duration of epilepsy, and the neuropsychological and developmental performance, in patients with refractory epilepsy, at the Costa Rica National Children’s Hospital Epilepsy Monitoring Unit: a 13-year hospital-based retrospective cohort.–Sixto Bogantes Ledezma, Maria Consuelo Rodriguez-Roblero, Gabriel Torrealba Acosta, Juan Luis SeguraValverde, Roberto Brian-Gago P14.11-011 Perampanel associated with developmental regression in patient with FRRS1L mutation–Chen Yan, Hussam Shaker, Nicole Herrick, Prakash Kotagal, Ajay Gupta P14.11-012 Atypical abnormal eye movements in PNPO-related epilepsy–Sara Pavitt, Amanda Sandoval Karamian, Gaurav Chattree, Jenna Marie Klotz, Shannon M. Beres P14.11-013 Sexual and Reproductive Health in Adolescent and Young Adult Women with Epilepsy: a Qualitative Study of Pediatric Neurologists and Epileptologists–Laura Anne Kirkpatrick, Amy Collins, Yoshimi Sogawa, Traci Kazmerski P14.11-014 Nonepileptic Events in Children and Adolescents in New Onset Seizure Clinic–Jungsook Yeom, Jenny Lin, Seunghyo Kim, Ton J. DeGrauw, Sookyong Koh

Thursday, Apvril 30

P14.10-018 The Neuroemergencies Management and Transfers (NEMAT) Program: A System of Care to Improve Outcomes for Patients Transferred for Neurological Emergencies– Neha Dangayach, Ian Cossentino, Deeksha Chada, Nicki Mohammadi, Natalia Romano Spica, Julianne Kleitsch, Daniel Karasik, John Liang, Kaitlin Johanna Reilly, Alexandra S. Reynolds, Cappi C Lay, Christopher Kellner, Johanna Therese Fifi, Errol Lloyd Gordon, Stanley Tuhrim, Joshua Bederson, Neha Dangayach

POSTER SESSIONS

P14.10-010 Potency and Safety of Ketamine in Neuro-critical Care Intensive care Unit- A Single Centre experience–Premkumar Nattanmai Chandrasekaran, Keerthivaas Premkumar, Kathryn Qualls, Niraj Ashok Arora, saurabh kataria P14.10-011 How Much Propofol Treats Status Epilepticus?–Joel Michael Oster, Kimberly Ann Parkerson, Joshua A. Kornbluth, Deborah M. Green-LaRoche, Matthew Tucker, Fesharaki Tabaeizadeh, Bushra Dakhilallah, Yash Malai, George Plummer P14.10-012 Cerebral edema with Refractory Intracranial Hypertension Secondary to Lamotrigine Overdose–Madihah Amima Hepburn, Naresh Mullaguri, Sunil H. Rathore, Vikram Bhinder, Dhimant Dani P14.10-013 Goals-Of-Care Decision Aid for Critically Ill TBI Patients: Development and Feasibility Testing–Susanne Muehlschlegel, David Y. Hwang, Julie Flahive, Thomas Michael Quinn, Chris Lee, Jesse Moskowitz, Kelsey Goostrey, Kelsey Jones, Jolanta Pach, Andrea Knies, Lori A. Shutter, Robert J. Goldberg, Kathleen M Mazor P14.10-014 Gabapentin Role in Improving outcome of Patients with Severe Traumatic Brain Injury (GRIPs TBI)–Rebekah Proctor, Sherry Stephens-Gibson, Lucy Patricia McEuen, Kyla Leon, Rebekah Proctor P14.10-015 Traumatic Interhemispheric Subdural Hematomas – clinical significance, management and outcome.– Etienne Leveille, Ahmed Alazri, Charles Couturier, Solon Schur, Mohammed Maleki, Judith Marcoux P14.10-016 Quantitative Pupillometry and Intracranial Pressure in Neuro ICU Patients– Meghan Hutch, Xiang Zhao, Hanife Saglam, Oluwafemi Balogun, Brenton Prescott, David M. Greer, Stelios M. Smirnakis, Charlene Jennifer Ong P14.10-017 Temporal and spatial patterns of inflammation and oxidative injury in human SCI–Tobias Zrzavy, Carmen Schwaiger, Thomas Berger, Oleg Butovsky, Hans Lassmann, Romana Hoeftberger

AAN.com/view/20AM 199

POSTER SESSION 15

CME

0 Thursday, April 30

12:00 p.m.–1:00 p.m.

Thursday, April 30

POSTER SESSIONS

Poster Session 15 1. Multiple Sclerosis: Clinical Assessments and Outcome Measures 2: 1-001 to 1-021 2. Autoimmune Neurology 8: 2-001 to 2-012 3. Movement Disorders: Tremor 2: 3-001 to 3-009 Dystonia, Tics, and Restless Legs Syndrome 1: 3-010 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 2: 4-001 to 4-010 5. General Neurology: Clinical Science: Cohorts and Case Series 2: 5-001 to 5-011 6. Headache 1: 6-001 to 6-012 7. Peripheral Neuropathy 5: 7-001 to 7-003 Acquired Myopathies/Other Neuromuscular Disorders 1: 7-004 to 7-015 8. Behavioral and Cognitive Neurology: Non neurodegenerative Disorders 3: 8-001 to 8-005 Aging and Dementia: Neuropsychology and Clinical Trials 1: 8-006 to 8-012 9. Stroke Prevention, Risk Factors, Complications, and Recovery 2: 9-001 to 9-018 10. Neurocritical Care: Epilepsy and TBI 2: 10-001 to 10-010 Neurocritical Care: Cerebrovascular Disease and Cardiac Arrest 1: 10-011 to 10-018 11. Child Neurology and Developmental Neurology: Neurogenetics 3: 11-001 to 11-003 Child Neurology and Developmental Neurology: Neuromuscular Disease 2: 11-004 to 11-015

Multiple Sclerosis: Clinical Assessments and Outcome Measures 2

P15.1-001 Spinal Cord Area Correlates with Disability and Quality of Life in Progressive MS: A Baseline MRI Analysis from the SPI2 Phase 3 Trial of MD1003 (high dose Pharmaceutical grade Biotin)–Amber M. Alexander, Valerie A J Block, Nico Papinutto, Anand Rajesh, Tristan Gundel, Douglas L. Arnold, Frederic Sedel, Bruce A. C. Cree, Roland G. Henry P15.1-002 Characterizing Long-Term Disability Progression Outcomes in NARCOMS Registry MS Participants Taking Dimethyl Fumarate–Amber Salter, Samantha Lancia, Gary Raymond Cutter, Robert J. Fox, Ruth-Ann Marrie, Jason P. Mendoza, James B. Lewin P15.1-003 Kappa free light chain in multiple sclerosis: higher sensitivity but lower specificity than oligoclonal bands.–Xavier Ayrignac, Chantal Cognot Pons, Sophie Huby, Laurence Chaudey, Clarisse Carra-Dalliere, Mahmoud Charif, Frederic Pinna, Nelly Ginestet, Sylvain Lehmann, Pierre Labauge, Thierry Vincent

P15.1-004 Using Machine Learning to Extract Expanded Disability Status Scale (EDSS) Scores from Consult Notes–Zhen Yang, Chloe Pou-Prom, David Dai, Tony Antoniou, Ashley Jones, Jiwon Oh, Muhammad Mamdani P15.1-005 Disability assessment in the Google Maps era: a feasibility study to explore a new clinical opportunity–Gianmarco Abbadessa, Luigi Lavorgna, Pietro Iaffaldano, Roberta Lanzillo, Sabrina Esposito, Domenico Ippolito, Maddalena Sparaco, Simone Cepparulo, Giacomo Lus, Rosa Viterbo, Marinella Clerico, Paolo Ragonese, Giovanna Borriello, Elisabetta Signoriello, Maria Trojano, Gioacchino Tedeschi, Simona Bonavita P15.1-006 A claims-based proxy for the EDSS score in multiple sclerosis using German claims data–Marco Ghiani, Erwan Muros-Le Rouzic, Lisa Brullinger, Ulf Maywald, Thomas Wilke, Licinio Manuel Craveiro P15.1-007 Multiple Sclerosis Patient’s Health Care Utilization Influenced by MS Wellness Shared Medical Appointments – A Single Center Experience–Justin Abbatemarco, Jeffrey Alan Cohen,

200 2020 AAN Annual Meeting

Belinda Udeh, Sonu Bassi, Thomas Percy, Mary R. Rensel P15.1-008 Treatment and Comorbidities of Trigeminal Neuralgia in Patients Diagnosed with Multiple Sclerosis at a Large Tertiary Medical Center–Preethy Pankaj, Daniel Krashin, Natalia Murinova P15.1-009 Video oculography as a complementary tool to Brain MRI to confirm early demyelinating process in Multiple Sclerosis Subtypes.–Kevin Polet, Solange Hesse, Heloise Joly, Adeline Morisot, Mikael Cohen, Benoit Kullmann, Christine Lebrun-Frenay, Alain Pesce P15.1-010 Demographic and health related factors associated with use of exercise and mind-body therapies in people with multiple sclerosis–Grace Clark, Lindsey B. Wooliscroft, Carin Waslo, Angela Senders, Elizabeth Silbermann, Anna Orban, Jessica Rice, Vijayshree Yadav, Rebecca Spain, Michelle Cameron P15.1-011 A cross-sectional exploration of four CSF and plasma biomarkers across headache, multiple sclerosis, and neuromyelitis optica spectrum

disorder–Robert H. Gross, Alanna Ritchie, Stefan Sillau, Kavita Nair, Courtney Knapp, Sean Selva, Gregory Owens, Jeffrey L. Bennett, Enrique Alvarez, Timothy L. Vollmer P15.1-012 Tailoring B-cells depleting therapy in MS according to memory B-cells monitoring: a pilot study–Giovanni Novi, Sabrina Fabbri, Francesca Bovis, Elvira Sbragia, Paola Gazzola, Ilaria Maietta, Giacomo Boffa, Maria Cellerino, Caterina Lapucci, Nicolo Bruschi, Elisabetta Capello, Alice Laroni, Giovanni Luigi Mancardi, Maria Pia Sormani, Matilde Inglese, Antonio Uccelli P15.1-013 Comparing HCP and Patient Perceptions of Conversations about Disease Progression in MS–Mitzi Joi Williams, Elisabeth Gulowsen Celius, Sven Schippling, Jane Shanahan, Nektaria Alexandri P15.1-014 Changes in Oxygen Saturation and the Retinal Nerve Fibre Layer in Patients with Optic Neuritis during a Six-Month Followup–Pavel Hok, Tereza Svrcinova, Irena Šinova, Tomas Dornak, Michal Kral, Petra Hubnerova, Jan Mares, Petr Kanovsky, Martin Šin

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

P15.2-001 Functioning and Disability in Neurosarcoidosis from the Patient Perspective–Brandon P. Moss, Deborah M. Miller, Daniel Culver P15.2-002 Optical coherence tomography demonstrates occult optic neuropathy in neurosarcoidosis–Ruth Andrea Salazar Camelo, Olwen Murphy, Jeffrey Lambe, Angeliki Filippatou, Peter A. Calabresi, Shiv Saidha, Carlos A. Pardo-Villamizar P15.2-003 First Case of an Anterior Spinal Artery Stroke in Neurosarcoidosis: A case report and review of literature–Nirav Sanghani, Machteld E. Hillen P15.2-004 Neurosarcoidosis presenting as limbic encephalitis– Ashmanie Mahatoo, Anvi Gadani, Yan Zhang, Matthew Aaron Tremblay P15.2-005 Neurosarcoidosis with Radiographic Findings Consistent with CLIPPERS–Ali Yahia Mohamud P15.2-006 Cerebral Aspergillosis Masquerading as Progression of Neurosarcoidosis in a Patient with Biopsy Proven Pulmonary Sarcoidosis–William Ueng, Maya Hrachova, Mari Perez-Rosendahl, George R. Hanna, Gilbert Cadena, Xiao-Tang Kong P15.2-007 Clinical features of isolated optic neuritis due to sarcoidosis: an institutional experience–Sushant Puri, Zulma M. Hernandez-Peraza, Nadera Sweiss, Peter Macintosh P15.2-008 Immunoglobulin G4-related hypertrophic pachymeningitis mimicking temporal arteritis: A case report– Jee-young Han, Sreelakshmi Panginikkod, Thomas W. Smith, Peggy W Wu, Mehdi Ghasemi P15.2-009 Characteristic Imaging Findings of Susac Syndrome: A Case Report–Arthur De Castro Reis Mauricio, Mauricio José Medeiros, Rafael Frizon, Camila Silva, Larissa Inacio, Larissa Fogaca, Leticia Mathias P15.2-010 Granulomatosis with Polyangiitis-Associated Hypertrophic Pachymeningitis as a Neurosarcoidosis Mimic–Joshua Kramer, Jessica Frey, Ann Murray P15.2-011 A Case of Refractory Necrotizing Idiopathic Hypophysitis

Presenting as Recurrent Bitemporal Hemianopsia–Brigid Prayson, Hera Ashraf Kamdar, Daniel Prevedello, Luciano Prevedello, Stephen J. Kolb P15.2-012 Amyloid Beta-related Angiitis in the Immunosuppressed: A Case Report–Thomas Anthony Nelson, Bo Carl Leung, Serguei Bannykh, Jignesh Patel, Kevin Shah, Oana Maria Dumitrascu Movement Disorders: Tremor 2

P15.3-001 An Open-Label, Phase 1b Study of the Neuroactive Steroid GABAA Receptor Positive Allosteric Modulator SAGE-324 in Essential Tremor–James F. Paskavitz, David Nguyen, Min Qin, Angela Wehr, James Doherty, Steve Kanes P15.3-002 Progression from Mild Cognitive Impairment to Dementia in an Essential Tremor Cohort–Elan D. Louis, Keith Radler, Maria Anna Zdrodowska, Hollie Dowd, Tess Cersonsky, Stephanie Cosentino P15.3-003 Higher Prevalence of Tremor in Patients with Amyloidosis Than in the General Population– Thomas Ryan Ford, Alexis Ariel Clay, Michelle Kaku, Stephanie L. Bissonnette P15.3-004 Elderly Diagnosis of Essential Tremor as a Possible Confound for Prodromal Parkinson’s Disease–Joseph Seemiller, Micaela Rose Owens, Tyler Crissinger, Nicole Joseph, Mihai Cosmin Sandulescu P15.3-005 Characterization of Tremor in Children Using Accelerometry and The Kinarm.– Alex Medina Escobar, Nicholas Cothros, Davide E. Martino, Sean Dukelow, Adam Kirton, Emmanuel Roze, Elaheh Nosratmirshekarlou, Tamara M. Pringsheim P15.3-006 Treatment Patterns in Patients with Essential Tremor– Chintan Shah, Fariha Jamal, George Robert Jackson, Aliya Sarwar P15.3-007 Mechanistic PK/PD Model of Neuroactive Steroid GABAA Positive Allosteric Modulation and Effects on TETRAS Assessment in Essential Tremor–David Nguyen, Anne Smith, Min Qin, Ethan Hoffman, James F. Paskavitz, Angela Wehr, Suki Malhi, Amy E. Bullock, Abdul J. Sankoh, Albert Robichaud, Steve Kanes, James Doherty, Michael Quirk P15.3-008 A case of Klienfelter Syndrome With Chromosome 3

Anomaly presenting with LinguoPalato-Perioral Tremor–Sajish Jacob, Rahul V. Sonone P15.3-009 Prevalence of Cognitive Impairment among Essential Tremor patients–Susana Lopez, Oscar Esquivel, Cynthia Guadalupe Sarabia-tapia, R Arturo AbundesCorona, Emmanuel EscobarValdivia, Omar Cardenas-Sanchez, Fanny Herrera-Rodriguez, Yazmin Rios-Solis, Amin Cervantes-Arriaga, Mayela De Jesus Rodriguez Violante Dystonia, Tics, and Restless Legs Syndrome 1

P15.3-010 Gaps in the Management of Cervical Dystonia with Botulinum Toxin A: Findings from an Online Patient Survey– Cynthia L. Comella, Joaquim Ferreira, Savary Om P15.3-011 ANO3 Mutations in Chinese Dystonia: a Genetic Screening Study Using NextGeneration Sequencing–Shanglin Li, Lin Wang, Yingmai Yang, Jun Ma, Xinhua Wan P15.3-012 DYT-TUBB4A (DYT4 dystonia): New Genetic and Clinical Observations in three Families– Julien François Bally, Sarah Camargos, Laurie J. Ozelius, Patricia C. Aguiar, Anthony E. Lang P15.3-013 Metabolic Brain Networks in Dystonia with Deep Brain Stimulation–Koji Fujita, Hideo Mure, Ryoma Morigaki, Taku Matsuda, Ryosuke Miyamoto, Satoshi Goto, Yasushi Takagi, Yuishin Izumi P15.3-014 Botulinum Toxin Overdoses and Association with Medication Errors–Rashid Kazerooni P15.3-015 Management and Quality of Life of Dystonia Patients in Europe: A Survey Towards Care from a Patients’ Experience–Maja Relja, Vladimir Miletic, Alberto Albanese, Kailash P. Bhatia, Dirk W. Dressler, Joaquim Ferreira, Joachim Krauss, Elena Moro, Marina Tijssen, Marie Vidailhet P15.3-016 CBIT response in clinical practice: The potential importance of comorbidities and tic location–Shannon Chiu, Wissam Georges Deeb, Leonardo B. Almeida, Heather Simpson, Michael S. Okun, Irene Malaty

AAN.com/view/20AM 201

Thursday, April 30

Autoimmune Neurology 8

POSTER SESSIONS

P15.1-015 Automated EDSS scoring using a mobile App and Machine learning.–Charisse D. Litchman, Charisse D. Litchman, Charisse D. Litchman, larry rubin, Timothy K. Vartanian P15.1-016 Ocrelizumab treatment is not associated with an increase in anti-JCV antibody index–Torge Rempe, Aaron M. Carlson, Augusto A. Miravalle, Tirisham Gyang P15.1-017 Validation of Timed 25Foot Walk Benchmarks in People with Multiple Sclerosis–Emily S. Riser, Tracy Tracy, Ganisher Davlyatov, James Rimmer, Tapan Mehta, Robert W Motl P15.1-018 Change in Expanded Timed Get-Up-and-Go is Associated with the Expanded Disability Status Scale and Timed 25-Foot Walk in the New York State Multiple Sclerosis Consortium–Bianca WeinstockGuttman, Katelyn S. Kavak, Natasha Qutab, Osman Ozel, Karen Zakalik, Caila B. Vaughn P15.1-019 The Multiple Sclerosis Comorbidity Index as a Tool for EDSS Prediction: Comparison to the Charlson Comorbidity Index and Elixhauser Comorbidity Measure–Hammad Khan, Konrad Knusel, Farren Briggs, Faisal Abdulmunim Alsallom, Crystal Sau, Sophia Woodson, Alessandro Serra, Hesham Ahmed Abboud P15.1-020 Prospective Analysis of Cerebrospinal Fluid Protein Levels Reveals Candidate Biomarkers for Disability Outcome in Multiple Sclerosis–Aksel Siva, Elif Everest, Ugur Uygunoglu, Derya Yavuz, Alper Bulbul, Melih Tutuncu, Sabahattin Saip, Timucin Avsar, Eda T. Turanli P15.1-021 Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS)–Ahmed Abdelhak, Andre Huss, Alexander Stahmann, Makbule Senel, Markus Krumbholz, Markus Kowarik, Joachim Havla, Tania Kuempfel, Ingo Kleiter, isabella Wuestinger, Uwe Zettl, Margit schwartz, Tim Friede, Albert C. Ludolph, Ulf Ziemann, Martin Kerschensteiner, Reinhard Hohlfeld, Hayrettin Tumani

POSTER SESSION 15 P15.3-017 Cost-Analysis of the Use of IncobotulinumtoxinA and AbobotulinumtoxinA for the Treatment of Post-Stroke Upper Limb Spasticity Based on Recommended Dosing for Muscles and Clinical Patterns–Marie-Eve Gendron, Denis Vezina

Thursday, April 30

POSTER SESSIONS

Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 2

P15.4-001 Hospital readmissions in older adults with epilepsy in the US - a population-based study– Cristina Schreckinger, Jung-Yi Lin, Churl-Su Kwon, Parul Agarwal, Madhu Mazumdar, Mandip Singh Dhamoon, Nathalie Jette P15.4-002 Outcome of Epilepsy in Older Adults; Preliminary Analysis– Ajaz Sheikh, Sidra Saleem, Anum Hamid Riaz, Naeem Mahfooz, Vicki A. Ramsey-Williams, Hongyan Li, Imran I. Ali P15.4-003 Are seizures associated with increased odds of 30-day readmission after Traumatic Brain Injury? Evidence from the National Readmission Database 2014.–Alain Zingraff Lekoubou Looti, Michelle Kwon, Kinfe Bishu, Bruce I. Ovbiagele P15.4-004 National Institute of Neurological Disorders and Stroke Epilepsy Common Data Element Updates: Seizure Severity Instruments, Diagnostic Tools, and MRI Recommendations–Katelyn Elizabeth Gay, Joan Austin, Jacqueline French, William D. Gaillard, Ruth Shinnar, Nicholas Barbaro, Daniel H. Lowenstein, Muniza Sheikh, Damon Collie, Joy R. Esterlitz, Vicky Whittemore, Carolina Mendoza-Puccini P15.4-005 Reducing seizure burden significantly improves patient reported outcomes and decreases health resource utilization amongst patients with convulsive seizures.–Shehryar Sheikh, Nicholas Thompson, Feride H. Frech, Manoj Malhotra, Lara Jehi P15.4-006 Communication Among Adult Patients Living With Epilepsy, Caregivers, and Healthcare Professionals: A 2-way Street?– Nancy Santilli, Lucretia Long, Danielle Becker, Jane Babrowicz, Eugenia Peck P15.4-007 Incidence of AntiEpileptic Drug Related Falls–Alaa

CME

Hajjar, Ebony Jackson-Shaheed, Lawrence J. Hirsch, Hamada Hamid Altalib P15.4-008 Computational analysis of Seizure Clusters in electronic diary free text notes–Katherine Werbaneth, Joyce A. Cramer, Eyal Bartfeld, Robert S. Fisher P15.4-009 Perspectives on Epilepsy-Related Fears Among Adult Patients Living With Epilepsy, Caregivers, and Healthcare Professionals–John M. Stern, Patricia E. Penovich, Danielle Becker, Lucretia Long, Nancy Santilli, Eugenia Peck P15.4-010 Poor Epilepsy Self Management and Self Efficacy Skills in EMU Patients–HaeWon Shin, Sana Chopra, Darcy Subramaniam, Linh Ngo, Shabina Sheikh, Erin Carrier, Angela Wabulya General Neurology: Clinical Science: Cohorts and Case Series 2

P15.5-001 NeuroimagingGuided Thrombolytic Treatment in Wake-Up Stroke: A Literature Review.–Mohamed Elfil, Mohamed Eldokmak, Alireza Baratloo, Nada Ahmed, Hardik Amin, Brian Koo P15.5-002 Association between Helicobacter pylori Infection and Stroke: A Systematic review and Meta-analysis of Observational Studies–Mohamed Fahmy Doheim, Ahmad Amr Altaweel, Mohamed Gamal Hessen, Alaa Ahmed Elshinbary, Amira Abo Hegil Abo Ali, Toqa Mahmoud Dahy, Mahmoud Dibas, Atef khairy sharaf P15.5-003 Circadian Rhythm Pattern Of Stroke : Study From Sudan.–Tahir H. Obeid, Maisa Elfadul, Noon Hakim P15.5-004 Homocysteine: A Potential Risk Factor for Peripheral Neuropathy–Rebecca T. Lin, Favio Bumanlag, Anita Khanna Mehta, Xiaohong Si, Nae Dun, Jin Jun Luo P15.5-005 Intraepidermal nerve fiber densitiy in non-diabetic with and without antecedents of DM2 in comparision with diabetic patients at the center of Mexico– Moises Misael Hernandez, Juan Castanedo-Cazares, Olga JohnsonPonce, Maria del Pilar Fonseca-Leal, Edgar Abad-Guangorena, Carlos Gallegos Rios, Ildefonso RodriguezLeyva

202 2020 AAN Annual Meeting

0 Thursday, April 30 P15.5-006 Spinal epidural lipomatosis with progressive myelopathy in patients with Type 1 Diabetes Mellitus: a novel association?–Ilya Kister, Robert William Charlson, Girish Fatterpekar, Michael Smith, Maksim Shapiro, Christopher William, Itay Lotan P15.5-007 Dynamic Cerebral Autoregulation in Patients With Type 2 Diabetes Mellitus–Myint Thein Naing, Ohnmar Saw, Ohnmar Saw, Nwe Nwe Win P15.5-008 Semi-Automatic Analysis of the Cytoarchitecture in Brodmann Area 23Ventral of the Posterior Cingulate Gyrus–Nicholas Tost, Khateeb Raza, Prabhdeep Singh, Benjamin Shin, Deepak Salem, Mitchell Witkowski, Neha Patel, Michael Boyle, James Fisher, Cynthia Alms, Kevin Izadi, Micah DeBenedetto, Nicola Palomero-Gallagher, Karl Ziles, Este Armstrong P15.5-009 Facial Nerve Enhancement on MRI Associated With A Longer Course of Bell’s Palsy?–Nestor Guarionex Beltre, Hsien Lee Lau, David J. Adams P15.5-010 The association of dilated perivascular spaces (PVS) and microstructural white matter integrity:A Population-Based Study–Zi-Yue Liu, Mei-jun Shu, SiYu Chen, Feifei Zhai, Fei Han, Lixin Zhou, Jun Ni, Ming Yao, Zhengyu Jin, Shuyang Zhang, Liying Cui, Yi-Cheng Zhu P15.5-011 Neurological Complications After Liver Transplantation: An Argentinian Cohort.–Miguel Saucedo, Fabio Gonzalez, Marta Bala, Anibal Chertcoff, Lucrecia Bandeo, Maria Sol Pacha, Luciana Vanesa Leon Cejas, Marcela Uribe Roca, Pablo Bonardo, Oscar Martinez, Ricardo C. Reisin Headache 1

P15.6-001 Impact of Primary Headache Disorder on Quality of Life Among School Children in Kuwait–Fajer AlHamdan, Sameera Shuaibi, Abdelrahman AlAshqar, Samar Farouk Ahmed, Raed Alroughani, Jasem Yousef Al-Hashel

12:00 p.m.–1:00 p.m. P15.6-002 Clinical Predictors associated with Persistent versus Acute Post-Traumatic Headache– Lik Hang Tommy Chan, Yohannes W. Woldeamanuel P15.6-003 The clinical characteristics of new daily persistent headache in childhood: a matched case control study.– Priyanka Shekhawat, Alexandra Shade Silver, Jessica Oppenheimer, Amelia Katharine Boehme, Robert H. Fryer P15.6-004 The State of the Headache Fellowship Application Process and Attitudes towards the Match: Interview of US Headache Fellowship Program Directors– Niushen Zhang, Cynthia Emilie Armand, Thomas Berk, Deborah I. Friedman P15.6-005 Resilience and Vulnerability in Adolescents with Chronic Headache: a Population Study–Renato Arruda, Luis Anunciacao, Marco Antonio Arruda P15.6-006 Patient-Reported Sensitivity to Medications in a Headache Specialty Clinic–Natalia Murinova, Michael Flamm, Sau Mui Chan-Goh, Melissa Schorn, Daniel Krashin P15.6-007 Headache Characteristics in the Post-partum of Patients with Hypertensive Complications During Pregnancy.– Carlos Alberto Soto-Rincon, Alejandro R. Marfil-Rivera, Luis Fernández, Mario Cristobal Nino, Aldo Garcia-Heredia, Beatriz Chávez, Juan Fernando Gongora Rivera P15.6-008 Cerebrospinal Fluid Leak in the context of Pars Interarticularis Fracture: A Case Series–Lik Hang Tommy Chan, Robert Cowan, Nada A. Hindiyeh, Syed Hashmi, Bryan Lanzman, Ian Carroll P15.6-009 Introducing the National Headache Medicine Fellowship Opportunities Website–Niushen Zhang, Cynthia Emilie Armand, Thomas Berk, Noah Rosen P15.6-010 Using Pediatric Quality of Life (PedsQL) Survey to Guide Headache Disorder Management and Gauge Treatment: One Institution’s Ongoing Experience.– Thara Bala, Irene R. Patniyot, Deanna Duggan, Shannon M. DiCarlo = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number P15.6-011 A Retrospective Cohort Study of Urgent Care Visits and Revisits for Headache and Migraine in New York City–Kina Zhou, Benjamin Friedman, , Mia T. Minen P15.6-012 Impact of Pubertal Status on the Prevalence of Primary Headache Disorder Among Female School Children in Kuwait.– Abdelrahman AlAshqar, Sameera Shuaibi, Fajer AlHamdan, Samar Farouk Ahmed, Raed Alroughani, Jasem Yousef Al-Hashel Peripheral Neuropathy 5

Acquired Myopathies/Other Neuromuscular Disorders 1

Behavioral and Cognitive Neurology: Nonneurodegenerative Disorders 3

P15.8-001 Fatal Neurologic Complication of Schizophrenia and Psychogenic Polydipsia: A Case Report–Erin Rebecca Fiedler P15.8-002 Non-Alcoholic Wernicke’s Encephalopathy in a Middle-aged Male Presenting with Psychosis–Ana Verdecia, Meghan Hubert, Kasser Saba P15.8-003 An Unusually Rapid Onset and Fulminant Course of Sporadic Creutzfeldt-Jakob Disease in a Young Patient–Smeer Salam,

Aging and Dementia: Neuropsychology and Clinical Trials 1

Alzheimer’s Disease: A 10-year follow-up study.–Salvatore Mazzeo, Valentina Bessi, Silvia Bagnoli, Marco Carraro, Irene Piaceri, Laura Bracco, Benedetta Nacmias, Sandro Sorbi, Valentina Bessi P15.8-011 Validation of SATURN; an Inexpensive, Freely-available, and Fully Self-administered Cognitive Screening Test.–David P. Bissig, Deniz Erten-Lyons, Helmi L. Lutsep, Jeffrey A. Kaye P15.8-012 Assessment of shortterm memory using a gamified tablet-based task–Younes Adam Tabi, Sanjay Manohar, Masud Husain

8 9

P15.8-006 Impact of Season on Disability and Related Measures in Older Adults: A Cross-Sectional Observational Study–Rebecca Wu, Shahmir Sohail, Robert Dawe, Lei Yu, David A. Bennett, Aron S. Buchman, Andrew Lim P15.8-007 The North American Prodromal Synucleinopathy (NAPS) Consortium: Baseline Neuropsychological Findings in 70 Participants–Julie A. Fields, Bradley F. Boeve, Leah Kathleen Forsberg, Erik Kent St. Louis, Ruth Kraft, Kevin R. Nelson, Paul Timm, Luke Teigen, Alon Y. Avidan, Adreanne Rivera, Ronald Postuma, Amelie Pelletier, Michael J. Howell, Josh De Kam, Kelly Ryberg, Rebekah Summers, Donald Biwise, Daniel Huddleston, Cathy WoodSiverio, Carole Seeley, Aleksandar Videnovic, Matthew Stauder, Samantha Hersh, Walter A. Kukull, Jennifer Svoboda McLeland, Yo-El Ju P15.8-008 Personality Traits as Predictors of Pre-dementia Syndromes in Older Adults.– Emmeline Ayers, Joe Verghese P15.8-009 Intrusions in episodic memory in preclinical autosomal dominant Alzheimer’s disease: Contributions of education and occupation to optimal recall–Liliana A. Ramirez-Gomez, Yamile Bocanegra, Celina Pluim, Ana Baena, Clara Vila-Castelar, Felipe Jain, Margarita Giraldo, Claudia Alejandra Munoz, Victoria Tirado, Eliana Henao, Francisco T. Lopera, Yakeel Quiroz P15.8-010 Assessing the effectiveness of SCD-plus criteria in predicting the progression to

Stroke Prevention, Risk Factors, Complications, and Recovery 2

P15.9-001 Albuminuria Detection and Management in Patients admitted with Ischemic Stroke and Intracranial Hemorrhage: A Pilot Quality Assurance Project to Target Reduction of Recurrent Stroke Risk.–Steven Yang, Annie Lee Hsieh, Kevin Lo, Maria Virginia Diaz Rojas, Jonathan Dissin, Janani Rangaswami P15.9-002 Improving Outcomes for In-Hospital Stroke: A Single Center Study–Angela M. Hawkins, Harold H. Morris P15.9-003 The “weekend effect” – Does it impact acute stroke care?–Anand Vilaschandra Patel, Sami Bajwa, Sneh Preet Munder, Karalyn Pappas, Jeffrey M. Katz, Richard Libman P15.9-004 The Effects of Thrombolysis and Thrombectomy on Patient-centered Non-modified Rankin Scale (mRS) Outcome Measures in Patients with Minormoderate Stroke: A Systematic Review–Adam Michael Book, Leah Kuzmuk, Thalia S. Field P15.9-005 Data Mining applied to Poststroke Depression in Colombian Elderly Patients–Gabriel D. Pinilla Monsalve, Maria Gonzalez-Velez, Pablo Amaya-Gonzalez P15.9-006 Head-to-head comparison of social network assessments in stroke survivors– Simona Nedelcu, Morgan Prust, Abigail Halm, Amber Nieves, Amar Dhand

AAN.com/view/20AM 203

Thursday, April 30

P15.7-004 Triple M: A case of Nivolumab-induced myasthenic crisis, myocarditis and myositis– Katelyn Oliveira, Kara Stavros, Jacob Didion P15.7-005 Vanishing Muscle; A Disappearing Act and Its Multiple Etiologies–Sonia M. CaraballoCartagena, Gishlaine Alfonso P15.7-006 Understanding Mitochondrial DNA Maintenance Disorders at the Single Muscle Fibre Level–Diana Lehmann, Hannah S Rosa, Mariana C Rocha, Stephan Zierz, Robert W Taylor, Douglas M. Turnbull, Amy E Vincent P15.7-007 A New Case Of Spastic Paraplegia Type 64 Due To A Missense Mutation In The ENTPD1 Gene–Alier Marrero, Nicolas Crapoulet, Alier Marrero P15.7-008 A Novel Dominant HSPD1 Mutation In Hereditary Spastic Paraplegia Complicated

Michael Koenig, Dilip Singh, Amir Adeli P15.8-004 Alcoholic Wernicke’s Encephalopathy Presenting with Isolated Cerebellar Diffusion Restriction–Gaurav Thakur, Mangala Gopal, Kasser Saba, Arun Ramamurthy P15.8-005 Moderate-Severe TBI as a Progressive Disorder: Cognitive declines in the Chronic Stages of Injury–Alana Changoor, Brenda Colella, Georges Monette, Robin Green

POSTER SESSIONS

P15.7-001 Immunomodulatory and Anti-oxidative Effect of the Direct TRPV1 Receptor Agonist Capsaicin on Schwann Cells– Kalliopi Pitarokoili, Alina Blush, Jeremias Motte, Melissa Sgodzai, Hussein Bachir, Rafael M. Klimas, Bjorn Ambrosius, Ralf Gold, Gisa Ellrichmann, Thomas Gruter P15.7-002 Acetylcholine Receptor Antibodies in a patient with Sensory Neuropathy–Shitiz K. Sriwastava, Robert P. Lisak P15.7-003 Rapidly Progressive Dorsal Cord Syndrome: A Case Of Synergistic Multinutrient Deficiency–Benjamin Lin, Ramiro Gabriel Castro Apolo, Jaspreet Johal, Keithan Sivakumar, Alison L. Walsh

by Leukoencephalopathy And Cognitive Dysfunction–Mika Martikainen, Marja Hietala P15.7-009 Clinical and genetic features of SPG11: A Single Center Experience–Arman Cakar, Hasim Gezegen, Ceren Tunca, Elif Bayraktar, Nazli Basak, Hacer Durmus, Fatma Yesim Parman P15.7-010 Botulinum Toxin in the Management of Refractory Sialorrhea in Patients with Neuromuscular Disease–Harsh Singh, Tejas Mehta, Shivangi Singh, Raghav Govindarajan P15.7-011 Novel approaches for quantifying muscle disuse: A study of rotator cuff injury–Akashleena Mallick, Badria Munir, Hilda Victoria Gutierrez, Sarah Verga, Hawa Yusuf, Arun Ramappa, Joseph DeAngelis, Jim Wu, Seward B. Rutkove P15.7-012 Spherical Nucleic Acids (SNAs) for the Treatment of Neurologic Diseases–Grant Thomas Corbett, Lauren Ruth Moore, Scott Mix, Andrew Schook, SubbaRao Nallagatla, Weston Daniel, Leo Kelly, Bart Anderson P15.7-013 A Novel Homozygous TRIM32 Mutation in a NonHutterite Patient with Limb-Girdle Muscular Dystrophy–Pritikanta Paul, Margherita Milone, Jennifer Anne Tracy, Teerin Liewluck P15.7-014 Dual mutation- CLCN1 and Col12A1 with clinical Myotonia–Maria Sarfraz, Ehtesham Khalid P15.7-015 Stiff Limb Syndrome: A Rare Variant of Stiff Person’s Syndrome–Benjamin Lin, Keithan Sivakumar, Hussam A. Yacoub, Jay D. Varrato, Alison L. Walsh, Alissa Eileen Romano

Thursday, April 30

POSTER SESSIONS

POSTER SESSION 15 P15.9-007 Remote Management of Post-stroke Patients with Smartphone-based Management System Integrated in Clinical Care–Hyong-Min Kwon, Do Yeon Kim P15.9-008 Aphemia Following a Non-dominant Sub-insular Stroke: Unveiling the Foix-Chavany-Marie Phenomenon–Saurav Das, Naga Krishnakanth Madireddy, Satheesh Kumar Bokka, Michael Haboubi, Jignesh J. Shah, Tracy Ander, Wei Liu, Kerri S. Remmel P15.9-009 An Inpatient Scoring System To Prevent Hospital Acquired Pneumonia on Stroke Service–Mudassir Farooqui, Mishel Farasatpour, Sayid Suriya, Dania Qaryouti, Atif Zafar P15.9-010 Factors And Hospital Charges Associated With Prolonged Length Of Hospitalization In Patients Admitted With Ischemic Stroke In The United States–Iqra N Akhtar, Saqib A. Chaudhry, Mohammad-Rauf A. Chaudhry, Sairah Bashir, Mohsain Gill, Adnan I. Qureshi P15.9-011 Stroke Characteristics in Post-Stroke Epilepsy Cohort: A Single Center Experience–KaHo Wong, Cecilia Peterson, Lilly fagatele, Mugdha Jaitpal, Amir Manzoor Arain, Blake Newman, Adam De Havenon P15.9-012 Ischemic Stroke Strikes Autonomic Nervous System– Ashish Susvirkar P15.9-013 National Estimates Of Recurrent Ischemic Stroke Among Patients Undergoing Carotid Revascularization: Effect Of Treatment Modality–Sairah Bashir, Saqib A. Chaudhry, Yun Fang, Iqra N Akhtar, Ameer Hassan, Mohammad-Rauf A. Chaudhry, Mohsain Gill, Muhammad Fareed Suri, Farhan Siddiq, Camilo Ramiro Gomez, Adnan I. Qureshi P15.9-014 Inpatient Complications and Mortality of Stroke in Costa Rica: A seven-year hospital-based acute stroke registry of 1319 patients–Cesar E EscamillaOcanas, Gabriel Torrealba Acosta, Rahul Damani, Anthony O’Brien, Renyu Liu, Miguel Barboza-Elizondo, Kenneth Carazo, Huberth Fernandez P15.9-015 Shorter Hospital Stays are Associated with Undiagnosed Diabetes in Ischemic Cerebrovascular Patients–Coleton

CME

Towles, Patrick Kitzman, Juan Lopez-Alvarenga, Michael Dobbs P15.9-016 Predicting Outcome in Acute Posterior Circulation Strokes treated with Interventional Thrombectomy in a Middle Eastern Stroke Center–Tehniyat Baig, Wajiha Yousuf, Naveed Akhtar P15.9-017 Patterns of DomainSpecific Recovery Over 90 days from Acute Ischemic Stroke Onset–Laura Heitsch, Robynne Braun, Adam De Havenon, John Cole, Arne Lindgren, Steven C. Cramer, Bradford B. Worrall P15.9-018 Does Age Affect Functional Improvement in Stroke Patients During Inpatient Rehabilitation?–Shayandokht Taleb, Dorothea Parker, Amy Durand, Melissa Huynh, Xu Zhang, Monica Verduzco, Sean I. Savitz Neurocritical Care: Epilepsy and TBI 2

P15.10-001 Contiguous Neurosciences Intensive Care Unit (NSICU) Admissions and Patient Outcomes–Deeksha Chada, Nicki Mohammadi, Alexandra S. Reynolds, Cappi C Lay, Kaitlin Johanna Reilly, Neha Dangayach, John Liang P15.10-002 Ventilator Associated Pneumonia Incidence with different Positive End-Expiratory Pressure (PEEP) settings in a Neurological ICU serving rural patients–Klepper A. Garcia, Manan Shah P15.10-003 A Rare Case Of Dysferlinopathy With Recurrent Rhabdomyolysis–Subhendu Rath, Hamza Coban, Annie S. Daniel P15.10-004 Serotonin Syndrome with Exposure from Tetrahydrocannabinol: a Case Report to Highlight the Side Effects of Increasing Use of CBD Products– Christine Tschoe, Leilani Johnson, Ava Giugliano, Aarti Sarwal P15.10-005 Innovative MutliApproach Therapy for Treatment of Extrapontine Myelinolysis–Chelsea Clareann Yager, Chelsea Clareann Yager P15.10-006 Ketone Bodies Induce Oxidative Stress and Apoptosis on Human Microglial Cell Line– Hongxin Chen, Nizar Souayah P15.10-007 A Healthy Young Man With Headache and Trochlear Nerve Palsy – “The Great Masquerader” presenting

204 2020 AAN Annual Meeting

0 Thursday, April 30 as Tuberculous Meningitis: A Case Report–Olga Gomez Siegert, Martha Robinson, Casey R. Dunn, Aimee M. Aysenne P15.10-008 Case Report: Intracranial Miliary Metastatic Disease in a Patient with Primary Ductal Carcinoma of the Breast– Belle Victoria English, Mohammed Kananeh, M. Kamran Athar P15.10-009 Does Insurance Status of Patients Treated in a Neurocritical Care Facility Affect the Length of their Hospital Stay? One Hospital’s Experience–Ian Cossentino, John Liang, Neha Dangayach, on Behalf of the Mt Sinai NEMAT Research Group P15.10-010 Case Report of Reversible Toxic Leukoencephalopathy Secondary to Cocaine Inhalation with Hydrocephalus on Presentation– Anna Volski, Daniel Halvorsen, Jonathan P. Hosey, Jennifer Axelband Neurocritical Care: Cerebrovascular Disease and Cardiac Arrest 1

P15.10-011 Refractory Orolingual Angioedema after Alteplase Treatment: A Novel Approach– Martha Robinson, Olga Gomez Siegert, Aimee M. Aysenne, Casey R. Dunn P15.10-012 Clopidogrel versus Prasugrel towards Prevention of Stent Thrombosis of Intracranial Aneurysm – A metanalysis and literature review–Cailtin Mulvihill, Salman Assad, Danny Jayasuriya, Justin Michael Nolte, Samrina Hanif P15.10-013 Shorter intensive care unit stay (12 hours) post thrombolysis is safe and reduces length of stay for minor stroke patients–Muhib Khan, Tricia Tubergen, Laurel Packard, Danielle Gritters, Hattie LaCroix, Andrea Goosen, Angela Frye, Nicole Wills, Joseph Zachariah, Elysia James, Elysia James, Justin Singer, Nabil Wees, Nadeem I. Khan, Jiangyong Min P15.10-014 Escaping the web: Antiplatelet insufficient for stroke prevention in Carotid Artery Web– Charles DeMello Schutt, Swetha Renati, Jorge Jose Pesquera, Daniel John Kaplan, Maxim Mokin, David Z. Rose

12:00 p.m.–1:00 p.m. P15.10-015 Opioid use during hospitalization for Subarachnoid Hemorrhage is associated with continued use at follow up–Matthew N. Jaffa, Michael Armahizer, WanTsu Chang, Melissa Motta, Gunjan Parikh, Neeraj Badjatia, Nicholas Allen Morris P15.10-016 EEG Sleep Architecture as a Biomarker after Non-traumatic Subarachnoid Hemorrhage–Christopher Wilkins, Kathryn Hagen, Andrew Treister, Paul V. Motika, Holly E. Hinson P15.10-017 Steroids have mild transient effects on headache in patients with Subarachnoid Hemorrhage–Arshom Foroutan, Matthew N. Jaffa, Nikhil M. Patel, Michael Armahizer, Gunjan Parikh, WanTsu Chang, Melissa Motta, Neeraj Badjatia, Nicholas Allen Morris P15.10-018 Safety and Clinical Outcome of Good-Grade Aneurysmal Subarachnoid Hemorrhage in Non-Intensive Care Units–Clare Angeli Guinto Enriquez, Jose Danilo Bengzon Diestro, Abdelsimar Omar, Romergryko G. Geocadin, Gerardo Legaspi Child Neurology and Developmental Neurology: Neurogenetics 3

P15.11-001 Movement Disorders in Women with X-Linked Adrenoleukodystrophy–Melanie De Las Alas Supnet, Christopher D. Stephen, Haley Andonian, Nutan Sharma, Florian Eichler P15.11-002 Cannabidiol Transdermal Gel for the Treatment of Fragile X Syndrome: Post hoc Responder Analysis and Pattern of Efficacy on domains of the Aberrant Behavior Checklist-FXS (ABC-CFXS)–Joseph Palumbo, Wei Du, Helen Heussler, Natalie Silove, Jonathan Cohen P15.11-003 Central Nervous System/Vestibular abnormalities in Oculo-Auriculo-Vertebral Spectrum Disorders–Jyotika Singh, Jules Constantinou

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number Child Neurology and Developmental Neurology: Neuromuscular Disease 2

P15.11-004 Early Clinical Experience with Onasemnogene Abeparvovec in Spinal Muscular Atrophy (SMA) Type 2 Patients at a Single Center–Susan Matesanz, Elizabeth Anne Kichula P15.11-005 Real-World Treatment Patterns and Outcomes in Patients with Spinal Muscular Atrophy Collected from the RESTORE Registry–Laurent Servais, John W. Day, Madhu Nagappa, Jan Kirschner, Eugenio Mercuri, Francesco Muntoni, Perry Shieh, Eduardo Tizzano, Isabelle Desguerre, Susana Quijano-Roy, Kyoko Saito, Marcus Droege, Omar Dabbous, Ankita Shah, Khan Farid, Fred Anderson, Richard S. Finkel P15.11-006 Sex Difference in a New Mild Mouse Model of Spinal Muscular Atrophy–Marc-Olivier Deguise, Alexandra Tierney, Lucia Chehade, Ariane Beauvais, JeanMarc Renaud, Brittany Paul, Yves De Repentigny, Sabrina Gagnon, Mohamed Thabet, Rashmi Kothary P15.11-007 A Search for Systemic Manifestations of Spinal Muscular Atrophy (SMA): A Matched-Cohort Study Using Insurance Claims Data in the USA–Julie Mouchet, Scott Lipnick, Spyros Roumpanis, Rupali

Naik, Etienne Regulier, Renata Scalco, Basil T. Darras P15.11-008 Assessment of Awareness of the Early Clinical Features of Spinal Muscular Atrophy (SMA) Amongst Neurology and Child Neurology Residents and Fellows–Rosangel Esperanza Cruz, Lisa Belter, Jill Jarecki P15.11-009 Identical twins with progressive gait disturbance due to a novel SPG11 mutation–Rahul Dilip Abhyankar, Susan T. Iannaccone P15.11-010 Characterizing commercially- and Medicaidinsured registrants with Duchenne muscular dystrophy (DMD) in the United States (US)–Shelagh Szabo, Alexa Klimchak, Christina Qian, Evan Popoff, Susan T. Iannaccone, Katherine Gooch P15.11-011 Understanding the Role of the DMD Protein Dystrophin in the Subventricular Zone–Andrea Arreguin, Holly Colognato P15.11-012 Deflazacort Or Prednisone Treatment for Duchenne Muscular Dystrophy (DMD) RealWorld Outcomes at Cincinnati Children’s Hospital Medical Center (CCHMC)–Jessica Marden, Claudio Santos, Panayiota Trifillis, Jonathan Freimark, Zhiwen Yao, Zhiwen Yao, James Signorovitch, Cuixia Tian, Brenda L Y Wong

P15.11-013 Improved Metabolic and Bone Health in Boys with Duchenne Muscular Dystrophy Treated with High Dose Pulse Weekend Corticosteroids compared to Daily Dosing–Aaron Simon Zelikovich, Mattia Quattrocelli, Elizabeth McNally, Nancy L. Kuntz P15.11-014 Promising Results for Kearns-Sayre Syndrome of First in Man Treatment by Mitochondrial Augmentation Therapy–Omer Bar Yosef, Elad Jacoby, Noah Gruber, Nira Varda-Bloom, Einat Azaria, Etzyona Eisenstein, Sharon Barak, Jaana Ahonniska-Assa, Yair Anikster, Amos Toren P15.11-015 “MEGAS”: Mitochondrial Encephalopathy, Gastric Dysmotility, and Seizures– Marika Antimisiaris, Mark Earl Pierce, Bryan M. Gough

Giving patients hope. It’s been our mission since 1978. Visit Booth 311 to learn more about SPINRAZA (nusinersen injection) TM

nusinersen injection

AAN.com/view/20AM 205

POSTER SESSION 16

CME

0 Thursday, April 30

5:30 p.m.–6:30 p.m.

Thursday, April 30

POSTER SESSIONS

Poster Session 16 1. Multiple Sclerosis: Clinical Assessments and Outcome Measures 3: 1-001 to 1-019 2. Autoimmune Neurology 9: 2-001 to 2-013 3. Dystonia, Tics, and Restless Legs Syndrome 2: 3-001 to 3-017 4. Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 3: 4-001 to 4-009 5. General Neurology: Clinical Science: Cohorts and Case Series 3: 5-001 to 5-011 6. Headache 2: 6-001 to 6-013 7. Acquired Myopathies/Other Neuromuscular Disorders 2: 7-001 to 7-014 8. Aging and Dementia: Neuropsychology and Clinical Trials 2: 8-001 to 8-012 9. Stroke Prevention, Risk Factors, Complications, and Recovery 3: 9-001 to 9-018 10. Neurocritical Care: Cerebrovascular Disease and Cardiac Arrest 2: 10-001 to 10-018 11. Child Neurology and Developmental Neurology: Seizures and Epilepsy 2: 11-001 to 11-015

Multiple Sclerosis: Clinical Assessments and Outcome Measures 3

P16.1-001 Modification of Facial emotion observation strategies in demyelinating disease spectrum : an eye-tracking study.–Kevin Polet, Solange Hesse, Heloise Joly, Adeline Morisot, Mikael Cohen, Benoit Kullmann, Christine LebrunFrenay, Alain Pesce P16.1-002 Serum soluble TWEAK in relapsing and progressive multiple sclerosis patients.–Xavier Ayrignac, sylvie carmona, Thierry Vincent, Clarisse Carra-Dalliere, Mahmoud Charif, Frederic Pinna, Sophie Desplat Jego, Pierre Labauge P16.1-003 IgG index for multiple sclerosis diagnosis: old test do the trick–Yang Zheng, Yin-Xi Zhang, Fan Yang, Mei-Ping Ding P16.1-004 A single-center, prospective, cross-sectional study to evaluate the reliability and validity of the modified Manual Muscle Test for persons with multiple sclerosis–Nico Van der Maas, Regula Steinlin Egli, Marcus D’Souza, Deborah Vogt P16.1-005 The Rise of Connected Tools in Medicine : Evaluating

Neurological Deficits in Lower Limbs With The MYO Armband in Multiple Sclerosis Patients– Salimata Gassama, Salimata Gassama, Salimata Gassama, David Laplaud, Salimata Gassama, Salimata Gassama, Salimata Gassama, Said Moussaoui, David Laplaud, Pierre-Antoine Gourraud P16.1-006 Foot-tapping ability is associated with walking ability in relapsing-remitting and progressive multiple sclerosis–Sumire Sato, Jules D Miehm, John Buonaccorsi, Caitlin Rajala, Jongil Lim, Farnaz Khalighinejad, Carolina Ionete, Jane A Kent, Richard EA van Emmerik P16.1-007 Neurofilament Light Chain and Levels of Fatigue are Reduced by Dimethyl Fumarate Independent of Inflammatory Neuroaxonal Damage–Tobias Sejbaek, Louise Andersen, Malte Roar Eriksen, Helle Hvilsted Nielsen, Maria Louise Elkjaer, Mads Henrik Ravnborg, Zsolt Illes P16.1-008 Safety and Efficacy of Ocrelizumab in Patients who Transitioned Directly from Alemtuzumab Therapy–Paul Miller, Vince Tran, Rawan Jarrar, Vince Tran, Jill Marie Olson, Tamara Miller, Augusto A. Miravalle

206 2020 AAN Annual Meeting

P16.1-009 Increased Burden of Susceptibility Variants in Familial Multiple Sclerosis–Elif Everest, Ugur Uygunoglu, Melih Tutuncu, Sabahattin Saip, Taskin Duman, Brien Riley, Aksel Siva, Eda T. Turanli P16.1-010 From Therapy Enrollment to First Dose - a Quality Improvement Initiative for MS Care–Jamie Bolling, Carlos Eduardo Vervloet Sollero, Tirisham Gyang, Aaron M. Carlson P16.1-011 The Best Motion Sensor Localization For Ataxic Gait Assessment–Ondrej Dostal, Ondrej Dostal, Ales Prochazka, Oldrich Vysata, Ladislav Pazdera, Martin Valis P16.1-012 An Attempt to Subclassify and Understand Further the MS/NMOSD “Overlap” Syndromes and Beyond…–Bade Gulec, Ugur Uygunoglu, Melih Tutuncu, Cengiz Yalcinkaya, Sabahattin Saip, Aksel Siva P16.1-013 Should Elderly MS Patients Follow Conventional Dosing of Ocrelizumab?–Soumya Bouchachi, Machteld E. Hillen P16.1-014 Two-Year Interim Results of the MS-CQI Research Collaborative–Brant Oliver

P16.1-015 Associations Between Vascular Comorbidity, Visual Acuity and Optical Coherence Tomography in Secondary Progressive Multiple Sclerosis–Kathleen Shangraw, Chad Murchison, Andrea Hildebrand, Rebecca Spain P16.1-016 Network MetaAnalysis for Cumulative Disability Accumulation in Relapsing Multiple Scelorsis–Alexander Keenan, Hannah Guiang, Elizabeth Salvo, Aaron Situ, Sumeet Singh P16.1-017 Application of the 2017 McDonald criteria for the diagnosis of Multiple Sclerosis after a first demyelinating event in patients from Argentina.–Pagani Cassara Fatima, Maria Celeste Curbelo, Guido Vazquez, Lucas Sedeño, Judith Diana Steinberg, Adriana Carra, Vladimiro Sinay P16.1-018 Natural Course of Relapsing Tumefactive Multiple Sclerosis and Tumefactive Demyelinating Lesions–Ozgu Kizek, Faruk Ugur Dogan, Tuncay Gunduz, Murat Kurtuncu, Mefkure Eraksoy P16.1-019 Can Sjogren’s Mimic MS or be an MS+ Syndrome?– Armistead Williams

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number Autoimmune Neurology 9

P16.3-001 Transcriptomic Analysis Of Dystonia-Related Genes Reveals Functional Convergence Within Specific Cell Types And Shared Neurobiology With Psychiatric Disorders–Niccolò Mencacci, Regina Reynolds, Sonia Garcia Ruiz, Jana Vandrovcova, Paola Forabosco, Mike Weale, John Hardy, Juan Botia, Mina Ryten P16.3-002 Family-Based Genome Analysis Identifies Clinically Relevant de novo Variants in Pediatric Dystonia–Bahareh Adhamimojarad, Yue Yin, Ian Backstrom, Ryan Yuen, Teesta B. Soman P16.3-003 Longterm Adherence and Global Self Perceived Response to Botulinum Neurotoxin are Determined by the Treatment Indication, up to 23 Years Real World Evidence from a Single Center Retrospective Cohort Study–John-Ih Lee, Alexander Jansen, Ulrike Kahlen, Marek Moll, Marius Ringelstein, Hans Bigalke, Orhan Aktas, Alexia Moldovan, Julia Waskoenig, Sebastian Jander, Michael Gliem, Alfons Schnitzler, Hans-Peter Hartung, Harald Hefter, Philipp Albrecht P16.3-004 TAF1 expression in X-Linked Dystonia-Parkinsonism– Jamal Al Ali, Shivangi Shah, Christine A. Vaine, Naoto Ito, William Hendriks, Benjamin Currall, Michael Talkowski, Laurie J.

P16.3-014 Social Cognition Is Abnormal in Cervical Dystonia but Not Blepharospasm–Jeanne Feuerstein, Samantha K. Holden, Stefan Sillau, Brian D. Berman P16.3-015 Botulinum Toxin Therapy for Medication and DBS Refractory Foot Dystonia of Parkinsonism–Muthu Kuzhali Ganapathy, Mustafa S. Siddiqui P16.3-016 Chemo-denervation of Oromandibular Dystonia with Botulinum toxins: Five-year experience–Muhammad Atif Ameer, Nabeel M. Syed, John M. Bertoni, Amy Hellman, Diego Torres-Russotto, Danish Bhatti P16.3-017 A Unique Case of Tourette’s Motor Tic Myelopathy with a Cervical Contrast-Enhancing Lesion, Resolving with Medical Therapy–Robert James Ure, Alice Zhabokritsky, Thomas D. Steeves, Gil Midroni Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 3

P16.4-001 Standardized Ictal Assessment: Improving the Quality of an Epilepsy Monitoring Unit–Brian James Hanrahan, Lynn Liu P16.4-002 ED Visits and Readmissions Following Epilepsy Monitoring Unit Discharge–Jocelyn F. Bautista, Alison M. Fields P16.4-003 Epileptic seizures after cardiovascular surgery–Carla Florencia Bolano Diaz, Guido Vazquez, Jesica Pszenyckyj, Franco Emanuel Appiani, Blas Couto, Alejandro Thomson, Carlos Santiago Claverie, Pamela Bobadilla, Analia Calle, Veronica Campanille, Ricardo Daniel Bernater, Maria Elena Fontela, Patricia Acosta, Roberto Favaloro, Alfredo Thomson P16.4-004 Incidence of Seizure and Associated Risk Factors in Patients in the Medical Intensive Care Unit (ICU) at Memorial Sloan Kettering Cancer Center (MSKCC) In 2016-2017–Saeedeh Azary, Christopher Caravanos, Anne S. Reiner, Katherine Panageas, Vikram Dhawan, Edward Avila P16.4-005 A Hospital Based Cross-sectional Study Among Women With Epilepsy In Addis Ababa, Ethiopia–Hanna Belay

AAN.com/view/20AM 207

Thursday, April 30

Dystonia, Tics, and Restless Legs Syndrome 2

Ozelius, Cristopher Bragg, Xandra O. Breakefield P16.3-005 Impact of Injection Schedule Flexibility on Patient Satisfaction with Botulinum Toxin Treatment for Cervical Dystonia– Vivay Peter Misra, David Charles, Carlo Colosimo, Tae Mo Chung, Pascal Maisonobe, Savary Om P16.3-006 Mortality in Restless Leg Syndrome: A-11 year-year follow up study.–Esther Cubo Delgado, Carla Collazo, Cesar Gallego-Nieto, Miren Elizari, Cesar Gallego-Nieto P16.3-007 Puerto Rican family cohort presenting with rapid-onset dystonia-parkinsonism due to an ATP1A3 Pathogenic Variant– Alexandra M. Montalvo Acevedo, Natalia Rodriguez, Mayela Marie Diaz Diaz, Jocelyn Montalvo, Jessica Gonzalez Montes, Mireya M. Bolo-Diaz, Janice Rodriguez Hernandez, Marisel Vazquez P16.3-008 Two Heterozygous SNYE1 Mutations Presenting as Spasmodic Adductor Dysphonia, Task-specific Jaw Dystonia, Generalized Dystonia, and Ataxia in a Jamaican Man.–Sviatoslav Redko, Pratibha Surathi, Erin Michelle Feinstein P16.3-009 Decreased Therapeutic Effect Over Time Amongst Botulinum Toxin Agents–Rashid Kazerooni P16.3-010 Evaluation following the Switch from AbobotulinumtoxinA to IncobotulinumtoxinA of dystonia service in an outpatient setting– Hemalal Wimalaratna, Kally Patel P16.3-011 Malignant Tics: Two Cases with Management Strategies to Prevent Long Term Complications–Mariam Hull, Mered Parnes P16.3-012 Expanding the Phenotypic Presentation in KCNA2 Mutation: Tics and Stereotypies– Joseph Legacy, Matthew Robert Burns, Ahmad El Kouzi, Wissam Georges Deeb, Irene Malaty P16.3-013 Cost-Utility Analysis of Flexible Intervals with IncobotulinumtoxinA Versus Fixed Dosing with OnabotulinumtoxinA in the Management of Cervical Dystonia and Blepharospasm in Major Canadian Markets–MarieEve Gendron, Rashid Kazerooni, Denis Vezina

POSTER SESSIONS

P16.2-001 Cognitive Impairment in Neuro-Behcet’s and Behcet’s Disease–Merve Atik, Mesude Tutuncu, Melih Tutuncu, Ugur Uygunoglu, Ayhan Bingol, Sabahattin Saip, Aksel Siva P16.2-002 Demographics, Clinical Characteristics and Neurologic Manifestations of CVID-Associated Granulomatous Disease in a Multi-Institutional Dataset–Tammy L. Smith, Shamik Bhattacharyya, Leonard Calabrese, James Everett Eaton, Jonathan Ross Galli, Rula Hajj-Ali, Carlos A. Pardo-Villamizar, Amanda Lee Piquet, Barney J. Stern, Jinny O. Tavee, Stacey Clardy P16.2-003 Cognitive and Depressive Symptoms in Adults with Common Variable Immunodeficiency (CVID)–Bruno Ivo De Almeida, Lawanda Esquibel, Leah Millsap, Julia Klein, Jonathan Ross Galli, Melissa M. Cortez, M. Mateo Paz Soldan, Adi Gundlapalli, John E. Greenlee, John W. Rose, Harry Haydon Hill, Ka-Ho Wong, Stacey Clardy P16.2-004 ANCA Negative Eosinophilic Granulomatosis with Polyangiitis in Patient with Multiple Autoimmune Disorders.–Shaweta Khosa, Shri Kant Mishra, Anthony M. Bradshaw, Catherine Stanecki, Frank Diaz, Robert Freundlich P16.2-005 Simultaneous Central and Peripheral Demyelination in A Patient with Systemic Lupus Erythematosus–Masumeh Hatami, Shivika Chandra, Thy Nguyen P16.2-006 CLIPPERS in the Setting of Systemic Lupus Erythematosus–Ronald Alvarado Dyer, Faddi Ghassan M. Saleh Velez, John Thomas Fortunato, Laura Castillo-Saavedra, Veronica Kate Penyak Cipriani, Adil Javed P16.2-007 Tumefactive CNS Demyelination in Pregnancy: A Diagnostic and Therapeutic Challenge–Terri Milburn, Amy Rice Harrison, Dinesh V. Jillella P16.2-008 Fulminant CNS Demyelination After Discontinuation of TNFInhibitor(TNFi) therapy–Michael Benjamin Beeler, Virginia Baker P16.2-009 Parry-Romberg Syndrome: Case Report and Review–Marcus Cimino, John G. Kelsey, Edward Chang

P16.2-010 Recurrent Post-Partum Rhombencephalitis Associated With Anti-Centromere Antibody: A Case Report–Alier Marrero, Andy Jin, Jean Mamelona, Byrne D. Harper P16.2-011 An Unusual presentation of Rheumatoid Meningitis in the Pre-clinical period of Rheumatoid Arthritis–Luis Guillermo Manrique, Dronacharya Lamichhane P16.2-012 MelkerssonRosenthal Syndrome with Hearing Impairment.–Sania Atta, Adil Iqbal, Brij M. Ahluwalia-Singh P16.2-013 IgG4 Related Disease Presenting As a Cerebral Mass With Leptomeningeal Enhancement–Gina Susana PerezGiraldo, Sarah R. Durica, Juliane Chainakul, Ahmad Al-Awwad, Nidhiben A. Anadani

Thursday, April 30

POSTER SESSIONS

POSTER SESSION 16 P16.4-006 What Happens to Glucose During Multidien Interictal or Ictal Cycles?–Sanjay Kubsad, Alexa Pappas, Nicole M. Warner, Alan Haltiner, Ryder Gwinn, Maxime Baud, Michael J. Doherty P16.4-007 Knowledge of Women Issues and Epilepsy among Doctors in Gujarat–Samir Patel, Ripal Patel P16.4-008 Caregivers and Compounding Pharmacies: Identifying Unmet Needs–Danielle Boyce, Orrin Devinsky, Kathryn Hart P16.4-009 Vaping and Seizure Risk: A Case Report–Timothy Quezada, Bahareh Sianati, James P. Valeriano General Neurology: Clinical Science: Cohorts and Case Series 3

P16.5-001 Hepatic Reflections in Brain: The Clinicoradiological Spectrum–Monali Chaturvedi, Suman Kushwaha, Aldrin Anthony, Renu Gupta P16.5-002 Liver Damage in High Blood Pressure Diseases in Pregnancy is related with Cognitive Capacity Decreasement–Aldo Garcia-Heredia, Luis Fernández, Carlos Alberto Soto-Rincon, Mario Cristobal Nino, Juan Fernando Gongora Rivera P16.5-003 The Risk of Renal Hemorrhage in Adult Patients Burdened by Kidney Manifestations of Tuberous Sclerosis.–Lauren Alexandra Neal, Mary T. Silvia, Jane Boggs, Theodore B Stem, Daniel B Rukstalis, Matthew C Miles, Roy E. Strowd P16.5-004 Determinants of post lumbar puncture headache – the role of cerebrospinal fluid volume–Gadi Miron, Gadi Miron, Nurit Omer, Tanya Gurevich, Yair Mina, Meir Kestenbaum, Jesse M. Cedarbaum, Nir Giladi, Anat Mirelman, Avner Thaler P16.5-005 Transient Neurological Sequela After Interscalene Block: A case series–Sri Raghav Seshu Sista, Dronacharya Lamichhane, Victor Chan, Bo Gustafsson P16.5-006 Retinal Pathology Occurs in Stiff Person Syndrome– Jeffrey Lambe, Alissa Rothman, Jerry Prince, Shiv Saidha, Peter A. Calabresi, Scott Douglas Newsome P16.5-007 Hashimoto’s Encephalopathy: A Spectrum Disorder?–Ali M. Kh. Al-Salahat,

CME

Rola Khodair, Khansa Saheblal Tamboli, Rasha Abumustafa, Musab Ali, Boulenouar Mesraoua, Yasir Osman Mohamed P16.5-008 Classic and overlapping Miller Fisher syndrome: Clinical and electrophysiological features– Guillermo Delgado-García, Juan Carlos Lopez, Sofia Garcia Trejo, Roberto Cervantes Uribe, Edwin S. Vargas P16.5-009 Elucidating the Role of Myeloperoxidase in Distinguishing Acute Encephalitis Syndrome of Infectious, Immune mediated and Unknown Etiology–Vivek Varun, Renu Gupta, Suman Kushwaha, Monali Chaturvedi P16.5-010 Neurological Symptoms in Patients with Zinc deficiency: A Case Series with Documented Blood Levels–Madhureeta Achari, Cesar E Escamilla-Ocanas, Nazaneen Amjadi P16.5-011 Copper levels in maintenance plasmapheresis–Chen Yan, Megan Sheehan, Robert G. Wilson Headache 2

P16.6-001 Neuropathic Otalgia: Rare and Treatable Ear Pains– Aarushi Suneja, Sarah Mandani, Ashhar Ali P16.6-002 America’s Headache– Shirley Ju, Kenneth Shubin Stein P16.6-003 The Headache That Broke My Heart: Cluster and Bradycardia–Jyotika Singh, Ashhar Ali P16.6-004 Minotaur Syndrome as a difficult to treat headache: prospects for diagnosis and treatment.–Rogelio DominguezMoreno, Felipe Arturo Vega-Boada, Isael Reyes-Melo, Erwin Chiquete P16.6-005 Clinical Features of Headaches in Elderly Patients. PREMECEF Results.–Luis Fernández, Alejandro R. MarfilRivera P16.6-006 Anxiety, Depression and Lifestyle Patterns among Adolescents from India with Primary Headache–Sachin MANOHAR Kokane, Devashish Devrao Ruikar, Sudhindra Vooturi, Basawaraj Khubba, PRACHI LIGADE, Mahadev Gavane, Dilip Deshmukh, Satish Pawar, Basawaraj Khubba P16.6-007 Relation of Headache Frequency to Cognitive Status in Veterans of Iraq (OIF) and

208 2020 AAN Annual Meeting

0 Thursday, April 30 Afghanistan (OEF) wars who have had a Deployment-Related TBI (DTBI)–James R. Couch, Blair Apple, Kenneth Stewart P16.6-008 Factors Associated with Subsequent Cerebral Vascular Disease after Emergency Department Headache Visits: a nested case-control study–Jenny Lu, Richard B. Lipton, Khadean Moncrieffe, Daniel L. Labovitz, Ava L. Liberman P16.6-009 Sleep Disorders in Mexican Pediatric Patients with Headache.–Nelly M NavaRodriguez, Luis Fernández, Beatriz Chávez, Alejandro R. Marfil-Rivera P16.6-010 Coining the Pablo Picasso Syndrome–Ritika Suri, Ashhar Ali P16.6-011 A Case of High Intracranial Pressure and Dural Ectasia–Sandhya Ravikumar P16.6-012 Needle Design and the Occurence of Post-dural Puncture Headache - a Randomized, Doubleblind Study Comparing 22G Sprotte and Quincke–Ane Skaare Sjulstad, Francis Odeh, Farid Khan Baloch, Diana Hristova Berg, Kathrine Arntzen, Karl Alstadhaug P16.6-013 Prevalence of Primary Headache Disorder Among School Children of Kuwait.–Sameera Shuaibi, Abdelrahman AlAshqar, Fajer AlHamdan, Raed Alroughani, Samar Farouk Ahmed, Jasem Yousef Al-Hashel Acquired Myopathies/Other Neuromuscular Disorders 2

P16.7-001 Striving to improve outcome measures for inclusion body myositis through novel dynamometer and modifications of the current functional rating scale–Ava Yun Lin, Catherine Siener, Michelle Seiffert, Conrad Weihl, Leo Hong-Li Wang P16.7-002 Spinal Cord Pathology in Sporadic Inclusion Body Myositis–Sahara Cathcart, Ericka P. Simpson, Suzanne Powell, Anithachristy Arumanayagam, Andreana Rivera, Stanley H. Appel, Matthew D. Cykowski P16.7-003 Clinical Correlates of Variant KLRG1-expressing T cells in Inclusion Body Myositis–Namita Goyal, Steven A. Greenberg, Jonathan Cauchi, Nadia Araujo, Vivian Li, Marie Wencel, Tyler Irani, Armando Villalta, Tahseen Mozaffar

5:30 p.m.–6:30 p.m. P16.7-004 Cricopharyngeal bar in inclusion body myositis: A red flag–Kenichiro Taira, Toshiyuki Yamamoto, Madoka MoriYoshimura, Satoru Fujita, Yasushi Oya, Ichizo Nishino, Yuji Takahashi P16.7-005 Application of electrical impedance myography to capture disease progression in inclusion body myositis–Bhaskar Roy, Seward B. Rutkove, Kristin Qi, Richard J. Nowak P16.7-006 Sporadic Inclusion Body Myositis with skeletal muscle interstitial Amyloidosis–Mazen S. Alamr, Margherita Milone, Elie Naddaf, Teerin Liewluck P16.7-007 Expanding the Phenotype of MDA5 Antibody Positive Dermatomyositis–Gema Estefania Giler, Maria Kristina Casanova Dorotan, Justin Y. Kwan P16.7-008 Acute Overlap Syndrome with Myopathy Associated with Anti-signal Recognition Particle Antibodies and Sarcoidosis–Catherine Daley, Adrian Opala, Jinny O. Tavee P16.7-009 Successful recovery of anti-SRP myopathy with subcutaneous methotrexate after 17 years of poor response to immunomodulation.–Yohei Harada, Debra Guntrum, Aravindhan Veerapandiyan, Andrew Mammen, David N. Herrmann P16.7-010 Acute Necrotizing Myositis in Systemic Lupus Erythematous–Jonathan Cauchi, Mari Perez-Rosendahl, Tahseen Mozaffar P16.7-011 Myopathy: an underrecognized manifestation of vasculitis–Marcus Vinicius Rocha Pinto, Kenneth Warrington, Matthew Koster, Elie Naddaf P16.7-012 Prevalence and Autoantibody Associations of Ectopic Lymphoid Structures among Patients with Idiopathic Inflammatory Myopathies–Naohiro Uchio, Atsushi Unuma, Akatsuki Kubota, Jun Shimizu, Tatsushi Toda P16.7-013 Voriconazole-Induced Periostitis Presenting as Diffuse Myalgias–Ashley E. Anderson, Niloofar Yari, Thomas Chai, Girish Shroff, Chad Strange, Sheetal Shroff P16.7-014 Correlation of Spontaneous Activity on Needle Electromyography with

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number Pathological Changes on Muscle Biopsies–Maria Kristina Casanova Dorotan, Justin Y. Kwan Aging and Dementia: Neuropsychology and Clinical Trials 2

P16.9-001 Ischemic Heart Disease and Decline in Cognitive Function in the First Year after Stroke–Michael O’Sullivan, Paul Wright P16.9-002 A Stroke Survivor Pilot program is Feasible and Improves Patient Satisfaction–Jorge Delgadilo, Eric Pancoska, Jenny Im, Anusha Gaddam, Ken Gordon, Ilana Spokoyny P16.9-003 Box Checking for Comprehensive Stroke Care Metrics of Depression Screening: Does it Actually Equate to Better Treatment–Parneet Kaur Grewal, Ray Mirembo, William Mathias, Jessica Doyle Lee

with Ischemic Stroke as an Initial Manifestation in the First Trimester of Pregnancy and Good Clinical Course: a Case Report–Masashi Watanabe, Kensho Okamoto P16.9-014 Poor Risk Factor Control And Lower Levels Of Physical Activity Predict Incident Major Cardiovascular Events In Patients With Symptomatic Vertebrobasilar Disease: A Post-hoc Analysis Of The SAMMPRIS Trial–Leah Croll, Andrew D. Chang, Erica Scher, Koto Ishida, Jose L. Torres, Howard Riina, Denis Vezina, Aaron S. Lord, Shadi Yaghi P16.9-015 The combined presence of hypertension and vitamin D deficiency increased the probability of the occurrence of small vessel disease in China–Junliang Yuan P16.9-016 Stem cell therapy modulates inflammasome signaling in stroke: Possible involvement of Mitochondria?–Pallab Bhattacharya, Deepaneeta Sarmah, Aishika Datta, Harpreet Kaur, Kiran Kalia, Dileep R. Yavagal P16.9-017 Long-term Clinical Neurological Outcome and Predictors of Outcome following Arterial Ischemic Stroke of Childhood–Tatia Aprasidze P16.9-018 Progressive Ischemic Strokes With Malignant Cerebral Edema In a Patient With Concomitant Varicella Zoster Virus(VZV)Vasculopathy And Giant Cell Arteritis(GCA)–Shilpa Haldal, Rohan Sharma, Mitesh P. Lotia, Vishank Arun Shah, Krishna Nalleballe Neurocritical Care: Cerebrovascular Disease and Cardiac Arrest 2

P16.10-001 Subarachnoid Hemorrhage Early Brain Edema Score is Associated with Shunt Dependence and Worse Clinical Outcomes–Syeda Dania Shujaat, Chao Xu, Dee Wu, Bappaditya Ray, Gopichandh Danala, Jorge Guy Ortiz-Garcia, Masoom J. Desai P16.10-002 Revisiting the Hunt Hess Scale: Evaluation after EVD placement better predicts mortality–Nicki Mohammadi, Kaitlin Johanna Reilly, John Liang, Deeksha Chada, Natalia Romano Spica, Alexandra S. Reynolds, Neha Dangayach, Christopher Kellner, Cappi C Lay, Neha Dangayach

AAN.com/view/20AM 209

Thursday, April 30

Stroke Prevention, Risk Factors, Complications, and Recovery 3

P16.9-004 Antidepressant Use for Improving Functional Ischemic Stroke Outcomes–Stephanie Kazi, Divyajot S Sandhu, Caleb Heiberger, Tej Mehta, Douglas Yim P16.9-005 Unplanned Interruption of Acute Rehabilitation after Stroke–Amanda Ann Herrmann, Gretchen Niemioja, Ella Chrenka, Sally Imad Othman, Katherine Podoll, Annika Oie, Haitham Hussein P16.9-006 When Are You Going to Come Down? Impact of Substance Use Disorder on Stroke Outcomes– Jessica Doyle Lee, Thomas Lawler P16.9-007 Safety and Efficacy of Percutaneous Transluminal Angioplasty for Atherosclerotic Stenosis of Vertebral Artery Origin–Roman Herzig, Dagmar Krajickova, Antonin Krajina, Vendelin Chovanec, Miroslav Lojik, Jan Raupach, Ondrej Renc, Oldrich Vysata, Libor Simunek, Martin Valis P16.9-008 Symptomatic Intracranial Hemorrhage after Basilar Artery Occlusion Thrombectomies–Paige Banyas, Yasmin Aziz, Shashvat Desai, Daniel Tonetti, Ashutosh P. Jadhav P16.9-009 Posterior Circulation Collaterals and Outcomes in Acute Basilar Occlusion–Neethu Gopal, James F. Meschia, Rabih G Tawk, Thomas G. Brott, Vivek Gupta, Sukhwinder Sandhu, Mohammed K. Badi, Michelle P. Lin P16.9-010 Stroke and Death Rate in Patient Cohort Studies of Extracranial Vertebral Artery Stenosis: A Systematic Review– Ahmer Asif, Omar Saeed, Adnan I. Qureshi P16.9-011 Acute Obstructive Hydrocephalus and Ischemic Stroke as the Complications of Vertebrobasilar Dolichoectasia: A Case Report–Jie Pan, Smathorn Thakolwiboon, Khondoker Alam, Amputch Karukote P16.9-012 The prevalence of albuminuria in patients diagnosed with acute hemorrhagic and ischemic stroke - a prospective cohort study from a single stroke center–Annie Lee Hsieh, Steven Yang, Kevin Lo, Maria Virginia Diaz Rojas, Jonathan Dissin, Janani Rangaswami P16.9-013 Appropriate Management for a Patient of Moyamoya Disease Presenting

POSTER SESSIONS

P16.8-001 Argentine Validation of the Spanish Version of the Montreal Cognitive Assessment Test (MoCA-S) and its usefulness in Mild Cognitive Impairment and Dementia in Elderly.–Carla Portinari, Hector Gaston Graviotto, Marcos Sorbara, Cecilia Serrano P16.8-002 Confrontation Naming Deficit in Lewy Body Dementia Patients with Alzheimer’s Disease Co-Pathology–Erica Howard, Katheryn Cousins, Katya Rascovsky, Naomi Nevler, Thomas F. Tropea, Alice Chen-Plotkin, Andrew D. Siderowf, Daniel Weintraub, Leslie Michael Shaw, John Q. Trojanowski, Murray Grossman, David Irwin P16.8-003 A fully automated cognitive screening tool based on assessment of speech and language–Ronan O’Malley, Bahman Mirheidari, Kirsty Harkness, Traci Walker, Markus Reuber, Annalena Venneri, Heidi Christensen, Daniel Blackburn P16.8-004 Bilingualism Associated With Delay in Dementia Onset and Loss of the Second Language–Golnoush Akhlaghipour, Diana Chavez, Mario F. Mendez P16.8-005 Network Analysis of Verbal Fluency in Individuals with Incident Cognitive Impairment– Justin Bushnell, Diana Svaldi, Matthew Ryan Ayers, Virginia Wadley, Joaquin Goni, David Glenn Clark P16.8-006 Motoric Cognitive Risk Syndrome and Incident Dementia: Results from a Population-Based Prospective and Observational Cohort Study–Harmehr Sekhon, Cyrille Launay, Yves Rolland, AnneMarie Schott, Gilles Allali, Olivier Beauchet P16.8-007 Masupirdine (SUVN502), a 5-HT6 receptor antagonist in combination with Donepezil and Memantine in moderate Alzheimer’s patients–Ramakrishna Nirogi, Pradeep Jayarajan, Vinod Goyal, Satish Jeta, Anil Shinde, Gopi Bhyrapuneni, Jyothsna Ravula, Venkat Jasti

P16.8-008 BAN2401 In Early Alzheimer’s Disease: A PlaceboControlled, Double-Blind, ParallelGroup, 18-Month Study With An Open-Label Extension Phase To Confirm Safety And Efficacy–Shau Yu Lynch, Michael C. Irizarry, Shobha Dhadda, Yong Zhang, Jinping Wang, Tanya Bogoslovsky, Larisa Reyderman, June Kaplow, Heather Bradley, Martin Rabe, Keiichiro Totsuka, Lynn D. Kramer, Harald Hampel, Chad J Swanson P16.8-009 COR388 for the Treatment of Alzheimer’s Disease– Michael Detke, Casey Lynch, Leslie Holsinger, Shirin Kapur, Dave Hennings, Debasish Raha, Sean Broce, Mai Nguyen, Florian Ermini, Ursula Haditsch, Mark Ryder, Ira J. Goodman, Stephen Thein, Stephen Dominy P16.8-010 Tele-Mindfulness for Dementia’s Family Caregivers– Shadi Zarei, Gita Lakhanpal, Joel Sadavoy P16.8-011 Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with gantenerumab–Gregory Klein, Paul Delmar, Geoffrey A. Kerchner, Carsten Hofmann, Danielle AbiSaab, Smilijana Ristic, Andrew Davis, Nicola Voyle, Monika Baudler, Paulo Pacheco Fontoura, Rachelle Doody P16.8-012 Machine Learning Models Can Improve Efficiency of Alzheimer’s Disease Clinical Trials.–Ali Ezzati, Richard B. Lipton

Thursday, April 30

POSTER SESSIONS

POSTER SESSION 16 P16.10-003 Moyomoya Syndrome Related to Right Middle Cerebral Artery Aneurysm Stent Occlusion Causing Subarachnoid Hemorrhage–Pranusha Pinna, Lauren Koffman, Tara Ashley Kimbrough, Lauren Koffman P16.10-004 Assessing efficacy of four factor prothrombin complex concentrate (4FPCC) for reversal of direct factor Xa inhibitors in intracranial hemorrhages at an academic medical center–Lindsey Coppiano, Kendyl Caroline Wood, Jody Rocker, Klepper A. Garcia, Manan Shah P16.10-005 Recovery after Hemorrhagic Stroke: the Power of Family Presence at the Bedside– Natalia Romano Spica, Dominic Nistal, Julianne Kleitsch, Nicki Mohammadi, Trevor Hardigan, Rui Song, Jamie Rumsey, Alexandra S. Reynolds, John Liang, Cappi C Lay, Jay Mocco, Christopher Kellner, Neha Dangayach, on Behalf of the Mt Sinai NEMAT Research Group P16.10-006 Non-Traumatic Subdural Hemorrhage and Risk of Arterial Ischemic Events–Melvin Parasram, Xian Wu, Ivan Diaz, Neal S. Parikh, Costantino Iadecola, Alexander Merkler, Guido Jose Falcone, Judy Ch’ang, Babak Navi, Kevin N. Sheth, Hooman Kamel, Santosh Bhaskar Murthy P16.10-007 Posterior Reversible Encephalopathy Syndrome after transplantation–Franco Emanuel Appiani, Jesica Pszenyckyj, Carla Florencia Bolano Diaz, Guido Vazquez, Carlos Santiago Claverie, Natalia Finocchiaro, Diego Minarro, Alfredo Thomson P16.10-008 Radiographic Distribution of Spinal Cord Segment Involvement Seen in Posterior Reversible Encephalopathy Syndrome with Spinal Cord Involvement.–William Scharpf, Jonathan Greco, Jonathan Greco, Scott L. Silliman P16.10-009 Hot Off the PRES: A Case Series on Posterior Reversible Encephalopathy Syndrome with Hemorrhagic Conversion Associated with Phenylephrine– Areesha Khan, Prasuna Kamireddi, Phong Thanh Vu, Muhammad M. Alvi, Matthew Smith P16.10-010 Broken Heart, Broken Mind: Posterior Reversible Encephalopathy Syndrome and

CME

Takotsubo Cardiomyopathy in the Neuro ICU–Yasmin Aghajan, Samuel Snider P16.10-011 Difficult Brain Death Examination After Undetermined Toxic Ingestion–Danielle B. Cross, Nina H. Kim P16.10-012 Retrospective Chart Review on Declaration of Brain Death across a Hospital System– Stacey A. Williamson, Kristine H. O’Phelan P16.10-013 Advanced Diffusion Kurtosis Imaging Improves Arousal Recovery Prediction in Comatose Survivors of Cardiac Arrest– Matthew N. Jaffa, Jiacheng Zhuo, Prashant Raghavan, Stephanie Chen, Gunjan Parikh P16.10-014 Functional Outcome of Post Cardiac Arrest Patients Who Underwent Therapeutic Hypothermia–Julian Paul AginLiebes, Toluwalase Oluwakemi Tofade, Rajanigandhi Hanumanthu, Machteld E. Hillen P16.10-015 Pilot Study of Orexin as an Indicator of Coma Recovery– Aileen Cangiano-Heath, Elizbieta Wirkowski, Yuehjien Gu, Joseph Adachi, Bradley Ashcroft BS, Susan M. Fiore, Sima Mofakham, Brian Wright P16.10-016 Acute fulminant cerebral edema: a profile of 5 pediatric cases from a tertiary care center.–Carlyn Patterson Gentile, Duriel Isaiah Hardy, Sonika Agarwal P16.10-017 Predictors of Withdrawal of Life Sustaining Treatments in ECMO Patients–Julia Carlson, Clare Enriquez, Glenn Whitman, Dan Choi, Romergryko G. Geocadin, Julia Carlson P16.10-018 Paraparesis after extracorporeal membrane oxygenation: A report of two cases and review of literature–Niloofar Yari, Ashley E. Anderson, Mohammad Obadah Nakawah, Sheetal Shroff

210 2020 AAN Annual Meeting

0 Thursday, April 30 Child Neurology and Developmental Neurology: Seizures and Epilepsy 2

P16.11-001 Standardization of Evaluation for Seizures During Therapeutic Hypothermia (TH) in Neonates with Hypoxic Ischemic Encephalopathy (HIE): A Quality Improvement (QI) Initiative–Justin Rosati, Jennifer ToTran Nguyen P16.11-002 Combined Conventional and AmplitudeIntegrated EEG Monitoring in Neonates: A Prospective Study–Sarah Grace Buttle, Brigitte Lemyre, Erick Sell, Stephanie Redpath, Srinivas Bulusu, Richard Webster, Daniela Pohl P16.11-003 The Use of Midazolam for Refractory Neonatal Seizures– Matthew Martin, Margie A. Ream P16.11-004 Impact of recurrent seizures on white matter in non-structural neonatal epilepsy– Amanda Sandoval Karamian, Courtney Wusthoff, Kristen Yeom, Juliet Klasing Knowles P16.11-005 Improving Bedside Seizure Care of Pediatric Epilepsy Monitoring Unit (EMU) Patients: Creation and Implementation of a Standardized Protocol–Sara Pavitt, Alison Carley, Brenda E. Porter, Juliet Klasing Knowles P16.11-006 Patterns of Disease and Predictors of Severity in Rasmussen’s Encephalitis- a Retrospective Series of Thirty-Nine Cases–Rohit Ninan Benjamin, Sangeetha Yoganathan, Karthik Muthusamy, Vivek Mathew, Ari Chacko, Geeta Chacko, Krishna Prabhu, Maya Thomas P16.11-007 Management practices for West syndrome in South Asia–Priyanka Madaan, Prem Chand, Kyaw Linn, Jithangi Wanigasinghe, Mimi Lhamu Mynak, Prakash Poudel, Raili Riikonen, Sandeep Negi, Jitendra Sahu P16.11-008 Keep Off the Grass: Artisanal versus Pharmaceutical Cannabidiol in Pediatric Refractory Epilepsy Patients–Nathan Tyler Cohen, Joan A. Conry, John M. Schreiber P16.11-009 iPSC-generated motor neurons from patients with PTEN deficiency as a model to elucidate mechanisms underlying aberrant circuit development in autism spectrum disorder–Michelle Allen-

5:30 p.m.–6:30 p.m. sharpley, Michelle Allen-sharpley, Kirsten Ludwig, Michael Condro, Julian Martinez Agosto, Dhruv Sareen, Harley Ian Kornblum P16.11-010 An Online Survey of Caregivers of Patients with SCN8Arelated epilepsy–Celene Grayson, Cynthia Harden, Constanza Luzon, Simon Pimstone, Ernesto Aycardi, Noam Butterfield P16.11-011 Non-Syndromic Autistic Spectral Disorders in Tamilian Chldren Commonly Associated with Brain imaging anomalies and Spectral EEG changes–Sunil K. Narayan, Mohan Rao JS, Nagarajan K, Faruq Mohammed, Preeti Kandasamy, Mahadevan Subramaniam P16.11-012 Psychogenic Nonepileptic Events in Pediatric Patients with Autism–Daniel Freedman, Debbie Terry, Laurie Enciso, Kristen Trott, Maggie Burch, Dara V. Albert P16.11-013 Utility of Video EEG (VEEG) in the Assessment of Staring Spells (SS) in Children with Autism–Smriti Verma, Stephen G. Jones, Kapil Arya P16.11-014 Prescribing Practices and Antiepileptic Drug Choice in Benign Epilepsy with Centrotemporal Spikes–Mariam Hull, Robert Clinton Stowe, Jon Alan Cokley, Imad T. Jarjour P16.11-015 The Phenotypic Spectrum of Epilepsy in DesantoShinawi Syndrome–Abdulla Alawadhi, Ken Myers

= Research

POSTER SESSION 17: NEUROINFLAMMATION 0 Friday, May 1 11:30 a.m.–1:00 p.m. CME

Poster Session 17

MS and CNS Inflammatory Disease 1

suboptimal response with prior disease-modifying therapy–Bianca Weinstock-Guttman, Robert A. Bermel, Csilla Csoboth, Gary Raymond Cutter, Mark S. Freedman, Thomas Leist, Xiaoye Ma, Bruno C. Musch, Anthony Reder, James M. Stankiewicz, Jerry S. Wolinsky P17.1-008 Assessing myelin loss in the white matter near to and distant from chronic black holes in multiple sclerosis.–Dhairya Lakhani, Sijin Wen, Si Gao, Karina Ciccone, Seth A. Smith, Junzhong Xu, Richard Darrell Dortch, Francesca Bagnato P17.1-009 Effect of teriflunomide on brain volume loss in patients with relapsing multiple sclerosis of differing ages in TEMSO–Jiwon Oh, Jens Wuerfel, Bhupendra O. Khatri, Aaron E. Miller, Jihad Said Inshasi, Byoung Joon Kim, Albert Saiz, Alex Lublin, Elizabeth Poole, Till Sprenger P17.1-010 Changing Patterns in Disease-Modifying Therapy Selection for Treatment-Naive Multiple Sclerosis in the United States–Patricia K. Coyle, Jennifer Robinson, Virginia Schobel

P17.1-011 Autologous hematopoietic stem cell transplantation versus alemtuzumab in aggressive MS: a retrospective real-word study–Caterina Lapucci, Giacomo Boffa, Elvira Sbragia, Elisabetta Capello, Daniela Curro, Alice Laroni, Luca Roccatagliata, Antonio Uccelli, Francesca Gualandi, Giovanni Luigi Mancardi, Matilde Inglese P17.1-012 Increased John Cunningham Virus Seroconversion Rates Seen in a Southern Hemisphere International Cohort of Natalizumab Treated Patients– Chris Dwyer, Vilija Jokubaitis, James Stankovich, Josephine Baker, John T. Carey, Trevor J. Kilpatrick, Kylie Fryer, Ernest G. Butler, Jodi Haartsen, Helmut Butzkueven, Adriana Cartwright, Neil Shuey, Jennifer Coleman, Richard A L Macdonell, Louise Rath, Yara D. Fragoso, Anneke Van Der Walt P17.1-013 Early preferential repopulation of anti-inflammatory B cells following an initial treatment of ocrelizumab in patients with multiple sclerosis–Koji Shinoda, Ayman Rezk, Rui Li, Amit Bar-Or

AAN.com/view/20AM 211

Friday, May 1

P17.1-001 Identifying Gaps in Knowledge, Skill and Confidence Among MS Specialists to Facilitate Appropriate Evolutions in MS Care–Klaus Schmierer, Morgan Peniuta, Jiwon Oh, Thomas Leist, Patrice Lazure, Sophie Peloquin P17.1-002 Multiple Sclerosis Disease-Modifying Therapy: Recent Switch Patterns Among United States Neurologists– Patricia K. Coyle, Jennifer Robinson, Jennifer Robinson P17.1-003 Association of Serum Neurofilament Biomarker Levels with Quality of Life and Healthcare Utilization in Patients with Multiple Sclerosis–Kristin Marissa Galetta, Chinmay Deshpande, Brian Curran Healy, Bonnie Glanz, Marina Ollervides Ziehn, Shristi Saxena, Anu Paul, Fermisk Saleh, Mikaela Collins, Patricia Gaitan-Walsh, Paola Castro-Mendoza, Howard L. Weiner, Tanuja Chitnis P17.1-004 Characterizing Long-Term Disability Progression Outcomes in NARCOMS Registry MS Participants Taking Dimethyl

Fumarate–Amber Salter, Samantha Lancia, Gary Raymond Cutter, Robert J. Fox, Ruth-Ann Marrie, Jason P. Mendoza, James B. Lewin P17.1-005 Menarche and Relapses in Girls with Pediatric Multiple Sclerosis–Kristen M. Krysko, Michael Waltz, Tanuja Chitnis, Bianca Weinstock-Guttman, Gregory S. Aaen, Leslie A. Benson, Yolanda C. Harris, Lauren B. Krupp, Timothy E. Lotze, Soe Soe Mar, Jayne Ness, Mary R. Rensel, Moses Rodriguez, John W. Rose, Alice Rutatangwa, Teri Schreiner, Emmanuelle Waubant, Theron Charles Casper, Jennifer Graves P17.1-006 Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine Treated Patients at the 96 Week Timepoint (CLARITY) Using Deconvolution Algorithms– Irinia Kalatskaya, Gavin Giovannoni, Thomas Leist, Per Soelberg Sorensen, Ursula Boschert, Julie E. Demartino, Alex Rolfe P17.1-007 Two-year results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had a

POSTER SESSIONS

1. MS and CNS Inflammatory Disease 1: 1-001 to 1-020 2. MS and CNS Inflammatory Disease 2: 2-001 to 2-004 Autoimmune Neurology 1: 2-005 to 2-013 3. Autoimmune Neurology 2: 3-001 to 3-013 Movement Disorders 1: 3-014 to 3-017 4. Movement Disorders 2: 4-001 to 4-011 5. General Neurology: 5-001 to 5-006 Epilepsy/Clinical Neurophysiology (EEG): 5-007 to 5-013 6. Headache: 6-001 to 6-004 Autonomic Disorders: 6-005 to 6-007 Neurocritical Care: 6-008 to 6-009 7. Neuromuscular/Clinical Neurophysiology (EMG): 7-001 to 7-014 8. Aging and Dementia: 8-001 to 8-004 Behavioral and Cognitive Neurology: 8-005 Cerebrovascular Disease and Interventional Neurology 1: 8-006 to 8-012 9. Cerebrovascular Disease and Interventional Neurology 2: 9-001 to 9-021 10. Neuro-oncology: 10-001 to 10-007 Infectious Disease: 10-008 to 10-015 Global Health: 10-016 11. Child Neurology and Developmental Neurology: 11-001 to 11-006 Neuro Trauma and Sports Neurology: 11-007 Neuro-ophthalmology/Neuro-otology: 11-008 Sleep: 11-009 to 11-010 Research Methodology and Education: 11-011 to 11-012 Neuro-rehabilitation: 11-013

POSTER SESSION 17: NEUROINFLAMMATION 0 Friday, May 1 11:30 a.m.–1:00 p.m.

Friday, May 1

POSTER SESSIONS

CME

P17.1-014 Effect of Alemtuzumab (LEMTRADA®) Treatment on the Peripheral Immune Repertoire in Multiple Sclerosis Patients– Sumanta Barman, Armin Scheffler, Tobias Ruck, Christoph Lehrich, Vera Balz, Heinz Wiendl, Sven G. Meuth, Hans-Peter Hartung, Nico Melzer, Norbert Goebels P17.1-015 Herpes Zoster Virus (HZV) Infections among Multiple Sclerosis Patients Treated with Various Disease Modifying Therapies–Nicola Carlisle, Sam Hooshmand, Michelle Maynard, Leah Hoffman, Ahmed Z. Obeidat P17.1-016 Human Gut-Derived Commensal Bacterium Suppresses Neuroinflammation via MicrobeAssociated Molecular Patterns– John Michael Sanchez, Daniel Doty, Ana Beatriz DePaula-Silva, Jane Libbey, Robert Fujinami P17.1-017 Clinical profile of African-American and Caucasian patients with Multiple Sclerosis– Maria Petracca, Amgad Droby, Mohamed-Mounir El Mendili, Swetha Paduri, Nicole Graziano, Natalie Saba, Arielle Falcone, Daniel Peter Kurz, Claire Riley, Jonathan Howard, Sylvia Klineova, Matilde Inglese P17.1-018 Determining the Impact of Ocrelizumab on Chronic Active Lesions in Multiple Sclerosis Utilizing Quantitative Susceptibility Mapping–Neha Safi, Sneha Pandya, Thanh Nguyen, Weiyuan Huang, Ulrike Kaunzner, Nancy M. Nealon, Jai Perumal, Timothy K. Vartanian, Yi Wang, Susan Gauthier P17.1-019 3T vs. 7T MRI Scan Protocols to Assess Deep Grey Matter Lesions and Atrophy in Relapsing-remitting Multiple Sclerosis–Youmna Jalkh, Renxin Chu, Shahamat Tauhid, Brian Curran Healy, Howard L. Weiner, Rohit Bakshi, Jonathan D. Zurawski P17.1-020 Clinical Disability Worsening Correlates Preferentially with Atrophy of Thalamic Subregions in Patients with Multiple Sclerosis–Kedar Mahajan, Kunio Nakamura, Daniel Ontaneda

MS and CNS Inflammatory Disease 2

P17.2-001 Risk Stratification for Demyelinating Disease Secondary to TNF-Alpha Inhibitor Exposure– Amy Wei-Hsin Yu, Maggie Pecsok, Erin Longbrake, Sarah Flanagan Wesley P17.2-002 Functional Outcomes Differ Between Vascular and Inflammatory Myelopathies–Maria Alejandra Garcia-Dominguez, Xue Yi Chen, Olwen Murphy, Paula Barreras, Jose Alejandro Ramirez, Carlos A. Pardo-Villamizar P17.2-003 White Matter Myelin Alterations are Diffuse in Neuromyelitis Optica Spectrum Disorders and Prevail on Axonal Damage–Laura Cacciaguerra, Maria Assunta Rocca, Loredana Storelli, Marta Radaelli, Vittorio Martinelli, Massimo Filippi P17.2-004 Cladribine supresses the activity of neuromyelitis optica: two year follow up study–Konrad Rejdak, Ewa Papuc Autoimmune Neurology 1

P17.2-005 Long term outcomes in Myelin Oligodendrocyte Glycoprotein-IgG (MOG-IgG) Associated Disorders–Alfonso Sebastian Lopez, Marina Buciuc, Elia Sechi, Sean J. Pittock, John Chen, Brian G. Weinshenker, Divyanshu Dubey, Amy Kunchok, Jan-Mendelt Tillema, Eoin P. Flanagan P17.2-006 Increased Likelihood of Relapse in Pediatric AntiMOG Acute Disseminated Encephalomyelitis (ADEM) and Optic Neuritis (ON) vs. Seronegative ADEM and ON Patients–Kristen Fisher, Alfred Balasa, Nikita Shukla, Timothy E. Lotze P17.2-007 Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study– Jacqueline Palace, Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, KaiChen Wang, Shulian Shang, Marcus Yountz, Roisin Armstrong, Dean M. Wingerchuk P17.2-008 Impact of Eculizumab on Hospitalization Rates and

212 2020 AAN Annual Meeting

Relapse Treatment in Patients with Aquaporin-4 AntibodyPositive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study–Ho Jin Kim, Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Kenji P Fujita, Marcus Yountz, Roisin Armstrong, Dean M. Wingerchuk P17.2-009 Autologous haematopoietic stem cell transplantation in multiple sclerosis and other immune-mediated neurological diseases: guidelines and recommendations of the European Society for Blood and Marrow Transplantation and the Joint Accreditation Committee of the International Society for Cellular Therapy–Basil Sharrack, Riccardo Saccardi, Tobias Alexander, Badoglio Manuela, Joachim Burman, Dominique Farge, Raffaella Greco, Helen Jessop, Majid Kazmi, Kirill Kirgizov, Myriam Labopin, Giovanni Luigi Mancardi, Roland M G Martin, John Moore, Paolo Muraro, Montserrat Rovira, Maria Pia Sormani, John Snowden P17.2-010 Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 AntibodyPositive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study–Achim Berthele, Sean J. Pittock, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, KaiChen Wang, Shulian Shang, Marcus Yountz, Roisin Armstrong, Dean M. Wingerchuk P17.2-011 Clinical Phenotypes, Predictors of Relapse, and Response to Treatment in Myelin Oligodendrocyte GlycoproteinAntibody Associated Disorders– Wendy Sulina Vargas, Anusha Yeshokumar, Seth Nathatn Levin, Christopher Langston, Claudiu Iulian Diaconu, Rebecca Gabrielle Straus Farber, Kiran Thakur, Libby Levine, Kaho Onomichi, Katherine Nelson, Michelle Fabian, Ilena George, Ilana B. Katz Sand, Sylvia Klineova, Rachel Brandstadter, Sam H. Horng, Fred D. Lublin, Nancy M. Nealon, Deepak Jyotindra Soneji, Kiersten

Marie Dykstra, Zongqi Xia, Philip De Jager, Claire Riley P17.2-012 Clinical Course and Treatment Response in a Cohort of Pediatric Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease– Xinran Xiang, Stephen Russell Deputy, Rashmi Rao P17.2-013 Harnessing the power of social media to learn about a very rare disorder: survey of Facebook group about paroxysmal symptoms in Neuromyelitis Optica Spectrum Disorder–Itay Lotan, Tamar Bacon, Michael Levy, Ilya Kister Autoimmune Neurology 2

P17.3-001 Brazilian autoimmune encephalitis network (BrAIN): preliminary results from a nationwide multicentric study–Fabio Fieni Toso, Rene De Araújo Gleizer, Bruna Dias, Maria Eduarda Slhessarenko, Alessandra Dellavance, Luiz Eduardo Andrade, Romana Hoeftberger, Orlando Graziani Povoas Barsottini, Livia Almeida Dutra Antonio P17.3-002 AMPAR Autoimmunity: Neurological, Oncological and Serological Accompaniments.– Cecilia Zivelonghi, Andrew McKeon, Elia Sechi, Kevin O’Connor, Sean J. Pittock, Divyanshu Dubey, Vanda A. Lennon, Eoin P. Flanagan, Anastasia Zekeridou P17.3-003 REM Sleep Without Atonia and Sleep Disturbances in Patients with LGI1 and CASPR2 Autoimmunity–Michelle Devine, John Craig Feemster, Elizabeth Lieske, Stuart McCarter, David James Sandness, Tyler Steele, Bradley F. Boeve, Michael H. Silber, Andrew McKeon, Erik Kent St. Louis P17.3-004 Frequency and clinical significance of seronegative antiNMDAR encephalitis–Mar *use 299015 Guasp, Yasmina MódenaOuarzi, Thais Armangue, Josep O. Dalmau, Francesc R. Graus P17.3-005 Longitudinal Changes in Driving Behavior Following Antibody-Mediated Encephalitis– Gregory S. Day, Ganesh Babulal, Ganesh Rajasekar, Sarah Stout, Catherine M. Roe P17.3-006 Specific Psychiatric Features Identify Anti-NMDAR Encephalitis Before Neurological = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Movement Disorders 1

P17.3-014 TPH2 Gene and Childhood Trauma moderates the clinical and circuit-level phenotype of functional movement disorders– Primavera Spagnolo, Gina Norato, Carine W. Maurer, Sepideh Akbaripanahi, Coiln Hodgkinson, David Goldman, Silvina Horovitz, Mark Hallett P17.3-015 Gender Differences in Distribution of Lewy Body Pathology in Individuals with Parkinson’s Disease–Katherine Iannuzzelli, Catherine Bakker, Jumana Tariq A Alshaikh, Jee Bang, Ankur Butala, Cherie Marvel, Emile Sami Moukheiber, Maitreyi Murthy, Alexander Pantelyat, Olga Pletnikova, Gregory Pontone, Gerson Suarez-Cedeno, Juan C. Troncoso, Kelly A. Mills, Ted M. Dawson, Liana Rosenthal P17.3-016 Exploring the Parkinson’s disease phenome in the UK Biobank population–Daniel Belete, Benjamin Jacobs, Anette E. Schrag, Alastair John Noyce Movement Disorders 2

P17.4-001 Gait Measures from Videos Detect Parkinsonian Gait in Older Adults with Dementia– Andrea Sabo, Kimberley-Dale Ng, Sina Mehdizadeh, Babak Taati, Andrea Iaboni P17.4-002 Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the CSF of individuals with Parkinson’s disease–Alan Fowler, Yasar Alejandro Torres-Yaghi, Fernando L. Pagan, Michaeline Hebron, Barbara Wilmarth, Abigail Catherine Lawler, Elizabeth E. Mundel, Nadia Yusuf, James N. Starr, Muhammad Waseem Anjum, Shahnaz Miri, Steven Wayne Nakano, Amelia Carwin,

Sara Matar, Jaeil Ahn, Charbel E H Moussa P17.4-003 Nilotinib is reasonably safe and may halt the disease progression in moderately severe Parkinson’s disease patients– Fernando L. Pagan, Michaeline Hebron, Barbara Wilmarth, Yasar Alejandro Torres-Yaghi, Abigail Catherine Lawler, Elizabeth E. Mundel, Nadia Yusuf, James N. Starr, Muhammad Waseem Anjum, Shahnaz Miri, Steven Wayne Nakano, Amelia Carwin, Myrna Arellano, Sara Matar, Jaeil Ahn, Charbel E H Moussa P17.4-004 First Results for The BeyoND Study: An open-label international, multicenter study evaluating the long-term safety of ND0612 in patients with idiopathic Parkinson’s disease–Stuart H. Isaacson, Werner Poewe, Tanya Simuni, Sheila Oren, Ryan J. Case, C. Warren Olanow P17.4-005 Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advance Parkinson’s Disease–Kalpana Merchant, Tanya Simuni, Brian Fiske, Christopher Coffey, Helen Matthews, Richard Wyse, Patrik Brundin, David K. Simon, Michael Schwarzschild, David Weiner, Jamie Lynn Adams, Charles Stanley Venuto, Laura Trusso, Liana Baker, Melissa Kostrzebski, Tina Ward, Gary Rafaloff P17.4-006 Modeling PD Progression in the PPMI Cohort: Implications for Clinical Trial Design–Christopher Coffey, Michael Brumm, Andrew D. Siderowf, Tanya Simuni, Douglas Galasko, Brit Mollenhauer, Lana Chahine, Vanessa Arnedo, Mark Frasier, Caroline M. Tanner, Kathleen Poston, Daniel Weintraub, Samantha J. Hutten, Karl D. Kieburtz, Kenneth L. Marek, Nichole Daegle P17.4-007 Coping with Parkinson’s Disease: A Mexican Study–Cynthia Guadalupe Sarabia-tapia, Susana Lopez, Oscar Esquivel, Yazmin Rios, Amin Cervantes-Arriaga, Mayela De Jesus Rodriguez Violante P17.4-008 Is It Possible to Eliminate Hospital Administered Haloperidol For the Acute Management of Agitation in

Patients with Parkinsonism? A Quality Improvement Initiative– Katelyn Cecilia Klee Bird, Taylor Francoeur, Betsy Thomas, Na Wang, Stephanie L. Bissonnette P17.4-009 Fampridine and acetazolamide for the treatment of episodic ataxia type 2 (EAT2TREAT): a randomised, double-blind, placebo-controlled, three-period crossover trial– Michael Strupp, Ulrich Mansmann, Carolin Muth P17.4-010 Adipose-derived Mesenchymal Stem Cells Ameliorate Neuroinflammation and promote neurogenesis in a Transgenic Mouse Model of Huntington’s disease–Erin FurrStimming, Jose Moruno-Manchon, Karthik Prabhakara, Akshita Kumar, Naama Toledano Furman, Alex Villarreal, Gabriela D. Colpo, Antonio Teixeira, Andrey Tsvetkov, Scott Douglas Olson P17.4-011 Analyzing Sex Differences in Huntington’s Disease using Enroll-HD–Erin Furr-Stimming, Samantha Hentosh, Liang Zhu, Joseph Weldon Furr, Natalia Pessoa Rocha General Neurology

P17.5-001 Risk of Recurrent Stroke or Transient Ischemic Attack due to Abrupt Discontinuation of Aspirin: A Case Series–Rachael Wojcik, Jessica Greger, Kory Zelen, Traci Aladeen, Michelle Rainka, Erica S. Westphal, Vernice E. Bates, Francis Michael Gengo P17.5-002 Fast Neuro = Expedited Access–Melissa Reider-Demer, Shuvro Roy, Timothy Edward Ryan, Marc R. Nuwer, Inna Keselman P17.5-003 Determinants of post lumbar puncture headache – the role of cerebrospinal fluid volume–Gadi Miron, Gadi Miron, Nurit Omer, Tanya Gurevich, Yair Mina, Meir Kestenbaum, Jesse M. Cedarbaum, Nir Giladi, Anat Mirelman, Avner Thaler P17.5-004 Association of Serum Uric acid with Amyotrophic lateral sclerosis–Md Raknuzzaman P17.5-005 Relationships Between Forced Vital Capacity and Respiratory Sub-domain Scale on the ALSFRS-R–Cuiping Zhao, Xiaotian Ma, James P. Wymer

AAN.com/view/20AM 213

Friday, May 1

Immunodeficiency (CVID) Evaluate the Prevalence of Headache and Pain in Patients with Common Variable Immunodeficiency (CVID)– Lawanda Esquibel, Bruno Ivo De Almeida, Leah Millsap, Jonathan Ross Galli, Adi Gundlapalli, M. Mateo Paz Soldan, Julia Klein, Melissa M. Cortez, John W. Rose, John E. Greenlee, Harry Haydon Hill, Ka-Ho Wong, Stacey Clardy

POSTER SESSIONS

Deterioration–Nicola Warren, Cullen Mark O’Gorman, Andrew Swayne, Dan Siskind, Stefan Blum P17.3-007 Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study–Kazuo Fujihara, Achim Berthele, Ho Jin Kim, Michael Levy, Ichiro Nakashima, Celia Oreja Guevara, Jacqueline Palace, Sean J. Pittock, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Marcus Yountz, Larisa Miller, Imran Tanvir, Roisin Armstrong, Dean M. Wingerchuk P17.3-008 Longer Term Seizure Outcomes in a Retrospective Autoimmune Epilepsy Cohort– Sahar Noorani, Divyanshu Dubey, Kan Ding, Ryan Hays, Steven Vernino, Rohit Das P17.3-009 Neuronal uptake, antibody binding, and injury by anti-Ma2 antibodies in organotypic cultures of rat brain: a possible role for anti-Ma2 antibody in production of neurological disease–Jonathan Ross Galli, Kenneth E. Hill, Susan Clawson, Blair Wood, Stacey Clardy, Noel Carlson, John E. Greenlee P17.3-010 Influence of Autoimmune Antibody Testing on Neurohospitalists’ use of Immunotherapy–Kristin Marissa Galetta, Amy Rosen, Galina Gheihman, Joshua P. Klein, Shamik Bhattacharyya P17.3-011 Validation of a Surface Plasmon Resonance Assay for the Diagnostic Detection and Characterization of Muscle-specific Kinase (MuSK) Antibodies in Myasthenia Gravis (MG) Patients– Ebrima Gibbs, Tariq M. Aziz, Hans Frykman P17.3-012 Paraneoplastic Myeloneuropathies: characterization of a distinguishable phenotype and clinical outcomes–Shailee Samir Shah, Rocio Vazquez Do Campo, Sean J. Pittock, Andrew McKeon, Neeraj Kumar, Eoin P. Flanagan, Christopher J. Klein, Divyanshu Dubey P17.3-013 Evaluation of the Prevalence of Headache and Pain of Unknown Cause in Patients with Common Variable

POSTER SESSION 17: NEUROINFLAMMATION 0 Friday, May 1 11:30 a.m.–1:00 p.m. CME

P17.5-006 Quantitative Magnetisation Transfer Brain Imaging Reveals Altered Biological Integrity of Motor Regions in Amyotrophic Lateral Sclerosis– Andrew Barritt, Rebecca Broad, Nicholas Dowell, Peter N. Leigh, Mara Cercignani

Friday, May 1

POSTER SESSIONS

Epilepsy/Clinical Neurophysiology (EEG)

P17.5-007 Interim Safety and Effectiveness Outcomes from a Prospective Post-Approval Trial of the RNS® System–HaeWon Shin, Martha Morrell P17.5-008 Antiepileptic Drug (AED) Treatment in Juvenile Myoclonic Epilepsy (JME): a Population-based Study–Ahyuda Oh, Hyunmi Kim P17.5-009 EEG reactivity predicts outcomes in cardiac arrest patients.–Vikram Bhinder, Stephen Hantus, Vineet Punia, Christopher R. Newey P17.5-010 Neonatal Seizure Burden during Therapeutic Hypothermia: Predictive value of EEG in the first 24 hrs–Kshama Ojha, Abhinav Pal, Gregory N. Barnes, Dan Stewart P17.5-011 Cardiology Perspective on Seizure Related Bradyarrhythmias and SUDEP: A Survey Study–Mark Farrenburg, Aniket Rali, Anna Grodzinsky, Y. Madhu Reddy, Patrick Landazuri P17.5-012 Status Epilepticus per se Did Not Lead to CSF Pleocytosis within the First 24 Hours–Sargun Bajaj, Donald Griesdale, Yahya Aghakhani, Farzad Moien Afshari P17.5-013 Improving Cognitive Assessment of Adult Epilepsy Monitoring Unit Patients–Wendy Chen, Victoria Deardon Liu, Kimford J. Meador, Scheherazade Le Headache P17.6-001 Evaluation of Triggers of Status Migrainosus and its impact on morbidity.–Urvish K. Patel, Liseth Katia Lavado, Dhaivat Janakbhai Shah, Preeti Malik, Maryam Hussain, Vikrant Bhatnagar, Ashish Vikrant Kapoor, Kogulavadanan Arumaithurai, Tapan R. Kavi P17.6-002 Changes in Work Productivity and Interictal Burden: Results from a Randomized,

Double-Blind, Placebo-Controlled Clinical Trial Evaluating Galcanezumab in Adults with Treatment-Resistant Migraine (CONQUER)–David Garcia-Azorin, Janet Ford, Dawn C. Buse, Austin L Hand, Linda Wietecha, Holland Detke P17.6-003 Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study–John F. Rothrock, Richard Stark, Katherine Sommer, Andrew M. Blumenfeld P17.6-004 Anti-CGRP Class Reduces Migraine Burden Regardless of Concomitant Therapies in US Clinical Practice– Christopher Gottschalk, Kristen Henn, Jennifer Robinson, Virginia Schobel Autonomic Disorders

P17.6-005 An Open-Label Phase 2 Study to Explore the Durability of Effect, and Safety of Once-Daily Oral Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, for the Symptomatic Treatment of Neurogenic Orthostatic Hypotension in Subjects With Synucleinopathies–Horacio C. Kaufmann, Italo Biaggioni, Whedy Wang, Brett Haumann, Ross Vickery P17.6-006 Cutaneous phosphorylated a-synuclein as a biomarker for the a-synucleinopathies: a metaanalysis–Alice Tang, Sharika Rajan, Ana Isabel Penzlin, Valentina Galvis, Roy L. Freeman, Christopher H. Gibbons P17.6-007 Patients with a History of Mild Traumatic Brain Injury have Altered Autonomic Responses to Happy and Fearful Music.–Max Josef Hilz, Ruihao Wang, Dafin Muresanu, Mao Liu Neurocritical Care

6 6

P17.6-008 Potency and Safety of Ketamine in Neuro-critical Care Intensive care Unit- A Single Centre experience–Premkumar Nattanmai Chandrasekaran, Keerthivaas Premkumar, Kathryn Qualls, Niraj Ashok Arora, saurabh kataria P17.6-009 Temporal and spatial patterns of inflammation and oxidative injury in human

214 2020 AAN Annual Meeting

SCI–Tobias Zrzavy, Carmen Schwaiger, Thomas Berger, Oleg Butovsky, Hans Lassmann, Romana Hoeftberger Neuromuscular/Clinical Neurophysiology (EMG)

P17.7-001 Triggers and Risk Factors in Lumbosacral Radiculoplexus Neuropathy– Marcus Vinicius Rocha Pinto, Peng Soon Ng, Peter J. Dyck, Prabin Thapa, Ruple S. Laughlin, P. James B. Dyck P17.7-002 Peripheral Neuropathy outcome after 2-years of treatment with tafamidis in patients with only small fiber symptoms and nonVal30Met hATTR amyloidosis.– Maria Alejandra Gonzalez Duarte, Xel-Ha Dominguez-Vega, Giovanni Cortes-Leon, Sandra PerezCastaneda, Karla Cardenas-Soto P17.7-003 Humoral Immune Microvasculopathy: Treatable Motor-Sensory Axonal Polyneuropathies with C5b9 Deposition on Endoneurial Microvessels–Bhavesh Trikamji, Alan Pestronk P17.7-004 Distribution of mutations associated with congenital myasthenic syndromes (CMS): results from the first 54 specimens tested at a clinical reference laboratory–Sat Dev Batish, Lebron Lebron, Marc Meservey, Jeff S Radcliff, Zhenyuan Wang, Vivekananda Datta P17.7-005 Distribution of Serum Creatine Kinase Levels in Amyotrophic Lateral Sclerosis– Devin Elizabeth Prior, Elijah Stommel, Victoria Lawson, Jason Kandel, Nathaniel Michael Robbins P17.7-006 Early Treatment Effects of Riluzole in ALS: Isometric Strength Improvement in Sentinel Muscles Correlates with Improved Survival–Benjamin R. Brooks, Elena Bravver, Urvi G. Desai, Navid Jalali, William B. Dawson, William Bockenek, Scott C Lindblom, Fawn Paling, Stephanie Hawkins, Patricia Antunez, Tiffany Williamson, Nicole Lucas, Scott Holsten, Amber L. Ward, Lisa Ranzinger, Johnny Jones, Allison Newell-Sturdivant, Cynthia Lary P17.7-007 Cure SMA Care Center Network and SMA Clinical Data Registry with Electronic

Health Record Integration–Mary K. Schroth, Jamie Shish, Teresa Stewart, Abigail Paras, Adrian Segura P17.7-008 Predicting Survival in ALS Using Machine Learning Algorithms - a Preliminary Analysis–Bill Jacobsen, Shafeeq Ladha P17.7-009 Genetic Testing for ALS: The Incidence of Pathogenic, Likely Pathogenic, and Uncertain Variants in a Clinic-Based Population– Jennifer A. Roggenbuck, Marilly Palettas, Radha Patel, Adam Quick, Stephen J. Kolb P17.7-010 Striving to improve outcome measures for inclusion body myositis through novel dynamometer and modifications of the current functional rating scale–Ava Yun Lin, Catherine Siener, Michelle Seiffert, Conrad Weihl, Leo Hong-Li Wang P17.7-011 Understanding Mitochondrial DNA Maintenance Disorders at the Single Muscle Fibre Level–Diana Lehmann, Hannah S Rosa, Mariana C Rocha, Stephan Zierz, Robert W Taylor, Douglas M. Turnbull, Amy E Vincent P17.7-012 Modeling the Epidemiologic Burden of Duchenne Muscular Dystrophy (DMD) in the United States (US)–Alexa Klimchak, Karissa Johnston, Katherine Osenenko, Shelagh Szabo, Katherine Gooch P17.7-013 Factors that Influence Progression of Respiratory Dysfunction in Myotonic Dystrophy Type 1–Leigh Hartog, William D. Arnold, Samantha Jo LoRusso P17.7-014 Electrical Impedance Tomography as a Quantitative Measure of Pulmonary Function in ALS Patients–Badria Munir, Ethan K Murphy, Akashleena Mallick, Hilda Victoria Gutierrez, Fu Zhang, Christy Smith, Sean Levy, Courtney E. McIlduff, Hawa Yusuf, Ryan J Halter, Seward B. Rutkove

= Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

Aging and Dementia

P17.8-006 National Estimates Of Recurrent Intracranial Hemorrhage Among Patients With Ruptured Intracranial Aneurysms– Mohammad-Rauf A. Chaudhry, Saqib A. Chaudhry, Iqra N Akhtar, Werdah Zafar, Yun Fang, Ameer Hassan, Sairah Bashir, Mohsain Gill, Adnan I. Qureshi P17.8-007 The impact of obstructive sleep apnea on ruptured intracranial aneurysm–Oleg Y. Chernyshev, Shyamal Chandra Bir, Hugo Cuellar-Saenz, Roger E. Kelley P17.8-008 Timing of Diffusion Weighted Imaging Lesions after Primary Spontaneous Intracerebral Hemorrhage–Rajeev Garg, Mohammad Alberawi, Bichum Ouyang, Sayona John, Mehmet Kocak, Sudeep Bhabad, Miral Jhaveri, Thomas P. Bleck P17.8-009 Predict the Ischemic Volumes of Acute Stroke by Using Visual Assessment on CT Perfusion Source Imaging–Wenjie Cao, Wenjie Cao, Lumeng Yang, QIANG DONG P17.8-010 Re-Thinking the ‘Posterior’ in Posterior Reversible Encephalopathy Syndrome: A Single Center Chart Review of 95 Patients–Molly Bates, Kyle Darpel, Jessica Doyle Lee P17.8-011 Magnetic Resonance Vessel Wall Imaging in Central Nervous System Vasculitides: a Case-Series–Matthew Padrick, Marcel Maya, Shlee S. Song, Kyle Ogami, Nicholas Szumski, Zhaoyang Fan, Oana Maria Dumitrascu P17.8-012 Predictors Of Length Of Hospitalization In Patients Admitted With Intracerebral Hemorrhage In The United States–Sairah Bashir, Saqib A. Chaudhry, MohammadRauf A. Chaudhry, Iqra N Akhtar, Werdah Zafar, Adnan I. Qureshi

P17.9-001 Ischemic and Hemorrhagic Strokes after Left Atrial Appendage Occlusion (LAAO): A Mayo Clinic Case Series–Chia-Chun Chiang, Chieh-Ju Chao, Reza Arsanjani, Cumara Barahona O’Carroll, Holmes David, Paul Friedman, Thomas Munger, Mohamad Alkhouli, Peter Pollak, Eric Yang P17.9-002 Temporal trends of atrial fibrillation and/or rheumatic heart disease-related ischemic stroke, and anticoagulant use in Chinese population: an 8-year study–Junfeng Liu, Yanan Wang, Wen Guo, Yajun Cheng, Lu Wang, Wendan Tao, Shihong Zhang, Bo Wu, Ming Liu P17.9-003 UTility of echocardiograM in the workup Of ischemic STroke patients (UTMOST)–Meagan Maree Guay, Michael Daniel DeDominicis, Aadil Bharwani, Connor Lewicki, Anjali Shroff, Kanjana Perera P17.9-004 Safety and Efficacy of Tirofiban Among Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy: A Systematic Review and Metaanalysis–Hongchen Zhao, QIANG DONG, Wenjie Cao P17.9-005 Inpatient Telestroke Coverage Improves Guideline-based Diagnostic Stroke Evaluation: Results from the TELECAST trial–Matthew Keith Ronck, Monica Ngo, Eric Jaton, Leah Stinson, Kathryn Bard, Amelia Solei, Apameh Salari, Sarah A. Engkjer, Andrew Jiahao Zhang, Jae H. Kim, Christine Elizabeth Yeager, Oladi Sedjio Bentho, Benjamin Robert Miller, Christopher Streib P17.9-006 Emergency Department Factors that Negatively Impact Door To Needle Time In Acute Stroke–Andrew Hanna, Joshua Tsau, Tej Stead, Ankur Garg, Mohammed S. Khan, Paul Banerjee, Latha Ganti P17.9-007 Mobile Stroke Unit Operation in a Topographically Variable County–Ilana Spokoyny, Joey English, Jenny Im, Jorge Delgadillo, Eric Pancoska, Trish Entsminger, Nobl Barazangi P17.9-008 Short-term Outcome of Mechanical Thrombectomy for

8 8 9

P17.8-001 Long-read Sequencing Identifies GGC Repeat Expansions in NOTCH2NLC as the Cause of Neuronal Intranuclear Inclusion Disease–Jun Sone, Satomi Mitsuhashi, Atsushi Fujita, Hiroshi Takashima, Hiroshi Sugiyama, Yoshihisa Takiyama, Kengo Maeda, Fumiaki Tanaka, Yasushi Iwasaki, Mari Yoshida, Naomichi Matsumoto, Gen Sobue P17.8-002 Genetic Architecture Drives Differences in RNA Editing Rates between Alzheimer Disease Cases and Controls in Diverse Populations–Olivia Gardner, Lily Wang, Derek Van Booven, Patrice Whitehead, Kara Hamilton-Nelson, Larry D. Adams, Takiyah Starks, Natalia Hofmann, Jeffery M. Vance, Michael L. Cuccaro, Eden R. Martin, Goldie S. Byrd, Jonathan Haines, William Bush, Gary W. Beecham, Margaret A. Pericak-Vance, Anthony J. Griswold P17.8-003 Disentangling the Neuroanatomical Basis of Olfactory Dysfunction in the General Population–Ran Lu, N. Ahmad Aziz, Martin Reuter, Tony Stoecker, Monique M B Breteler P17.8-004 Exacerbation of Alzheimer’s Disease Neuropathology and Cognitive Deficits by Seizures–Sarah Gourmaud, David Stewart, Delia Maria Talos, Frances E. Jensen Behavioral and Cognitive Neurology

P17.8-005 Brief Smell Identification Test Performance in RBD, DLB and AD–Leah Kathleen Forsberg, Jeremy Syrjanen, Tanis J. Ferman, Bradley F. Boeve, Toji Miyagawa, Neill R. Graff-Radford, David S. Knopman, Jonathan GraffRadford, Rodolfo Savica, David T. Jones, Daniel A. Drubach, Julie A. Fields, Mary M. Machulda, John A. Lucas, Laura Andelman Allen, Erik Kent St. Louis, Michael H. Silber, Ronald C. Petersen

Acute Ischemic Stroke Patients on Therapeutic Anticoagulation– Klaudia Nowak, Justyna Derbisz, Ewa Wlodarczyk, Michal Paykart, Roman Pulyk, Pawel Brzegowy, Bartlomiej Lasocha, Tadeusz Popiela, Agnieszka Slowik P17.9-009 Improved Adherence to AHA Acute Stroke Treatment Guidelines Through Telestroke (TELECAST Trial)–Matthew Keith Ronck, Apameh Salari, Eric Jaton, Leah Stinson, Monica Ngo, Kathryn Bard, Amelia Solei, Sarah A. Engkjer, Andrew Jiahao Zhang, Jae H. Kim, Christine Elizabeth Yeager, Oladi Sedjio Bentho, Benjamin Robert Miller, Christopher Streib P17.9-010 National Estimates Of Recurrent Ischemic Stroke Among Patients Undergoing Carotid Revascularization: Effect Of Treatment Modality–Sairah Bashir, Saqib A. Chaudhry, Yun Fang, Iqra N Akhtar, Ameer Hassan, Mohammad-Rauf A. Chaudhry, Mohsain Gill, Muhammad Fareed Suri, Farhan Siddiq, Camilo Ramiro Gomez, Adnan I. Qureshi P17.9-011 Factors And Hospital Charges Associated With Prolonged Length Of Hospitalization In Patients Admitted With Ischemic Stroke In The United States–Iqra N Akhtar, Saqib A. Chaudhry, Mohammad-Rauf A. Chaudhry, Sairah Bashir, Mohsain Gill, Adnan I. Qureshi P17.9-012 Remote Management of Post-stroke Patients with Smartphone-based Management System Integrated in Clinical Care–Hyong-Min Kwon, Do Yeon Kim P17.9-013 Aphemia Following a Non-dominant Sub-insular Stroke: Unveiling the Foix-Chavany-Marie Phenomenon–Saurav Das, Naga Krishnakanth Madireddy, Satheesh Kumar Bokka, Michael Haboubi, Jignesh J. Shah, Tracy Ander, Wei Liu, Kerri S. Remmel P17.9-014 Radiologic Characteristic Of Perioperative Large Vessel Occlusions In Patients Who Underwent Transcatheter And Surgical Valve Replacement–Lucy Zhang, Joshua Santucci, Lacy Samuel Handshoe, Bhageeradh Mulpur

AAN.com/view/20AM 215

Friday, May 1

Cerebrovascular Disease and Interventional Neurology 2

POSTER SESSIONS

Cerebrovascular Disease and Interventional Neurology 1

POSTER SESSION 17: NEUROINFLAMMATION 0 Friday, May 1 11:30 a.m.–1:00 p.m.

Friday, May 1

POSTER SESSIONS

CME

P17.9-015 Biomarkers of Coagulation and Hemostatic Activation in the Post-Acute Period Effectively Rule Out Hypercoagulable States in Patients with Embolic Stroke of Undetermined Source–Michael Liu, Srikant Rangaraju, Deandrea Ellis, Alexander Duncan, Samir Belagaje, Trina Belair, Laura Bamford, Fadi B. Nahab P17.9-016 Investigation of S-Nitrosoglutathione in Stroke: A Systematic Review and MetaAnalysis of Literature in Pre-clinical and Clinical Research–Shimeng Liu, Haiqing Zheng, Wengui Yu, Viswanathan Ramakrishnan, Shreyansh Shah, Louis Fernando Gonzalez, Inderjit Singh, Carmelo Graffagnino, Wayne W. Feng P17.9-017 Systemic Inflammation Indexes Associated with the Severity and Functional Prognosis of Ischemic Stroke–Luis Fernández, Alejandro Gonzalez Aquines, Juan Fernando Gongora Rivera P17.9-018 Cost of Hospitalization for Stroke in a Low-Middle Income Country: Findings from a Public Tertiary Hospital in the Philippines–Jose Danilo Bengzon Diestro, Abdelsimar Omar, Robert Joseph Cruz Sarmiento, Clare Angeli Guinto Enriquez, Lennie Lynn Chua-De Castillo, Beverly Lorraine Ho, Kathleen Joy Khu, Jose Leonard R Pascual P17.9-019 National Trends In Utilization And Outcomes Of Endovascular Treatment In Acute Ischemic Stroke Patients In PreAnd Post-stent Retriever Era In The United States–Saqib A. Chaudhry, Ameer Hassan, Iqra N Akhtar, Mohammad-Rauf A. Chaudhry, Sairah Bashir, Wei Huang, Lakshmi Digala, Muhammad Fareed Suri, Werdah Zafar, Camilo Ramiro Gomez, Farhan Siddiq, Adnan I. Qureshi P17.9-020 Cardiovascular Events in LGBT (Lesbian, Gay, Bisexual, Transgender) : An Overlooked Disparity and a Call to Action– Shivani Naik, Sahil Naik, Gopika Kutty, Tamour Khan Tareen, Murali K. Kolikonda, Kerri S. Remmel, Wei Liu P17.9-021 Understanding Cultural and Knowledge Barriers to Acute Stroke Care in the Los Angeles

Filipino American Community– Antonio Moya, Eric M. Cheng, Vincent Grospe, Julia Brock, Linh Vo Neuro-oncology

Mackintosh, Richard Butterfield, Nan Zhang, Julia Lorence, Bernard Bendok, Richard Zimmerman, Kristin Swanson, Alyx B. Porter, Maciej M. Mrugala

Thiago Pinheiro, Rodrigo Queiroz Silveira, Leonardo Alves Araujo, Ana Carolina Ferreira, Ana Filipis, Caroline Bittar Braune, Osvaldo J M Nascimento

Infectious Disease P17.10-008 Mycobacteria avium complex (MAC) Brain Abscess in an AIDS Patient: Case Report and Literature Review–J. Clay Goodman, Shankar P. Gopinath, Wedad Alfarkh, Kenneth Muldrew, Andrew DiNardo P17.10-009 Encephalopathy with restricted diffusion in the splenium of corpus callosum in a case of Legionella Pneumophilia infection– Magdalena Stepien P17.10-010 Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis– Pria Anand, Shibani Sharon Mukerji, Jesse Thon, Shauna Gunaratne, Tracey Cho, Nagagopal Venna P17.10-011 Neurosyphilis in Adult Patients Presenting with Meningoencephalitis to The University Teaching Hospital in Lusaka, Zambia–Mashina Chomba, Sombo Fwoloshi, Eugene Mubanga, Igor J. Koralnik, Omar Siddiqi, Deanna Saylor P17.10-012 Progressive Multifocal Leukoencephalopathy Associated with Idiopathic CD4+ Lymphocytopenia in a Patient with Heterozygous STAT4 Mutation– Ayse Nur Ozdag Acarli, Can Tuzer, Tuncay Gunduz, Rashad Ismayilov, Erhan Pariltay, Asude Alpman, Ayca Aykut, Semra Demir, Figen Soylemezoglu, Murat Kurtuncu, Mefkure Eraksoy P17.10-013 HIV-Associated Neurocognitive Disorders at Moi Teaching and Referral Hospital, Eldoret, Kenya.–Amina Mohamed, Daniel Kinyanjui, Chrispine Oduor P17.10-014 Long term survival and 9-year follow-up of 14 HIVinfected adults with Progressive Multifocal Leucoencephalopathy– Mahmoud A. AbdelRazek, Golnaz Yadollahikhales, Rabab Elsadek, Aya A. Ouf, Nagagopal Venna P17.10-015 Facial Diplegia with distal paresthesias as variant of Guillain Barré Syndrome after Chikungunya infection: two case reports–Viviane Tavares Carvalho, Nathane Braga Da Silva Rezende,

Global Health

10 10 10 11

P17.10-001 Large Retrospective Institutional Review Identifies Novel Integrated Imaging and Clinical Markers as Early Independent Negative Prognostic Indicators of Glioblastoma Progression and Survival: A Proposed Supplement to RANO– Na Tosha N. Gatson, Shane Bross, Vinaykumar Puduvalli, Anand Mahadevan, Michel Lacroix, Syed Kazmi, Gino Mongelluzzo P17.10-002 The Effects of Dexamethasone on Mitogen Activated Protein Kinase-14 Signaling in Diffuse Intrinsic Pontine Glioma (DIPG) Cells–Collin Vinson, Pinki Chowdhury, Christopher Waker, Chanel Keoni, Kallol Kumar Set, Rob Lober P17.10-003 Use Of Non-Ablative Dose Of Radiation To Enhance Delivery Of Unmodified Morpholino Oligonucleotides In A Brain Tumor Model To Silence MGMT And Enhance The Efficacy Of ChemoRadiation–Prakash Ambady, Jeffrey Wu, Joshua Walker, Cymon Kersch, DreeAnna Morris, Jessica Bills, Samantha Holland, MIchael Pagel, Leslie Muldoon, Edward A. Neuwelt P17.10-004 Estrogen Hormone Replacement Therapy in Incidental Meningioma - A Growth Rate Analysis–Ryan T. Merrell, Laura Castillo-Saavedra, Carlen Amy Yuen, Andrew Wilmington, Mary Tilley Jenkins Vogel, Matthew Walker, David Olayinka Kamson P17.10-005 Hormone Levels Are Associated with Altered Brain Structure and Functional Connectivity in Prolactinomas– SHUN YAO, Wenli Chen, Haijun Wang P17.10-006 Finite Element Analysis Modeling of TTFields in Brain Metastasis According to Various Types of Cerebral Edema–Sindhu Reddy Pisati, Pyay San, Edwin Lok, Eric Tai-Lee Wong P17.10-007 Does the Location Matter? Characterization of the Anatomic Locations, Molecular Profiles, and Clinical Features of Gliomas–Christopher Patrick

216 2020 AAN Annual Meeting

P17.10-016 Comprehensive Profile of Antiviral Antibody Responses in Zika-associated GBS During the Zika Epidemic in Colombia–Beatriz Parra, Matthew Robinson, Dyvia Mohan, Daniel Monaco, Lyda Osorio, H. Benjamin Larman, Carlos A. Pardo-Villamizar Child Neurology and Developmental Neurology

P17.11-001 A Machine-Based Prediction Model of ADHD Using CPT Data–Itai Berger, Inbal Yahav Shenberger, Ortal Slobodin P17.11-002 Movement Disorders in Women with X-Linked Adrenoleukodystrophy–Melanie De Las Alas Supnet, Christopher D. Stephen, Haley Andonian, Nutan Sharma, Florian Eichler P17.11-003 Development of Silent Brain Lesions in Pediatric Patients with anti-MOG-Associated Demyelination–Giulia Fadda, Julia O’Mahony, Robert Allan Brown, Denise Castro, Giulia Longoni, Helen Branson, Leonard Herman Verhey, E. Ann Yeh, Ruth-Ann Marrie, Patrick Waters, Douglas L. Arnold, Brenda Banwell, Amit Bar-Or P17.11-004 Early magnetic resonance imaging as a predictor of outcome in pediatric traumatic brain injury–Anna Janas, Zachary D. Threlkeld, Max Wintermark, Sarah Lee P17.11-005 School Performance and Psychiatric Morbidity 6 Years after Pediatric Acute Disseminated Encephalomyelitis: A Nationwide Population-based Cohort Study–Magnus Spangsberg *Use 291171 Boesen, Annika Langkilde, Alfred Peter Born, Melinda Magyari, Morten Bjorn Blinkenberg, Tanuja Chitnis, Lau Thygesen, Frank Eriksson P17.11-006 Pediatric MS Subjects Have Reduced Walking Capacity Compared to Healthy Controls– James Nick Brenton, Emma Woolbright, Sue Min, Hitoshi Gene Koshiya, Myla D. Goldman = Research

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number Neuro Trauma and Sports Neurology

Neuro-rehabilitation

11 11

P17.11-007 Neurofilament Light-Chain Protein as A Potential Biomarker of Neurodegeneration and Progression in Former Contact Sports Athletes–Foad Taghdiri, Namita Multani, Miracle Ozzoude, Apameh Tarazi, Mozghan Khodadadi, Richard Wennberg, David J. Mikulis, Robin Green, Brenda Colella, Kaj Blennow, Henrik Zetterberg, Charles Tator, Carmela Tartaglia

P17.11-013 Effect of Transcranial Direct Current Stimulation on Severely Affected Arm-Hand Motor Function in Patients After An Acute ischemic Stroke–Meheroz Rabadi, Christopher Aston

Neuro-opthalmology/ Neuro-otology

POSTER SESSIONS

11 11

P17.11-008 Causes of Homonymous Macular Ganglion Cell Complex Atrophy on Optical Coherence Tomography without Significant Visual Field Changes–Mark Lukewich, Matthew Schlenker, Jonathan Micieli Sleep

P17.11-009 A Pilot, Placebocontrolled Clinical Trial of Cereset Research for Insomnia–Catherine Tegeler, Charles Tegeler, MD, Lindsay Howard, Kenzie Brown, Dawn Kellar, Lee Gerdes, Hossam Shaltout P17.11-010 Diffusion Tensor Imaging Evidence of Hypothalamic Injury in Traumatic Brain Injury Warfighters with Sleep Dysfunction–Brian Gerstenslager, Ping Hong Yeh, John Ollinger, Kimbra Kenney, John Werner Research Methodology and Education

Friday, May 1

P17.11-011 Neuro Day: An Innovative Curriculum to Connect Medical Students with Patients– Jessica Frey, Brandon Neeley, Gauri Pawar, Ann Murray P17.11-012 A Novel Goals of Care Communication Curriculum for Neurology Residents Improves Confidence and Skills–Tarini Goyal, Sylvia Bereknyei Merrell, Barbette Weimer-Elder, Merisa Kline, Carl Gold

AAN.com/view/20AM 217

Skills Workshops

Panel Discussions

Continuing the Conversation

Case-based

Education Blitz

Interactive

Games/ Competitions

Didactic

Audience Participation

Experiential Learning Areas

Effective Learning Designed For You Weâ&#x20AC;&#x2122;ve created over 500 expert-led educational and experiential learning area opportunities covering the full spectrum of neurology in formats that cater to your individual learning style. You benefit from getting a personalized way to keep up-to-date in your area of expertise. See list of programs on the following pages.

EXPERIENTIAL LEARNING AREAS Engaging talks & presentations that inspire learning

Experiential Learning Areas are located throughout the convention center* to help you advance intellectually, personally, and professionally. Academic Neurology

HeadTalks

Innovation Hub

Advancing Leadership in Neurology

Learn, share, and implement best practices to advance and succeed across the career span.

Taking care of your patients starts with taking care of you!

Experience unconventional education platforms.

Learn about core leadership competencies and topics.

Navigating Your Career

Explore, navigate, and advance your career through a variety of talks for multiple career stages.

Expand your mind into new ways of thinking about your profession. 4

Live Well

Policy, Practice, and Performance: Staying Ahead of Change

Empowering you to improve and increase revenue.

Research

Engage in cutting-edge science, knowledge sharing, and career recognition.

Learn more about each experiential learning area on the following pages and online at AAN.com/view/ela. (Pedestrian Walkway) Union Station

Bridge

Hotel

Exhibit Halls ABC

Meeting Rooms Street Parking

Ballroom Theatre

30 0

8 1

Hotel

4 00 Street Level

200 100

estr

(Ped

ay) alkw nW

50 0 2

NORTH BUILDING

600 7

Meeting Rooms Parking

Meeting Rooms

700

Exhibit Halls DEFG Ballroom F&G

80 0 *Locations current as of 2/10/2020.

SOUTH BUILDING

ACADEMIC NEUROLOGY The Academic Neurology Experiential Learning Area lineup is designed for everyone at every level of academia. The AAN strives to be indispensable to all our members and recognizes that their needs and priorities vary. We have launched an academic initiative to help bring together many of the resources, products, and programs that help support academic and neuroscience professionals throughout their careers. PRESENTATIONS: 45-minute talks (see next page for complete list) • Academic Neurology: What Is the AAN Doing to Help Academic Neurology? • Advancing the Educational Mission in Neurology Departments • Different Pathways to Becoming a Department Chair • The Third Leg? The Clinician in Academic Medicine CONVERSATION CORNER: Join small-group facilitated discussions with your peers.

PROGRAMS: longer format to allow deeper dives into topics • Accelerating Equity, Diversity, and Inclusion for Women in Medicine • Education Research Methodology Course • Funds Flow Models: What Works? What Doesn’t Work? • Mid-career Faculty Development Course

Located on Level 200 Near Room 205B

ACADEMIC NEUROLOGY Saturday, April 25

9:00 a.m.–10:00 a.m. Clerkship Administrators Part 1: Understanding the Liaison Committee on Medical Education (LCME) Standards for Accreditation Speaker(s): Celia Linton 10:00 a.m.–11:00 a.m. Implementing a Flipped Classroom Model to Enhance Student Education in Neurology Speaker(s): Christine R. Berry Amanda C. Jones, BA, C-TAGME John Reidy 11:00 a.m.–12:00 p.m. Identifying and Eliminating Barriers/ Challenges for Medical Students Choosing the Field of Neurology as a Specialty Speaker(s): Christine R. Berry Lorie M. Wolfanger, BS 2:00 p.m.–2:45 p.m. Your First Job: Private Practice vs. Academic Practice: Pros and Cons Speaker(s): J. Clay Goodman, MD, FAAN 3:00 p.m.–3:45 p.m. Philanthropy for Education Speaker(s): Madhu Soni, MD, FAAN

Sunday, April 26 8:00 a.m.–8:45 a.m. Neurology: We Want YOU! Speaker(s): Elisabeth B. Marsh, MD 11:00 a.m.–12:00 p.m. Identifying Areas of Burnout of Clerkship Coordinators and Improving Wellness Speaker(s): Renata Barylowicz Christina Cronin 3:00 p.m.–3:45 p.m. Different Pathways to Becoming a 0.75 Department Chair Speaker(s): Frances E. Jensen, MD, FAAN Cathy A. Sila, MD, FAAN Robin L. Brey, MD, FAAN CME

Monday, April 27 7:00 a.m.–7:45 a.m. Core Curriculum for a Required 0.75 Neurology Experience Speaker(s): Douglas J. Gelb, MD, PhD, FAAN Madhu Soni, MD, FAAN Joseph E. Safdieh, MD, FAAN CME

CME

11:00 a.m.–12:00 p.m. Creating a Handbook for Clerkship Administrators and Beyond…. Speaker(s): Celia Linton Caroline E. Martin, MA Lorie M. Wolfanger, BS Sheryll Marshall 1:00 p.m.–1:45 p.m. Navigating the Political Terrain: The Art of Avoiding Organizational Potholes Speaker(s): Cathie T. Siders, PhD 2:00 p.m.–2:45 p.m. Cómo participar en la Resident & Fellow Section de Neurology® (How to Get Involved in the Resident & Fellow Section of Neurology®) Speaker(s): Guillermo Ruben Delgado-Garcia, MD 3:00 p.m.–3:45 p.m. Academic Neurology: What Is the AAN Doing to Help Academic Neurology? Speaker(s): Ralph L. Sacco, MD, MS, FAHA, FAAN 4:00 p.m.–4:45 p.m. Top Ten Clinical, Educational, and 0.75 Leadership Pearls Speaker(s): Steven Galetta, MD, FAAN CME

Wednesday, April 29 8:00 a.m.–8:45 a.m. Grit, Resilience, and a Healthy 0.75 Dose of Fun: How to Succeed at Your Professional Organization Speaker(s): Brenda Banwell, MD, FAAN Maisha T. Robinson, MD, MS Orly Avitzur, MD, MBA, FAAN CME

1:00 p.m.–1:45 p.m. Advancing the Educational Mission 0.75 in Neurology Departments Speaker(s): David M. Greer, MD, FAAN CME

2:00 p.m.–2:45 p.m. Factors that Perpetuate Disparities in Academic Medicine: A Path Forward Speaker(s): Reena Parada Thomas, MD 5:00 p.m.–5:45 p.m. Neurohospitalist Models of 0.75 Care in an Academic Department: Opportunities and Challenges Speaker(s): S. Andrew Josephson, MD, FAAN CME

Thursday, April 30 8:00 a.m.–8:45 a.m. How to Increase Your International Presence? Speaker(s): Ann H. Tilton, MD, FAAN 1:00 p.m.–1:45 p.m. Team Science: Implications for 0.75 Promotions and Tenure Speaker(s): Mitchell S. V. Elkind, MD, MS, FAAN CME

Tuesday, April 28 7:00 a.m.–7:45 a.m. Key Findings from the Neurology Compensation and Productivity Survey for Academics Speaker(s): Melissa Yu, MD, FAAN J. Todd Barnes, MBA

4:00 p.m.–4:45 p.m. Consejos para publicar en revistas neurológicas (Getting Published in Neurology Journals: Tips and Tricks) Speaker(s): Jose G. Merino, MD, MPhil, FAAN

8:00 a.m.–8:45 a.m. Turning “Diversity Tax” into 0.75 Currency in Neurology Speaker(s): Roy H. Hamilton, MD, MS, FAAN CME

1:00 p.m.–1:45 p.m. Navigating a Career in Academic 0.75 Neurology: Accolades and Challenges Speaker(s): Shilpa Chitnis, MD, PhD, FAAN, FANA CME

2:00 p.m.–2:45 p.m. All Work and No Play: Don’t Let Work Interfere with Your Fun Speaker(s): Elaine C. Jones, MD, FAAN 3:00 p.m.–3:45 p.m. The Third Leg? The Clinician in 0.75 Academic Medicine Speaker(s): Kirk Roberts, MD, FAAN CME

5:00 p.m.–5:45 p.m. Mentorship: Pearls and Pitfalls 0.75 Speaker(s): Cynthia L. Comella, MD, FAAN

Talks that do not have CME will not have an icon.

CME

AAN.com/view/20AM 221

EXPERIENTIAL LEARNING AREAS

8:00 a.m.–9:00 a.m. Vital Roles of the Clerkship Coordinator/ Administrator Speaker(s): Caroline E. Martin, MA Lorie M. Wolfanger, BS Sheryll Marshall

8:00 a.m.–8:45 a.m. How to Create a Department That 0.75 Promotes Wellness Speaker(s): Jennifer Bickel, MD, FAAN

ADVANCING LEADERSHIP IN NEUROLOGY

The AAN’s Commitment to Leadership Development

Large shifts in the landscape of the health care industry have led to a gap between the skills that health care leaders possess and the skills their organizations need. Resources must be given to train, support, and prepare them for desired leadership roles, and assist members to achieve their desired level of leadership potential throughout their careers to increase patient and physician satisfaction. This area is a place for physicians to learn more about core leadership competencies and topics around equity, diversity, and inclusion.

PRESENTATION STAGE:

45-minute talks • Negotiation Skills • The Benefit of Diversity on Your Team • Women in Health Care Leadership

COACHING CORNER:

Advanced registration is required for some programs.

Located on Level 700 Outside Room 713

LEADERSHIP PROGRAMS:

Longer programs offering deeper dives into topics (see complete list of programs on page 248) • Women in Leadership: Empower or Imposter • The Impact of Conscious and Unconscious Biases • Leadership Challenges in Practice

ADVANCING LEADERSHIP IN NEUROLOGY Saturday, April 25 CME

12:00 p.m.–3:00 p.m. Leadership Challenges in Practice 3 Speaker(s): Brad C. Klein, MD, MBA, FAAN CME

1:30 p.m.–4:00 p.m. Educators’ Leadership Program Speaker(s): Jaffar Khan, MD, FAAN 3:00 p.m.–3:45 p.m. Eleven Things Not to Say to Your 0.75 Female Colleagues Speaker(s): Amaal J. Starling, MD CME

Sunday, April 26 12:00 p.m.–4:00 p.m. Chief Resident Leadership Program Speaker(s): Maisha T. Robinson, MD, MS 1:00 p.m.–1:45 p.m. Gratitude and Other “Soft” Skills 0.75 That Help You Thrive as a Leader Speaker(s): Jennifer Rose Molano, MD, FAAN CME

3:00 p.m.–3:45 p.m. Conflict Management: An Essential 0.75 Leadership Competency Speaker(s): Cathie T. Siders, PhD CME

4:00 p.m.–4:45 p.m. Blind Spots: The Impact of 0.75 Conscious and Unconscious Biases Speaker(s): Laraine Kaminsky Janis Miyasaki, MD, FAAN Jeffrey C. McClean, II, MD, FAAN Charles C. Flippen, II, MD, FAAN CME

5:00 p.m.–5:45 p.m. Self Promotion 0.75 Speaker(s): Amy Hessler, DO, FAAN CME

Monday, April 27

CME

4:00 p.m.–4:45 p.m. Are You Woke Enough to Lead? 0.75 Speaker(s): Nimish A. Mohile, MD, FAAN CME

2:00 p.m.–2:45 p.m. Time for a Check Up: How to 0.75 Successfully Navigate Compensation Negotiations as Women in Neurology Speaker(s): Melissa W. Ko, MD, FAAN Kavita Nair, PhD Brett M. Kissela, MD, FAAN, MS CME

3:00 p.m.–3:45 p.m. Microaggressions: How to Address 0.75 Discrimination and Unprofessional Behavior at Your Workplace Speaker(s): Ezgi Tiryaki, MD, FAAN Lauren R. Moo, MD CME

5:00 p.m.–5:45 p.m. One Day Fellow, Next Day Boss: 0.75 Reflections on Early-career Leadership Speaker(s): Maisha T. Robinson, MD, MS Gabriele C. De Luca, MD, PhD, FAAN CME

Tuesday, April 28 1:00 p.m.–1:45 p.m. EDI 101 for Neurology Leaders: The 0.75 Benefit of Diversity on Your Team Speaker(s): Lynn Gordon, MD, PhD Victoria S. Pelak, MD, FAAN CME

1:00 p.m.–3:30 p.m. Good to Great, Great to Gold: Applying 4 the (3 G) Strengths-based Approach to Enhance Your Toolkit as a Leader Speaker(s): Rachel Marie E. Salas, MD, FAAN Charlene Gamaldo, MD, FAAN CME

1:00 p.m.–4:00 p.m. Mitigating the Impact of Unconscious 3 Bias Speaker(s): Laraine Kaminsky CME

4:00 p.m.–4:45 p.m. Health Care Disparities in 0.75 Populations Speaker(s): Sharon Lewis, MD Alejandro Vargas, MD CME

5:00 p.m.–5:45 p.m. Women in Neurology: Thriving 0.75 Through Challenges Speaker(s): Jill M. Farmer, DO, MPH Divya Singhal, MD, FAAN CME

Thursday, April 30 1:00 p.m.–1:45 p.m. How and When to Speak Up as a 0.75 Bystander Speaker(s): Jennifer L. Hopp, MD, FAAN Thabele M. Leslie-Mazwi, MD CME

2:00 p.m.–2:45 p.m. Do You Need a Sponsor, Mentor(s) or Collaborator(s)? Speaker(s): Robert C. Griggs, MD, FAAN

2:00 p.m.–2:45 p.m. Managing Neurologic Disorders 0.75 in Transgender and Gender Diverse Patients Speaker(s): Eric Kaiser, MD, PhD

3:00 p.m.–3:45 p.m. The Importance of Mission, Vision, 0.75 and Purpose Speaker(s): Terrence L. Cascino, MD, FAAN

3:00 p.m.–3:45 p.m. Women in Health Care Leadership: 0.75 Time for Change Speaker(s): Renee M. Pazdan, MD, FAAN

4:00 p.m.–4:45 p.m. Leading Interdisciplinary Teams 0.75 Speaker(s): Mona Bahouth, MD Rachel Marie E. Salas, MD, FAAN

5:00 p.m.–5:45 p.m. How to Become a Leader in Your 0.75 Health System Speaker(s): Allison L. Weathers, MD, FAAN Gregory J. Esper, MD, MBA, FAAN Lyell K. Jones, MD, FAAN

CME

5:00 p.m.–5:45 p.m. Next Level Leadership: Building Your 0.75 Personal Development Plan Speaker(s): Laura Baugh, MD CME

1:00 p.m.–1:45 p.m. How to Get from Diversity to Inclusion: 0.75 The Difference of Being Invited to a Wednesday, April 29 Dance vs. Being Asked to Dance 1:00 p.m.–1:45 p.m. Speaker(s): Ezgi Tiryaki, MD, FAAN Tools and Resources to Combat 0.75 1:00 p.m.–3:00 p.m. Imposter Phenomenon Leadership in the Era of Burnout: A Speaker(s): Rachel Marie E. Salas, MD, FAAN 2 Practical Approach to Becoming a True Charlene Gamaldo, MD, FAAN Physician Leader 1:00 p.m.–5:00 p.m. Speaker(s): Terrence L. Cascino, MD, FAAN Strengths Foundations Workshop 4 2:00 p.m.–2:45 p.m. Speaker(s): Keri Bischoff Emotional Intelligence and Julie Anderson 0.75 Leadership Speaker(s): Joanne Smikle, PhD CME

CME

Friday, May 1 1:00 p.m.–1:45 p.m. Communicate Better! Presenting and 0.75 Pitching New Ideas Speaker(s): James Michael Hillis, MD Jonathan Santoro, MD CME

2:00 p.m.–2:45 p.m. Navigating Conflict 0.75 Speaker(s): Jennifer Bickel, MD, FAAN Renee M. Pazdan, MD, FAAN CME

CME

Talks that do not have CME will not have an icon.

AAN.com/view/20AM 223

EXPERIENTIAL LEARNING AREAS

7:00 a.m.–4:00 p.m. Women in Leadership: Empower or 6.5 Imposter: Leveraging Your Strengths as a Leader in Neurology Speaker(s): Orly Avitzur, MD, MBA, FAAN Julie Anderson Keri Bischoff Janice M. Massey, MD, FAAN

3:00 p.m.–3:45 p.m. Top Strengths and Shadow Sides in 0.75 Neurology Speaker(s): Keri Bischoff Julie Anderson

Health E dutainment A musement D iscussion Kick back, relax, and watch as the HeadTalks stage transforms into a platform for amazing storytelling, inspiring ideas, and unique experiences.

The 2020 lineup is packed with unconventional, thought-provoking, unexpected topics including: • Is There a Neurologist on the Flight? • The Salem Witch Trials: How Could That Possibly Happen? • Neuro HeadTalk: Story Slams • Standing on the Shoulders of Giants • The Teenage Brain: A Neuroscientist’s Survival Guide to Raising Adolescents and Young Adults

Located on Level 600

HEADTALKS Saturday, April 25

Tuesday, April 28 12:00 p.m.–1:00 p.m. What’s that in Your Brain: 50 Essential Instant Pathological Recognition Cases Speaker(s): J. Clay Goodman, MD, FAAN

1:30 p.m.–2:15 p.m. Is There a Neurologist on the Flight? Speaker(s): Joseph I. Sirven, MD, FAAN

1:30 p.m.–2:15 p.m. The Effects of Brain Damage on Creativity Speaker(s): Kenneth M. Heilman, MD, FAAN

2:30 p.m.–3:15 p.m. Reflections from Women in Medicine: The Other Side of Doctoring Speaker(s): Amtul Farheen, MD, FAAN

2:30 p.m.–3:15 p.m. All Things Ice Cream Speaker(s): Bryan Soronson, CRA, FACMPE, MPA

3:30 p.m.–4:15 p.m. Movement Disorders Case Studies: Diagnostic and Therapeutic Challenges Speaker(s): Aikaterini Kompoliti, MD, FAAN Anthony E. Lang, MD, FAAN

Sunday, April 26 12:15 p.m.–1:15 p.m. Who Wants to Be a Millionaire? Speaker(s): Jose H. Posas, MD 1:30 p.m.–2:15 p.m. The Teenage Brain: A Neuroscientist’s Survival Guide to Raising Adolescents and Young Adults Speaker(s): Frances E. Jensen, MD, FAAN 2:30 p.m.–3:15 p.m. Neuro-oncology Around the World – Global Perspective on Brain Cancer Patient Care Speaker(s): Maciej M. Mrugala, MD, PhD, MPH, FAAN Agnieszka Slowik, MD, FAAN Alejandro Zavala, MD 4:30 p.m.–5:15 p.m. Standing on the Shoulders of Giants Speaker(s): Robert C. Griggs, MD, FAAN

Monday, April 27 12:00 p.m.–1:00 p.m. Neuro-Jeopardy: Telencephalon Twisters Speaker(s): Laurice T. Yang, MD, MHA Veronica E. Santini, MD, MA 1:30 p.m.–2:15 p.m. Neuro HeadTalk: Story Slams Speaker(s): Joseph I. Sirven, MD, FAAN 2:30 p.m.–3:15 p.m. The Benefits and Barriers in Practicing Neurology in Canada vs. the US Speaker(s): Jennifer Bickel, MD, FAAN 3:30 p.m.–4:15 p.m. Neuro Exam Tricks and Tips Speaker(s): Nancy J. Newman, MD, FAAN Amy A. Pruitt, MD, FAAN 4:30 p.m.–5:15 p.m. Standing on the Shoulders of Giants Speaker(s): Thomas R. Swift, MD, FAAN

3:30 p.m.–4:15 p.m. The Neuroscience of Magic: Sleight of Hand Speaker(s): Steven J. Zuckerman, MD, FAAN

12:00 p.m.–1:00 p.m. The Neurology of Creativity at the Keyboard Speaker(s): Phillip L. Pearl, MD, FAAN 2:30 p.m.–3:15 p.m. Werewolves and Vampires: The Quest for the Truth Speaker(s): Brian James Hanrahan, MD 4:00 p.m.–5:00 p.m. NeuroZone Speaker(s): Bert B. Vargas, MD, FAAN Jennifer Bickel, MD, FAAN Mark Milstein, MD, FAAN

4:30 p.m.–5:15 p.m. Standing on the Shoulders of Giants Speaker(s): Claudia Kawas, MD

Wednesday, April 29 12:00 p.m.–1:00 p.m. Neurology Pictionary Speaker(s): Mark Milstein, MD, FAAN 1:30 p.m.–2:15 p.m. The Salem Witch Trials: How Could That Possibly Happen? Speaker(s): Ann H. Tilton, MD, FAAN 2:30 p.m.–3:15 p.m. Consejos prácticos para un buen examen neurológico (Neuro Exam Tips and Tricks) Speaker(s): Vladimir Hachinski, MD, DSc, FAAN Jose Biller, MD, FAAN, FACP, FAHA 3:30 p.m.–4:15 p.m. Ethical Conundrums in Neurology Speaker(s): Ariane Lewis, MD 4:30 p.m.–5:15 p.m. Standing on the Shoulders of Giants Speaker(s): Josep O. Dalmau, MD, PhD, FAAN

Thursday, April 30 1:30 p.m.–2:15 p.m. Live Intraoperative Monitoring Speaker(s): Constantine Moschonas, MD, FAAN 2:30 p.m.–3:15 p.m. Lost in Translation Speaker(s): Jose G. Merino, MD, MPhil, FAAN Joseph I. Sirven, MD, FAAN 3:30 p.m.–4:15 p.m. The Effects of Loneliness: Connectivity Matters Speaker(s): Stephanie Cacioppo, PhD 4:30 p.m.–5:15 p.m. Standing on the Shoulders of Giants Speaker(s): Phyllis C. Zee, MD, PhD

Talks that do not have CME will not have an icon.

AAN.com/view/20AM 225

EXPERIENTIAL LEARNING AREAS

12:00 p.m.–12:30 p.m. Welcome to the Annual Meeting (Navigating the App) Speaker(s): Carlayne E. Jackson, MD, FAAN

Friday, May 1

INNOVATION HUB Exploring your brain–the body’s final frontier

Join us for a fun, interactive, and unexpected journey into the future of neurology. Visit the Innovation Hub Experiential Learning Area to explore new technologies, discuss inspirational topics, and challenge yourself to think differently about patient care. Edutainment: • Medical Improv: Comedy as a Tool for Improving Patient Interaction • Wine & Paint Sessions • Brainstorm: A Competition for the Innovator in All of Us • Video Game Talks • Lively Panel Discussion • Photo Opps, Games, and More! Located on Level 800 Exhibit Halls D&E

INNOVATION HUB Sunday, April 26

1:30 p.m.–2:00 p.m. Development of Speech-based, Digital 1:00 p.m.–1:30 p.m. Biomarkers for Neuropsychiatric Disease You Died of Dysentery: Gaming in Education Speaker(s): Bill Simpson, PhD Speaker(s): Pearce Korb, MD, FAAN 2:00 p.m.–2:30 p.m. 1:30 p.m.–2:00 p.m. Author Your Own Future: Self-publishing The Future Is Now: Bringing Accessibility, in Neurology Availability, Affordability, Appropriateness, Speaker(s): Paul Johnson, MD and Acceptability with Telehealth and 2:30 p.m.–3:00 p.m. Digital Medicine in Neurology Twitter for Neurologists: Basics and Beyond Speaker(s): David J. Houghton, MD Speaker(s): Kathrin LaFaver, MD, FAAN 2:00 p.m.–2:30 p.m. 3:00 p.m.–3:30 p.m. Rotten Eggs: A Dozen Things to Be Wary of When Considering Treatments or Trials on Medical Improv: Comedy as a Tool for the Internet Improving Patient Interactions Speaker(s): Richard S. Bedlack, MD, PhD, FAAN Speaker(s): Jose H. Posas, MD Bert B. Vargas, MD, FAAN 2:30 p.m.–3:00 p.m. Live Tweeting: Don’t Just Join the Conversation, Influence It! Speaker(s): Aarti Sarwal, MD, FAAN Jeff Kraakevik, MD Justine Ker Kara Stavros, MD 3:00 p.m.–3:30 p.m. Medical Improv: Comedy as a Tool for Improving Patient Interactions Speaker(s): Daniel Joseph Ackerman, MD Jonathan K. Smith, MD, FAAN Robert W. Neel, MD 3:30 p.m.–4:00 p.m. From Research to Clinic: Implementing Brain Perfusion Quantification in an Outpatient Center Speaker(s): Nandor K. Pinter

Monday, April 27 11:30 a.m.–12:00 p.m. The Nerve: A Talk Show for our Neurology Community About What Makes Us Nervous and What Gets on Our Nerves Speaker(s): David A. Evans, MBA Daniel Joseph Ackerman, MD Anup D. Patel, MD, FAAN Allan Ding Wu, MD, FAAN Allison L. Weathers, MD, FAAN Jennifer Bickel, MD, FAAN 12:00 p.m.–12:30 p.m. Delivering Personalized Care to Patients at Risk for Alzheimer’s Dementia Speaker(s): Richard S. Isaacson, MD, FAAN

2:00 p.m.–2:30 p.m. Office Practice Mechanisms to Provide Services for the New CPT Codes Speaker(s): Bruce H. Cohen, MD, FAAN 2:30 p.m.–3:00 p.m. Lessons from the California Parkinson’s Disease Registry and What’s Next? Speaker(s): Allan Ding Wu, MD, FAAN 3:00 p.m.–3:30 p.m. Medical Improv: Comedy as a Tool for Improving Patient Interactions Speaker(s): Jonathan K. Smith, MD, FAAN Jennifer Bickel, MD, FAAN Mark Milstein, MD, FAAN 3:30 p.m.–4:00 p.m. Telemedicine FAILS: Limitations and Legal Liability Speaker(s): Eric Anderson, MD, PhD Jaime Hatcher-Martin, MD, PhD

Wednesday, April 29

3:30 p.m.–4:00 p.m. 2019 Brainstorm Competition Winner ALSUntangled Speaker(s): Richard S. Bedlack, MD, PhD, FAAN

11:30 a.m.–12:00 p.m. Patient-centered Innovations and AI in Transition of Care Speaker(s): Ann H. Tilton, MD, FAAN

4:00 p.m.–5:30 p.m. Brainstorm: A Competition for the Innovator in All of Us Speaker(s): Jose H. Posas, MD Pearce Korb, MD, FAAN Daniel Joseph Ackerman, MD David A. Evans, MBA Eric Anderson, MD, PhD Jaime Hatcher-Martin, MD, PhD Brad C. Klein, MD, MBA, FAAN

12:00 p.m.–12:30 p.m. Project ECHO and Neurology: Demand Shaping and Bridging Knowledge Gaps Speaker(s): Aiesha Ahmed, MD

Tuesday, April 28 11:30 a.m.–12:00 p.m. Methods and Directions for Applying Data Science in Neurology Speaker(s): Rishikesan Kamaleswaran 12:00 p.m.–12:30 p.m. The Evolving Use of Scribes in the Neurology Practice Speaker(s): Clayton Shanahan Jennifer McVige, MD Joseph V. Fritz, PhD Pearce Korb, MD, FAAN 12:30 p.m.–1:00 p.m. Models of Care That Work for You and Your Patients Speaker(s): Joel M. Kaufman, MD, FAAN 1:00 p.m.–1:30 p.m. Addictive by Design: The Evolution of Video Games Speaker(s): Eric Anderson, MD, PhD

12:30 p.m.–1:00 p.m. Incorporating a Pharmacist into your Neurology Practice for Free–Results of a Pilot 1:30 p.m.–2:00 p.m. Speaker(s): Robert M. Kropp, MD, FAAN Social Media for the Modern Neurologist: How Twitter Allows You to Amplify Your Voice and Engage Your Community of Physicians and Patients Speaker(s): Ima M. Ebong, MD Talks that do not have CME will not have an icon.

12:30 p.m.–1:00 p.m. What If? Digital Assessments Transforming Neurology Practice Speaker(s): Allen L. Gee, MD, PhD, FAAN 1:00 p.m.–1:30 p.m. Video Games in Neuro-rehab: Big Bucks or Xbox Speaker(s): Daniel Joseph Ackerman, MD 1:30 p.m.–2:00 p.m. Nutritional Neurology: Back to Basics and What to Look for Moving Forward Speaker(s): Madhureeta Achari, MD 2:00 p.m.–2:30 p.m. Shared Medical Appointments in the Memory Clinic Speaker(s): Elizabeth Joe, MD Soo Borson, MD 2:30 p.m.–3:00 p.m. The Midas Touchscreen: Turn Your App Idea into Gold Speaker(s): Zachary N. London, MD, FAAN 3:00 p.m.–3:30 p.m. Medical Improv: Comedy as a Tool for Improving Patient Interactions Speaker(s): Jennifer Bickel, MD, FAAN Jose H. Posas, MD Bert B. Vargas, MD, FAAN

AAN.com/view/20AM 227

EXPERIENTIAL LEARNING AREAS

12:30 p.m.–1:00 p.m. Non-epileptic Seizures—A Multidisciplinary Clinic Model, What Would Freud Say? Speaker(s): Laura A. Strom, MD

1:00 p.m.–1:30 p.m. An Overwatch of Video Games in Neurology: Peak Performance Is Less Than a Fortnite Away Speaker(s): Jose H. Posas, MD

LIVE WELL

YOU’RE MORE THAN YOUR CAREER

Achieving balance, well-being, and wholeness in all aspects of your life extends to the quality of care you provide your patients. Visit the Live Well Experiential Learning Area at the Annual Meeting to explore new ways to achieve success personally and professionally. BALANCE

• Yoga–Vinyasa • Guided Meditation

WELL-BEING

• Mindfulness Practices • Becoming a Sleep-healthy Neurologist

WHOLENESS

• Magnifying Your Life Through Poetry • Acupuncture Demonstrations

Located on Level 300 Outside Exhibit Hall A

LIVE WELL 7:00 a.m.–7:45 a.m. Yoga—Vinyasa Speaker(s): Jamie L. Palaganas, MD

7:00 a.m.–7:45 a.m. Yoga—Vinyasa Speaker(s): Jamie L. Palaganas, MD

1:00 p.m.–1:45 p.m. The Power of One 0.75 Speaker(s): Janis Miyasaki, MD, FAAN Jennifer Axelband, DO Jonathan P. Hosey, MD, FAAN

8:00 a.m.–8:45 a.m. Dancing with Parkinson’s 0.75 Speaker(s): Diviya Kaul, MD

8:00 a.m.–8:45 a.m. Neurological Disease Prevention 0.75 with Food Speaker(s): Tamika M. Burrus, MD, FAAN

2:00 p.m.–2:45 p.m. Patient-centered Care in Clinical 0.75 Neurology Speaker(s): Paul M. Schanfield, MD

1:00 p.m.–1:45 p.m. Fireside Chat: Burnout–What Do You Want to Know? Speaker(s): Ara Schlaman Hall, MD

3:00 p.m.–3:45 p.m. Café Talk: Growth Mindset 0.75 Speaker(s): Jennifer Rose Molano, MD, FAAN

Saturday, April 25

9:00 a.m.–9:45 a.m. Mindfulness Based Stress Reduction 0.75 (MBSR) Speaker(s): Ross P. Carne, MD, FRACP CME

10:00 a.m.–10:45 a.m. How Your Social Life Might Be Helping 0.75 (Or Harming) Your Brain Speaker(s): Joel Armando Salinas, MD CME

11:00 a.m.–11:45 a.m. Parenting While Doctoring Speaker(s): Lawrence A. Brzozowski, MD Paul G. Mathew, MD, FAAN, FAHS Nancy Hammond, MD Amtul Farheen, MD, FAAN Heidi George Moawad, MD 12:00 p.m.–12:45 p.m. The Ripple Effect of Positive Psychology 0.75 Speaker(s): Heidi B. Schwarz, MD, FAAN CME

3:00 p.m.–3:45 p.m. Tips for Better Sleep: More Reasons 0.75 to Love Bedtime Speaker(s): Smita H. Patel, DO

CME

2:00 p.m.–2:45 p.m. Understanding Essential Oils, Nature’s Relief Speaker(s): Belinda A. Savage-Edwards, MD, FAAN 3:00 p.m.–3:45 p.m. The Sleep Mythbuster!: Illuminating the 0.75 Facts and Fiction Toward Achieving the Sleep-healthy Neurologist Speaker(s): Logan D. Schneider, MD CME

4:00 p.m.–4:30 p.m. Guided Meditation Speaker(s): Divya Singhal, MD, FAAN 5:00 p.m.–6:00 p.m. Happiness Hour

CME

Sunday, April 26

Tuesday, April 28 7:00 a.m.–7:45 a.m. Yoga—Vinyasa Speaker(s): Jamie L. Palaganas, MD

7:00 a.m.–7:45 a.m. Yoga—Vinyasa Speaker(s): Jamie L. Palaganas, MD

8:00 a.m.–8:30 a.m. Mindfulness of Sound Speaker(s): Ross P. Carne, MD, FRACP

8:00 a.m.–8:30 a.m. Meditation: Awareness of Breath Speaker(s): Ross P. Carne, MD, FRACP

1:00 p.m.–1:45 p.m. Outsmart Stress 0.75 Speaker(s): Marie E. Pasinski, MD

1:00 p.m.–1:45 p.m. The Prevention of Stroke: No Pill’s 0.75 Gonna Cure This Ill Speaker(s): John W. McBurney, MD

2:00 p.m.–2:45 p.m. Magnifying Your Life Through Poetry 0.75 Speaker(s): Michael L. Wynn, DO, FAAN

CME

3:00 p.m.–3:45 p.m. 2:00 p.m.–2:45 p.m. Mindful Snacking 0.75 Speaker(s): Belinda A. Savage-Edwards, MD, Enhancing Personal and Professional 0.75 FAAN Well-being Through Appreciative Inquiry Speaker(s): Jeffrey Dewey, MD 4:00 p.m.–4:45 p.m. Fireside Chat: Work-Life Balance 3:00 p.m.–3:45 p.m. Speaker(s): Rochelle I. Frank, MD Practical Wellness Tips for the Busy 0.75 Neurologist 5:00 p.m.–5:45 p.m. Speaker(s): Rochelle I. Frank, MD Yoga - Vinyasa 4:00 p.m.–4:45 p.m. Speaker(s): Jamie L. Palaganas, MD Mindfulness-based Chronic Pain 0.75 Management Wednesday, April 29 Speaker(s): Paulette M. Licorish, MD 7:00 a.m.–7:45 a.m. CME

CME

4:00 p.m.–4:45 p.m. Fireside Chat: Thriving in Medicine–What Is Your Purpose? Speaker(s): Rochelle I. Frank, MD 5:00 p.m.–5:30 p.m. Nature Meditation Speaker(s): Paulette M. Licorish, MD

Thursday, April 30 7:00 a.m.–7:45 a.m. Yoga—Vinyasa Speaker(s): Andrew James Westwood, MD 1:00 p.m.–1:45 p.m. Poetry and Neurology Workshop Speaker(s): Michael L. Wynn, DO, FAAN 2:00 p.m.–2:45 p.m. Café Talk: Mindfulness in the Practice 0.75 of Clinical Neurology Speaker(s): Paul M. Schanfield, MD CME

3:00 p.m.–3:45 p.m. What About Wellness for Residents and Fellows? Speaker(s): Aimee Aoi Sato, MD 4:00 p.m.–4:45 p.m. Fireside Chat: Self-care–The Radical Idea That YOU Are a Priority Speaker(s): Ara Schlaman Hall, MD 5:00 p.m.–5:45 p.m. Hawaiian Hula Dance Speaker(s): Lisa Helene Smith, MD

Friday, May 1 7:00 a.m.–7:45 a.m. Yoga—Vinyasa Speaker(s): Andrew James Westwood, MD

CME

8:00 a.m.–8:45 a.m. Acupuncture Demonstration– Auriculotherapy Speaker(s): Jennifer Bickel, MD, FAAN

CME

1:00 p.m.–1:45 p.m. Mindful Eating 0.75 Speaker(s): Ara Schlaman Hall, MD

5:00 p.m.–5:45 p.m. Zumba Speaker(s): Alison E. Alford, MD

Yoga—Vinyasa Speaker(s): Andrew James Westwood, MD 8:00 a.m.–8:45 a.m. Acupuncture Demonstration - 4 Gates Speaker(s): Jennifer Bickel, MD, FAAN

Talks that do not have CME will not have an icon.

CME

2:00 p.m.–2:45 p.m. Fireside Chat: Self-compassion–Learning to Ignore Your Inner Critic Speaker(s): Ara Schlaman Hall, MD

AAN.com/view/20AM 229

EXPERIENTIAL LEARNING AREAS

CME

Monday, April 27

Navigating Your Career Just starting out

Building skills throughout your career

Hitting career milestones Collaborating with colleagues

CHOOSING YOUR CAREER ROUTE Whether your current location is “just starting out,” “seasoned veteran,” or somewhere in between, the Navigating Your Career Experiential Learning Area at the AAN Annual Meeting offers programs, mentoring, and networking opportunities to help you along your path to success. Set Your Destination (Early Career)

Turn-by-turn Guidance (Mid- to Late-career)

Rerouting (Career Evolution)

Located on Level 200 Room 205A

• Why Neurology? (for Medical Students) • Too Many Fellowship Choices: How to Zero in to Find the Subspecialty of Your Choice and the Best Job for Life • What Should Applicants Look for in a Program?

• Ask Me Anything About Choosing a Career in Teleneurology • Finding Neverland: Pathways to a Successful Academic Career in Global Neurology • Pursuing a Career in Industry

• Still Kicking and Crazy After All These Years: How to Remain Relevant and Engaged in Mid- to Late-Career • How to Successfully Incorporate APPs into Your Practice • How I Tried to Retire from Neurology but Couldn’t

NAVIGATING YOUR CAREER Saturday, April 25

10:00 a.m.–10:45 a.m. Expert Witness and Medical-legal 0.75 Neurology 101: What Is It and Is It for You? Speaker(s): Julie B. Schwartzbard, MD CME

1:00 p.m.–1:45 p.m. #ilooklikeaneuroonc Speaker(s): Alyx B. Porter, MD, FAAN 2:00 p.m.–2:45 p.m. Build a Better Foundation: Making Smart Decisions Early for a Better Career Speaker(s): Jonathan Ross Galli, MD 3:00 p.m.–3:45 p.m. Case Studies in Neuropalliative 0.75 Care: How My Patients Impacted My Career Choice Speaker(s): Maisha T. Robinson, MD, MS CME

Sunday, April 26 7:00 a.m.–7:45 a.m. Making the Most of Fellowship— 0.75 Setting Yourself Up for Success and Finding Your First Job Speaker(s): Kathryn S. Nevel, MD CME

8:00 a.m.–8:45 a.m. Great Expectations: How to Utilize Strength Coaching to Expect the Best for Your Future Speaker(s): Katherine B. Peters, MD, PhD, FAAN 1:00 p.m.–1:45 p.m. So You’ve Been Sued/Named in a Medical Malpractice – Now What? Speaker(s): =Richard E. Ferguson, MD, FAAN Adam De Havenon, MD 2:00 p.m.–2:45 p.m. Still Kicking and Crazy After All These 0.75 Years: How to Remain Relevant and Engaged in Mid- to Late-career Speaker(s): Ludwig Gutmann, MD, FAAN Laurie Gutmann, MD, FAAN Heidi B. Schwarz, MD, FAAN CME

3:00 p.m.–3:45 p.m. From All Different Practice Settings: 0.75 How to Navigate Discussions with Your Department Leadership Speaker(s): Jonathan P. Hosey, MD, FAAN Brenda Banwell, MD, FAAN James C. Stevens, MD, FAAN Stefan M. Pulst, MD, FAAN CME

4:00 p.m.–4:45 p.m. A Career in General Neurology: 0.75 Knowing Everything About Everything! Speaker(s): Kirk Roberts, MD, FAAN CME

Monday, April 27 7:00 a.m.–7:45 a.m. Ask Me Anything About Choosing a 0.75 Career in Teleneurology Speaker(s): Eric Anderson, MD, PhD CME

8:00 a.m.–8:45 a.m. The Mentor-Mentee Relationship: 0.75 What Works and What Doesn’t? Speaker(s): Ralph F. Jozefowicz, MD, FAAN CME

1:00 p.m.–1:45 p.m. Pursuing a Career in Movement 0.75 Disorders Speaker(s): Stanley Fahn, MD, FAAN CME

2:00 p.m.–2:45 p.m. Clinical Practice Through the Life Cycle 0.75 Speaker(s): Richard E. Ferguson, MD, FAAN CME

3:00 p.m.–3:45 p.m. Interviewing Skills for Students and Residents—How to Get into the Program You Want Speaker(s): Ezgi Tiryaki, MD, FAAN 4:00 p.m.–4:45 p.m. Advancing Your Career with the Resident and Fellow Section of Neurology: How to Write, Review, Join the Editorial Board, and Use the RFS for Your Residency Speaker(s): John J. Millichap, MD, FAAN Roy E. Strowd, III, MD 5:00 p.m.–5:45 p.m. Pursuing an Additional Degree: Is It for Me? Speaker(s): Joseph S. Kass, MD, JD, FAAN Andrea N. Leep Hunderfund, MD Richard E. Ferguson, MD, FAAN

Tuesday, April 28 8:00 a.m.–8:45 a.m. How to Successfully Incorporate APPs 0.75 into Your Practice Speaker(s): Rebecca R. Buttaccio, PA Richard E. Ferguson, MD, FAAN CME

1:00 p.m.–1:45 p.m. The Eyes Have It: Neuro0.75 ophthalmology Is the Career for You! Speaker(s): Valerie Biousse, MD Nancy J. Newman, MD, FAAN CME

2:00 p.m.–2:45 p.m. Understanding and Negotiating a Physician Employment Contract Speaker(s): David A. Evans, MBA 3:00 p.m.–3:45 p.m. Just Enough IS Good Enough: Parenting While Paving Your Career Path Speaker(s): Jill M. Farmer, DO, MPH

Talks that do not have CME will not have an icon.

4:00 p.m.–4:45 p.m. Private Practice: Can you be Successful? Speaker(s): Brad C. Klein, MD, MBA, FAAN 5:00 p.m.–5:45 p.m. Learn Something New Every 0.75 Day—The Life of the Academic Neurohospitalist Speaker(s): Jana Wold, MD Natalie R. Weathered, MD Carl Aaron Gold, MD Catherine Elizabeth Arnold Fiebelkorn, MD CME

Wednesday, April 29 7:00 a.m.–7:45 a.m. Too Many Fellowship Choices: How 0.75 to Zero in to Find the Subspecialty of Your Choice and the Best Job for Life Speaker(s): Shilpa Chitnis, MD, PhD, FAAN, FANA CME

8:00 a.m.–8:45 a.m. Pursuing a Career in Industry Speaker(s): Brandy R. Matthews, MD, FAAN 1:00 p.m.–1:45 p.m. Much Ado About Something: 0.75 Pursuing a Career in Autoimmune Neurology Speaker(s): Jenny Linnoila, MD, PhD Amanda Lee Piquet, MD CME

2:00 p.m.–2:45 p.m. From Private Practice to Academics 0.75 Speaker(s): Sarah M. Benish, MD, FAAN CME

3:00 p.m.–3:45 p.m. Fit For Duty: Practicing Neurology in the Military Speaker(s): Mill Etienne, MD, MPH, FAAN 4:00 p.m.–4:45 p.m. How I Tried to Retire from Neurology 0.75 but Couldn’t Speaker(s): Thomas R. Swift, MD, FAAN CME

5:00 p.m.–5:45 p.m. Why Neurology? (for Medical Students) Speaker(s): Jose H. Posas, MD

Thursday, April 30 8:00 a.m.–8:45 a.m. Bed Side to Boardroom: Tales of a 0.75 Neurohospitalist Speaker(s): Derek William Stitt, MD Roland Hamilton, Jr., MD CME

1:00 p.m.–1:45 p.m. Pursuing a Career in Neurocritical Care 0.75 Speaker(s): Angela N. Hays Shapshak, MD Matthew B. Maas, MD, FAAN CME

2:00 p.m.–2:45 p.m. Get Social on Social Media— #Networking101 for Professional Development Speaker(s): Aarti Sarwal, MD, FAAN

AAN.com/view/20AM 231

EXPERIENTIAL LEARNING AREAS

9:00 a.m.–9:45 a.m. What Should Applicants Look for in a Program? Speaker(s): Adam De Havenon, MD Peter Hannon, MD

5:00 p.m.–5:45 p.m. Success in Residency? Let’s Talk About It Speaker(s): Maisha T. Robinson, MD, MS Jeremy K. Cutsforth-Gregory, MD

NAVIGATING YOUR CAREER 3:00 p.m.–3:45 p.m. Optimizing Communication in Difficult 0.75 Patient Relationships Speaker(s): Veronica E. Santini, MD, MA CME

EXPERIENTIAL LEARNING AREAS

Friday, May 1 7:00 a.m.–7:45 a.m. Finding Neverland: Pathways to a 0.75 Successful Academic Career in Global Neurology Speaker(s): Deanna Saylor, MD, MHS Omar Siddiqi, MD CME

8:00 a.m.–8:45 a.m. Taking Neurology Outside of the 0.75 Office: Turning Advocacy into a Career Game-changer Speaker(s): Kara Stavros, MD CME

1:00 p.m.–1:45 p.m. Pursuing a Career in Sports 0.75 Neurology Speaker(s): Brian W. Hainline, MD, FAAN CME

2:00 p.m.–2:45 p.m. Setting the Stage for Success: 0.75 Building Your Career by Finding Your Mentor and Mentee Match Speaker(s): Sharon Lewis, MD CME

3:00 p.m.–3:45 p.m. Discovering What Drives You...and 0.75 What Keeps You Going Speaker(s): Sara E. Hocker, MD, FAAN CME

232 2020 AAN Annual Meeting

Talks that do not have CME will not have an icon.

POLICY, PRACTICE, AND PERFORMANCE:

Staying Ahead of Change • Located on the 700 level Vote at the polling station to let the AAN know your advocacy priorities

Wear green on Tuesday to show your support of AAN advocacy

POLICY

PRACTICE • Leadership • Management • Coding & Reimbursement • EHR

Ask specific operations questions about your practice

• Advocate • Take Action • Empower

Understand E/M, EEG, and other coding updates

Maximize your technology use

Discover the power of Neurology on the Hill

PERFORMANCE • Value-based Care • Data-driven Decisions • Quality Improvement

More easily report for MIPS, and understand your alternative choices

$ Know how guidelines and quality measures improve your value

POLICY, PRACTICE, & PERFORMANCE

EXPERIENTIAL LEARNING AREAS

Saturday, April 25 2:00 p.m.–2:45 p.m. Learning Healthcare Systems (LHS): An Overview Speaker(s): Susan T. Herman, MD, FAAN Zachary Grinspan, MD 4:00 p.m.–4:45 p.m. The Daily Coding Struggle: How to Make It Work Speaker(s): Korwyn Williams, MD, PhD, FAAN 5:00 p.m.–5:45 p.m. The How and Why of eConsults in Neurology Speaker(s): Allan Ding Wu, MD, FAAN

Sunday, April 26 8:00 a.m.–8:45 a.m. Talks for Trainees: Why Should I Care About Coding? Speaker(s): Kavit Shah, MD 1:00 p.m.–1:45 p.m. Quality Improvement Innovation Awards Speaker(s): Lyell K. Jones, MD, FAAN Anup D. Patel, MD, FAAN 2:00 p.m.–2:45 p.m. What Is Value? Speaker(s): Robert M. Kropp, MD, FAAN 3:10 p.m.–3:20 p.m. BusinessBytes: Decoding Coding Speaker(s): Neil A. Busis, MD, FAAN 4:00 p.m.–4:45 p.m. The Neurologist’s Guide to the ABCs of Drug Pricing in the US Speaker(s): Nicholas Elwood Johnson, MD, FAAN Kavita Nair, PhD 5:00 p.m.–5:45 p.m. What Can I Do to Help Lower Drug Prices for My Patients? Speaker(s): Nicholas Elwood Johnson, MD, FAAN

Monday, April 27 8:00 a.m.–8:45 p.m. Talks for Trainees: Personal Finances for Residents and Fellows Speaker(s): Sotirios Tony Keros, MD 12:00 p.m.–12:45 p.m. Different Practice Models for Success Speaker(s): Andrew M. Wilson, MD, MBA 1:00 p.m.–1:45 p.m. ICD-11: Global Impact on the Future of Neurology for the Next Generation Speaker(s): Hiral Shah, MD Raad A. Shakir, MD, FRCP, FAAN

234 2020 AAN Annual Meeting

2:00 p.m.–2:45 p.m. The Economics of APPs Speaker(s): Ashlea Lucas, PA Neil A. Busis, MD, FAAN 3:10 p.m.–3:20 p.m. BusinesBytes: #AANAdvocacy Speaker(s): Kara Stavros, MD 4:00 p.m.–4:45 p.m. What Your Practice Administrator Wants You to Know Speaker(s): Melissa Yu, MD, FAAN Leeann Garms 5:00 p.m.–5:45 p.m. Using Cybersecurity in Your Practice Speaker(s): Leeann Garms

Tuesday, April 28 8:00 a.m.–8:45 a.m. Talks for Trainees: How to Negotiate Your Employment Contract Speaker(s): Eva K. Ritzl, MD, FAAN 12:00 p.m.–12:45 p.m. Onboarding Your APPs: Prepare for Success Speaker(s): Calli Leighann Cook, DNP, APRN, FNP-C 1:00 p.m.–1:45 p.m. How to Successfully Publish Quality Improvement Projects Speaker(s): Anup D. Patel, MD, FAAN

2:00 p.m.–2:45 p.m. How Does Advocacy Help Build My Practice? Speaker(s): Kara Stavros, MD Vincent LaBarbera, MD 3:10 p.m.–3:20 p.m. BusinessBytes: Why Should I Be Using Data from the Neurology Compensation and Productivity Survey in My Practice? Speaker(s): David A. Evans, MBA 4:00 p.m.–5:30 p.m. EHR Pain Points: A Conversation with Representatives from Epic and Cerner Speaker(s): Allison L. Weathers, MD, FAAN

Thursday, April 30 8:00 a.m.–8:45 p.m. Talks for Trainees: Thinking About Practice Models in My Future Career Speaker(s): Daniel Joseph Ackerman, MD 12:00 p.m.–12:45 p.m. Using Axon Registry to Ease Your Datacollection Burden Speaker(s): Laurice T. Yang, MD, MHA 2:00 p.m.–2:45 p.m. FMLA, Disability, Legal Questions, and Other Paperwork Speaker(s): Joseph V. Fritz, PhD

2:00 p.m.–2:45 p.m. Making the Most of Your Career as an APP Speaker(s): Calli Leighann Cook, DNP, APRN, FNP-C 5:00 p.m.–5:45 p.m. How Can I Prepare for the E/M Changes that are Coming in 2021? Speaker(s): Neil A. Busis, MD, FAAN

Wednesday, April 29 8:00 a.m.–8:45 a.m. Talks for Trainees: Understanding Patients as Consumers Speaker(s): Allison L. Weathers, MD, FAAN 12:00 p.m.–12:45 p.m. Meet Your Practice Support Network: Ask Us Anything About Managing Your Practice Speaker(s): Barry K. Vaught, MD, FAAN Gurdesh Bedi, MD, FAAN Michael E. Markowski, DO, FAAN 1:00 p.m.–1:45 p.m. Preparing to Use Artificial Intelligence in Your Practice Speaker(s): Mark Mintz, MD, FAAN

Talks that do not have CME will not have an icon.

Statistics: Sample Size NIH Grant Review Process

Traditional Research

Tips to Sail Through the IRB

Are You My Mentor?

K Awards and Training Programs Neuroscience of Bias

RESEARCH

Scientific Sessions and Awards

National Institutes of Health Day Tuesday, April 28, 2020

EXPERIENTIAL LEARNING AREA

Join us at the intersection of cutting-edge science, knowledge sharing, and career recognition. The Research Experiential Learning Area brings together over 30 presentations, four scientific sessions, recognition of award and scholarship recipients, networking, and more.

Located on Level 300 Exhibit Hall C

RESEARCH Saturday, April 25 1:00 p.m.–1:45 p.m. So Your Paper Didn’t Get Accepted, 0.75 Now What? Speaker(s): Roy E. Strowd, III, MD

EXPERIENTIAL LEARNING AREAS

CME

2:00 p.m.–2:45 p.m. Peer Review of Scientific Articles – Tips on How to Respond to the Dreaded Reviewer #2 Speaker(s): Brian D. Berman, MD, MS, FAAN Scott Norris, MD 3:00 p.m.–3:45 p.m. From Disease Detectives to Disease Preventers: Neurology and Neuroscience Opportunities at CDC Speaker(s): James J. Sejvar, MD Shawna Mercer, MSc, PhD D. Kevin Horton, MSPH Christine Esper, MD

Sunday, April 26 7:00 a.m.–7:45 a.m. Much More Than Traumatic Brain Injury: Identifying Funding Opportunities from the Department of Defense Speaker(s): Ana-Claire L. Meyer, MD 8:00 a.m.–8:45 a.m. Are You My Mentor? How to Select a Good Mentor for Your Research Career Speaker(s): Deborah Hall, MD, PhD, FAAN 12:00 p.m.–12:45 p.m. Combating the Scientific Irreproducibility Crisis: Using Principles of Reproducible Scientific Design to Critically Evaluate Scientific Papers for Best-informed Patient Care Speaker(s): Bibiana Bielekova, MD, FAAN 1:00 p.m.–1:45 p.m. Clinical Genetic Testing for 0.75 Parkinson’s: Are We There Yet? Speaker(s): Tanya Simuni, MD, FAAN Tatiana Foroud, PhD Sohini Chowdhury CME

2:00 p.m.–2:45 p.m. How to Write and Publish Neurology Research Speaker(s): Mark Hallett, MD, FAAN Francois Boller, MD, PhD, FAAN

Monday, April 27 7:00 a.m.–7:45 a.m. Social Networking Sites for Researchers and Using Social Media Platforms Speaker(s): Brian D. Berman, MD, MS, FAAN Pearce Korb, MD, FAAN 8:00 a.m.–8:45 a.m. Mistakes, Mentoring, and Miracles: Transitioning from a Career Development Award to Independence Speaker(s): LynnMarie Trotti, MD

236 2020 AAN Annual Meeting

12:00 p.m.–12:45 p.m. TRANSCENDS (Training in Research for Academic Neurologists to Sustain Careers and Enhance the Numbers of Diverse Scholars) Program Overview Speaker(s): Bruce I. Ovbiagele, MD, MSc, FAAN 1:00 p.m.–1:45 p.m. Are You Including Underrepresented Populations in Your Clinical Research? Speaker(s): Temitayo Oyegbile, MD, PhD 2:00 p.m.–2:45 p.m. Grantwriting 101: Getting Started Speaker(s): Logan D. Schneider, MD 5:00 p.m.–5:45 p.m. Applying for AAN Research Fellowships 101 Speaker(s): Paul M. George, MD, PhD, MSE

Tuesday, April 28 8:00 a.m.–8:45 a.m. Welcome to NIH Day/Overview of NIH Funding Speaker(s): Walter J. Koroshetz, MD, FAAN 1:00 p.m.–1:30 p.m. Learn About Opportunities to Work with the NIH Intramural Program Speaker(s): Avindra Nath, MD, MBBS, FAAN 1:30 p.m.–2:00 p.m. NIH Grant Review Process & Tips for Writing a Successful Grant Application Speaker(s): Shanta Rajaram, PhD 2:00 p.m.–2:45 p.m. K Awards and Training Programs – Planning for a Career as an NIH Investigator Speaker(s): Adam L. Hartman, MD, FAAN 2:45 p.m.–3:15 p.m. NIH Funding and Professional Development Opportunities for Diverse Researchers Speaker(s): Richard T. Benson, MD, PhD 3:15 p.m.–4:00 p.m. Clinical Trials and Networks – NeuroNEXT, StrokeNET, SIREN, Alzheimer’s Clinical Trials Consortium and ADRD Opportunities Speaker(s): Clinton B. Wright, MD, FAAN 4:00 p.m.–4:00 p.m. Translational Research Speaker(s): Amir Tamiz 4:30 p.m.–5:15 p.m. Funding Opportunities in Pain Research and the HEAL Initiative Speaker(s): Michael Oshinsky, PhD Linda L. Porter, PhD

8:00 a.m.–8:45 a.m. How to Successfully Publish Quality Improvement Projects Speaker(s): Anup D. Patel, MD, FAAN 1:00 p.m.–1:45 p.m. How to Put Together an Effective Research Presentation Speaker(s): Enrique C. Leira, MD, MS, FAAN 2:00 p.m.–2:45 p.m. Ethical Issues in Clinical Research Speaker(s): Benjamin David Tolchin, MD Robin A. Conwit, MD, FAAN 5:00 p.m.–5:45 p.m. ”But We Always Use 20 Patients”—How NOT to Determine Sample Size Speaker(s): William Joseph Meurer, MD

Thursday, April 30 7:00 a.m.–7:45 a.m. Neuroscience of Bias in Research 0.75 Speaker(s): Jose H. Posas, MD CME

8:00 a.m.–8:45 a.m. Launching a Successful Research Program and Tips for Early-career Neurologists: Funding Clinically Oriented/ Translational Research Before R01 Speaker(s): Aasef Shaikh, MD 1:00 p.m.–1:45 p.m. Small Group Mock Review Sessions Speaker(s): Deborah Hall, MD, PhD, FAAN Robert C. Griggs, MD, FAAN Amy R. Brooks-Kayal, MD, FAAN Allan I. Levey, MD, PhD Temitayo Oyegbile, MD, PhD 2:00 p.m.–2:45 p.m. Residency Case Reports: How to Make a Small Amount of Effort Go a Long Way Speaker(s): Courtney Takahashi, MD 5:00 p.m.–5:45 p.m. Consejos para dar una charla científica efectiva (How to Prepare and Present Abstracts at the AAN Annual Meeting) Speaker(s): Enrique C. Leira, MD, MS, FAAN

Friday, May 1 8:00 a.m.–8:45 a.m. Statistically Speaking: How to Engage in Productive Collaborations with Statistical Colleagues Speaker(s): Christopher Coffey, PhD, FAAN

Wednesday, April 29 7:00 a.m.–7:45 a.m. K Is for Career Development Speaker(s): Holly E. Hinson, MD, MCR, FAAN

Talks that do not have CME will not have an icon.

2020 PROGRAMS BY TOPIC Aging, Dementia, Cognitive, and Behavioral Neurology

Saturday, April 25 7:00 a.m.–9:00 a.m.

Neurocognitive Assessment for Neurologists

9:30 a.m.–11:30 a.m.

C13 C15 C22

7:00 a.m.–9:00 a.m.

8:00 a.m.–9:00 a.m.

Poster Session 5

Aging and Dementia: Basic Science, Biomarkers, and Genetics 2 P5.8-001 –P5.8-011. . . . . . . . . . . . . . . . 145

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session . . . . . . . . . . . . . . . 64

Delivering Personalized Care to Patients 12:00 p.m.–1:00 p.m. at Risk for Alzheimer’s Dementia. . 227 P6 Poster Session 6

Aging and Dementia: Basic Science, Biomarkers, and Genetics 3 P6.8-001 –P6.8-007. . . . . . . . . . . . . . . 150 Behavioral and Cognitive Neurology: Other 1 P6.8-008 –P6.8-011 . . . . . . . . . . . . . . . 151

12:00 p.m.–1:00 p.m.

Poster Session 1

Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 1 P1.8-001 –P1.8-009. . . . . . . . . . . . . . . . 121

1:30 p.m.–3:30 p.m.

C31

Behavioral Neurology 2: Memory and Attention

4:15 p.m.–5:30 p.m.

Hot Topics Plenary Session . . . . 62

Sunday, April 26 7:00 a.m.–9:00 a.m.

C42

Neuroimaging Biomarkers Across the Dementia Spectrum

8:00 a.m.–9:00 a.m.

Poster Session 2

Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 2 P2.8-001 –P2.8-010 . . . . . . . . . . . . . . . 127

12:00 p.m.–1:00 p.m.

Poster Session 3

Aging and Dementia: Alzheimer’s Disease: Clinical and Imaging Correlates 3 P3.8-001 –P3.8-010 . . . . . . . . . . . . . . . 133

1:00 p.m.–3:00 p.m.

C98 S15

C114 Higher Cortical Visual Disorders: Casebased Review C123 Estudios de cohorte de latinoamericanos: enfermedad de Alzheimer, enfermedad de Huntington y derrame cerebral (Latin American Cohort Studies: Alzheimer’s, Huntington’s, and Stroke) S23 Aging and Dementia: Biomarkers and Clinical Trials . . . . . . . . . . . . . . . . 93 5:30 p.m.–6:30 p.m.

3:30 p.m.–5:30 p.m.

C67 C75

Frontotemporal Dementias Cognitive Behavioral Sleep Medicine: A Primer to a Discipline

5:30 p.m.–6:30 p.m.

Poster Session 4

Aging and Dementia: Basic Science, Biomarkers, and Genetics 1 P4.8-001 –P4.8-011. . . . . . . . . . . . . . . . 139

5:30 p.m.–6:30 p.m.

P10

Tuesday, April 28 7:00 a.m.–9:00 a.m.

7:00 a.m.–9:00 a.m.

C173 Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders 8:00 a.m.–9:00 a.m.

P11

Poster Session 8

Poster Session 9

Aging and Dementia: Retina and Nonalzheimer Dementia 1 P9.8-001 –P9.8-010 . . . . . . . . . . . . . . . 168

Aging and Dementia: Retina and Nonalzheimer Dementia 3 P11.8-001 –P11.8-010. . . . . . . . . . . . . . 179

Poster Session 12

Behavioral and Cognitive Neurology: Other 2 P12.8-001 –P12.8-009 . . . . . . . . . . . . . 185

1:00 p.m.–3:00 p.m.

C189 Assessment of Rapidly Progressive Dementias 1: Prion and Non-prion Neurodegenerative Diseases 3:30 p.m.–5:30 p.m.

C207 Assessment of Rapidly Progressive Dementias 2: Infections and Autoimmune Mediated Conditions 5:30 p.m.–6:30 p.m.

P13

Poster Session 13

Behavioral and Cognitive Neurology: Nonneurodegenerative Disorders 1 P13.8-001 –P13.8-011. . . . . . . . . . . . . . 191

Thursday, April 30 8:00 a.m.–9:00 a.m.

P14

Poster Session 14

Behavioral and Cognitive Neurology: Nonneurodegenerative Disorders 2 P14.8-001 –P14.8-011. . . . . . . . . . . . . . 197

12:00 p.m.–1:00 p.m.

Behavioral and Cognitive Neurology: Aging P15 and Neurodegenerative Disease 2 P8.8-001 –P8.8-009. . . . . . . . . . . . . . . 162

12:00 p.m.–1:00 p.m.

Poster Session 11

12:00 p.m.–1:00 p.m.

P12

C135 Update in Aging and Dementia 8:00 a.m.–9:00 a.m.

Aging and Dementia: Retina and Nonalzheimer Dementia 2 P10.8-001 –P10.8-010. . . . . . . . . . . . . . 174

Wednesday, April 29

Poster Session 7

Behavioral and Cognitive Neurology: Aging and Neurodegenerative Disease 1 P7.8-001 –P7.8-011. . . . . . . . . . . . . . . . 156

Poster Session 10

Poster Session 15

Aging and Dementia: Neuropsychology and Clinical Trials 1 P15.8-006 –P15.8-012. . . . . . . . . . . . . . 203 Behavioral and Cognitive Neurology: Nonneurodegenerative Disorders 3 P15.8-001 –P15.8-005 . . . . . . . . . . . . . 203

AAN.com/view/20AM 237

Aging/Dementia/Cognitive

Neurology Update 1: Movement Disorders, Behavioral Neurology, and Neuromuscular Diseases Aging and Dementia: Risk Factors and Genetics . . . . . . . . . . . . . . . . . . . 82

Chronic Traumatic Encephalopathy: Update Behavioral and Cognitive Neurology . . . . . . . . . . . . . . . . . . . . . . 89

3:30 p.m.–5:30 p.m.

1:00 p.m.–3:00 p.m.

C61

C143 Young Onset and Atypical Alzheimer’s Dementia

Clinicopathological Correlation Session 3:30 p.m.–5:30 p.m. in Dementia C159 Behavioral Management of 8:00 a.m.–8:45 a.m. Dementia Neurological Disease Prevention S33 Aging and Dementia: Non-Alzheimer with Food . . . . . . . . . . . . . . . . . . . . . 229 Dementia . . . . . . . . . . . . . . . . . . . . . . 99

C90

12:00 p.m.–12:30 p.m.

1:00 p.m.–3:00 p.m.

PROGRAMS BY TOPIC

Behavioral Neurology 1: Network Anatomy of Behavior and Language Severe TBI: From ICU to Rehabilitation Actualización en desordenes cognitivos y epilepsia (Update in Cognitive Disorders and Epilepsy)

Monday, April 27

2020 PROGRAMS BY TOPIC 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m.

C236 Mild Cognitive Impairment: Implications for Clinicians

C55

3:30 p.m.–5:30 p.m.

C244 Cognitive Impairment Due to Alzheimer’s Disease: Using Old Skills and New Tools for Diagnosis and Treatment

3:30 p.m.–5:30 p.m.

C69

5:30 p.m.–6:30 p.m.

PROGRAMS BY TOPIC

P16

Poster Session 16

Aging and Dementia: Neuropsychology and Clinical Trials 2 P16.8-001 –P16.8-012. . . . . . . . . . . . . . 209

Friday, May 1

8:00 a.m.–9:00 a.m.

11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation

Aging and Dementia P17.8-001 - P17.8.004. . . . . . . . . . . . . . 215

Saturday, April 25 Child Neurology: Neuromuscular/ Autoimmune Neurology

8:00 a.m.–9:00 a.m.

C12

Education Blitz: Evolution of Autoimmune Neurology

Poster Session 1

Autoimmune Neurology 1 P1.2-001 –P1.2-011. . . . . . . . . . . . . . . . 119

Sunday, April 26 8:00 a.m.–9:00 a.m.

Poster Session 2

Autoimmune Neurology 2 P2.2-001 –P2.2-011. . . . . . . . . . . . . . . . 125

12:00 p.m.–1:00 p.m.

Poster Session 3

Autoimmune Neurology 3 P3.2-001 –P3.2-011. . . . . . . . . . . . . . . . 131

238 2020 AAN Annual Meeting

Autoimmune Neurology 4 P4.2-001 –P4.2-003. . . . . . . . . . . . . . . . 137 Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 1 P4.2-004 –P4.2-012. . . . . . . . . . . . . . . . 137

8:00 a.m.–9:00 a.m.

P11

Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 2 P5.2-001 –P5.2-012. . . . . . . . . . . . . . . . 142

Poster Session 6

Autoimmune Neurology 5 P6.2-005 –P6.2-012. . . . . . . . . . . . . . . . 148 Autoimmune Neurology: Inflammatory Neuropathies, Myasthenia Gravis, and Treatment 3 P6.2-001 –P6.2-004 . . . . . . . . . . . . . . . 148

Autoimmune Neurological Disorders: Diagnosis, Biomarkers, and Epidemiology . . . . . . . . . . . . . . . . . . . 89

Tuesday, April 28 9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session . . . . . . . . . . . . . . . . . . . . . . . 65 12:00 p.m.–1:00 p.m.

Poster Session 9

Autoimmune Neurology 6 P9.2-001 –P9.2-012. . . . . . . . . . . . . . . . 166

3:30 p.m.–5:30 p.m.

S34

Clinical Trials and Therapeutics in Autoimmune Neurology . . . . . . . . . 100

P12

Poster Session 10

Autoimmune Neurology 7 P10.2-001 –P10.2-005. . . . . . . . . . . . . . 172 Autoimmune Neurology: Encephalitis 1 P10.2-006 –P10.2-011. . . . . . . . . . . . . . 172

Autoimmune Neurology: Encephalitis 2 P11.2-001 –P11.2-012. . . . . . . . . . . . . . 177

Poster Session 12

Autoimmune Neurology: Encephalitis 3 P12.2-001 –P12.2-007. . . . . . . . . . . . . . 183

1:00 p.m.–1:45 p.m.

Much Ado About Something: Pursuing a Career in Autoimmune Neurology . . . . . . . . . . . . . . . . . . . . . 231 1:00 p.m.–3:00 p.m.

S39

Autoimmune and Paraneoplastic Neurological Disorders: Clinical Characteristics and Diagnosis . . . . 103

5:30 p.m.–6:30 p.m.

P13

Poster Session 13

Autoimmune Neurology: NMOSD and MOG 1 P13.2-001 –P13.2-011. . . . . . . . . . . . . . 189

Thursday, April 30 8:00 a.m.–9:00 a.m.

P14

Poster Session 14

Autoimmune Neurology: NMOSD and MOG 2 P14.2-001 –P14.2-013. . . . . . . . . . . . . . 195

12:00 p.m.–1:00 p.m.

P15

Poster Session 15

Autoimmune Neurology 8 P15.2-001 –P15.2-012. . . . . . . . . . . . . . 201

1:00 p.m.–3:00 p.m.

C232 Autoimmune Neurology 1 Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes of the CNS and PNS 3:30 p.m.–5:30 p.m.

C247 Autoimmune Neurology 2 Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience 5:30 p.m.–6:30 p.m.

P16

5:30 p.m.–6:30 p.m.

P10

Poster Session 11

12:00 p.m.–1:00 p.m.

Poster Session 5

1:00 p.m.–3:00 p.m.

S16

C174 Clinical Pearls in Autoimmune Neurology: Real-world Cases

12:00 p.m.–1:00 p.m.

C270 Lewy Body Dementias

7:00 a.m.–9:00 a.m.

8:00 a.m.–9:00 a.m.

1:00 p.m.–3:00 p.m.

Autoimmune Neurology

Wednesday, April 29

Poster Session 4

Monday, April 27

C267 Education Blitz: Normal Pressure Hydrocephalus

12:00 p.m.–1:00 p.m.

Autoimmune Neurology

C253 Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration

C258 Vascular Cognitive Impairment and Dementia: Current Status and Future

Neuro-rheumatology: Neurologic Manifestations of Systemic Inflammatory and Autoimmune Disease 2

5:30 p.m.–6:30 p.m.

6:30 p.m.–9:30 p.m.

7:00 a.m.–9:00 a.m.

Neuro-rheumatology: Neurologic Manifestations of Systemic Inflammatory and Autoimmune Disease 1

Poster Session 16

Autoimmune Neurology 9 P16.2-001 –P16.2-013. . . . . . . . . . . . . . 207

Friday, May 1 11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation

Autoimmune Neurology 1 P17.2-005 - P17.2-013. . . . . . . . . . . . . . 212 Autoimmune Neurology 2 P17.3-001 - P17.03-013. . . . . . . . . . . . . 212

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area Stroke Epidemiology, Disparity, and Quality 1:00 p.m.–3:00 p.m. Improvement 2 C141 Cerebrovascular Disease 1: Prevention P4.9-001 –P4.9-015. . . . . . . . . . . . . . . . 139 S26 Cerebrovascular Disease: Systems

Cerebrovascular Disease and Interventional Neurology

Saturday, April 25

Monday, April 27

7:00 a.m.–9:00 a.m.

Update on Medical Management of Stroke

12:00 p.m.–1:00 p.m.

C88

8:00 a.m.–8:45 a.m.

Neurological Disease Prevention with Food . . . . . . . . . . . . . . . . . . . . . 229

Poster Session 1

Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 1 P1.9-001 –P1.9-021. . . . . . . . . . . . . . . . 122

7:00 a.m.–9:00 a.m.

C39 C40

Endovascular Management of Ischemic and Hemorrhagic Stroke Maximizing Quality of Life in Stroke, ALS, Parkinson’s Disease, and Dementia: A Palliative Approach

8:00 a.m.–9:00 a.m.

Poster Session 2

Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 2 P2.9-001 –P2.9-020. . . . . . . . . . . . . . . 128

9:15 a.m.–12:00 p.m.

Presidential Plenary Session . . . 63 12:00 p.m.–1:00 p.m.

Poster Session 3

Cerebrovascular Disease: Biomarkers, Animal Models, Genetics, and Imaging 3 P3.9-001 –P3.9-004. . . . . . . . . . . . . . . 133 Stroke Epidemiology, Disparity, and Quality Improvement 1 P3.9-005 –P3.9-021 . . . . . . . . . . . . . . . 133

1:00 p.m.–1:45 p.m.

The Prevention of Stroke: No Pill’s Gonna Cure This Ill . . . . . . . . . . . . . . 229 1:00 p.m.–3:00 p.m.

C51 C52

Child Neurology: A Case-based Approach Controversies in Stroke Treatment and Prevention

Cerebrovascular Disease: Intracerebral Hemorrhage . . . . . . . . . . . . . . . . . . . . 85

5:30 p.m.–6:30 p.m.

Poster Session 4

Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 1 P4.9-016 –P4.9-021. . . . . . . . . . . . . . . . 139

5:30 p.m.–6:30 p.m.

P10

Poster Session 5

Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 2 P5.9-001 –P5.9-021 . . . . . . . . . . . . . . . 145

12:00 p.m.–1:00 p.m.

Poster Session 6

Cerebrovascular Disease: In-patient Management, Secondary Prevention, and Heart Brain Connection 3 P6.9-001 –P6.9-020. . . . . . . . . . . . . . . 151

1:00 p.m.–3:00 p.m.

C104 Neurology Update 3: Stroke, Epilepsy, and Sleep 3:30 p.m.–5:30 p.m.

Poster Session 10

Systemic Disease and Stroke, Unusual Stroke Etiologies, and Cerebral Venous Sinus Thrombosis 1 P10.9-001 –P10.9-021. . . . . . . . . . . . . .174

Wednesday, April 29 7:00 a.m.–9:00 a.m.

C179 Current Management of Incidental and Asymptomatic Cerebrovascular Lesions 8:00 a.m.–9:00 a.m.

P11

Poster Session 11

Systemic Disease and Stroke, Unusual Stroke Etiologies, and Cerebral Venous Sinus Thrombosis 2 P11.9-001 –P11.9-021. . . . . . . . . . . . . . 180

12:00 p.m.–1:00 p.m.

C112 Neurologic Intensive Care 2: Vascular P12 Poster Session 12 Disease Systemic Disease and Stroke, Unusual C123 Estudios de cohorte de Stroke Etiologies, and Cerebral Venous latinoamericanos: enfermedad de Sinus Thrombosis 3 P12.9-001 –P12.9-010. . . . . . . . . . . . . . 185 Alzheimer, enfermedad de Huntington Cerebrovascular Disease: Intracerebral y derrame cerebral (Latin American Hemorrhage, SAH, Aneurysms, and Cohort Studies: Alzheimer’s, Vascular Malformations 1 Huntington’s, and Stroke) P12.9-011 –P12.9-021. . . . . . . . . . . . . . 186 Cerebrovascular Disease: Large Vessel S20 Occlusions and Thrombectomy . . . . . 92 1:00 p.m.–3:00 p.m. 5:30 p.m.–6:30 p.m. C185 Cerebrovascular Disease 3: Telestroke C194 Therapy in Neurology 3: Stroke and Poster Session 7 P7 Headache Cerebrovascular Disease: Telestroke, Prehospital, and Emergent Stroke Evaluation S37 Stroke Epidemiology: Risk and Treatment 1 Factors, Incidence, and Unique P7.9-001 –P7.9-021. . . . . . . . . . . . . . . . 156 Populations . . . . . . . . . . . . . . . . . . . . 102

Tuesday, April 28

3:30 p.m.–5:30 p.m.

C201 Sleep for the Practicing Neurologist 2: Disordered Sleep in Common Poster Session 8 P8 Neurologic Diseases Cerebrovascular Disease: Telestroke, Pre- C203 Cerebrovascular Disease 4: Update hospital, and Emergent Stroke Evaluation on Neuroimaging Modalities and and Treatment 2 Endovascular Therapies for Acute P8.9-001 –P8.9-020. . . . . . . . . . . . . . . 162 Ischemic Stroke 9:15 a.m.–11:30 a.m. S43 Stroke Recovery and Outcomes . . . 105 Clinical Trials Plenary 5:30 p.m.–6:30 p.m. Session . . . . . . . . . . . . . . . . . . . . . . . 65 P13 Poster Session 13 8:00 a.m.–9:00 a.m.

12:00 p.m.–1:00 p.m.

Poster Session 9

Cerebrovascular Disease: Telestroke, Prehospital, and Emergent Stroke Evaluation and Treatment 3 P9.9-001 –P9.9-021 . . . . . . . . . . . . . . . 169

Cerebrovascular Disease: Intracerebral Hemorrhage, SAH, Aneurysms, and Vascular Malformations 2 P13.9-001 –P13.9-021. . . . . . . . . . . . . 191

AAN.com/view/20AM 239

Cerebrovascular Disease

3:30 p.m.–5:30 p.m.

C157 Cerebrovascular Disease 2: Update on Guidance-based Diagnosis and Management of Hemorrhagic Stroke

PROGRAMS BY TOPIC

Case Studies: Challenging Acute Ischemic Stroke Cases

Sunday, April 26

3:30 p.m.–5:30 p.m.

8:00 a.m.–9:00 a.m.

1:30 p.m.–3:30 p.m.

C26

Life After Stroke

of Stroke Care . . . . . . . . . . . . . . . . . . 95

2020 PROGRAMS BY TOPIC Thursday, April 30

Sunday, April 26

8:00 a.m.–9:00 a.m.

P14

Poster Session 14

Cerebrovascular Disease: Intracerebral Hemorrhage, SAH, Aneurysms, and Vascular Malformations 3 P14.9-001 –P14.9-007 . . . . . . . . . . . . . 198 Stroke Prevention, Risk Factors, Complications, and Recovery 1 P14.9-008 –P14.9-021 . . . . . . . . . . . . . 198

12:00 p.m.–1:00 p.m.

PROGRAMS BY TOPIC

P15

Poster Session 15

Stroke Prevention, Risk Factors, Complications, and Recovery 2 P15.9-001 –P15.9-018. . . . . . . . . . . . . . 203

1:00 p.m.–3:00 p.m.

C228 Stroke in the Young Adult C237 Continuum® Test Your Knowledge: A Multiple-choice Question Review 1 3:30 p.m.–5:30 p.m.

C242 Child Neurology: Stroke S53 Stroke Prevention . . . . . . . . . . . . . . 111 P16

Friday, May 1 11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation

Cerebrovascular Disease and Interventional Neurology 1 P17.8-006 - P17.8-012. . . . . . . . . . . . . . 215 Cerebrovascular Disease and Interventional Neurology 2 P17.9-001 - P17.9-021. . . . . . . . . . . . . . 215

1:00 p.m.–3:00 p.m.

C51

C68 IS1

Monday, April 27

S38

C80

5:30 p.m.–6:30 p.m.

P13

Child Neurology: Genetic and Metabolic Testing in Pediatric Epilepsy Poster Session 5

Child Neurology and Developmental Neurology: Developmental Disabilities and Movement Disorders 1 P5.11-001 –P5.11-015 . . . . . . . . . . . . . . 146

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session . . . . . . . . . . . . . . . 64 1:00 p.m.–3:00 p.m.

C100 Treatment of Pediatric Multiple Sclerosis in the Current Era

Cerebrovascular Imaging and Biomarkers . . . . . . . . . . . . . . . . . . . . 114 Neurology Update 7: Stroke

C216 Integrating Sleep Medicine Concepts into Your Child Neurology Practice 8:00 a.m.–9:00 a.m.

C224 P14

Poster Session 8

Saturday, April 25 7:00 a.m.–9:00 a.m.

Child Neurology: Neuromuscular/ Autoimmune Neurology

9:30 a.m.–11:30 a.m.

C19

Neurogenetics: Diagnostic Dilemmas and Therapeutic Implications

1:30 p.m.–3:30 p.m.

C28

Child Neurology: Metabolic

240 2020 AAN Annual Meeting

Child Neurology and Developmental Neurology: Neurogenetics: Translating Knowledge to Therapy . . . . . . . . . . . 96

3:30 p.m.–5:30 p.m.

C156

Pediatric Neuro-oncology Update: Advances in Cures and Long-term Survivorship

Wednesday, April 29 7:00 a.m.–9:00 a.m.

C171 Child Neurology: Headache 9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session . . . . . . . . . . . . . . . 66

Education Blitz: Neonatal Neurology Update Poster Session 14 Child Neurology and Developmental Neurology: Neurogenetics 2 P14.11-001 –P14.11-008. . . . . . . . . . . . 199 Child Neurology and Developmental Neurology: Seizures and Epilepsy 1 P14.11-009 –P14.11-014 . . . . . . . . . . . . 199

12:00 p.m.–1:00 p.m.

P15

1:00 p.m.–3:00 p.m.

S27

Child Neurology and Developmental Neurology: Brain Injury: HIE, Stroke, Trauma, and Inflammation 2 P13.11-001 –P13.11-006. . . . . . . . . . . . 192 Child Neurology and Developmental Neurology: Neurogenetics 1 P13.11-007 –P13.11-015 . . . . . . . . . . . . 192

7:00 a.m.–9:00 a.m.

8:00 a.m.–9:00 a.m. Child Neurology and Developmental Neurology: Developmental Disabilities and Movement Disorders 2 P8.11-001 –P8.11-006. . . . . . . . . . . . . . 164 Child Neurology and Developmental Neurology: Neuromuscular Disease 1 P8.11-007 –P8.11-015. . . . . . . . . . . . . . 164

Poster Session 13

Thursday, April 30

Tuesday, April 28 P8

Child Neurology and Developmental Neurology: Acquired Brain Injury: Brain-Behavior Relationships . . . . . 103

C202 Autism Spectrum Disorders: What We Know and Where We Are Going

8:00 a.m.–9:00 a.m.

Child Neurology and Developmental Neurology: Brain Injury: HIE, Stroke, Trauma, and Inflammation 1 P12.11-001 –P12.11-015 . . . . . . . . . . . . 186

3:30 p.m.–5:30 p.m.

7:00 a.m.–9:00 a.m.

3:30 p.m.–4:30 p.m.

C274

Clinical EEG: Neonatal and Pediatric Invited Science: Child Neurology . . . . . . . . . . . . . . . . . . . . . . 76

Poster Session 12

1:00 p.m.–3:00 p.m.

Child Neurology: A Case-based Approach

3:30 p.m.–5:30 p.m.

1:00 p.m.–3:00 p.m.

S60

Education Blitz: Child Neurology: Concussion Presidential Plenary Session . . . 63

Poster Session 16

Stroke Prevention, Risk Factors, Complications, and Recovery 3 P16.9-001 –P16.9-018. . . . . . . . . . . . . . 209

P12

9:15 a.m.–12:00 p.m.

5:30 p.m.–6:30 p.m.

Child Neurology and Developmental Neurology

Child Neurology

C48

12:00 p.m.–1:00 p.m.

Poster Session 15

Child Neurology and Developmental Neurology: Neurogenetics 3 P15.11-001 –P15.11-003. . . . . . . . . . . . 204 Child Neurology and Developmental Neurology: Neuromuscular Disease 2 P15.11-004 –P15.11-015 . . . . . . . . . . . . 205

1:00 p.m.–3:00 p.m.

C228 Stroke in the Young Adult N5 Neuroscience in the Clinic: Testing for Common Neurodegenerative Disorders . . . . . . . . . . . . . . . . . . . . . . 74 3:30 p.m.–5:30 p.m.

C242 Child Neurology: Stroke 5:30 p.m.–6:30 p.m.

P16

Poster Session 16

Child Neurology and Developmental Neurology: Seizures and Epilepsy 2 P16.11-001 –P16.11-015 . . . . . . . . . . . . 210

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area

Friday, May 1 7:00 a.m.–9:00 a.m.

5:30 p.m.–6:30 p.m.

C260 Pediatric Neuro-ophthalmology Update 11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation Child Neurology and Developmental Neurology P17.11-001 - P17.11-006. . . . . . . . . . . . . 216

Epilepsy/Clinical Neurophysiology (EEG) 7:00 a.m.–9:00 a.m.

Video EEG: Name That Spell

C22

Acute and Chronic Clinical Epilepsy Update Explained in Six Cases Actualización en desordenes cognitivos y epilepsia (Update in Cognitive Disorders and Epilepsy)

12:00 p.m.–4:00 p.m.

C24

7:00 a.m.–9:00 a.m.

C43

Neurological Disease Prevention with Food . . . . . . . . . . . . . . . . . . . . . 229

Poster Session 2

Epilepsy/Clinical Neurophysiology (EEG): Surgery and Co-morbidities 2 P2.4-001 –P2.4-011 . . . . . . . . . . . . . . . 126

12:00 p.m.–1:00 p.m.

Poster Session 3

Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 1 P3.4-001 –P3.4-012 . . . . . . . . . . . . . . . 131

3:30 p.m.–5:30 p.m.

C68

Clinical EEG: Neonatal and Pediatric

Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 5 P8.4-001 –P8.4-004. . . . . . . . . . . . . . . 161 Epilepsy/Clinical Neurophysiology: Antiseizure Medications 1 P8.4-005 –P8.4-011 . . . . . . . . . . . . . . . 161

Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 2 P5.4-006 –P5.4-012 . . . . . . . . . . . . . . . 143 Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 3 P5.4-001 –P5.4-005. . . . . . . . . . . . . . . 143

Poster Session 6

Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 3 P6.4-001 –P6.4-012 . . . . . . . . . . . . . . . 149

12:30 p.m.–1:00 p.m.

Poster Session 9

Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 1 P9.4-001 –P9.4-009. . . . . . . . . . . . . . . 167

1:00 p.m.–3:00 p.m.

S25

Epilepsy/Clinical Neurophysiology (EEG) 2 . . . . . . . . . . . . . . . . . . . . . . . . . 95

1:00 p.m.–5:30 p.m.

C154 Skills Workshop: Neurophysiologic Intraoperative Monitoring 3:30 p.m.–5:30 p.m.

N3 S31

Neuroscience in the Clinic: Melatonin and Disrupted Sleep in Neurologic Disorders . . . . . . . . . . . . . 72 Epilepsy/Clinical Neurophysiology (EEG) 3 . . . . . . . . . . . . . . . . . . . . . . . . . 98

Incorporating a Pharmacist into your Neurology Practice for Free–Results of 5:30 p.m.–6:30 p.m. a Pilot . . . . . . . . . . . . . . . . . . . . . . . . 227 P10 Poster Session 10

Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 2 P10.4-001 –P10.4-011. . . . . . . . . . . . . . 173

1:00 p.m.–3:00 p.m.

C104 Neurology Update 3: Stroke, Epilepsy, and Sleep S13 Epilepsy/Clinical Neurophysiology (EEG) 1 . . . . . . . . . . . . . . . . . . . . . . . . . 88 N2 Neuroscience in the Clinic: Multimodal Tools for Cardiac Arrest Neuroprognostication . . . . . . . . . . . . 71 3:30 p.m.–5:30 p.m.

C115

The Evaluation and Care of Seizures in Adults with Intellectual and Developmental Disabilities (IDD): Challenges and Solutions

5:30 p.m.–6:30 p.m.

Poster Session 7

Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 4 P7.4-001 –P7.4-012. . . . . . . . . . . . . . . . 155

Wednesday, April 29 7:00 a.m.–9:00 a.m.

C170 Update in Epilepsy 8:00 a.m.–9:00 a.m.

P11

Poster Session 11

Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications 3 P11.4-001 –P11.4-002. . . . . . . . . . . . . . 178 Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/ Neurostimulation and Diet Therapies 1 P11.4-003 –P11.4-012. . . . . . . . . . . . . . 178

9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session . . . . . . . . . . . . . . . 66

AAN.com/view/20AM 241

Epilepsy/Clinical Neurophysiology (EEG)

C54

Child Neurology: A Case-based Approach Clinical EEG: Focal, Diffuse, and Epileptiform Abnormalities in Adults

Poster Session 5

12:00 p.m.–1:00 p.m.

1:00 p.m.–3:00 p.m.

C51

Poster Session 8

12:00 p.m.–1:00 p.m.

8:00 a.m.–9:00 a.m.

Clinical EEG: Normal EEG, Normal Variants, and How to Avoid the Common Pitfall of Overreading

8:00 a.m.–9:00 a.m.

Child Neurology: Genetic and Metabolic Testing in Pediatric Epilepsy 9:15 a.m.–11:30 a.m. C82 Critical Care EEG Monitoring Clinical Trials Plenary Session . . . . . . . . . . . . . . . . . . . . . . 65 8:00 a.m.–8:45 a.m.

Skills Workshop: Neurostimulation

Sunday, April 26

8:00 a.m.–9:00 a.m.

C80

Poster Session 1

Epilepsy/Clinical Neurophysiology (EEG): Surgery and Co-morbidities 1 P1.4-001 –P1.4-011. . . . . . . . . . . . . . . . 120

C130 Women With Epilepsy (WWE): Beyond Seizure Control

7:00 a.m.–9:00 a.m.

12:00 p.m.–1:00 p.m.

7:00 a.m.–9:00 a.m.

Monday, April 27

9:30 a.m.–11:30 a.m.

C20

Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus, SUDEP, and Basic Science 2 P4.4-001 –P4.4-008 . . . . . . . . . . . . . . . 137 Epilepsy/Clinical Neurophysiology (EEG): EEG, Clinical Epilepsy, and Genetics 1 P4.4-009 –P4.4-012. . . . . . . . . . . . . . . . 138

Tuesday, April 28

PROGRAMS BY TOPIC

Saturday, April 25

Poster Session 4

2020 PROGRAMS BY TOPIC 12:00 p.m.–1:00 p.m.

P12

Poster Session 12

Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/ Neurostimulation and Diet Therapies 2 P12.4-001 –P12.4-012. . . . . . . . . . . . . . 184

PROGRAMS BY TOPIC

1:00 p.m.–3:00 p.m.

P17

Poster Session 17: Neuroinflammation

S59

Epilepsy/Clinical Neurophysiology (EEG) 4 . . . . . . . . . . . . . . . . . . . . . . . . 114

3:30 p.m.–4:30 p.m.

3:30 p.m.–5:30 p.m.

C275

C208 Clinical Epilepsy 2: Considerations Across the Age Span: Pediatrics, Pregnancy, and Elderly N4 Neuroscience in the Clinic: The Neurology of Obesity . . . . . . . . . . . . . 73 5:30 p.m.–6:30 p.m.

P13

Poster Session 13

Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/ Neurostimulation and Diet Therapies 3 P13.4-001 –P13.4-003 . . . . . . . . . . . . . 190 Epilepsy/Clinical Neurophysiology: Antiseizure Medications 2 P13.4-004 –P13.4-010. . . . . . . . . . . . . . 190

Thursday, April 30 7:00 a.m.–9:00 a.m.

Neurology Update 8: Epilepsy

General Neurology

7:00 a.m.–7:45 a.m.

Yoga—Vinyasa . . . . . . . . . . . . . . . . 229

C5 C6 C7

Neuroendocrine Update: Nuts and Bolts of What You Need to Know Good Neurology in Challenging Conditions: Lessons from Military Neurology Neuroimaging for the General Neurologist: Spine

8:00 a.m.–8:45 a.m.

C10

8:00 a.m.–9:00 a.m.

Vital Roles of the Clerkship Coordinator/Administrator . . . . . . . 221

9:00 a.m.–9:45 a.m.

Mindfulness Based Stress Reduction (MBSR) . . . . . . . . . . . . . . . . . . . . . . . 229 What Should Applicants Look for in a Program? . . . . . . . . . . . . . . . . . . 231

12:00 p.m.–1:00 p.m.

Poster Session 15

9:00 a.m.–10:00 a.m.

Clerkship Administrators Part 1: Understanding the Liaison Committee on Medical Education (LCME) Standards for Accreditation . . . . . . 221

1:00 p.m.–3:00 p.m.

C230 Clinical Epilepsy 3: Advanced (Status, Beyond AED, Video EEG) C245 Clinical Epilepsy 4: Surgery 5:30 p.m.–6:30 p.m.

P16

Poster Session 16

Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 3 P16.4-001 –P16.4-009 . . . . . . . . . . . . . 207

Friday, May 1 7:00 a.m.–9:00 a.m.

C261 Status Epilepticus

Neurology Continuing Certification Prep Course Dancing with Parkinson’s . . . . . . . . 229

Poster Session 14

Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 2 P15.4-001 –P15.4-010. . . . . . . . . . . . . . 202

9:30 a.m.–11:30 a.m.

C19

Neurogenetics: Diagnostic Dilemmas and Therapeutic Implications

10:00 a.m.–10:45 a.m.

How Your Social Life Might Be Helping (Or Harming) Your Brain . . . . . . . . . . 229 10:00 a.m.–11:00 a.m.

Implementing a Flipped Classroom Model to Enhance Student Education in Neurology . . . . . . . . . . 221 11:00 a.m.–11:45 a.m.

Parenting While Doctoring . . . . . 229

242 2020 AAN Annual Meeting

Welcome to the Annual Meeting (Navigating the App) . . . . . . . . . . . . 225 12:00 p.m.–12:45 p.m.

The Ripple Effect of Positive Psychology . . . . . . . . . . . . . . . . . . . . 229

12:00 p.m.–1:00 p.m.

Poster Session 1

General Neurology: Clinical Case Reports 1 P1.5-001 –P1.5-013. . . . . . . . . . . . . . . . 120

1:30 p.m.–2:15 p.m.

Is There a Neurologist on the Flight? . . . . . . . . . . . . . . . . . . . . . . . . 225

7:00 a.m.–9:00 a.m.

8:00 a.m.–9:00 a.m.

P15

12:00 p.m.–12:30 p.m.

Saturday, April 25

7:00 a.m.–4:00 p.m.

Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 1 P14.4-004 –P14.4-009. . . . . . . . . . . . . 196 Epilepsy/Clinical Neurophysiology: Antiseizure Medications 3 P14.4-001 –P14.4-003 . . . . . . . . . . . . . 196

Identifying and Eliminating Barriers/ Challenges for Medical Students Choosing the Field of Neurology as a Specialty. . . . . . . . . . . . . . . . . . . . . . 221

C221 Epileptologists’ Secrets for the Busy General Neurologist: Localization, Imaging, and Fear of Surgery P14

11:00 a.m.–12:00 p.m.

Epilepsy/Clinical Neurophysiology (EEG) P17.5-007 - P17.5-013. . . . . . . . . . . . . . 214 1:00 p.m.–3:00 p.m.

C190 Clinical Epilepsy 1: Basics

3:30 p.m.–5:30 p.m.

General Neurology

11:30 a.m.–1:00 p.m.

1:30 p.m.–3:30 p.m.

C29 C33

Critical Care Consultations for Neurohospitalists Disparities in Care

2:00 p.m.–2:45 p.m.

Build a Better Foundation: Making Smart Decisions Early for a Better Career . . . . . . . . . . . . . . . . . . . . . . . . 231 Your First Job: Private Practice vs. Academic Practice: Pros and Cons . 221 2:30 p.m.–3:15 p.m.

Reflections from Women in Medicine: The Other Side of Doctoring . . . . . . . . . . . . . . . . . . . . . 225 3:00 p.m.–3:45 p.m.

Tips for Better Sleep: More Reasons to Love Bedtime . . . . . . . . 229 Philanthropy for Education . . . . . 221 3:00 p.m.–4:00 p.m.

AAN Business Meeting 4:15 p.m.–5:30 p.m.

Hot Topics Plenary Session . . . . 62 5:00 p.m.–5:45 p.m.

The How and Why of eConsults in Neurology . . . . . . . . . . . . . . . . . . . 234 5:45 p.m.–6:45 p.m.

Inspiration and Innovation Talks Featuring David Eagleman, PhD . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Sunday, April 26 7:00 a.m.–7:45 a.m.

Yoga—Vinyasa . . . . . . . . . . . . . . . . 229 Making the Most of Fellowship— Setting Yourself Up for Success and Finding Your First Job . . . . . . . . . . . 231

C46

1:30 p.m.–2:15 p.m.

United We Stand: Enhancing Your Practice with APPs

The Teenage Brain: A Neuroscientist’s Survival Guide to Raising Adolescents and Young Adults . . . . . . . . . . . . . . . 225

8:00 a.m.–8:30 a.m.

Meditation: Awareness of Breath . . . . . . . . . . . . . . . . . . . . . . . . 229

Rotten Eggs: A Dozen Things to Be Wary of When Considering Treatments or Trials on the Internet . . . . . . . . . . 227 2:00 p.m.–2:45 p.m.

Poster Session 2

General Neurology: Clinical Case Reports 2 P2.5-001 –P2.5-013 . . . . . . . . . . . . . . . 126

2:30 p.m.–3:00 p.m.

Live Tweeting: Don’t Just Join the Conversation, Influence It! . . . . . . . 227

9:15 a.m.–12:00 p.m.

Presidential Plenary Session . . . 63 11:00 a.m.–12:00 p.m.

2:30 p.m.–3:15 p.m.

Medical Improv: Comedy as a Tool for Improving Patient Interactions . . . . 227 3:00 p.m.–3:45 p.m.

Different Pathways to Becoming a Department Chair . . . . . . . . . . . . . . 221 Practical Wellness Tips for the Busy Neurologist . . . . . . . . . . . . . . . 229

12:15 p.m.–1:15 p.m.

Who Wants to Be a Millionaire? . . .225 12:30 p.m.–1:00 p.m.

Non-epileptic Seizures—A Multidisciplinary Clinic Model, What Would Freud Say? . . . . . . . . . . . . . . 227

3:30 p.m.–4:00 p.m.

From Research to Clinic: Implementing Brain Perfusion Quantification in an Outpatient Center . . . . . . . . . . . . . . . . . . . . . . . . 227

1:00 p.m.–1:30 p.m.

You Died of Dysentery: Gaming in Education . . . . . . . . . . . . . . . . . . . . . 227 1:00 p.m.–1:45 p.m.

The Prevention of Stroke: No Pill’s Gonna Cure This Ill . . . . . . . . . . . . . . 229 So You’ve Been Sued/Named in a Medical Malpractice – Now What? . . . . . . . . . . . . . . . . . . . . . . . . 231 1:00 p.m.–3:00 p.m.

C50 C60

1:00 p.m.–3:00 p.m.

C61

Neurology Update 1: Movement Disorders, Behavioral Neurology, and Neuromuscular Diseases The Future Is Now: Bringing Accessibility, Availability, Affordability, Appropriateness, and Acceptability with Telehealth and Digital Medicine in Neurology . . . . . . . . . . . . . . . . . . . 227

7:00 a.m.–7:45 a.m.

Yoga—Vinyasa . . . . . . . . . . . . . . . . 229 Ask Me Anything About Choosing a Career in Teleneurology . . . . . . . . . .231 Core Curriculum for a Required Neurology Experience . . . . . . . . . . . 221 7:00 a.m.–9:00 a.m.

C85

3:30 p.m.–5:30 p.m.

Neurologic Case Studies in Pregnancy

8:00 a.m.–8:45 a.m.

The Mentor-Mentee Relationship: What Works and What Doesn’t? . . 231 How to Create a Department That Promotes Wellness . . . . . . . . . 221 Neurological Disease Prevention with Food . . . . . . . . . . . . . . . . . . . . . 229 8:00 a.m.–9:00 a.m.

Poster Session 5

General Neurology: Clinical Case Reports 3 P5.5-001 –P5.5-013 . . . . . . . . . . . . . . . 143

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session . . . . . . . . . . . . . . . 64 11:00 a.m.–12:00 p.m.

Creating a Handbook for Clerkship Administrators and Beyond…. . . . . 221 11:30 a.m.–12:00 p.m.

The Nerve: A Talk Show for our Emergency Neurology: Evaluation Neurology Community About What of Coma, Meningitis, and Viral Makes Us Nervous and What Gets on Encephalitis in the Emergency Room Our Nerves . . . . . . . . . . . . . . . . . . . . 227 C74 Functional Neurologic Disorders 2: Neurobiology and Management of 12:00 p.m.–1:00 p.m. Functional Disorders Neuro-Jeopardy: Telencephalon C76 Neurology Update 2: Multiple Twisters . . . . . . . . . . . . . . . . . . . . . . 225 Sclerosis, Neuro-oncology, and Poster Session 6 P6 Headache General Neurology: Drugs and C77 Actualización científica 1 (Scientific Therapeutics 1 Update 1) P6.5-001 –P6.5-012 . . . . . . . . . . . . . . . 149 S12 General Neurology: Neurotherapeutics and Clinical Trials . . . . . . . . . . . . . . . . 87 1:00 p.m.–1:30 p.m. An Overwatch of Video Games in 4:00 p.m.–4:45 p.m. Neurology: Peak Performance Is Mindfulness-based Chronic Pain Less Than a Fortnite Away . . . . . . . 227 Management . . . . . . . . . . . . . . . . . . 229 1:00 p.m.–1:45 p.m. A Career in General Neurology: Fireside Chat: Burnout–What Do Knowing Everything About You Want to Know? . . . . . . . . . . . . . 229 Everything! . . . . . . . . . . . . . . . . . . . . 231

C65

AAN.com/view/20AM 243

General Neurology

Creating a Roadmap for a Diverse Workforce in Academic Neurology Functional Neurologic Disorders 1: Truth, Myth, and Misunderstanding

Monday, April 27

3:00 p.m.–3:30 p.m.

Poster Session 3

General Neurology: Health Services P3.5-001 –P3.5-010 . . . . . . . . . . . . . . . 132

Success in Residency? Let’s Talk About It . . . . . . . . . . . . . . . . . . . . . . . 231 Zumba . . . . . . . . . . . . . . . . . . . . . . 229

Neuro-oncology Around the World – Global Perspective on Brain Cancer Patient Care . . . . . . . . . . . . . . . . . . . 225

Identifying Areas of Burnout of Clerkship Coordinators and Improving Wellness . . . . . . . . . . . . . 221 12:00 p.m.–1:00 p.m.

5:00 p.m.–5:45 p.m.

PROGRAMS BY TOPIC

Enhancing Personal and Professional Well-being Through Appreciative Inquiry . . . . . . . . . . . . . . . . . . . . . . . . 229 Still Kicking and Crazy After All These Years: How to Remain Relevant and Engaged in Mid- to Late-career . . . 231

8:00 a.m.–9:00 a.m.

Standing on the Shoulders of Giants . . . . . . . . . . . . . . . . . . . . . . . . 225

2:00 p.m.–2:30 p.m.

8:00 a.m.–8:45 a.m.

Neurology: We Want YOU! . . . . 221 Great Expectations: How to Utilize Strength Coaching to Expect the Best for Your Future . . . . . . . . . . . . . 231

4:30 p.m.–5:15 p.m.

2020 PROGRAMS BY TOPIC Navigating the Political Terrain: The Art of Avoiding Organizational Potholes . . . . . . . . . . . . . . . . . . . . . . 221

C123

1:00 p.m.–3:00 p.m.

C103 Clinical Neurology for Advanced Practice Providers C104 Neurology Update 3: Stroke, Epilepsy, and Sleep 1:00 p.m.–5:30 p.m.

AAN Health Care Equity Symposium . . . . . . . . . . . . . . . . . . . 38

PROGRAMS BY TOPIC

1:30 p.m.–2:00 p.m.

Development of Speechbased, Digital Biomarkers for Neuropsychiatric Disease . . . . . . . . 227 1:30 p.m.–2:15 p.m.

Neuro HeadTalk: Story Slams . . . 225 2:00 p.m.–2:30 p.m.

Author Your Own Future: Selfpublishing in Neurology . . . . . . . . . . 227 2:00 p.m.–2:45 p.m.

Clinical Practice Through the Life Cycle . . . . . . . . . . . . . . . . . . . . . . . . . 231 Understanding Essential Oils, Nature’s Relief . . . . . . . . . . . . . . . . . 229 2:30 p.m.–3:00 p.m.

Twitter for Neurologists: Basics and Beyond . . . . . . . . . . . . . . . . . . . . . . . 227 3:00 p.m.–3:30 p.m.

Medical Improv: Comedy as a Tool for Improving Patient Interactions . . . . 227 3:00 p.m.–3:45 p.m.

4:00 p.m.–4:30 p.m.

Guided Meditation . . . . . . . . . . . . . . 229 4:00 p.m.–4:45 p.m.

C111 Neurologic Complications of Medical Disease C120 Advances in Neurogenetics C121 Neurology Update 4: Neuro-infectious Disease, Neuro-otology, and Neuroophthalmology

244 2020 AAN Annual Meeting

8:00 a.m.–9:00 a.m.

Poster Session 8

General Neurology: Clinical Case Reports 4 P8.5-011 –P8.5-013. . . . . . . . . . . . . . . . 161 General Neurology: Drugs and Therapeutics 2 P8.5-001 –P8.5-010 . . . . . . . . . . . . . . . 161

9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session . . . . . . . . . . . . . . . . . . . . . . . 65 12:00 p.m.–12:30 p.m.

Top Ten Clinical, Educational, and The Evolving Use of Scribes in the Leadership Pearls . . . . . . . . . . . . . . . 221 Neurology Practice . . . . . . . . . . . . . 227 Advancing Your Career with the 12:00 p.m.–1:00 p.m. Resident and Fellow Section of What’s that in Your Brain: 50 Neurology: How to Write, Review, Join Essential Instant Pathological the Editorial Board, and Use the RFS Recognition Cases . . . . . . . . . . . . . . 225 for Your Residency . . . . . . . . . . . . . . 231 Poster Session 9 P9

4:00 p.m.–5:30 p.m.

Brainstorm: A Competition for the Innovator in All of Us . . . . . . . . . . . . 227 4:30 p.m.–5:15 p.m.

Standing on the Shoulders of Giants . . . . . . . . . . . . . . . . . . . . . . . . 225 5:00 p.m.–5:45 p.m.

Pursuing an Additional Degree: Is It for Me? . . . . . . . . . . . . . . . . . . . . . . . 231 5:00 p.m.–6:00 p.m.

Happiness Hour . . . . . . . . . . . . . . . . 229

Tuesday, April 28 7:00 a.m.–7:45 a.m.

Yoga—Vinyasa . . . . . . . . . . . . . . . . 229 Key Findings from the Neurology Compensation and Productivity Survey for Academics . . . . . . . . . . . 221

The Sleep Mythbuster!: Illuminating the Facts and Fiction Toward Achieving the Sleep-healthy Neurologist . . . . 229 Interviewing Skills for Students and 7:00 a.m.–9:00 a.m. Residents—How to Get into the C125 Principles of Genomic Medicine: Program You Want . . . . . . . . . . . . . . 231 Clinical Exome Sequencing in Neurologic Disease 3:30 p.m.–4:00 p.m. Drugs and Toxin-induced Neurologic C132 2019 Brainstorm Competition Winner Emergencies ALSUntangled . . . . . . . . . . . . . . . . . 227 C133 Neurologic Conditions in 3:30 p.m.–4:15 p.m. Transgender Patients Neuro Exam Tricks and Tips . . . . . . 225 8:00 a.m.–8:30 a.m. 3:30 p.m.–5:30 p.m.

General Neurology

S21

Estudios de cohorte de latinoamericanos: enfermedad de Alzheimer, enfermedad de Huntington y derrame cerebral (Latin American Cohort Studies: Alzheimer’s, Huntington’s, and Stroke) Neuroepidemiology . . . . . . . . . . . . . . 92

Mindfulness of Sound . . . . . . . . . 229 8:00 a.m.–8:45 a.m.

Turning “Diversity Tax” into Currency in Neurology . . . . . . . . . . . 221 How to Successfully Incorporate APPs into Your Practice . . . . . . . . . . 231

Neuroepidemiology 1 P9.5-001 –P9.5-010 . . . . . . . . . . . . . . . 167

12:30 p.m.–1:00 p.m.

Models of Care That Work for You and Your Patients . . . . . . . . . . . . . . . 227 1:00 p.m.–1:30 p.m.

Addictive by Design: The Evolution of Video Games . . . . . . . . . . . . . . . . 227 1:00 p.m.–1:45 p.m.

Outsmart Stress . . . . . . . . . . . . . . . . 229 Navigating a Career in Academic Neurology: Accolades and Challenges . . . . . . . . . . . . . . . . . . . . 221 1:00 p.m.–3:00 p.m.

C140 Mitochondrial Disorders in Neurology C150 Therapy in Neurology 1: Epilepsy and Neuromuscular Disorders 1:30 p.m.–2:00 p.m.

Social Media for the Modern Neurologist: How Twitter Allows You to Amplify Your Voice and Engage Your Community of Physicians and Patients . . . . . . . . . . . . . . . . . . . . . . . 227 1:30 p.m.–2:15 p.m.

The Effects of Brain Damage on Creativity . . . . . . . . . . . . . . . . . . . . . 225 2:00 p.m.–2:30 p.m.

Office Practice Mechanisms to Provide Services for the New CPT Codes . . . . . . . . . . . . . . . . . . . . . . . . 227 2:00 p.m.–2:45 p.m.

Magnifying Your Life Through Poetry . . . . . . . . . . . . . . . . . . . . . . . . 229 Understanding and Negotiating a Physician Employment Contract . . . 231 All Work and No Play: Don’t Let Work Interfere with Your Fun . . . . . 221

Lessons from the California Parkinson’s Disease Registry and What’s Next? . . . . . . . . . . . . . . . . . . 227 2:30 p.m.–3:15 p.m.

All Things Ice Cream. . . . . . . . . . . . 225 3:00 p.m.–3:30 p.m.

Medical Improv: Comedy as a Tool for Improving Patient Interactions . . . . 227 3:00 p.m.–3:45 p.m.

3:30 p.m.–4:00 p.m.

Telemedicine FAILS: Limitations and Legal Liability . . . . . . . . . . . . . . 227 3:30 p.m.–4:15 p.m.

The Neuroscience of Magic: Sleight of Hand . . . . . . . . . . . . . . . . 225 3:30 p.m.–5:30 p.m.

Pursuing a Career in Industry . . . . . 231 Grit, Resilience, and a Healthy Dose of Fun: How to Succeed at Your Professional Organization . . . . . . . . 221 Acupuncture Demonstration - 4 Gates . . . . . . . . . . . . . . . . . . . . . . . . . 229 9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session . . . . . . . . . . . . . . . . . . . . . . . 66 Patient-centered Innovations and AI in Transition of Care . . . . . . . 227 Project ECHO and Neurology: Demand Shaping and Bridging Knowledge Gaps . . . . . . . . . . . . . . . 227 12:00 p.m.–1:00 p.m.

Neurology Pictionary . . . . . . . . . . . . 225 12:30 p.m.–1:00 p.m.

What If? Digital Assessments Transforming Neurology Practice . . . . . . . . . . . . . . . . . . . . . . . 227

4:00 p.m.–4:45 p.m.

1:00 p.m.–1:45 p.m.

Standing on the Shoulders of Giants . . . . . . . . . . . . . . . . . . . . . . . . 225 5:00 p.m.–5:45 p.m.

Mentorship: Pearls and Pitfalls . . . . . . . . . . . . . . . . . . . . . . . . 221 Yoga - Vinyasa . . . . . . . . . . . . . . . . . 229 Learn Something New Every Day—The Life of the Academic Neurohospitalist . . . . . . . . . . . . . . . 231 5:30 p.m.–6:30 p.m.

P10

Poster Session 10

Wednesday, April 29 7:00 a.m.–7:45 a.m.

Yoga—Vinyasa . . . . . . . . . . . . . . . . 229 Too Many Fellowship Choices: How to Zero in to Find the Subspecialty of Your Choice and the Best Job for Life . . . . . . . . . . . . . . . . . . . . . . . . . . 231

Medical Improv: Comedy as a Tool for Improving Patient Interactions . . . . 227 3:00 p.m.–3:45 p.m.

Café Talk: Growth Mindset . . . . . . . 229 Fit For Duty: Practicing Neurology in the Military . . . . . . . . . . . . . . . . . . 231 3:30 p.m.–4:15 p.m.

Ethical Conundrums in Neurology . . . . . . . . . . . . . . . . . . . . . 225

Video Games in Neuro-rehab: Big Bucks or Xbox . . . . . . . . . . . . . . 227

3:30 p.m.–5:30 p.m.

C211

Expanding the Neurologist’s Toolbox: When and How to Recommend Cognitive Behavioral or Mindfulness-based Psychotherapies C212 Therapy in Neurology 4: Movement Disorders and Neuroimmunology C213 Actualización científica 2 (Scientific Update 2) N4 Neuroscience in the Clinic: The Neurology of Obesity . . . . . . . . . . . . . 73 4:00 p.m.–4:45 p.m.

Fireside Chat: Thriving in Medicine– What Is Your Purpose? . . . . . . . . . . 229 Health Care Disparities in Populations . . . . . . . . . . . . . . . . . . . . 223 How I Tried to Retire from Neurology but Couldn’t . . . . . . . . . . 231

The Power of One . . . . . . . . . . . . 229 1:00 p.m.–3:00 p.m.

C193 Clinical Pearls: Learning from Complex Cases: Simple Lessons that Apply to Everyday Problems C194 Therapy in Neurology 3: Stroke and Headache 1:30 p.m.–2:00 p.m.

Nutritional Neurology: Back to Basics and What to Look for Moving Forward . . . . . . . . . . . . . . . . 227

4:30 p.m.–5:15 p.m.

Standing on the Shoulders of Giants . . . . . . . . . . . . . . . . . . . . . . . . 225 5:00 p.m.–5:30 p.m.

Nature Meditation . . . . . . . . . . . . 229 5:00 p.m.–5:45 p.m.

Why Neurology? (for Medical Students) . . . . . . . . . . . . . . . . . . . . . 231 Neurohospitalist Models of Care in an Academic Department: Opportunities and Challenges . . . . 221

1:30 p.m.–2:15 p.m.

The Salem Witch Trials: How Could That Possibly Happen? . . . . . 225 2:00 p.m.–2:30 p.m.

Shared Medical Appointments in the Memory Clinic . . . . . . . . . . . . . . 227

5:30 p.m.–6:30 p.m.

P13

2:00 p.m.–2:45 p.m.

Patient-centered Care in Clinical Neurology . . . . . . . . . . . . . . . . . . . . . 229 Factors that Perpetuate Disparities in Academic Medicine: A Path Forward . . . . . . . . . . . . . . . . . . . . . . 221 2:30 p.m.–3:00 p.m.

The Midas Touchscreen: Turn Your App Idea into Gold . . . . . . . . . . 227

Poster Session 13

General Neurology: Clinical Case Reports 5 P13.5-001 –P13.5-011. . . . . . . . . . . . . . 190

Thursday, April 30 7:00 a.m.–7:45 a.m.

Yoga—Vinyasa . . . . . . . . . . . . . . . . 229 7:00 a.m.–9:00 a.m.

C214

Women’s Neurology: Beyond Pregnancy

AAN.com/view/20AM 245

General Neurology

Neuroepidemiology 2 P10.5-001 –P10.5-009 . . . . . . . . . . . . . 173

3:00 p.m.–3:30 p.m.

12:00 p.m.–12:30 p.m.

1:00 p.m.–1:30 p.m.

4:30 p.m.–5:15 p.m.

Consejos prácticos para un buen examen neurológico (Neuro Exam Tips and Tricks) . . . . . . . . . . . . . . . . . 225

11:30 a.m.–12:00 p.m.

C160 LGBTQI Health in Neurology C166 Therapy in Neurology 2: Neuroophthalmology and Critical Care Fireside Chat: Work-Life Balance . . . . . . . . . . . . . . . . . . . . . . . 229 Private Practice: Can you be Successful? . . . . . . . . . . . . . . . . . . . 231

2:30 p.m.–3:15 p.m.

PROGRAMS BY TOPIC

Just Enough IS Good Enough: Parenting While Paving Your Career Path . . . . . . . . . . . . . . . . . . . . . . . . . . 231 The Third Leg? The Clinician in Academic Medicine . . . . . . . . . . . . . 221 Mindful Snacking . . . . . . . . . . . . . 229

8:00 a.m.–8:45 a.m.

2020 PROGRAMS BY TOPIC C219 Neurologic Complications of Medical and Surgical Therapies C220 Cannabis Update in Neurology

3:30 p.m.–4:15 p.m.

8:00 a.m.–8:45 a.m.

3:30 p.m.–5:30 p.m.

How to Increase Your International Presence? . . . . . . . . . . . . . . . . . . . . . 221 Bed Side to Boardroom: Tales of a Neurohospitalist . . . . . . . . . . . . . . . 231 8:00 a.m.–9:00 a.m.

PROGRAMS BY TOPIC

P14

Poster Session 14

General Neurology: Clinical Science: Cohorts and Case Series 1 P14.5-001 –P14.5-009 . . . . . . . . . . . . . 196

9:15 a.m.–11:30 a.m.

P15

4:00 p.m.–4:45 p.m.

Fireside Chat: Self-care–The Radical Idea That YOU Are a Priority . . . . . . 229

General Neurology: Clinical Science: Cohorts and Case Series 2 P15.5-001 –P15.5-011. . . . . . . . . . . . . . 202

1:00 p.m.–2:00 p.m.

Inspiration and Innovation Talks Featuring Maria Konnikova, PhD . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

5:00 p.m.–5:45 p.m.

Hawaiian Hula Dance . . . . . . . . . 229 5:30 p.m.–6:30 p.m.

P16

1:30 p.m.–2:15 p.m.

Friday, May 1 7:00 a.m.–7:45 a.m.

Yoga—Vinyasa . . . . . . . . . . . . . . . . 229 7:00 a.m.–9:00 a.m.

C265 CNS Toxicities C266 Food for Thought: Nutrition and Neurologic Disease 8:00 a.m.–8:45 a.m.

Taking Neurology Outside of the Office: Turning Advocacy into a Career Game-changer . . . . . . . . . . . 232 Acupuncture Demonstration– Auriculotherapy . . . . . . . . . . . . . . . . 229

2:00 p.m.–2:45 p.m.

Lost in Translation . . . . . . . . . . . . . . 225 3:00 p.m.–3:45 p.m.

Optimizing Communication in Difficult Patient Relationships . . . . . . . . . . . . 232 What About Wellness for Residents and Fellows? . . . . . . . . . . 229

General Neurology: Clinical Science: Cohorts and Case Series 3 P16.5-001 –P16.5-011. . . . . . . . . . . . . . 208

C257 Case Studies: Test Your Knowledge: A Case-based Approach to Neuroimaging

Live Intraoperative Monitoring . . . . 225 Café Talk: Mindfulness in the Practice of Clinical Neurology . . . . . . . . . . . . 229 Get Social on Social Media— #Networking101 for Professional Development . . . . . . . . . . . . . . . . . . 231

Poster Session 16

6:30 p.m.–9:30 p.m.

1:00 p.m.–3:00 p.m.

C235 Neuroimaging for the General Neurologist 1: Brain C237 Continuum® Test Your Knowledge: A Multiple-choice Question Review 1 S51 General Neurology: Models of Clinical Care and Disease . . . . . . . . 110

9:15 a.m.–11:30 a.m.

Neurology Year in Review Plenary Session . . . . . . . . . . . . . . . 68

Werewolves and Vampires: The Quest for the Truth . . . . . . . . . . . . . . 225 4:00 p.m.–5:00 p.m.

NeuroZone . . . . . . . . . . . . . . . . . . . . 225

Global Health

Sunday, April 26 3:30 p.m.–4:15 p.m.

P17

12:00 p.m.–1:00 p.m.

The Neurology of Creativity at the Keyboard . . . . . . . . . . . . . . . . . . . . . 225 1:00 p.m.–1:45 p.m.

Poster Session 9

Global Health P9.10-001 –P9.10-013. . . . . . . . . . . . . . 169

Wednesday, April 29 7:00 a.m.–9:00 a.m.

C177 The Global Burden of Neurologic Diseases 4:00 p.m.–4:45 p.m.

Health Care Disparities in Populations . . . . . . . . . . . . . . . . . . . . 223

Thursday, April 30 8:00 a.m.–8:45 a.m.

How to Increase Your International Presence? . . . . . . . . . . . . . . . . . . . . . 221 3:30 p.m.–5:30 p.m.

C240 Tropical Neurology

Friday, May 1 7:00 a.m.–7:45 a.m.

Finding Neverland: Pathways to a Successful Academic Career in Global Neurology . . . . . . . . . . . . . . . 232

Poster Session 17: Neuroinflammation General Neurology P17.5-001 - P17.5.006. . . . . . . . . . . . . . 213

Global Health . . . . . . . . . . . . . . . . . . . 84

Tuesday, April 28

11:30 a.m.–1:00 p.m.

Mindful Eating . . . . . . . . . . . . . . . 229

246 2020 AAN Annual Meeting

2:30 p.m.–3:15 p.m.

Standing on the Shoulders of Giants . . . . . . . . . . . . . . . . . . . . . . . . 225

1:00 p.m.–1:45 p.m.

Poetry and Neurology Workshop . . . . . . . . . . . . . . . . . . . . . 229 Team Science: Implications for Promotions and Tenure . . . . . . . . . . 221

Setting the Stage for Success: Building Your Career by Finding Your Mentor and Mentee Match . . . . . . 232 Fireside Chat: Self-compassion– Learning to Ignore Your Inner Critic . . . . . . . . . . . . . . . . . . . . . . . . . 229

4:30 p.m.–5:15 p.m.

Poster Session 15

2:30 p.m.–3:15 p.m. Global Health

C250 Neuroimaging for the General Neurologist 2: Brain C251 Continuum® Test Your Knowledge: A Multiple-choice Question Review 2 S57 General Neurology: Diagnostic Testing and Disease Biomarkers . . . . . . . . . 113

Controversies in Neurology Plenary Session . . . . . . . . . . . . . . . 67 12:00 p.m.–1:00 p.m.

2:00 p.m.–2:45 p.m.

The Effects of Loneliness: Connectivity Matters . . . . . . . . . . . 225

11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation Global Health P17.10-016 . . . . . . . . . . . . . . . . . . . . . . . 216

Headache

Saturday, April 25 9:30 a.m.–11:30 a.m.

C14

Hot Topics in Headaches and Related Disorders 1: Unusual Headaches, Childhood Headaches, and Concussion Management

12:00 p.m.–1:00 p.m.

Poster Session 1

1:30 p.m.–3:30 p.m.

C32

Hot Topics in Headaches and Related Disorders 2: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances

C99

Poster Session 2

Headache: Therapeutics 2 P2.6-001 –P2.6-011. . . . . . . . . . . . . . . 126

12:00 p.m.–1:00 p.m.

Poster Session 3

Headache: Therapeutics 3 P3.6-001 –P3.6-013 . . . . . . . . . . . . . . . 132

1:00 p.m.–3:00 p.m.

Headache I . . . . . . . . . . . . . . . . . . . . . 81

3:30 p.m.–5:30 p.m.

C76 S8

Neurology Update 2: Multiple Sclerosis, Neuro-oncology, and Headache Migraine Therapeutics . . . . . . . . . . . 85

5:30 p.m.–6:30 p.m.

Poster Session 4

Headache: Therapeutics 4 P4.6-001 –P4.6-013. . . . . . . . . . . . . . . . 138

Monday, April 27 Skills Workshop: Practical Training in Injection Techniques in the Treatment of Headache Disorders

Headache: Therapeutics 7 P7.6-001 –P7.6-013. . . . . . . . . . . . . . . . 155

Tuesday, April 28 9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session . . . . . . . . . . . . . . . . . . . . . . . 65

Headache: Therapeutics 5 P5.6-001 –P5.6-013 . . . . . . . . . . . . . . . 144

12:00 p.m.–1:00 p.m.

Poster Session 6

Headache: Therapeutics 6 P6.6-001 –P6.6-013 . . . . . . . . . . . . . . . 149

Poster Session 15

Headache 1 P15.6-001 –P15.6-012. . . . . . . . . . . . . . 202

3:30 p.m.–5:30 p.m.

C246 Comprehensive Migraine Update 2: Advances in Acute, Preventive and Cognitive Behavioral Therapies 5:30 p.m.–6:30 p.m.

P16

Poster Session 16

Headache 2 P16.6-001 –P16.6-013. . . . . . . . . . . . . . 208

C145 Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches, Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches

C254 Case Studies: Challenging Headache Cases

3:30 p.m.–5:30 p.m.

11:30 a.m.–1:00 p.m.

6:30 p.m.–9:30 p.m.

Friday, May 1

C161 Introduction to Primary Headache Disorders: Migraine and Other Primary Headaches, Including Tension-type, Hypnic, Primary Stabbing, Nummular Headache Syndromes, Epicrania Fugax, and Retinal Migraine

P17

Wednesday, April 29

C273

Poster Session 17: Neuroinflammation Headache P17.6-001 - P17.6-004. . . . . . . . . . . . . . 214

1:00 p.m.–3:00 p.m.

S58

Headache Therapeutics . . . . . . . . . 114

3:30 p.m.–4:30 p.m.

Neurology Update 6: Headache

7:00 a.m.–9:00 a.m.

C171 Child Neurology: Headache

Infectious Disease

8:00 a.m.–9:00 a.m.

P11

Poster Session 11

Headache: Migraine 1 P11.6-001 –P11.6-012. . . . . . . . . . . . . . 179

12:00 p.m.–1:00 p.m.

P12

4:15 p.m.–5:30 p.m.

Hot Topics Plenary Session . . . . 62

Poster Session 12

Headache: Migraine 2 P12.6-001 –P12.6-013. . . . . . . . . . . . . . 184

1:00 p.m.–3:00 p.m.

C194 Therapy in Neurology 3: Stroke and Headache 5:30 p.m.–6:30 p.m.

P13

Saturday, April 25

Poster Session 13

Sunday, April 26 9:15 a.m.–12:00 p.m.

Presidential Plenary Session . . . 63 1:00 p.m.–3:00 p.m.

Infectious Disease: Neurovirology and Bacterial Complications . . . . . . . . . . 81

Headache Science 1 P13.6-001 –P13.6-010. . . . . . . . . . . . . . 190

AAN.com/view/20AM 247

Infectious Disease

Poster Session 5

P15

1:00 p.m.–3:00 p.m.

8:00 a.m.–9:00 a.m.

12:00 p.m.–1:00 p.m.

C116 Emergency and Inpatient Management 1:00 p.m.–3:00 p.m. of Migraine and Other Headache C231 Comprehensive Migraine Update 1: Disorders Migraine Diagnosis, Pathophysiology, 5:30 p.m.–6:30 p.m. and Comorbidities Poster Session 7 P7 S47 Headache II . . . . . . . . . . . . . . . . . . . .108

7:00 a.m.–9:00 a.m.

C91

Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management

3:30 p.m.–5:30 p.m.

Sunday, April 26 8:00 a.m.–9:00 a.m.

P14.6-001 –P14.6-010. . . . . . . . . . . . . . 197

1:00 p.m.–3:00 p.m.

PROGRAMS BY TOPIC

Headache: Therapeutics 1 P1.6-001 –P1.6-013. . . . . . . . . . . . . . . . 120

Thursday, April 30

Incorporating a Pharmacist into your 8:00 a.m.–9:00 a.m. Neurology Practice for Free–Results of P14 Poster Session 14 a Pilot . . . . . . . . . . . . . . . . . . . . . . . . 227 Headache Science 2

2020 PROGRAMS BY TOPIC Monday, April 27 3:30 p.m.–5:30 p.m.

5:30 p.m.–6:30 p.m.

P13

C121 Neurology Update 4: Neuro-infectious Disease, Neuro-otology, and Neuroophthalmology

Tuesday, April 28 8:00 a.m.–9:00 a.m.

C137 Education Blitz: Emerging Infectious Diseases of the Central Nervous System

PROGRAMS BY TOPIC

12:00 p.m.–1:00 p.m.

Neurovirology 1 P9.10-014 –P9.10-018. . . . . . . . . . . . . . 170

1:00 p.m.–3:00 p.m.

S28

Infectious Disease: Chronic Meningitis and the Immunosuppressed . . . . . . . 96

C155

7:00 a.m.–9:00 a.m.

C169 Infections of the Nervous System 1: Diagnostic Testing of Neurologic Infections 8:00 a.m.–9:00 a.m.

P11

3:30 p.m.–5:30 p.m.

C240 Tropical Neurology

Friday, May 1 11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation

Infectious Disease P17.10-008 - P17.10-015 . . . . . . . . . . . . 216

Leadership

Saturday, April 25 7:00 a.m.–4:00 p.m.

C11

C23 C36

C183 Infections of the Nervous System 2: Neuro-ID Emergencies 3:30 p.m.–5:30 p.m.

C200 Infections of the Nervous System 3: Advanced Topics in Infectious Neurology

248 2020 AAN Annual Meeting

Educators’ Leadership Program

3:00 p.m.–3:45 p.m.

Eleven Things Not to Say to Your Female Colleagues . . . . . . . . . . . . . . 223

Sunday, April 26 8:00 a.m.–8:45 a.m.

Great Expectations: How to Utilize Strength Coaching to Expect the Best for Your Future . . . . . . . . . . . . . 231

Poster Session 12

1:00 p.m.–3:00 p.m.

Leadership Challenges in Practice

1:30 p.m.–4:00 p.m.

12:00 p.m.–1:00 p.m. Fungi, Parasites, and Spirochetes 2 P12.10-001 –P12.10-011. . . . . . . . . . . . 186 Tuberculosis and Other Bacterial Infections 1 P12.10-012 –P12.10-019. . . . . . . . . . . . 186

Women in Leadership: Empower or Imposter: Leveraging Your Strengths as a Leader in Neurology

12:00 p.m.–3:00 p.m.

Poster Session 11

NeuroHIV, Neurovirology, and Rare Bacteria 2 P11.10-001 –P11.10-014 . . . . . . . . . . . . 180 Fungi, Parasites, and Spirochetes 1 P11.10-015 –P11.10-018. . . . . . . . . . . . . 181

Self Promotion . . . . . . . . . . . . . . . 223

8:00 a.m.–8:45 a.m.

C226 Differential Diagnosis of Neurologic Infections

Poster Session 10

Wednesday, April 29

5:00 p.m.–5:45 p.m.

1:00 p.m.–3:00 p.m.

New Therapeutic Options for CNS Infections

NeuroHIV, Neurovirology, and Rare Bacteria 1 P10.10-013 –P10.10-018. . . . . . . . . . . . 175 Neurovirology 2 P10.10-001 –P10.10-012. . . . . . . . . . . . 175

Blind Spots: The Impact of Conscious and Unconscious Biases . . . . . . . . . . . . . . . . . . . . . . . . 223

Monday, April 27

5:30 p.m.–6:30 p.m.

P10

Fungi, Parasites, and Spirochetes 3 P13.10-001 –P13.10-005. . . . . . . . . . . . 192 Tuberculosis and Other Bacterial Infections 2 P13.10-006 –P13.10-017. . . . . . . . . . . . 192

4:00 p.m.–4:45 p.m.

Thursday, April 30

3:30 p.m.–5:30 p.m.

P12

Leadership

Poster Session 9

Poster Session 13

12:00 p.m.–4:00 p.m.

C49

Chief Resident Leadership Program

1:00 p.m.–1:45 p.m.

Gratitude and Other “Soft” Skills That Help You Thrive as a Leader . . 223 3:00 p.m.–3:45 p.m.

Different Pathways to Becoming a Department Chair . . . . . . . . . . . . . . 221 Conflict Management: An Essential Leadership Competency . . . . . . . . . 223

The Mentor-Mentee Relationship: What Works and What Doesn’t? . . 231 1:00 p.m.–1:45 p.m.

How to Get from Diversity to Inclusion: The Difference of Being Invited to a Dance vs. Being Asked to Dance . . . . . . . . . . . . . . . . 223 1:00 p.m.–3:00 p.m.

C108 Leadership in the Era of Burnout: A Practical Approach to Becoming a True Physician Leader 2:00 p.m.–2:45 p.m.

Emotional Intelligence and Leadership . . . . . . . . . . . . . . . . . . . . 223 3:00 p.m.–3:45 p.m.

Academic Neurology: What Is the AAN Doing to Help Academic Neurology? . . . . . . . . . . . . . . . . . . . . 221 Top Strengths and Shadow Sides in Neurology . . . . . . . . . . . . . . . . . . . . . 223 4:00 p.m.–4:45 p.m.

Are You Woke Enough to Lead? . . . . . . . . . . . . . . . . . . . . . . . . .223 Top Ten Clinical, Educational, and Leadership Pearls . . . . . . . . . . . . . . . 221 5:00 p.m.–5:45 p.m.

One Day Fellow, Next Day Boss: Reflections on Early-career Leadership. . . . . . . . . . . . . . . . . . . .223

Tuesday, April 28 8:00 a.m.–8:45 a.m.

Turning “Diversity Tax” into Currency in Neurology . . . . . . . . . . . 221 1:00 p.m.–1:45 p.m.

EDI 101 for Neurology Leaders: The Benefit of Diversity on Your Team . . . . . . . . . . . . . . . . . . . . . . . . . 223 1:00 p.m.–3:30 p.m.

C152 Good to Great, Great to Gold: Applying the (3 G) Strengths-based Approach to Enhance Your Toolkit as a Leader 1:00 p.m.–4:00 p.m.

C153 Mitigating the Impact of Unconscious Bias

3:00 p.m.–3:45 p.m.

Do You Need a Sponsor, Mentor(s) or Collaborator(s)? . . . . . . . . . . . . . . 223 3:00 p.m.–3:45 p.m.

5:00 p.m.–5:45 p.m.

The Importance of Mission, Vision, and Purpose . . . . . . . . . . . . . . . . . . . 223 4:00 p.m.–4:45 p.m.

Leading Interdisciplinary Teams . . . . . . . . . . . . . . . . . . . . . . . . 223

How to Become a Leader in Your Health System . . . . . . . . . . . . . . . . . 223

Friday, May 1 1:00 p.m.–1:45 p.m.

12:00 p.m.–1:00 p.m.

2:00 p.m.–2:45 p.m.

Wednesday, April 29 8:00 a.m.–8:45 a.m.

Clinical Genetic Testing for Parkinson’s: Are We There Yet? . . . 236 1:00 p.m.–3:00 p.m.

C56 C61

Movement Disorders

C70 S11

1:00 p.m.–1:45 p.m.

Saturday, April 25 8:00 a.m.–8:45 a.m.

1:00 p.m.–5:00 p.m.

C196 Strengths Foundations Workshop 2:00 p.m.–2:45 p.m.

Time for a Check Up: How to Successfully Navigate Compensation Negotiations as Women in Neurology . . . . . . . . . . . . 223

Dancing with Parkinson’s . . . . . . . . 229

C17

12:00 p.m.–1:00 p.m.

Microaggressions: How to Address Discrimination and Unprofessional Behavior at Your Workplace . . . . . . 223 Health Care Disparities in Populations . . . . . . . . . . . . . . . . . . . . 223 5:00 p.m.–5:45 p.m.

1:00 p.m.–1:45 p.m.

2:00 p.m.–2:45 p.m.

Managing Neurologic Disorders in Transgender and Gender Diverse Patients . . . . . . . . . . . . . . . . . . . . . . . 223

Parkinson’s Disease: Exercise, Mental Health, and Social Determinants 1 P1.3-009 –P1.3-017. . . . . . . . . . . . . . . . 119 Surgical Therapies in Movement Disorders 1 P1.3-001 –P1.3-008. . . . . . . . . . . . . . . . 119

C34

7:00 a.m.–9:00 a.m.

C83

7:00 a.m.–9:00 a.m.

C40

Maximizing Quality of Life in Stroke, ALS, Parkinson’s Disease, and Dementia: A Palliative Approach

8:00 a.m.–9:00 a.m.

Parkinson’s Disease Update

8:00 a.m.–8:45 a.m.

Neurological Disease Prevention with Food . . . . . . . . . . . . . . . . . . . . . 229 8:00 a.m.–9:00 a.m.

3:30 p.m.–4:15 p.m.

Sunday, April 26

Parkinson’s Disease Biomarkers and Pathophysiology P4.3-001 –P4.3-017. . . . . . . . . . . . . . . . 137

Monday, April 27

Update in Movement Disorders Movement Disorders Case Studies: Diagnostic and Therapeutic Challenges . . . . . . . . . . . . . . . . . . . . 225

Poster Session 4

Poster Session 5 t

Huntington’s Disease and Tardive Syndromes 1 P5.3-001 –P5.3-017 . . . . . . . . . . . . . . . 142

12:00 p.m.–1:00 p.m.

Poster Session 6

Huntington’s Disease and Tardive Syndromes 2 P6.3-001 –P6.3-015 . . . . . . . . . . . . . . . 148

1:00 p.m.–1:45 p.m.

Pursuing a Career in Movement Disorders . . . . . . . . . . . . . . . . . . . . . 231 1:00 p.m.–3:00 p.m.

C101 The Dystonias: Diagnosis, Treatment and Update on Etiologies Parkinson’s Disease: Exercise, Mental C107 Actualización en trastornos del Health, and Social Determinants 2 movimiento (Update in Movement P2.3-008 –P2.3-014 . . . . . . . . . . . . . . . 125 Disorders) Surgical Therapies in Movement Disorders Parkinson’s Disease Biomarkers and S17 2 Pathophysiology . . . . . . . . . . . . . . . . . 90 P2.3-001 –P2.3-007. . . . . . . . . . . . . . . 125 Poster Session 2

AAN.com/view/20AM 249

Movement Disorders

How and When to Speak Up as a Bystander . . . . . . . . . . . . . . . . . . . . . 223 Team Science: Implications for Promotions and Tenure . . . . . . . . . . 221

Poster Session 1

1:30 p.m.–3:30 p.m.

Women in Neurology: Thriving Through Challenges . . . . . . . . . . . . . 223

Thursday, April 30

Tourette Syndrome: Assessment and Management

Nonmotor Manifestations of Parkinson’s Disease 2 Huntington’s Disease, Tardive Dyskinesia, and Functional Movement Disorders . . . . . . . . . . . . . . . . . . . . . . 86

5:30 p.m.–6:30 p.m.

9:30 a.m.–11:30 a.m.

3:00 p.m.–3:45 p.m.

4:00 p.m.–4:45 p.m.

Nonmotor Manifestations of Parkinson’s Disease 1 Neurology Update 1: Movement Disorders, Behavioral Neurology, and Neuromuscular Diseases

3:30 p.m.–5:30 p.m.

Grit, Resilience, and a Healthy Dose of Fun: How to Succeed at Your Professional Organization . . . . . . . . 221 Tools and Resources to Combat Imposter Phenomenon . . . . . . . . . . 223

Parkinson’s Disease Genetics and Imaging 2 P3.3-001 –P3.3-017 . . . . . . . . . . . . . . . 131

PROGRAMS BY TOPIC

Navigating Conflict . . . . . . . . . . . 223 Setting the Stage for Success: Building Your Career by Finding Your Mentor and Mentee Match . . . . . . 232

Poster Session 3

1:00 p.m.–1:45 p.m.

Communicate Better! Presenting and Pitching New Ideas . . . . . . . . . .223

5:00 p.m.–5:45 p.m.

Next Level Leadership: Building Your Personal Development Plan . . . . . . 223 Mentorship: Pearls and Pitfalls . . . . . . . . . . . . . . . . . . . . . . . . 221

Parkinson’s Disease Genetics and Imaging 1 P2.3-015 –P2.3-017. . . . . . . . . . . . . . . . 126

Women in Health Care Leadership: Time for Change . . . . . . . . . . . . . . . . 223

2020 PROGRAMS BY TOPIC 3:30 p.m.–5:30 p.m.

8:00 a.m.–9:00 a.m.

C118 Spinocerebellar and Spastic Ataxias: Diagnosis and Management C123 Estudios de cohorte de latinoamericanos: enfermedad de Alzheimer, enfermedad de Huntington y derrame cerebral (Latin American Cohort Studies: Alzheimer’s, Huntington’s, and Stroke) IS2 Invited Science: Movement Disorders . . . . . . . . . . . . . . . . . . . . . . 76

P11

P12

PROGRAMS BY TOPIC

Atypical Parkinsonism and Ataxia 1 P7.3-001 –P7.3-015. . . . . . . . . . . . . . . . 154

7:00 a.m.–9:00 a.m.

C134 Movement Disorders for the General Neurologist 1: New Concepts in the Diagnosis and Management of Parkinson’s Disease 8:00 a.m.–9:00 a.m.

Poster Session 8

Atypical Parkinsonism and Ataxia 2 P8.3-001 –P8.3-011. . . . . . . . . . . . . . . 160 Parkinson’s Disease Clinical Trials and Methodology 1 P8.3-012 –P8.3-017. . . . . . . . . . . . . . . . 160

12:00 p.m.–1:00 p.m.

Poster Session 9

Parkinson’s Disease Clinical Trials and Methodology 2 P9.3-001 –P9.3-017 . . . . . . . . . . . . . . . 166

C147 Movement Disorders for the General Neurologist 2: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia 3:30 p.m.–5:30 p.m.

C163 Movement Disorders for the General Neurologist 3: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics 5:30 p.m.–6:30 p.m.

Wednesday, April 29 7:00 a.m.–9:00 a.m.

C175 Paroxysmal Movement Disorders

250 2020 AAN Annual Meeting

Functional Neurologic Disorders and Miscellaneous Movement Disorder Topics 1 P12.3-015 –P12.3-017. . . . . . . . . . . . . . 183 Motor and Non-motor Features of Parkinson’s Disease 2 P12.3-001 –P12.3-014. . . . . . . . . . . . . . 183

C192 Therapy of Movement Disorders: A Case-based Approach S41 Parkinson’s Disease Interventions and Clinical Trials . . . . . . . . . . . . . . . 104

1:00 p.m.–3:00 p.m.

C233 Deep Brain Stimulation 1: Basic Principles and Programming in Movement Disorders S50 Ataxia, Dystonia, and Atypical Parkinsonism . . . . . . . . . . . . . . . . . . 109 N5 Neuroscience in the Clinic: Testing for Common Neurodegenerative Disorders . . . . . . . . . . . . . . . . . . . . . . 74 3:30 p.m.–5:30 p.m.

C248 Deep Brain Stimulation 2: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders C251 Continuum® Test Your Knowledge: A Multiple-choice Question Review 2 S55 Movement Disorders: Neuromodulation, Circuits, and Management . . . . . . . . . . . . . . . . . . 112 5:30 p.m.–6:30 p.m.

P16

1:00 p.m.–5:30 p.m.

C198 Skills Workshop: Clinical Uses of Botulinum Toxin for Dystonia 3:30 p.m.–5:30 p.m.

C201 Sleep for the Practicing Neurologist 2: Disordered Sleep in Common Neurologic Diseases C210 Evaluating Tremor in the Office 5:30 p.m.–6:30 p.m.

P13

Poster Session 13

Functional Neurologic Disorders and Miscellaneous Movement Disorder Topics 2 P13.3-001 –P13.3-017. . . . . . . . . . . . . . 189

7:00 a.m.–9:00 a.m.

Poster Session 16

Dystonia, Tics, and Restless Legs Syndrome 2 P16.3-001 –P16.3-017. . . . . . . . . . . . . . 207

6:30 p.m.–9:30 p.m.

C255 Case Studies: Unusual Movement Disorders

Friday, May 1 7:00 a.m.–9:00 a.m.

C263 Balance and Gait Disorders 11:30 a.m.–1:00 p.m.

P17

Thursday, April 30

Poster Session 17: Neuroinflammation

Movement Disorders 1 P17.3-014-P17.3-017. . . . . . . . . . . . . . . 213 Movement Disorders 2 P17.4-001-P17.4-011. . . . . . . . . . . . . . . 213

1:00 p.m.–3:00 p.m.

C218 Diagnosis and Treatment of Functional Movement Disorders

C269 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment

8:00 a.m.–9:00 a.m.

3:30 p.m.–4:30 p.m.

P14

Poster Session 10

Parkinson’s Disease Clinical Trials and Methodology 3 P10.3-001 –P10.3-009 . . . . . . . . . . . . . 172 Tools and Technology to Measure Parkinson’s Disease Symptoms 1 P10.3-010 –P10.3-017. . . . . . . . . . . . . . 172

Poster Session 12

1:00 p.m.–3:00 p.m.

P10

MS and CNS Inflammatory Disease

Poster Session 7

Tuesday, April 28

Motor and Non-motor Features of Parkinson’s Disease 1 P11.3-010 –P11.3-017. . . . . . . . . . . . . . 177 Tools and Technology to Measure Parkinson’s Disease Symptoms 2 P11.3-001 –P11.3-009. . . . . . . . . . . . . . 177

12:00 p.m.–1:00 p.m.

5:30 p.m.–6:30 p.m.

Poster Session 11

Poster Session 14

Motor and Non-motor Features of Parkinson’s Disease 3 P14.3-001 –P14.3-007 . . . . . . . . . . . . . 195 Movement Disorders: Tremor 1 P14.3-008 –P14.3-017. . . . . . . . . . . . . . 196

C272

MS and CNS Inflammatory Disease

12:00 p.m.–1:00 p.m.

P15

Poster Session 15

Dystonia, Tics, and Restless Legs Syndrome 1 P15.3-010 –P15.3-017. . . . . . . . . . . . . . 201 Movement Disorders: Tremor 2 P15.3-001 –P15.3-009 . . . . . . . . . . . . . 201

Neurology Update 5: Movement Disorders

Saturday, April 25 12:00 p.m.–1:00 p.m.

Poster Session 1

Multiple Sclerosis: Neuroimaging 1 P1.1-001 –P1.1-022. . . . . . . . . . . . . . . . 118

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area

Sunday, April 26 7:00 a.m.–9:00 a.m.

C44

5:30 p.m.–6:30 p.m.

Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-making

8:00 a.m.–9:00 a.m.

12:00 p.m.–1:00 p.m.

Poster Session 3

Multiple Sclerosis: Clinical Trials and Disease-modifying Therapy . . . . . . . 83

3:30 p.m.–5:30 p.m.

C76 S10

Neurology Update 2: Multiple Sclerosis, Neuro-oncology, and Headache Multiple Sclerosis: Biomarkers and Outcome Measures . . . . . . . . . . . . . . 86 Poster Session 4

Multiple Sclerosis: Epidemiology 1 P4.1-009 –P4.1-020. . . . . . . . . . . . . . . . 136 Multiple Sclerosis: Immunology and Basic Science 2 P4.1-001 –P4.1-008. . . . . . . . . . . . . . . . 136

Monday, April 27 8:00 a.m.–9:00 a.m.

Poster Session 5

Multiple Sclerosis: Epidemiology 2 P5.1-001 –P5.1-006. . . . . . . . . . . . . . . . 141 Multiple Sclerosis: Prognosis P5.1-007 –P5.1-016. . . . . . . . . . . . . . . . 141 Multiple Sclerosis: Therapeutics MOA and Safety 1 P5.1-017 –P5.1-023. . . . . . . . . . . . . . . . 142

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session . . . . . . . . . . . . . . . 64 12:00 p.m.–1:00 p.m.

3:30 p.m.–5:30 p.m.

C124 Multiple Sclerosis Therapy: Symptom Management 8:00 a.m.–9:00 a.m.

Poster Session 6

Multiple Sclerosis: Therapeutics MOA and Safety 2 P6.1-001 –P6.1-022. . . . . . . . . . . . . . . . 147

1:00 p.m.–3:00 p.m.

C100 Treatment of Pediatric Multiple Sclerosis in the Current Era 3:30 p.m.–5:30 p.m.

C117 S24

Pregnancy and Breastfeeding in Multiple Sclerosis Pregnancy, Pediatric MS, and Early MS . . . . . . . . . . . . . . . . . . . . . . . . . . . .94

Poster Session 8

Multiple Sclerosis: Clinical Trials and Therapeutics 2 P8.1-001 –P8.1-022. . . . . . . . . . . . . . . . 159

C209 Multiple Sclerosis Therapy: Diseasemodifying Treatment 2 S45 Multiple Sclerosis: Imaging . . . . . . . 106 5:30 p.m.–6:30 p.m.

P13

9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session . . . . . . . . . . . . . . . . . . . . . . . 65 12:00 p.m.–1:00 p.m.

Poster Session 9

Multiple Sclerosis: Clinical Trials and Therapeutics 3 P9.1-001 –P9.1-022. . . . . . . . . . . . . . . 165

1:00 p.m.–3:00 p.m.

C146 Multiple Sclerosis Overview 1: Clinical Pearls S29 Multiple Sclerosis: Disease-modifying Therapy . . . . . . . . . . . . . . . . . . . . . . . . 97

Poster Session 13

Multiple Sclerosis: Clinical Practice and Decision-making 3 P13.1-001 –P13.1-015. . . . . . . . . . . . . . 188 Neuromyelitis Optica and Other Autoimmune Disorders 1 P13.1-016 –P13.1-022. . . . . . . . . . . . . . 189

Thursday, April 30 7:00 a.m.–9:00 a.m.

C217

MS Across the Lifespan

8:00 a.m.–9:00 a.m.

P14

Poster Session 14 Neuromyelitis Optica and Other Autoimmune Disorders 2 P14.1-001 –P14.1-016. . . . . . . . . . . . . . 194 Multiple Sclerosis: Clinical Assessments and Outcome Measures 1 P14.1-017 –P14.1-022. . . . . . . . . . . . . . 195

3:30 p.m.–5:30 p.m.

C162 Multiple Sclerosis Overview 2: Clinical Advances 12:00 p.m.–1:00 p.m. C168 Actualización en esclerosis múltiple y P15 Poster Session 15 optica de neuromyelitis (Update in MS Multiple Sclerosis: Clinical Assessments and Neuromyelitis Optica) and Outcome Measures 2 P15.1-001 –P15.1-021. . . . . . . . . . . . . . 200 N3 Neuroscience in the Clinic: Melatonin and Disrupted Sleep in 1:00 p.m.–3:00 p.m. Neurologic Disorders . . . . . . . . . . . . . 72 S49 Multiple Sclerosis: Basic Science . . 109 5:30 p.m.–6:30 p.m.

P10

Poster Session 10

Multiple Sclerosis: Symptom Assessment and Management P10.1-001 –P10.1-022. . . . . . . . . . . . . . 171

Wednesday, April 29 8:00 a.m.–9:00 a.m.

C182 Education Blitz: Multiple Sclerosis P11 Poster Session 11

Multiple Sclerosis Special Populations: Pregnancy and Pediatrics P11.1-001 –P11.1-014. . . . . . . . . . . . . . . 176 Multiple Sclerosis: Clinical Practice and Decision-making 1 P11.1-015 –P11.1-021. . . . . . . . . . . . . . . 177

3:30 p.m.–5:30 p.m.

C251 Continuum® Test Your Knowledge: A Multiple-choice Question Review 2 S54 Multiple Sclerosis: Disease Progression, Disease-modifying Therapy, and Clinical Considerations . . . . . . . . . . . . . . . . . 111 5:30 p.m.–6:30 p.m.

P16

Poster Session 16

Multiple Sclerosis: Clinical Assessments and Outcome Measures 3 P16.1-001 –P16.1-019. . . . . . . . . . . . . . 206

Friday, May 1 7:00 a.m.–9:00 a.m.

C262 Diagnostic Pearls in Myelitis: a Casebased Approach AAN.com/view/20AM 251

MS and CNS Inflammatory Disease

1:00 p.m.–3:00 p.m.

7:00 a.m.–9:00 a.m.

5:30 p.m.–6:30 p.m.

Multiple Sclerosis: Clinical Practice and Decision-making 2 P12.1-001 –P12.1-022. . . . . . . . . . . . . . 182

Tuesday, April 28

1:00 p.m.–3:00 p.m.

Poster Session 12

PROGRAMS BY TOPIC

Multiple Sclerosis: Immunology and Basic Science 1 P3.1-001 –P3.1-022. . . . . . . . . . . . . . . . 130

Multiple Sclerosis: Clinical Trials and Therapeutics 1 P7.1-012 –P7.1-022 . . . . . . . . . . . . . . . . 153 Multiple Sclerosis: Therapeutics MOA and Safety 3 P7.1-001 –P7.1-011. . . . . . . . . . . . . . . . 153

12:00 p.m.–1:00 p.m.

P12

C191 Multiple Sclerosis Therapy: Diseasemodifying Treatment 1 S40 Multiple Sclerosis: Clinical Trials . . 104

Poster Session 2

Multiple Sclerosis: Neuroimaging 2 P2.1-001 –P2.1-022. . . . . . . . . . . . . . . . 124

Poster Session 7

2020 PROGRAMS BY TOPIC 11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation MS and CNS Inflammatory Disease 1 P17.1-001 - P17.1-020. . . . . . . . . . . . . . . 211 MS and CNS Inflammatory Disease 2 P17.2-001 - P17.2-004. . . . . . . . . . . . . . 212

1:00 p.m.–3:00 p.m.

C268 Neuromyelitis Optica Spectrum Disorders

Tuesday, April 28 7:00 a.m.–9:00 a.m.

C128 Sports Neurology: Enhancing Athletic Performance 1:00 p.m.–3:00 p.m.

C142 Neurologic Intensive Care 3: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction

PROGRAMS BY TOPIC

Saturday, April 25 9:30 a.m.–11:30 a.m.

C15

Severe TBI: From ICU to Rehabilitation

1:30 p.m.–3:30 p.m.

C29

Critical Care Consultations for Neurohospitalists

4:15 p.m.–5:30 p.m.

Hot Topics Plenary Session . . . . 62

Sunday, April 26 7:00 a.m.–7:45 a.m.

Much More Than Traumatic Brain Injury: Identifying Funding Opportunities from the Department of Defense . . . . . . . . . . . . . . . . . . . . . . 236 8:00 a.m.–9:00 a.m.

C48

Education Blitz: Child Neurology: Concussion

1:00 p.m.–5:30 p.m.

C62

Skills Workshop: Brain Death: How to Perform a Brain Death Evaluation, Avoid Pitfalls, and Convey the News to the Family

3:30 p.m.–5:30 p.m.

C65

Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

Monday, April 27 NeuroTrauma/Critical Care/ Sports

7:00 a.m.–9:00 a.m.

C82

Critical Care EEG Monitoring

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session . . . . . . . . . . . . . . . 64 1:00 p.m.–3:00 p.m.

C96

Neurologic Intensive Care 1: The Essentials

3:30 p.m.–5:30 p.m.

C112 Neurologic Intensive Care 2: Vascular Disease 252 2020 AAN Annual Meeting

Sports Neurology and Neuro Trauma . . . . . . . . . . . . . . . . . . . . . . . . 97

3:30 p.m.–5:30 p.m.

C158 Neurologic Intensive Care 4: Case Studies in the ICU C166 Therapy in Neurology 2: Neuroophthalmology and Critical Care 5:30 p.m.–6:30 p.m.

P10

Poster Session 10

Sports Neurology and Neuro Trauma 1 P10.11-001 –P10.11-012 . . . . . . . . . . . . 175

Wednesday, April 29

Poster Session 15

Neurocritical Care: Cerebrovascular Disease and Cardiac Arrest 1 P15.10-011 –P15.10-018. . . . . . . . . . . . 204 Neurocritical Care: Epilepsy and TBI 2 P15.10-001 –P15.10-010. . . . . . . . . . . . 204

1:00 p.m.–1:45 p.m.

Pursuing a Career in Neurocritical Care. . . . . . . . . . . . . . . . . . . . . . . . . .231

3:30 p.m.–4:45 p.m.

S30

Neuro Trauma, Critical Care, and Sports Neurology

12:00 p.m.–1:00 p.m.

P15

1:00 p.m.–3:00 p.m.

S48

Neurocritical Care: Traumatic Brain Injury and Goals-of-care Decisionmaking . . . . . . . . . . . . . . . . . . . . . . . 108

3:30 p.m.–5:30 p.m.

C252 Cuidados neurocríticos (Neurocritical Care) 5:30 p.m.–6:30 p.m.

P16

Poster Session 16

Neurocritical Care: Cerebrovascular Disease and Cardiac Arrest 2 P16.10-001 –P16.10-018. . . . . . . . . . . . 209

7:00 a.m.–9:00 a.m.

Friday, May 1

C178 Emergency Room Neuroophthalmology

11:30 a.m.–1:00 p.m.

P17

8:00 a.m.–9:00 a.m.

P11

Poster Session 11

Sports Neurology and Neuro Trauma 2 P11.11-001 –P11.11-013. . . . . . . . . . . . . 181

1:00 p.m.–3:00 p.m.

C201 Sleep for the Practicing Neurologist 2: Disordered Sleep in Common Neurologic Diseases C204 Concussion: Chronic Symptoms— Selected Considerations for Why Your Patient May Not be Getting Better S46 Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron/Charcot Marie Tooth . . . . . 107

Pursuing a Career in Sports Neurology . . . . . . . . . . . . . . . . . . . . . 232 1:00 p.m.–3:00 p.m.

S61

C215 Sports Concussion: Event Coverage Foundational Skills and Sport Specific Pearls 8:00 a.m.–9:00 a.m.

P14

Poster Session 14

Neurocritical Care: Epilepsy and TBI 1 P14.10-001 –P14.10-018. . . . . . . . . . . . 198

Neurocritical Care: Cerebrovascular Disease . . . . . . . . . . . . . . . . . . . . . . . 115

3:00 p.m.–3:45 p.m.

Discovering What Drives You...and What Keeps You Going . . . . . . . . . . 232

Neuromuscular and Clinical Neurophysiology (EMG)

Thursday, April 30 7:00 a.m.–9:00 a.m.

Neurocritical Care P17.6-008 - P17.6-009. . . . . . . . . . . . . . 214 Neuro Trauma and Sports Neurology P17.11-007 . . . . . . . . . . . . . . . . . . . . . . . 217

1:00 p.m.–1:45 p.m.

C186 Concussion: Topics in Acute Concussion 3:30 p.m.–5:30 p.m.

Poster Session 17: Neuroinflammation

Saturday, April 25 7:00 a.m.–9:00 a.m.

Child Neurology: Neuromuscular/ Autoimmune Neurology

9:30 a.m.–11:30 a.m.

C18

Clinical EMG 1: Principles and Practice of NCS and Needle EMG

Poster Session 1

Neuromuscular and Clinical Neurophysiology (EMG): Imaging, Neurophysiology, and Outcome Measures 1 P1.7-001 –P1.7-014. . . . . . . . . . . . . . . . 121

1:30 p.m.–3:30 p.m.

C35

Clinical EMG 2: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography

Sunday, April 26

8:00 a.m.–9:00 a.m.

Contemporary Clinical Issues Plenary Session . . . . . . . . . . . . . . . 64 12:00 p.m.–1:00 p.m.

8:00 a.m.–9:00 a.m.

Poster Session 2

Neuromuscular and Clinical Neurophysiology (EMG): Imaging, Neurophysiology, and Outcome Measures 2 P2.7-001 –P2.7-014. . . . . . . . . . . . . . . . 127

12:00 p.m.–1:00 p.m.

Poster Session 3

Neuromuscular Junction Disorders 1 P3.7-001 –P3.7-014. . . . . . . . . . . . . . . . 133

1:00 p.m.–3:00 p.m.

C51 C57 C61 S6

Child Neurology: A Case-based Approach Neuromuscular Junction Disorders 1: Myasthenia Gravis, Ocular, and MuSK Myasthenia Neurology Update 1: Movement Disorders, Behavioral Neurology, and Neuromuscular Diseases Neuromuscular and Clinical Neurophysiology (EMG): Genetic Muscle Disorders . . . . . . . . . . . . . . . . 84 Neuromuscular Junction Disorders 2: Toxins, Lambert-Eaton Syndrome, and Less Common Disorders of Neuromuscular Transmission

C102 Peripheral Neuropathy 2: Approach to Sensory Neuropathies and Neuropathies Associated with Rheumatologic and Hematologic Disorders S18 Neuromuscular and Clinical Neurophysiology (EMG): Neuroimaging, Outcome Measures, and Biomarkers . . . . . . . . . . . . . . . . . 91

3:30 p.m.–4:30 p.m.

S19

Peripheral Neuropathy 1: Anatomical Basis and Acquired Demyelinating Neuropathies

P10

Autonomic Disorders . . . . . . . . . . . . . 91

C119 Peripheral Neuropathy 3: Genetic Neuropathies: Molecular Diagnosis and Treatment Perspectives 5:30 p.m.–6:30 p.m.

Poster Session 7

Amyotrophic Lateral Sclerosis 3 P7.7-001 –P7.7-007. . . . . . . . . . . . . . . . 156 Spinal Muscular Atrophy/Motor Neuron Disorders 1 P7.7-008 –P7.7-014. . . . . . . . . . . . . . . . 156

Tuesday, April 28 8:00 a.m.–9:00 a.m.

12:00 p.m.–1:00 p.m.

Poster Session 9

Inherited Muscle Disorders 2 P10.7-001 –P10.7-014. . . . . . . . . . . . . . 173

Wednesday, April 29 7:00 a.m.–9:00 a.m.

C176 Mastering EMG Waveform Recognition Skills in Just Two Hours! 8:00 a.m.–9:00 a.m.

P11

Poster Session 11

Inherited Muscle Disorders 3 P11.7-001 –P11.7-008. . . . . . . . . . . . . . 179 Peripheral Neuropathy 1 P11.7-009 –P11.7-015 . . . . . . . . . . . . . . 179

12:00 p.m.–1:00 p.m.

P12

Poster Session 12

Peripheral Neuropathy 2 P12.7-001 –P12.7-014. . . . . . . . . . . . . . 185

1:00 p.m.–3:00 p.m.

C184 Evaluation and Management of Autonomic Disorders: Autonomic Testing, Failure, and Peripheral Neuropathies 3:30 p.m.–5:30 p.m.

S46

Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron/Charcot Marie Tooth . . . . . 107

5:30 p.m.–6:30 p.m.

P13

Poster Session 8

Amyotrophic Lateral Sclerosis 4 P8.7-001 –P8.7-006. . . . . . . . . . . . . . . . 162 Spinal Muscular Atrophy/Motor Neuron Disorders 2 P8.7-007 –P8.7-014. . . . . . . . . . . . . . . . 162

Poster Session 10

Poster Session 13

Peripheral Neuropathy 3 P13.7-001 –P13.7-014. . . . . . . . . . . . . . 191

Thursday, April 30 8:00 a.m.–9:00 a.m.

P14

Poster Session 14

Peripheral Neuropathy 4 P14.7-001 –P14.7-014. . . . . . . . . . . . . . 197

Inherited Muscle Disorders 1 P9.7-012 –P9.7-015. . . . . . . . . . . . . . . . 168 Spinal Muscular Atrophy/Motor Neuron Disorders 3 P9.7-001 –P9.7-011. . . . . . . . . . . . . . . . 168

AAN.com/view/20AM 253

Neuromuscular and Clinical Neurophysiology (EMG)

C87

5:30 p.m.–6:30 p.m.

3:30 p.m.–5:30 p.m.

Neuromuscular Junction Disorders 2 P4.7-001 –P4.7-012. . . . . . . . . . . . . . . . 138

7:00 a.m.–9:00 a.m.

C164 Clinical Approach to Muscle Disease 2: Inflammatory Myopathies and Muscle Pathology S35 Amyotrophic Lateral Sclerosis . . . . 100

C109 Skills Workshop: Neuromuscular Ultrasound

Poster Session 4

Monday, April 27

3:30 p.m.–5:30 p.m.

1:00 p.m.–5:30 p.m.

5:30 p.m.–6:30 p.m.

Amyotrophic Lateral Sclerosis 2 P6.7-011 –P6.7-015. . . . . . . . . . . . . . . . 150 Autonomic Disorders 2 P6.7-001 –P6.7-010. . . . . . . . . . . . . . . . 150

C142 Neurologic Intensive Care 3: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction C148 Clinical Approach to Muscle Disease 1: Role of Antibodies, Muscle Imaging, and Genetic Testing IS3 Invited Science: Neuromuscular . . 77

1:00 p.m.–3:00 p.m.

3:30 p.m.–5:30 p.m.

C71

Poster Session 6

1:00 p.m.–3:00 p.m.

PROGRAMS BY TOPIC

C45

Maximizing Quality of Life in Stroke, ALS, Parkinson’s Disease, and Dementia: A Palliative Approach Clinical EMG 3: Practical Applications of EMG in Neuromuscular Disease

Amyotrophic Lateral Sclerosis 1 P5.7-008 –P5.7-015. . . . . . . . . . . . . . . . 144 Autonomic Disorders 1 P5.7-001 –P5.7-007. . . . . . . . . . . . . . . . 144

9:15 a.m.–11:30 a.m.

7:00 a.m.–9:00 a.m.

C40

Poster Session 5

2020 PROGRAMS BY TOPIC 12:00 p.m.–1:00 p.m.

P15

Poster Session 15

Acquired Myopathies/Other Neuromuscular Disorders 1 P15.7-004 –P15.7-015. . . . . . . . . . . . . . 203 Peripheral Neuropathy 5 P15.7-001 –P15.7-003. . . . . . . . . . . . . . 203

1:00 p.m.–3:00 p.m.

C234 Small Fiber Neuropathies: Sensory, Autonomic, and Both 1: Focus on Autonomic Nervous System

Sunday, April 26

Friday, May 1

8:00 a.m.–9:00 a.m.

11:30 a.m.–1:00 p.m.

PROGRAMS BY TOPIC

C238 Skills Workshop: EMG: Basic C249 Small Fiber Neuropathies: Sensory, Autonomic, and Both 2: Focus on Sensory Nervous System S56 Neuromuscular Therapeutics . . . . . 113 5:30 p.m.–6:30 p.m.

P16

Poster Session 16

Basic Science and Clinical Neuro-oncology 2 P2.10-001 –P2.10-014. . . . . . . . . . . . . . 128

Poster Session 3

Basic Science and Clinical Neuro-oncology 3 P3.10-001 –P3.10-003. . . . . . . . . . . . . . 134 Neuro-oncology: Clinical Cases and More 1 P3.10-004 –P3.10-015. . . . . . . . . . . . . . 134

Neurology Update 2: Multiple Sclerosis, Neuro-oncology, and Headache

5:30 p.m.–6:30 p.m.

Poster Session 4

Neuro-oncology: Clinical Cases and More 2 P4.10-001 –P4.10-015. . . . . . . . . . . . . . 140

6:30 p.m.–9:30 p.m.

Monday, April 27

C256 Case Studies: Diagnosis and Management of Unusual Cases in Neuromuscular Disease

1:00 p.m.–3:00 p.m.

7:00 a.m.–9:00 a.m.

C264

Video Case Studies in Neuromuscular Disorders

11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation Neuromuscular/Clinical Neurophysiology (EMG) P17.7-001 - P17.7-014. . . . . . . . . . . . . . . 214

1:00 p.m.–3:00 p.m.

C271 Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis

S14

Neuro-oncology . . . . . . . . . . . . . . . . . 88

Tuesday, April 28

Neuro-oncology

12:00 p.m.–1:00 p.m.

Poster Session 1

Basic Science and Clinical Neuro-oncology 1 P1.10-001 –P1.10-015. . . . . . . . . . . . . . 122

1:00 p.m.–1:45 p.m.

#ilooklikeaneuroonc . . . . . . . . . . 231

254 2020 AAN Annual Meeting

7:00 a.m.–9:00 a.m.

Nystagmus and Saccadic Intrusions Made Simple

4:15 p.m.–5:30 p.m.

Hot Topics Plenary Session . . . . 62

Sunday, April 26 7:00 a.m.–9:00 a.m.

C41

Neuro-ophthalmology 1: Visual Loss, Optic Neuropathies, and Papilledema

1:00 p.m.–3:00 p.m.

C53

Neuro-ophthalmology 2: Optic Neuritis, Visual Fields, and Anisocoria

3:30 p.m.–5:30 p.m.

C66

Neuro-ophthalmology 3: Diplopia, Ocular Motility Disorders, and Nystagmus

C126 The Palliative Care Guide in Neurology: 5:30 p.m.–6:30 p.m. Poster Session 4 Best Practice in Communication, P4 Neuro-ophthalmology/Neuro-otology 1 Advance Care Planning, and End-of-life Care of Patients with Brain Tumors P4.11-001 –P4.11-013 . . . . . . . . . . . . . . 140 and Other Life-limiting Neurologic Disorders Monday, April 27 3:30 p.m.–5:30 p.m.

7:00 a.m.–9:00 a.m.

C156

C81

Pediatric Neuro-oncology Update: Advances in Cures and Long-term Survivorship

Wednesday, April 29 C172 Neuro-oncology in 2020: Navigating Current Trends 1:00 p.m.–3:00 p.m.

Saturday, April 25

Neuro-oncology P17.10-001 - P17.10-007 . . . . . . . . . . . . 216

Saturday, April 25

7:00 a.m.–9:00 a.m.

Neuro-oncology

Poster Session 17: Neuroinflammation

Neuro-opthalmology/ Neuro-otology

3:30 p.m.–5:30 p.m.

C76

Acquired Myopathies/Other Neuromuscular Disorders 2 P16.7-001 –P16.7-014. . . . . . . . . . . . . . 208

Friday, May 1

P17

12:00 p.m.–1:00 p.m.

1:00 p.m.–5:30 p.m. 3:30 p.m.–5:30 p.m.

Poster Session 2

C187 Neurologic Consultations in Cancer Patients 1 3:30 p.m.–5:30 p.m.

C205 Neurologic Consultations in Cancer Patients 2

Thursday, April 30 3:30 p.m.–5:30 p.m.

C243 Core Principles of Brain Tumors

Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia

12:00 p.m.–1:00 p.m.

Poster Session 6

Neuro-ophthalmology/Neuro-otology 2 P6.11-001 –P6.11-013. . . . . . . . . . . . . . 152

3:30 p.m.–5:30 p.m.

C114 Higher Cortical Visual Disorders: Casebased Review C121 Neurology Update 4: Neuro-infectious Disease, Neuro-otology, and Neuroophthalmology

Tuesday, April 28 7:00 a.m.–9:00 a.m.

C129 Neuro-ophthalmology: Overview and Update

Poster Session 9

Neuro-ophthalmology/Neuro-otology 3 P9.11-001 –P9.11-013. . . . . . . . . . . . . . 170

1:00 p.m.–1:45 p.m.

The Eyes Have It: Neuroophthalmology Is the Career for You! . . . . . . . . . . . . . . . . . . . . . . . . . . 231 3:30 p.m.–5:30 p.m.

C27 C30

C178 Emergency Room Neuroophthalmology 1:00 p.m.–3:00 p.m.

C188 Neuro-otology Basics: Peripheral Vestibular Disorders

3:30 p.m.–5:30 p.m.

C206 Neuro-otology Advanced: Central Disorders of Dizziness

Thursday, April 30

1:00 p.m.–3:00 p.m.

C229

Ophthalmic Imaging for Neurologists: OCT and Funduscopy in the 21st Century C237 Continuum® Test Your Knowledge: A Multiple-choice Question Review 1

Friday, May 1 7:00 a.m.–9:00 a.m.

C260 Pediatric Neuro-ophthalmology Update 11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation

C16

Addiction

C30

C38

Rehabilitation in Neurology

3:30 p.m.–5:30 p.m.

C64

Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy

Monday, April 27 7:00 a.m.–9:00 a.m.

C79

Neuro-rehabilitation Update

5:30 p.m.–6:30 p.m.

3:00 p.m.–3:45 p.m.

Case Studies in Neuropalliative Care: How My Patients Impacted My Career Choice . . . . . . . . . . . . . . . . . . 231

Sunday, April 26 7:00 a.m.–9:00 a.m.

C40

Poster Session 7

Neuro-rehabilitation 1 P7.2-001 –P7.2-012. . . . . . . . . . . . . . . . 154

C127

Spinal Cord Rehabilitation

Poster Session 8

Neuro-rehabilitation 2 P8.2-001 –P8.2-013. . . . . . . . . . . . . . . . 160

1:00 p.m.–3:00 p.m.

C142 Neurologic Intensive Care 3: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction

C64

Frontiers in Neuroscience Plenary Session . . . . . . . . . . . . . . . 66 1:00 p.m.–3:00 p.m.

S41

Parkinson’s Disease Interventions and Clinical Trials . . . . . . . . . . . . . . . . . . 104

3:30 p.m.–4:30 p.m.

S42

Neuro-rehabilitation . . . . . . . . . . . . 105

Friday, May 1

Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy

4:00 p.m.–4:45 p.m.

Mindfulness-based Chronic Pain Management . . . . . . . . . . . . . . . . . . 229

Monday, April 27 7:00 a.m.–9:00 a.m.

C91

Wednesday, April 29 9:15 a.m.–11:30 a.m.

Neuroscience in the Clinic: Novel Approaches to Pain Management . . 70

3:30 p.m.–5:30 p.m.

8:00 a.m.–9:00 a.m.

Maximizing Quality of Life in Stroke, ALS, Parkinson’s Disease, and Dementia: A Palliative Approach

1:00 p.m.–3:00 p.m.

Tuesday, April 28 7:00 a.m.–9:00 a.m.

Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome

Skills Workshop: Practical Training in Injection Techniques in the Treatment of Headache Disorders

1:00 p.m.–3:00 p.m.

C97

Core Concepts in Pain Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids

3:30 p.m.–5:30 p.m.

C113 Core Concepts in Pain Management: Safe and Appropriate Opioid Prescribing in Neurology

11:30 a.m.–1:00 p.m.

P17

Neuro-rehabilitation

Saturday, April 25 9:30 a.m.–11:30 a.m.

C15

Severe TBI: From ICU to Rehabilitation

Poster Session 17: Neuroinflammation Tuesday, April 28 Neuro-rehabilitation P17.11-013. . . . . . . . . . . . . . . . . . . . . . . . 217

7:00 a.m.–9:00 a.m.

C126 The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurologic Disorders AAN.com/view/20AM 255

Neuro-rehabilitation

Neuro-ophthalmology/Neuro-otology P17.11-008 . . . . . . . . . . . . . . . . . . . . . . . 217

9:30 a.m.–11:30 a.m.

7:00 a.m.–9:00 a.m.

C222 Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings

Saturday, April 25

1:30 p.m.–3:30 p.m.

1:00 p.m.–5:30 p.m.

C199 Skills Workshop: Neuro-ophthalmology and Neurovestibular Exam Lab

Pain and Palliative Care

Sunday, April 26

Wednesday, April 29 7:00 a.m.–9:00 a.m.

Myelopathies: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome

PROGRAMS BY TOPIC

C166 Therapy in Neurology 2: Neuroophthalmology and Critical Care S32 Neuro-ophthalmology/ Neuro-otology . . . . . . . . . . . . . . . . . . 98

1:30 p.m.–3:30 p.m.

2020 PROGRAMS BY TOPIC 1:00 p.m.–3:00 p.m.

8:00 a.m.–8:45 a.m.

C139 How to Deliver Bad News

Wednesday, April 29 8:00 a.m.–9:00 a.m.

P11

Improving Delivery of Care and Novel Treatments for Pain and Palliative Patients 1 P11.5-001 –P11.5-012. . . . . . . . . . . . . . 178

PROGRAMS BY TOPIC

Poster Session 12

Improving Delivery of Care and Novel Treatments for Pain and Palliative Patients 2 P12.5-001 –P12.5-012. . . . . . . . . . . . . . 184

1:00 p.m.–1:45 p.m.

3:30 p.m.–4:45 p.m.

S52

From Bench to Bedside with Novel Treatments for Pain . . . . . . . . . . . . . 110

1:00 p.m.–3:00 p.m.

C59

Practice, Policy, and Ethics

Expert Witness and Medical-legal Neurology 101: What Is It and Is It for You? . . . . . . . . . . . . . . . . . . . . . 231 2:00 p.m.–2:45 p.m.

Learning Healthcare Systems (LHS): An Overview . . . . . . . . . . . . . 234 4:00 p.m.–4:45 p.m.

The Daily Coding Struggle: How to Make It Work . . . . . . . . . . . . . . . . . . 234 5:00 p.m.–5:45 p.m.

The How and Why of eConsults in Neurology . . . . . . . . . . . . . . . . . . . . . 234

C40 C47

Access in Academic Neurology: Strategies to Improve Access and Improve Ambulatory Clinic Workflow Maximizing Quality of Life in Stroke, ALS, Parkinson’s Disease, and Dementia: A Palliative Approach Contemporary Concerns About Brain Death Determination

The Benefits and Barriers in Practicing Neurology in Canada vs. the US . . . . . . . . . . . . . . . . . . . . . . . . 225 3:10 p.m.–3:20 p.m.

BusinesBytes: #AANAdvocacy . . . . . . . . . . . . . . . . 234 3:30 p.m.–5:30 p.m.

S22

From All Different Practice Settings: How to Navigate Discussions with Your Department Leadership . . . . . 231

What Your Practice Administrator Wants You to Know . . . . . . . . . . . . . 234 5:00 p.m.–5:45 p.m.

Using Cybersecurity in Your Practice . . . . . . . . . . . . . . . . . . . . . . . 234

3:10 p.m.–3:20 p.m.

BusinessBytes: Decoding Coding . . . . . . . . . . . . . . . . . . . . . . . . 234 3:30 p.m.–5:30 p.m.

Burnout and Resilience: Strategies and Evidence for Enhancing Well-being

4:00 p.m.–4:45 p.m.

The Neurologist’s Guide to the ABCs of Drug Pricing in the US . . . . 234

Tuesday, April 28 7:00 a.m.–9:00 a.m.

C131

Becoming an Agent of Change in Neurology Using Quality Improvement C136 Negotiating Like a Boss: Narrowing the Gender Gap 8:00 a.m.–8:45 a.m.

Talks for Trainees: How to Negotiate Your Employment Contract . . . . . . . 234

5:00 p.m.–5:45 p.m.

What Can I Do to Help Lower Drug Prices for My Patients? . . . . . . . . . . 234

8:00 a.m.–9:00 a.m.

Monday, April 27 7:00 a.m.–9:00 a.m.

C86

Residents in Private Practice

12:00 p.m.–12:45 p.m.

12:00 p.m.–1:00 p.m.

1:00 p.m.–1:45 p.m.

Starting a Practice From the Ground Up: A Guide for Neurologists C106 Source of Truth 2:00 p.m.–2:45 p.m.

Clinical Practice Through the Life Cycle . . . . . . . . . . . . . . . . . . . . . . . . . 231

Poster Session 9

Advocacy, Alzheimer’s Disease, and the Unconventional 2 P9.6-001 –P9.6-006. . . . . . . . . . . . . . . 167 Practice, Policy, and Ethics: Improving the Lives of Patients and Providers 1 P9.6-009 –P9.6-015 . . . . . . . . . . . . . . . 168

1:00 p.m.–1:45 p.m.

How to Successfully Publish Quality Improvement Projects . . . . . . . . . . . 234

1:00 p.m.–3:00 p.m.

C94

Advocacy, Alzheimer’s Disease, and the Unconventional 1 P8.6-001 –P8.6-013 . . . . . . . . . . . . . . . 161

Onboarding Your APPs: Prepare for Success . . . . . . . . . . . . . . . . . . . . 234

Different Practice Models for Success . . . . . . . . . . . . . . . . . . . . . . . 234 ICD-11: Global Impact on the Future of Neurology for the Next Generation . . . . . . . . . . . . . . . . . . . . 234

Poster Session 8

12:00 p.m.–12:45 p.m.

8:00 a.m.–8:45 p.m.

Talks for Trainees: Personal Finances for Residents and Fellows . . . . . . . . 234

Practice, Policy, and Ethics: Improving Patient Care and the Rise of Telemedicine . . . . . . . . . . . . . . . . . . . 93

4:00 p.m.–4:45 p.m.

3:00 p.m.–3:45 p.m.

7:00 a.m.–9:00 a.m.

C37

Coding 101: E&M, Basic Procedures, Non-face-to-face, and New Codes What Is Value? . . . . . . . . . . . . . . . 234

Saturday, April 25 10:00 a.m.–10:45 a.m.

2:30 p.m.–3:15 p.m.

2:00 p.m.–2:45 p.m.

C73

Sunday, April 26 Practice, Policy, and Ethics

So You’ve Been Sued/Named in a Medical Malpractice – Now What? . . . . . . . . . . . . . . . . . . . . . . . . 231 Quality Improvement Innovation Awards . . . . . . . . . . . . . . . . . . . . . . . 234

The Power of One . . . . . . . . . . . . 229

Thursday, April 30

The Economics of APPs . . . . . . . . 234

1:00 p.m.–1:45 p.m.

Poster Session 11

12:00 p.m.–1:00 p.m.

P12

Talks for Trainees: Why Should I Care About Coding? . . . . . . . . . . . . . . . . . 234

1:00 p.m.–3:00 p.m.

C138

An Engaged Patient Is a Healthy Patient: Patient Engagement in Theory and Practice

2:00 p.m.–2:45 p.m.

Understanding and Negotiating a Physician Employment Contract . . . 231

256 2020 AAN Annual Meeting

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Session IS = Invited Science Session = Additional Fee Required = New in 2020 = Experiential Learning Area

Making the Most of Your Career as an APP . . . . . . . . . . . . . . . . . . . . . 234

12:00 p.m.–12:45 p.m.

Using Axon Registry to Ease Your Data-collection Burden . . . . . . . . . . 234

4:00 p.m.–4:45 p.m.

Private Practice: Can you be Successful? . . . . . . . . . . . . . . . . . . . 231

2:00 p.m.–2:45 p.m.

FMLA, Disability, Legal Questions, and Other Paperwork . . . . . . . . . . . 234

5:00 p.m.–5:45 p.m.

How Can I Prepare for the E/M Changes that are Coming in 2021? . . . . . . . . . . . . . . . . . . . . . . . . 234

Saturday, April 25

1:00 p.m.–1:45 p.m.

From Private Practice to Academics . . . . . . . . . . . . . . . . . . . . 231 Factors that Perpetuate Disparities in Academic Medicine: A Path Forward . . . . . . . . . . . . . . . . 221 How Does Advocacy Help Build My Practice? . . . . . . . . . . . . . . . . . . . . . . 234 3:10 p.m.–3:20 p.m.

BusinessBytes: Why Should I Be Using Data from the Neurology Compensation and Productivity Survey in My Practice? . . . . . . . . . . 234 4:00 p.m.–5:30 p.m.

C276

Thursday, April 30 8:00 a.m.–8:45 p.m.

Talks for Trainees: Thinking About Practice Models in My Future Career . . . . . . . . . . . . . . . . . . 234

3:00 p.m.–3:45 p.m.

Philanthropy for Education . . . . . 221 From Disease Detectives to Disease Preventers: Neurology and Neuroscience Opportunities at CDC . . . . . . . . . . . . . . . . . . . . . . . . . . 236

Clerkship and Program Directors Conference Program Coordinator’s Role and Opportunities

8:30 a.m.–9:30 a.m.

C277

Surf’s Up: Riding the Wave to Onboarding and Offboarding

9:00 a.m.–9:45 a.m.

What Should Applicants Look for in a Program? . . . . . . . . . . . . . . . . . . . . . . 231

3:00 p.m.–4:00 p.m.

C285

7:00 a.m.–7:45 a.m.

Making the Most of Fellowship— Setting Yourself Up for Success and Finding Your First Job . . . . . . . . . . . 231 Much More Than Traumatic Brain Injury: Identifying Funding Opportunities from the Department of Defense . . . . . . . . . . . . . . . . . . . . . . 236

Administrative Overview for the Academic Administrator

10:00 a.m.–10:30 a.m.

C279

Saving Time and Seeing the Bigger Picture with Your Data

8:00 a.m.–8:45 a.m.

Are You My Mentor? How to Select a Good Mentor for Your Research Career . . . . . . . . . . . . . . . . . . . . . . . . 236 Neurology: We Want YOU! . . . . 221

10:30 a.m.–11:00 a.m.

C280

Foundations of Resident Orientation Planning

11:00 a.m.–12:00 p.m.

C281

Resident Education and Clinical Training Model: “4 + 2 System”

12:00 p.m.–4:00 p.m.

C25

Resident Basic Science 1: Neuropharmacology

12:00 p.m.–4:00 p.m.

Futures in Neurological Research Boot Camp 1:00 p.m.–1:45 p.m.

So Your Paper Didn’t Get Accepted, Now What? . . . . . . . . . . . . . . . . . . . 236

Surveys, Surveys, Surveys! How to prepare for the ACGME Survey, and what to do with the results

Sunday, April 26

9:30 a.m.–10:00 a.m.

C278

Using Milestones and Clinical Competency Committee Results for Program Improvement

8:00 a.m.–9:00 a.m.

C287

Clerkship Coordinator Speed Mentoring C286 Program Outcomes and the Next Accreditation System: The Self-Study, Site Visit and the A to Z’s of Program Coordination – An Opportunity, Not a Burden 11:00 a.m.–12:00 p.m.

C288

ACGME Web ADS: The Overview and Implementation in Accredited Programs

AAN.com/view/20AM 257

Research/Education/History

EHR Pain Points: A Conversation with Representatives from Epic and Cerner . . . . . . . . . . . . . . . . . . . . . . . . 234

C284

8:00 a.m.–8:30 a.m.

Preparing to Use Artificial Intelligence in Your Practice . . . . . . 234 2:00 p.m.–2:45 p.m.

Peer Review of Scientific Articles – Tips on How to Respond to the Dreaded Reviewer #2 . . . . . . . . . . . 236 Your First Job: Private Practice vs. Academic Practice: Pros and Cons . . . . . . . . . . . . . . . . . . . . . . . . . 221

7:00 a.m.–12:30 p.m.

12:00 p.m.–12:45 p.m.

Meet Your Practice Support Network: Ask Us Anything About Managing Your Practice . . . . . . . . . 234

2:00 p.m.–2:45 p.m.

PROGRAMS BY TOPIC

Research Methodology, Education, and History

8:00 a.m.–8:45 a.m.

Talks for Trainees: Understanding Patients as Consumers . . . . . . . . . . 234

Clerkship Administrators Part 2: Understanding Leadership Qualities

2:00 p.m.–3:00 p.m.

Wednesday, April 29 C181 How to Run a Practice: Business Strategies for Neurology Private Practices and the Future

C282

Taking Neurology Outside of the Office: Turning Advocacy into a Career Game-changer . . . . . . . . . . . . . . . . . 232

Practice, Policy, and Ethics: Improving the Lives of Patients and Providers 2 P10.6-001 –P10.6-012. . . . . . . . . . . . . . 173

Preparing for Resident Recruitment .

1:00 p.m.–4:00 p.m.

8:00 a.m.–8:45 a.m.

Poster Session 10

7:00 a.m.–9:00 a.m.

C283

Friday, May 1

5:30 p.m.–6:30 p.m.

P10

1:00 p.m.–2:00 p.m.

2020 PROGRAMS BY TOPIC 12:00 p.m.–12:45 p.m.

Combating the Scientific Irreproducibility Crisis: Using Principles of Reproducible Scientific Design to Critically Evaluate Scientific Papers for Best-informed Patient Care . . . . . . .236

C289 P5

12:30 p.m.–5:30 p.m.

Medical Student Symposium: Careers in Neurology 1:00 p.m.–3:00 p.m.

PROGRAMS BY TOPIC

C58

1:00 p.m.–5:30 p.m.

C63

Resident Basic Science 2: Neuroanatomy: All the Lesions

From All Different Practice Settings: How to Navigate Discussions with Your Department Leadership . . . . . 231 Different Pathways to Becoming a Department Chair . . . . . . . . . . . . . . 221 3:30 p.m.–5:30 p.m.

C72 C78

Recent History: The Development of Neurologic Subspecialties 2 Accelerating Equity, Diversity, and Inclusion for Women in Medicine

5:00 p.m.–5:45 p.m.

Success in Residency? Let’s Talk About It . . . . . . . . . . . . . . . . . . . . . . . 231

Monday, April 27 7:00 a.m.–7:45 a.m.

Core Curriculum for a Required Neurology Experience . . . . . . . . . . . 221 Social Networking Sites for Researchers and Using Social Media Platforms . . . . . . . . . . . . . . . . . . . . . 236 7:00 a.m.–9:00 a.m.

C89

Epidemiology and Neurology: The Importance of Data for Disease Prevention and Control Service Line Models: Successes and Challenges

8:00 a.m.–8:45 a.m.

Mistakes, Mentoring, and Miracles: Transitioning from a Career Development Award to Independence . . . . . . . . . . . . . . . . . . 236 8:00 a.m.–9:00 a.m.

C291

Clerkship Coordinator Speed Mentoring

258 2020 AAN Annual Meeting

3:30 p.m.–4:30 p.m.

C292

C122

TRANSCENDS (Training in Research for Academic Neurologists to Sustain Careers and Enhance the Numbers of Diverse Scholars) Program Overview . . . . . . . . . . . . . . . . . . . . . 236

Advancing Your Career with the Resident and Fellow Section of Neurology: How to Write, Review, Join the Editorial Board, and Use the RFS for Your Residency . . . . . . . . . . . . . . 231 5:00 p.m.–5:45 p.m.

Applying for AAN Research Fellowships 101 . . . . . . . . . . . . . . . . 236 5:30 p.m.–6:30 p.m.

12:00 p.m.–1:00 p.m.

Poster Session 6

Graduate Medical Education: Pedagogy 1 P6.10-011 –P6.10-014. . . . . . . . . . . . . . 151 Medical Education: Expansion and Outreach 2 P6.10-001 –P6.10-006. . . . . . . . . . . . . . 151 Undergraduate Medical Education 2 P6.10-007 –P6.10-010. . . . . . . . . . . . . . 151

1:00 p.m.–1:45 p.m.

Are You Including Underrepresented Populations in Your Clinical Research? . . . . . . . . . . . . . . . . . . . . . 236 1:00 p.m.–3:00 p.m.

C105 Faculty Development: Enhancing Your Role in Student and Resident Training C106 Source of Truth 1:00 p.m.–5:30 p.m.

C110 Resident Basic Science 3: Neuropathology 2:00 p.m.–2:45 p.m.

Grantwriting 101: Getting Started . . . . . . . . . . . . . . . . . . . . . . . 236 Cómo participar en la Resident & Fellow Section de Neurology® (How to Get Involved in the Resident & Fellow Section of Neurology®) . . . 221 2:00 p.m.–3:00 p.m.

ABPN Continuing Certification Information Session 3:00 p.m.–3:45 p.m.

Academic Neurology: What Is the AAN Doing to Help Academic Neurology? . . . . . . . . . . . . . . . . . . . . 221

Faculty Compensation Plans

4:00 p.m.–4:45 p.m.

Complex Scheduling in an Academic Neurology Department C290 It’s a Professional Career! Program Administrator Education and Title Reclassification 12:00 p.m.–12:45 p.m.

How to Think Like a Neurologist: A.B. Baker Award for Lifetime Achievement in Neurologic Education Keynote Address

3:30 p.m.–5:30 p.m.

C93

How to Write and Publish Neurology Research . . . . . . . . . . . . 236 3:00 p.m.–3:45 p.m.

Medical Education: Expansion and Outreach 1 P5.10-001 –P5.10-007. . . . . . . . . . . . . . 146 Undergraduate Medical Education 1 P5.10-008 –P5.10-015. . . . . . . . . . . . . . 146

11:00 a.m.–12:00 p.m.

2:00 p.m.–2:45 p.m.

C84

Research/Education/History

Recent History: The Development of Neurologic Subspecialties 1

Program Evaluation Committee (PEC) Review and Best Practices Poster Session 5

Poster Session 7

History of Neurology P7.5-001 –P7.5-012. . . . . . . . . . . . . . . . 155 Graduate Medical Education: Pedagogy 2 P7.10-001 –P7.10-016. . . . . . . . . . . . . . 157

Tuesday, April 28 7:00 a.m.–7:45 a.m.

Key Findings from the Neurology Compensation and Productivity Survey for Academics . . . . . . . . . . . 221 7:00 a.m.–9:00 a.m.

C136

Negotiating Like a Boss: Narrowing the Gender Gap

8:00 a.m.–8:45 a.m.

Welcome to NIH Day/Overview of NIH Funding . . . . . . . . . . . . . . . . . . . 236 8:00 a.m.–9:00 a.m.

C293 P8

Associate Professors – What Are Your Needs? How Can The AAN Support You Poster Session 8

Graduate Medical Education: Wellness and Value P8.10-001 –P8.10-015. . . . . . . . . . . . . . 163

11:30 a.m.–12:00 p.m.

Methods and Directions for Applying Data Science in Neurology . . . . . . . 227 1:00 p.m.–1:30 p.m.

Learn About Opportunities to Work with the NIH Intramural Program . . 236

C144 How to Design Meaningful Clinical Trials C149 Leading Your Successful Transition Out of Fellowship or Final Year of Residency C151 Education Research Methodology Course 1:30 p.m.–2:00 p.m.

NIH Grant Review Process & Tips for Writing a Successful Grant Application . . . . . . . . . . . . . . . . . . . . 236

1:00 p.m.–1:45 p.m.

1:00 p.m.–2:00 p.m.

S36

NIH Funding and Professional Development Opportunities for Diverse Researchers . . . . . . . . . . . . 236

3:30 p.m.–5:30 p.m.

2:00 p.m.–2:45 p.m.

From Private Practice to Academics . . . . . . . . . . . . . . . . . . . . 231 Ethical Issues in Clinical Research . . . . . . . . . . . . . . . . . . . . . . 236

4:00 p.m.–4:00 p.m.

S43 S44

Stroke Recovery and Outcomes . . . 105 Research Methodology and Education . . . . . . . . . . . . . . . . . . . . . 106 ”But We Always Use 20 Patients”—How NOT to Determine Sample Size . . . . . . . . . . . . . . . . . . . 236

Finding Neverland: Pathways to a Successful Academic Career in Global Neurology . . . . . . . . . . . . . . . 232 8:00 a.m.–8:45 a.m.

Statistically Speaking: How to Engage in Productive Collaborations with Statistical Colleagues . . . . . . . 236 11:30 a.m.–1:00 p.m.

P17

Thursday, April 30

Poster Session 17: Neuroinflammation

Research Methodology and Education P17.11-011 - P17.11-012. . . . . . . . . . . . . 217

7:00 a.m.–7:45 a.m.

Neuroscience of Bias in Research . . . . . . . . . . . . . . . . . . . . . . 236

Sleep

7:00 a.m.–9:00 a.m.

C223 Mid-career Faculty Development Course

Saturday, April 25

8:00 a.m.–8:45 a.m.

C21

Launching a Successful Research Program and Tips for Early-career Neurologists: Funding Clinically Oriented/Translational Research Before R01 . . . . . . . . . . . . . . . . . . . . 236

4:30 p.m.–5:15 p.m.

1:00 p.m.–1:45 p.m.

Wednesday, April 29

Small Group Mock Review Sessions . . . . . . . . . . . . . . . . . . . . . . 236

7:00 a.m.–7:45 a.m.

Too Many Fellowship Choices: How to Zero in to Find the Subspecialty of Your Choice and the Best Job for Life . . . . . . . . . . . . 231 K Is for Career Development . . . . . . 236

7:00 a.m.–7:45 a.m.

5:00 p.m.–5:45 p.m.

Translational Research . . . . . . . . . . 236 Funding Opportunities in Pain Research and the HEAL Initiative . . 236

Friday, May 1

3:30 p.m.–5:30 p.m.

C165

Digital Technology for Neurology Education: Creation, Curation, Collaboration C167 Funds Flow Models: What Works? What Doesn’t Work? S35 Amyotrophic Lateral Sclerosis . . . . 100

Consejos para dar una charla científica efectiva (How to Prepare and Present Abstracts at the AAN Annual Meeting) . . . . . . . . . . . . . . . 236

C197 Research Career Symposium

3:15 p.m.–4:00 p.m.

Clinical Trials and Networks – NeuroNEXT, StrokeNET, SIREN, Alzheimer’s Clinical Trials Consortium and ADRD Opportunities . . . . . . . . . 236

5:00 p.m.–5:45 p.m.

History of Neurology . . . . . . . . . . . . 102

1:00 p.m.–3:00 p.m.

C225

Developing a Successful and Solvent Clinical Trials Program in an Academic Department: Why and How

2:00 p.m.–2:45 p.m.

9:30 a.m.–11:30 a.m.

12:00 p.m.–1:00 p.m.

Poster Session 1

Sleep Medicine: Covering New Grounds 1 P1.11-001 –P1.11-012. . . . . . . . . . . . . . . 123

3:00 p.m.–3:45 p.m.

Tips for Better Sleep: More Reasons to Love Bedtime . . . . . . . . 229

Sunday, April 26 8:00 a.m.–9:00 a.m.

Residency Case Reports: How to Make a Small Amount of Effort Go a Long Way . . . . . . . . . . . . . . . . . . . . . 236

7:00 a.m.–9:00 a.m.

Approaching the Management of Common Sleep Disorders

Poster Session 2

Sleep Medicine: Covering New Grounds 2 P2.11-001 –P2.11-006. . . . . . . . . . . . . . 129 Sleep Medicine: Focus on Therapies 1 P2.11-007 –P2.11-013. . . . . . . . . . . . . . 129

3:30 p.m.–5:30 p.m.

12:00 p.m.–1:00 p.m.

8:00 a.m.–8:45 a.m.

C239

How to Successfully Publish Quality Improvement Projects . . . . . . . . . . . 236

Poster Session 3

Sleep Medicine: Focus on Therapies 2 P3.11-001 –P3.11-013. . . . . . . . . . . . . . 134

1:00 p.m.–3:00 p.m.

Sleep Medicine: Highlights 2020 . . . 82

AAN.com/view/20AM 259

Sleep

C180 Division Chief Roundtable: ChairChief Synergy: Working with the Department Chair to “Manage Up”

Boot Camp for Division Chiefs and Aspiring Leaders

PROGRAMS BY TOPIC

2:45 p.m.–3:15 p.m.

Consejos para publicar en revistas neurológicas (Getting Published in Neurology Journals: Tips and Tricks) . . . . . . . . . . . . . . . . . . . . . . . . 221

1:00 p.m.–5:30 p.m.

2:00 p.m.–2:45 p.m.

K Awards and Training Programs – Planning for a Career as an NIH Investigator . . . . . . . . . . . . . . . . . . . 236

4:00 p.m.–4:45 p.m.

How to Put Together an Effective Research Presentation . . . . . . . . . . 236 Advancing the Educational Mission in Neurology Departments . . . . . . . 221

2020 PROGRAMS BY TOPIC 3:30 p.m.–5:30 p.m.

C75

Cognitive Behavioral Sleep Medicine: A Primer to a Discipline

Monday, April 27 8:00 a.m.–9:00 a.m.

C92

Education Blitz: Insomnia

1:00 p.m.–3:00 p.m.

Sleep-Disordered Breathing in Neurology Populations: From Lab to Clinic C104 Neurology Update 3: Stroke, Epilepsy, and Sleep

PROGRAMS BY TOPIC

C95

3:00 p.m.–3:45 p.m.

The Sleep Mythbuster!: Illuminating the Facts and Fiction Toward Achieving the Sleep-healthy Neurologist . . . . 229

Tuesday, April 28 9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session . . . . . . . . . . . . . . . . . . . . . . . 65 3:30 p.m.–5:30 p.m.

Neuroscience in the Clinic: Melatonin and Disrupted Sleep in Neurologic Disorders . . . . . . . . . . . . . 72

Wednesday, April 29 1:00 p.m.–3:00 p.m.

C195 Sleep for the Practicing Neurologist: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence 3:30 p.m.–5:30 p.m.

C201 Sleep for the Practicing Neurologist 2: Disordered Sleep in Common Neurologic Diseases

Thursday, April 30 7:00 a.m.–9:00 a.m.

C216 Integrating Sleep Medicine Concepts into Your Child Neurology Practice 1:00 p.m.–3:00 p.m.

C227 Using Sleep Medicine to Help Solve Difficult Neurologic Cases

Sleep

3:30 p.m.–5:30 p.m.

C241 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist

Friday, May 1 7:00 a.m.–9:00 a.m.

C259 Sleep for Resiliency, Recovery, and Performance

260 2020 AAN Annual Meeting

11:30 a.m.–1:00 p.m.

P17

Poster Session 17: Neuroinflammation Sleep P17.11-009 - P17.11-010. . . . . . . . . . . . . 217

Beyond the Bedside Series

The Business Side of Treating Patients As you learn about providing top-notch care to your patients in a clinical setting, this new series is designed to teach strategies that are crucial to your practiceâ&#x20AC;&#x2122;s success. The new Beyond the Bedside Series will take place from 11:00 a.m.â&#x20AC;&#x201C;12:00 p.m. before select courses Sunday through Wednesday at the Annual Meeting. Join a Neurologist and Business Administrator to ask questions about the business side of your practice.

Scheduled Topics: Sunday, April 26: Beyond the Bedside: The Business of Epilepsy (precedes C54: Clinical EEG in the same location)

Monday, April 27: Beyond the Bedside: The Business of Multiple Sclerosis (precedes C146: Multiple Sclerosis Overview I: Clinical Pearls in the same location) Tuesday, April 28: Beyond the Bedside: The Business of Telestroke (precedes C185: Cerebrovascular Disease III: Telestroke in the same location) Wednesday, April 29: Beyond the Bedside: The Business of Sleep (precedes C195: Sleep for the Practicing Neurologist I in the same location)

GENERAL INFORMATION ACCREDITATION ACCME Accreditation

The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AANI holds Accreditation with Commendation, the ACCME highest level of recognition for a CME provider.

AMA Credit Designation

The AANI designates this live activity for a maximum of (*) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. *See individual program descriptions for the maximum number of credits per program.

Claiming CME

To claim CME hours, attendees must complete program evaluations in the AAN Conferences mobile app or at AAN.com/view/CME after the attendee has been verified onsite as eligible for credit and attended the program. Transcripts will be available approximately six to eight weeks following the close of the conference. AAN members can also access their transcript via NeuroTracker™ at AAN.com/view/NeuroTracker.

Certificates for Non-Physicians

Non-physicians participating in this program will receive an acknowledgement of participation indicating attendance at an activity designated for AMA PRA Category 1 Credit(s)™.

ABPN Statement

The American Board of Psychiatry and Neurology has reviewed the AAN conference and has approved this program as a part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of continuing certification.

262 2020 AAN Annual Meeting

AMA CME Definition/Educational Content of Certified CME

The AMA HOD and the Council on Medical Education have defined continuing medical education as follows: CME consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is the body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. (HOD policy #300.988)

Definition of Certified CME • •

Nonpromotional learning activities certified for credit prior to the activity by an organization authorized by the credit system owner, or Nonpromotional learning activities for which the credit system owner directly awards credit

Accredited CME providers may certify nonclinical subjects (e.g., office management, patient-physician communications, faculty development) for AMA PRA Category 1 Credit™ as long as these are appropriate to a physician audience and benefit the profession, patient care, or public health. CME activities may describe or explain complementary and alternative health care practices. As with any CME activity, these need to include discussion of the existing level of scientific evidence that supports the practices. However, education that advocates specific alternative therapies or teaches how to perform associated procedures, without scientific evidence or general acceptance among the profession that supports their efficacy and safety, cannot be certified for AMA PRA Category 1 Credit™.

Content Validation

The AANI, as an ACCME accredited provider, is responsible for validating the clinical content of CME activities that it provides. Specifically, (1) All the recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.(2) All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

DISCLAIMERS/DISCLOSURES Disclaimers

Faculty Disclosure of Commercial Relationships

A diversity of opinions exists in the medical field and the views of the conference faculty do not represent those of the AAN/ AANI or constitute endorsement by the AAN/AANI. The AAN/ AANI disclaims any and all liability for the claims that may result from the use or nonuse of information, publications, therapies, and/or services discussed at its conferences.

Unlabeled Use Disclosure

The primary purpose of this program is to meet the educational needs of its members and address practice gaps by providing practice oriented and scientifically based educational activities that will maintain and advance competence and performance in the field of neurology.

The activities conducted, and content distributed, at this conference are for educational purposes only and do not constitute or substitute professional medical advice, diagnosis, or treatment. EEGs, examples of neurologic exams, and other activities conducted at conferences are not for diagnostic or treatment purposes, do not establish a patient-physician relationship, do not constitute the practice of medicine, and are not conclusive as to the absence or presence of any health condition. The AAN does not recommend or endorse any specific physicians, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided is solely at attendeeâ&#x20AC;&#x2122;s own risk. The AAN is not liable to any attendee or anyone else for any decision made or action taken by based on reliance upon the information provided during the program.

Consistent with the AAN/AANI and ACCME policies, faculty must disclose any relevant financial relationship with the manufacturer(s) discussed in their presentation, so that learners may form their own judgments about material discussed during the educational activity. Full disclosure of facultyâ&#x20AC;&#x2122;s commercial relationships will appear in the individual program materials and in the AAN Conferences Mobile App.

The AANI requires all faculty members to disclose if a product is not labeled for the use being discussed or that the product is still investigational. Such disclosures will appear in the individual program materials.

Grants

Some education and scientific programs are supported in part by educational grants from commercial entities. Disclosure of the educational grant is done through acknowledgment statements on the program materials, signs outside of the room, and verbally from the podium. Although educational grants are received, all programs are developed and implemented solely by the AAN. The terms, conditions, and purposes of the commercial support are documented in a written agreement between the AANI and commercial supporter.

Liability

Attendee assumes any and all liability associated with attendance at and participation in (including volunteering in any programming) activities, and releases the American Academy of Neurology, the American Academy of Neurology Institute, and their contractors, from any claims that may arise. The AAN is not liable for any claims whatsoever for personal injury, illness, death, or damages of any kind as a result of or caused by attendance and participation (including volunteering in any programming). Attendance and participation is voluntary.

AAN.com/view/20AM 263

GENERAL INFORMATION MEETING POLICIES Anti-harassment

Child Attendance

Language

Exhibit Hall Children under the age of 16 must be accompanied by an adult.

The AAN is committed to providing a conference environment that is free from all forms of discrimination and harassment. The Meetings Anti-Harassment Policy promotes the AAN’s values by defining the expectations for all participants at any AAN conference and related social events. Violations of this Policy may be reported to Member Services at (800) 879-1960, memberservices@aan.com, or to Academy staff on-site. The official language of AAN conferences is English. No simultaneous translation is available.

Press and Media Room

Only authorized media may use the Press and Media Room. Journalists must check in at the Press and Media Room and provide proper credentials. For more information, email Renee Tessman at rtessman@aan.com or call (612) 928-6137.

RFID Notice

Attendance in certain AAN meeting rooms will be captured by Radio Frequency Identification (RFID). The attendee’s Annual Meeting ID badge includes an embedded RF chip. As the attendee enters and exits these meeting rooms, the electronic reader will capture the attendee’s AAN member ID number, Annual Meeting registration number, and the time of entry and exit. This information will be used exclusively by the AAN to plan future meetings. No information will be sold to or shared with anyone outside of AAN.

Educational and Scientific Sessions Children under the age of 16 are not allowed in educational or scientific programs. Children under the age of 16 are allowed in the live streaming and overflow viewing areas when accompanied by an adult. Children 16 or older interested in attending education or scientific programming must register as a Student. Student registration is free.

Alcohol Anyone under the age of 21 is not permitted to attend events in which alcohol is served.

Consent to AAN Use of Images

All portions of AAN conferences may be photographed, videotaped, or recorded for future rebroadcast, distribution, promotion, or other commercial purpose. By attending the conference, you are consenting to being recorded, photographed, and videotaped without acknowledgment, payment, or remuneration of any kind. Any recordings, photographs, or videos of any nature are the sole property of AAN and its successors and assignees.

HOTEL AND REGISTRATION POLICIES Program/Conference Cancellation

Special Accommodations

Cancelling Your Registration

Hotel Policies

Programs are subject to cancellation if enrollment is insufficient. The AAN is not responsible for airfare, hotel, or other costs incurred by participants in the event of cancellation. An administrative fee of $100 USD will be applied for all cancellations made on or prior to the early registration deadline of March 5, 2020. Cancellations received after the early registration and before the advance registration deadline of April 2, 2020, will be charged $200 USD. Cancellations received after the advance registration deadline will not receive a refund. Refunds will be granted in US dollars and may not reflect the initial amount paid due to currency exchange rate fluctuations. No refunds are granted for amounts of $20 USD or less. 264 2020 AAN Annual Meeting

The AAN strives to accommodate all visitors. If you require special accommodation to attend an AAN conference, submit your request while registering or contact Brooke Martin at bmartin@aan.com. Hotel policies such as check-in and check-out and cancellation can be found on AAN.com/view/20AM. Cancelling your registration does not cancel your hotel reservation.

Policies for individual hotels are listed on the housing reservations website, including:

• Check-In /Check-Out time • Deposit or guarantee arrangements • Cancellation policies

72ND ANNUAL MEETING EXHIBITORS* Abbott AbbVie, Inc. ACADIA Pharmaceuticals Inc. Acorda Therapeutics, Inc. Adamas Pharmaceuticals, Inc. Akcea Therapeutics Alexion Pharmaceuticals Allergan, Inc. Alnylam Pharmaceuticals Alzheimer’s Association American Board of Psychiatry and Neurology, Inc. (ABPN) American Headache Society American Stroke Association Amgen Amneal Pharmaceuticals LLC Amylyx Pharmaceuticals Arbor Pharmacueticals, LLC argenx Audentes AveXis Banner Health Baptist Health Medical Group (Kentucky) Baylor Scott & White Health BC Neuroimmunology Lab Inc. Biogen Biohaven Pharmaceuticals BioSerenity, Inc Biospective Boston Scientific BrainCheck Cadwell Industries, Inc. Cambridge Brain Sciences Cambridge University Press Catalyst Pharmaceuticals, Inc Celgene Corporation Cleveland Clinic CNS Vital Signs Combinostics CompHealth Cone Health Corinthian Reference Lab Cure SMA Cutaneous NeuroDiagnostics Cyclic Vomiting Syndrome Association Defeat MSA Alliance Demos Medical, an Imprint of Springer Publishing DynaMed/EBSCO Dysautonomia International

Dystonia Medical Research Foundation Canada Eisai Inc. Eli Lilly and Company Elsevier eNeura Inc. European Academy of Neurology Genentech Global Kinetics Corporation Great Lakes NeuroTechnologies Inc. Greenwich Biosciences, Inc. Grifols Hayes Locums HCA Healthcare Health Monitor Network Henry Ford Health System Holland Hospital Horizon Health Network icometrix Image Monitoring USA Impel NeuroPharma Inova Health System Insightec, Inc. Inspire Medical Systems, Inc. Interacoustics Interior Health Intermountain Healthcare International Essential Tremor Foundation International Parkinson and Movement Disorder Society (MDS) Invitae Ipsen Biopharmaceuticals, Inc. Jackson & Coker LT JAMA Network Janssen Research & Development Jari Electrode Supply KabaFusion Kaiser Permanente KRONUS, Inc. Kyowa Kirin, Inc. LabCorp Lewy Body Dementia Association LivaNova LocumTenens.com Lundbeck Managing Epilepsy Well Network Mayo Clinic Laboratories

Mayo Clinic Referring Provider Office Medday Pharmaceuticals MedLink Neurology Medscape Neurology Medtronic Merck KGaA Merz Neurosciences Mitsubishi Tanabe Pharma America MotherToBaby Pregnancy Studies MULTIGON INDUSTRIES,INC. Multiple Sclerosis Foundation Mylan Inc. National ALS Registry National Ataxia Foundation National Institute of Neurological Disorders and Stroke (NINDS) Natus NEALS Consortium Neurocrine Biosciences, Inc. Neurocritical Care Society Neurology Advisor Neurology Reviews NeuroPace, Inc. NIHON KOHDEN AMERICA NINDS CDE Project Northern Health Northwell Health Novartis Pharmaceuticals Ochsner Health System Optum Infusion Services Oxford University Press PatientPoint Penn State Health PerkinElmer Genomics Piramal Critical Care PracticeLink Provider Solutions + Development PTC Therapeutics Quest Diagnostics Ra Pharma Reata Pharmaceuticals RightEye RosmanSearch RSC Diagnostic Services Rush University Medical Center Sage Therapeutics, Inc. Saint Luke’s Marion Bloch Neuroscience Institute

Sanofi Genzyme Sarepta Therapeutics Satsuma Pharmaceuticals, Inc. Sensonics International SK life science SOC Telemed Spartanburg Regional Healthcare System Spastic Paraplegia Foundation Springer Nature Stratus an Alliance Company Sunovion Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc. Teva Pharmaceuticals THERANICA, USA Tourette Association of America TrueLearn UCB United Council for Neurologic Subspecialties University of Florida Health Shands Hospital Upsher-Smith Laboratories, LLC US WorldMeds Variantyx, Inc. Verana Health Viela Bio Voyager Therapeutics Weatherby Healthcare Wiley Wolters Kluwer World Federation of Neurology Xoran Technologies, LLC. Zeto, Inc. Zogenix, Inc.

*As of February 7, 2020

AAN.com/view/20AM 265

THANK YOU

2020 Annual Meeting Supporters* The American Academy of Neurology (AAN) thanks the following companies, foundations, and organizations for their demonstrated vision, commitment, and strong support of programs which find answers and improve lives through neurologic education and research. AbbVie, Inc.

»» Exhibit Hall Passport

Acorda Therapeutics, Inc.

»» Exhibit/On-site Guide Advertisement

Adamas Pharmaceuticals, Inc.

»» Hotel Door Drop Insert »» Exhibit Hall Passport »» Scientific Program Advertisement

Akcea Therapeutics »» »» »» »» »»

AANextra Advertisement Exhibit/On-site Guide Advertisement Exhibit Hall Passport Hotel Door Drop Bag Industry Therapeutics Update

Alexion Pharmaceuticals, Inc.

»» C268 Neuromyelitis Optica Spectrum Disorders »» Industry Therapeutic Updates

Allergan, Inc. »» »» »» »» »» »» »» »» »» »»

Brain Health Fair Gold Sponsor Cell Phone Charging Station Cell Phone Charging Locker Exhibit Hall Entrance Carpet Graphics Exhibit Hall Pillar Marketing Exhibit Hall Passport Hotel Door Drop Insert C198 Skills Workshop: Clinical Uses of Botulinum Toxin for Dystonia C231 Comprehensive Migraine Update 1: Migraine Diagnosis, Pathophysiology, and Comorbidities C224 Comprehensive Migraine Update 2: Advances in Acute, Preventive, and Cognitive Behavioral Therapies

Alnylam Pharmaceuticals

»» Exhibit Hall Passport »» Exhibit/On-site Guide Advertisement

Amgen

»» Hotel Door Drop Inserts »» Industry Therapeutic Update

Amneal Specialty, a division of Amneal Pharmaceuticals LLC »» Exhibit Hall Passport

Amylyx Pharmaceuticals

»» Poster Hall Tabletop Graphics »» Exhibit/On-site Guide Advertisement »» Cell Phone Charging Station

Arbor Pharmaceuticals, LLC »» Exhibit Hall Passport

Audentes Therapeutics

»» Exhibit/On-site Guide Advertisement »» Hotel Door Drop Insert

266 2020 AAN Annual Meeting

AveXis, Inc. »» »» »» »» »» »»

AANextra Advertisement Cell Phone Charging Stations Exhibit/On-site Guide Advertisement Exhibit Hall Buzz Café Hotel Door Drop Insert Industry Therapeutic Update

Biogen »» »» »» »» »» »» »» »» »» »» »»

AANextra Advertisement Convention Centre Charging Lounges Exhibit Hall Charging Lounges Exhibit Hall Charging Tables Exhibit Hall Digital Billboard Exhibit Hall Tabletop Graphics Fellows Scholarship Fund Hotel Door Drop Inserts Industry Therapeutic Updates Resident Scholarship Fund Scientific Program Advertisements

Biohaven Pharmaceuticals »» »» »» »» »»

Exhibit Hall Footprints Exhibit Hall Pillar Marketing Exhibit Hall Passport Hotel Door Drop Insert Industry Therapeutic Update

Catalyst Pharmaceuticals

»» C71 Neuromuscular Junction Disorders 2: Toxins, Lambert-Eaton Syndrome, and Less Common Disorders of Neuromuscular Transmission

Celgene Corporation »» »» »» »» »» »»

AANextra Advertisement Exhibit/On-site Guide Advertisement Exhibit Hall Footprints Exhibit Hall Passport Hotel Key Cards and Card Holders Industry Therapeutic Update

Eisai Inc. »» »» »» »»

5k Run/1k Walk for Brain Research AANextra Advertisement Brain Health Fair Silver Sponsor Hotel Door Drop Insert

EMD Serono, Inc. »» »» »» »» »» »»

AAN Conferences Mobile App Sponsor Exhibit Hall Overhead Exit Banner Exhibit Hall Presentation Stage Exhibit Hall Tabletop Graphics Industry Therapeutic Update Poster Hall Tabletop Graphics

Genentech, a member of the Roche Group »» »» »» »» »» »» »» »»

5k Run/1k Walk for Brain Research Exhibit/On-site Guide Advertisement Exhibit Hall Footprints Exhibit Hall Pillar Marketing Exhibit Hall Pillar Wrapped Charging Seating Exhibit Hall Presentation Stage Hotel Door Drop Inserts Industry Therapeutic Updates

Greenwich Biosciences, Inc. »» »» »» »» »» »» »» »»

AANextra Advertisement Brain Health Fair Silver Sponsor Exhibit Hall Passport Fellows Scholarship Fund Hotel Door Drop Insert Resident Scholarship Fund C124 Multiple Sclerosis Therapy: Symptom Management C208 Clinical Epilepsy 2: Considerations Across the Age Span: Pediatrics, Pregnancy, and Elderly

Grifols »» »» »» »»

AANextra Advertisement Exhibit/On-site Guide Advertisement Industry Therapeutic Update C57 Neuromuscular Junction Disorders 1: Myasthenia Gravis, Ocular, and MuSK Myasthenia

Harmony Biosciences

»» C195 Sleep for the Practicing Neurologist: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence

Jazz Pharmaceuticals, Inc.

»» C216 Integrating Sleep Medicine Concepts into Your Child Neurology Practice

KabaFusion

»» Exhibit Hall Passport

Novartis Pharmaceuticals Corporation »» »» »» »» »» »» »» »» »» »» »» »» »» »»

Convention Centre Charging Lounges Exhibit Aisle Carpet Exhibit Hall Buzz Café Exhibit Hall Charging Table Exhibit Hall Lamp Posts Exhibit Hall Park Benches Exhibit Hall Pillar Marketing Exhibit Hall Tabletop Graphics Exhibit Hall Wayfinding Map Hotel Door Drop Inserts Industry Therapeutic Update Poster Hall Charging Hubs Poster Hall Tabletop Graphics Scientific Program Advertisement

Quest Diagnostics

»» Exhibit Hall Passport

Sage Therapeutics Inc.

»» Exhibit Hall Entrance Wall Clings

Sanofi Genzyme

»» Exhibit/On-site Guide Advertisement »» Industry Therapeutic Updates »» Residents Scholarship Fund

SK life science, a subsidiary of SK biopharmaceuticals »» Exhibit Hall Passport »» Hotel Door Drop Insert

Sunovion Pharmaceuticals Inc. »» »» »» »» »» »» »»

AANextra Advertisement Exhibit/On-site Guide Advertisement Exhibit Hall Buzz Café Exhibit Hall Tabletop Graphics Exhibit Hall Passport Hotel Door Drop Inserts Industry Therapeutic Update

KRONUS, Inc.

Supernus Pharmaceuticals, Inc.

Kyowa Kirin, Inc.

Teva CNS

Lundbeck

UCB, Inc.

»» AANextra Advertisement »» General Support of the Annual Meeting

»» »» »» »»

Hotel Door Drop Bag Exhibit/On-site Guide Advertisement Exhibit Hall Tabletop Graphics Industry Therapeutic Updates

Medtronic

»» C248 Deep Brain Stimulation 2: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders

Merz Neurosciences

»» C101 The Dystonias: Diagnosis, Treatment, and Update on Etiologies

Mitsubishi Tanabe Pharma America, Inc. »» Hotel Door Drop Insert

Neurocrine Biosciences

»» AANextra Advertisement »» Hotel Door Drop Insert

»» Exhibit Hall Passport

»» Exhibit Hall Charging Lounge

»» AANextra Advertisement »» Industry Therapeutic Update

Variantyx, Inc.

»» Exhibit Hall Passport

Wolters Kluwer Health, AAN Partnering Publisher for: Neurology®, Neurology® Clinical Practice, Neurology® Neuroimmunology & Neuroinflammation, Neurology® Genetics, Continuum®, Neurology Today®, and Brain & Life® »» »» »» »» »»

Annual Meeting Bookbag Brain Health Fair Bookbag Convention Center Wifi Access Exhibit Hall Passport Posters Online

*As of February 7, 2020

AAN.com/view/20AM 267

INDUSTRY THERAPEUTIC UPDATES*

Saturday, April 25 | Monday, April 27 â&#x20AC;&#x201C; Wednesday, April 29 Join industry representatives for unique opportunities to learn about current therapies and projects in the industry pipeline. Registration for these informational sessions is free and open to all registered Annual Meeting attendees.

Saturday, April 25 | 7:00 p.m. Grifols USA Location: InterContinental Toronto Centre Room: Ballroom

UCB, Inc. Location: Delta Hotels Toronto Downtown Room: SOCO ABC Ballroom

Monday, April 27 | 7:00 p.m. Akcea Therapeutics Location: Delta Hotels Toronto Downtown Room: Kensington A Ballroom

Genentech, a member of the Roche group Location: InterContinental Toronto Centre Room: Ontario & Niagara Ballroom

Alexion Pharmaceuticals Location: Delta Hotels Toronto Downtown Room: SOCO AB Ballroom

Lundbeck Location: Delta Hotels Toronto Downtown Room: Kensington B Ballroom

Amgen Location: Delta Hotels Toronto Downtown Room: SOCO C Ballroom

Sanofi Genzyme Location: The Westin Harbour Castle, Toronto Room: Regatta Ballroom

Biogen Location: Fairmont Royal York Room: Concert Hall

Sunovion Pharmaceuticals, Inc. Location: Fairmont Royal York Room: Ballroom

Biohaven Pharmaceuticals Location: InterContinental Toronto Centre Room: Ballroom

*As of January 31, 2020. Subject to change.

RSVP is recommended for these events. Learn more at AAN.com/view/itu. No CME will be given by any accredited organization for the Industry Therapeutic Updates, and the AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

Tuesday, April 28 | 7:00 p.m. Alexion Pharmaceuticals Location: Delta Hotels Toronto Downtown Room: SOCO C Ballroom

Genentech, a member of the Roche group Location: InterContinental Toronto Centre Room: Ontario & Niagara Ballroom

AveXis, Inc. Location: InterContinental Toronto Centre Room: Ballroom

Lundbeck Location: The Westin Harbour Castle, Toronto Room: Regatta Ballroom

Biogen Location: Delta Hotels Toronto Downtown Room: SOCO AB Ballroom

Novartis Pharmaceuticals Corporation Location: Fairmont Royal York Room: Ballroom

Genentech, a member of the Roche group Location: Fairmont Royal York Room: Concert Hall

Sanofi Genzyme Location: Delta Hotels Toronto Downtown Room: Kensington Ballroom

Wednesday, April 29 | 7:00 p.m. Biogen Location: Fairmont Royal York Room: Canadian Ballroom Celgene Corporation Location: InterContinental Toronto Centre Room: Ballroom

EMD Serono, Inc. Location: Fairmont Royal York Room: Concert Hall

J O I N US

SIDNEY CROSBY Pittsburgh Penguins

EMILIA CLARKE Actor

JIM CRAMER CNBC Host

Commitment to Cures Award

Public Leadership in Neurology Award

Ambassador Award & Master of Ceremonies

Support the important work to cure brain diseases and disorders while enjoying an evening at the Hilton Toronto. Join us to celebrate a community driven to find a cure. For tickets and more information, please visit AmericanBrainFoundation.org/C2C.

Thank You

2O20 Industry Roundtable Members* The American Academy of Neurology and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurologic disease.

$50,000 Members

$40,000 Members

$25,000 Members

• Avanir Pharmaceuticals, Inc.

• Adamas Pharmaceuticals, Inc.

• Ovid Therapeutics

• argenx

• Amneal Specialty, a division of

• SK life science, a subsidiary of SK

• Grifols

Amneal Pharmaceuticals LLC • Ipsen Biopharmaceuticals, Inc. • Medtronic, Inc. • Mitsubishi Tanabe Pharma America, Inc.

$10,000 Members biopharmaceuticals • UCB, Inc. • Viela Bio

• Sage Therapeutics

*Commitments as of January 1, 2020

VISIT AAN BOOTHS & CONNECT WITH US AT THE ANNUAL MEETING

Stop by the AAN booths while you’re at the Annual Meeting to learn more about our organization.

MEMBER SERVICES - LEVEL 200

• Join the AAN or renew your AAN membership • Update your member profile, including your publication preferences • Get your questions answered regarding all the incomparable benefits of AAN membership

PUBLICATIONS - LEVEL 200

PODCAST

• Attend presentations at the Publications Stage by José G. Merino, MD, MPhil, FAAN, the new editor-in-chief of Neurology®, and others • Subscribe to Continuum® and Continuum® Audio and purchase back issues in print • Join us to celebrate the 15th anniversary of the Neurology Residents and Fellows section • Learn how to earn CME credits from Neurology articles and Neurology Podcast • Learn about the latest offerings from all of the AAN publications, including Neurology Today®

AMERICAN BRAIN FOUNDATION - LEVEL 200

• Learn about our mission to unite donors and researchers to cure brain disease • Meet our award recipients and learn about research funding opportunities • Find out how you can join the Brain Squad • Show your support with one of our exclusive t-shirts

NEUROLOGY CAREER CENTER - LEVEL 600

• Pick up a copy of the Career Compass Job Guide • Participate in the Online Job Fair • Pick up great swag, including t-shirts, flash drives, pens, and more

ONLINE LEARNING PROGRAMS - LEVEL 600

• Get information and support on the Academy’s online learning programs • Enter for a chance to win a subscription to Annual Meeting On Demand • Learn about our newly launched Neurology Question of the Day mobile app

Booth locations subject to change.

YOUR MEETING. YOUR WAY. Now there are more ways than ever before to experience the Annual Meeting. This year, the way you experience the AAN Annual Meeting is completely up to you. There are so many different options for learning, viewing, and engaging, including in-person sessions, an overflow viewing area, live streaming from anywhere in the convention center through the AAN Conferences Mobile App, and the option to purchase over 500 hours of content for a full two years with Annual Meeting On Demand. Learn more at AAN.com/view/20AM.

Download the AAN Conferences Mobile App today!

Available for iOSÂŽ and Android devices

201 Chicago Avenue Minneapolis, MN 55415

Future AAN Annual Meeting Dates and Locations 73rd AAN Annual Meeting

74th AAN Annual Meeting

75th AAN Annual Meeting

San Francisco, CA April 17–April 23, 2021

Seattle, WA April 2–April 8, 2022

Boston, MA April 22–April 28, 2023

AAN Member Services: (800) 879-1960

Use #AANAM and follow the AAN